,nctId,phase,recruitment,therapies,title,Therapies_id
0,NCT01655225,Phase I,Recruiting,"[{'id': 1214, 'therapyName': 'LY3023414 + Midazolam '}, {'id': 1215, 'therapyName': ' LY3023414 + Letrozole '}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of LY3023414 in Participants With Advanced Cancer,1215
0,NCT03159117,Phase I,Recruiting,"[{'id': 5707, 'therapyName': ' PF-06688992'}]",Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma,5707
0,NCT02035137,,Recruiting,"[{'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1426, 'therapyName': '131I-MIBG + Irinotecan + Vincristine'}, {'id': 1427, 'therapyName': '131I-MIBG + Vorinostat'}]",131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinistat,1425
1,NCT01175356,Phase I,Completed,"[{'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}]","Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin",1425
2,NCT03126916,Phase III,Not yet recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 5595, 'therapyName': 'Isotretinoin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 2286, 'therapyName': 'Dinutuximab  '}]",Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma,1425
0,NCT02035137,,Recruiting,"[{'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1426, 'therapyName': '131I-MIBG + Irinotecan + Vincristine'}, {'id': 1427, 'therapyName': '131I-MIBG + Vorinostat'}]",131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinistat,1426
0,NCT02035137,,Recruiting,"[{'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1426, 'therapyName': '131I-MIBG + Irinotecan + Vincristine'}, {'id': 1427, 'therapyName': '131I-MIBG + Vorinostat'}]",131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinistat,1427
0,NCT03030885,Phase I,Recruiting,"[{'id': 5804, 'therapyName': '131I-MIP-1095'}]",Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC),5804
0,NCT01384253,Phase I,Completed,"[{'id': 1540, 'therapyName': '212Pb-TCMC-Trastuzumab + Trastuzumab '}]",Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy,1540
0,NCT01386580,Phase Ib/II,Completed,"[{'id': 974, 'therapyName': '2B3-101'}, {'id': 1274, 'therapyName': '2B3-101 + Trastuzumab'}]","An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.",974
0,NCT01386580,Phase Ib/II,Completed,"[{'id': 974, 'therapyName': '2B3-101'}, {'id': 1274, 'therapyName': '2B3-101 + Trastuzumab'}]","An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.",1274
0,NCT02425306,Phase Ib/II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2620, 'therapyName': '6MHP vaccine'}, {'id': 2595, 'therapyName': 'poly ICLC  '}]",Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma,2620
1,NCT02382549,Phase Ib/II,Recruiting,"[{'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 2620, 'therapyName': '6MHP vaccine'}]",A Clinical Trial to Evaluate a Helper Peptide Vaccine Plus Vemurafenib in Melanoma,2620
2,NCT02385669,Phase Ib/II,Recruiting,"[{'id': 2620, 'therapyName': '6MHP vaccine'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma,2620
0,NCT02342782,Phase I,Recruiting,"[{'id': 2485, 'therapyName': '90Y basiliximab'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 2392, 'therapyName': 'Cytarabine + Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}]",Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma,2485
0,NCT02990416,Phase Ib/II,Not yet recruiting,"[{'id': 5137, 'therapyName': 'A-dmDT390-bisFv(UCHT1) + Pembrolizumab'}]",A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma,5137
0,NCT02412462,Phase I,Completed,"[{'id': 4317, 'therapyName': 'AB-16B5'}]",Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy,4317
0,NCT02391480,Phase I,Recruiting,"[{'id': 4028, 'therapyName': 'ABBV-075'}]",A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer,4028
0,NCT02565758,Phase I,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 3846, 'therapyName': 'ABBV-085'}]","ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors",3846
0,NCT03000257,Phase I,Recruiting,"[{'id': 5766, 'therapyName': 'ABBV-181'}]",A Study of ABBV-181 in Participants With Advanced Solid Tumors,5766
0,NCT02365662,Phase I,Recruiting,"[{'id': 2914, 'therapyName': 'ABBV-221'}]",A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor,2914
0,NCT03071757,Phase I,Recruiting,"[{'id': 5446, 'therapyName': 'ABBV-368'}, {'id': 5447, 'therapyName': 'ABBV-368 + Nivolumab'}]","A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors",5446
0,NCT03071757,Phase I,Recruiting,"[{'id': 5446, 'therapyName': 'ABBV-368'}, {'id': 5447, 'therapyName': 'ABBV-368 + Nivolumab'}]","A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors",5447
0,NCT02099058,Phase I,Recruiting,"[{'id': 1743, 'therapyName': 'ABBV-399 + Carboplatin'}, {'id': 1364, 'therapyName': 'ABBV-399 + Erlotinib'}, {'id': 1363, 'therapyName': 'ABBV-399'}, {'id': 1366, 'therapyName': 'ABBV-399 + Bevacizumab'}, {'id': 1365, 'therapyName': 'ABBV-399 + Cetuximab'}]","A Phase 1/1b Study With ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors",1363
0,NCT02099058,Phase I,Recruiting,"[{'id': 1743, 'therapyName': 'ABBV-399 + Carboplatin'}, {'id': 1364, 'therapyName': 'ABBV-399 + Erlotinib'}, {'id': 1363, 'therapyName': 'ABBV-399'}, {'id': 1366, 'therapyName': 'ABBV-399 + Bevacizumab'}, {'id': 1365, 'therapyName': 'ABBV-399 + Cetuximab'}]","A Phase 1/1b Study With ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors",1366
0,NCT02099058,Phase I,Recruiting,"[{'id': 1743, 'therapyName': 'ABBV-399 + Carboplatin'}, {'id': 1364, 'therapyName': 'ABBV-399 + Erlotinib'}, {'id': 1363, 'therapyName': 'ABBV-399'}, {'id': 1366, 'therapyName': 'ABBV-399 + Bevacizumab'}, {'id': 1365, 'therapyName': 'ABBV-399 + Cetuximab'}]","A Phase 1/1b Study With ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors",1743
0,NCT02099058,Phase I,Recruiting,"[{'id': 1743, 'therapyName': 'ABBV-399 + Carboplatin'}, {'id': 1364, 'therapyName': 'ABBV-399 + Erlotinib'}, {'id': 1363, 'therapyName': 'ABBV-399'}, {'id': 1366, 'therapyName': 'ABBV-399 + Bevacizumab'}, {'id': 1365, 'therapyName': 'ABBV-399 + Cetuximab'}]","A Phase 1/1b Study With ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors",1365
0,NCT02099058,Phase I,Recruiting,"[{'id': 1743, 'therapyName': 'ABBV-399 + Carboplatin'}, {'id': 1364, 'therapyName': 'ABBV-399 + Erlotinib'}, {'id': 1363, 'therapyName': 'ABBV-399'}, {'id': 1366, 'therapyName': 'ABBV-399 + Bevacizumab'}, {'id': 1365, 'therapyName': 'ABBV-399 + Cetuximab'}]","A Phase 1/1b Study With ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors",1364
0,NCT02955251,Phase I,Recruiting,"[{'id': 5051, 'therapyName': 'ABBV-428 + Nivolumab'}, {'id': 5050, 'therapyName': 'ABBV-428'}]","A Study Evaluating Safety and Pharmacokinetics, and the Recommended Phase 2 Dose (RPTD) of ABBV-428 in Participants With Advanced Solid Tumors",5050
0,NCT02955251,Phase I,Recruiting,"[{'id': 5051, 'therapyName': 'ABBV-428 + Nivolumab'}, {'id': 5050, 'therapyName': 'ABBV-428'}]","A Study Evaluating Safety and Pharmacokinetics, and the Recommended Phase 2 Dose (RPTD) of ABBV-428 in Participants With Advanced Solid Tumors",5051
0,NCT03082209,Phase I,Recruiting,"[{'id': 5756, 'therapyName': 'ABBV-621'}]",A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously Treated Solid Tumors and Hematologic Malignancies,5756
0,NCT02988960,Phase I,Recruiting,"[{'id': 5143, 'therapyName': 'ABBV-927 + Nivolumab'}, {'id': 5142, 'therapyName': 'ABBV-927'}]","A Study of ABBV-927, an Immunotherapy, in Participants With Advanced Solid Tumors",5142
0,NCT02988960,Phase I,Recruiting,"[{'id': 5143, 'therapyName': 'ABBV-927 + Nivolumab'}, {'id': 5142, 'therapyName': 'ABBV-927'}]","A Study of ABBV-927, an Immunotherapy, in Participants With Advanced Solid Tumors",5143
0,NCT02939807,Phase II,Recruiting,"[{'id': 3301, 'therapyName': 'ABC294640'}]",A Phase II Study of ABC294640 as Second-Line Monotherapy in Patients With Advanced Hepatocellular Carcinoma,3301
1,NCT02229981,Phase Ib/II,Recruiting,"[{'id': 3301, 'therapyName': 'ABC294640'}]",An Early-Phase Clinical Trial Evaluating ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma,3301
2,NCT02757326,Phase Ib/II,Recruiting,"[{'id': 3301, 'therapyName': 'ABC294640'}]",ABC294640 in Refractory / Relapsed Multiple Myeloma,3301
0,NCT02450539,Phase II,"Active, not recruiting","[{'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer,802
1,NCT02688088,Phase I,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 3729, 'therapyName': 'Caffeine + Dextromethorphan + Midazolam + Warfarin'}]",A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body,802
2,NCT02981342,Phase II,Recruiting,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 5175, 'therapyName': 'Abemaciclib + LY3023414'}, {'id': 5176, 'therapyName': 'Abemaciclib + Galunisertib'}]",A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma,802
3,NCT02644460,Phase I,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors,802
4,NCT02675231,Phase II,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 744, 'therapyName': 'Fulvestrant'}]","A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer",802
5,NCT03130439,Phase II,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}]","Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer",802
6,NCT02152631,Phase III,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 802, 'therapyName': 'Abemaciclib'}]",A Study of LY2835219 in Participants With Previously Treated Lung Cancer,802
7,NCT03155997,Phase III,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",A Study to Compare Treatment After Surgery of Abemaciclib (LY2835219) Combined With Standard Endocrine Therapy Versus Endocrine Therapy Alone in Participants With Breast Cancer,802
8,NCT02117648,,Completed,"[{'id': 1690, 'therapyName': 'Abemaciclib + Clarithromycin'}, {'id': 802, 'therapyName': 'Abemaciclib'}]", A Study of LY2835219 in Participants With Cancer,802
9,NCT02747004,Phase II,Recruiting,"[{'id': 4387, 'therapyName': 'Abemaciclib + Loperamide'}, {'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 2256, 'therapyName': 'Abemaciclib + Tamoxifen'}]",A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer (nextMONARCH 1),802
10,NCT03220646,Phase II,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",The Purpose of This Study is to Test Any Good and Bad Effects of a Study Drug Called Abemaciclib (LY2835219) in Patients With Recurrent Brain Tumors.,802
11,NCT02107703,Phase III,"Active, not recruiting","[{'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer,802
12,NCT02846987,Phase II,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",Study of Abemaciclib in Dedifferentiated Liposarcoma,802
13,NCT02308020,Phase II,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer That Has Spread to the Brain,802
14,NCT02981940,Phase II,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",A Study of Abemaciclib in Recurrent Glioblastoma,802
15,NCT02441946,Phase II,Completed,"[{'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 2700, 'therapyName': 'Loperamide'}, {'id': 633, 'therapyName': 'Anastrozole'}]","A Phase 2 Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer",802
16,NCT02079636,Phase I,Recruiting,"[{'id': 1069, 'therapyName': 'LY3023414'}, {'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC),802
17,NCT02792725,Expanded access,Available,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer,802
0,NCT02057133,Phase I,Recruiting,"[{'id': 2254, 'therapyName': 'Abemaciclib + Letrozole'}, {'id': 2257, 'therapyName': 'Abemaciclib + Exemestane'}, {'id': 2258, 'therapyName': 'Everolimus + Exemestane + LY2835219'}, {'id': 2255, 'therapyName': 'Abemaciclib + Anastrozole'}, {'id': 2256, 'therapyName': 'Abemaciclib + Tamoxifen'}, {'id': 2259, 'therapyName': 'Abemaciclib + Trastuzumab'}]",A Study of LY2835219 in Combination With Hormone Therapies for Breast Cancer That Has Spread,2255
0,NCT02246621,Phase III,"Active, not recruiting","[{'id': 1854, 'therapyName': 'Abemaciclib + Anastrozole + Letrozole'}, {'id': 1853, 'therapyName': 'Anastrozole + Letrozole'}]",A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer,1854
0,NCT03099174,Phase I,Recruiting,"[{'id': 5514, 'therapyName': 'Abemaciclib + Xentuzumab'}, {'id': 5515, 'therapyName': 'Abemaciclib + Letrozole + Xentuzumab'}, {'id': 5516, 'therapyName': 'Abemaciclib + Anastrozole + Xentuzumab'}, {'id': 5517, 'therapyName': 'Abemaciclib + Fulvestrant + Xentuzumab'}]",This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.,5516
0,NCT02117648,,Completed,"[{'id': 1690, 'therapyName': 'Abemaciclib + Clarithromycin'}, {'id': 802, 'therapyName': 'Abemaciclib'}]", A Study of LY2835219 in Participants With Cancer,1690
0,NCT02057133,Phase I,Recruiting,"[{'id': 2254, 'therapyName': 'Abemaciclib + Letrozole'}, {'id': 2257, 'therapyName': 'Abemaciclib + Exemestane'}, {'id': 2258, 'therapyName': 'Everolimus + Exemestane + LY2835219'}, {'id': 2255, 'therapyName': 'Abemaciclib + Anastrozole'}, {'id': 2256, 'therapyName': 'Abemaciclib + Tamoxifen'}, {'id': 2259, 'therapyName': 'Abemaciclib + Trastuzumab'}]",A Study of LY2835219 in Combination With Hormone Therapies for Breast Cancer That Has Spread,2257
0,NCT03099174,Phase I,Recruiting,"[{'id': 5514, 'therapyName': 'Abemaciclib + Xentuzumab'}, {'id': 5515, 'therapyName': 'Abemaciclib + Letrozole + Xentuzumab'}, {'id': 5516, 'therapyName': 'Abemaciclib + Anastrozole + Xentuzumab'}, {'id': 5517, 'therapyName': 'Abemaciclib + Fulvestrant + Xentuzumab'}]",This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.,5517
0,NCT02981342,Phase II,Recruiting,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 5175, 'therapyName': 'Abemaciclib + LY3023414'}, {'id': 5176, 'therapyName': 'Abemaciclib + Galunisertib'}]",A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma,5176
0,NCT02057133,Phase I,Recruiting,"[{'id': 2254, 'therapyName': 'Abemaciclib + Letrozole'}, {'id': 2257, 'therapyName': 'Abemaciclib + Exemestane'}, {'id': 2258, 'therapyName': 'Everolimus + Exemestane + LY2835219'}, {'id': 2255, 'therapyName': 'Abemaciclib + Anastrozole'}, {'id': 2256, 'therapyName': 'Abemaciclib + Tamoxifen'}, {'id': 2259, 'therapyName': 'Abemaciclib + Trastuzumab'}]",A Study of LY2835219 in Combination With Hormone Therapies for Breast Cancer That Has Spread,2254
0,NCT03099174,Phase I,Recruiting,"[{'id': 5514, 'therapyName': 'Abemaciclib + Xentuzumab'}, {'id': 5515, 'therapyName': 'Abemaciclib + Letrozole + Xentuzumab'}, {'id': 5516, 'therapyName': 'Abemaciclib + Anastrozole + Xentuzumab'}, {'id': 5517, 'therapyName': 'Abemaciclib + Fulvestrant + Xentuzumab'}]",This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.,5515
0,NCT02747004,Phase II,Recruiting,"[{'id': 4387, 'therapyName': 'Abemaciclib + Loperamide'}, {'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 2256, 'therapyName': 'Abemaciclib + Tamoxifen'}]",A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer (nextMONARCH 1),4387
0,NCT02981342,Phase II,Recruiting,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 5175, 'therapyName': 'Abemaciclib + LY3023414'}, {'id': 5176, 'therapyName': 'Abemaciclib + Galunisertib'}]",A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma,5175
0,NCT02784795,Phase I,Recruiting,"[{'id': 4374, 'therapyName': 'Cisplatin + Gemcitabine + LY3039478'}, {'id': 4375, 'therapyName': 'Carboplatin + Gemcitabine + LY3039478'}, {'id': 4372, 'therapyName': 'LY3039478 + LY3023414'}, {'id': 4373, 'therapyName': 'Abemaciclib + LY3039478'}, {'id': 4371, 'therapyName': 'LY3039478 + Taladegib'}, {'id': 2958, 'therapyName': 'LY3039478'}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors,4373
0,NCT02779751,Phase II,Recruiting,"[{'id': 4242, 'therapyName': 'Abemaciclib + Pembrolizumab'}]",A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer,4242
0,NCT02745769,Phase I,Recruiting,"[{'id': 4208, 'therapyName': 'LY2801653 + Ramucirumab'}, {'id': 4209, 'therapyName': 'Abemaciclib + Ramucirumab'}]",A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents,4209
0,NCT02057133,Phase I,Recruiting,"[{'id': 2254, 'therapyName': 'Abemaciclib + Letrozole'}, {'id': 2257, 'therapyName': 'Abemaciclib + Exemestane'}, {'id': 2258, 'therapyName': 'Everolimus + Exemestane + LY2835219'}, {'id': 2255, 'therapyName': 'Abemaciclib + Anastrozole'}, {'id': 2256, 'therapyName': 'Abemaciclib + Tamoxifen'}, {'id': 2259, 'therapyName': 'Abemaciclib + Trastuzumab'}]",A Study of LY2835219 in Combination With Hormone Therapies for Breast Cancer That Has Spread,2256
1,NCT02747004,Phase II,Recruiting,"[{'id': 4387, 'therapyName': 'Abemaciclib + Loperamide'}, {'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 2256, 'therapyName': 'Abemaciclib + Tamoxifen'}]",A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer (nextMONARCH 1),2256
0,NCT02977780,Phase II,Recruiting,"[{'id': 1000, 'therapyName': 'CC-115'}, {'id': 5028, 'therapyName': 'Abemaciclib + Temozolomide'}, {'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 5029, 'therapyName': 'Neratinib + Temozolomide'}]",INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT),5028
0,NCT02057133,Phase I,Recruiting,"[{'id': 2254, 'therapyName': 'Abemaciclib + Letrozole'}, {'id': 2257, 'therapyName': 'Abemaciclib + Exemestane'}, {'id': 2258, 'therapyName': 'Everolimus + Exemestane + LY2835219'}, {'id': 2255, 'therapyName': 'Abemaciclib + Anastrozole'}, {'id': 2256, 'therapyName': 'Abemaciclib + Tamoxifen'}, {'id': 2259, 'therapyName': 'Abemaciclib + Trastuzumab'}]",A Study of LY2835219 in Combination With Hormone Therapies for Breast Cancer That Has Spread,2259
0,NCT03099174,Phase I,Recruiting,"[{'id': 5514, 'therapyName': 'Abemaciclib + Xentuzumab'}, {'id': 5515, 'therapyName': 'Abemaciclib + Letrozole + Xentuzumab'}, {'id': 5516, 'therapyName': 'Abemaciclib + Anastrozole + Xentuzumab'}, {'id': 5517, 'therapyName': 'Abemaciclib + Fulvestrant + Xentuzumab'}]",This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.,5514
0,NCT02254785,Phase II,Recruiting,"[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}]",Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer,1805
1,NCT01685125,Phase II,"Active, not recruiting","[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,1805
2,NCT02257736,Phase III,"Active, not recruiting","[{'id': 1948, 'therapyName': 'ARN-509 + Abiraterone'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC),1805
3,NCT02987543,Phase III,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",Study of Olaparib (Lynparza) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study),1805
4,NCT02034552,Phase II,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC),1805
5,NCT01576172,Phase II,"Active, not recruiting","[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 954, 'therapyName': 'Veliparib'}]",Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,1805
6,NCT01949337,Phase III,"Active, not recruiting","[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,1805
7,NCT02268175,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate,1805
8,NCT01848067,Phase Ib/II,"Active, not recruiting","[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 626, 'therapyName': 'Alisertib'}]","Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer",1805
9,NCT01717053,Phase II,"Active, not recruiting","[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 759, 'therapyName': 'Goserelin'}]","Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer",1805
10,NCT01485861,Phase II,"Active, not recruiting","[{'id': 750, 'therapyName': 'GDC-0980'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 747, 'therapyName': 'Ipatasertib'}]",Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy,1805
11,NCT01681433,Phase II,Terminated,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1807, 'therapyName': 'OGX-427'}]",OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone,1805
12,NCT01751451,Phase II,"Active, not recruiting","[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1814, 'therapyName': 'Degarelix'}]","3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy",1805
13,NCT02217566,Phase II,"Active, not recruiting","[{'id': 1805, 'therapyName': 'Abiraterone'}]","Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy",1805
14,NCT01972217,Phase II,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 837, 'therapyName': 'Olaparib'}]",Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer,1805
15,NCT03072238,Phase III,Recruiting,"[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 5438, 'therapyName': 'Abiraterone + Ipatasertib'}]","Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer",1805
16,NCT02403505,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1814, 'therapyName': 'Degarelix'}]",Discovery Stage Clinical Study About Oncology Drugs and Single Nucleotide Polymorphisms,1805
17,NCT01517802,Phase III,Recruiting,"[{'id': 1805, 'therapyName': 'Abiraterone'}]",A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate,1805
18,NCT02043678,Phase III,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}]","Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms",1805
19,NCT01786265,Phase II,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1814, 'therapyName': 'Degarelix'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone,1805
20,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1805
21,NCT01503229,Phase II,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,1805
22,NCT02353715,Phase I,Recruiting,"[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2648, 'therapyName': 'Sipuleucel-T'}]","Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge), Abiraterone Acetate (Zytiga) or Enzalutamide (Xtandi) Undergoing Cardiopulmonary EXercise Testing",1805
23,NCT01543776,Phase II,"Active, not recruiting","[{'id': 1805, 'therapyName': 'Abiraterone'}]",Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer,1805
24,NCT02025010,Phase II,"Active, not recruiting","[{'id': 1805, 'therapyName': 'Abiraterone'}]",Phase II Clinical Trial of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer With Correlative Assessment of Hormone Intermediates.,1805
25,NCT01553188,Phase II,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1218, 'therapyName': 'Trebananib'}]",AMG 386 and Abiraterone for Advanced Prostate Cancer,1805
26,NCT02379390,Phase II,Terminated,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}]",Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enz (PRIMCAB),1805
27,NCT01845792,Phase II,Completed,"[{'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer,1805
28,NCT01961843,Phase I,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",Abiraterone Acetate for Castrate Resistant Prostate Cancer,1805
29,NCT02415621,Phase I,Recruiting,"[{'id': 1805, 'therapyName': 'Abiraterone'}]",Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer,1805
30,NCT02125357,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",Sequencing Abiraterone and Enzalutamide in mCRPC,1805
31,NCT02090114,Phase II,Recruiting,"[{'id': 2591, 'therapyName': 'Andriol'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistant (The RESTORE Study),1805
0,NCT02849990,Phase II,Recruiting,"[{'id': 4510, 'therapyName': 'Abiraterone + ARN-509 + Degarelix + Indomethacin + Prednisone'}]","Androgen Receptor Antagonist ARN-509, Abiraterone Acetate, Prednisone, Degarelix, and Indomethacin in Treating Patients With Localized Prostate Cancer Before Surgery",4510
0,NCT03009981,Phase III,Recruiting,"[{'id': 5523, 'therapyName': 'Abiraterone + ARN-509 + Degarelix + Prednisone'}, {'id': 5524, 'therapyName': 'ARN-509 + Degarelix'}, {'id': 1814, 'therapyName': 'Degarelix'}]",A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer,5523
0,NCT02913196,Phase I,Recruiting,"[{'id': 4767, 'therapyName': 'Abiraterone + ARN-509 + Docetaxel + Prednisone'}]","Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC",4767
0,NCT03141671,Phase II,Not yet recruiting,"[{'id': 5742, 'therapyName': 'Bicalutamide + Gonadorelin'}, {'id': 5743, 'therapyName': 'Abiraterone + ARN-509 + Gonadorelin + Prednisone'}]",Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509),5743
0,NCT02772588,Phase II,Recruiting,"[{'id': 4206, 'therapyName': 'Abiraterone + ARN-509 + Leuprolide'}]",AASUR in High Risk Prostate Cancer,4206
1,NCT03298087,Phase II,Not yet recruiting,"[{'id': 4206, 'therapyName': 'Abiraterone + ARN-509 + Leuprolide'}]",Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer,4206
0,NCT02903368,Phase II,Recruiting,"[{'id': 3079, 'therapyName': 'Abiraterone + Leuprolide + Prednisone'}, {'id': 4758, 'therapyName': 'Abiraterone + ARN-509 + Leuprolide + Prednisone'}]",Neoadjuvant And Adjuvant Abiraterone Acetate + Aptilutamide Prostate Cancer Undergoing Prostatectomy,4758
0,NCT02703623,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}, {'id': 3844, 'therapyName': 'Cabazitaxel + Carboplatin'}]",A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer (DynaMO),2649
1,NCT02123758,Phase I,"Active, not recruiting","[{'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}]",A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer,2649
2,NCT02531516,Phase III,Recruiting,"[{'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",An Efficacy and Safety Study of JNJ-56021927 (ARN-509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy,2649
3,NCT03098836,Phase II,Recruiting,"[{'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}]",Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer,2649
4,NCT03279250,Phase II,Not yet recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1947, 'therapyName': 'ARN-509'}]",Effects of Apalutamide Plus LHRH Agonist or Apalutamide Plus Abiraterone Acetate Plus LHRH Agonist for Six Months for Prostate Cancer Patients at High Risk for Recurrence,2649
5,NCT02949284,Phase II,Recruiting,"[{'id': 1947, 'therapyName': 'ARN-509'}, {'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}]","Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery",2649
0,NCT01741753,Phase I,Terminated,"[{'id': 2499, 'therapyName': 'Abiraterone + BKM120 + Prednisone'}]",BKM120+Abiraterone Acetate for Metastatic CRPC,2499
0,NCT02903160,Phase II,Recruiting,"[{'id': 4759, 'therapyName': 'Abiraterone + Cabazitaxel + Carboplatin + Enzalutamide + Prednisone'}]","Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)",4759
0,NCT01254864,Phase II,"Active, not recruiting","[{'id': 1817, 'therapyName': 'Abiraterone + Sunitinib'}, {'id': 1818, 'therapyName': 'Abiraterone + Dasatinib\t'}]",Maximum Androgen Depletion,1818
0,NCT02758132,Phase I,Terminated,"[{'id': 4182, 'therapyName': 'Abiraterone + Denosumab + Enzalutamide + Prednisone'}, {'id': 4183, 'therapyName': 'Denosumab + Enzalutamide'}]","Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases",4182
0,NCT03150056,Phase I,Recruiting,"[{'id': 6034, 'therapyName': 'Abiraterone + GSK525762'}, {'id': 6035, 'therapyName': 'Enzalutamide + GSK525762'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer,6034
0,NCT03072238,Phase III,Recruiting,"[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 5438, 'therapyName': 'Abiraterone + Ipatasertib'}]","Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer",5438
0,NCT02543255,Phase II,Recruiting,"[{'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 3079, 'therapyName': 'Abiraterone + Leuprolide + Prednisone'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]",Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial),3079
1,NCT02903368,Phase II,Recruiting,"[{'id': 3079, 'therapyName': 'Abiraterone + Leuprolide + Prednisone'}, {'id': 4758, 'therapyName': 'Abiraterone + ARN-509 + Leuprolide + Prednisone'}]",Neoadjuvant And Adjuvant Abiraterone Acetate + Aptilutamide Prostate Cancer Undergoing Prostatectomy,3079
0,NCT02887976,Phase III,Not yet recruiting,"[{'id': 4678, 'therapyName': 'Abiraterone + Methylprednisolone'}]",Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201,4678
0,NCT01828476,Phase II,Terminated,"[{'id': 1316, 'therapyName': 'Hydroxychloroquine'}, {'id': 2597, 'therapyName': 'Abiraterone + Navitoclax'}]",Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer,2597
0,NCT02807805,Phase II,Recruiting,"[{'id': 4377, 'therapyName': 'Abiraterone + Niclosamide + Prednisone'}]","Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer",4377
0,NCT03012321,Phase II,Recruiting,"[{'id': 5226, 'therapyName': 'Abiraterone + Prednisone + Olaparib'}, {'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}, {'id': 837, 'therapyName': 'Olaparib'}]","Abiraterone Acetate, Olaparib, and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer With DNA Repair Defects",2748
1,NCT01715285,Phase III,"Active, not recruiting","[{'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}]","A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)",2748
2,NCT01688492,Phase Ib/II,"Active, not recruiting","[{'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-na&#239;ve Patients With Progressive Metastatic Castration-resistant Prostate Cancer,2748
3,NCT01940276,Phase II,"Active, not recruiting","[{'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}]",Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer,2748
4,NCT02218606,Phase II,Recruiting,"[{'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}]",Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer,2748
5,NCT02429193,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}]",Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA (BARRIER-P),2748
6,NCT03016741,FDA approved,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}]",Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer,2748
0,NCT03012321,Phase II,Recruiting,"[{'id': 5226, 'therapyName': 'Abiraterone + Prednisone + Olaparib'}, {'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}, {'id': 837, 'therapyName': 'Olaparib'}]","Abiraterone Acetate, Olaparib, and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer With DNA Repair Defects",5226
0,NCT01254864,Phase II,"Active, not recruiting","[{'id': 1817, 'therapyName': 'Abiraterone + Sunitinib'}, {'id': 1818, 'therapyName': 'Abiraterone + Dasatinib\t'}]",Maximum Androgen Depletion,1817
0,NCT02081378,Phase I,Recruiting,"[{'id': 2484, 'therapyName': 'ABL001'}, {'id': 829, 'therapyName': 'Nilotinib'}]","A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)",2484
1,NCT03106779,Phase III,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 2484, 'therapyName': 'ABL001'}]","Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs",2484
0,NCT02399137,Phase II,"Active, not recruiting","[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1073, 'therapyName': 'MM-141'}]",A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer,619
1,NCT02265510,Phase I,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2747, 'therapyName': 'INCB052793'}, {'id': 688, 'therapyName': 'Bortezomib'}]","An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies",619
2,NCT02331251,Phase Ib/II,"Active, not recruiting","[{'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 619, 'therapyName': 'Abraxane'}]",Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus),619
3,NCT02229149,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1105, 'therapyName': 'Capecitabine'}]","Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer",619
4,NCT01620190,Phase II,"Active, not recruiting","[{'id': 619, 'therapyName': 'Abraxane'}]",Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer,619
5,NCT02574078,Phase I,Recruiting,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2114, 'therapyName': 'Bevacizumab + Pemetrexed'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",A Master Protocol Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate 370),619
6,NCT01572038,Phase III,"Active, not recruiting","[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE),619
7,NCT01647828,Phase Ib/II,Completed,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2547, 'therapyName': 'Tarextumab'}]",A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer,619
8,NCT02999477,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 619, 'therapyName': 'Abraxane'}]",A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer,619
9,NCT02489903,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 3680, 'therapyName': 'RRx-001'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 619, 'therapyName': 'Abraxane'}]","RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens",619
10,NCT02073487,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1583, 'therapyName': 'Trastuzumab emtansine + Lapatinib'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 619, 'therapyName': 'Abraxane'}]",Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab With Lapatinib and Paclitaxel,619
11,NCT02138383,Phase I,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer,619
12,NCT02367794,Phase III,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC),619
13,NCT03136406,Phase Ib/II,Recruiting,"[{'id': 1018, 'therapyName': 'GI-4000'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 6163, 'therapyName': 'ETBX-011'}, {'id': 3060, 'therapyName': 'ALT-803'}]",QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy,619
14,NCT02020707,Phase I,Suspended,"[{'id': 619, 'therapyName': 'Abraxane'}]",Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery,619
15,NCT02227940,Phase I,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 2554, 'therapyName': 'Ceritinib + Gemcitabine'}]",Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer,619
16,NCT02819518,Phase III,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355),619
17,NCT02250326,Phase II,"Active, not recruiting","[{'id': 1950, 'therapyName': 'Abraxane + Azacitidine'}, {'id': 619, 'therapyName': 'Abraxane'}]",Safety and Efficacy Study of Nab-Paclitaxel With CC-486 and Nab-Paclitaxel Monotherapy as Second Line Treatment for Advanced Nonsquamous Non-small Cell Lung Cancer,619
18,NCT03181100,Phase II,Recruiting,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}, {'id': 3049, 'therapyName': 'Atezolizumab + nab-paclitaxel'}, {'id': 4825, 'therapyName': 'Atezolizumab + Vemurafenib + Cobimetinib'}, {'id': 5606, 'therapyName': 'Atezolizumab + Paclitaxel'}]",Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas,619
19,NCT02048943,Phase I,Withdrawn,"[{'id': 1372, 'therapyName': 'Dovitinib + Gemcitabine + Abraxane'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 721, 'therapyName': 'Dovitinib'}]","Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer",619
20,NCT02425891,Phase III,"Active, not recruiting","[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of MPDL3280A in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Patients With Previously Untreated Metastatic Triple Negative Breast Cancer,619
21,NCT01858883,Phase I,Completed,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2406, 'therapyName': 'INCB039110'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Safety Study of INCB039110 in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors,619
22,NCT02565758,Phase I,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 3846, 'therapyName': 'ABBV-085'}]","ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors",619
23,NCT02788981,Phase II,Recruiting,"[{'id': 4350, 'therapyName': 'Mifepristone + Nab-paclitaxel'}, {'id': 619, 'therapyName': 'Abraxane'}]","A Trial of Nanoparticle Albumin-Bound Paclitaxel (Nab-Paclitaxel, Abraxane) With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer",619
24,NCT03197935,Phase III,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer (IMpassion031),619
25,NCT02503358,Phase I,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}, {'id': 619, 'therapyName': 'Abraxane'}]",Selumetinib and Nab-Paclitaxel (Albumin-stabilized Nanoparticle Formulation) as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer,619
26,NCT02009449,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2621, 'therapyName': 'AM0010 '}, {'id': 619, 'therapyName': 'Abraxane'}]",A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors,619
0,NCT01113476,Phase I,Recruiting,"[{'id': 1144, 'therapyName': 'Abraxane + Avastin + Gemcitabine'}]","Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies",1144
0,NCT02250326,Phase II,"Active, not recruiting","[{'id': 1950, 'therapyName': 'Abraxane + Azacitidine'}, {'id': 619, 'therapyName': 'Abraxane'}]",Safety and Efficacy Study of Nab-Paclitaxel With CC-486 and Nab-Paclitaxel Monotherapy as Second Line Treatment for Advanced Nonsquamous Non-small Cell Lung Cancer,1950
0,NCT00733408,Phase II,"Active, not recruiting","[{'id': 1496, 'therapyName': 'Abraxane + Bevacizumab + Erlotinib'}]",Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer,1496
0,NCT01412229,Phase II,"Active, not recruiting","[{'id': 1957, 'therapyName': 'Abraxane + Carboplatin + Cetuximab'}]",Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck,1957
1,NCT02270814,Phase II,Recruiting,"[{'id': 1957, 'therapyName': 'Abraxane + Carboplatin + Cetuximab'}, {'id': 1956, 'therapyName': 'Abraxane + Cisplatin + Cetuximab'}]","Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma",1957
0,NCT02270814,Phase II,Recruiting,"[{'id': 1957, 'therapyName': 'Abraxane + Carboplatin + Cetuximab'}, {'id': 1956, 'therapyName': 'Abraxane + Cisplatin + Cetuximab'}]","Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma",1956
0,NCT02336087,Phase I,Recruiting,"[{'id': 2204, 'therapyName': 'Abraxane + Gemcitabine + Metformin'}]","Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Metastatic Pancreatic Cancer",2204
0,NCT02349867,Phase I,Recruiting,"[{'id': 2429, 'therapyName': 'Abraxane + Gemcitabine + Sorafenib + Vorinostat'}]","Gemcitabine Hydrochloride, Nab-Paclitaxel, Radiation Therapy, Sorafenib Tosylate,Vorinostat in Treating Previously Untreated Pancreatic Cancer Patients",2429
0,NCT02379416,Phase I,Recruiting,"[{'id': 2490, 'therapyName': 'Abraxane + Nilotinib'}]",Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors,2490
0,NCT02309177,Phase I,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2489, 'therapyName': 'Abraxane + Nivolumab'}]","Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer",2489
0,NCT02317991,Phase II,Recruiting,"[{'id': 2039, 'therapyName': 'Abraxane + Ramucirumab'}]",Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer,2039
1,NCT02730247,Phase II,Recruiting,"[{'id': 2039, 'therapyName': 'Abraxane + Ramucirumab'}]",Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC),2039
0,NCT02065466,Phase Ib/II,Withdrawn,"[{'id': 1380, 'therapyName': 'Abraxane + Temozolomide + Bevacizumab'}]","Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases",1380
0,NCT02540876,Phase I,Recruiting,"[{'id': 975, 'therapyName': 'ABT-348'}]",Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery,975
1,NCT02478320,Phase II,Recruiting,"[{'id': 975, 'therapyName': 'ABT-348'}]",Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors,975
0,NCT02573324,Phase II,Recruiting,"[{'id': 976, 'therapyName': 'ABT-414'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification,976
1,NCT02343406,Phase II,Recruiting,"[{'id': 2075, 'therapyName': 'Lomustine'}, {'id': 976, 'therapyName': 'ABT-414'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma,976
2,NCT01741727,Phase II,Completed,"[{'id': 976, 'therapyName': 'ABT-414'}]",A Study of ABT-414 in Subjects With Solid Tumors,976
3,NCT01800695,Phase I,Completed,"[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 976, 'therapyName': 'ABT-414'}]",Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme,976
0,NCT01472016,Phase I,Completed,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1063, 'therapyName': 'ABT-700'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",Study of ABT-700 in Subjects With Advanced Solid Tumors,1063
0,NCT02448251,Phase Ib/II,Recruiting,"[{'id': 2909, 'therapyName': 'AC0010MA'}]","Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer",2909
0,NCT02448303,Phase II,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab Alone and In Combination With ACP-196 in Subjects With Advanced Non-small Cell Lung Cancer,1605
1,NCT02351739,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1605, 'therapyName': 'Acalabrutinib'}]",Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum-refractory Metastatic Bladder Cancer,1605
2,NCT02570711,Phase II,Terminated,"[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",Study of Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Previously Untreated Metastatic Pancreatic Cancer,1605
3,NCT02586857,Phase Ib/II,Recruiting,"[{'id': 1605, 'therapyName': 'Acalabrutinib'}]","A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)",1605
4,NCT02328014,Phase Ib/II,Recruiting,"[{'id': 3265, 'therapyName': 'ACP-319'}, {'id': 1605, 'therapyName': 'Acalabrutinib'}]","ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies",1605
5,NCT02029443,Phase Ib/II,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}]","ACP-196, a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia",1605
6,NCT02180711,Phase I,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}]","An Open-label, Phase 1b Study of ACP 196 in Subjects With Follicular Lymphoma",1605
7,NCT02537444,Phase II,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer (KEYNOTE191),1605
8,NCT02362035,Phase Ib/II,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]","ACP-196 in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (KEYNOTE145)",1605
9,NCT02213926,Phase II,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}]","An Open-label, Phase 2 Study of ACP 196 in Subjects With Mantle Cell Lymphoma",1605
10,NCT02970318,Phase III,Recruiting,"[{'id': 2324, 'therapyName': 'Bendamustine + Idelalisib + Rituximab'}, {'id': 1605, 'therapyName': 'Acalabrutinib'}]",A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL,1605
11,NCT02211014,Phase I,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]","An Open-Label, Phase 1b Study of ACP-196 With and Without Dexamethasone in Subjects With Multiple Myeloma",1605
12,NCT02337829,Phase II,Recruiting,"[{'id': 1605, 'therapyName': 'Acalabrutinib'}]",ACP-196 in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL,1605
13,NCT02717611,Phase II,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}]",A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy,1605
14,NCT02475681,Phase III,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]","Elevate CLL TN: Study of Obinutuzumab + Chlorambucil, ACP-196 + Obinutuzumab, and ACP-196 in Subjects With Previously Untreated CLL",1605
15,NCT02477696,Phase III,Recruiting,"[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",Elevate CLL R/R: Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia,1605
16,NCT02180724,Phase I,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}]","An Open-label, Phase 1b Study of ACP 196 in Subjects With Waldenström Macroglobulinemia",1605
17,NCT02362048,Phase II,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer,1605
18,NCT02454179,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1605, 'therapyName': 'Acalabrutinib'}]",Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Head and Neck Squamous Cell Carcinoma,1605
0,NCT02717624,Phase I,"Active, not recruiting","[{'id': 3996, 'therapyName': 'Acalabrutinib + Bendamustine + Rituximab'}]",A Study of ACP-196 in Combination With Bendamustine and Rituximab in Subjects With Mantle Cell Lymphoma,3996
1,NCT02972840,Phase III,Recruiting,"[{'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 3996, 'therapyName': 'Acalabrutinib + Bendamustine + Rituximab'}]",A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma,3996
0,NCT02296918,Phase I,"Active, not recruiting","[{'id': 3477, 'therapyName': 'Acalabrutinib + Obinutuzumab'}]",ACP-196 in Combination With Obinutuzumab in Relapsed/Refractory or Untreated CLL/SLL/PLL,3477
0,NCT03205046,Phase Ib/II,Recruiting,"[{'id': 6188, 'therapyName': 'Acalabrutinib + Vistusertib'}]",A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies,6188
0,NCT02648490,Phase I,Recruiting,"[{'id': 3939, 'therapyName': 'Acetaminophen + Dexamethasone + Diphenhydramine + Ondansetron'}, {'id': 3938, 'therapyName': 'HLX07'}]","An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers",3939
0,NCT02328014,Phase Ib/II,Recruiting,"[{'id': 3265, 'therapyName': 'ACP-319'}, {'id': 1605, 'therapyName': 'Acalabrutinib'}]","ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies",3265
0,NCT02091063,Phase Ib/II,Recruiting,"[{'id': 1613, 'therapyName': 'ACY-1215'}]",ACY-1215 for Relapsed/Refractory Lymphoid Malignancies,1613
1,NCT01323751,Phase Ib/II,Completed,"[{'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}, {'id': 1613, 'therapyName': 'ACY-1215'}]",Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma,1613
0,NCT02856568,Phase I,Withdrawn,"[{'id': 4526, 'therapyName': 'ACY-1215 + Cisplatin + Gemcitabine'}]","Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma",4526
0,NCT02787369,Phase I,"Active, not recruiting","[{'id': 4273, 'therapyName': 'ACY-1215 + Idelalisib '}, {'id': 4272, 'therapyName': 'ACY-1215 + Ibrutinib'}]",ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL,4272
0,NCT02787369,Phase I,"Active, not recruiting","[{'id': 4273, 'therapyName': 'ACY-1215 + Idelalisib '}, {'id': 4272, 'therapyName': 'ACY-1215 + Ibrutinib'}]",ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL,4273
0,NCT02632071,Phase I,Recruiting,"[{'id': 3313, 'therapyName': 'ACY-1215 + nab-paclitaxel'}]",Phase I of ACY-1215 + Nab-paclitaxel in Breast Cancer,3313
0,NCT02661815,Phase I,"Active, not recruiting","[{'id': 3469, 'therapyName': 'ACY-1215 + Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer",3469
0,NCT02189343,Phase I,"Active, not recruiting","[{'id': 1614, 'therapyName': 'ACY-1215 + Pomalidomide + Dexamethasone'}]",Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed-and-Refractory Multiple Myeloma,1614
1,NCT01997840,Phase Ib/II,"Active, not recruiting","[{'id': 1614, 'therapyName': 'ACY-1215 + Pomalidomide + Dexamethasone'}]",ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma,1614
0,NCT02935790,Phase I,Completed,"[{'id': 3312, 'therapyName': 'ACY-241 + Ipilimumab + Nivolumab'}]",Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab,3312
1,NCT02635061,Phase I,Recruiting,"[{'id': 3312, 'therapyName': 'ACY-241 + Ipilimumab + Nivolumab'}]",Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer,3312
0,NCT03050814,Phase II,Suspended,"[{'id': 1524, 'therapyName': 'Fluorouracil + Bevacizumab + Capecitabine + Leucovorin + Oxaliplatin'}, {'id': 5336, 'therapyName': 'Ad-CEA + Bevacizumab + FOLFOX'}]",Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer,5336
0,NCT02423902,Phase Ib/II,"Active, not recruiting","[{'id': 4250, 'therapyName': 'Ad-RTS-IL-12 plus AL'}]",A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer,4250
0,NCT03281382,Phase I,Recruiting,"[{'id': 6283, 'therapyName': 'Ad5-yCD/mutTKSR39rep-hIL12 '}]",Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic Cancer,6283
0,NCT02842125,Phase I,Recruiting,"[{'id': 5879, 'therapyName': 'Ad5CMV-p53 gene + Capecitabine'}]",Safety and Efficacy of Intra-Arterial Ad-p53 in Liver Metastases of Solid Tumors,5879
0,NCT03125200,Phase I,Recruiting,"[{'id': 5689, 'therapyName': 'ADCT-502'}]",Study of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression,5689
0,NCT01825603,Phase I,Recruiting,"[{'id': 4952, 'therapyName': 'ADH-1 + Cisplatin + Gemcitabine'}]","ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed By Surgery",4952
0,NCT02101593,Phase I,Completed,"[{'id': 2424, 'therapyName': 'ADI-PEG 20'}]",Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer,2424
0,NCT02831933,Phase II,Recruiting,"[{'id': 4462, 'therapyName': 'AdV-tk + Nivolumab'}]",Trial of Stereotactic Body Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma (ENSIGN),4462
0,NCT02768363,Phase II,Recruiting,"[{'id': 5172, 'therapyName': 'AdV-tk + Valacyclovir'}, {'id': 5171, 'therapyName': 'Valacyclovir'}]",Randomized Controlled Trial of ProstAtak Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES),5172
1,NCT03131037,Phase I,Recruiting,"[{'id': 5172, 'therapyName': 'AdV-tk + Valacyclovir'}]",Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer,5172
2,NCT03004183,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 5172, 'therapyName': 'AdV-tk + Valacyclovir'}]",SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC,5172
3,NCT01436968,Phase III,Recruiting,"[{'id': 5171, 'therapyName': 'Valacyclovir'}, {'id': 5172, 'therapyName': 'AdV-tk + Valacyclovir'}]",Phase 3 Study of ProstAtak Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer,5172
0,NCT02002182,Phase II,Recruiting,"[{'id': 3090, 'therapyName': 'ADXS11-001'}]","ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer",3090
1,NCT02399813,Phase Ib/II,"Active, not recruiting","[{'id': 3090, 'therapyName': 'ADXS11-001'}]",Phase 2 Study of ADXS11-001 in Subjects With Anal Cancer or Cancer of the Rectum,3090
2,NCT02291055,Phase Ib/II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3090, 'therapyName': 'ADXS11-001'}]",Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head &amp; Neck Cancer,3090
3,NCT02853604,Phase III,Recruiting,"[{'id': 3090, 'therapyName': 'ADXS11-001'}]",Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer (AIM2CERV),3090
4,NCT02164461,Phase Ib/II,"Active, not recruiting","[{'id': 3090, 'therapyName': 'ADXS11-001'}]",ADXS11-001 High Dose HPV+ Cervical Cancer,3090
0,NCT02325557,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3050, 'therapyName': 'ADXS31-142 '}]",ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046,3050
0,NCT02386501,,Recruiting,"[{'id': 4654, 'therapyName': 'ADXS31-164'}]",Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors,4654
0,NCT01430416,Phase I,"Active, not recruiting","[{'id': 621, 'therapyName': 'AEB071'}]",Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients,621
1,NCT02285244,Phase II,Withdrawn,"[{'id': 621, 'therapyName': 'AEB071'}]","Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation",621
0,NCT02273219,Phase I,Recruiting,"[{'id': 1861, 'therapyName': 'AEB071 + BYL719'}]",Trial of AEB071 in Combination With BYL719 in Patients With Melanoma,1861
0,NCT01854606,Phase Ib/II,Completed,"[{'id': 1951, 'therapyName': 'AEB071 + Everolimus'}]",Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma,1951
0,NCT02514174,FDA approved,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}]",Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older,623
1,NCT02122172,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}]",Afatinib in Advanced Refractory Urothelial Cancer,623
2,NCT01746251,Phase II,"Active, not recruiting","[{'id': 623, 'therapyName': 'Afatinib'}]",Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation,623
3,NCT01824823,Phase II,Terminated,"[{'id': 623, 'therapyName': 'Afatinib'}]",Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence,623
4,NCT02423525,Phase I,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}]",Safety Study of Afatinib for Brain Cancer,623
5,NCT02491099,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}]",A Phase II Evaluation of Afatinib,623
6,NCT01649284,Phase I,Approved for marketing,"[{'id': 623, 'therapyName': 'Afatinib'}]",Afatinib Expanded Access Program,623
7,NCT01553942,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Afatinib With CT and RT for EGFR-Mutant NSCLC,623
8,NCT02451553,Phase I,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]","Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer",623
9,NCT02438722,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 694, 'therapyName': 'Cetuximab'}]","S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer",623
10,NCT02795156,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations,623
11,NCT02115048,Phase II,"Active, not recruiting","[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 794, 'therapyName': 'Letrozole'}]",Clinical Study for the Treatment of Breast Cancer the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone,623
12,NCT02541903,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}]",Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma,623
13,NCT01647711,Phase I,Completed,"[{'id': 623, 'therapyName': 'Afatinib'}]","A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations",623
14,NCT02271906,Phase II,Terminated,"[{'id': 623, 'therapyName': 'Afatinib'}]",The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting,623
15,NCT02465060,Phase II,Recruiting,"[{'id': 660, 'therapyName': 'AZD9291'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 958, 'therapyName': 'VS-6063'}, {'id': 765, 'therapyName': 'GSK2636771'}]",NCI-MATCH Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,623
16,NCT02506517,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}]",A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene,623
17,NCT02695290,Phase III,Terminated,"[{'id': 623, 'therapyName': 'Afatinib'}]",Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3),623
18,NCT01345669,Phase III,Terminated,"[{'id': 623, 'therapyName': 'Afatinib'}]",LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy,623
19,NCT01783587,Phase I,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer,623
20,NCT02372006,Phase I,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}]",Phase I Trial of Afatinib in Pediatric Tumours,623
21,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,623
0,NCT01732640,Phase Ib/II,Completed,"[{'id': 2442, 'therapyName': 'Afatinib + Carboplatin + Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.,2442
0,NCT02979977,Phase II,Recruiting,"[{'id': 4190, 'therapyName': 'Afatinib + Cetuximab'}]",Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Recurrent or Metastatic Squamous Cell Cancers of the Head and Neck,4190
0,NCT01814553,Phase III,Completed,"[{'id': 1374, 'therapyName': 'Afatinib + Loperamide'}]", ADAM-Afatinib Diarrhea Assessment and Management,1374
0,NCT03054038,Phase I,Recruiting,"[{'id': 5363, 'therapyName': 'Afatinib + Necitumumab'}]",Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer,5363
0,NCT02274012,Phase II,Withdrawn,"[{'id': 2441, 'therapyName': 'Afatinib + Paclitaxel'}]","Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment of HER2 Amplified Advanced Gastric, Gastroesophageal Junction and Esophageal Cancer",2441
0,NCT02364609,Phase I,Recruiting,"[{'id': 2435, 'therapyName': 'Afatinib + Pembrolizumab'}]",Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib,2435
1,NCT03157089,Phase II,Not yet recruiting,"[{'id': 2435, 'therapyName': 'Afatinib + Pembrolizumab'}]",Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung (LUX-Lung IO),2435
0,NCT01522768,Phase II,Recruiting,"[{'id': 1106, 'therapyName': 'Afatinib + Trastuzumab'}]", Afatinib (BIBW 2992) and Trastuzumab in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer,1106
0,NCT02993159,Phase II,Recruiting,"[{'id': 5132, 'therapyName': 'Afimoxifene'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]",Tamoxifen Citrate or Afimoxifene in Treating Patients With Estrogen Receptor Positive Breast Cancer,5132
0,NCT02101918,Phase II,"Active, not recruiting","[{'id': 624, 'therapyName': 'Aflibercept'}]",Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery,624
1,NCT02235324,Phase II,Withdrawn,"[{'id': 1841, 'therapyName': 'Aflibercept + Leucovorin + Fluorouracil'}, {'id': 624, 'therapyName': 'Aflibercept'}]","Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer",624
2,NCT01747551,Phase II,"Active, not recruiting","[{'id': 624, 'therapyName': 'Aflibercept'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer,624
3,NCT01669720,Phase II,Terminated,"[{'id': 624, 'therapyName': 'Aflibercept'}]",Adjuvant Aflibercept for Metastatic Colorectal Cancer,624
4,NCT02046538,Phase II,Withdrawn,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 624, 'therapyName': 'Aflibercept'}]",Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer,624
5,NCT01258855,Phase II,"Active, not recruiting","[{'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 624, 'therapyName': 'Aflibercept'}]",Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,624
0,NCT01661972,Phase Ib/II,Completed,"[{'id': 2368, 'therapyName': 'Aflibercept + Capecitabine'}]",Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer,2368
0,NCT01571284,Phase III,Completed,"[{'id': 2095, 'therapyName': 'Aflibercept + FOLFIRI'}]",Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen,2095
1,NCT02045030,Phase II,Terminated,"[{'id': 2095, 'therapyName': 'Aflibercept + FOLFIRI'}]",Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer,2095
0,NCT02235324,Phase II,Withdrawn,"[{'id': 1841, 'therapyName': 'Aflibercept + Leucovorin + Fluorouracil'}, {'id': 624, 'therapyName': 'Aflibercept'}]","Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer",1841
0,NCT01652196,Phase II,"Active, not recruiting","[{'id': 2367, 'therapyName': 'Aflibercept + mFOLFOX-6'}]",Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer,2367
0,NCT02159989,Phase I,Recruiting,"[{'id': 1595, 'therapyName': 'Aflibercept + MLN0128'}]",MLN0128 and Ziv-Aflibercept in Treating Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery,1595
0,NCT02298959,Phase I,Recruiting,"[{'id': 2369, 'therapyName': 'Aflibercept + Pembrolizumab'}]",Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors,2369
0,NCT03192202,Phase Ib/II,Recruiting,"[{'id': 4389, 'therapyName': 'AFM13'}]",AFM13 in Relapsed/Refractory Cutaneous Lymphomas,4389
0,NCT02665650,Phase I,Recruiting,"[{'id': 4390, 'therapyName': 'AFM13 + Pembrolizumab'}]",Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma,4390
0,NCT01531894,Phase II,"Active, not recruiting","[{'id': 625, 'therapyName': 'Afuresertib'}]",Continuation Study of the Oral AKT Inhibitor GSK2110183,625
1,NCT01428492,Phase I,Completed,"[{'id': 625, 'therapyName': 'Afuresertib'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma,625
0,NCT02235740,Phase I,Terminated,"[{'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1839, 'therapyName': 'Afuresertib + Carfilzomib'}]","A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)",1839
0,NCT02074839,Phase I,"Active, not recruiting","[{'id': 1491, 'therapyName': 'AG-120'}]",Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation,1491
1,NCT02989857,Phase III,Recruiting,"[{'id': 1491, 'therapyName': 'AG-120'}]",Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy),1491
2,NCT02632708,Phase I,Recruiting,"[{'id': 1491, 'therapyName': 'AG-120'}, {'id': 2982, 'therapyName': 'Enasidenib'}, {'id': 3431, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide + Mitoxantrone'}]",Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation,1491
3,NCT02073994,Phase I,"Active, not recruiting","[{'id': 1491, 'therapyName': 'AG-120'}]","Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation",1491
4,NCT03173248,Phase III,Recruiting,"[{'id': 4002, 'therapyName': 'AG-120 + Azacitidine'}, {'id': 1491, 'therapyName': 'AG-120'}]",Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Patients With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation (AGILE),1491
0,NCT02677922,Phase Ib/II,Recruiting,"[{'id': 4002, 'therapyName': 'AG-120 + Azacitidine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 4003, 'therapyName': 'Azacitidine + Enasidenib'}]",A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML),4002
1,NCT03173248,Phase III,Recruiting,"[{'id': 4002, 'therapyName': 'AG-120 + Azacitidine'}, {'id': 1491, 'therapyName': 'AG-120'}]",Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Patients With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation (AGILE),4002
0,NCT02492737,Phase I,"Active, not recruiting","[{'id': 2995, 'therapyName': 'AG-881'}]",Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation,2995
1,NCT02481154,Phase I,Recruiting,"[{'id': 2995, 'therapyName': 'AG-881'}]","Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation",2995
0,NCT02694822,Phase I,Recruiting,"[{'id': 5695, 'therapyName': 'AGEN1884'}]","AGEN-1884, an Anti-CTLA-4 Antibody, in Advanced Solid Cancers",5695
0,NCT03104699,Phase Ib/II,Recruiting,"[{'id': 5693, 'therapyName': 'AGEN2034'}]",Phase 1 / 2 Study of AGEN2034 in Advanced Tumors and Cervical Cancer,5693
0,NCT02170389,Phase I,Withdrawn,"[{'id': 4075, 'therapyName': 'AGS-003'}]",Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer,4075
0,NCT02639182,Phase II,Recruiting,"[{'id': 4220, 'therapyName': 'AGS-16C3F'}, {'id': 649, 'therapyName': 'Axitinib'}]",A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma,4220
0,NCT03092934,Phase Ib/II,Recruiting,"[{'id': 5753, 'therapyName': 'AK-01'}]",A Study of AK-01 in Solid Tumors,5753
0,NCT01465802,Phase II,Completed,"[{'id': 714, 'therapyName': 'Dacomitinib'}, {'id': 1392, 'therapyName': 'Alclometasone'}, {'id': 1391, 'therapyName': 'Doxycycline'}]",Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO,1392
0,NCT01258855,Phase II,"Active, not recruiting","[{'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 624, 'therapyName': 'Aflibercept'}]",Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,1167
1,NCT02027935,Phase II,Recruiting,"[{'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4,1167
2,NCT01640301,Phase Ib/II,Suspended,"[{'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 2901, 'therapyName': 'WT1 senstized T cells'}]","Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant",1167
3,NCT01409174,Phase Ib/II,Terminated,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1299, 'therapyName': 'Interferon alfa-2b '}]",IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma,1167
4,NCT01038778,Phase Ib/II,"Active, not recruiting","[{'id': 1541, 'therapyName': 'Entinostat'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer,1167
5,NCT03224871,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC.,1167
6,NCT01174121,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer,1167
7,NCT01701674,Phase I,"Active, not recruiting","[{'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts,1167
8,NCT02118285,Phase I,Completed,"[{'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 2575, 'therapyName': 'Epacadostat'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}]","Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer",1167
9,NCT01857934,Phase II,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 2627, 'therapyName': 'Levetiracetam'}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 2458, 'therapyName': 'Hu14.18K322A'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}]",Therapy for Children With Advanced Stage Neuroblastoma,1167
10,NCT00338377,Phase II,Recruiting,"[{'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization,1167
11,NCT02620865,Phase Ib/II,Suspended,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}]",Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer,1167
12,NCT02796352,Phase II,Terminated,"[{'id': 1167, 'therapyName': 'Aldesleukin'}]",A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study,1167
13,NCT03190941,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 6061, 'therapyName': 'anti-KRAS G12V mTCR cells'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*1101 Patients,1167
14,NCT01218867,Phase Ib/II,Completed,"[{'id': 984, 'therapyName': 'Anti-VEGFR2 CAR CD8 lymphocytes'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes,1167
15,NCT01593670,Phase II,Terminated,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes,1167
16,NCT01993719,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Immunotherapy Using Tumor Infiltrating Lymphocytes Comparing 2 Different Conditioning Regimens for Patients With Metastatic Melanoma,1167
17,NCT02621021,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab,1167
18,NCT03056599,,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1733, 'therapyName': 'interferon gamma '}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 3420, 'therapyName': 'trabectedin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma,1167
19,NCT03126916,Phase III,Not yet recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 5595, 'therapyName': 'Isotretinoin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 2286, 'therapyName': 'Dinutuximab  '}]",Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma,1167
20,NCT03240861,Phase I,Not yet recruiting,"[{'id': 6116, 'therapyName': 'Busulfan + Fludarabine'}, {'id': 3933, 'therapyName': 'Filgrastim + Plerixafor'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer (NYESO SCT),1167
0,NCT00301990,Phase II,Unknown status,"[{'id': 2098, 'therapyName': 'Aldesleukin + Bevacizumab'}]",Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer,2098
0,NCT02070406,Phase I,Recruiting,"[{'id': 3409, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine '}, {'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}]","Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies",3409
1,NCT02775292,Phase I,Recruiting,"[{'id': 3409, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine '}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}]","Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1",3409
2,NCT02652455,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 3409, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine '}, {'id': 2055, 'therapyName': 'Urelumab'}]","Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma",3409
3,NCT01898793,Phase Ib/II,Recruiting,"[{'id': 3409, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine '}, {'id': 5300, 'therapyName': 'ALT-803 + Cyclophosphamide + Fludarabine phosphate'}]",Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS),3409
0,NCT02500576,Phase II,Recruiting,"[{'id': 5683, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine + Mesna + Pembrolizumab'}]","MK-3475 With Lymphodepletion, TIL and High or Low Dose Interleukin-2 (IL-2)",5683
0,NCT02858310,Phase I,Recruiting,"[{'id': 4562, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine + Pembrolizumab'}]",E7 TCR T Cells With or Without PD-1 Blockade for Human Papillomavirus-Associated Cancers,4562
0,NCT03068624,Phase I,Recruiting,"[{'id': 5733, 'therapyName': 'Aldesleukin + Cyclophosphamide + Ipilimumab'}]",Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4 for Patients With Metastatic Uveal Melanoma,5733
0,NCT02757391,Phase I,Not yet recruiting,"[{'id': 4193, 'therapyName': 'Aldesleukin + Cyclophosphamide + Pembrolizumab'}]",T Cell Immunotherapy Plus Anti-PD1 Antibody in Advanced Solid Malignancies,4193
0,NCT02173093,Phase Ib/II,Recruiting,"[{'id': 2058, 'therapyName': 'Aldesleukin + GD2Bi-a ATC + Sargramostim '}]",Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma,2058
0,NCT02203604,Phase II,"Active, not recruiting","[{'id': 1612, 'therapyName': 'Aldesleukin + Ipilimumab'}]",High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery,1612
0,NCT02130869,Phase I,Recruiting,"[{'id': 2378, 'therapyName': 'Bendamustine + Cytarabine + Etoposide'}, {'id': 2460, 'therapyName': 'Busulfan + Hu14.18K322A'}, {'id': 2459, 'therapyName': 'Aldesleukin + Melphalan + Sargramostim'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas,2459
0,NCT02989714,Phase Ib/II,Recruiting,"[{'id': 5139, 'therapyName': 'Aldesleukin + Nivolumab'}]","Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer",5139
0,NCT02964078,Phase II,Recruiting,"[{'id': 4165, 'therapyName': 'Aldesleukin + Pembrolizumab'}]",Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer,4165
1,NCT03111901,Phase Ib/II,Not yet recruiting,"[{'id': 4165, 'therapyName': 'Aldesleukin + Pembrolizumab'}]",Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer,4165
2,NCT02748564,Phase II,Recruiting,"[{'id': 4165, 'therapyName': 'Aldesleukin + Pembrolizumab'}]",Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma,4165
3,NCT03260504,Phase I,Not yet recruiting,"[{'id': 4165, 'therapyName': 'Aldesleukin + Pembrolizumab'}]",Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer,4165
0,NCT01754376,Phase II,Terminated,"[{'id': 1229, 'therapyName': 'Aldesleukin + Vemurafenib'}]",Combined BRAF-Targeted Therapy and Immunotherapy for Melanoma,1229
1,NCT01683188,Phase III,Terminated,"[{'id': 1229, 'therapyName': 'Aldesleukin + Vemurafenib'}]", HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma,1229
0,NCT01603212,Phase Ib/II,Completed,"[{'id': 1188, 'therapyName': 'Aldesleukin + Vemurafenib + IFN A2b'}]"," Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor",1188
0,NCT02049905,Phase III,Completed,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1440, 'therapyName': 'Aldoxorubicin'}, {'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}]",Phase 3 Study to Treat Patients With Soft Tissue Sarcomas,1440
1,NCT02200757,Phase II,Recruiting,"[{'id': 1440, 'therapyName': 'Aldoxorubicin'}, {'id': 942, 'therapyName': 'Topotecan'}]",Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer,1440
0,NCT01849783,Phase II,Recruiting,"[{'id': 1852, 'therapyName': 'Melphalan + Bortezomib + Thalidomide + Dexamethasone'}, {'id': 3435, 'therapyName': 'Aldoxorubicin + Cisplatin + Cyclophosphamide + Dexamethasone + Etoposide'}]",Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma,3435
0,NCT02177695,Phase II,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2564, 'therapyName': 'Aldoxorubicin + Cisplatin + Filgrastim + Methotrexate + Vinblastine'}]","S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer",2564
0,NCT02412670,Phase II,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2668, 'therapyName': 'Aldoxorubicin + Cisplatin + Methotrexate + Vincristine'}]",Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer,2668
0,NCT00740805,Phase I,"Active, not recruiting","[{'id': 2989, 'therapyName': 'Aldoxorubicin + Cyclophosphamide + Veliparib'}]","Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma",2989
0,NCT02560051,Phase II,Recruiting,"[{'id': 1814, 'therapyName': 'Degarelix'}, {'id': 3087, 'therapyName': 'Aldoxorubicin + Docetaxel + Estramustine + Ketoconazole'}]",Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,3087
0,NCT02261805,Phase Ib/II,Terminated,"[{'id': 3052, 'therapyName': 'Aldoxorubicin + Ganetespib'}]",A Phase I/II Study of Ganetespib in Combination With Doxorubicin,3052
0,NCT02431559,Phase Ib/II,Recruiting,"[{'id': 3101, 'therapyName': 'Aldoxorubicin + MEDI4736 + Motolimod'}]","A Phase 1/2 Study of Motolimod (VTX-2337) and MEDI4736 in Subjects With Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin (PLD) is Indicated",3101
0,NCT02626455,Phase III,Recruiting,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 3388, 'therapyName': 'Aldoxorubicin +Cyclophosphamide + Prednisone + Rituximab + Vincristine'}, {'id': 995, 'therapyName': 'Copanlisib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL),3388
0,NCT02075840,Phase III,"Active, not recruiting","[{'id': 698, 'therapyName': 'Alectinib'}, {'id': 706, 'therapyName': 'Crizotinib'}]","ALEX Study: A Randomized, Phase III Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Patients",698
1,NCT02521051,Phase Ib/II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 698, 'therapyName': 'Alectinib'}]","Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer",698
2,NCT01871805,Phase Ib/II,"Active, not recruiting","[{'id': 698, 'therapyName': 'Alectinib'}]",A Study of CH5424802/RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer,698
3,NCT02091141,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 698, 'therapyName': 'Alectinib'}, {'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]","My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors",698
4,NCT02271139,Phase III,No longer available,"[{'id': 698, 'therapyName': 'Alectinib'}]",Expanded Access Study of Alectinib for Patients With ALK-Rearranged Non-Small Cell Lung Cancer Previously Treated With Crizotinib,698
5,NCT03194893,Phase III,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 698, 'therapyName': 'Alectinib'}]",A Roll Over Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer,698
6,NCT01801111,Phase II,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 698, 'therapyName': 'Alectinib'}]",A Study of RO5424802 in Patients With Non-Small Cell Lung Cancer Who Have ALK Mutation and Failed Crizotinib Treatment,698
7,NCT03131206,Phase Ib/II,Recruiting,"[{'id': 698, 'therapyName': 'Alectinib'}]",A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer,698
8,NCT03178552,Phase II,Recruiting,"[{'id': 4686, 'therapyName': 'Carboplatin + Cisplatin + Gemcitabine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 4616, 'therapyName': 'Carboplatin + Cisplatin + Pemetrexed'}, {'id': 698, 'therapyName': 'Alectinib'}]",A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST),698
0,NCT02013219,Phase I,"Active, not recruiting","[{'id': 3490, 'therapyName': 'Alectinib + Atezolizumab'}, {'id': 1352, 'therapyName': 'Atezolizumab + Erlotinib'}]",A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer,3490
0,NCT03202940,Phase Ib/II,Recruiting,"[{'id': 5971, 'therapyName': 'Alectinib + Cobimetinib'}]",A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC,5971
0,NCT02653196,Phase II,Terminated,"[{'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 3948, 'therapyName': 'Cyclosporine + Mycophenolate mofetil + Tacrolimus'}]",A Multi-Institutional Phase II Feasibility Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors,1205
1,NCT01256398,Phase II,"Active, not recruiting","[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1824, 'therapyName': 'Vincristine + Methotrexate + Mercaptopurine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,1205
2,NCT01625351,Phase I,"Active, not recruiting","[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}]",A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas,1205
0,NCT00520130,Phase Ib/II,"Active, not recruiting","[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2305, 'therapyName': 'Alemtuzumab + Cyclosporine'}, {'id': 2306, 'therapyName': 'Rituximab + Fludarabine + EPOCH'}, {'id': 2307, 'therapyName': 'Fludarabine + EPOCH'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,2305
0,NCT01898078,Phase I,"Active, not recruiting","[{'id': 626, 'therapyName': 'Alisertib'}]", Food Effect Study of Alisertib (MLN8237) in Patients With Advanced Solid Tumors or Lymphomas,626
1,NCT02530619,Phase I,Recruiting,"[{'id': 626, 'therapyName': 'Alisertib'}]",Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia,626
2,NCT02560025,Phase II,"Active, not recruiting","[{'id': 626, 'therapyName': 'Alisertib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML,626
3,NCT01471964,Phase Ib/II,Suspended,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 626, 'therapyName': 'Alisertib'}]","Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer",626
4,NCT02551055,Phase I,Terminated,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 626, 'therapyName': 'Alisertib'}, {'id': 3146, 'therapyName': 'TAK-659'}, {'id': 1033, 'therapyName': 'MLN1117'}]","MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma",626
5,NCT02038647,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 626, 'therapyName': 'Alisertib'}]",Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC),626
6,NCT02114229,Phase II,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2449, 'therapyName': 'Methotrexate + Cisplatin + Cyclophosphamide + Vincristine'}, {'id': 626, 'therapyName': 'Alisertib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 942, 'therapyName': 'Topotecan'}]",Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors,626
7,NCT02259010,Phase I,"Active, not recruiting","[{'id': 626, 'therapyName': 'Alisertib'}, {'id': 1026, 'therapyName': 'Itraconazole'}]",A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma,626
8,NCT02186509,Phase I,Recruiting,"[{'id': 626, 'therapyName': 'Alisertib'}]",Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas,626
9,NCT01848067,Phase Ib/II,"Active, not recruiting","[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 626, 'therapyName': 'Alisertib'}]","Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer",626
10,NCT01897012,Phase I,Recruiting,"[{'id': 1075, 'therapyName': 'romidepsin'}, {'id': 626, 'therapyName': 'Alisertib'}]",Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas,626
11,NCT01799278,Phase II,"Active, not recruiting","[{'id': 626, 'therapyName': 'Alisertib'}]",A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer,626
12,NCT02219789,Phase I,"Active, not recruiting","[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 626, 'therapyName': 'Alisertib'}]",Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery,626
13,NCT02187991,Phase II,Recruiting,"[{'id': 626, 'therapyName': 'Alisertib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer,626
14,NCT02860000,Phase II,Recruiting,"[{'id': 4561, 'therapyName': 'Alisertib + Fulvestrant'}, {'id': 626, 'therapyName': 'Alisertib'}]","Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer",626
15,NCT02293005,Phase II,"Active, not recruiting","[{'id': 626, 'therapyName': 'Alisertib'}]",Alisertib in Malignant Mesothelioma,626
16,NCT02700022,Phase I,"Active, not recruiting","[{'id': 626, 'therapyName': 'Alisertib'}, {'id': 3395, 'therapyName': 'R-EPOCH'}]",A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas,626
17,NCT02214147,Phase I,Completed,"[{'id': 626, 'therapyName': 'Alisertib'}]",Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function,626
18,NCT02319018,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 626, 'therapyName': 'Alisertib'}]",Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors,626
19,NCT01844583,Phase I,Completed,"[{'id': 1239, 'therapyName': 'Alisertib  + Esomeprazole'}, {'id': 1240, 'therapyName': 'Alisertib + Rifampin'}, {'id': 626, 'therapyName': 'Alisertib'}]","Safety, Tolerability and PK of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib",626
0,NCT01844583,Phase I,Completed,"[{'id': 1239, 'therapyName': 'Alisertib  + Esomeprazole'}, {'id': 1240, 'therapyName': 'Alisertib + Rifampin'}, {'id': 626, 'therapyName': 'Alisertib'}]","Safety, Tolerability and PK of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib",1239
0,NCT01677559,Phase I,"Active, not recruiting","[{'id': 1226, 'therapyName': 'Alisertib + Abraxane'}]",Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies,1226
0,NCT01695941,Phase I,Recruiting,"[{'id': 3581, 'therapyName': 'Alisertib + Bortezomib + Rituximab'}]","Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma",3581
0,NCT02780011,Phase I,Not yet recruiting,"[{'id': 4301, 'therapyName': 'Alisertib + Brentuximab vedotin'}]",Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies,4301
0,NCT02860000,Phase II,Recruiting,"[{'id': 4561, 'therapyName': 'Alisertib + Fulvestrant'}, {'id': 626, 'therapyName': 'Alisertib'}]","Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer",4561
0,NCT01924260,Phase I,"Active, not recruiting","[{'id': 1289, 'therapyName': 'Alisertib + Gemcitabine'}]",Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer,1289
0,NCT01601535,Phase Ib/II,"Active, not recruiting","[{'id': 2628, 'therapyName': 'Alisertib + Irinotecan + Temozolomide'}]",Study of MLN8237 in Combination With Irinotecan and Temozolomide,2628
0,NCT02719691,Phase I,Recruiting,"[{'id': 4214, 'therapyName': 'Alisertib + MLN0128'}]",Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,4214
1,NCT02812056,Phase I,Withdrawn,"[{'id': 4214, 'therapyName': 'Alisertib + MLN0128'}]",Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies,4214
0,NCT01639911,Phase I,Completed,"[{'id': 1212, 'therapyName': 'Alisertib + Pazopanib'}]",MLN8237 and Pazopanib in Combination for Solid Tumors,1212
0,NCT01844583,Phase I,Completed,"[{'id': 1239, 'therapyName': 'Alisertib  + Esomeprazole'}, {'id': 1240, 'therapyName': 'Alisertib + Rifampin'}, {'id': 626, 'therapyName': 'Alisertib'}]","Safety, Tolerability and PK of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib",1240
0,NCT02799095,Phase I,Recruiting,"[{'id': 4298, 'therapyName': 'ALKS 4230'}]",A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors,4298
0,NCT02629809,Phase II,Recruiting,"[{'id': 3628, 'therapyName': 'Allopurinol'}, {'id': 3627, 'therapyName': 'Cyclophosphamide + Fludarabine + Obinutuzumab'}, {'id': 768, 'therapyName': 'Ibrutinib'}]","First-line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL)",3628
1,NCT03150693,Phase III,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 3628, 'therapyName': 'Allopurinol'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]",Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia,3628
0,NCT00602693,Phase I,Completed,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2311, 'therapyName': 'Allopurinol + Cyclophosphamide + Fludarabine'}]",T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer,2311
0,NCT03128879,Phase II,"Active, not recruiting","[{'id': 5876, 'therapyName': 'Allopurinol + Ibrutinib + Venetoclax'}]",Study of Venetoclax (ABT-199) Added to Ibrutinib in Patients With High-Risk Chronic Lymphocytic Leukemia (CLL),5876
0,NCT02620839,Phase I,Recruiting,"[{'id': 5627, 'therapyName': 'Alpelisib + Cisplatin'}]",Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies,5627
0,NCT03056755,Phase II,Recruiting,"[{'id': 5929, 'therapyName': 'Alpelisib + Fulvestrant'}, {'id': 1553, 'therapyName': 'Letrozole + BYL719'}]","Efficacy and Safety of Treatment With Alpelisib Plus Endocrine Therapy in Patients With HR+, HER2-negative aBC, With PIK3CA Mutations, Whose Disease Has Progressed on or After CDK 4/6 Treatment With an Aromatase Inhibitor (AI) or Fulvestrant",5929
0,NCT02734615,Phase I,Recruiting,"[{'id': 4441, 'therapyName': 'Alpelisib + LSZ 102'}, {'id': 4440, 'therapyName': 'LSZ 102 + Ribociclib'}, {'id': 4439, 'therapyName': 'LSZ 102'}]",Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers,4441
0,NCT00092222,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1187, 'therapyName': 'Alpha 2 Interferon'}, {'id': 2211, 'therapyName': 'EPOCH'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1008, 'therapyName': 'Doxil'}]",Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity,1187
0,NCT02264613,Phase Ib/II,Recruiting,"[{'id': 2273, 'therapyName': 'ALRN-6924'}]",Safety Study of ALRN-6924 in Patients With Advanced Solid Tumors,2273
1,NCT02909972,Phase I,Recruiting,"[{'id': 4755, 'therapyName': 'ALRN-6924 + Cytarabine'}, {'id': 2273, 'therapyName': 'ALRN-6924'}]",Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome,2273
0,NCT02909972,Phase I,Recruiting,"[{'id': 4755, 'therapyName': 'ALRN-6924 + Cytarabine'}, {'id': 2273, 'therapyName': 'ALRN-6924'}]",Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome,4755
0,NCT01625260,Phase Ib/II,"Active, not recruiting","[{'id': 2187, 'therapyName': 'ALT-801'}, {'id': 2191, 'therapyName': 'ALT-801 + Gemcitabine'}]",A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer,2187
1,NCT01326871,Phase Ib/II,"Active, not recruiting","[{'id': 2187, 'therapyName': 'ALT-801'}]",A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer,2187
0,NCT01625260,Phase Ib/II,"Active, not recruiting","[{'id': 2187, 'therapyName': 'ALT-801'}, {'id': 2191, 'therapyName': 'ALT-801 + Gemcitabine'}]",A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer,2191
0,NCT02099539,Phase Ib/II,Recruiting,"[{'id': 3060, 'therapyName': 'ALT-803'}]",A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma,3060
1,NCT01885897,Phase Ib/II,Recruiting,"[{'id': 3060, 'therapyName': 'ALT-803'}]",IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT,3060
2,NCT02989844,Phase II,Recruiting,"[{'id': 3060, 'therapyName': 'ALT-803'}]",QUILT-3.035: Relapse Prophylaxis With ALT-803 for AML and MDS Pts Following Allo HSCT,3060
3,NCT01946789,Phase I,Recruiting,"[{'id': 3060, 'therapyName': 'ALT-803'}]",A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors,3060
4,NCT03054909,Phase I,Not yet recruiting,"[{'id': 3060, 'therapyName': 'ALT-803'}]",QUILT-2.021: Phase I of IP Followed by SQ ALT-803 for Ovarian Cancer,3060
5,NCT03136406,Phase Ib/II,Recruiting,"[{'id': 1018, 'therapyName': 'GI-4000'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 6163, 'therapyName': 'ETBX-011'}, {'id': 3060, 'therapyName': 'ALT-803'}]",QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy,3060
0,NCT03022825,Phase II,Recruiting,"[{'id': 5238, 'therapyName': 'ALT-803 + BCG solution'}]",QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer,5238
0,NCT03050216,Phase II,Recruiting,"[{'id': 5300, 'therapyName': 'ALT-803 + Cyclophosphamide + Fludarabine phosphate'}]",Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML,5300
1,NCT01898793,Phase Ib/II,Recruiting,"[{'id': 3409, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine '}, {'id': 5300, 'therapyName': 'ALT-803 + Cyclophosphamide + Fludarabine phosphate'}]",Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS),5300
0,NCT03127098,Phase Ib/II,"Active, not recruiting","[{'id': 6239, 'therapyName': 'ALT-803 + ETBX-011'}]","QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer",6239
0,NCT02559674,Phase Ib/II,Recruiting,"[{'id': 3095, 'therapyName': 'ALT-803 + Gemcitabine + nab-paclitaxel'}]",ALT-803 in Patients With Advanced Pancreatic Cancer Conjunction With Gemcitabine and Nab-Paclitaxel,3095
0,NCT03228667,Phase II,Not yet recruiting,"[{'id': 3061, 'therapyName': 'ALT-803 + Nivolumab'}, {'id': 6037, 'therapyName': 'ALT-803 + Pembrolizumab'}]","QUILT-3.055: A Phase IIb, Single-Arm, Open-Label Study of ALT-803 in Combination With Pembrolizumab or Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Disease Progression Following an Initial Response to Treatment With PD-1 Checkpoint Inhibitor Therapy",3061
1,NCT02523469,Phase Ib/II,Recruiting,"[{'id': 3061, 'therapyName': 'ALT-803 + Nivolumab'}]","ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer",3061
0,NCT03228667,Phase II,Not yet recruiting,"[{'id': 3061, 'therapyName': 'ALT-803 + Nivolumab'}, {'id': 6037, 'therapyName': 'ALT-803 + Pembrolizumab'}]","QUILT-3.055: A Phase IIb, Single-Arm, Open-Label Study of ALT-803 in Combination With Pembrolizumab or Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Disease Progression Following an Initial Response to Treatment With PD-1 Checkpoint Inhibitor Therapy",6037
0,NCT02384954,Phase Ib/II,Recruiting,"[{'id': 3936, 'therapyName': 'ALT-803 + Rituximab'}]",ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma (iNHL) in Conjunction With Rituximab,3936
0,NCT02228811,Phase I,"Active, not recruiting","[{'id': 1656, 'therapyName': 'Altiratinib'}]",A Study of DCC-2701 in Participants With Advanced Solid Tumors,1656
0,NCT02520011,Phase II,Recruiting,"[{'id': 628, 'therapyName': 'Alvocidib'}, {'id': 2393, 'therapyName': 'Cytarabine + Mitoxantrone'}]",Alvocidib Biomarker-driven Phase 2 AML Study,628
0,NCT03298984,Phase I,Not yet recruiting,"[{'id': 6300, 'therapyName': 'Alvocidib + Cytarabine + Daunorubicin'}]",Ph I Study of Alvocidib and Cytarabine/Duanorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).,6300
0,NCT03013218,Phase I,Recruiting,"[{'id': 5211, 'therapyName': 'ALX148'}, {'id': 5212, 'therapyName': 'ALX148 + Atezolizumab'}, {'id': 5213, 'therapyName': 'ALX148 + Trastuzumab'}]",A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma,5211
0,NCT03013218,Phase I,Recruiting,"[{'id': 5211, 'therapyName': 'ALX148'}, {'id': 5212, 'therapyName': 'ALX148 + Atezolizumab'}, {'id': 5213, 'therapyName': 'ALX148 + Trastuzumab'}]",A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma,5212
0,NCT03013218,Phase I,Recruiting,"[{'id': 5211, 'therapyName': 'ALX148'}, {'id': 5212, 'therapyName': 'ALX148 + Atezolizumab'}, {'id': 5213, 'therapyName': 'ALX148 + Trastuzumab'}]",A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma,5213
0,NCT02009449,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2621, 'therapyName': 'AM0010 '}, {'id': 619, 'therapyName': 'Abraxane'}]",A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors,2621
0,NCT02923921,Phase III,Recruiting,"[{'id': 5849, 'therapyName': 'AM0010 + mFOLFOX-6'}, {'id': 5850, 'therapyName': 'mFOLFOX-6'}]",Study of AM0010 With FOLFOX Compared to FOLFOX Alone Second-line Tx in Pts With Metastatic Pancreatic Cancer,5849
0,NCT02357147,Phase II,"Active, not recruiting","[{'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 3513, 'therapyName': 'Amatuximab'}]",Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM). (ARTEMIS),3513
0,NCT01723020,Phase I,Completed,"[{'id': 1452, 'therapyName': 'AMG 232'}]",A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma,1452
1,NCT03107780,Phase I,Not yet recruiting,"[{'id': 1452, 'therapyName': 'AMG 232'}]",MDM2 Inhibitor AMG-232 in Treating Patients With Recurrent or Newly Diagnosed Glioblastoma,1452
2,NCT02016729,Phase I,Completed,"[{'id': 2, 'therapyName': 'Trametinib'}, {'id': 1452, 'therapyName': 'AMG 232'}]",A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia,1452
3,NCT03217266,Phase I,Not yet recruiting,"[{'id': 1452, 'therapyName': 'AMG 232'}]",MDM2 Inhibitor AMG-232 and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma,1452
0,NCT03041688,Phase I,Not yet recruiting,"[{'id': 6185, 'therapyName': 'AMG 232 + Decitabine'}]","MDM2 Inhibitor AMG-232 and Decitabine in Treating Patients With Relapsed, Refractory, or Newly-Diagnosed Acute Myeloid Leukemia",6185
0,NCT02110355,Phase Ib/II,Recruiting,"[{'id': 1454, 'therapyName': 'AMG 232 + Trametinib'}, {'id': 1453, 'therapyName': 'AMG 232 + Trametinib + Dabrafenib'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma,1454
0,NCT02110355,Phase Ib/II,Recruiting,"[{'id': 1454, 'therapyName': 'AMG 232 + Trametinib'}, {'id': 1453, 'therapyName': 'AMG 232 + Trametinib + Dabrafenib'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma,1453
0,NCT01253707,Phase I,Completed,"[{'id': 1064, 'therapyName': 'AMG 337'}]",A Study of AMG 337 in Subjects With Advanced Solid Tumors,1064
1,NCT02016534,Phase II,Terminated,"[{'id': 1064, 'therapyName': 'AMG 337'}]",Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors,1064
2,NCT02344810,Phase Ib/II,Unknown status,"[{'id': 1064, 'therapyName': 'AMG 337'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]","C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer",1064
0,NCT03296696,Phase I,Not yet recruiting,"[{'id': 6261, 'therapyName': 'AMG 596'}]",Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma,6261
0,NCT00858377,Phase I,"Active, not recruiting","[{'id': 983, 'therapyName': 'AMG 900'}]",A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors,983
0,NCT01233687,Phase Ib/II,Completed,"[{'id': 629, 'therapyName': 'AMG102'}, {'id': 4, 'therapyName': 'Erlotinib'}]",AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer,629
1,NCT02213289,Phase Ib/II,Recruiting,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1913, 'therapyName': 'FOLTAX'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 629, 'therapyName': 'AMG102'}]",PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression,629
2,NCT02154490,Phase II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 1016, 'therapyName': 'GDC-0032'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 629, 'therapyName': 'AMG102'}]",Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,629
0,NCT01061788,Phase I,Recruiting,"[{'id': 1138, 'therapyName': 'AMG479 + Everolimus + Panitumumab'}]","A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer",1138
0,NCT02713529,Phase Ib/II,Recruiting,"[{'id': 4170, 'therapyName': 'AMG820 + Pembrolizumab'}]",Safety Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer,4170
0,NCT02481830,Phase III,"Active, not recruiting","[{'id': 2951, 'therapyName': 'Amrubicin'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 942, 'therapyName': 'Topotecan'}]",Efficacy Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer,2951
0,NCT03144245,Phase I,Recruiting,"[{'id': 5711, 'therapyName': 'AMV-564'}]",Study of AMV564 in Patients With AML,5711
0,NCT01624766,Phase I,Recruiting,"[{'id': 1199, 'therapyName': 'Everolimus + Denosumab'}, {'id': 1192, 'therapyName': 'Anakinra + Everolimus'}]",Anakinra or Denosumab and Everolimus in Advanced Cancer,1192
0,NCT01216176,Phase Ib/II,"Active, not recruiting","[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 912, 'therapyName': 'Saracatinib'}]",A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZDO530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer,633
1,NCT02689921,Phase II,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 738, 'therapyName': 'Exemestane'}]",NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (NEOADAPT),633
2,NCT01160211,Phase III,"Active, not recruiting","[{'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 738, 'therapyName': 'Exemestane'}]","A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer",633
3,NCT02648477,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer,633
4,NCT02753686,Phase I,Recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 1966, 'therapyName': 'Exemestane + Everolimus'}]",Treatment of Canadian Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy (Treat ER+ight),633
5,NCT00921115,Phase II,"Active, not recruiting","[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.,633
6,NCT02441946,Phase II,Completed,"[{'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 2700, 'therapyName': 'Loperamide'}, {'id': 633, 'therapyName': 'Anastrozole'}]","A Phase 2 Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer",633
7,NCT00570323,Phase II,"Active, not recruiting","[{'id': 1911, 'therapyName': 'Anastrozole  + Fulvestrant'}, {'id': 633, 'therapyName': 'Anastrozole'}]",Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer,633
8,NCT02269670,Phase II,"Active, not recruiting","[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1869, 'therapyName': 'Megestrol'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 633, 'therapyName': 'Anastrozole'}]",Everolimus and Hormone Therapy in Treating Patients With Advanced Hormone Receptor Positive Breast Cancer That Has Progressed or Recurred on Everolimus and Exemestane Therapy,633
9,NCT02947685,Phase III,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 947, 'therapyName': 'Trastuzumab'}]","Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (PATINA)",633
10,NCT02476786,Phase II,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}]",Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score,633
11,NCT02040857,Phase II,"Active, not recruiting","[{'id': 738, 'therapyName': 'Exemestane'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}]",Palbociclib + Endocrine Therapy for HR + BrCa,633
12,NCT03238703,FDA approved,Not yet recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}]","Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer",633
13,NCT01824836,Phase I,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}]",Anastrozole in Treating Aromatase Inhibitor Musculoskeletal Symptoms in Female Patients With Stage I-III Breast Cancer,633
14,NCT03304080,,Not yet recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 850, 'therapyName': 'Palbociclib'}]","Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in Her-positive, Her2-positive Metastatic Breast",633
15,NCT01674140,Phase III,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}]",S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,633
16,NCT02206984,Phase I,Recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Endocrine Response in Women With Invasive Lobular Breast Cancer,633
17,NCT01723774,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 759, 'therapyName': 'Goserelin'}]",PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer,633
18,NCT02188745,Phase II,Recruiting,"[{'id': 738, 'therapyName': 'Exemestane'}, {'id': 1643, 'therapyName': 'Estradiol'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}]",ER Reactivation Therapy for Breast Cancer,633
19,NCT02278120,Phase III,"Active, not recruiting","[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 790, 'therapyName': 'Ribociclib'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 633, 'therapyName': 'Anastrozole'}]","Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer",633
20,NCT01491737,Phase II,"Active, not recruiting","[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]","A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer",633
21,NCT01953588,Phase III,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,633
22,NCT02204098,Phase I,Recruiting,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]",Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy,633
23,NCT01272037,Phase III,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}]","Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",633
24,NCT02095184,Phase I,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}]",GCC 1366 Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients,633
25,NCT01197170,Phase I,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Hormone Blockade in Combination With Targeted Agents,633
0,NCT00570323,Phase II,"Active, not recruiting","[{'id': 1911, 'therapyName': 'Anastrozole  + Fulvestrant'}, {'id': 633, 'therapyName': 'Anastrozole'}]",Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer,1911
1,NCT02000596,Phase II,Terminated,"[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1911, 'therapyName': 'Anastrozole  + Fulvestrant'}]",Trastuzmab and Pertuzumab Alone or in Combination With Hormonal Therapy or Chemotherapy With Eribulin in Women Aged 60 and Over With HER2/Neu Overexpressed Locally Advanced or MBC,1911
0,NCT02291913,Phase II,"Active, not recruiting","[{'id': 2267, 'therapyName': 'Everolimus + Tamoxifen'}, {'id': 2268, 'therapyName': 'Anastrozole + Everolimus'}, {'id': 1589, 'therapyName': 'Fulvestrant + Everolimus'}, {'id': 1621, 'therapyName': 'Everolimus + Letrozole'}, {'id': 2269, 'therapyName': 'Everolimus + Toremifene'}, {'id': 1966, 'therapyName': 'Exemestane + Everolimus'}]",Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer,2268
0,NCT02246621,Phase III,"Active, not recruiting","[{'id': 1854, 'therapyName': 'Abemaciclib + Anastrozole + Letrozole'}, {'id': 1853, 'therapyName': 'Anastrozole + Letrozole'}]",A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer,1853
0,NCT02942355,Phase II,Recruiting,"[{'id': 4974, 'therapyName': 'Anastrozole + Palbociclib'}]",Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer,4974
0,NCT02090114,Phase II,Recruiting,"[{'id': 2591, 'therapyName': 'Andriol'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistant (The RESTORE Study),2591
1,NCT02286921,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2591, 'therapyName': 'Andriol'}]","Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance",2591
0,NCT02839681,Phase II,Recruiting,"[{'id': 4593, 'therapyName': 'Anetumab ravtansine'}]",Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma,4593
1,NCT02824042,Phase I,Recruiting,"[{'id': 4594, 'therapyName': 'Anetumab ravtansine + Itraconazole'}, {'id': 4593, 'therapyName': 'Anetumab ravtansine'}]",Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole,4593
2,NCT03023722,Phase II,Recruiting,"[{'id': 4593, 'therapyName': 'Anetumab ravtansine'}]",Phase II Anetumab Ravtansine as 2nd Line Treatment for Pancreatic Cancer,4593
0,NCT02639091,Phase I,Recruiting,"[{'id': 4617, 'therapyName': 'Anetumab ravtansine + Cisplatin + Pemetrexed'}]",Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors,4617
0,NCT02824042,Phase I,Recruiting,"[{'id': 4594, 'therapyName': 'Anetumab ravtansine + Itraconazole'}, {'id': 4593, 'therapyName': 'Anetumab ravtansine'}]",Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole,4594
0,NCT03016377,Phase I,Not yet recruiting,"[{'id': 3585, 'therapyName': 'Anti-CD19 CAR T'}]",Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia,3585
0,NCT03190941,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 6061, 'therapyName': 'anti-KRAS G12V mTCR cells'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*1101 Patients,6061
0,NCT02083250,Phase I,Recruiting,"[{'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 3201, 'therapyName': 'Busulfan + Clofarabine + Fludarabine'}]",Fludarabine/Clofarabine/Busulfan Combined With SAHA in Acute Leukemia,1844
1,NCT00305682,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant,1844
2,NCT02790515,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation,1844
3,NCT00550992,Phase I,Unknown status,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia,1844
4,NCT00084695,Phase II,Unknown status,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases,1844
5,NCT01701986,Phase Ib/II,Recruiting,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 3992, 'therapyName': 'Busulfan + Clofarabine + Gemcitabine'}]",Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas,1844
6,NCT02722668,Phase II,Recruiting,"[{'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}]",UCB Transplant for Hematological DIseases Using a Non Myeloablative Prep,1844
7,NCT02472392,Phase I,Completed,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}]",Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma,1844
8,NCT02508038,Phase I,Recruiting,"[{'id': 2971, 'therapyName': 'Zoledronic acid'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}]", Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa,1844
0,NCT02462252,Phase II,Recruiting,"[{'id': 4411, 'therapyName': 'anti-thymocyte globulin + BKT140 + Cyclosporine + Methylprednisolone'}]","Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome",4411
0,NCT01218867,Phase Ib/II,Completed,"[{'id': 984, 'therapyName': 'Anti-VEGFR2 CAR CD8 lymphocytes'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes,984
0,NCT02047344,Phase II,Recruiting,"[{'id': 985, 'therapyName': 'Antroquinonol'}]","Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC",985
0,NCT02094573,Phase II,"Active, not recruiting","[{'id': 634, 'therapyName': 'AP26113'}]","A Phase 2, Multicenter, Randomized Study of AP26113",634
1,NCT01449461,Phase Ib/II,"Active, not recruiting","[{'id': 634, 'therapyName': 'AP26113'}]",A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113,634
2,NCT02706626,Phase II,Recruiting,"[{'id': 634, 'therapyName': 'AP26113'}]",Trial of Brigatinib After Treatment With Second-Generation ALK Inhibitors,634
3,NCT02737501,Phase III,"Active, not recruiting","[{'id': 634, 'therapyName': 'AP26113'}, {'id': 706, 'therapyName': 'Crizotinib'}]",ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in ALK-positive Advanced Non-Small Cell Lung Cancer Patients,634
4,NCT02784158,Phase I,No longer available,"[{'id': 634, 'therapyName': 'AP26113'}]",An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer,634
0,NCT02716116,Phase Ib/II,Recruiting,"[{'id': 3981, 'therapyName': 'AP32788'}]",A Trial of AP32788 in Non-Small Cell Lung Cancer,3981
0,NCT01497704,Phase Ib/II,Completed,"[{'id': 986, 'therapyName': 'Apatinib'}]",Dose-Escalation and Safety Trial of YN968D1,986
1,NCT03042611,Phase III,Recruiting,"[{'id': 986, 'therapyName': 'Apatinib'}]",Efficacy and Safety Trial of Apatinib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Patients With Gastric Cancer,986
0,NCT02935907,Phase I,Recruiting,"[{'id': 5826, 'therapyName': 'APG-115'}]",APG-115 in Patients With Advanced Solid Tumors or Lymphomas,5826
0,NCT03080311,Phase I,Recruiting,"[{'id': 5757, 'therapyName': 'APG-1252'}]",A Study of APG-1252 in Patients With SCLC or Other Solid Tumors,5757
0,NCT03087591,Phase I,Recruiting,"[{'id': 5751, 'therapyName': 'APN401'}]","APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery",5751
0,NCT03072043,Phase Ib/II,Recruiting,"[{'id': 5445, 'therapyName': 'APR-246 + Azacitidine'}]",Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms,5445
0,NCT02098343,Phase Ib/II,Recruiting,"[{'id': 1953, 'therapyName': 'Carboplatin + Doxorubicin'}, {'id': 1952, 'therapyName': 'APR-246 + Carboplatin + Doxorubicin'}]","p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246",1952
0,NCT02482168,Phase I,Recruiting,"[{'id': 3835, 'therapyName': 'APX005M'}]",Study of the CD40 Agonistic Monoclonal Antibody APX005M,3835
0,NCT03214250,Phase Ib/II,Recruiting,"[{'id': 6047, 'therapyName': 'Gemcitabine + nab-paclitaxel + Nivolumab'}, {'id': 6048, 'therapyName': 'APX005M + Gemcitabine + nab-paclitaxel'}, {'id': 6049, 'therapyName': 'APX005M + Gemcitabine + nab-paclitaxel + Nivolumab'}]",Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma,6048
0,NCT03214250,Phase Ib/II,Recruiting,"[{'id': 6047, 'therapyName': 'Gemcitabine + nab-paclitaxel + Nivolumab'}, {'id': 6048, 'therapyName': 'APX005M + Gemcitabine + nab-paclitaxel'}, {'id': 6049, 'therapyName': 'APX005M + Gemcitabine + nab-paclitaxel + Nivolumab'}]",Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma,6049
0,NCT03123783,Phase Ib/II,Recruiting,"[{'id': 5608, 'therapyName': 'APX005M + Nivolumab'}]",CD40 Agonistic Antibody APX005M in Combination With Nivolumab,5608
0,NCT03165994,Phase II,Not yet recruiting,"[{'id': 5797, 'therapyName': 'APX005M + Paclitaxel + Carboplatin'}]",APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers,5797
0,NCT02706353,Phase Ib/II,Recruiting,"[{'id': 3836, 'therapyName': 'APX005M + Pembrolizumab'}]",APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma,3836
0,NCT02282917,Phase I,Recruiting,"[{'id': 987, 'therapyName': 'AR-42'}]",Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma,987
0,NCT01798901,Phase I,"Active, not recruiting","[{'id': 1751, 'therapyName': 'AR-42 + Decitabine'}]",AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia,1751
0,NCT02569320,Phase I,Suspended,"[{'id': 4299, 'therapyName': 'AR-42 + Dexamethasone + Pomalidomide'}]",HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma,4299
0,NCT02795819,Phase I,Suspended,"[{'id': 4267, 'therapyName': 'AR-42 + Pazopanib'}]",Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer,4267
0,NCT02949284,Phase II,Recruiting,"[{'id': 1947, 'therapyName': 'ARN-509'}, {'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}]","Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery",1947
1,NCT01790126,Phase II,"Active, not recruiting","[{'id': 1947, 'therapyName': 'ARN-509'}]",The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer,1947
2,NCT02906605,Phase II,Withdrawn,"[{'id': 1947, 'therapyName': 'ARN-509'}, {'id': 4890, 'therapyName': 'ARN-509 + JNJ-64041809'}]","A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer",1947
3,NCT01946204,Phase III,"Active, not recruiting","[{'id': 1947, 'therapyName': 'ARN-509'}]",A Study of ARN-509 in Men With Non-Metastatic Castration-Resistant Prostate Cancer,1947
4,NCT02489318,Phase III,"Active, not recruiting","[{'id': 1947, 'therapyName': 'ARN-509'}]",A Phase 3 Study of JNJ-56021927 Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With Low-Volume mHSPC,1947
5,NCT02578797,Phase I,"Active, not recruiting","[{'id': 1947, 'therapyName': 'ARN-509'}]",A JNJ-56021927 (ARN-509) QT/QTc Study,1947
6,NCT02721979,Phase II,Not yet recruiting,"[{'id': 1947, 'therapyName': 'ARN-509'}]",ARN-509 in Treating Patients With Prostate Cancer Who Are in Active Surveillance,1947
7,NCT03279250,Phase II,Not yet recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1947, 'therapyName': 'ARN-509'}]",Effects of Apalutamide Plus LHRH Agonist or Apalutamide Plus Abiraterone Acetate Plus LHRH Agonist for Six Months for Prostate Cancer Patients at High Risk for Recurrence,1947
0,NCT02257736,Phase III,"Active, not recruiting","[{'id': 1948, 'therapyName': 'ARN-509 + Abiraterone'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC),1948
0,NCT03009981,Phase III,Recruiting,"[{'id': 5523, 'therapyName': 'Abiraterone + ARN-509 + Degarelix + Prednisone'}, {'id': 5524, 'therapyName': 'ARN-509 + Degarelix'}, {'id': 1814, 'therapyName': 'Degarelix'}]",A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer,5524
0,NCT03093272,Phase II,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 5521, 'therapyName': 'ARN-509 + Docetaxel'}]",A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer,5521
0,NCT02106507,Phase I,"Active, not recruiting","[{'id': 2303, 'therapyName': 'ARN-509 + Everolimus'}]",ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate,2303
0,NCT02906605,Phase II,Withdrawn,"[{'id': 1947, 'therapyName': 'ARN-509'}, {'id': 4890, 'therapyName': 'ARN-509 + JNJ-64041809'}]","A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer",4890
0,NCT02770391,Phase II,Recruiting,"[{'id': 4207, 'therapyName': 'ARN-509 + Leuprolide'}]",ARN-509 and Leuprolide in Intermediate and High-risk Prostate Cancer,4207
1,NCT02811809,Phase II,Not yet recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 4207, 'therapyName': 'ARN-509 + Leuprolide'}]",Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer,4207
0,NCT02924766,Phase I,Recruiting,"[{'id': 4832, 'therapyName': 'ARN-509 + Niraparib'}]",A Safety and Pharmacokinetics Study of Niraparib Plus Apalutamide in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE),4832
0,NCT03230318,Phase III,Recruiting,"[{'id': 2900, 'therapyName': 'ARQ 087'}]",ARQ 087 in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma,2900
1,NCT01752920,Phase I,"Active, not recruiting","[{'id': 2900, 'therapyName': 'ARQ 087'}]",Phase 1 Dose Escalation Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors,2900
0,NCT03162536,Phase I,Recruiting,"[{'id': 5224, 'therapyName': 'ARQ 531'}]","Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies",5224
0,NCT02761694,Phase I,Recruiting,"[{'id': 4331, 'therapyName': 'ARQ 751'}]","Phase 1 Study of ARQ 751 in Solid Tumors With AKT1, 2, 3 Genetic Alterations, Activating PI3K Mutations or PTEN-null",4331
0,NCT02476955,Phase I,Recruiting,"[{'id': 635, 'therapyName': 'ARQ092'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Open-label Phase 1b Study of ARQ 092 in Combination With Carboplatin Plus Paclitaxel,635
1,NCT01473095,Phase I,"Active, not recruiting","[{'id': 635, 'therapyName': 'ARQ092'}]",Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma,635
0,NCT02025192,Phase I,"Active, not recruiting","[{'id': 1560, 'therapyName': 'ARRY-380 + Trastuzumab'}, {'id': 1577, 'therapyName': 'ARRY-380 + Capecitabine'}]",A Phase 1b Study of ONT-380 Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer,1577
0,NCT02614794,Phase II,Recruiting,"[{'id': 3340, 'therapyName': 'ARRY-380 + Capecitabine + Trastuzumab'}, {'id': 1409, 'therapyName': 'Capecitabine + Trastuzumab'}]",Study of ONT-380 vs Placebo in Combo w/ Capecitabine & Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer,3340
0,NCT03054363,Phase Ib/II,Not yet recruiting,"[{'id': 5334, 'therapyName': 'ARRY-380 + Palbociclib + Letrozole'}]","Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer",5334
0,NCT03043313,Phase II,Recruiting,"[{'id': 1560, 'therapyName': 'ARRY-380 + Trastuzumab'}]",Tucatinib (ONT-380) and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer (MOUNTAINEER)Tucatinib (ONT-380) and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer (MOUNTAINEER) (MOUNTAINEER),1560
1,NCT01921335,Phase I,"Active, not recruiting","[{'id': 1560, 'therapyName': 'ARRY-380 + Trastuzumab'}]",Phase I Dose-escalation Trial of ARRY-380 in Combination With Trastuzumab in Participants With Brain Metastases From HER2+ Breast Cancer,1560
2,NCT02025192,Phase I,"Active, not recruiting","[{'id': 1560, 'therapyName': 'ARRY-380 + Trastuzumab'}, {'id': 1577, 'therapyName': 'ARRY-380 + Capecitabine'}]",A Phase 1b Study of ONT-380 Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer,1560
0,NCT01983501,Phase I,"Active, not recruiting","[{'id': 1573, 'therapyName': 'ARRY-380 + Trastuzumab emtansine'}]",A Phase 1b Study of ONT-380 Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer,1573
0,NCT02880371,Phase Ib/II,Recruiting,"[{'id': 4608, 'therapyName': 'ARRY-382 + Pembrolizumab'}]",A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors,4608
0,NCT01397734,Phase I,"Active, not recruiting","[{'id': 640, 'therapyName': 'Arsenic trioxide'}]",Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML),640
1,NCT01835288,Phase II,Withdrawn,"[{'id': 640, 'therapyName': 'Arsenic trioxide'}]",Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,640
2,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,640
3,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,640
0,NCT01409161,Phase II,Recruiting,"[{'id': 3685, 'therapyName': 'Arsenic trioxide + Gemtuzumab ozogamicin + Tretinoin'}]","Acute Promyelocytic Leukemia (APL) Treated With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin",3685
1,NCT02339740,Phase III,Recruiting,"[{'id': 3686, 'therapyName': 'Cytarabine + Dexamethasone + Idarubicin + Mitoxantrone'}, {'id': 3685, 'therapyName': 'Arsenic trioxide + Gemtuzumab ozogamicin + Tretinoin'}]",Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia,3685
0,NCT02699723,Phase I,Not yet recruiting,"[{'id': 3791, 'therapyName': 'Arsenic trioxide + Itraconazole'}]",Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer,3791
0,NCT02961283,Phase I,Recruiting,"[{'id': 5827, 'therapyName': 'ASN003'}]",Study of ASN003 in Subjects With Advanced Solid Tumors,5827
0,NCT02038673,Phase I,Completed,"[{'id': 3584, 'therapyName': 'ASP5878'}]",An Open-label Phase I Study of Oral ASP5878 at Single and Multiple Doses in Patients With Solid Tumors,3584
0,NCT02588261,Phase III,"Active, not recruiting","[{'id': 1082, 'therapyName': 'ASP8273'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations,1082
1,NCT03082300,Phase I,Terminated,"[{'id': 1082, 'therapyName': 'ASP8273'}]",A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations,1082
2,NCT02674555,Phase I,Withdrawn,"[{'id': 1082, 'therapyName': 'ASP8273'}]","A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors",1082
3,NCT03042013,Phase II,Withdrawn,"[{'id': 1082, 'therapyName': 'ASP8273'}]",A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study,1082
4,NCT02113813,Phase I,"Active, not recruiting","[{'id': 1082, 'therapyName': 'ASP8273'}]",A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations,1082
0,NCT03164057,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia,2206
1,NCT03020030,Phase III,Recruiting,"[{'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents,2206
2,NCT02521493,Phase III,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 5912, 'therapyName': 'Asparaginase Erwinia chrysanthemi'}, {'id': 5215, 'therapyName': 'mitoxantrone hydrochloride'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2206, 'therapyName': 'Asparaginase'}]",Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome,2206
3,NCT02538926,Phase II,Not yet recruiting,"[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 3212, 'therapyName': 'Doxorubicin + Etoposide + Vincristine '}, {'id': 2206, 'therapyName': 'Asparaginase'}]","Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",2206
4,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,2206
0,NCT02101853,Phase III,Recruiting,"[{'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 2347, 'therapyName': 'Leucovorin + Pegaspargase  + Vincristine'}, {'id': 2346, 'therapyName': 'Mercaptopurine + Thioguanine'}, {'id': 2348, 'therapyName': 'Asparaginase + Cyclophosphamide + Etoposide'}, {'id': 2345, 'therapyName': 'Cytarabine + Dexamethasone+ Methotrexate '}]",Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia,2348
0,NCT01371981,Phase III,"Active, not recruiting","[{'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2392, 'therapyName': 'Cytarabine + Etoposide'}, {'id': 2393, 'therapyName': 'Cytarabine + Mitoxantrone'}, {'id': 2394, 'therapyName': 'Asparaginase + Cytarabine'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,2394
1,NCT02723994,Phase II,Recruiting,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 2346, 'therapyName': 'Mercaptopurine + Thioguanine'}, {'id': 2394, 'therapyName': 'Asparaginase + Cytarabine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}]",A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia,2394
0,NCT02521493,Phase III,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 5912, 'therapyName': 'Asparaginase Erwinia chrysanthemi'}, {'id': 5215, 'therapyName': 'mitoxantrone hydrochloride'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2206, 'therapyName': 'Asparaginase'}]",Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome,5912
0,NCT02103478,Phase Ib/II,"Active, not recruiting","[{'id': 1759, 'therapyName': 'ASTX727'}]",Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral CDAi in Patients With MDS,1759
0,NCT01633541,Phase II,Recruiting,"[{'id': 644, 'therapyName': 'AT-101'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer,644
0,NCT03270176,Phase I,Recruiting,"[{'id': 6178, 'therapyName': 'AT-406 + Avelumab'}]",A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy,6178
0,NCT01712217,Phase Ib/II,"Active, not recruiting","[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 645, 'therapyName': 'AT13387'}]",A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib,645
1,NCT02572453,Phase II,Recruiting,"[{'id': 645, 'therapyName': 'AT13387'}]","AT13387 in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-cell Lymphoma",645
2,NCT02381535,Phase I,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 645, 'therapyName': 'AT13387'}]",Hsp90 Inhibitor AT13387 in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin,645
3,NCT02474173,Phase I,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 645, 'therapyName': 'AT13387'}]",HSP90 Inhibitor AT13387 and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer,645
4,NCT02503709,Phase I,Recruiting,"[{'id': 2727, 'therapyName': 'AT7519'}, {'id': 645, 'therapyName': 'AT13387'}]",Hsp90 Inhibitor AT13387 and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,645
0,NCT02097225,Phase I,Recruiting,"[{'id': 1362, 'therapyName': 'AT13387 + Dabrafenib + Trametinib'}]","Hsp90 Inhibitor AT13387, Dabrafenib, and Trametinib in Treating Patients With Recurrent Melanoma That is Metastatic or Cannot be Removed by Surgery",1362
0,NCT02503709,Phase I,Recruiting,"[{'id': 2727, 'therapyName': 'AT7519'}, {'id': 645, 'therapyName': 'AT13387'}]",Hsp90 Inhibitor AT13387 and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,2727
0,NCT02655822,Phase I,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 3571, 'therapyName': 'CPI-444 '}]",Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers,1201
1,NCT03023423,Phase Ib/II,Recruiting,"[{'id': 5236, 'therapyName': 'Atezolizumab + Daratumumab'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (DARZALEX),1201
2,NCT03014648,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC),1201
3,NCT02589717,FDA approved,Approved for marketing,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",An Expanded Access Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy,1201
4,NCT03133390,Phase II,Recruiting,"[{'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",Atezolizumab With or Without Bevacizumab in Cisplatin-ineligible Patients,1201
5,NCT03197935,Phase III,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer (IMpassion031),1201
6,NCT03141684,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",Atezolizumab in Treating Patients With Newly Diagnosed and Metastatic Alveolar Soft Part Sarcoma That Cannot Be Removed by Surgery,1201
7,NCT02420821,Phase III,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of MPDL3280A (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma,1201
8,NCT02844816,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer,1201
9,NCT02431208,Phase I,Suspended,"[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of Atezolizumab (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) Administered With or Without Lenalidomide in Participants With Multiple Myeloma (MM),1201
10,NCT03120676,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma,1201
11,NCT02409342,Phase III,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Comparative Study of MPDL3280A (Anti-PDL1 Antibody) With Cisplatin or Carboplatin + Pemetrexed in Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC),1201
12,NCT02541604,Phase I,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MPDL3280A (Anti-PD-L1 Antibody) in Pediatric and Young Adult Participants With Solid Tumors",1201
13,NCT03206047,Phase Ib/II,Recruiting,"[{'id': 4693, 'therapyName': 'Atezolizumab + SGI-110'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 5982, 'therapyName': 'Atezolizumab + SGI-110 + DEC-205-NY-ESO-1 fusion protein vaccine'}]","Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1201
14,NCT01903993,Phase II,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Randomized Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - &quot;POPLAR&quot;,1201
15,NCT02657434,Phase III,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer,1201
16,NCT02927301,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]","A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Stage IB, II, or IIIA Resectable and Untreated Non-Small Cell Lung Cancer (NSCLC)",1201
17,NCT01375842,Phase I,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Phase 1 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors,1201
18,NCT02792192,Phase Ib/II,Recruiting,"[{'id': 4456, 'therapyName': 'Atezolizumab + BCG solution'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-risk Non-muscle-invasive Bladder Cancer (NMIBC) Participants,1201
19,NCT02108652,Phase II,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of MPDL3280A in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer,1201
20,NCT02784483,Phase I,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]","Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma",1201
21,NCT02912559,Phase III,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair or Microsatellite Instability,1201
22,NCT02463994,Phase I,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC,1201
23,NCT02708680,Phase Ib/II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 5129, 'therapyName': 'Entinostat + Atezolizumab'}]",Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In,1201
24,NCT02410512,Phase I,Recruiting,"[{'id': 2729, 'therapyName': 'MOXR0916'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and MPDL3280A in Patients With Locally Advanced or Metastatic Solid Tumors,1201
25,NCT02471846,Phase I,"Active, not recruiting","[{'id': 2888, 'therapyName': 'GDC-0919'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors,1201
26,NCT02031458,Phase II,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - BIRCH,1201
27,NCT02304393,Phase I,Recruiting,"[{'id': 2672, 'therapyName': 'RO7009789'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of RO7009789 in Combination With MPDL3280A in Patients With Locally Advanced and Metastatic Solid Tumors,1201
28,NCT02323191,Phase I,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 2004, 'therapyName': 'LY3022855'}]",A Study of RO5509554 and MPDL3280A Administered in Combination in Patients With Advanced Solid Tumors,1201
29,NCT03024996,Phase III,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy (IMmotion010),1201
30,NCT02425891,Phase III,"Active, not recruiting","[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of MPDL3280A in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Patients With Previously Untreated Metastatic Triple Negative Breast Cancer,1201
31,NCT02350673,Phase I,Recruiting,"[{'id': 2886, 'therapyName': 'RO6895882'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of Intravenous RO6895882 and MPDL3280A Combination in Patients With Locally Advanced and/or Metastatic Solid Tumors,1201
32,NCT02848651,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of Atezolizumab (MPDL3280A) as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC): Clinical Evaluation of Novel Blood-Based Diagnostics [B-F1RST],1201
33,NCT02409355,Phase III,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of MPDL3280A Compared With Gemcitabine + Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer,1201
34,NCT02599454,Phase I,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer,1201
35,NCT02928406,Phase III,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract,1201
36,NCT03191786,Phase III,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}]",A Study of Atezolizumab Compared With Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Containing Therapy,1201
37,NCT02367781,Phase III,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}]",A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel in Patients With Non-Squamous Non-Small Cell Lung Cancer,1201
38,NCT02451423,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",Study of MPDL3280A in Bladder Cancer,1201
39,NCT02788279,Phase III,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}]",A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma,1201
40,NCT02862275,Phase 0,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer,1201
41,NCT02508870,Phase I,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]","A Safety and Pharmacology Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes",1201
42,NCT02302807,Phase III,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Study of MPDL3280A Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer,1201
43,NCT02008227,Phase III,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Randomized Phase 3 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - OAK,1201
44,NCT02091141,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 698, 'therapyName': 'Alectinib'}, {'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]","My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors",1201
45,NCT03024437,Phase Ib/II,"Active, not recruiting","[{'id': 5129, 'therapyName': 'Entinostat + Atezolizumab'}, {'id': 5235, 'therapyName': 'Atezolizumab + Entinostat + Bevacizumab'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma,1201
46,NCT02609984,Phase II,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 3273, 'therapyName': 'G305 + ID-LV305'}]",Trial of CMB305 and Atezolizumab in Patients With Sarcoma,1201
47,NCT01984242,Phase II,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) as Monotherapy or in Combination With Avastin (Bevacizumab) Compared to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma,1201
48,NCT02486718,Phase III,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer,1201
49,NCT03201458,Phase II,Not yet recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery,1201
50,NCT02458638,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",An Open Label Study of MPDL3280A in Advanced Solid Tumors,1201
51,NCT03115801,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers,1201
52,NCT02450331,Phase III,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]","IMvigor 010 Study: Anti-Programmed Death-Ligand 1 (PD-L1) Antibody MPDL3280A Treatment Versus Observation as Adjuvant Therapy in Patients With PD-L1 Positive, High Risk Muscle Invasive Bladder Cancer After Cystectomy",1201
53,NCT02849496,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 4511, 'therapyName': 'Atezolizumab + Veliparib'}, {'id': 954, 'therapyName': 'Veliparib'}]",Veliparib and Atezolizumab Either Alone or in Combination in Treating Patients With Stage III-IV Triple Negative Breast Cancer,1201
54,NCT03029832,Phase II,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 5451, 'therapyName': 'Atezolizumab + MOXR0916'}]",A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy,1201
55,NCT03178552,Phase II,Recruiting,"[{'id': 4686, 'therapyName': 'Carboplatin + Cisplatin + Gemcitabine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 4616, 'therapyName': 'Carboplatin + Cisplatin + Pemetrexed'}, {'id': 698, 'therapyName': 'Alectinib'}]",A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST),1201
56,NCT03148418,Phase II,Not yet recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study in Participants Previously Enrolled in a Genentech? and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study,1201
57,NCT02525757,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",MPDL3280A With Chemoradiation for Lung Cancer,1201
58,NCT03237780,Phase II,Not yet recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 6098, 'therapyName': 'Atezolizumab + Eribulin'}]",Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer,1201
59,NCT02997228,Phase III,Not yet recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 5126, 'therapyName': 'Bevacizumab + Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin'}]","Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Microsatellite Instability-High Metastatic Colorectal Cancer",1201
60,NCT02367794,Phase III,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC),1201
61,NCT02400814,Phase I,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer,1201
0,NCT02792192,Phase Ib/II,Recruiting,"[{'id': 4456, 'therapyName': 'Atezolizumab + BCG solution'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-risk Non-muscle-invasive Bladder Cancer (NMIBC) Participants,4456
0,NCT03074513,Phase II,Recruiting,"[{'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}]",Atezolizumab and Bevacizumab in Rare Solid Tumors,4595
1,NCT03133390,Phase II,Recruiting,"[{'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",Atezolizumab With or Without Bevacizumab in Cisplatin-ineligible Patients,4595
2,NCT03175432,Phase II,Recruiting,"[{'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}]",Study of BEvacizumab in Combination With ATezolizumab in Patients With Untreated Melanoma Brain Metastases  (BEAT-MBM),4595
3,NCT03181100,Phase II,Recruiting,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}, {'id': 3049, 'therapyName': 'Atezolizumab + nab-paclitaxel'}, {'id': 4825, 'therapyName': 'Atezolizumab + Vemurafenib + Cobimetinib'}, {'id': 5606, 'therapyName': 'Atezolizumab + Paclitaxel'}]",Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas,4595
4,NCT02921269,Phase II,Suspended,"[{'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}]","Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer",4595
0,NCT02873195,Phase II,Not yet recruiting,"[{'id': 2097, 'therapyName': 'Bevacizumab + Capecitabine'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer,1202
1,NCT01984242,Phase II,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) as Monotherapy or in Combination With Avastin (Bevacizumab) Compared to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma,1202
2,NCT01633970,Phase I,"Active, not recruiting","[{'id': 1203, 'therapyName': 'Atezolizumab + Carboplatin + Paclitaxel'}, {'id': 1204, 'therapyName': 'Atezolizumab + Carboplatin + Pemetrexed'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Avastin (Bevacizumab) and/or With Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors,1202
3,NCT02715531,Phase I,Recruiting,"[{'id': 3947, 'therapyName': 'Atezolizumab + Gemcitabine + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors,1202
4,NCT02724878,Phase II,Recruiting,"[{'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma,1202
0,NCT02366143,Phase III,"Active, not recruiting","[{'id': 2370, 'therapyName': 'Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel'}, {'id': 1489, 'therapyName': 'Nab-paclitaxel + Carboplatin + Bevacizumab'}, {'id': 1203, 'therapyName': 'Atezolizumab + Carboplatin + Paclitaxel'}]",TBAA Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer,2370
1,NCT03038100,Phase III,Recruiting,"[{'id': 2370, 'therapyName': 'Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel'}, {'id': 1152, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel'}]","A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (IMagyn050)",2370
0,NCT02839707,Phase II,Recruiting,"[{'id': 4496, 'therapyName': 'Atezolizumab + Bevacizumab + Doxil'}, {'id': 4495, 'therapyName': 'Atezolizumab + Doxil'}, {'id': 1673, 'therapyName': 'Doxil + Bevacizamub'}]","Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",4496
0,NCT03280563,Phase Ib/II,Not yet recruiting,"[{'id': 6269, 'therapyName': 'Atezolizumab + Ipatasertib'}, {'id': 6270, 'therapyName': 'Atezolizumab + Bevacizumab + Exemestane'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 6271, 'therapyName': 'Atezolizumab + Bevacizumab + Fulvestrant'}, {'id': 6272, 'therapyName': 'Atezolizumab + Bevacizumab + Tamoxifen'}, {'id': 6273, 'therapyName': 'Atezolizumab + Ipatasertib + Fulvestrant'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 6268, 'therapyName': 'Atezolizumab + Fulvestrant'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer,6270
0,NCT03280563,Phase Ib/II,Not yet recruiting,"[{'id': 6269, 'therapyName': 'Atezolizumab + Ipatasertib'}, {'id': 6270, 'therapyName': 'Atezolizumab + Bevacizumab + Exemestane'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 6271, 'therapyName': 'Atezolizumab + Bevacizumab + Fulvestrant'}, {'id': 6272, 'therapyName': 'Atezolizumab + Bevacizumab + Tamoxifen'}, {'id': 6273, 'therapyName': 'Atezolizumab + Ipatasertib + Fulvestrant'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 6268, 'therapyName': 'Atezolizumab + Fulvestrant'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer,6271
0,NCT03280563,Phase Ib/II,Not yet recruiting,"[{'id': 6269, 'therapyName': 'Atezolizumab + Ipatasertib'}, {'id': 6270, 'therapyName': 'Atezolizumab + Bevacizumab + Exemestane'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 6271, 'therapyName': 'Atezolizumab + Bevacizumab + Fulvestrant'}, {'id': 6272, 'therapyName': 'Atezolizumab + Bevacizumab + Tamoxifen'}, {'id': 6273, 'therapyName': 'Atezolizumab + Ipatasertib + Fulvestrant'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 6268, 'therapyName': 'Atezolizumab + Fulvestrant'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer,6272
0,NCT02174172,Phase I,Recruiting,"[{'id': 6252, 'therapyName': 'Atezolizumab + Bevacizumab +Peg-interferon alfa-2a'}, {'id': 6253, 'therapyName': 'Atezolizumab + Interferon alfa-2b'}, {'id': 6250, 'therapyName': 'Atezolizumab + Peg-interferon alfa-2a'}, {'id': 6249, 'therapyName': 'Atezolizumab + Ipilimumab'}, {'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}]",A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors,6252
0,NCT03193190,Phase Ib/II,Recruiting,"[{'id': 5942, 'therapyName': 'Atezolizumab + BKT140'}, {'id': 5940, 'therapyName': 'Gemcitabine + Nab-Paclitaxel + mFOLFOX-6'}, {'id': 5941, 'therapyName': 'Atezolizumab + PEGPH20'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC),5942
1,NCT03281369,Phase Ib/II,Not yet recruiting,"[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 6274, 'therapyName': 'mFOLFOX-6 + Atezolizumab + Cobimetinib'}, {'id': 6275, 'therapyName': 'mFOLFOX-6 + Atezolizumab'}, {'id': 6276, 'therapyName': 'Atezolizumab + Linagliptin'}, {'id': 5941, 'therapyName': 'Atezolizumab + PEGPH20'}, {'id': 5942, 'therapyName': 'Atezolizumab + BKT140'}, {'id': 1721, 'therapyName': 'Ramucirumab + Paclitaxel'}, {'id': 5850, 'therapyName': 'mFOLFOX-6'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (UMBRELLA),5942
0,NCT02500407,Phase I,Recruiting,"[{'id': 6305, 'therapyName': 'Atezolizumab + BTCT4465A'}]",A Safety and Pharmacokinetic Study of BTCT4465A as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL),6305
0,NCT03170960,Phase Ib/II,Recruiting,"[{'id': 6094, 'therapyName': 'Atezolizumab + Cabozantinib'}]",Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors,6094
1,NCT03264066,Phase II,Not yet recruiting,"[{'id': 6094, 'therapyName': 'Atezolizumab + Cabozantinib'}]",A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors,6094
0,NCT03206203,Phase II,Recruiting,"[{'id': 5983, 'therapyName': 'Atezolizumab + Carboplatin'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer,5983
0,NCT02763579,Phase III,Recruiting,"[{'id': 4164, 'therapyName': 'Atezolizumab + Carboplatin + Etoposide'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer (IMpower133),4164
1,NCT02748889,Phase Ib/II,Terminated,"[{'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}, {'id': 4164, 'therapyName': 'Atezolizumab + Carboplatin + Etoposide'}]",Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer,4164
2,NCT03041311,Phase II,Recruiting,"[{'id': 5541, 'therapyName': 'Atezolizumab + Carboplatin + Etoposide + Trilaciclib'}, {'id': 4164, 'therapyName': 'Atezolizumab + Carboplatin + Etoposide'}]","Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Extensive Stage Small Cell Lung Cancer (SCLC)",4164
0,NCT03041311,Phase II,Recruiting,"[{'id': 5541, 'therapyName': 'Atezolizumab + Carboplatin + Etoposide + Trilaciclib'}, {'id': 4164, 'therapyName': 'Atezolizumab + Carboplatin + Etoposide'}]","Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Extensive Stage Small Cell Lung Cancer (SCLC)",5541
0,NCT02807636,Phase III,Recruiting,"[{'id': 4450, 'therapyName': 'Atezolizumab + Carboplatin + Gemcitabine'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",The Effect of Atezolizumab in Combination With Gemcitabine/Carboplatin and Gemcitabine/Carboplatin Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Therapy,4450
0,NCT02716038,Phase II,Recruiting,"[{'id': 3946, 'therapyName': 'Atezolizumab + Carboplatin + nab-Paclitaxel'}]","Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC",3946
0,NCT01633970,Phase I,"Active, not recruiting","[{'id': 1203, 'therapyName': 'Atezolizumab + Carboplatin + Paclitaxel'}, {'id': 1204, 'therapyName': 'Atezolizumab + Carboplatin + Pemetrexed'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Avastin (Bevacizumab) and/or With Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors,1203
1,NCT02366143,Phase III,"Active, not recruiting","[{'id': 2370, 'therapyName': 'Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel'}, {'id': 1489, 'therapyName': 'Nab-paclitaxel + Carboplatin + Bevacizumab'}, {'id': 1203, 'therapyName': 'Atezolizumab + Carboplatin + Paclitaxel'}]",TBAA Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer,1203
2,NCT02883062,Phase II,Not yet recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1203, 'therapyName': 'Atezolizumab + Carboplatin + Paclitaxel'}]","Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer",1203
0,NCT01633970,Phase I,"Active, not recruiting","[{'id': 1203, 'therapyName': 'Atezolizumab + Carboplatin + Paclitaxel'}, {'id': 1204, 'therapyName': 'Atezolizumab + Carboplatin + Pemetrexed'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Avastin (Bevacizumab) and/or With Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors,1204
0,NCT02989584,Phase Ib/II,Recruiting,"[{'id': 5140, 'therapyName': 'Atezolizumab + Cisplatin + Gemcitabine'}]",A Pilot Safety Study of Atezolizumab Combination With Cisplatin + Gemcitabine in Pts With Metastatic Bladder Cancer,5140
1,NCT03093922,Phase II,Recruiting,"[{'id': 5140, 'therapyName': 'Atezolizumab + Cisplatin + Gemcitabine'}]",A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer,5140
0,NCT03228537,Phase I,Not yet recruiting,"[{'id': 6036, 'therapyName': 'Atezolizumab + Cisplatin + Pemetrexed'}]","Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma",6036
0,NCT02630186,Phase Ib/II,"Active, not recruiting","[{'id': 3575, 'therapyName': 'Atezolizumab + CO1686'}]",A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC,3575
0,NCT03281369,Phase Ib/II,Not yet recruiting,"[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 6274, 'therapyName': 'mFOLFOX-6 + Atezolizumab + Cobimetinib'}, {'id': 6275, 'therapyName': 'mFOLFOX-6 + Atezolizumab'}, {'id': 6276, 'therapyName': 'Atezolizumab + Linagliptin'}, {'id': 5941, 'therapyName': 'Atezolizumab + PEGPH20'}, {'id': 5942, 'therapyName': 'Atezolizumab + BKT140'}, {'id': 1721, 'therapyName': 'Ramucirumab + Paclitaxel'}, {'id': 5850, 'therapyName': 'mFOLFOX-6'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (UMBRELLA),1343
1,NCT03280563,Phase Ib/II,Not yet recruiting,"[{'id': 6269, 'therapyName': 'Atezolizumab + Ipatasertib'}, {'id': 6270, 'therapyName': 'Atezolizumab + Bevacizumab + Exemestane'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 6271, 'therapyName': 'Atezolizumab + Bevacizumab + Fulvestrant'}, {'id': 6272, 'therapyName': 'Atezolizumab + Bevacizumab + Tamoxifen'}, {'id': 6273, 'therapyName': 'Atezolizumab + Ipatasertib + Fulvestrant'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 6268, 'therapyName': 'Atezolizumab + Fulvestrant'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer,1343
2,NCT03181100,Phase II,Recruiting,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}, {'id': 3049, 'therapyName': 'Atezolizumab + nab-paclitaxel'}, {'id': 4825, 'therapyName': 'Atezolizumab + Vemurafenib + Cobimetinib'}, {'id': 5606, 'therapyName': 'Atezolizumab + Paclitaxel'}]",Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas,1343
3,NCT03273153,Phase III,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma,1343
4,NCT02788279,Phase III,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}]",A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma,1343
5,NCT03201458,Phase II,Not yet recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery,1343
6,NCT03193190,Phase Ib/II,Recruiting,"[{'id': 5942, 'therapyName': 'Atezolizumab + BKT140'}, {'id': 5940, 'therapyName': 'Gemcitabine + Nab-Paclitaxel + mFOLFOX-6'}, {'id': 5941, 'therapyName': 'Atezolizumab + PEGPH20'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC),1343
7,NCT01988896,Phase I,"Active, not recruiting","[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors,1343
8,NCT03108131,Phase II,Recruiting,"[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",Cobimetinib and Atezolizumab in Advanced Rare Tumors,1343
9,NCT03178851,Phase I,Recruiting,"[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",A Study Evaluating Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy,1343
0,NCT03202316,Phase II,Recruiting,"[{'id': 5970, 'therapyName': 'Atezolizumab + Cobimetinib + Eribulin'}]",Study of Triple Combination of Atezolizumab + Cobimetinib + Eribulin (ACE) in Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer,5970
0,NCT03023423,Phase Ib/II,Recruiting,"[{'id': 5236, 'therapyName': 'Atezolizumab + Daratumumab'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (DARZALEX),5236
0,NCT02495636,Phase II,Withdrawn,"[{'id': 4204, 'therapyName': 'Atezolizumab + DEC-205-NY-ESO-1 fusion protein vaccine'}]","Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer",4204
0,NCT02839707,Phase II,Recruiting,"[{'id': 4496, 'therapyName': 'Atezolizumab + Bevacizumab + Doxil'}, {'id': 4495, 'therapyName': 'Atezolizumab + Doxil'}, {'id': 1673, 'therapyName': 'Doxil + Bevacizamub'}]","Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",4495
0,NCT03024437,Phase Ib/II,"Active, not recruiting","[{'id': 5129, 'therapyName': 'Entinostat + Atezolizumab'}, {'id': 5235, 'therapyName': 'Atezolizumab + Entinostat + Bevacizumab'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma,5235
0,NCT03016312,Phase III,Recruiting,"[{'id': 5204, 'therapyName': 'Atezolizumab + Enzalutamide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]","IMbassador250: A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen",5204
0,NCT02298153,Phase I,"Active, not recruiting","[{'id': 2636, 'therapyName': 'Atezolizumab + Epacadostat'}]",A Study of MPDL3280A in Combination With INCB024360 in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer,2636
0,NCT03237780,Phase II,Not yet recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 6098, 'therapyName': 'Atezolizumab + Eribulin'}]",Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer,6098
0,NCT02013219,Phase I,"Active, not recruiting","[{'id': 3490, 'therapyName': 'Alectinib + Atezolizumab'}, {'id': 1352, 'therapyName': 'Atezolizumab + Erlotinib'}]",A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer,1352
0,NCT03073525,Phase II,Recruiting,"[{'id': 5558, 'therapyName': 'Atezolizumab + FANG vaccine'}]",Trial of Atezolizumab and Vigil for Advanced Gynecological Cancers (A Companion Study to CL-PTL-119),5558
0,NCT03280563,Phase Ib/II,Not yet recruiting,"[{'id': 6269, 'therapyName': 'Atezolizumab + Ipatasertib'}, {'id': 6270, 'therapyName': 'Atezolizumab + Bevacizumab + Exemestane'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 6271, 'therapyName': 'Atezolizumab + Bevacizumab + Fulvestrant'}, {'id': 6272, 'therapyName': 'Atezolizumab + Bevacizumab + Tamoxifen'}, {'id': 6273, 'therapyName': 'Atezolizumab + Ipatasertib + Fulvestrant'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 6268, 'therapyName': 'Atezolizumab + Fulvestrant'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer,6268
0,NCT02715531,Phase I,Recruiting,"[{'id': 3947, 'therapyName': 'Atezolizumab + Gemcitabine + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors,3947
0,NCT02174172,Phase I,Recruiting,"[{'id': 6252, 'therapyName': 'Atezolizumab + Bevacizumab +Peg-interferon alfa-2a'}, {'id': 6253, 'therapyName': 'Atezolizumab + Interferon alfa-2b'}, {'id': 6250, 'therapyName': 'Atezolizumab + Peg-interferon alfa-2a'}, {'id': 6249, 'therapyName': 'Atezolizumab + Ipilimumab'}, {'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}]",A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors,6253
0,NCT03280563,Phase Ib/II,Not yet recruiting,"[{'id': 6269, 'therapyName': 'Atezolizumab + Ipatasertib'}, {'id': 6270, 'therapyName': 'Atezolizumab + Bevacizumab + Exemestane'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 6271, 'therapyName': 'Atezolizumab + Bevacizumab + Fulvestrant'}, {'id': 6272, 'therapyName': 'Atezolizumab + Bevacizumab + Tamoxifen'}, {'id': 6273, 'therapyName': 'Atezolizumab + Ipatasertib + Fulvestrant'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 6268, 'therapyName': 'Atezolizumab + Fulvestrant'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer,6269
0,NCT03280563,Phase Ib/II,Not yet recruiting,"[{'id': 6269, 'therapyName': 'Atezolizumab + Ipatasertib'}, {'id': 6270, 'therapyName': 'Atezolizumab + Bevacizumab + Exemestane'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 6271, 'therapyName': 'Atezolizumab + Bevacizumab + Fulvestrant'}, {'id': 6272, 'therapyName': 'Atezolizumab + Bevacizumab + Tamoxifen'}, {'id': 6273, 'therapyName': 'Atezolizumab + Ipatasertib + Fulvestrant'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 6268, 'therapyName': 'Atezolizumab + Fulvestrant'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer,6273
0,NCT02174172,Phase I,Recruiting,"[{'id': 6252, 'therapyName': 'Atezolizumab + Bevacizumab +Peg-interferon alfa-2a'}, {'id': 6253, 'therapyName': 'Atezolizumab + Interferon alfa-2b'}, {'id': 6250, 'therapyName': 'Atezolizumab + Peg-interferon alfa-2a'}, {'id': 6249, 'therapyName': 'Atezolizumab + Ipilimumab'}, {'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}]",A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors,6249
0,NCT02926833,Phase Ib/II,Recruiting,"[{'id': 4830, 'therapyName': 'Atezolizumab + KTE-C19'}]",A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ZUMA-6),4830
0,NCT02631577,Phase I,Suspended,"[{'id': 3387, 'therapyName': 'Atezolizumab + lenalidomide + Obinutuzumab'}]",A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma,3387
0,NCT03281369,Phase Ib/II,Not yet recruiting,"[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 6274, 'therapyName': 'mFOLFOX-6 + Atezolizumab + Cobimetinib'}, {'id': 6275, 'therapyName': 'mFOLFOX-6 + Atezolizumab'}, {'id': 6276, 'therapyName': 'Atezolizumab + Linagliptin'}, {'id': 5941, 'therapyName': 'Atezolizumab + PEGPH20'}, {'id': 5942, 'therapyName': 'Atezolizumab + BKT140'}, {'id': 1721, 'therapyName': 'Ramucirumab + Paclitaxel'}, {'id': 5850, 'therapyName': 'mFOLFOX-6'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (UMBRELLA),6276
0,NCT03029832,Phase II,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 5451, 'therapyName': 'Atezolizumab + MOXR0916'}]",A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy,5451
0,NCT02794571,Phase I,Recruiting,"[{'id': 4269, 'therapyName': 'Atezolizumab + MTIG7192A '}, {'id': 4268, 'therapyName': 'MTIG7192A '}]",Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors,4269
0,NCT02530489,Phase II,Recruiting,"[{'id': 3049, 'therapyName': 'Atezolizumab + nab-paclitaxel'}]",Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A,3049
1,NCT03181100,Phase II,Recruiting,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}, {'id': 3049, 'therapyName': 'Atezolizumab + nab-paclitaxel'}, {'id': 4825, 'therapyName': 'Atezolizumab + Vemurafenib + Cobimetinib'}, {'id': 5606, 'therapyName': 'Atezolizumab + Paclitaxel'}]",Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas,3049
0,NCT02846623,Phase II,Recruiting,"[{'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}]",Atezolizumab (PD-L1 mAb) in Combination With Obinutuzumab and Ibrutinib in Patients With Relapsed Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL),1975
1,NCT02596971,Phase I,Recruiting,"[{'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 1231, 'therapyName': 'Bendamustine'}]",Safety and Efficacy of MPDL3280A in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus CHOP in Patients With Follicular Lymphoma or Diffuse Large B-Cell Lymphoma,1975
2,NCT02220842,Phase I,Recruiting,"[{'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}]",A Safety and Pharmacology Study of MPDL3280A Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma,1975
3,NCT02174172,Phase I,Recruiting,"[{'id': 6252, 'therapyName': 'Atezolizumab + Bevacizumab +Peg-interferon alfa-2a'}, {'id': 6253, 'therapyName': 'Atezolizumab + Interferon alfa-2b'}, {'id': 6250, 'therapyName': 'Atezolizumab + Peg-interferon alfa-2a'}, {'id': 6249, 'therapyName': 'Atezolizumab + Ipilimumab'}, {'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}]",A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors,1975
0,NCT02729896,Phase Ib/II,Recruiting,"[{'id': 4362, 'therapyName': 'Atezolizumab + Obinutuzumab + Polatuzumab Vedotin'}]","A Study of Obinutuzumab, Polatuzumab Vedotin, and Atezolizumab in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",4362
0,NCT03125902,Phase III,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 5606, 'therapyName': 'Atezolizumab + Paclitaxel'}]",A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IMpassion131),5606
1,NCT03181100,Phase II,Recruiting,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}, {'id': 3049, 'therapyName': 'Atezolizumab + nab-paclitaxel'}, {'id': 4825, 'therapyName': 'Atezolizumab + Vemurafenib + Cobimetinib'}, {'id': 5606, 'therapyName': 'Atezolizumab + Paclitaxel'}]",Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas,5606
0,NCT03125928,Phase II,Recruiting,"[{'id': 5600, 'therapyName': 'Atezolizumab + Paclitaxel + Trastuzumab + Pertuzumab'}]","Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer",5600
0,NCT02174172,Phase I,Recruiting,"[{'id': 6252, 'therapyName': 'Atezolizumab + Bevacizumab +Peg-interferon alfa-2a'}, {'id': 6253, 'therapyName': 'Atezolizumab + Interferon alfa-2b'}, {'id': 6250, 'therapyName': 'Atezolizumab + Peg-interferon alfa-2a'}, {'id': 6249, 'therapyName': 'Atezolizumab + Ipilimumab'}, {'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}]",A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors,6250
0,NCT03193190,Phase Ib/II,Recruiting,"[{'id': 5942, 'therapyName': 'Atezolizumab + BKT140'}, {'id': 5940, 'therapyName': 'Gemcitabine + Nab-Paclitaxel + mFOLFOX-6'}, {'id': 5941, 'therapyName': 'Atezolizumab + PEGPH20'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC),5941
1,NCT03281369,Phase Ib/II,Not yet recruiting,"[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 6274, 'therapyName': 'mFOLFOX-6 + Atezolizumab + Cobimetinib'}, {'id': 6275, 'therapyName': 'mFOLFOX-6 + Atezolizumab'}, {'id': 6276, 'therapyName': 'Atezolizumab + Linagliptin'}, {'id': 5941, 'therapyName': 'Atezolizumab + PEGPH20'}, {'id': 5942, 'therapyName': 'Atezolizumab + BKT140'}, {'id': 1721, 'therapyName': 'Ramucirumab + Paclitaxel'}, {'id': 5850, 'therapyName': 'mFOLFOX-6'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (UMBRELLA),5941
0,NCT02814669,Phase I,Recruiting,"[{'id': 4881, 'therapyName': 'Atezolizumab + Ra 223'}]",Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor,4881
1,NCT03208712,Phase I,Not yet recruiting,"[{'id': 4881, 'therapyName': 'Atezolizumab + Ra 223'}]",Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy,4881
0,NCT02650713,Phase I,Recruiting,"[{'id': 3412, 'therapyName': 'Atezolizumab + RO6958688 '}]","A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors",3412
0,NCT03289962,Phase I,Not yet recruiting,"[{'id': 6234, 'therapyName': 'RO7198457'}, {'id': 6235, 'therapyName': 'Atezolizumab + RO7198457'}]",A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors,6235
0,NCT03206047,Phase Ib/II,Recruiting,"[{'id': 4693, 'therapyName': 'Atezolizumab + SGI-110'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 5982, 'therapyName': 'Atezolizumab + SGI-110 + DEC-205-NY-ESO-1 fusion protein vaccine'}]","Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",4693
1,NCT02892318,Phase I,Recruiting,"[{'id': 4693, 'therapyName': 'Atezolizumab + SGI-110'}]",A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML),4693
2,NCT02935361,Phase Ib/II,Recruiting,"[{'id': 4693, 'therapyName': 'Atezolizumab + SGI-110'}]",Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed,4693
0,NCT03206047,Phase Ib/II,Recruiting,"[{'id': 4693, 'therapyName': 'Atezolizumab + SGI-110'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 5982, 'therapyName': 'Atezolizumab + SGI-110 + DEC-205-NY-ESO-1 fusion protein vaccine'}]","Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",5982
0,NCT03024216,Phase I,Recruiting,"[{'id': 5642, 'therapyName': 'Atezolizumab + Sipuleucel-T'}]",Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients Who Have Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer,5642
0,NCT03174197,Phase Ib/II,Recruiting,"[{'id': 5872, 'therapyName': 'Atezolizumab + Temozolomide'}]",Atezolizumab (aPDL1) + Temozolomide and Radiation for Newly Diagnosed Glioblastoma (GBM),5872
0,NCT03292172,Phase I,Not yet recruiting,"[{'id': 6286, 'therapyName': 'Atezolizumab + TEN-010'}]","A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer",6286
0,NCT02605915,Phase I,Recruiting,"[{'id': 3250, 'therapyName': 'Atezolizumab + Trastuzumab'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 856, 'therapyName': 'Pertuzumab'}]",Safety and Pharmacokinetics of Atezolizumab in Combination With Trastuzumab Emtansine or With Trastuzumab and Pertuzumab in Participants With HER2-Positive Breast Cancer,3250
1,NCT02924883,Phase II,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 3250, 'therapyName': 'Atezolizumab + Trastuzumab'}]",A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab and Taxane Based Therapy,3250
0,NCT02543645,Phase Ib/II,Terminated,"[{'id': 3086, 'therapyName': 'Atezolizumab + Varlilumab'}]",A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer,3086
0,NCT02849496,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 4511, 'therapyName': 'Atezolizumab + Veliparib'}, {'id': 954, 'therapyName': 'Veliparib'}]",Veliparib and Atezolizumab Either Alone or in Combination in Treating Patients With Stage III-IV Triple Negative Breast Cancer,4511
0,NCT01656642,Phase I,"Active, not recruiting","[{'id': 1216, 'therapyName': 'Atezolizumab + vemurafenib'}]", A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Vemurafinib (Zelboraf&#174;) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma,1216
0,NCT02908672,Phase III,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 4825, 'therapyName': 'Atezolizumab + Vemurafenib + Cobimetinib'}]",A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Participants With Metastatic or Unresectable Locally Advanced Melanoma,4825
1,NCT03181100,Phase II,Recruiting,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}, {'id': 3049, 'therapyName': 'Atezolizumab + nab-paclitaxel'}, {'id': 4825, 'therapyName': 'Atezolizumab + Vemurafenib + Cobimetinib'}, {'id': 5606, 'therapyName': 'Atezolizumab + Paclitaxel'}]",Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas,4825
0,NCT01980823,Phase I,Recruiting,"[{'id': 1576, 'therapyName': 'Atorvastatin + Metformin'}]",Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer,1576
1,NCT02497638,Phase II,Recruiting,"[{'id': 1576, 'therapyName': 'Atorvastatin + Metformin'}]",LIpitor and biGuanide to Androgen Delay Trial,1576
0,NCT01898715,Phase I,Recruiting,"[{'id': 4296, 'therapyName': 'ATR-101'}]",Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma,4296
0,NCT03052127,Phase I,Recruiting,"[{'id': 5828, 'therapyName': 'AU-011'}]",Phase 1B Study in Subjects With Small to Medium Primary Choroidal Melanoma,5828
0,NCT01737502,Phase II,Recruiting,"[{'id': 2301, 'therapyName': 'Auranofin + Sirolimus'}]",PKCi and mTOR Inhibition With Auranofin+Sirolimus for Squamous Cell Lung Cancer,2301
0,NCT00889954,Phase I,"Active, not recruiting","[{'id': 1403, 'therapyName': 'Autologous TGF beta resistant HER2 EBV CTLs'}]",Her2 and TGFBeta CTLs in Treatment of Her2 Positive Malignancy,1403
0,NCT01752400,Phase II,"Active, not recruiting","[{'id': 647, 'therapyName': 'AUY922'}]",AUY922 for Advanced ALK-positive NSCLC,647
1,NCT01854034,Phase II,Completed,"[{'id': 647, 'therapyName': 'AUY922'}]",Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR,647
2,NCT01646125,,Terminated,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 647, 'therapyName': 'AUY922'}, {'id': 854, 'therapyName': 'Pemetrexed'}]"," An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations",647
3,NCT01772797,Phase I,Completed,"[{'id': 789, 'therapyName': 'Ceritinib'}, {'id': 647, 'therapyName': 'AUY922'}]",Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer,647
0,NCT01294826,Phase I,Completed,"[{'id': 1996, 'therapyName': 'AUY922 + Cetuximab'}]",Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer,1996
0,NCT01784640,Phase I,"Active, not recruiting","[{'id': 1270, 'therapyName': 'AUY922 + Pemetrexed'}]",Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer,1270
0,NCT01884740,Phase Ib/II,Recruiting,"[{'id': 1654, 'therapyName': 'Avastin + Cetuximab'}]",Phase I/II Trial Of Super-Selective Intraarterial Infusion Of Erbitux and Bevacizumab For Treatment Of Relapsed/Refractory Intracranial Glioma In Patients Under 22 Years Of Age,1654
0,NCT03278379,Phase II,Not yet recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab in G2-3 NET (NET-002),3144
1,NCT03136406,Phase Ib/II,Recruiting,"[{'id': 1018, 'therapyName': 'GI-4000'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 6163, 'therapyName': 'ETBX-011'}, {'id': 3060, 'therapyName': 'ALT-803'}]",QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy,3144
2,NCT03158883,Phase I,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients,3144
3,NCT02155647,Phase II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200),3144
4,NCT02625610,Phase III,Recruiting,"[{'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}]",Avelumab in First-Line Gastric Cancer (JAVELIN Gastric 100),3144
5,NCT02603419,Phase I,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS),3144
6,NCT02718417,Phase III,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100),3144
7,NCT02968940,Phase III,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma,3144
8,NCT02912572,Phase II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]","Study of Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer",3144
9,NCT03000179,Phase II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma,3144
10,NCT02875613,Phase II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer,3144
11,NCT03006848,Phase II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma,3144
12,NCT02395172,Phase III,"Active, not recruiting","[{'id': 3144, 'therapyName': 'Avelumab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200),3144
13,NCT02625623,Phase III,"Active, not recruiting","[{'id': 3144, 'therapyName': 'Avelumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300),3144
14,NCT03035630,Phase II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma,3144
15,NCT03076554,Phase II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy,3144
16,NCT03288350,Phase II,Not yet recruiting,"[{'id': 1930, 'therapyName': 'Cisplatin + Docetaxel + Fluorouracil'}, {'id': 3144, 'therapyName': 'Avelumab'}]",mDCF + Avelumab in Resectable Esophago-gastric Adenocarcinoma (EGA),3144
17,NCT02576574,Phase III,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100),3144
18,NCT03271372,Phase III,Not yet recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Adjuvant Avelumab in Merkel Cell Cancer (ADAM),3144
19,NCT02584829,Phase Ib/II,Suspended,"[{'id': 3156, 'therapyName': 'IFN-B'}, {'id': 3144, 'therapyName': 'Avelumab'}]",Localized Radiation Therapy or Recombinant Interferon Beta and MSB0010718C With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma,3144
20,NCT02603432,Phase III,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100),3144
21,NCT03050554,Phase Ib/II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Stereotactic Body Radiation Therapy (SBRT) Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC),3144
22,NCT03267836,Phase I,Not yet recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma,3144
23,NCT02915523,Phase Ib/II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}, {'id': 5559, 'therapyName': 'Avelumab + Entinostat'}]",Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer,3144
24,NCT02859454,Phase II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab for People With Recurrent Respiratory Papillomatosis,3144
25,NCT01772004,Phase I,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor),3144
26,NCT02584634,Phase I,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 869, 'therapyName': 'PF-06463922'}]","Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)",3144
27,NCT02580058,Phase III,"Active, not recruiting","[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 3144, 'therapyName': 'Avelumab'}]",A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer,3144
28,NCT03047473,Phase II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme (SEJ),3144
29,NCT03278405,Phase Ib/II,Not yet recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab in G3 NEC (NET-001),3144
30,NCT02943317,Phase I,Recruiting,"[{'id': 958, 'therapyName': 'VS-6063'}, {'id': 3144, 'therapyName': 'Avelumab'}]","Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer",3144
0,NCT02684006,Phase III,Recruiting,"[{'id': 3145, 'therapyName': 'Avelumab + Axitinib'}, {'id': 930, 'therapyName': 'Sunitinib'}]",A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101),3145
1,NCT02493751,Phase I,"Active, not recruiting","[{'id': 3145, 'therapyName': 'Avelumab + Axitinib'}]",A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer,3145
0,NCT02953561,Phase Ib/II,Recruiting,"[{'id': 5372, 'therapyName': 'Avelumab + Azacitidine'}]",Avelumab (antiPDL1) and Azacytidine in Acute Myeloid Leukemia (AML),5372
0,NCT02951156,Phase III,Recruiting,"[{'id': 5088, 'therapyName': 'Avelumab + Azacitidine + Utomilumab'}, {'id': 5087, 'therapyName': 'Avelumab + Rituximab + Utomilumab'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 5090, 'therapyName': 'Gemcitabine + Oxaliplatin + Rituximab'}, {'id': 5089, 'therapyName': 'Avelumab + Bendamustine + Rituximab'}]","Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)",5088
0,NCT02951156,Phase III,Recruiting,"[{'id': 5088, 'therapyName': 'Avelumab + Azacitidine + Utomilumab'}, {'id': 5087, 'therapyName': 'Avelumab + Rituximab + Utomilumab'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 5090, 'therapyName': 'Gemcitabine + Oxaliplatin + Rituximab'}, {'id': 5089, 'therapyName': 'Avelumab + Bendamustine + Rituximab'}]","Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)",5089
0,NCT03217747,Phase Ib/II,Recruiting,"[{'id': 5052, 'therapyName': 'Avelumab + Cisplatin'}, {'id': 6044, 'therapyName': 'Avelumab + PF-04518600 + Utomilumab'}, {'id': 6043, 'therapyName': 'Avelumab + Utomilumab'}, {'id': 6045, 'therapyName': 'Avelumab + PF-04518600'}]",Study to Evaluate the Safety and Tolerability of Avelumab in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies,5052
1,NCT02952586,Phase III,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 5052, 'therapyName': 'Avelumab + Cisplatin'}]",Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100),5052
0,NCT03258398,Phase II,Recruiting,"[{'id': 6238, 'therapyName': 'Avelumab + eFT508'}, {'id': 4005, 'therapyName': 'eFT508'}]",A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer,6238
0,NCT02915523,Phase Ib/II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}, {'id': 5559, 'therapyName': 'Avelumab + Entinostat'}]",Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer,5559
0,NCT02994953,Phase I,Recruiting,"[{'id': 5131, 'therapyName': 'Avelumab + NHS-IL12'}]","A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12)",5131
0,NCT03217747,Phase Ib/II,Recruiting,"[{'id': 5052, 'therapyName': 'Avelumab + Cisplatin'}, {'id': 6044, 'therapyName': 'Avelumab + PF-04518600 + Utomilumab'}, {'id': 6043, 'therapyName': 'Avelumab + Utomilumab'}, {'id': 6045, 'therapyName': 'Avelumab + PF-04518600'}]",Study to Evaluate the Safety and Tolerability of Avelumab in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies,6045
0,NCT03217747,Phase Ib/II,Recruiting,"[{'id': 5052, 'therapyName': 'Avelumab + Cisplatin'}, {'id': 6044, 'therapyName': 'Avelumab + PF-04518600 + Utomilumab'}, {'id': 6043, 'therapyName': 'Avelumab + Utomilumab'}, {'id': 6045, 'therapyName': 'Avelumab + PF-04518600'}]",Study to Evaluate the Safety and Tolerability of Avelumab in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies,6044
0,NCT02951156,Phase III,Recruiting,"[{'id': 5088, 'therapyName': 'Avelumab + Azacitidine + Utomilumab'}, {'id': 5087, 'therapyName': 'Avelumab + Rituximab + Utomilumab'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 5090, 'therapyName': 'Gemcitabine + Oxaliplatin + Rituximab'}, {'id': 5089, 'therapyName': 'Avelumab + Bendamustine + Rituximab'}]","Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)",5087
0,NCT03074318,Phase Ib/II,Recruiting,"[{'id': 5444, 'therapyName': 'Avelumab + trabectedin'}]",Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery,5444
0,NCT03217747,Phase Ib/II,Recruiting,"[{'id': 5052, 'therapyName': 'Avelumab + Cisplatin'}, {'id': 6044, 'therapyName': 'Avelumab + PF-04518600 + Utomilumab'}, {'id': 6043, 'therapyName': 'Avelumab + Utomilumab'}, {'id': 6045, 'therapyName': 'Avelumab + PF-04518600'}]",Study to Evaluate the Safety and Tolerability of Avelumab in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies,6043
1,NCT02554812,Phase I,Recruiting,"[{'id': 6043, 'therapyName': 'Avelumab + Utomilumab'}]",A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley),6043
0,NCT03268057,Phase Ib/II,Recruiting,"[{'id': 6153, 'therapyName': 'Avelumab + VX15/2503'}]",VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer,6153
0,NCT03094169,Phase I,Recruiting,"[{'id': 5755, 'therapyName': 'AVID100'}]",AVID100 in Advanced Epithelial Carcinomas,5755
0,NCT01526473,Phase I,"Active, not recruiting","[{'id': 1068, 'therapyName': 'AVX901'}]",A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901,1068
0,NCT01649180,Phase II,Terminated,"[{'id': 649, 'therapyName': 'Axitinib'}]",NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma (PrE0801),649
1,NCT01967576,Phase II,"Active, not recruiting","[{'id': 649, 'therapyName': 'Axitinib'}]","Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma",649
2,NCT02667886,Phase Ib/II,Recruiting,"[{'id': 649, 'therapyName': 'Axitinib'}, {'id': 3570, 'therapyName': 'X4P-001'}]",Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma,649
3,NCT02129647,Phase II,Recruiting,"[{'id': 649, 'therapyName': 'Axitinib'}]",Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas,649
4,NCT03092856,Phase II,Recruiting,"[{'id': 649, 'therapyName': 'Axitinib'}, {'id': 5522, 'therapyName': 'Axitinib + PF-04518600'}]",Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer,649
5,NCT00828919,Phase I,"Active, not recruiting","[{'id': 649, 'therapyName': 'Axitinib'}]",Continuing Access To AG- 013736 (A406) For Patients Previously Receiving AG 013736 In Clinical Trials,649
6,NCT01540526,Phase I,Completed,"[{'id': 649, 'therapyName': 'Axitinib'}]",Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib,649
7,NCT01321437,Phase II,"Active, not recruiting","[{'id': 649, 'therapyName': 'Axitinib'}]",Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma,649
8,NCT02579811,Phase II,Recruiting,"[{'id': 649, 'therapyName': 'Axitinib'}]",Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer,649
9,NCT01508117,Phase II,Terminated,"[{'id': 649, 'therapyName': 'Axitinib'}]",Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients,649
10,NCT02762513,Phase II,Recruiting,"[{'id': 649, 'therapyName': 'Axitinib'}]",Expansion Trial for Axitinib In Head And Neck Cancer,649
11,NCT02164838,Phase I,"Active, not recruiting","[{'id': 649, 'therapyName': 'Axitinib'}]",VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors,649
12,NCT01533948,Phase II,Terminated,"[{'id': 649, 'therapyName': 'Axitinib'}]",Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery,649
13,NCT01599754,Phase III,"Active, not recruiting","[{'id': 649, 'therapyName': 'Axitinib'}]",Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients,649
14,NCT02693535,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 690, 'therapyName': 'Bosutinib'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer,649
15,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,649
16,NCT01409200,Phase II,Recruiting,"[{'id': 649, 'therapyName': 'Axitinib'}]",Neoadjuvant Axitinib in Prostate Cancer,649
17,NCT02560012,Phase II,Terminated,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Personalized Targeted Inhibitors Treatment in Renal Cell Cancer,649
18,NCT02639182,Phase II,Recruiting,"[{'id': 4220, 'therapyName': 'AGS-16C3F'}, {'id': 649, 'therapyName': 'Axitinib'}]",A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma,649
19,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,649
20,NCT01727336,Phase II,"Active, not recruiting","[{'id': 1245, 'therapyName': 'Dalantercept + Axitinib'}, {'id': 649, 'therapyName': 'Axitinib'}]", Study of Dalantercept in Patients With Advanced Renal Cell Carcinoma,649
0,NCT02782403,Phase Ib/II,Recruiting,"[{'id': 4241, 'therapyName': 'Axitinib + Bosutinib'}]","Axitinib and Bosutinib for Patients With Chronic Myeloid Leukemia in Chronic, Accelerated or Blastic Phases",4241
0,NCT01999972,Phase I,"Active, not recruiting","[{'id': 1350, 'therapyName': 'Axitinib + Crizotinib'}]",A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors,1350
0,NCT03172754,Phase Ib/II,Recruiting,"[{'id': 5837, 'therapyName': 'Axitinib + Nivolumab'}]",Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma,5837
0,NCT02133742,Phase I,"Active, not recruiting","[{'id': 2494, 'therapyName': 'Axitinib + Pembrolizumab'}]","A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer",2494
1,NCT02636725,Phase II,Recruiting,"[{'id': 2494, 'therapyName': 'Axitinib + Pembrolizumab'}]",Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas,2494
2,NCT02853331,Phase III,Recruiting,"[{'id': 2494, 'therapyName': 'Axitinib + Pembrolizumab'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426),2494
0,NCT03092856,Phase II,Recruiting,"[{'id': 649, 'therapyName': 'Axitinib'}, {'id': 5522, 'therapyName': 'Axitinib + PF-04518600'}]",Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer,5522
0,NCT02535533,Phase I,Recruiting,"[{'id': 3474, 'therapyName': 'Axitinib + Selenomethionine'}]",SLM + Axitinib for Clear Cell RCC,3474
0,NCT01721577,Phase Ib/II,Unknown status,"[{'id': 2745, 'therapyName': 'AXL1717'}]",Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas,2745
0,NCT02269943,Phase II,"Active, not recruiting","[{'id': 651, 'therapyName': 'Azacitidine'}]",Safety and Efficacy of Oral Azacitidine in Previously Treated Subjects With Locally Advanced or Metastatic Nasopharyngeal Carcinoma,651
1,NCT02942290,Phase II,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 1637, 'therapyName': 'GDC-0199 + Azacitidine'}]",A Study Evaluating Venetoclax in Combination With Azacitidine Compared With Azacitidine Alone in Participants With Previously Untreated Higher-Risk Myelodysplastic Syndromes (MDS),651
2,NCT02088541,Phase II,"Active, not recruiting","[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}]",Selinexor (KPT-330) in Older Patients With Relapsed AML,651
3,NCT02701673,Phase Ib/II,Withdrawn,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1078, 'therapyName': 'Belinostat'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}]",Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma,651
4,NCT02775903,Phase II,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 4178, 'therapyName': 'Azacitidine + MEDI4736'}]",An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Subjects With Acute Myeloid Leukemia (AML),651
5,NCT02920008,Phase III,Recruiting,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1949, 'therapyName': 'SGI-110'}]","Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia",651
6,NCT01787487,Phase III,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}]",Evaluation of RUX and AZA Combination as a Therapy For Patients With Myelofibrosis And Myelodysplastic Syndrome/ Myeloproliferative Neoplasm,651
7,NCT01720225,Phase II,"Active, not recruiting","[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk,651
8,NCT02343536,Phase I,Recruiting,"[{'id': 2488, 'therapyName': 'Cyclophosphamide + Prednisone + Rituximab + Vincristine'}, {'id': 651, 'therapyName': 'Azacitidine'}]","A Phase 1, Open-label,Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma",651
9,NCT02530463,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS),651
10,NCT03151304,Phase II,Recruiting,"[{'id': 5987, 'therapyName': 'Azacitidine + Pracinostat'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes,651
11,NCT02348489,Phase III,"Active, not recruiting","[{'id': 1949, 'therapyName': 'SGI-110'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 650, 'therapyName': 'Decitabine'}]","SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction",651
12,NCT03151408,Phase III,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 5987, 'therapyName': 'Azacitidine + Pracinostat'}]",An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia,651
13,NCT02469415,Phase II,Terminated,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2006, 'therapyName': 'Pacritinib'}]",Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS),651
14,NCT02508870,Phase I,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]","A Safety and Pharmacology Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes",651
15,NCT02721875,Phase I,Terminated,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 957, 'therapyName': 'Volasertib'}]",Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes,651
16,NCT02400281,Phase Ib/II,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 705, 'therapyName': 'Crenolanib'}, {'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}]",Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients,651
17,NCT02421939,Phase III,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 3193, 'therapyName': 'Cytarabine + Fludarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2865, 'therapyName': 'Gilteritinib'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,651
18,NCT01892371,Phase Ib/II,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 882, 'therapyName': 'Quizartinib'}]",AC220 With 5-Aza or Low Dose Cytarabine,651
19,NCT02599649,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2583, 'therapyName': 'Lirilumab '}]",Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS),651
20,NCT02752035,Phase II,Recruiting,"[{'id': 2865, 'therapyName': 'Gilteritinib'}, {'id': 651, 'therapyName': 'Azacitidine'}]","A Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation in Patients Not Eligible for Intensive Induction Chemotherapy",651
21,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,651
22,NCT02993523,Phase III,Recruiting,"[{'id': 1637, 'therapyName': 'GDC-0199 + Azacitidine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Elderly Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy,651
23,NCT03092674,Phase II,Not yet recruiting,"[{'id': 1736, 'therapyName': 'Decitabine + Cytarabine'}, {'id': 2471, 'therapyName': 'Azacitidine + Midostaurin'}, {'id': 3196, 'therapyName': 'Azacitidine + Nivolumab'}, {'id': 651, 'therapyName': 'Azacitidine'}]","Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",651
24,NCT03164057,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia,651
25,NCT02129101,Phase I,"Active, not recruiting","[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 1428, 'therapyName': 'Sonidegib'}]",Azacitidine and Sonidegib in Treating Patients With Myeloid Malignancies,651
26,NCT02374099,Phase II,"Active, not recruiting","[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant,651
27,NCT02577406,Phase III,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 2982, 'therapyName': 'Enasidenib'}]",An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation (IDHENTIFY),651
28,NCT02204020,Phase II,Withdrawn,"[{'id': 651, 'therapyName': 'Azacitidine'}]",Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS,651
29,NCT01814826,Phase I,"Active, not recruiting","[{'id': 1688, 'therapyName': 'MLN4924'}, {'id': 651, 'therapyName': 'Azacitidine'}]",Study of MLN4924 Plus Azacitidine in Treatment-Naïve Patients With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older,651
30,NCT02265510,Phase I,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2747, 'therapyName': 'INCB052793'}, {'id': 688, 'therapyName': 'Bortezomib'}]","An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies",651
31,NCT00887068,Phase III,"Active, not recruiting","[{'id': 651, 'therapyName': 'Azacitidine'}]",Randomized Allogeneic Azacitidine Study,651
32,NCT02610777,Phase II,"Active, not recruiting","[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 1688, 'therapyName': 'MLN4924'}]","An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)",651
33,NCT00946647,Phase II,"Active, not recruiting","[{'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 651, 'therapyName': 'Azacitidine'}]","A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).",651
34,NCT02178072,Phase II,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}]","Window Trial 5-aza in HNSCC, T-tare",651
35,NCT02281084,Phase II,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 4178, 'therapyName': 'Azacitidine + MEDI4736'}]",Safety and Efficacy Study of CC-486 and Durvalumab in Subjects With Myelodysplastic Syndromes,651
36,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,651
37,NCT02546986,Phase II,"Active, not recruiting","[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer,651
38,NCT02677922,Phase Ib/II,Recruiting,"[{'id': 4002, 'therapyName': 'AG-120 + Azacitidine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 4003, 'therapyName': 'Azacitidine + Enasidenib'}]",A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML),651
39,NCT01993641,Phase II,Completed,"[{'id': 1758, 'therapyName': 'Pracinostat'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 650, 'therapyName': 'Decitabine'}]",Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA,651
40,NCT01928576,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1541, 'therapyName': 'Entinostat'}, {'id': 651, 'therapyName': 'Azacitidine'}]",Phase II Anti-PD1 Epigenetic Priming Study in NSCLC.,651
0,NCT03013998,Phase Ib/II,Recruiting,"[{'id': 4003, 'therapyName': 'Azacitidine + Enasidenib'}, {'id': 5539, 'therapyName': 'Azacitidine + Entospletinib'}, {'id': 5536, 'therapyName': 'Cytarabine + Daunorubicin + Samalizumab'}, {'id': 5538, 'therapyName': 'Azacitidine + BI 836858'}]",Study of Biomarker-Based Treatment of Acute Myeloid Leukemia,5538
0,NCT01545947,Phase I,Completed,"[{'id': 1149, 'therapyName': 'Azacitidine + CC-223'}, {'id': 1147, 'therapyName': 'Erlotinib + CC-223'}]"," Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer",1149
0,NCT02954653,Phase I,Recruiting,"[{'id': 6087, 'therapyName': 'PF-06747143'}, {'id': 6092, 'therapyName': 'Cytarabine + Daunorubicin + PF-06747143'}, {'id': 6093, 'therapyName': 'Azacitidine + Decitabine + PF-06747143'}]","A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia",6093
0,NCT03161223,Phase Ib/II,Not yet recruiting,"[{'id': 5882, 'therapyName': 'Durvalumab + Romidepsin'}, {'id': 4178, 'therapyName': 'Azacitidine + MEDI4736'}, {'id': 5881, 'therapyName': 'Azacitidine + Durvalumab + Romidepsin'}, {'id': 5880, 'therapyName': 'Durvalumab + Pralatrexate + Romidepsin'}]","Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma",5881
0,NCT03013998,Phase Ib/II,Recruiting,"[{'id': 4003, 'therapyName': 'Azacitidine + Enasidenib'}, {'id': 5539, 'therapyName': 'Azacitidine + Entospletinib'}, {'id': 5536, 'therapyName': 'Cytarabine + Daunorubicin + Samalizumab'}, {'id': 5538, 'therapyName': 'Azacitidine + BI 836858'}]",Study of Biomarker-Based Treatment of Acute Myeloid Leukemia,4003
1,NCT02677922,Phase Ib/II,Recruiting,"[{'id': 4002, 'therapyName': 'AG-120 + Azacitidine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 4003, 'therapyName': 'Azacitidine + Enasidenib'}]",A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML),4003
0,NCT01935947,Phase II,Terminated,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2645, 'therapyName': 'Azacitidine + Entinostat'}, {'id': 2646, 'therapyName': 'Docetaxel + Irinotecan + Pemetrexed '}]",Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer,2645
1,NCT01305499,Phase II,Recruiting,"[{'id': 2645, 'therapyName': 'Azacitidine + Entinostat'}]",A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML),2645
0,NCT03013998,Phase Ib/II,Recruiting,"[{'id': 4003, 'therapyName': 'Azacitidine + Enasidenib'}, {'id': 5539, 'therapyName': 'Azacitidine + Entospletinib'}, {'id': 5536, 'therapyName': 'Cytarabine + Daunorubicin + Samalizumab'}, {'id': 5538, 'therapyName': 'Azacitidine + BI 836858'}]",Study of Biomarker-Based Treatment of Acute Myeloid Leukemia,5539
0,NCT01983969,Phase Ib/II,"Active, not recruiting","[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2557, 'therapyName': 'Azacitidine + Gemcitabine + vorinostat'}]",Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma,2557
0,NCT03248479,Phase I,Not yet recruiting,"[{'id': 6133, 'therapyName': 'Azacitidine + Hu5F9-G4'}, {'id': 4947, 'therapyName': 'Hu5F9-G4'}]",Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination With Azacitidine in Patients With Hematological Malignancies,6133
0,NCT02553941,Phase I,Recruiting,"[{'id': 3632, 'therapyName': 'Azacitidine + Ibrutinib'}]",Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome,3632
0,NCT02959437,Phase Ib/II,Recruiting,"[{'id': 5477, 'therapyName': 'Azacitidine + INCB024360 + Pembrolizumab'}]",Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206),5477
0,NCT02281084,Phase II,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 4178, 'therapyName': 'Azacitidine + MEDI4736'}]",Safety and Efficacy Study of CC-486 and Durvalumab in Subjects With Myelodysplastic Syndromes,4178
1,NCT02811497,Phase II,Recruiting,"[{'id': 4178, 'therapyName': 'Azacitidine + MEDI4736'}]",Study of Azacitidine and Durvalumab in Advanced Solid Tumors (METADUR),4178
2,NCT03161223,Phase Ib/II,Not yet recruiting,"[{'id': 5882, 'therapyName': 'Durvalumab + Romidepsin'}, {'id': 4178, 'therapyName': 'Azacitidine + MEDI4736'}, {'id': 5881, 'therapyName': 'Azacitidine + Durvalumab + Romidepsin'}, {'id': 5880, 'therapyName': 'Durvalumab + Pralatrexate + Romidepsin'}]","Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma",4178
3,NCT02775903,Phase II,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 4178, 'therapyName': 'Azacitidine + MEDI4736'}]",An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Subjects With Acute Myeloid Leukemia (AML),4178
4,NCT02117219,Phase I,Recruiting,"[{'id': 4178, 'therapyName': 'Azacitidine + MEDI4736'}]",Phase 1 Study to Evaluate MEDI4736 in MDS,4178
0,NCT03092674,Phase II,Not yet recruiting,"[{'id': 1736, 'therapyName': 'Decitabine + Cytarabine'}, {'id': 2471, 'therapyName': 'Azacitidine + Midostaurin'}, {'id': 3196, 'therapyName': 'Azacitidine + Nivolumab'}, {'id': 651, 'therapyName': 'Azacitidine'}]","Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",2471
1,NCT01093573,Phase Ib/II,"Active, not recruiting","[{'id': 2471, 'therapyName': 'Azacitidine + Midostaurin'}]",Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia,2471
0,NCT03238248,Phase II,Recruiting,"[{'id': 6164, 'therapyName': 'Azacitidine + MLN4924'}]",Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors,6164
0,NCT02397720,Phase II,Recruiting,"[{'id': 3196, 'therapyName': 'Azacitidine + Nivolumab'}]",A Study of Nivolumab (BMS-936558) in Combination With 5-azacytidine (Vidaza) for the Treatment of Patients With Refractory/ Relapsed Acute Myeloid Leukemia,3196
1,NCT03092674,Phase II,Not yet recruiting,"[{'id': 1736, 'therapyName': 'Decitabine + Cytarabine'}, {'id': 2471, 'therapyName': 'Azacitidine + Midostaurin'}, {'id': 3196, 'therapyName': 'Azacitidine + Nivolumab'}, {'id': 651, 'therapyName': 'Azacitidine'}]","Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",3196
0,NCT03094637,Phase II,Not yet recruiting,"[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}]",Azacitidine and Pembrolizumab for Patients With Myelodysplastic Syndrome (MDS),2496
1,NCT02900560,Phase II,Recruiting,"[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}]",Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer,2496
2,NCT02845297,Phase II,Recruiting,"[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}]",Phase 2 Study of Azacitidine in Combination With Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients and in Newly Diagnosed Older (?65 Years) AML Patients,2496
3,NCT03264404,Phase II,Recruiting,"[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}]",Azacitidine and Pembrolizumab in Pancreatic Cancer,2496
4,NCT02512172,Phase I,Recruiting,"[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}, {'id': 5728, 'therapyName': 'Romidepsin + Pembrolizumab'}, {'id': 5782, 'therapyName': 'Azacitidine + Pembrolizumab + Romidepsin'}]",A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer,2496
5,NCT02260440,Phase II,"Active, not recruiting","[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}]",A Phase 2 Study of MK-3475 in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer,2496
6,NCT02816021,Phase II,Recruiting,"[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}]",Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma,2496
0,NCT02512172,Phase I,Recruiting,"[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}, {'id': 5728, 'therapyName': 'Romidepsin + Pembrolizumab'}, {'id': 5782, 'therapyName': 'Azacitidine + Pembrolizumab + Romidepsin'}]",A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer,5782
0,NCT02367456,Phase Ib/II,Recruiting,"[{'id': 4177, 'therapyName': 'Azacitidine + PF-04449913'}]","A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In 1st Line MDS, AML and CMML Patients",4177
0,NCT02829840,Phase Ib/II,Withdrawn,"[{'id': 4464, 'therapyName': 'Azacitidine + Ponatinib'}]","Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)",4464
0,NCT03151304,Phase II,Recruiting,"[{'id': 5987, 'therapyName': 'Azacitidine + Pracinostat'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes,5987
1,NCT03151408,Phase III,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 5987, 'therapyName': 'Azacitidine + Pracinostat'}]",An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia,5987
0,NCT01926587,Phase Ib/II,Recruiting,"[{'id': 2320, 'therapyName': 'Azacitidine + Regorafenib'}]",Oral Rigosertib in Combination With Azacitidine,2320
0,NCT01537744,Phase I,Completed,"[{'id': 1396, 'therapyName': 'Azacitidine + Romidepsin'}]","A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Non-small Cell Lung Cancer",1396
0,NCT01869114,Phase II,Recruiting,"[{'id': 2233, 'therapyName': 'Azacitidine + Sirolimus'}]",Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy,2233
0,NCT02588105,Phase I,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 3557, 'therapyName': 'AZD0156'}]",Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer,3557
0,NCT03217838,Phase Ib/II,Recruiting,"[{'id': 3547, 'therapyName': 'AZD2811'}]","Safety, Tolerability, and Efficacy of AZD2811 Nanoparticles in Patients With Relapsed AML/High-Risk Myelodysplastic Syndrome or Treatment-Naïve Patients.",3547
1,NCT02579226,Phase I,Recruiting,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 3547, 'therapyName': 'AZD2811'}]","A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors",3547
0,NCT02228369,Phase I,"Active, not recruiting","[{'id': 660, 'therapyName': 'AZD9291'}, {'id': 2912, 'therapyName': 'AZD3759'}]","Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer",2912
0,NCT02546661,Phase I,Recruiting,"[{'id': 654, 'therapyName': 'AZD4547'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer",654
1,NCT02154490,Phase II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 1016, 'therapyName': 'GDC-0032'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 629, 'therapyName': 'AMG102'}]",Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,654
2,NCT02465060,Phase II,Recruiting,"[{'id': 660, 'therapyName': 'AZD9291'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 958, 'therapyName': 'VS-6063'}, {'id': 765, 'therapyName': 'GSK2636771'}]",NCI-MATCH Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,654
0,NCT02740985,Phase I,Recruiting,"[{'id': 4223, 'therapyName': 'AZD4635'}, {'id': 4349, 'therapyName': 'AZD4635 + MEDI4736'}]",A Phase 1 Clinical Study of AZD4635 and Durvalumab in Patients With Advanced Solid Malignancies,4223
0,NCT02740985,Phase I,Recruiting,"[{'id': 4223, 'therapyName': 'AZD4635'}, {'id': 4349, 'therapyName': 'AZD4635 + MEDI4736'}]",A Phase 1 Clinical Study of AZD4635 and Durvalumab in Patients With Advanced Solid Malignancies,4349
0,NCT03101839,Phase I,Recruiting,"[{'id': 5914, 'therapyName': 'AZD4785'}]",Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours,5914
0,NCT02583477,Phase Ib/II,Recruiting,"[{'id': 3099, 'therapyName': 'AZD5069 + MEDI4736'}, {'id': 3163, 'therapyName': 'Gemcitabine + MEDI4736 + nab-paclitaxel'}]",Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma,3099
1,NCT02499328,Phase Ib/II,Recruiting,"[{'id': 3098, 'therapyName': 'AZD9150 + MEDI4736'}, {'id': 3099, 'therapyName': 'AZD5069 + MEDI4736'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2782, 'therapyName': 'AZD9150 '}]",Study to Assess Combination of MEDI4736 With Either AZD9150 or AZD5069 in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck,3099
0,NCT03205176,Phase I,Recruiting,"[{'id': 4910, 'therapyName': 'AZD5153'}]",Phase I Study of AZD5153 in Patients With Relapsed or Refractory Solid Tumors and Lymphomas,4910
0,NCT01226316,Phase I,Recruiting,"[{'id': 655, 'therapyName': 'AZD5363'}]","Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules",655
1,NCT02208375,Phase Ib/II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 655, 'therapyName': 'AZD5363'}, {'id': 991, 'therapyName': 'Vistusertib'}]",mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Cancer,655
0,NCT02576444,Phase II,Recruiting,"[{'id': 3140, 'therapyName': 'MK-1775 + Olaparib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 3141, 'therapyName': 'Olaparib + Vistusertib'}, {'id': 3139, 'therapyName': 'AZD5363 + Olaparib'}]",OLAParib COmbinations,3139
0,NCT01625286,Phase Ib/II,"Active, not recruiting","[{'id': 2192, 'therapyName': 'AZD5363 + Paclitaxel'}]","Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients",2192
0,NCT02264678,Phase Ib/II,Recruiting,"[{'id': 2881, 'therapyName': 'AZD6738'}, {'id': 4737, 'therapyName': 'AZD6738 + Carboplatin'}, {'id': 4738, 'therapyName': 'AZD6738 + MEDI4736'}, {'id': 4739, 'therapyName': 'AZD6738 + Olaparib'}]",Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents,2881
1,NCT03022409,Phase I,Not yet recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 2881, 'therapyName': 'AZD6738'}]",A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC),2881
0,NCT02264678,Phase Ib/II,Recruiting,"[{'id': 2881, 'therapyName': 'AZD6738'}, {'id': 4737, 'therapyName': 'AZD6738 + Carboplatin'}, {'id': 4738, 'therapyName': 'AZD6738 + MEDI4736'}, {'id': 4739, 'therapyName': 'AZD6738 + Olaparib'}]",Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents,4737
0,NCT02264678,Phase Ib/II,Recruiting,"[{'id': 2881, 'therapyName': 'AZD6738'}, {'id': 4737, 'therapyName': 'AZD6738 + Carboplatin'}, {'id': 4738, 'therapyName': 'AZD6738 + MEDI4736'}, {'id': 4739, 'therapyName': 'AZD6738 + Olaparib'}]",Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents,4738
0,NCT02264678,Phase Ib/II,Recruiting,"[{'id': 2881, 'therapyName': 'AZD6738'}, {'id': 4737, 'therapyName': 'AZD6738 + Carboplatin'}, {'id': 4738, 'therapyName': 'AZD6738 + MEDI4736'}, {'id': 4739, 'therapyName': 'AZD6738 + Olaparib'}]",Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents,4739
0,NCT01884285,Phase I,Recruiting,"[{'id': 992, 'therapyName': 'AZD8186'}]",AZD8186 First Time In Patient Ascending Dose Study,992
0,NCT03218826,Phase I,Not yet recruiting,"[{'id': 6046, 'therapyName': 'AZD8186 + Docetaxel'}]",PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery,6046
0,NCT02260661,Phase I,Completed,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 2013, 'therapyName': 'AZD8835'}]","Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours",2013
0,NCT02499328,Phase Ib/II,Recruiting,"[{'id': 3098, 'therapyName': 'AZD9150 + MEDI4736'}, {'id': 3099, 'therapyName': 'AZD5069 + MEDI4736'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2782, 'therapyName': 'AZD9150 '}]",Study to Assess Combination of MEDI4736 With Either AZD9150 or AZD5069 in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck,2782
1,NCT02417753,Phase II,Terminated,"[{'id': 2782, 'therapyName': 'AZD9150 '}]","AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites",2782
0,NCT02499328,Phase Ib/II,Recruiting,"[{'id': 3098, 'therapyName': 'AZD9150 + MEDI4736'}, {'id': 3099, 'therapyName': 'AZD5069 + MEDI4736'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2782, 'therapyName': 'AZD9150 '}]",Study to Assess Combination of MEDI4736 With Either AZD9150 or AZD5069 in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck,3098
1,NCT02983578,Phase II,Recruiting,"[{'id': 3098, 'therapyName': 'AZD9150 + MEDI4736'}]","AZD9150 With MEDI4736 in Patients With Advanced Pancreatic, Non-Small Lung and Colorectal Cancer",3098
2,NCT02549651,Phase I,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3098, 'therapyName': 'AZD9150 + MEDI4736'}]",MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Diffuse Large B-cell Lymphoma (D4190C00023),3098
0,NCT01802632,Phase Ib/II,"Active, not recruiting","[{'id': 660, 'therapyName': 'AZD9291'}]", AZD9291 First Time In Patients Ascending Dose Study,660
1,NCT02451852,Phase I,No longer available,"[{'id': 660, 'therapyName': 'AZD9291'}]",AZD9291 US Expanded Access Program,660
2,NCT02161770,Phase I,Completed,"[{'id': 660, 'therapyName': 'AZD9291'}]",Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment,660
3,NCT02197234,Phase I,"Active, not recruiting","[{'id': 1645, 'therapyName': 'AZD9291 + Simvastatin'}, {'id': 660, 'therapyName': 'AZD9291'}]",Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC,660
4,NCT02474355,Phase III,Recruiting,"[{'id': 660, 'therapyName': 'AZD9291'}]",Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC,660
5,NCT02151981,Phase III,"Active, not recruiting","[{'id': 660, 'therapyName': 'AZD9291'}]",AZD9291 Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer,660
6,NCT02163733,Phase I,"Active, not recruiting","[{'id': 660, 'therapyName': 'AZD9291'}]",Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer,660
7,NCT02454933,Phase III,"Active, not recruiting","[{'id': 660, 'therapyName': 'AZD9291'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours,660
8,NCT02971501,Phase II,Recruiting,"[{'id': 660, 'therapyName': 'AZD9291'}, {'id': 4366, 'therapyName': 'Bevacizumab + Osimertinib'}]",Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases,660
9,NCT02465060,Phase II,Recruiting,"[{'id': 660, 'therapyName': 'AZD9291'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 958, 'therapyName': 'VS-6063'}, {'id': 765, 'therapyName': 'GSK2636771'}]",NCI-MATCH Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,660
10,NCT02759835,Phase II,Recruiting,"[{'id': 660, 'therapyName': 'AZD9291'}]","Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib",660
11,NCT02511106,Phase III,Recruiting,"[{'id': 660, 'therapyName': 'AZD9291'}]","AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy",660
12,NCT03191149,Phase II,Not yet recruiting,"[{'id': 660, 'therapyName': 'AZD9291'}]",Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations,660
13,NCT02228369,Phase I,"Active, not recruiting","[{'id': 660, 'therapyName': 'AZD9291'}, {'id': 2912, 'therapyName': 'AZD3759'}]","Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer",660
14,NCT02296125,Phase III,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 660, 'therapyName': 'AZD9291'}, {'id': 751, 'therapyName': 'Gefitinib'}]",AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer,660
15,NCT02317016,Phase I,"Active, not recruiting","[{'id': 660, 'therapyName': 'AZD9291'}, {'id': 2928, 'therapyName': 'Rosuvastatin'}]","Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer",660
16,NCT02157883,Phase I,"Active, not recruiting","[{'id': 1026, 'therapyName': 'Itraconazole'}, {'id': 660, 'therapyName': 'AZD9291'}]","Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)",660
17,NCT02197247,Phase I,"Active, not recruiting","[{'id': 1644, 'therapyName': 'AZD9291 + Rifampin'}, {'id': 660, 'therapyName': 'AZD9291'}]","Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC",660
18,NCT02496663,Phase I,Recruiting,"[{'id': 826, 'therapyName': 'Necitumumab'}, {'id': 660, 'therapyName': 'AZD9291'}]",EGFR Inhibitor AZD9291 and Necitumumab in Treating Patients With EGFR-Positive Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor,660
19,NCT02179671,Phase II,Completed,"[{'id': 1117, 'therapyName': 'Selumetinib + Docetaxel'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 660, 'therapyName': 'AZD9291'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer",660
0,NCT02143466,Phase I,Recruiting,"[{'id': 2224, 'therapyName': 'AZD9291 + Savolitinib'}, {'id': 2225, 'therapyName': 'Osimertinib + Selumetinib'}, {'id': 2223, 'therapyName': 'AZD9291 + MEDI4736'}]",AZD9291 in Combination With Ascending Doses of Novel Therapeutics,2223
0,NCT02503722,Phase I,Recruiting,"[{'id': 2994, 'therapyName': 'AZD9291 + MLN0128'}]",TORC1/2 Inhibitor INK128 and EGFR Inhibitor AZD9291 in Treating Patients With Advanced EGFR Mutation Positive Non-small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor,2994
0,NCT02197247,Phase I,"Active, not recruiting","[{'id': 1644, 'therapyName': 'AZD9291 + Rifampin'}, {'id': 660, 'therapyName': 'AZD9291'}]","Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC",1644
0,NCT02143466,Phase I,Recruiting,"[{'id': 2224, 'therapyName': 'AZD9291 + Savolitinib'}, {'id': 2225, 'therapyName': 'Osimertinib + Selumetinib'}, {'id': 2223, 'therapyName': 'AZD9291 + MEDI4736'}]",AZD9291 in Combination With Ascending Doses of Novel Therapeutics,2224
0,NCT02197234,Phase I,"Active, not recruiting","[{'id': 1645, 'therapyName': 'AZD9291 + Simvastatin'}, {'id': 660, 'therapyName': 'AZD9291'}]",Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC,1645
0,NCT02780713,Phase I,Completed,"[{'id': 2997, 'therapyName': 'AZD9496'}]",A Study to Assess the Pharmacokinetics and Safety of Different Forms and Formulations of AZD9496 in Healthy Subjects (PK),2997
1,NCT02248090,Phase I,"Active, not recruiting","[{'id': 2997, 'therapyName': 'AZD9496'}]",AZD9496 First Time in Patients Ascending Dose Study,2997
0,NCT02401542,Phase II,Recruiting,"[{'id': 2934, 'therapyName': 'B-701'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Phase 2 Study of B-701 in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma,2934
0,NCT03123055,Phase I,Recruiting,"[{'id': 5615, 'therapyName': 'B-701 + Atezolizumab'}]",A Study of B-701 in Combination With Atezolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma (U22),5615
0,NCT02925533,Phase I,Terminated,"[{'id': 4831, 'therapyName': 'B-701 + Pembrolizumab'}]",Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract,4831
0,NCT03250299,Phase I,Recruiting,"[{'id': 4908, 'therapyName': 'BAL101553'}]",Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma,4908
0,NCT01526096,Phase I,Recruiting,"[{'id': 5985, 'therapyName': 'Basiliximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 1207, 'therapyName': 'Melphalan'}]",Stem Cell Transplantation for Patients With Multiple Myeloma,5985
1,NCT02366728,,Recruiting,"[{'id': 5985, 'therapyName': 'Basiliximab'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",DC Migration Study for Newly-Diagnosed GBM,5985
0,NCT01476839,Phase I,Recruiting,"[{'id': 6258, 'therapyName': 'Basiliximab + 90Y basiliximab + Carmustine + Cytarbine + Etoposide + Melphalan'}]",Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma,6258
0,NCT02651610,Phase II,Withdrawn,"[{'id': 3545, 'therapyName': 'Bavituximab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer,3545
0,NCT01634685,Phase I,"Active, not recruiting","[{'id': 3684, 'therapyName': 'Bavituximab + Capecitabine'}]","A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma",3684
0,NCT02989870,Phase I,Recruiting,"[{'id': 5138, 'therapyName': 'Bavituximab + Sorafenib'}]",Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma,5138
0,NCT03139916,Phase II,Recruiting,"[{'id': 5634, 'therapyName': 'Bavituximab + Temozolomide'}]",Phase II Clinical Trial of Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma,5634
0,NCT02369029,Phase I,Terminated,"[{'id': 2598, 'therapyName': 'BAY 1238097 '}]","BAY1238097, First in Man",2598
0,NCT02746081,Phase I,Recruiting,"[{'id': 3987, 'therapyName': 'BAY 1436032'}]",Phase I Study of BAY1436032 in Isocitrate Dehydrogenase-1 (IDH1)-Mutant Advanced Solid Tumors,3987
0,NCT02457351,Phase I,Completed,"[{'id': 663, 'therapyName': 'BAY1000394'}, {'id': 1026, 'therapyName': 'Itraconazole'}]",Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study,663
1,NCT02656849,Phase II,Withdrawn,"[{'id': 663, 'therapyName': 'BAY1000394'}]","BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors",663
2,NCT02161419,Phase II,Terminated,"[{'id': 663, 'therapyName': 'BAY1000394'}]",RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer,663
0,NCT01728311,Phase I,Completed,"[{'id': 666, 'therapyName': 'BAY1082439'}]",Open Label Study of BAY1082439 in Patients With Advanced Cancer,666
0,NCT01915576,Phase I,Completed,"[{'id': 994, 'therapyName': 'BAY1125976'}]",Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients,994
0,NCT02345382,Phase I,Completed,"[{'id': 4027, 'therapyName': 'BAY1143572'}]",Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia,4027
1,NCT01938638,Phase I,Completed,"[{'id': 4027, 'therapyName': 'BAY1143572'}]",Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer,4027
0,NCT02138812,Phase I,"Active, not recruiting","[{'id': 3448, 'therapyName': 'BAY1161909 + Paclitaxel'}]",Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel,3448
0,NCT02368951,Phase I,Terminated,"[{'id': 2931, 'therapyName': 'BAY1187982'}]","Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)",2931
0,NCT02366949,Phase I,Recruiting,"[{'id': 3447, 'therapyName': 'BAY1217389 + Paclitaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel,3447
0,NCT03127735,Phase I,Recruiting,"[{'id': 5698, 'therapyName': 'BAY1436032'}]",BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML),5698
0,NCT03188965,Phase I,Recruiting,"[{'id': 5962, 'therapyName': 'BAY1895344'}]",First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas,5962
0,NCT02631590,Phase II,Recruiting,"[{'id': 3315, 'therapyName': 'BAY80-6946 + Cisplatin + Gemcitabine'}]",Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma,3315
0,NCT02448771,Phase Ib/II,Recruiting,"[{'id': 2738, 'therapyName': 'Bazedoxifene + Palbociclib'}]",A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer,2738
0,NCT02658929,Phase I,Recruiting,"[{'id': 5278, 'therapyName': 'bb2121'}]",Study of bb2121 in Multiple Myeloma,5278
0,NCT02232620,Phase II,Recruiting,"[{'id': 1945, 'therapyName': 'BBI503'}]",A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors,1945
1,NCT02432326,Phase I,Recruiting,"[{'id': 1945, 'therapyName': 'BBI503'}, {'id': 2057, 'therapyName': 'BBI608'}]",A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors,1945
2,NCT02432690,Phase II,"Active, not recruiting","[{'id': 1945, 'therapyName': 'BBI503'}]",A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation,1945
3,NCT02232633,Phase II,Recruiting,"[{'id': 1945, 'therapyName': 'BBI503'}]",A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer,1945
4,NCT01781455,Phase Ib/II,Recruiting,"[{'id': 1945, 'therapyName': 'BBI503'}]",A Study of BBI503 in Adult Patients With Advanced Solid Tumors,1945
5,NCT02483247,Phase Ib/II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1945, 'therapyName': 'BBI503'}]",A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer,1945
0,NCT02279719,Phase Ib/II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2361, 'therapyName': 'BBI503 + Sorafenib'}, {'id': 2362, 'therapyName': 'BBI608 + Sorafenib'}]","A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma",2361
0,NCT02178956,Phase III,"Active, not recruiting","[{'id': 2057, 'therapyName': 'BBI608'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer,2057
1,NCT02432326,Phase I,Recruiting,"[{'id': 1945, 'therapyName': 'BBI503'}, {'id': 2057, 'therapyName': 'BBI608'}]",A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors,2057
2,NCT02315534,Phase Ib/II,Recruiting,"[{'id': 2057, 'therapyName': 'BBI608'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma,2057
3,NCT02352558,Phase I,"Active, not recruiting","[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 2057, 'therapyName': 'BBI608'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]","A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies",2057
4,NCT01775423,Phase Ib/II,Unknown status,"[{'id': 2057, 'therapyName': 'BBI608'}]",A Study of BBI608 in Adult Patients With Advanced Malignancies,2057
5,NCT02024607,Phase Ib/II,"Active, not recruiting","[{'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}, {'id': 2093, 'therapyName': 'BBI608 + Bevacizumab'}, {'id': 2094, 'therapyName': 'BBI608 + Regorafenib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2057, 'therapyName': 'BBI608'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer,2057
6,NCT02753127,Phase III,Recruiting,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 2057, 'therapyName': 'BBI608'}]",A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CanStem303C),2057
7,NCT02467361,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2057, 'therapyName': 'BBI608'}]",A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers,2057
0,NCT02024607,Phase Ib/II,"Active, not recruiting","[{'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}, {'id': 2093, 'therapyName': 'BBI608 + Bevacizumab'}, {'id': 2094, 'therapyName': 'BBI608 + Regorafenib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2057, 'therapyName': 'BBI608'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer,2093
0,NCT01776307,Phase II,Recruiting,"[{'id': 2090, 'therapyName': 'BBI608 + Cetuximab'}, {'id': 2091, 'therapyName': 'BBI608 + Capecitabine'}, {'id': 2092, 'therapyName': 'BBI608 + Panitumumab'}]",A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer,2091
0,NCT01776307,Phase II,Recruiting,"[{'id': 2090, 'therapyName': 'BBI608 + Cetuximab'}, {'id': 2091, 'therapyName': 'BBI608 + Capecitabine'}, {'id': 2092, 'therapyName': 'BBI608 + Panitumumab'}]",A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer,2090
0,NCT02231723,Phase I,"Active, not recruiting","[{'id': 2630, 'therapyName': 'BBI608 + Gemcitabine + nab-paclitaxel'}]",A Study of BBI608 in Combination With Gemcitabine and Nab-Paclitaxel in Adult Patients With Metastatic Pancreatic Adenocarcinoma,2630
1,NCT02993731,Phase III,Recruiting,"[{'id': 2630, 'therapyName': 'BBI608 + Gemcitabine + nab-paclitaxel'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma (CanStem111P),2630
0,NCT01325441,Phase Ib/II,Recruiting,"[{'id': 2586, 'therapyName': 'BBI608 + Paclitaxel'}]",A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies,2586
1,NCT02826161,Phase III,Terminated,"[{'id': 2586, 'therapyName': 'BBI608 + Paclitaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer (CanStem43L)",2586
0,NCT01776307,Phase II,Recruiting,"[{'id': 2090, 'therapyName': 'BBI608 + Cetuximab'}, {'id': 2091, 'therapyName': 'BBI608 + Capecitabine'}, {'id': 2092, 'therapyName': 'BBI608 + Panitumumab'}]",A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer,2092
0,NCT02024607,Phase Ib/II,"Active, not recruiting","[{'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}, {'id': 2093, 'therapyName': 'BBI608 + Bevacizumab'}, {'id': 2094, 'therapyName': 'BBI608 + Regorafenib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2057, 'therapyName': 'BBI608'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer,2094
0,NCT02279719,Phase Ib/II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2361, 'therapyName': 'BBI503 + Sorafenib'}, {'id': 2362, 'therapyName': 'BBI608 + Sorafenib'}]","A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma",2362
0,NCT03091660,Phase III,Recruiting,"[{'id': 5478, 'therapyName': 'BCG Tokyo-172 Strain Solution'}, {'id': 4455, 'therapyName': 'BCG solution'}]",Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer,4455
0,NCT02808143,Phase I,Recruiting,"[{'id': 4457, 'therapyName': 'BCG solution + Pembrolizumab'}]",Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer,4457
0,NCT03091660,Phase III,Recruiting,"[{'id': 5478, 'therapyName': 'BCG Tokyo-172 Strain Solution'}, {'id': 4455, 'therapyName': 'BCG solution'}]",Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer,5478
0,NCT01686165,Phase II,"Active, not recruiting","[{'id': 1078, 'therapyName': 'Belinostat'}, {'id': 897, 'therapyName': 'Rituximab'}]",Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma,1078
1,NCT02142530,Phase I,Recruiting,"[{'id': 1078, 'therapyName': 'Belinostat'}, {'id': 1624, 'therapyName': 'Carfilzomib'}]",Carfilzomib Plus Belinostat in Relapsed/Refractory NHL,1078
2,NCT01273155,Phase I,Recruiting,"[{'id': 1078, 'therapyName': 'Belinostat'}]",Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction,1078
3,NCT02679131,Phase I,Recruiting,"[{'id': 1078, 'therapyName': 'Belinostat'}]","To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.",1078
4,NCT02680795,Phase I,Recruiting,"[{'id': 1078, 'therapyName': 'Belinostat'}]","To Evaluate the Safety and Pharmacokinetics of Belinostat in Patients Who Have Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes",1078
5,NCT02532192,Phase I,Withdrawn,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1689, 'therapyName': 'Fluconazole'}, {'id': 1078, 'therapyName': 'Belinostat'}]","A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma",1078
6,NCT02701673,Phase Ib/II,Withdrawn,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1078, 'therapyName': 'Belinostat'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}]",Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma,1078
0,NCT00926640,Phase I,Completed,"[{'id': 1123, 'therapyName': 'Belinostat + Cisplatin + Etoposide'}]",A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers,1123
0,NCT02381548,Phase I,"Active, not recruiting","[{'id': 3197, 'therapyName': 'Belinostat + MK-1775'}]",Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia,3197
0,NCT02875002,Phase I,Not yet recruiting,"[{'id': 4826, 'therapyName': 'Belinostat + Volasertib'}]",Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas,4826
0,NCT02737046,Phase II,Recruiting,"[{'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 2624, 'therapyName': 'peginterferon alfa-2b'}, {'id': 4361, 'therapyName': 'Belinostat + Zidovudine'}]",Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma,4361
0,NCT01415752,Phase II,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1164, 'therapyName': 'lenalidomide'}]","Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",1231
1,NCT01871675,Phase I,Completed,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1024, 'therapyName': 'Duvelisib'}, {'id': 1231, 'therapyName': 'Bendamustine'}]","Phase Ib Study of IPI-145 in Combination With Bendamustine, Rituximab or Bendamustine/Rituximab in Hematologic Malignancies",1231
2,NCT02153580,Phase I,"Active, not recruiting","[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1231, 'therapyName': 'Bendamustine'}]","Cellular Immunotherapy Following Cyclophosphamide in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia",1231
3,NCT02018861,Phase I,"Active, not recruiting","[{'id': 2406, 'therapyName': 'INCB039110'}, {'id': 3097, 'therapyName': 'INCB039110 + INCB050465'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 3088, 'therapyName': 'INCB050465 '}]","A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies",1231
4,NCT02005471,Phase III,"Active, not recruiting","[{'id': 1562, 'therapyName': 'Venetoclax'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 897, 'therapyName': 'Rituximab'}]",A Study of GDC-0199 (ABT-199) Plus MabThera/Rituxan (Rituximab) Compared With Bendamustine Plus MabThera/Rituxan (Rituximab) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,1231
5,NCT02162888,Phase I,Completed,"[{'id': 1231, 'therapyName': 'Bendamustine'}]","A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients",1231
6,NCT01326702,Phase Ib/II,Completed,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1231, 'therapyName': 'Bendamustine'}]"," Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors",1231
7,NCT02596971,Phase I,Recruiting,"[{'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 1231, 'therapyName': 'Bendamustine'}]",Safety and Efficacy of MPDL3280A in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus CHOP in Patients With Follicular Lymphoma or Diffuse Large B-Cell Lymphoma,1231
8,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1231
0,NCT01286272,Phase II,"Active, not recruiting","[{'id': 3909, 'therapyName': 'Bendamustine + Ofatumumab'}, {'id': 3910, 'therapyName': 'Bendamustine + Bortezomib + Ofatumumab'}]",Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma,3910
0,NCT01177683,Phase Ib/II,"Active, not recruiting","[{'id': 3349, 'therapyName': 'Bendamustine + Bortezomib + pegylated liposomal-doxorubicin'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma,3349
0,NCT02130869,Phase I,Recruiting,"[{'id': 2378, 'therapyName': 'Bendamustine + Cytarabine + Etoposide'}, {'id': 2460, 'therapyName': 'Busulfan + Hu14.18K322A'}, {'id': 2459, 'therapyName': 'Aldesleukin + Melphalan + Sargramostim'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas,2378
0,NCT02240719,Phase I,Recruiting,"[{'id': 2336, 'therapyName': 'Bendamustine + Everolimus'}]",Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer,2336
0,NCT01671904,Phase I,"Active, not recruiting","[{'id': 3638, 'therapyName': 'Bendamustine + GDC-0199 + Obinutuzumab'}, {'id': 3637, 'therapyName': 'Bendamustine + GDC-0199 + Rituximab'}]","A Study of Venetoclax (GDC-0199, ABT-199) in Combination With Bendamustine And MabThera/Rituxan in Participants With Chronic Lymphocytic Leukemia",3638
0,NCT02187861,Phase II,"Active, not recruiting","[{'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 3637, 'therapyName': 'Bendamustine + GDC-0199 + Rituximab'}, {'id': 3937, 'therapyName': 'GDC-0199 + Rituximab'}]",A Study Evaluating the Safety and Efficacy of GDC-0199 (ABT-199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or GDC-0199 Plus Rituximab in Patients With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma,3637
1,NCT01671904,Phase I,"Active, not recruiting","[{'id': 3638, 'therapyName': 'Bendamustine + GDC-0199 + Obinutuzumab'}, {'id': 3637, 'therapyName': 'Bendamustine + GDC-0199 + Rituximab'}]","A Study of Venetoclax (GDC-0199, ABT-199) in Combination With Bendamustine And MabThera/Rituxan in Participants With Chronic Lymphocytic Leukemia",3637
0,NCT01980888,Phase III,Terminated,"[{'id': 2324, 'therapyName': 'Bendamustine + Idelalisib + Rituximab'}]",Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia,2324
1,NCT02970318,Phase III,Recruiting,"[{'id': 2324, 'therapyName': 'Bendamustine + Idelalisib + Rituximab'}, {'id': 1605, 'therapyName': 'Acalabrutinib'}]",A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL,2324
0,NCT03039114,Phase I,Recruiting,"[{'id': 6260, 'therapyName': 'Bendamustine + INCB050465 + Obinutuzumab'}]",Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102),6260
0,NCT02733042,Phase Ib/II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 4278, 'therapyName': 'lenalidomide + MEDI4736 + Rituximab'}, {'id': 4279, 'therapyName': 'Bendamustine + MEDI4736 + Rituximab'}, {'id': 2573, 'therapyName': 'Ibrutinib + MEDI4736'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia (FUSION NHL 001)",4279
0,NCT01286272,Phase II,"Active, not recruiting","[{'id': 3909, 'therapyName': 'Bendamustine + Ofatumumab'}, {'id': 3910, 'therapyName': 'Bendamustine + Bortezomib + Ofatumumab'}]",Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma,3909
0,NCT01216683,Phase II,Unknown status,"[{'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1164, 'therapyName': 'lenalidomide'}]","Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma",2323
1,NCT02257567,Phase Ib/II,"Active, not recruiting","[{'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 4226, 'therapyName': 'Polatuzumab Vedotin'}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]",A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma,2323
2,NCT02972840,Phase III,Recruiting,"[{'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 3996, 'therapyName': 'Acalabrutinib + Bendamustine + Rituximab'}]",A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma,2323
3,NCT01974440,Phase III,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}]","A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma",2323
4,NCT02187861,Phase II,"Active, not recruiting","[{'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 3637, 'therapyName': 'Bendamustine + GDC-0199 + Rituximab'}, {'id': 3937, 'therapyName': 'GDC-0199 + Rituximab'}]",A Study Evaluating the Safety and Efficacy of GDC-0199 (ABT-199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or GDC-0199 Plus Rituximab in Patients With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma,2323
5,NCT02576275,Phase III,Withdrawn,"[{'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 1024, 'therapyName': 'Duvelisib'}]",A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA),2323
6,NCT02626455,Phase III,Recruiting,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 3388, 'therapyName': 'Aldoxorubicin +Cyclophosphamide + Prednisone + Rituximab + Vincristine'}, {'id': 995, 'therapyName': 'Copanlisib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL),2323
7,NCT02951156,Phase III,Recruiting,"[{'id': 5088, 'therapyName': 'Avelumab + Azacitidine + Utomilumab'}, {'id': 5087, 'therapyName': 'Avelumab + Rituximab + Utomilumab'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 5090, 'therapyName': 'Gemcitabine + Oxaliplatin + Rituximab'}, {'id': 5089, 'therapyName': 'Avelumab + Bendamustine + Rituximab'}]","Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)",2323
8,NCT01732926,Phase III,Terminated,"[{'id': 1023, 'therapyName': 'Idelalisib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}]",Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas,2323
0,NCT02954406,Phase I,Recruiting,"[{'id': 5150, 'therapyName': 'Lenalidomide + TAK-659'}, {'id': 5149, 'therapyName': 'Ibrutinib + TAK-659'}, {'id': 5148, 'therapyName': 'Gemcitabine + TAK-659'}, {'id': 5147, 'therapyName': 'Bendamustine + Rituximab + TAK-659'}, {'id': 5146, 'therapyName': 'Bendamustine + TAK-659'}]","A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma",5147
0,NCT02954406,Phase I,Recruiting,"[{'id': 5150, 'therapyName': 'Lenalidomide + TAK-659'}, {'id': 5149, 'therapyName': 'Ibrutinib + TAK-659'}, {'id': 5148, 'therapyName': 'Gemcitabine + TAK-659'}, {'id': 5147, 'therapyName': 'Bendamustine + Rituximab + TAK-659'}, {'id': 5146, 'therapyName': 'Bendamustine + TAK-659'}]","A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma",5146
0,NCT01532089,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib With or Without Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer With EGFR Mutations,667
1,NCT01937715,Phase II,Terminated,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1040, 'therapyName': 'PF-05212384'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer,667
2,NCT01327612,Phase II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 746, 'therapyName': 'Ganitumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1458, 'therapyName': 'Conatumumab'}]",Open Label Extension Study of Conatumumab and AMG 479,667
3,NCT01967810,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2053, 'therapyName': 'GRN1005'}]",ANG1005 in Patients With Recurrent High-Grade Glioma,667
4,NCT01700400,Phase I,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]"," Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer",667
5,NCT01765582,Phase II,Terminated,"[{'id': 1523, 'therapyName': 'Fluorouracil + Capecitabine + Irinotecan + Leucovorin + Oxaliplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}]",STEAM: A Study of Sequential and Concurrent FOLFOXIRI/Avastin (Bevacizumab) Regimens Versus FOLFOX/Avastin in First-Line in Patients With Metastatic Colorectal Cancer,667
6,NCT01217931,Phase II,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy,667
7,NCT02606305,Phase I,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 3232, 'therapyName': 'IMGN853'}]","Study of IMGN853 in Comb. With Bevacizumab, Carboplatin or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer",667
8,NCT00184015,,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 688, 'therapyName': 'Bortezomib'}]","Bortezomib and Bevacizumab (""BB-mib-mab"") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)",667
9,NCT00828009,Phase II,Unknown status,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 2142, 'therapyName': 'Emepepimut-S  '}, {'id': 1092, 'therapyName': 'Carboplatin'}]",BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery,667
10,NCT01305213,Phase Ib/II,Completed,"[{'id': 1186, 'therapyName': 'Fosbretabulin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Bevacizumab With or Without Fosbretabulin Tromethamine in Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer",667
11,NCT01648348,Phase Ib/II,"Active, not recruiting","[{'id': 1242, 'therapyName': 'TRC105'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme,667
12,NCT01588431,Phase II,"Active, not recruiting","[{'id': 1987, 'therapyName': 'Cisplatin + Docetaxel + Cetuximab'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer,667
13,NCT01083966,Phase I,Suspended,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Intraarterial Cerebral Infusion of Avastin for Vestibular Schwannoma (Acoustic Neuroma),667
14,NCT01925573,Phase I,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",NOVOTTF-100A+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344),667
15,NCT01356290,Phase II,Recruiting,"[{'id': 1475, 'therapyName': 'Thalidomide'}, {'id': 4418, 'therapyName': 'Fenofibrate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2124, 'therapyName': 'Celecoxib'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}]",Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma (MEMMAT),667
16,NCT01392209,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}]",Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma,667
17,NCT00461773,Phase II,Unknown status,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer,667
18,NCT01803282,Phase I,Recruiting,"[{'id': 3320, 'therapyName': 'GS-5745'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Safety and Tolerability Study in Solid Tumors,667
19,NCT01588184,Phase III,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",An Extension Study to Provide Continued Avastin Therapy to Patients With Solid Tumours Who Were Previously Enrolled in a Roche/Genentech Sponsored Study,667
20,NCT03136406,Phase Ib/II,Recruiting,"[{'id': 1018, 'therapyName': 'GI-4000'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 6163, 'therapyName': 'ETBX-011'}, {'id': 3060, 'therapyName': 'ALT-803'}]",QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy,667
21,NCT01213238,Phase I,"Active, not recruiting","[{'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab",667
22,NCT00565851,Phase III,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 3045, 'therapyName': 'Docetaxel + Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Carboplatin, Paclitaxel and Gemcitabine With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",667
23,NCT02521051,Phase Ib/II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 698, 'therapyName': 'Alectinib'}]","Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer",667
24,NCT02563002,Phase III,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177),667
25,NCT01933815,Phase Ib/II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2274, 'therapyName': 'TPI 287'}]",Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma,667
26,NCT01139723,Phase I,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1616, 'therapyName': 'MINT1526A'}]","A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors",667
27,NCT01578551,Phase II,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",A Randomized Phase II Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma.,667
28,NCT01471054,Phase II,Terminated,"[{'id': 1480, 'therapyName': 'Dexamethasone intravitreal implant'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma,667
29,NCT01263782,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 701, 'therapyName': 'Cixutumumab'}]",BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer,667
30,NCT01916447,Phase I,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2426, 'therapyName': 'trifluridine/tipiracil hydrochloride'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.,667
31,NCT02768389,Phase I,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma,667
32,NCT02120287,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme,667
33,NCT02285959,Phase I,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme,667
34,NCT01954030,Phase Ib/II,Terminated,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 999, 'therapyName': 'Carboxyamidotriazole Orotate'}]",Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure,667
35,NCT02305758,Phase II,Completed,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 954, 'therapyName': 'Veliparib'}]",Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer,667
36,NCT01985763,Phase Ib/II,Completed,"[{'id': 757, 'therapyName': 'Genistein'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Genistein in Treatment of Metastatic Colorectal Cancer,667
37,NCT01197170,Phase I,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Hormone Blockade in Combination With Targeted Agents,667
38,NCT03032484,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 5260, 'therapyName': 'Bevacizumab + TVB-2640'}]",TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma,667
39,NCT01445509,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 717, 'therapyName': 'Dasatinib'}]",Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors,667
40,NCT02511405,Phase III,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2276, 'therapyName': 'VB-111'}]","A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)",667
41,NCT02574663,Phase I,"Active, not recruiting","[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2022, 'therapyName': 'TGR-1202'}]",TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors,667
42,NCT01727089,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1243, 'therapyName': 'Bevacizumab + TRC105'}]", Bevacizumab With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Kidney Cancer,667
43,NCT01107626,Phase III,"Active, not recruiting","[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,667
44,NCT01860638,Phase III,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2075, 'therapyName': 'Lomustine'}]",A Comparison of Continuous Avastin (Bevacizumab) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Patients With Glioblastoma,667
45,NCT02456857,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 936, 'therapyName': 'Temsirolimus'}]","Liposomal Doxorubicin, Bevacizumab and Temsirolimus (DAT) in Triple-Negative Breast Cancer (TNBC) Insensitive to Standard Neoadjuvant Chemotherapy",667
46,NCT01206530,Phase Ib/II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1316, 'therapyName': 'Hydroxychloroquine'}]",FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer,667
47,NCT01331616,Phase I,Unknown status,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab,667
48,NCT01344824,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}]","Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Who Are Light or Never Smokers",667
49,NCT02490878,Phase II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases,667
50,NCT02754362,Phase II,Enrolling by invitation,"[{'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 667, 'therapyName': 'Bevacizumab'}]",A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma,667
51,NCT01526837,Phase I,Terminated,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence,667
52,NCT01351415,Phase III,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer,667
53,NCT02743078,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma,667
54,NCT01814813,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}]",Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,667
55,NCT01894451,Phase I,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy,667
56,NCT02138617,Phase II,Recruiting,"[{'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1715, 'therapyName': 'Fluorouracil'}]",Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer,667
57,NCT02446431,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1076, 'therapyName': 'Valproic acid'}]",Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence,667
58,NCT01767792,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}]",Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas,667
59,NCT02010606,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma,667
60,NCT02420821,Phase III,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of MPDL3280A (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma,667
61,NCT01132014,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1154, 'therapyName': 'Dacarbazine'}]",Autologous OC-DC Vaccine in Ovarian Cancer,667
62,NCT02436993,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting,667
63,NCT00378638,Phase II,Unknown status,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer,667
64,NCT01061515,Phase I,Recruiting,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}]",Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer,667
65,NCT02847559,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma,667
66,NCT02157103,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}]",A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma,667
67,NCT01459380,Phase I,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",667
68,NCT00879437,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1076, 'therapyName': 'Valproic acid'}]",Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas,667
69,NCT01187199,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 936, 'therapyName': 'Temsirolimus'}]","Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer",667
70,NCT01894061,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma,667
71,NCT01201850,Phase I,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",The Role of Bevacizumab in the Treatment of Radiation Necrosis in Children With Central Nervous System Tumors,667
72,NCT01390948,Phase II,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",A Study of Avastin (Bevacizumab) in Combination With Temolozomide (TMZ) and Radiotherapy in Paediatric and Adolescent Patients With High-Grade Glioma,667
73,NCT01182350,Phase II,"Active, not recruiting","[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}, {'id': 2116, 'therapyName': 'Bevacizumab + Erlotinib + Temozolomide'}, {'id': 1146, 'therapyName': 'Bevacizumab + Erlotinib'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG),667
74,NCT01898130,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy,667
75,NCT02663271,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma,667
76,NCT03149003,Phase II,Recruiting,"[{'id': 5986, 'therapyName': 'Bevicizumab + DSP-7888'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy (WIZARD201G),667
77,NCT02078648,Phase Ib/II,"Active, not recruiting","[{'id': 3010, 'therapyName': 'SL-701'}, {'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme",667
78,NCT02661815,Phase I,"Active, not recruiting","[{'id': 3469, 'therapyName': 'ACY-1215 + Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer",667
79,NCT02272413,Phase III,"Active, not recruiting","[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin Plus Chemotherapy in Patients With Lung Cancer,667
80,NCT01495988,Phase II,Terminated,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 342, 'therapyName': 'Vemurafenib'}]",Trial of Vemurafenib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma,667
81,NCT01516216,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Study of Vitamin D in Untreated Metastatic Colorectal Cancer,667
82,NCT02413853,Phase II,Withdrawn,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1083, 'therapyName': 'Pri-724'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer,667
83,NCT02974621,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]",Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma,667
84,NCT01266031,Phase Ib/II,Completed,"[{'id': 2110, 'therapyName': 'Bevacizumab + Vorinostat'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma,667
85,NCT00976573,,Completed,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma",667
86,NCT02017717,Phase III,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Randomized Study of Nivolumab Versus Bevacizumab and a Safety Study of Nivolumab in Adult Subjects With Recurrent Glioblastoma (GBM) (CheckMate 143),667
87,NCT02429843,Phase I,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1242, 'therapyName': 'TRC105'}]",A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer,667
88,NCT02884648,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab in Ovarian Cancer Patients With Disease at Second-look Surgery,667
89,NCT01015222,Phase I,"Active, not recruiting","[{'id': 1032, 'therapyName': 'methylnaltrexone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies",667
90,NCT01743950,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab,667
91,NCT02414165,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 3211, 'therapyName': 'Toca 511 + Toca FC'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA (Toca5),667
92,NCT01454102,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)",667
93,NCT01269853,Phase Ib/II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA,667
94,NCT01580969,Phase Ib/II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]","Repeat Radiation, Minocycline and Bevacizumab in Patients With Recurrent Glioma",667
95,NCT02648711,Phase I,"Active, not recruiting","[{'id': 708, 'therapyName': 'CRLX101'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Alternative Dosing for CRLX101 Alone and With Avastin in Advanced Solid Tumors,667
96,NCT01756352,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}]",FET-PET for Evaluation of Response of Recurrent GBM to Avastin,667
97,NCT01903330,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1873, 'therapyName': 'Sargramostim'}]",ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme,667
98,NCT01248949,Phase I,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1176, 'therapyName': 'MEDI3617'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors,667
99,NCT01788280,Phase I,Not yet recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab,667
100,NCT01730950,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,667
101,NCT00602329,Phase II,Unknown status,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer,667
102,NCT01569984,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Radiosensitization of AVASTIN; (Bevacizumab) With Stereotactic Body Radiotherapy for Colorectal Liver Metastasis,667
103,NCT00588770,Phase III,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1835, 'therapyName': 'Docetaxel + Cisplatin'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 1834, 'therapyName': 'Docetaxel + Carboplatin'}, {'id': 1832, 'therapyName': 'Carboplatin + Fluorouracil\t'}]",Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,667
104,NCT00968240,Phase I,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab),667
105,NCT02648477,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer,667
106,NCT01312376,Phase I,"Active, not recruiting","[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1227, 'therapyName': 'CD3/CD28 costimulated vaccine-primed autologous T-cells'}, {'id': 1222, 'therapyName': 'OC-DC vaccine'}]",Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer,667
107,NCT01966003,Phase III,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2141, 'therapyName': 'Bevacizumab-awwb'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer,667
108,NCT01493843,Phase II,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 749, 'therapyName': 'GDC-0941'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer,667
109,NCT02833701,Phase I,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma,667
110,NCT01067469,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2118, 'therapyName': 'Bevacizumab + Lomustine'}]",Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM),667
111,NCT01625936,Phase I,Unknown status,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 708, 'therapyName': 'CRLX101'}]",CRLX101 Plus Bevacizumab in Advanced RCC,667
112,NCT01811498,Phase Ib/II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM,667
113,NCT00356031,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab and Radiation Therapy for Sarcomas,667
0,NCT02158520,Phase II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1261, 'therapyName': 'Bevacizumab + Abraxane'}]",Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery,1261
0,NCT02997228,Phase III,Not yet recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 5126, 'therapyName': 'Bevacizumab + Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin'}]","Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Microsatellite Instability-High Metastatic Colorectal Cancer",5126
0,NCT01435395,Phase I,Completed,"[{'id': 2122, 'therapyName': 'Bevacizumab + Bortezomib + Temozolomide'}]","Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme",2122
0,NCT02988843,Phase II,Recruiting,"[{'id': 5144, 'therapyName': 'Bevacizumab + Brentuximab vedotin'}]",Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors,5144
0,NCT02873195,Phase II,Not yet recruiting,"[{'id': 2097, 'therapyName': 'Bevacizumab + Capecitabine'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer,2097
1,NCT02669173,Phase I,Recruiting,"[{'id': 2097, 'therapyName': 'Bevacizumab + Capecitabine'}]",Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma,2097
2,NCT01722162,Phase II,Completed,"[{'id': 2097, 'therapyName': 'Bevacizumab + Capecitabine'}]",Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer,2097
0,NCT00780494,Phase II,Unknown status,"[{'id': 2096, 'therapyName': 'Bevacizumab + Capecitabine + Carboplatin'}]","Ph II of Capecitabine, Carboplatin and Bevacizumab for Gastroesophageal Junction and Gastric Carcinoma",2096
0,NCT01525082,Phase II,"Active, not recruiting","[{'id': 2073, 'therapyName': 'Bevacizumab + Capecitabine + Temozolomide'}]","Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors",2073
0,NCT01295944,Phase II,Recruiting,"[{'id': 2074, 'therapyName': 'Bevacizumab + Carboplatin'}]",Carboplatin and Bevacizumab for Recurrent Ependymoma,2074
1,NCT01386710,Phase Ib/II,Suspended,"[{'id': 2074, 'therapyName': 'Bevacizumab + Carboplatin'}]",Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma,2074
2,NCT00936936,Phase II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2101, 'therapyName': 'Etoposide + Ifosfamide'}, {'id': 2100, 'therapyName': 'Docetaxel + Gemcitabine + Melphalan'}, {'id': 2074, 'therapyName': 'Bevacizumab + Carboplatin'}]",High-dose Chemotherapy for Poor-prognosis Relapsed Germ-Cell Tumors,2074
0,NCT01146795,Phase II,Terminated,"[{'id': 1152, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel'}]",Neoadjuvant Therapy for Ovarian Cancer,1152
1,NCT02364999,Phase III,"Active, not recruiting","[{'id': 1152, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel'}]",A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC,1152
2,NCT03038100,Phase III,Recruiting,"[{'id': 2370, 'therapyName': 'Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel'}, {'id': 1152, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel'}]","A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (IMagyn050)",1152
3,NCT02810457,Phase III,Recruiting,"[{'id': 1152, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel'}]",Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer (AVANA),1152
4,NCT01239732,Phase III,Completed,"[{'id': 1152, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel'}]",A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer,1152
0,NCT01649947,Phase II,Completed,"[{'id': 1487, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel + Hydroxychloroquine'}, {'id': 1488, 'therapyName': 'Paclitaxel + Carboplatin + Hydroxychloroquine'}]",Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II,1487
0,NCT02039674,Phase Ib/II,"Active, not recruiting","[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}, {'id': 2104, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 2106, 'therapyName': 'Ipilimumab + Pembrolizumab '}, {'id': 2107, 'therapyName': 'Erlotinib + Pembrolizumab '}, {'id': 2108, 'therapyName': 'Gefitinib + Pembrolizumab '}]",A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021),2104
0,NCT02348255,Phase II,Withdrawn,"[{'id': 2371, 'therapyName': 'Bevacizumab + Carmustine'}]",NovoTTF-100A in Combination With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse,2371
0,NCT02292758,Phase II,Recruiting,"[{'id': 1923, 'therapyName': 'Bevacizumab + Cetuximab + Irinotecan'}, {'id': 1874, 'therapyName': 'Cetuximab + Irinotecan'}]","Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in KRAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer",1923
0,NCT02853318,Phase II,Recruiting,"[{'id': 4528, 'therapyName': 'Bevacizumab + Cyclophosphamide + Pembrolizumab'}]","Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",4528
0,NCT00885326,Phase I,"Active, not recruiting","[{'id': 2072, 'therapyName': 'Bevacizumab + Cyclophosphamide + Zoledronic acid'}]","N2007-02:Bevacizumab,Cyclophosphamide,and Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma",2072
0,NCT01959490,Phase II,Completed,"[{'id': 1486, 'therapyName': 'Bevacizumab + Doxorubicin + Cyclophosphamide + Paclitaxel '}, {'id': 1485, 'therapyName': 'Trastuzumab + Docetaxel + Carboplatin'}]",Trastuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer,1486
0,NCT02923739,Phase II,Recruiting,"[{'id': 4836, 'therapyName': 'Bevacizumab + Emactuzumab + Paclitaxel'}, {'id': 2123, 'therapyName': 'Bevacizumab + Paclitaxel'}]","Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer - REDIRECT",4836
0,NCT01130519,Phase II,Recruiting,"[{'id': 1146, 'therapyName': 'Bevacizumab + Erlotinib'}]",A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer,1146
1,NCT02045446,Phase II,"Active, not recruiting","[{'id': 1146, 'therapyName': 'Bevacizumab + Erlotinib'}, {'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}]",Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC),1146
2,NCT01182350,Phase II,"Active, not recruiting","[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}, {'id': 2116, 'therapyName': 'Bevacizumab + Erlotinib + Temozolomide'}, {'id': 1146, 'therapyName': 'Bevacizumab + Erlotinib'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG),1146
0,NCT01182350,Phase II,"Active, not recruiting","[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}, {'id': 2116, 'therapyName': 'Bevacizumab + Erlotinib + Temozolomide'}, {'id': 1146, 'therapyName': 'Bevacizumab + Erlotinib'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG),2116
0,NCT02342379,Phase II,"Active, not recruiting","[{'id': 2144, 'therapyName': 'Bevacizumab + Evofosfamide'}]",TH-302 in Combination With Bevacizumab for Glioblastoma,2144
1,NCT01403610,Phase II,Completed,"[{'id': 2144, 'therapyName': 'Bevacizumab + Evofosfamide'}, {'id': 1317, 'therapyName': 'Evofosfamide'}]",Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab,2144
0,NCT02141295,Phase II,Completed,"[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 1598, 'therapyName': 'RO5520985'}, {'id': 1599, 'therapyName': 'Bevacizumab + Fluorouracil + Leucovorin'}, {'id': 1600, 'therapyName': 'RO5520985 + Leucovorin + Fluorouracil'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study Comparing the Efficacy and Safety of RO5520985 and FOLFOX With Bevacizumab and FOLFOX in Patients With Untreated Metastatic Colorectal Cancer (McCAVE),1599
0,NCT00602602,Phase II,"Active, not recruiting","[{'id': 2102, 'therapyName': 'Bevacizumab + Fluorouracil + Oxaliplatin'}, {'id': 1296, 'therapyName': 'Gemcitabine + Bevacizumab + Oxaliplatin'}, {'id': 1297, 'therapyName': 'Gemcitabine + Bevacizumab'}]","Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer",2102
0,NCT01442935,Phase II,"Active, not recruiting","[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}, {'id': 2181, 'therapyName': 'Bevacizumab + FOLFIRI'}, {'id': 2182, 'therapyName': 'Cetuximab + FOLFOX'}, {'id': 2183, 'therapyName': 'Bevacizumab + FOLFIRINOX'}, {'id': 2184, 'therapyName': 'Cetuximab + FOLFIRINOX'}]",Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases,2181
0,NCT01442935,Phase II,"Active, not recruiting","[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}, {'id': 2181, 'therapyName': 'Bevacizumab + FOLFIRI'}, {'id': 2182, 'therapyName': 'Cetuximab + FOLFOX'}, {'id': 2183, 'therapyName': 'Bevacizumab + FOLFIRINOX'}, {'id': 2184, 'therapyName': 'Cetuximab + FOLFIRINOX'}]",Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases,2183
0,NCT01052363,Phase I,Withdrawn,"[{'id': 2109, 'therapyName': 'Bevacizumab + Fosbretabulin'}]",OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas,2109
0,NCT01106872,Phase Ib/II,Completed,"[{'id': 1466, 'therapyName': 'Bevacizumab + Gemcitabine + Docetaxel + Valproic Acid '}]","Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas",1466
0,NCT02386826,Phase I,Recruiting,"[{'id': 2600, 'therapyName': 'Bevacizumab + INC280'}]","INC280 Combined With Bevacizumab to Evaluate Glioblastoma Multiforme, Metastatic Colorectal Cancer, and Metastatic Renal Cell Carcinoma Patients",2600
0,NCT01999270,Phase I,Completed,"[{'id': 2112, 'therapyName': 'Bevacizumab + Irinotecan'}]",Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors,2112
0,NCT03093155,Phase II,Recruiting,"[{'id': 1122, 'therapyName': 'Bevacizumab + Ixabepilone'}, {'id': 781, 'therapyName': 'Ixabepilone'}]",Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab,1122
1,NCT00923130,Phase II,Completed,"[{'id': 1122, 'therapyName': 'Bevacizumab + Ixabepilone'}]",Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer,1122
0,NCT01067469,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2118, 'therapyName': 'Bevacizumab + Lomustine'}]",Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM),2118
0,NCT02330562,Phase I,Recruiting,"[{'id': 2166, 'therapyName': 'Bevacizumab + Marizomib'}]",Study of Marizomib With Bevacizumab in Bevacizumab-Na&#239;ve Subjects With WHO Grade IV Malignant Glioma,2166
0,NCT02336165,Phase II,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2117, 'therapyName': 'Bevacizumab + MEDI4736'}]",Phase 2 Study of MEDI4736 in Patients With Glioblastoma,2117
0,NCT02754856,Phase I,Recruiting,"[{'id': 4097, 'therapyName': 'Bevacizumab + MEDI4736 + Tremelimumab + FOLFOX'}]",Tremelimumab (Anti-CTLA-4) Plus MEDI4736 (Anti-PD-L1) in Resectable Colorectal Cancer Liver Metastases.,4097
0,NCT02835833,Phase I,Recruiting,"[{'id': 4498, 'therapyName': 'Bevacizumab + Nintedanib'}]",Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors,4498
0,NCT02354131,Phase Ib/II,Recruiting,"[{'id': 832, 'therapyName': 'Niraparib'}, {'id': 4254, 'therapyName': 'Bevacizumab + Niraparib'}]",Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer (AVANOVA),4254
0,NCT02873962,Phase II,Recruiting,"[{'id': 2111, 'therapyName': 'Bevacizumab + Nivolumab'}]",A Phase II Study Of Nivolumab/ Bevacizumab,2111
1,NCT02210117,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 2111, 'therapyName': 'Bevacizumab + Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab vs Nivolumab + Bevacizumab vs Nivolumab + Ipilimumab in Metastatic Renal Cell Carcinoma (mRCC),2111
0,NCT02803203,Phase Ib/II,Recruiting,"[{'id': 4366, 'therapyName': 'Bevacizumab + Osimertinib'}]",Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers,4366
1,NCT02971501,Phase II,Recruiting,"[{'id': 660, 'therapyName': 'AZD9291'}, {'id': 4366, 'therapyName': 'Bevacizumab + Osimertinib'}]",Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases,4366
0,NCT01871571,Phase II,Recruiting,"[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}]","Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer",1484
1,NCT01212822,Phase II,"Active, not recruiting","[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}]",Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer,1484
2,NCT01442935,Phase II,"Active, not recruiting","[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}, {'id': 2181, 'therapyName': 'Bevacizumab + FOLFIRI'}, {'id': 2182, 'therapyName': 'Cetuximab + FOLFOX'}, {'id': 2183, 'therapyName': 'Bevacizumab + FOLFIRINOX'}, {'id': 2184, 'therapyName': 'Cetuximab + FOLFIRINOX'}]",Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases,1484
3,NCT02141295,Phase II,Completed,"[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 1598, 'therapyName': 'RO5520985'}, {'id': 1599, 'therapyName': 'Bevacizumab + Fluorouracil + Leucovorin'}, {'id': 1600, 'therapyName': 'RO5520985 + Leucovorin + Fluorouracil'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study Comparing the Efficacy and Safety of RO5520985 and FOLFOX With Bevacizumab and FOLFOX in Patients With Untreated Metastatic Colorectal Cancer (McCAVE),1484
4,NCT01006369,Phase II,Completed,"[{'id': 1316, 'therapyName': 'Hydroxychloroquine'}, {'id': 1601, 'therapyName': 'Capecitabine + Oxaliplatin + Bevacizumab'}, {'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}]","Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer",1484
5,NCT02997228,Phase III,Not yet recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 5126, 'therapyName': 'Bevacizumab + Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin'}]","Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Microsatellite Instability-High Metastatic Colorectal Cancer",1484
6,NCT01622543,Phase II,"Active, not recruiting","[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 893, 'therapyName': 'Reolysin'}]",Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer,1484
7,NCT01765582,Phase II,Terminated,"[{'id': 1523, 'therapyName': 'Fluorouracil + Capecitabine + Irinotecan + Leucovorin + Oxaliplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}]",STEAM: A Study of Sequential and Concurrent FOLFOXIRI/Avastin (Bevacizumab) Regimens Versus FOLFOX/Avastin in First-Line in Patients With Metastatic Colorectal Cancer,1484
0,NCT02047214,Phase II,Terminated,"[{'id': 2123, 'therapyName': 'Bevacizumab + Paclitaxel'}]",Safety and Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy,2123
1,NCT02923739,Phase II,Recruiting,"[{'id': 4836, 'therapyName': 'Bevacizumab + Emactuzumab + Paclitaxel'}, {'id': 2123, 'therapyName': 'Bevacizumab + Paclitaxel'}]","Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer - REDIRECT",2123
0,NCT02681549,Phase II,Recruiting,"[{'id': 2119, 'therapyName': 'Bevacizumab + Pembrolizumab'}]",Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer,2119
1,NCT02337491,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2119, 'therapyName': 'Bevacizumab + Pembrolizumab'}]",Pembrolizumab +/- Bevacizumab for Recurrent GBM,2119
2,NCT02313272,Phase I,Recruiting,"[{'id': 2119, 'therapyName': 'Bevacizumab + Pembrolizumab'}]",Phase I Trial of HFSRT With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas,2119
3,NCT02348008,Phase Ib/II,"Active, not recruiting","[{'id': 2119, 'therapyName': 'Bevacizumab + Pembrolizumab'}]",Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma,2119
0,NCT00254319,Phase II,Unknown status,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2114, 'therapyName': 'Bevacizumab + Pemetrexed'}]",Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC),2114
1,NCT02574078,Phase I,Recruiting,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2114, 'therapyName': 'Bevacizumab + Pemetrexed'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",A Master Protocol Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate 370),2114
0,NCT01339039,Phase I,Terminated,"[{'id': 2120, 'therapyName': 'Bevacizumab + Plerixafor'}]",Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma,2120
0,NCT01274624,Phase I,"Active, not recruiting","[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 2099, 'therapyName': 'Bevacizumab + Reolysin'}]",Study of REOLYSIN; in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer,2099
0,NCT01478321,Phase II,"Active, not recruiting","[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}]",Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas,2115
1,NCT03128047,Phase I,Recruiting,"[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}]",HUMC 1612: Optune NovoTTF-200A System,2115
2,NCT01182350,Phase II,"Active, not recruiting","[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}, {'id': 2116, 'therapyName': 'Bevacizumab + Erlotinib + Temozolomide'}, {'id': 1146, 'therapyName': 'Bevacizumab + Erlotinib'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG),2115
3,NCT01891747,Phase Ib/II,"Active, not recruiting","[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}]", A Phase I/II Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma,2115
4,NCT01149850,Phase II,"Active, not recruiting","[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}]",Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma,2115
5,NCT02343549,Phase II,Recruiting,"[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}]",LCI-NEU-NOV-001 Study of a Device Worn on the Head in Combination With Chemo to Treat Brain Cancer,2115
6,NCT00660621,Phase II,Unknown status,"[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}]","A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma",2115
0,NCT00761644,Phase I,"Active, not recruiting","[{'id': 1121, 'therapyName': 'Bevacizumab + Temsirolimus + Doxil'}]","Doxil, Bevacizumab and Temsirolimus Trial",1121
0,NCT01749384,Phase I,Completed,"[{'id': 1254, 'therapyName': 'Bevacizumab + Tivantinib'}]",Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery,1254
0,NCT01806064,Phase I,"Active, not recruiting","[{'id': 1243, 'therapyName': 'Bevacizumab + TRC105'}]", A Phase 1B Dose-escalation Study of TRC105 in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma,1243
1,NCT02664961,Phase II,Recruiting,"[{'id': 1243, 'therapyName': 'Bevacizumab + TRC105'}]",Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN),1243
2,NCT01727089,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1243, 'therapyName': 'Bevacizumab + TRC105'}]", Bevacizumab With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Kidney Cancer,1243
0,NCT02654639,Phase II,"Active, not recruiting","[{'id': 3682, 'therapyName': 'Bevacizumab + trifluridine/tipiracil hydrochloride'}]",Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer,3682
0,NCT03032484,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 5260, 'therapyName': 'Bevacizumab + TVB-2640'}]",TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma,5260
0,NCT01260506,Phase Ib/II,Unknown status,"[{'id': 2277, 'therapyName': 'Bevacizumab + VB-111'}]",Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme,2277
0,NCT00989651,Phase I,"Active, not recruiting","[{'id': 3047, 'therapyName': 'Bevacizumab + Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]","Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",3047
0,NCT02840409,Phase II,Recruiting,"[{'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 5178, 'therapyName': 'Bevacizumab + Vinblastine'}]",Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG),5178
0,NCT01266031,Phase Ib/II,Completed,"[{'id': 2110, 'therapyName': 'Bevacizumab + Vorinostat'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma,2110
0,NCT01966003,Phase III,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2141, 'therapyName': 'Bevacizumab-awwb'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer,2141
0,NCT03149003,Phase II,Recruiting,"[{'id': 5986, 'therapyName': 'Bevicizumab + DSP-7888'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy (WIZARD201G),5986
0,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,3159
0,NCT01508104,Phase Ib/II,Terminated,"[{'id': 1321, 'therapyName': 'BEZ235 + Everolimus'}, {'id': 735, 'therapyName': 'Everolimus'}]",Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors,1321
0,NCT02610361,Phase I,"Active, not recruiting","[{'id': 4025, 'therapyName': 'BGB-283'}]",Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors,4025
0,NCT03150862,Phase Ib/II,Recruiting,"[{'id': 2947, 'therapyName': 'BGB-290'}, {'id': 6124, 'therapyName': 'BGB-290 + Temozolomide'}]",A Study Assessing BGB-290 With Radiation and/or Temozolomide (TMZ) in Subjects With Newly Diagnosed or Recurrent Glioblastoma,2947
0,NCT03150810,Phase Ib/II,Recruiting,"[{'id': 6124, 'therapyName': 'BGB-290 + Temozolomide'}]","Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors",6124
1,NCT03150862,Phase Ib/II,Recruiting,"[{'id': 2947, 'therapyName': 'BGB-290'}, {'id': 6124, 'therapyName': 'BGB-290 + Temozolomide'}]",A Study Assessing BGB-290 With Radiation and/or Temozolomide (TMZ) in Subjects With Newly Diagnosed or Recurrent Glioblastoma,6124
0,NCT02343120,Phase I,Recruiting,"[{'id': 2544, 'therapyName': 'BGB-3111'}]",Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies,2544
1,NCT03053440,Phase III,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 2544, 'therapyName': 'BGB-3111'}]",A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM),2544
0,NCT02569476,Phase I,Recruiting,"[{'id': 4682, 'therapyName': 'BGB-3111 + Obinutuzumab'}]",BGB 3111 in Combination With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies,4682
0,NCT02488408,Phase I,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 2660, 'therapyName': 'BGB-324'}]",Multicenter Open-label Study of BGB324 as a Single Agent and in Combination With Cytarabine in Patients With AML,2660
0,NCT02922777,Phase I,Recruiting,"[{'id': 5973, 'therapyName': 'BGB-324 + Docetaxel'}]",Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.,5973
0,NCT02424617,Phase Ib/II,Recruiting,"[{'id': 2684, 'therapyName': 'BGB-324 + Erlotinib'}]",A Study of BGB324 in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer,2684
0,NCT03184571,Phase II,Recruiting,"[{'id': 5964, 'therapyName': 'BGB-324 + Pembrolizumab'}]",BGB324 in Combination With Pembrolizumab in Patients With Advanced NSCLC,5964
1,NCT03184558,Phase II,Recruiting,"[{'id': 5964, 'therapyName': 'BGB-324 + Pembrolizumab'}]",BGB324 in Combination With Pembrolizumab in Patients With TNBC,5964
0,NCT02407990,Phase I,Recruiting,"[{'id': 5871, 'therapyName': 'BGB-A317'}]","Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Subjects With Advanced Tumors",5871
0,NCT01004224,Phase I,"Active, not recruiting","[{'id': 674, 'therapyName': 'BGJ398'}]",A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies,674
1,NCT02150967,Phase II,Recruiting,"[{'id': 674, 'therapyName': 'BGJ398'}]","A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma",674
2,NCT02160041,Phase II,Recruiting,"[{'id': 674, 'therapyName': 'BGJ398'}]",BGJ398 for Patients With Tumors With FGFR Genetic Alterations,674
3,NCT02706691,Phase II,Not yet recruiting,"[{'id': 674, 'therapyName': 'BGJ398'}]","Pan FGFR Kinase Inhibitor BGJ398 in Treating Patients With FGFR1-3 Translocated, Mutated, or Amplified Recurrent Head and Neck Cancer",674
4,NCT02657486,Phase I,Recruiting,"[{'id': 674, 'therapyName': 'BGJ398'}]",BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder,674
5,NCT01975701,Phase II,"Active, not recruiting","[{'id': 674, 'therapyName': 'BGJ398'}]",A Phase 2 Study of BGJ398 in Patients With Recurrent GBM,674
6,NCT02312804,Phase I,Withdrawn,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 674, 'therapyName': 'BGJ398'}]",Ph Ib/BGJ398/Cervix and Other Solid Tumors,674
0,NCT01928459,Phase I,Completed,"[{'id': 1293, 'therapyName': 'BGJ398 + BYL719'}]",Phase 1b Trial of BGJ398/BYL719 in Solid Tumors,1293
0,NCT01820364,Phase II,Terminated,"[{'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}, {'id': 1260, 'therapyName': 'Encorafenib + Ribociclib'}, {'id': 1337, 'therapyName': 'Encorafenib + BKM120'}, {'id': 1336, 'therapyName': 'BGJ398 + Encorafenib'}, {'id': 1338, 'therapyName': 'Capmatinib + Encorafenib'}]", LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma,1336
0,NCT02575508,Phase Ib/II,Withdrawn,"[{'id': 3142, 'therapyName': 'BGJ398 + Fluorouracil + Irinotecan + Oxaliplatin'}]",Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer,3142
0,NCT02257541,Phase Ib/II,"Active, not recruiting","[{'id': 2284, 'therapyName': 'BGJ398 + Imatinib'}]",BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST),2284
0,NCT03164772,Phase Ib/II,Not yet recruiting,"[{'id': 5818, 'therapyName': 'BI 1361849 + Durvalumab + Tremelimumab'}]",Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With NSCLC,5818
0,NCT03156114,Phase I,Recruiting,"[{'id': 5692, 'therapyName': 'BI 754091'}, {'id': 5690, 'therapyName': 'BI 754111'}]",This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.,5692
1,NCT02952248,Phase I,Recruiting,"[{'id': 5692, 'therapyName': 'BI 754091'}]",A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours,5692
0,NCT03166631,Phase I,Recruiting,"[{'id': 6263, 'therapyName': 'BI 754091 + BI 891065'}, {'id': 6262, 'therapyName': 'BI 891065'}]",A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread,6263
0,NCT03156114,Phase I,Recruiting,"[{'id': 5692, 'therapyName': 'BI 754091'}, {'id': 5690, 'therapyName': 'BI 754111'}]",This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.,5690
0,NCT01296932,Phase I,Completed,"[{'id': 4276, 'therapyName': 'BI 836826'}]",BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL),4276
0,NCT02759016,Phase I,Recruiting,"[{'id': 4277, 'therapyName': 'BI 836826 + Ibrutinib'}]","Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients Who Have Received at Least One Prior Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib",4277
0,NCT02538614,Phase Ib/II,Terminated,"[{'id': 4396, 'therapyName': 'BI 836826 + Idelalisib '}]",Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia,4396
0,NCT01690624,,Recruiting,"[{'id': 5537, 'therapyName': 'BI 836858'}]",BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients in Complete Remission With High Risk to Relapse,5537
1,NCT02240706,Phase II,Recruiting,"[{'id': 5537, 'therapyName': 'BI 836858'}]",Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes,5537
0,NCT02632721,Phase II,Recruiting,"[{'id': 5540, 'therapyName': 'BI 836858 + Decitabine'}, {'id': 650, 'therapyName': 'Decitabine'}]",A Study to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML),5540
0,NCT03166631,Phase I,Recruiting,"[{'id': 6263, 'therapyName': 'BI 754091 + BI 891065'}, {'id': 6262, 'therapyName': 'BI 891065'}]",A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread,6262
0,NCT00002651,Phase III,Completed,"[{'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 759, 'therapyName': 'Goserelin'}]",Hormone Therapy in Treating Men With Stage IV Prostate Cancer,1507
1,NCT01342367,Phase I,Recruiting,"[{'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 2643, 'therapyName': 'Dutasteride'}, {'id': 2644, 'therapyName': 'Finasteride'}]",Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer,1507
2,NCT02064036,Phase I,Recruiting,"[{'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate,1507
3,NCT01674270,Phase II,Completed,"[{'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 1814, 'therapyName': 'Degarelix'}]",Degarelix Neo-Adjuvant Radical Prostatectomy Trial,1507
4,NCT02058706,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 795, 'therapyName': 'Leuprolide'}]",LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer,1507
5,NCT02059213,Phase II,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 795, 'therapyName': 'Leuprolide'}]", A Phase II Study of Androgen Deprivation Therapy With or Without PD 0332991 in RB-Positive Metastatic Prostate Cancer,1507
6,NCT00541047,Phase III,"Active, not recruiting","[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS),1507
7,NCT02366494,Phase I,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Micro RNAs to Predict Response to Androgen Deprivation Therapy,1507
8,NCT03147196,Phase II,Recruiting,"[{'id': 5686, 'therapyName': 'Raloxifene + Bicalutamide'}, {'id': 5685, 'therapyName': 'Raloxifene'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery,1507
9,NCT00936390,Phase III,"Active, not recruiting","[{'id': 742, 'therapyName': 'Flutamide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,1507
10,NCT02614859,Phase II,Recruiting,"[{'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 1031, 'therapyName': 'Metformin'}]",Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients,1507
11,NCT01420250,Phase I,"Active, not recruiting","[{'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}]",Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer,1507
12,NCT01809691,Phase III,"Active, not recruiting","[{'id': 2671, 'therapyName': 'Orteronel '}, {'id': 1507, 'therapyName': 'Bicalutamide'}]","S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",1507
13,NCT02531516,Phase III,Recruiting,"[{'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",An Efficacy and Safety Study of JNJ-56021927 (ARN-509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy,1507
14,NCT02346253,Phase Ib/II,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 1814, 'therapyName': 'Degarelix'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 759, 'therapyName': 'Goserelin'}]",High-Dose Brachytherapy in Treating Patients With Prostate Cancer,1507
15,NCT02582749,Phase II,Recruiting,"[{'id': 4618, 'therapyName': 'Bicalutamide + Ra 223'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases,1507
0,NCT03070886,Phase III,Recruiting,"[{'id': 5450, 'therapyName': 'Bicalutamide + Docetaxel + Flutamide + Goserelin + Leuprolide + Nilutamide'}, {'id': 5449, 'therapyName': 'Bicalutamide + Flutamide + Goserelin + Leuprolide + Nilutamide'}]",Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery,5450
0,NCT03043807,Phase II,Recruiting,"[{'id': 3945, 'therapyName': 'Bicalutamide + Docetaxel + Leuprolide'}]",A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy,3945
1,NCT02716974,Phase I,Recruiting,"[{'id': 3945, 'therapyName': 'Bicalutamide + Docetaxel + Leuprolide'}]",A Study of Definitive Therapy to Treat Prostate Cancer,3945
0,NCT03070886,Phase III,Recruiting,"[{'id': 5450, 'therapyName': 'Bicalutamide + Docetaxel + Flutamide + Goserelin + Leuprolide + Nilutamide'}, {'id': 5449, 'therapyName': 'Bicalutamide + Flutamide + Goserelin + Leuprolide + Nilutamide'}]",Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery,5449
0,NCT03141671,Phase II,Not yet recruiting,"[{'id': 5742, 'therapyName': 'Bicalutamide + Gonadorelin'}, {'id': 5743, 'therapyName': 'Abiraterone + ARN-509 + Gonadorelin + Prednisone'}]",Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509),5742
0,NCT02605486,Phase Ib/II,Recruiting,"[{'id': 3252, 'therapyName': 'Bicalutamide + Palbociclib'}]",Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC),3252
0,NCT02582749,Phase II,Recruiting,"[{'id': 4618, 'therapyName': 'Bicalutamide + Ra 223'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases,4618
0,NCT02479178,Phase II,Terminated,"[{'id': 3640, 'therapyName': 'BIND-014'}]","A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck  (iNSITE2)",3640
0,NCT03271047,,Recruiting,"[{'id': 807, 'therapyName': 'Binimetinib'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation,807
1,NCT01801358,Phase Ib/II,Terminated,"[{'id': 807, 'therapyName': 'Binimetinib'}, {'id': 1114, 'therapyName': 'MEK162 + AEB071'}]", A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma,807
2,NCT01927341,Phase Ib/II,Completed,"[{'id': 807, 'therapyName': 'Binimetinib'}, {'id': 845, 'therapyName': 'Panitumumab'}]","Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors",807
3,NCT01885195,Phase II,Completed,"[{'id': 807, 'therapyName': 'Binimetinib'}]",MEK162 for Patients With RAS/RAF/MEK Activated Tumors,807
4,NCT02285439,Phase Ib/II,Recruiting,"[{'id': 807, 'therapyName': 'Binimetinib'}]",MEK 162 for Children w/Progressive/Recurrent Cancer/Study for Children w/Low-Grade Gliomas/Other Ras/Raf/MAP Pathway Activated Tumors,807
5,NCT03170206,Phase Ib/II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 807, 'therapyName': 'Binimetinib'}, {'id': 5838, 'therapyName': 'Binimetinib + Palbociclib'}]",Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor Binimetinib (MEK162) for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer,807
6,NCT01849874,Phase III,"Active, not recruiting","[{'id': 807, 'therapyName': 'Binimetinib'}]","A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer",807
7,NCT02089230,Phase Ib/II,Recruiting,"[{'id': 807, 'therapyName': 'Binimetinib'}]","Phase I/II MEK162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy",807
8,NCT01763164,Phase III,"Active, not recruiting","[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 807, 'therapyName': 'Binimetinib'}]",Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma,807
9,NCT03231306,Phase II,Not yet recruiting,"[{'id': 807, 'therapyName': 'Binimetinib'}]",Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas (NF108-BINI),807
0,NCT02928224,Phase III,Recruiting,"[{'id': 1916, 'therapyName': 'Cetuximab + Encorafenib'}, {'id': 4886, 'therapyName': 'Binimetinib + Cetuximab + LGX818'}, {'id': 1874, 'therapyName': 'Cetuximab + Irinotecan'}, {'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}]",Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (BEACON CRC),4886
0,NCT02451865,Phase I,Withdrawn,"[{'id': 2740, 'therapyName': 'Binimetinib + Docetaxel'}]","Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer",2740
0,NCT02263898,Phase II,Withdrawn,"[{'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}]",Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations,1100
1,NCT02159066,Phase II,"Active, not recruiting","[{'id': 1101, 'therapyName': 'Binimetinib + Encorafenib + Ribociclib'}, {'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}, {'id': 2216, 'therapyName': 'LGX818 + MEK162 + INC280'}, {'id': 2215, 'therapyName': 'LGX818 + MEK162 + BKM120'}, {'id': 2214, 'therapyName': 'LGX818 + MEK162 + BGJ398'}]","LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma",1100
2,NCT01543698,Phase Ib/II,"Active, not recruiting","[{'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}, {'id': 1101, 'therapyName': 'Binimetinib + Encorafenib + Ribociclib'}]",A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors,1100
3,NCT01820364,Phase II,Terminated,"[{'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}, {'id': 1260, 'therapyName': 'Encorafenib + Ribociclib'}, {'id': 1337, 'therapyName': 'Encorafenib + BKM120'}, {'id': 1336, 'therapyName': 'BGJ398 + Encorafenib'}, {'id': 1338, 'therapyName': 'Capmatinib + Encorafenib'}]", LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma,1100
4,NCT01909453,Phase III,"Active, not recruiting","[{'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 796, 'therapyName': 'Encorafenib'}, {'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}]",Study Comparing Combination of LGX818 Plus MEK162 and LGX818 Monotherapy Versus Vemurafenib in BRAF Mutant Melanoma,1100
0,NCT02159066,Phase II,"Active, not recruiting","[{'id': 1101, 'therapyName': 'Binimetinib + Encorafenib + Ribociclib'}, {'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}, {'id': 2216, 'therapyName': 'LGX818 + MEK162 + INC280'}, {'id': 2215, 'therapyName': 'LGX818 + MEK162 + BKM120'}, {'id': 2214, 'therapyName': 'LGX818 + MEK162 + BGJ398'}]","LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma",1101
1,NCT01543698,Phase Ib/II,"Active, not recruiting","[{'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}, {'id': 1101, 'therapyName': 'Binimetinib + Encorafenib + Ribociclib'}]",A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors,1101
0,NCT02613650,Phase I,Recruiting,"[{'id': 3247, 'therapyName': 'Binimetinib + FOLFIRI'}]",A Trial of FOLFIRI With MEK162 in Patients With Advanced KRAS Positive Metastatic Colorectal Cancers,3247
0,NCT03170206,Phase Ib/II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 807, 'therapyName': 'Binimetinib'}, {'id': 5838, 'therapyName': 'Binimetinib + Palbociclib'}]",Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor Binimetinib (MEK162) for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer,5838
0,NCT03106415,Phase Ib/II,Recruiting,"[{'id': 5568, 'therapyName': 'Binimetinib + Pembrolizumab'}]",Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer,5568
0,NCT03158103,Phase I,Recruiting,"[{'id': 5730, 'therapyName': 'Binimetinib + PLX3397'}]",A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST),5730
0,NCT01781572,Phase Ib/II,"Active, not recruiting","[{'id': 5, 'therapyName': 'Binimetinib + Ribociclib'}]",A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma,5
0,NCT01940172,Phase I,Completed,"[{'id': 1458, 'therapyName': 'Conatumumab'}, {'id': 2647, 'therapyName': 'Birinapant  '}]",Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer,2647
0,NCT02587962,Phase Ib/II,Recruiting,"[{'id': 6160, 'therapyName': 'Birinapant  + Pembrolizumab'}]",Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors,6160
0,NCT01016886,Phase Ib/II,"Active, not recruiting","[{'id': 1897, 'therapyName': 'Bisoprolol'}, {'id': 1896, 'therapyName': 'Perindopril'}]",Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research,1897
0,NCT01695473,Phase II,"Active, not recruiting","[{'id': 680, 'therapyName': 'BKM120'}]",Neoadjuvant BKM120 in High-risk Prostate Cancer,680
1,NCT01911325,Phase Ib/II,Terminated,"[{'id': 680, 'therapyName': 'BKM120'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients,680
2,NCT01820325,Phase II,Terminated,"[{'id': 680, 'therapyName': 'BKM120'}]", Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer,680
3,NCT02220855,Phase II,Recruiting,"[{'id': 680, 'therapyName': 'BKM120'}]",A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas,680
4,NCT02340780,Phase II,"Active, not recruiting","[{'id': 680, 'therapyName': 'BKM120'}]",Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia,680
5,NCT01719250,Phase I,Completed,"[{'id': 680, 'therapyName': 'BKM120'}]",Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma,680
6,NCT01396499,Phase I,Completed,"[{'id': 680, 'therapyName': 'BKM120'}]","Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias",680
7,NCT01571024,Phase I,Completed,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 680, 'therapyName': 'BKM120'}]", BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer,680
8,NCT01816984,Phase Ib/II,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 680, 'therapyName': 'BKM120'}]",PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,680
9,NCT01833169,Phase II,Completed,"[{'id': 680, 'therapyName': 'BKM120'}]",BKM120 for Patients With PI3K-activated Tumors,680
10,NCT02301364,Phase II,Completed,"[{'id': 680, 'therapyName': 'BKM120'}]",Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL),680
0,NCT02117817,Phase I,Withdrawn,"[{'id': 1367, 'therapyName': 'BKM120 + Abraxane'}]","Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer",1367
0,NCT01349660,Phase Ib/II,"Active, not recruiting","[{'id': 1178, 'therapyName': 'BKM120 + Bevacizumab'}]",Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme,1178
1,NCT01283048,Phase I,Completed,"[{'id': 1178, 'therapyName': 'BKM120 + Bevacizumab'}]",Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma,1178
0,NCT01300962,Phase I,"Active, not recruiting","[{'id': 1538, 'therapyName': 'BKM120 + Capecitabine + Lapatinib'}, {'id': 1537, 'therapyName': 'BKM120 + Capecitabine + Trastuzumab'}, {'id': 1536, 'therapyName': 'BKM120 + Capecitabine'}, {'id': 1535, 'therapyName': 'BYL719 + Capecitabine'}]",Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer,1536
1,NCT02000882,Phase II,"Active, not recruiting","[{'id': 1536, 'therapyName': 'BKM120 + Capecitabine'}]",Capecitabine + BKM120 TNBC BC Brain Met,1536
0,NCT01300962,Phase I,"Active, not recruiting","[{'id': 1538, 'therapyName': 'BKM120 + Capecitabine + Lapatinib'}, {'id': 1537, 'therapyName': 'BKM120 + Capecitabine + Trastuzumab'}, {'id': 1536, 'therapyName': 'BKM120 + Capecitabine'}, {'id': 1535, 'therapyName': 'BYL719 + Capecitabine'}]",Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer,1538
0,NCT01300962,Phase I,"Active, not recruiting","[{'id': 1538, 'therapyName': 'BKM120 + Capecitabine + Lapatinib'}, {'id': 1537, 'therapyName': 'BKM120 + Capecitabine + Trastuzumab'}, {'id': 1536, 'therapyName': 'BKM120 + Capecitabine'}, {'id': 1535, 'therapyName': 'BYL719 + Capecitabine'}]",Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer,1537
0,NCT01934361,Phase Ib/II,Completed,"[{'id': 2500, 'therapyName': 'BKM120 + Lomustine'}, {'id': 2501, 'therapyName': 'BKM120 + Carboplatin'}]",Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme,2501
0,NCT01297452,Phase I,Completed,"[{'id': 1183, 'therapyName': 'BKM120 + Carboplatin + Paclitaxel'}]",BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors,1183
0,NCT02113878,Phase I,Recruiting,"[{'id': 1691, 'therapyName': 'BKM120 + Cisplatin'}]",Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck,1691
0,NCT01540253,Phase I,Completed,"[{'id': 1330, 'therapyName': 'BKM120 + Docetaxel'}]","PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic",1330
0,NCT01487265,Phase II,"Active, not recruiting","[{'id': 1319, 'therapyName': 'BKM120 + Erlotinib'}]",Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib,1319
0,NCT02194049,Phase I,Completed,"[{'id': 1626, 'therapyName': 'BKM120 + Etoposide + Cisplatin'}]","Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer",1626
0,NCT01470209,Phase I,"Active, not recruiting","[{'id': 1314, 'therapyName': 'BKM120 + Everolimus'}]",A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies,1314
0,NCT02088684,Phase Ib/II,"Active, not recruiting","[{'id': 2315, 'therapyName': 'BKM120 + Fulvestrant + LEE011'}, {'id': 2316, 'therapyName': 'Fulvestrant + LEE011'}, {'id': 2317, 'therapyName': 'BYL719 + Fulvestrant + LEE011'}]",Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer,2315
0,NCT01971489,Phase I,Withdrawn,"[{'id': 1304, 'therapyName': 'BKM120 + Gemcitabine + Cisplatin'}]","PI3K Inhibitor BKM120, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors",1304
0,NCT02614508,Phase I,"Active, not recruiting","[{'id': 3630, 'therapyName': 'BKM120 + Ibrutinib'}, {'id': 3629, 'therapyName': 'BKM120 + Ofatumumab'}]",Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,3630
1,NCT02756247,Phase I,Recruiting,"[{'id': 3630, 'therapyName': 'BKM120 + Ibrutinib'}]",A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma,3630
0,NCT01870726,Phase Ib/II,Completed,"[{'id': 2461, 'therapyName': 'BKM120 + INC280'}]",Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Gliobastoma,2461
0,NCT01923168,Phase II,Completed,"[{'id': 1570, 'therapyName': 'BKM120 + Letrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 1553, 'therapyName': 'Letrozole + BYL719'}]","Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women",1570
0,NCT01934361,Phase Ib/II,Completed,"[{'id': 2500, 'therapyName': 'BKM120 + Lomustine'}, {'id': 2501, 'therapyName': 'BKM120 + Carboplatin'}]",Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme,2500
0,NCT02614508,Phase I,"Active, not recruiting","[{'id': 3630, 'therapyName': 'BKM120 + Ibrutinib'}, {'id': 3629, 'therapyName': 'BKM120 + Ofatumumab'}]",Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,3629
0,NCT01623349,Phase I,"Active, not recruiting","[{'id': 2171, 'therapyName': 'BYL719 + Olaparib'}, {'id': 2170, 'therapyName': 'BKM120 + Olaparib'}]",Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer,2170
0,NCT01572727,Phase II,Completed,"[{'id': 1545, 'therapyName': 'BKM120 + Paclitaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation",1545
1,NCT01852292,Phase II,Completed,"[{'id': 1545, 'therapyName': 'BKM120 + Paclitaxel'}]",Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy,1545
0,NCT01591421,Phase Ib/II,"Active, not recruiting","[{'id': 1990, 'therapyName': 'BKM120 + Panitumumab'}]",P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Patients With Metastatic or Advanced RAS-Wild Type Colorectal Cancer.,1990
0,NCT01723800,Phase I,Completed,"[{'id': 1112, 'therapyName': 'BKM120 + Pemetrexed + Carboplatin'}]"," PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer",1112
0,NCT02049541,Phase I,"Active, not recruiting","[{'id': 2502, 'therapyName': 'BKM120 + Rituximab'}]",Study of BKM120; Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma,2502
0,NCT02303041,Phase I,"Active, not recruiting","[{'id': 1547, 'therapyName': 'BKM120 + Sonidegib'}]",Erismodegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma,1547
1,NCT01576666,Phase Ib/II,Completed,"[{'id': 1547, 'therapyName': 'BKM120 + Sonidegib'}]","Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors",1547
0,NCT01473901,Phase I,Completed,"[{'id': 4474, 'therapyName': 'BKM120 + Temozolomide'}]",A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma,4474
0,NCT01512251,Phase Ib/II,Completed,"[{'id': 1322, 'therapyName': 'BKM120 + Vemurafenib'}]",BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma,1322
0,NCT02639559,Phase II,Recruiting,"[{'id': 2849, 'therapyName': 'BKT140'}]",Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies,2849
1,NCT02826486,Phase II,Recruiting,"[{'id': 4757, 'therapyName': 'BKT140 + Pembrolizumab'}, {'id': 2849, 'therapyName': 'BKT140'}]",Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202) (COMBAT),2849
0,NCT01838395,Phase II,Completed,"[{'id': 3168, 'therapyName': 'BKT140 + Cytarabine'}]",Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients,3168
0,NCT02763384,Phase II,Recruiting,"[{'id': 4275, 'therapyName': 'BKT140 + Nelarabine'}]",BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma,4275
0,NCT02826486,Phase II,Recruiting,"[{'id': 4757, 'therapyName': 'BKT140 + Pembrolizumab'}, {'id': 2849, 'therapyName': 'BKT140'}]",Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202) (COMBAT),4757
1,NCT02907099,Phase II,Recruiting,"[{'id': 4757, 'therapyName': 'BKT140 + Pembrolizumab'}]",Pembrolizumab and BL-8040 in Metastatic Pancreatic Cancer,4757
0,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1137
1,NCT01042522,Phase II,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1137, 'therapyName': 'Bleomycin'}]","Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors",1137
0,NCT03033914,Phase I,Recruiting,"[{'id': 5296, 'therapyName': 'Dacarbazine + Doxorubicin + Vinblastine + Nivolumab'}, {'id': 5295, 'therapyName': 'Bleomycin + Dacarbazine + Doxorubicin + Vinblastine + Nivolumab'}]",A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma,5295
0,NCT02790515,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation,1876
1,NCT02101853,Phase III,Recruiting,"[{'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 2347, 'therapyName': 'Leucovorin + Pegaspargase  + Vincristine'}, {'id': 2346, 'therapyName': 'Mercaptopurine + Thioguanine'}, {'id': 2348, 'therapyName': 'Asparaginase + Cyclophosphamide + Etoposide'}, {'id': 2345, 'therapyName': 'Cytarabine + Dexamethasone+ Methotrexate '}]",Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia,1876
2,NCT03117751,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,1876
0,NCT03263572,Phase II,Not yet recruiting,"[{'id': 6155, 'therapyName': 'Blinatumomab + Cytarabine + Dexamethasone + Methotrexate + Ponatinib'}, {'id': 6156, 'therapyName': 'Blinatumomab + Dexamethasone + Ponatinib'}]",Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),6155
0,NCT03263572,Phase II,Not yet recruiting,"[{'id': 6155, 'therapyName': 'Blinatumomab + Cytarabine + Dexamethasone + Methotrexate + Ponatinib'}, {'id': 6156, 'therapyName': 'Blinatumomab + Dexamethasone + Ponatinib'}]",Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),6156
0,NCT02997761,Phase II,Recruiting,"[{'id': 5125, 'therapyName': 'Blinatumomab + Ibrutinib'}]",Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia,5125
0,NCT02879695,Phase I,Recruiting,"[{'id': 4613, 'therapyName': 'Blinatumomab + Ipilimumab + Nivolumab'}]",Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia,4613
0,NCT03160079,Phase Ib/II,Recruiting,"[{'id': 5839, 'therapyName': 'Blinatumomab + Pembrolizumab'}]",Blinatumomab and Pembrolizumab for Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia With High Marrow Lymphoblasts,5839
0,NCT02561988,Phase I,Recruiting,"[{'id': 2941, 'therapyName': 'BLU-285'}]",Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies,2941
1,NCT02508532,Phase I,Recruiting,"[{'id': 2941, 'therapyName': 'BLU-285'}]",Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors,2941
0,NCT02508467,Phase I,Recruiting,"[{'id': 3165, 'therapyName': 'BLU-554'}]",A Phase 1 Study of BLU-554 in Patients With Hepatocellular Carcinoma and Cholangiocarcinoma,3165
0,NCT03037385,Phase I,Recruiting,"[{'id': 5530, 'therapyName': 'BLU-667'}]","Phase 1 Study of BLU-667 in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors",5530
0,NCT02829723,Phase Ib/II,Recruiting,"[{'id': 2844, 'therapyName': 'BLZ945'}, {'id': 5071, 'therapyName': 'BLZ945 + PDR001'}]",Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors,2844
0,NCT02829723,Phase Ib/II,Recruiting,"[{'id': 2844, 'therapyName': 'BLZ945'}, {'id': 5071, 'therapyName': 'BLZ945 + PDR001'}]",Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors,5071
0,NCT03184870,Phase Ib/II,Recruiting,"[{'id': 5905, 'therapyName': 'BMS-813160 + Fluorouracil + Irinotecan + Leucovorin'}, {'id': 5903, 'therapyName': 'BMS-813160 + Nivolumab'}, {'id': 5904, 'therapyName': 'BMS-813160 + Gemcitabine + nab-paclitaxel'}, {'id': 5902, 'therapyName': 'BMS-813160'}]",A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors,5902
0,NCT03184870,Phase Ib/II,Recruiting,"[{'id': 5905, 'therapyName': 'BMS-813160 + Fluorouracil + Irinotecan + Leucovorin'}, {'id': 5903, 'therapyName': 'BMS-813160 + Nivolumab'}, {'id': 5904, 'therapyName': 'BMS-813160 + Gemcitabine + nab-paclitaxel'}, {'id': 5902, 'therapyName': 'BMS-813160'}]",A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors,5905
0,NCT03184870,Phase Ib/II,Recruiting,"[{'id': 5905, 'therapyName': 'BMS-813160 + Fluorouracil + Irinotecan + Leucovorin'}, {'id': 5903, 'therapyName': 'BMS-813160 + Nivolumab'}, {'id': 5904, 'therapyName': 'BMS-813160 + Gemcitabine + nab-paclitaxel'}, {'id': 5902, 'therapyName': 'BMS-813160'}]",A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors,5904
0,NCT03184870,Phase Ib/II,Recruiting,"[{'id': 5905, 'therapyName': 'BMS-813160 + Fluorouracil + Irinotecan + Leucovorin'}, {'id': 5903, 'therapyName': 'BMS-813160 + Nivolumab'}, {'id': 5904, 'therapyName': 'BMS-813160 + Gemcitabine + nab-paclitaxel'}, {'id': 5902, 'therapyName': 'BMS-813160'}]",A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors,5903
0,NCT01292655,Phase I,"Active, not recruiting","[{'id': 2545, 'therapyName': 'BMS-906024'}]",Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors,2545
1,NCT01653470,Phase I,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 2545, 'therapyName': 'BMS-906024'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors",2545
2,NCT01363817,Phase I,"Active, not recruiting","[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2545, 'therapyName': 'BMS-906024'}]",Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma,2545
0,NCT02247349,Phase Ib/II,"Active, not recruiting","[{'id': 4534, 'therapyName': 'BMS-986012'}, {'id': 4535, 'therapyName': 'BMS-986012 + Nivolumab'}]",BMS-986012 in Relapsed/Refractory SCLC,4534
0,NCT02815592,Phase Ib/II,"Active, not recruiting","[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 4563, 'therapyName': 'BMS-986012 + Cisplatin + Etoposide'}, {'id': 4564, 'therapyName': 'BMS-986012 + Carboplatin + Etoposide'}]",Trial of BMS-986012 in Combination With Platinum and Etoposide,4564
0,NCT02815592,Phase Ib/II,"Active, not recruiting","[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 4563, 'therapyName': 'BMS-986012 + Cisplatin + Etoposide'}, {'id': 4564, 'therapyName': 'BMS-986012 + Carboplatin + Etoposide'}]",Trial of BMS-986012 in Combination With Platinum and Etoposide,4563
0,NCT02247349,Phase Ib/II,"Active, not recruiting","[{'id': 4534, 'therapyName': 'BMS-986012'}, {'id': 4535, 'therapyName': 'BMS-986012 + Nivolumab'}]",BMS-986012 in Relapsed/Refractory SCLC,4535
0,NCT01968109,Phase I,Recruiting,"[{'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 4196, 'therapyName': 'BMS-986016'}]",Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors,4196
1,NCT02061761,Phase Ib/II,Recruiting,"[{'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 4196, 'therapyName': 'BMS-986016'}]",Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies,4196
0,NCT02996110,Phase II,Recruiting,"[{'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (FRACTION-RCC),4197
1,NCT02935634,Phase II,Recruiting,"[{'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer (FRACTION-GC),4197
2,NCT02750514,Phase II,Recruiting,"[{'id': 1813, 'therapyName': 'Dasatinib + Nivolumab'}, {'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Study to Test Combination Treatments in People With Advanced Non-Small Cell Lung Cancer,4197
3,NCT01968109,Phase I,Recruiting,"[{'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 4196, 'therapyName': 'BMS-986016'}]",Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors,4197
4,NCT02061761,Phase Ib/II,Recruiting,"[{'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 4196, 'therapyName': 'BMS-986016'}]",Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies,4197
0,NCT02341625,Phase Ib/II,"Active, not recruiting","[{'id': 4923, 'therapyName': 'BMS-986148'}, {'id': 4924, 'therapyName': 'BMS-986148 + Nivolumab'}]",A Study of BMS-986148 in Patients With Select Advanced Solid Tumors,4923
0,NCT02341625,Phase Ib/II,"Active, not recruiting","[{'id': 4923, 'therapyName': 'BMS-986148'}, {'id': 4924, 'therapyName': 'BMS-986148 + Nivolumab'}]",A Study of BMS-986148 in Patients With Select Advanced Solid Tumors,4924
0,NCT02598960,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 3559, 'therapyName': 'BMS-986156'}]",A Study of BMS-986156 Given Alone and in Combination With Nivolumab in Subjects With Advanced Solid Tumors,3559
0,NCT02737475,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 4030, 'therapyName': 'BMS-986178'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Study of BMS-986178 Monotherapy or in Combination With Nivolumab or Ipilimumab in Subjects With Advanced Solid Tumors,4030
0,NCT02754141,Phase Ib/II,Recruiting,"[{'id': 4195, 'therapyName': 'BMS-986179 + Nivolumab'}]",A Study of BMS-986179 Administered in Combination With Nivolumab in Advanced Cancers,4195
0,NCT02828124,Phase Ib/II,"Active, not recruiting","[{'id': 5628, 'therapyName': 'BMS-986183'}, {'id': 5629, 'therapyName': 'BMS-986183 + Nivolumab'}]",A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer,5628
0,NCT02828124,Phase Ib/II,"Active, not recruiting","[{'id': 5628, 'therapyName': 'BMS-986183'}, {'id': 5629, 'therapyName': 'BMS-986183 + Nivolumab'}]",A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer,5629
0,NCT03247283,,Recruiting,"[{'id': 3568, 'therapyName': 'BMS-986205'}]",Pharmacokinetics and Metabolism Study in Healthy Male Participants,3568
0,NCT02658890,Phase Ib/II,Recruiting,"[{'id': 3569, 'therapyName': 'BMS-986205 + Nivolumab'}]","Safety, Tolerability, Pharmacokinetic/Pharmacodynamic and Preliminary Efficacy Study of BMS-986205 Administered in Combination With Nivolumab in Advanced Cancers",3569
0,NCT02913313,Phase Ib/II,Recruiting,"[{'id': 4888, 'therapyName': 'BMS-986207 + Nivolumab'}, {'id': 4887, 'therapyName': 'BMS-986207 '}]",A Study to Evaluate the Safety and Tolerability of Monoclonal Antibody BMS-986207 Alone and in Combination With Nivolumab in Advanced (Solid Tumor) Cancers,4887
0,NCT02913313,Phase Ib/II,Recruiting,"[{'id': 4888, 'therapyName': 'BMS-986207 + Nivolumab'}, {'id': 4887, 'therapyName': 'BMS-986207 '}]",A Study to Evaluate the Safety and Tolerability of Monoclonal Antibody BMS-986207 Alone and in Combination With Nivolumab in Advanced (Solid Tumor) Cancers,4888
0,NCT03110107,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 5552, 'therapyName': 'BMS-986218 + Nivolumab'}, {'id': 5551, 'therapyName': 'BMS-986218'}]",First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Patients With Advanced Solid Tumors,5551
0,NCT03110107,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 5552, 'therapyName': 'BMS-986218 + Nivolumab'}, {'id': 5551, 'therapyName': 'BMS-986218'}]",First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Patients With Advanced Solid Tumors,5552
0,NCT03251924,Phase Ib/II,Recruiting,"[{'id': 6136, 'therapyName': 'BMS-986226 + Nivolumab'}, {'id': 6135, 'therapyName': 'BMS-986226 + Ipilimumab'}, {'id': 6134, 'therapyName': 'BMS-986226'}]",A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors,6134
0,NCT03251924,Phase Ib/II,Recruiting,"[{'id': 6136, 'therapyName': 'BMS-986226 + Nivolumab'}, {'id': 6135, 'therapyName': 'BMS-986226 + Ipilimumab'}, {'id': 6134, 'therapyName': 'BMS-986226'}]",A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors,6135
0,NCT03251924,Phase Ib/II,Recruiting,"[{'id': 6136, 'therapyName': 'BMS-986226 + Nivolumab'}, {'id': 6135, 'therapyName': 'BMS-986226 + Ipilimumab'}, {'id': 6134, 'therapyName': 'BMS-986226'}]",A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors,6136
0,NCT02419417,Phase Ib/II,Recruiting,"[{'id': 2811, 'therapyName': 'BMS986158'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Study of BMS-986158 in Subjects With Select Advanced Solid Tumors,2811
0,NCT02990468,Phase I,Recruiting,"[{'id': 5840, 'therapyName': 'BMX-001 + Cisplatin'}]","A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer (BMX-HN)",5840
0,NCT02655601,Phase Ib/II,Recruiting,"[{'id': 5841, 'therapyName': 'BMX-001 + Temozolomide'}, {'id': 1141, 'therapyName': 'Temozolomide'}]","Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001",5841
0,NCT02703779,Phase II,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 3933, 'therapyName': 'Filgrastim + Plerixafor'}]",Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM),688
1,NCT01216683,Phase II,Unknown status,"[{'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1164, 'therapyName': 'lenalidomide'}]","Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma",688
2,NCT00184015,,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 688, 'therapyName': 'Bortezomib'}]","Bortezomib and Bevacizumab (""BB-mib-mab"") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)",688
3,NCT02440464,Phase II,Recruiting,"[{'id': 3321, 'therapyName': 'Tacrolimus + Methotrexate'}, {'id': 1359, 'therapyName': 'Ixazomib'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302),688
4,NCT01695330,Phase II,Terminated,"[{'id': 688, 'therapyName': 'Bortezomib'}]",Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens,688
5,NCT01453101,Phase II,"Active, not recruiting","[{'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma,688
6,NCT02605356,Phase Ib/II,Withdrawn,"[{'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma,688
7,NCT01241708,Phase III,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}]",Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma ((Mel/MelVel)),688
8,NCT02265510,Phase I,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2747, 'therapyName': 'INCB052793'}, {'id': 688, 'therapyName': 'Bortezomib'}]","An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies",688
9,NCT03117751,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,688
10,NCT02308280,Phase II,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}]",Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients,688
11,NCT01371981,Phase III,"Active, not recruiting","[{'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2392, 'therapyName': 'Cytarabine + Etoposide'}, {'id': 2393, 'therapyName': 'Cytarabine + Mitoxantrone'}, {'id': 2394, 'therapyName': 'Asparaginase + Cytarabine'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,688
12,NCT01453088,Phase II,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older,688
13,NCT02112916,Phase III,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,688
14,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,688
15,NCT01833143,Phase II,"Active, not recruiting","[{'id': 688, 'therapyName': 'Bortezomib'}]",Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D,688
16,NCT02553460,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I,688
17,NCT02139397,Phase Ib/II,Recruiting,"[{'id': 2629, 'therapyName': 'Eflornithine'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Study of DFMO in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma,688
18,NCT02343042,Phase Ib/II,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 2479, 'therapyName': 'Dexamethasone + Selinexor'}, {'id': 1622, 'therapyName': 'Pomalidomide'}]",Phase 1b/2 Study of Selinexor (KPT-330) in Combination w/ Backbone Treatments for Resistant/Refractory Multiple Myeloma,688
19,NCT03136146,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1090, 'therapyName': 'Ofatumumab'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]","Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)",688
20,NCT02352558,Phase I,"Active, not recruiting","[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 2057, 'therapyName': 'BBI608'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]","A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies",688
21,NCT03004287,Phase II,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy,688
22,NCT01313897,Phase II,Completed,"[{'id': 688, 'therapyName': 'Bortezomib'}]","UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma (NK2010-35)",688
23,NCT01863550,Phase III,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,688
24,NCT00114738,Phase II,"Active, not recruiting","[{'id': 3395, 'therapyName': 'R-EPOCH'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 688, 'therapyName': 'Bortezomib'}]",EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma,688
25,NCT01415752,Phase II,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1164, 'therapyName': 'lenalidomide'}]","Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",688
26,NCT01769209,Phase II,"Active, not recruiting","[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 1830, 'therapyName': 'Vincristine + Dexamethasone + Pegaspargase + Doxorubicin'}]",Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,688
27,NCT02195479,Phase III,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 1207, 'therapyName': 'Melphalan'}]",A Study of Combination of Daratumumanb and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma,688
28,NCT02559778,Phase I,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2629, 'therapyName': 'Eflornithine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 717, 'therapyName': 'Dasatinib'}]",Pediatric Precision Laboratory Advanced Neuroblastoma Therapy,688
29,NCT02535806,Phase II,Terminated,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults,688
30,NCT00092222,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1187, 'therapyName': 'Alpha 2 Interferon'}, {'id': 2211, 'therapyName': 'EPOCH'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1008, 'therapyName': 'Doxil'}]",Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity,688
31,NCT01428492,Phase I,Completed,"[{'id': 625, 'therapyName': 'Afuresertib'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma,688
32,NCT02419755,Phase II,Terminated,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies,688
33,NCT03056599,,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1733, 'therapyName': 'interferon gamma '}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 3420, 'therapyName': 'trabectedin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma,688
34,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,688
35,NCT01522872,Phase Ib/II,"Active, not recruiting","[{'id': 1317, 'therapyName': 'Evofosfamide'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma,688
0,NCT02188368,Phase II,Recruiting,"[{'id': 1625, 'therapyName': 'Bortezomib + Carfilzomib + Clarithromycin'}, {'id': 1674, 'therapyName': 'Doxil + Pomalidomide'}, {'id': 1622, 'therapyName': 'Pomalidomide'}]",Pomalidomide for Lenalidomide for Failures,1625
0,NCT01439750,Phase Ib/II,"Active, not recruiting","[{'id': 3394, 'therapyName': 'Bortezomib + Cladribine + Rituximab'}]","Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)",3394
0,NCT02211755,Phase I,Recruiting,"[{'id': 3063, 'therapyName': 'Bortezomib + Clofarabine'}]",Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors,3063
0,NCT01146834,Phase III,Recruiting,"[{'id': 3345, 'therapyName': 'Bortezomib + Filgrastim'}, {'id': 5459, 'therapyName': 'Bortezomib + Cyclophosphamide + G-CSF'}, {'id': 5460, 'therapyName': 'Bortezomib + Cyclophosphamide'}]",Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma,5460
0,NCT02951819,Phase II,Recruiting,"[{'id': 4951, 'therapyName': 'Bortezomib + Cyclophosphamide + Daratumumab + Dexamethasone'}]",A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma,4951
0,NCT01146834,Phase III,Recruiting,"[{'id': 3345, 'therapyName': 'Bortezomib + Filgrastim'}, {'id': 5459, 'therapyName': 'Bortezomib + Cyclophosphamide + G-CSF'}, {'id': 5460, 'therapyName': 'Bortezomib + Cyclophosphamide'}]",Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma,5459
0,NCT01729338,Phase II,Terminated,"[{'id': 3358, 'therapyName': 'Bortezomib + Cyclophosphamide + lenalidomide'}]",Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma,3358
0,NCT01954784,Phase I,Terminated,"[{'id': 3434, 'therapyName': 'Bortezomib + Cyclosporine + Mycophenolate'}, {'id': 1164, 'therapyName': 'lenalidomide'}]",Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma,3434
0,NCT01734928,Phase III,"Active, not recruiting","[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}]","Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma",2470
1,NCT01998971,Phase I,Recruiting,"[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1475, 'therapyName': 'Thalidomide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 3323, 'therapyName': 'Montelukast'}]",A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma,2470
2,NCT01323751,Phase Ib/II,Completed,"[{'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}, {'id': 1613, 'therapyName': 'ACY-1215'}]",Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma,2470
3,NCT01919086,Phase II,"Active, not recruiting","[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}]",Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma,2470
4,NCT02136134,Phase III,"Active, not recruiting","[{'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}]",Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma,2470
5,NCT02755597,Phase III,Recruiting,"[{'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}, {'id': 3436, 'therapyName': 'Bortezomib + Dexamethasone + GDC-0199\t'}]",A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy,2470
6,NCT03110562,Phase III,Recruiting,"[{'id': 5639, 'therapyName': 'Selinexor + Bortezomib + Dexamethasone'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}]","Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma (BOSTON)",2470
7,NCT01470131,Phase III,Unknown status,"[{'id': 804, 'therapyName': 'Masitinib'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}]",A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma,2470
0,NCT01711528,Phase I,"Active, not recruiting","[{'id': 3437, 'therapyName': 'Bortezomib + Dexamethasone + Dinaciclib'}]","Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma",3437
0,NCT02718833,Phase II,Recruiting,"[{'id': 4031, 'therapyName': 'Bortezomib + Dexamethasone + Elotuzumab + Panobinostat'}]","A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma",4031
0,NCT02755597,Phase III,Recruiting,"[{'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}, {'id': 3436, 'therapyName': 'Bortezomib + Dexamethasone + GDC-0199\t'}]",A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy,3436
1,NCT01794507,Phase I,"Active, not recruiting","[{'id': 3436, 'therapyName': 'Bortezomib + Dexamethasone + GDC-0199\t'}]",A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy,3436
0,NCT03168100,Phase II,Recruiting,"[{'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}, {'id': 3353, 'therapyName': 'Elotuzumab + Dexamethasone + Lenalidomide'}]","2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma",3342
1,NCT01668719,Phase Ib/II,Recruiting,"[{'id': 3343, 'therapyName': 'Elotuzumab'}, {'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}]","S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",3342
2,NCT01208662,Phase III,Recruiting,"[{'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}]","Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65  (DFCI 10-106)",3342
3,NCT02874742,Phase II,Recruiting,"[{'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}]","Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma",3342
4,NCT02720510,Phase II,Recruiting,"[{'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}]","A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)",3342
5,NCT02375555,Phase II,"Active, not recruiting","[{'id': 3343, 'therapyName': 'Elotuzumab'}, {'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}]","Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM",3342
6,NCT02441686,Phase II,"Active, not recruiting","[{'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}]","Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma",3342
0,NCT01440582,Phase I,"Active, not recruiting","[{'id': 3362, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide + Panobinostat'}]",Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients,3362
1,NCT01965353,Phase I,"Active, not recruiting","[{'id': 3362, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide + Panobinostat'}]",A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma,3362
0,NCT01728259,Phase I,Suspended,"[{'id': 4501, 'therapyName': 'Bortezomib + Dexamethasone + Pomalidomide'}]","First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD",4501
0,NCT02928029,Phase Ib/II,Recruiting,"[{'id': 6161, 'therapyName': 'Bortezomib + Dexamethasone + radium Ra 223 dichloride'}]",Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma,6161
0,NCT02514382,Phase I,Recruiting,"[{'id': 3432, 'therapyName': 'Bortezomib + Dexamethasone + Reolysin'}]","Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma",3432
0,NCT02666209,Phase I,No longer available,"[{'id': 3556, 'therapyName': 'Bortezomib + Dexamethasone + Ulocuplumab'}, {'id': 3555, 'therapyName': 'Dexamethasone + lenalidomide + Ulocuplumab'}]",Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma,3556
0,NCT02783625,Phase I,Recruiting,"[{'id': 4240, 'therapyName': 'Bortezomib + Duvelisib'}, {'id': 4239, 'therapyName': 'Duvelisib + romidepsin '}]",Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas,4240
0,NCT02719613,Phase II,Recruiting,"[{'id': 4533, 'therapyName': 'Bortezomib + Elotuzumab + Dexamethasone + lenalidomide'}]",Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab,4533
0,NCT00671112,Phase I,Terminated,"[{'id': 2234, 'therapyName': 'Bortezomib + Everolimus'}]",Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma,2234
0,NCT01146834,Phase III,Recruiting,"[{'id': 3345, 'therapyName': 'Bortezomib + Filgrastim'}, {'id': 5459, 'therapyName': 'Bortezomib + Cyclophosphamide + G-CSF'}, {'id': 5460, 'therapyName': 'Bortezomib + Cyclophosphamide'}]",Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma,3345
1,NCT02220608,Phase I,Completed,"[{'id': 3345, 'therapyName': 'Bortezomib + Filgrastim'}]",Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma,3345
0,NCT01163357,Phase I,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2288, 'therapyName': 'Bortezomib + Fludarabine + Melphalan'}]","Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma",2288
0,NCT02658396,Phase I,Withdrawn,"[{'id': 3427, 'therapyName': 'Bortezomib + GO-203-2C'}]",GO-203-2C + Bortezomib For Relapsed Or Refractory MM,3427
0,NCT02312102,Phase I,Recruiting,"[{'id': 3220, 'therapyName': 'Bortezomib + lenalidomide'}]",Phase I Study of Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation,3220
0,NCT00996385,Phase II,Unknown status,"[{'id': 3064, 'therapyName': 'Bortezomib + Oxaliplatin'}]",Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma,3064
0,NCT01736943,Phase II,Recruiting,"[{'id': 3184, 'therapyName': 'Bortezomib + pegylated liposomal-doxorubicin'}]",Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia,3184
0,NCT00903968,Phase Ib/II,Completed,"[{'id': 3348, 'therapyName': 'Bortezomib + Plerixafor'}]",Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma,3348
0,NCT02484261,Phase I,Recruiting,"[{'id': 3191, 'therapyName': 'Bortezomib + Pravastatin'}]",Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children,3191
0,NCT02613598,Phase I,Recruiting,"[{'id': 3262, 'therapyName': 'Bortezomib + Ruxolitinib'}]",Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma,3262
0,NCT02254551,Phase II,Terminated,"[{'id': 1954, 'therapyName': 'Bortezomib + Sonidegib'}]",Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma,1954
0,NCT01861314,Phase I,"Active, not recruiting","[{'id': 1793, 'therapyName': 'Bortezomib + Sorafenib + Decitabine   '}]","Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia",1793
0,NCT01534260,Phase Ib/II,Recruiting,"[{'id': 2366, 'therapyName': 'Bortezomib + Sorafenib + vorinostat'}]","Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype",2366
0,NCT00998010,Phase II,"Active, not recruiting","[{'id': 3055, 'therapyName': 'Bortezomib + Temozolomide'}]","Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma",3055
0,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,690
1,NCT03106779,Phase III,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 2484, 'therapyName': 'ABL001'}]","Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs",690
2,NCT02130557,Phase III,"Active, not recruiting","[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 770, 'therapyName': 'Imatinib'}]","A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia",690
3,NCT01331291,Phase II,Completed,"[{'id': 690, 'therapyName': 'Bosutinib'}]",Bosutinib in Adult Patients With Recurrent Glioblastoma,690
4,NCT02228382,FDA approved,"Active, not recruiting","[{'id': 690, 'therapyName': 'Bosutinib'}]",Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors,690
5,NCT02906696,Phase II,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}]",Bosutinib Dose-Optimization Study in Chronic Myeloid Leukemia (CML),690
6,NCT01903733,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}]",Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008,690
7,NCT02693535,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 690, 'therapyName': 'Bosutinib'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer,690
0,NCT02311998,Phase Ib/II,Recruiting,"[{'id': 3200, 'therapyName': 'Bosutinib + inotuzumab ozogamicin'}]",Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive Philadelphia-Chromosome (PC) Positive Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia (CML),3200
0,NCT03023319,Phase I,Recruiting,"[{'id': 5237, 'therapyName': 'Bosutinib + Pemetrexed'}]",Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors,5237
0,NCT02650804,Phase II,Recruiting,"[{'id': 5759, 'therapyName': 'BPM 31510'}, {'id': 5842, 'therapyName': 'BPM 31510 + Gemcitabine'}]",BPM31510 Administered Intravenously With or Without Gemcitabine in Advanced Pancreatic Cancer Patients,5759
0,NCT02650804,Phase II,Recruiting,"[{'id': 5759, 'therapyName': 'BPM 31510'}, {'id': 5842, 'therapyName': 'BPM 31510 + Gemcitabine'}]",BPM31510 Administered Intravenously With or Without Gemcitabine in Advanced Pancreatic Cancer Patients,5842
0,NCT02065869,Phase Ib/II,Recruiting,"[{'id': 6053, 'therapyName': 'BPX-501'}, {'id': 5992, 'therapyName': 'Rimiducid'}]",Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant,6053
1,NCT02487459,Phase I,Not yet recruiting,"[{'id': 6053, 'therapyName': 'BPX-501'}, {'id': 5992, 'therapyName': 'Rimiducid'}]",Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies,6053
2,NCT02786485,Phase I,Not yet recruiting,"[{'id': 5992, 'therapyName': 'Rimiducid'}, {'id': 6053, 'therapyName': 'BPX-501'}]",Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT,6053
3,NCT01744223,Phase Ib/II,Recruiting,"[{'id': 5992, 'therapyName': 'Rimiducid'}, {'id': 6053, 'therapyName': 'BPX-501'}]",Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant,6053
0,NCT02477878,Phase I,Recruiting,"[{'id': 5995, 'therapyName': 'BPX-601'}, {'id': 5992, 'therapyName': 'Rimiducid'}]",Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant,5995
0,NCT02743611,Phase I,Recruiting,"[{'id': 5992, 'therapyName': 'Rimiducid'}, {'id': 5991, 'therapyName': 'BPX-701'}]",Dose Finding Study Evaluating Safety and Feasibility in Patients With Relapsed or Refractory Myeloid Neoplasms,5991
0,NCT02684292,Phase III,Recruiting,"[{'id': 2486, 'therapyName': 'Brentuximab vedotin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204),2486
1,NCT03138499,Phase III,Recruiting,"[{'id': 2486, 'therapyName': 'Brentuximab vedotin'}, {'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}]","Phase III Trial of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,",2486
2,NCT03233347,,Not yet recruiting,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 2486, 'therapyName': 'Brentuximab vedotin'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","Doxorubicin Hydrochloride, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma",2486
3,NCT01716806,Phase II,Recruiting,"[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}, {'id': 5055, 'therapyName': 'Brentuximab vedotin + Bendamustine'}, {'id': 5056, 'therapyName': 'Brentuximab vedotin + Dacarbazine'}, {'id': 2486, 'therapyName': 'Brentuximab vedotin'}]",A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL),2486
4,NCT02408042,Phase Ib/II,Withdrawn,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2486, 'therapyName': 'Brentuximab vedotin'}]",Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme),2486
0,NCT01716806,Phase II,Recruiting,"[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}, {'id': 5055, 'therapyName': 'Brentuximab vedotin + Bendamustine'}, {'id': 5056, 'therapyName': 'Brentuximab vedotin + Dacarbazine'}, {'id': 2486, 'therapyName': 'Brentuximab vedotin'}]",A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL),5055
1,NCT02927769,Phase II,Recruiting,"[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}, {'id': 5055, 'therapyName': 'Brentuximab vedotin + Bendamustine'}]","A Study of Nivolumab + Brentuximab Vedotin in Children, Adolescents, and Young Adults With Classic Hodgkin Lymphoma (cHL) After Failure of First Line Therapy, Followed by Brentuximab Vedotin + Bendamustine for Participants With a Suboptimal Response (CheckMate 744)",5055
0,NCT02729961,Phase Ib/II,Not yet recruiting,"[{'id': 4169, 'therapyName': 'Brentuximab vedotin + Ceritinib'}]",Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma,4169
0,NCT01716806,Phase II,Recruiting,"[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}, {'id': 5055, 'therapyName': 'Brentuximab vedotin + Bendamustine'}, {'id': 5056, 'therapyName': 'Brentuximab vedotin + Dacarbazine'}, {'id': 2486, 'therapyName': 'Brentuximab vedotin'}]",A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL),5056
0,NCT02744612,Phase II,Recruiting,"[{'id': 4300, 'therapyName': 'Brentuximab vedotin + Ibrutinib'}]",Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma,4300
0,NCT01896999,Phase I,Recruiting,"[{'id': 2487, 'therapyName': 'Brentuximab vedotin + Ipilimumab'}]",Ipilimumab and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma,2487
0,NCT02429375,Phase Ib/II,"Active, not recruiting","[{'id': 3264, 'therapyName': 'Brentuximab vedotin + Mocetinostat'}]",Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma,3264
0,NCT02758717,Phase II,Recruiting,"[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}]",Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma,3263
1,NCT01716806,Phase II,Recruiting,"[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}, {'id': 5055, 'therapyName': 'Brentuximab vedotin + Bendamustine'}, {'id': 5056, 'therapyName': 'Brentuximab vedotin + Dacarbazine'}, {'id': 2486, 'therapyName': 'Brentuximab vedotin'}]",A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL),3263
2,NCT03138499,Phase III,Recruiting,"[{'id': 2486, 'therapyName': 'Brentuximab vedotin'}, {'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}]","Phase III Trial of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,",3263
3,NCT02572167,Phase Ib/II,"Active, not recruiting","[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}]",A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma,3263
4,NCT02581631,Phase Ib/II,Recruiting,"[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}]",A Safety and Efficacy Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas (CheckMate 436),3263
5,NCT03057795,Phase II,Recruiting,"[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}]",Nivolumab and Brentuximab Vedotin After Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Classical Hodgkin Lymphoma,3263
6,NCT02927769,Phase II,Recruiting,"[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}, {'id': 5055, 'therapyName': 'Brentuximab vedotin + Bendamustine'}]","A Study of Nivolumab + Brentuximab Vedotin in Children, Adolescents, and Young Adults With Classic Hodgkin Lymphoma (cHL) After Failure of First Line Therapy, Followed by Brentuximab Vedotin + Bendamustine for Participants With a Suboptimal Response (CheckMate 744)",3263
0,NCT01778439,Phase I,Completed,"[{'id': 839, 'therapyName': 'Brontictuzumab'}]",A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors,839
1,NCT01703572,Phase I,Completed,"[{'id': 839, 'therapyName': 'Brontictuzumab'}]",A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies,839
0,NCT03031691,Phase I,"Active, not recruiting","[{'id': 5261, 'therapyName': 'Brontictuzumab + Trifluridine'}]",A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer,5261
0,NCT01769768,Phase I,Completed,"[{'id': 1428, 'therapyName': 'Sonidegib'}, {'id': 2505, 'therapyName': 'Warfarin'}, {'id': 2506, 'therapyName': 'Bupropion'}]",Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients,2506
0,NCT00550992,Phase I,Unknown status,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia,1206
1,NCT03259503,Phase Ib/II,Not yet recruiting,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas,1206
2,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,1206
3,NCT03126916,Phase III,Not yet recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 5595, 'therapyName': 'Isotretinoin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 2286, 'therapyName': 'Dinutuximab  '}]",Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma,1206
4,NCT02793544,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide,1206
5,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1206
6,NCT02251821,Phase II,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 2006, 'therapyName': 'Pacritinib'}, {'id': 823, 'therapyName': 'Momelotinib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis,1206
7,NCT02472392,Phase I,Completed,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}]",Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma,1206
8,NCT01625351,Phase I,"Active, not recruiting","[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}]",A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas,1206
9,NCT01707004,Phase I,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1206, 'therapyName': 'Busulfan'}]",Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,1206
10,NCT02701673,Phase Ib/II,Withdrawn,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1078, 'therapyName': 'Belinostat'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}]",Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma,1206
0,NCT02083250,Phase I,Recruiting,"[{'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 3201, 'therapyName': 'Busulfan + Clofarabine + Fludarabine'}]",Fludarabine/Clofarabine/Busulfan Combined With SAHA in Acute Leukemia,3201
0,NCT01701986,Phase Ib/II,Recruiting,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 3992, 'therapyName': 'Busulfan + Clofarabine + Gemcitabine'}]",Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas,3992
0,NCT01621477,Phase II,Terminated,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}]",T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant,2469
1,NCT00857389,Phase II,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies,2469
2,NCT00990249,Phase II,Completed,"[{'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}]",Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation,2469
0,NCT00513474,Phase I,Completed,"[{'id': 2313, 'therapyName': 'Rasburicase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2314, 'therapyName': 'Busulfan + Cyclophosphamide + Etoposide'}]",Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant,2314
0,NCT02221310,Phase II,Recruiting,"[{'id': 3932, 'therapyName': 'Busulfan + Cyclophosphamide + Gemtuzumab ozogamicin'}]",Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS,3932
0,NCT03240861,Phase I,Not yet recruiting,"[{'id': 6116, 'therapyName': 'Busulfan + Fludarabine'}, {'id': 3933, 'therapyName': 'Filgrastim + Plerixafor'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer (NYESO SCT),6116
0,NCT00679536,Phase Ib/II,Unknown status,"[{'id': 1846, 'therapyName': 'Busulfan + Fludarabine + anti-thymocyte globulin'}]",Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors,1846
1,NCT01823198,Phase Ib/II,Recruiting,"[{'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1846, 'therapyName': 'Busulfan + Fludarabine + anti-thymocyte globulin'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies,1846
0,NCT02057770,Phase I,Recruiting,"[{'id': 5724, 'therapyName': 'Busulfan + Fludarabine phosphate + Cyclophosphamide'}, {'id': 5647, 'therapyName': 'Tocilizumab'}]",Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,5724
0,NCT02961816,Phase II,Withdrawn,"[{'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 4976, 'therapyName': 'Busulfan + Gemcitabine + Melphalan + Panobinostat'}, {'id': 4977, 'therapyName': 'Dexamethasone + Filgrastim + Palifermin + Rituximab'}]",Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma,4976
0,NCT02130869,Phase I,Recruiting,"[{'id': 2378, 'therapyName': 'Bendamustine + Cytarabine + Etoposide'}, {'id': 2460, 'therapyName': 'Busulfan + Hu14.18K322A'}, {'id': 2459, 'therapyName': 'Aldesleukin + Melphalan + Sargramostim'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas,2460
0,NCT00020566,Phase III,Unknown status,"[{'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2670, 'therapyName': 'Vincristine + Doxorubicin + Dactinomycin + Ifosfamide + Etoposide'}]","Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma",2558
1,NCT00084695,Phase II,Unknown status,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases,2558
2,NCT01175356,Phase I,Completed,"[{'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}]","Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin",2558
3,NCT02506959,Phase II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma,2558
4,NCT01505569,Phase I,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2101, 'therapyName': 'Etoposide + Ifosfamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Auto Transplant for High Risk or Relapsed Solid or CNS Tumors,2558
5,NCT01983969,Phase Ib/II,"Active, not recruiting","[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2557, 'therapyName': 'Azacitidine + Gemcitabine + vorinostat'}]",Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma,2558
6,NCT02589145,Phase Ib/II,Recruiting,"[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 3278, 'therapyName': 'Enoxaparin'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}]",Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype,2558
7,NCT01857934,Phase II,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 2627, 'therapyName': 'Levetiracetam'}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 2458, 'therapyName': 'Hu14.18K322A'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}]",Therapy for Children With Advanced Stage Neuroblastoma,2558
0,NCT03247088,Phase Ib/II,Recruiting,"[{'id': 6122, 'therapyName': 'Busulfan + Sorafenib + Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Study Of Sorafenib Added To Busulfan And Fludarabine Conditioning Regimen In Patients With Relapsed/Refractory AML Undergoing Stem Cell Transplantation,6122
0,NCT02296242,Phase Ib/II,Completed,"[{'id': 997, 'therapyName': 'BVD-523'}]",Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes,997
1,NCT01781429,Phase Ib/II,"Active, not recruiting","[{'id': 997, 'therapyName': 'BVD-523'}]","Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies",997
0,NCT02608229,Phase I,Recruiting,"[{'id': 3249, 'therapyName': 'BVD-523 + Gemcitabine + nab-paclitaxel'}]",BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer,3249
0,NCT02537223,Phase I,Recruiting,"[{'id': 691, 'therapyName': 'BYL719'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer,691
1,NCT02437318,Phase III,Recruiting,"[{'id': 691, 'therapyName': 'BYL719'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.,691
2,NCT01219699,Phase I,"Active, not recruiting","[{'id': 691, 'therapyName': 'BYL719'}, {'id': 744, 'therapyName': 'Fulvestrant'}]"," A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene",691
0,NCT01708161,Phase I,Completed,"[{'id': 1109, 'therapyName': 'BYL719 + AMG 479'}]",A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors,1109
0,NCT01300962,Phase I,"Active, not recruiting","[{'id': 1538, 'therapyName': 'BKM120 + Capecitabine + Lapatinib'}, {'id': 1537, 'therapyName': 'BKM120 + Capecitabine + Trastuzumab'}, {'id': 1536, 'therapyName': 'BKM120 + Capecitabine'}, {'id': 1535, 'therapyName': 'BYL719 + Capecitabine'}]",Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer,1535
1,NCT02550743,Phase I,Recruiting,"[{'id': 1535, 'therapyName': 'BYL719 + Capecitabine'}]","BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study",1535
0,NCT02282371,Phase I,Recruiting,"[{'id': 1837, 'therapyName': 'BYL719 + Cetuximab'}]",Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC),1837
1,NCT01602315,Phase Ib/II,Terminated,"[{'id': 1837, 'therapyName': 'BYL719 + Cetuximab'}]",A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma,1837
0,NCT03207529,Phase I,Not yet recruiting,"[{'id': 3751, 'therapyName': 'BYL719 + Enzalutamide'}]",Study of BYL719 (Alpelisib) in Combination With Androgen Receptor Inhibitor (Enzalutamide) in Patients With Androgen Receptor (AR)-Positive and PTEN Positive Metastatic Breast Cancer,3751
0,NCT02077933,Phase I,"Active, not recruiting","[{'id': 1384, 'therapyName': 'BYL719 + Everolimus'}, {'id': 1385, 'therapyName': 'BYL719 + Everolimus + Exemestane'}]","Study of Safety and Efficacy of BYL719 With Everolimus or BYL719 With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors",1384
0,NCT02077933,Phase I,"Active, not recruiting","[{'id': 1384, 'therapyName': 'BYL719 + Everolimus'}, {'id': 1385, 'therapyName': 'BYL719 + Everolimus + Exemestane'}]","Study of Safety and Efficacy of BYL719 With Everolimus or BYL719 With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors",1385
0,NCT01870505,Phase I,"Active, not recruiting","[{'id': 2318, 'therapyName': 'BYL719 + Exemestane'}, {'id': 1553, 'therapyName': 'Letrozole + BYL719'}]",BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer,2318
0,NCT02088684,Phase Ib/II,"Active, not recruiting","[{'id': 2315, 'therapyName': 'BKM120 + Fulvestrant + LEE011'}, {'id': 2316, 'therapyName': 'Fulvestrant + LEE011'}, {'id': 2317, 'therapyName': 'BYL719 + Fulvestrant + LEE011'}]",Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer,2317
0,NCT02155088,Phase I,"Active, not recruiting","[{'id': 1870, 'therapyName': 'BYL719 + Gemcitabine + Abraxane'}]",BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer,1870
0,NCT02144038,Phase Ib/II,Completed,"[{'id': 2419, 'therapyName': 'BYL719 + LGH447'}, {'id': 2402, 'therapyName': 'LGH447 '}]",Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma,2419
0,NCT01822613,Phase Ib/II,Completed,"[{'id': 2282, 'therapyName': 'Docetaxel + Irinotecan + Paclitaxel'}, {'id': 2283, 'therapyName': 'BYL719 + LJM716'}]",Study of Safety and Efficacy of the Combination of LJM716 and BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC),2283
0,NCT02167854,Phase I,Recruiting,"[{'id': 2059, 'therapyName': 'BYL719 + LJM716 + Trastuzumab'}]","Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer",2059
0,NCT01449058,Phase Ib/II,Completed,"[{'id': 1311, 'therapyName': 'BYL719 + MEK162'}]",A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors,1311
0,NCT02379247,Phase Ib/II,Recruiting,"[{'id': 2503, 'therapyName': 'BYL719 + nab-paclitaxel'}]",BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer,2503
0,NCT01623349,Phase I,"Active, not recruiting","[{'id': 2171, 'therapyName': 'BYL719 + Olaparib'}, {'id': 2170, 'therapyName': 'BKM120 + Olaparib'}]",Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer,2171
0,NCT02051751,Phase I,Completed,"[{'id': 1379, 'therapyName': 'BYL719 + Paclitaxel'}]",A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer,1379
0,NCT02038010,Phase I,"Active, not recruiting","[{'id': 1575, 'therapyName': 'BYL719 + Trastuzumab emtansine'}]",BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx,1575
0,NCT03195699,Phase I,Not yet recruiting,"[{'id': 5961, 'therapyName': 'C188-9'}]","Phase I Study of Oral STAT3 Inhibitor, C188-9, in Patients With Advanced Cancers",5961
0,NCT02812875,Phase I,Recruiting,"[{'id': 5885, 'therapyName': 'CA-170'}]","A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas",5885
0,NCT01845792,Phase II,Completed,"[{'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer,1571
1,NCT02543255,Phase II,Recruiting,"[{'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 3079, 'therapyName': 'Abiraterone + Leuprolide + Prednisone'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]",Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial),1571
2,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,1571
3,NCT01420250,Phase I,"Active, not recruiting","[{'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}]",Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer,1571
4,NCT02218606,Phase II,Recruiting,"[{'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}]",Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer,1571
5,NCT02379390,Phase II,Terminated,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}]",Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enz (PRIMCAB),1571
6,NCT01513733,Phase I,Completed,"[{'id': 2699, 'therapyName': 'Tasquinimod'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}]",The CATCH Prostate Cancer Trial Cabazitaxel And Tasquinimod in Men With Prostate Cancer,1571
7,NCT02254785,Phase II,Recruiting,"[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}]",Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer,1571
0,NCT02703623,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}, {'id': 3844, 'therapyName': 'Cabazitaxel + Carboplatin'}]",A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer (DynaMO),3844
1,NCT03263650,Phase II,Recruiting,"[{'id': 3844, 'therapyName': 'Cabazitaxel + Carboplatin'}, {'id': 837, 'therapyName': 'Olaparib'}]",Randomized Phase II Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC,3844
0,NCT02522715,Phase Ib/II,Recruiting,"[{'id': 3056, 'therapyName': 'Cabazitaxel + Enzalutamide'}, {'id': 2188, 'therapyName': 'Prednisone'}]","Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Hormone-Resistant Prostate Cancer",3056
0,NCT01934894,Phase II,Terminated,"[{'id': 1572, 'therapyName': 'Cabazitaxel + Lapatinib'}]",Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases,1572
0,NCT01639508,Phase II,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes,998
1,NCT02036476,Phase II,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma,998
2,NCT02867592,Phase II,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]","Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors",998
3,NCT01703065,Phase I,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib in Treating Men With Castration-Resistant Prostate Cancer,998
4,NCT01961765,Phase I,Completed,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia,998
5,NCT01866293,Phase Ib/II,Completed,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma,998
6,NCT01582295,Phase I,Completed,"[{'id': 998, 'therapyName': 'cabozantinib'}]",XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease,998
7,NCT01630590,Phase II,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer,998
8,NCT01835145,Phase II,"Active, not recruiting","[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye,998
9,NCT03201250,,Not yet recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma,998
10,NCT02260531,Phase II,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Cabozantinib + / - Trastuzumab In Breast Cancer Patients w/ Brain Metastases,998
11,NCT02761057,Phase II,Recruiting,"[{'id': 2161, 'therapyName': 'Savolitinib'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}]","Cabozantinib-S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer",998
12,NCT02885324,Phase II,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Pilot Study of Cabozantinib for Recurrent or Progressive High-Grade Glioma in Children,998
13,NCT02315430,Phase II,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]","Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",998
14,NCT01835158,Phase II,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1236, 'therapyName': 'Cabozantinib + Sunitinib'}]",Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,998
15,NCT01812668,Phase I,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer,998
16,NCT01709435,Phase I,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]", Cabozantinib in Treating Younger Patients With Recurrent or Refractory Solid Tumors,998
17,NCT01811212,Phase II,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer,998
18,NCT02041260,Phase II,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]",A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting,998
19,NCT01688999,Phase II,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib for Advanced Urothelial Cancer,998
20,NCT01834651,Phase II,Completed,"[{'id': 998, 'therapyName': 'cabozantinib'}]",A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases,998
21,NCT01865747,Phase III,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}]",A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma,998
22,NCT01908426,Phase III,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib,998
23,NCT01935934,Phase II,Suspended,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer,998
24,NCT01588821,Phase II,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib in Advanced Solid Malignancies,998
25,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,998
26,NCT01822522,Phase I,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib-S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus,998
27,NCT02101736,Phase II,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 (16 Years +),998
28,NCT02132598,Phase II,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases,998
29,NCT01466036,Phase II,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors,998
30,NCT01755195,Phase II,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib for Adults With Advanced Soft Tissue Sarcoma,998
31,NCT02302833,Phase I,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib for Malignant Pheochromocytoma,998
0,NCT01683994,Phase I,"Active, not recruiting","[{'id': 2069, 'therapyName': 'cabozantinib + Docetaxel'}]",Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer,2069
0,NCT03213626,Phase II,Not yet recruiting,"[{'id': 1255, 'therapyName': 'Cabozantinib + Erlotinib'}]",Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma,1255
1,NCT01866410,Phase II,"Active, not recruiting","[{'id': 1255, 'therapyName': 'Cabozantinib + Erlotinib'}]",Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer,1255
0,NCT01441947,Phase II,"Active, not recruiting","[{'id': 1965, 'therapyName': 'cabozantinib + Fulvestrant'}]",Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer,1965
0,NCT01663272,Phase I,"Active, not recruiting","[{'id': 2070, 'therapyName': 'Cabozantinib + Gemcitabine'}]",A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer,2070
0,NCT03141177,Phase III,Recruiting,"[{'id': 2068, 'therapyName': 'Cabozantinib + Ipilimumab + Nivolumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 2067, 'therapyName': 'Cabozantinib + Nivolumab'}]",A Study of Nivolumab Combined With Cabozantinib or Nivolumab and Ipilimumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER),2068
0,NCT03299946,Phase I,Not yet recruiting,"[{'id': 2067, 'therapyName': 'Cabozantinib + Nivolumab'}]",Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC),2067
1,NCT02496208,Phase I,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2067, 'therapyName': 'Cabozantinib + Nivolumab'}]",Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors,2067
2,NCT03141177,Phase III,Recruiting,"[{'id': 2068, 'therapyName': 'Cabozantinib + Ipilimumab + Nivolumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 2067, 'therapyName': 'Cabozantinib + Nivolumab'}]",A Study of Nivolumab Combined With Cabozantinib or Nivolumab and Ipilimumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER),2067
0,NCT01835158,Phase II,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1236, 'therapyName': 'Cabozantinib + Sunitinib'}]",Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,1236
0,NCT01835184,Phase I,Terminated,"[{'id': 1235, 'therapyName': 'Cabozantinib + Vemurafenib'}]",Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery,1235
0,NCT02688088,Phase I,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 3729, 'therapyName': 'Caffeine + Dextromethorphan + Midazolam + Warfarin'}]",A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body,3729
0,NCT00536991,Phase Ib/II,Terminated,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 2889, 'therapyName': 'calcitriol'}, {'id': 2858, 'therapyName': 'Ketoconazole'}]","Calcitriol, Ketoconazole, and Hydrocortisone in Treating Patients With Advanced or Recurrent Prostate Cancer",2889
0,NCT02358863,Phase I,Terminated,"[{'id': 4311, 'therapyName': 'Docetaxel + Irinotecan'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1835, 'therapyName': 'Docetaxel + Cisplatin'}, {'id': 1406, 'therapyName': 'Camptosar + Cisplatin'}, {'id': 4310, 'therapyName': 'Epirubicin + Docetaxel'}, {'id': 4309, 'therapyName': 'Capecitabine + Docetaxel'}]",Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach (mEGA),1406
0,NCT02332655,Phase Ib/II,"Active, not recruiting","[{'id': 2632, 'therapyName': 'Cannabidiol'}]",Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome,2632
0,NCT02314117,Phase III,"Active, not recruiting","[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer,1105
1,NCT01497392,Phase I,Completed,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 721, 'therapyName': 'Dovitinib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]"," Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers",1105
2,NCT02483247,Phase Ib/II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1945, 'therapyName': 'BBI503'}]",A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer,1105
3,NCT01729923,Phase II,Terminated,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 2124, 'therapyName': 'Celecoxib'}]",A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer,1105
4,NCT01921751,Phase II,Terminated,"[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery,1105
5,NCT02042443,Phase II,Completed,"[{'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 2, 'therapyName': 'Trametinib'}]",Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery,1105
6,NCT01061515,Phase I,Recruiting,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}]",Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer,1105
7,NCT02981342,Phase II,Recruiting,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 5175, 'therapyName': 'Abemaciclib + LY3023414'}, {'id': 5176, 'therapyName': 'Abemaciclib + Galunisertib'}]",A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma,1105
8,NCT02451553,Phase I,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]","Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer",1105
9,NCT01828554,Phase III,Recruiting,"[{'id': 1105, 'therapyName': 'Capecitabine'}]",Capecitabine Pharmacokinetics(PK)-Actual Versus Ideal Body Weight,1105
10,NCT02119663,Phase III,Terminated,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1615, 'therapyName': 'Ruxolitinib + Capecitabine'}]",A Study of Ruxolitinib in Pancreatic Cancer Patients,1105
11,NCT01997333,Phase II,"Active, not recruiting","[{'id': 3597, 'therapyName': 'Glembatumumab vedotin'}, {'id': 1105, 'therapyName': 'Capecitabine'}]","Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer",1105
12,NCT03093870,Phase II,Not yet recruiting,"[{'id': 5543, 'therapyName': 'Capecitabine + Varlitinib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer,1105
13,NCT02009449,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2621, 'therapyName': 'AM0010 '}, {'id': 619, 'therapyName': 'Abraxane'}]",A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors,1105
14,NCT02305186,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer,1105
15,NCT02083653,Phase II,"Active, not recruiting","[{'id': 931, 'therapyName': 'SYM004'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer,1105
16,NCT01213238,Phase I,"Active, not recruiting","[{'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab",1105
17,NCT01945775,Phase III,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 682, 'therapyName': 'Talazoparib'}, {'id': 728, 'therapyName': 'Eribulin'}]","A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)",1105
18,NCT02297230,Phase Ib/II,Completed,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}]",Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics,1105
19,NCT02492711,Phase III,Recruiting,"[{'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 808, 'therapyName': 'MGAH22'}]",Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer,1105
20,NCT02921256,Phase II,Recruiting,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 4838, 'therapyName': 'Capecitabine + Veliparib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Veliparib and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer,1105
21,NCT02423954,Phase Ib/II,"Active, not recruiting","[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus),1105
22,NCT02555657,Phase III,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119),1105
23,NCT02117479,Phase III,Terminated,"[{'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1),1105
24,NCT02000622,Phase III,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.,1105
25,NCT02229149,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1105, 'therapyName': 'Capecitabine'}]","Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer",1105
26,NCT02178644,Phase I,Recruiting,"[{'id': 1699, 'therapyName': 'KD018'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Pilot Trial of KD018 With Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Rectal Cancer,1105
27,NCT02244489,Phase I,Terminated,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 823, 'therapyName': 'Momelotinib'}]",Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma,1105
28,NCT02494583,Phase III,"Active, not recruiting","[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062),1105
29,NCT02120417,Phase II,Terminated,"[{'id': 1615, 'therapyName': 'Ruxolitinib + Capecitabine'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer,1105
30,NCT03136406,Phase Ib/II,Recruiting,"[{'id': 1018, 'therapyName': 'GI-4000'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 6163, 'therapyName': 'ETBX-011'}, {'id': 3060, 'therapyName': 'ALT-803'}]",QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy,1105
31,NCT02688712,Phase II,Recruiting,"[{'id': 5788, 'therapyName': 'Capecitabine + Galunisertib'}, {'id': 5789, 'therapyName': 'Fluorouracil + Galunisertib'}, {'id': 2409, 'therapyName': 'Galunisertib'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer,1105
0,NCT03221426,Phase III,Recruiting,"[{'id': 3999, 'therapyName': 'Capecitabine + Cisplatin'}, {'id': 6050, 'therapyName': 'Capecitabine + Cisplatin + Pembrolizumab'}, {'id': 6051, 'therapyName': 'Cisplatin + Fluorouracil + Pembrolizumab'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}]",Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585),3999
1,NCT02726399,Phase II,Recruiting,"[{'id': 3999, 'therapyName': 'Capecitabine + Cisplatin'}, {'id': 3998, 'therapyName': 'Ramucirumab + Trastuzumab'}]",Ramucirumab With Trastuzumab and Capecitabine/Cisplatin in Patients With Metastatic HER2-Positive Gastroesophageal Junction and Gastric Cancer,3999
0,NCT03221426,Phase III,Recruiting,"[{'id': 3999, 'therapyName': 'Capecitabine + Cisplatin'}, {'id': 6050, 'therapyName': 'Capecitabine + Cisplatin + Pembrolizumab'}, {'id': 6051, 'therapyName': 'Cisplatin + Fluorouracil + Pembrolizumab'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}]",Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585),6050
0,NCT02954536,Phase II,Recruiting,"[{'id': 4945, 'therapyName': 'Capecitabine + Cisplatin + Pembrolizumab + Trastuzumab'}]",Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer,4945
0,NCT01450696,Phase III,Terminated,"[{'id': 1899, 'therapyName': 'Capecitabine + Cisplatin + Trastuzumab'}]",HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer,1899
0,NCT01873833,Phase II,Recruiting,"[{'id': 1559, 'therapyName': 'Capecitabine + Cyclophosphamide + Lapatinib + Trastuzumab'}]","Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer",1559
0,NCT02358863,Phase I,Terminated,"[{'id': 4311, 'therapyName': 'Docetaxel + Irinotecan'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1835, 'therapyName': 'Docetaxel + Cisplatin'}, {'id': 1406, 'therapyName': 'Camptosar + Cisplatin'}, {'id': 4310, 'therapyName': 'Epirubicin + Docetaxel'}, {'id': 4309, 'therapyName': 'Capecitabine + Docetaxel'}]",Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach (mEGA),4309
0,NCT02611960,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 4203, 'therapyName': 'Capecitabine + Docetaxel + Gemcitabine'}]","Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122, KEYNOTE-122)",4203
0,NCT03152370,Phase I,Recruiting,"[{'id': 5798, 'therapyName': 'E7046 + mFOLFOX-6'}, {'id': 5805, 'therapyName': 'Capecitabine + E7046'}]",Preoperative Radiotherapy and E7046 in Rectum Cancer (PRAER 1),5805
0,NCT02918162,Phase II,Recruiting,"[{'id': 4776, 'therapyName': 'Capecitabine + Epirubicin + Oxaliplatin + Pembrolizumab'}]",Perioperative Chemo and Pembrolizumab in Gastric Cancer,4776
0,NCT02199236,Phase I,Recruiting,"[{'id': 1619, 'therapyName': 'Capecitabine + Fluorouracil'}]",Dose Escalation Trial of Endoluminal High-Dose-Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management,1619
0,NCT01774786,Phase III,"Active, not recruiting","[{'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 1894, 'therapyName': 'Capecitabine + Fluorouracil + Cisplatin + Trastuzumab'}]",A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction or Gastric Cancer,1894
0,NCT02004262,Phase II,Completed,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2383, 'therapyName': 'Capecitabine + Fluorouracil + Gemcitabine '}]",Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting,2383
0,NCT02688712,Phase II,Recruiting,"[{'id': 5788, 'therapyName': 'Capecitabine + Galunisertib'}, {'id': 5789, 'therapyName': 'Fluorouracil + Galunisertib'}, {'id': 2409, 'therapyName': 'Galunisertib'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer,5788
0,NCT02935309,Phase I,Recruiting,"[{'id': 4779, 'therapyName': 'Capecitabine + Lenvatinib'}]",Phase I Study of Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma,4779
1,NCT02915172,Phase I,Withdrawn,"[{'id': 4779, 'therapyName': 'Capecitabine + Lenvatinib'}]",Lenvatinib and Capecitabine in Patients With Advanced Malignancies,4779
0,NCT01494662,Phase II,"Active, not recruiting","[{'id': 1543, 'therapyName': 'Capecitabine + Neratinib'}, {'id': 828, 'therapyName': 'Neratinib'}]",HKI-272 for HER2-Positive Breast Cancer and Brain Metastases,1543
1,NCT01808573,Phase III,"Active, not recruiting","[{'id': 1399, 'therapyName': 'Lapatinib + Capecitabine'}, {'id': 1543, 'therapyName': 'Capecitabine + Neratinib'}]",A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting,1543
0,NCT02780700,Phase II,Terminated,"[{'id': 2589, 'therapyName': 'Capecitabine + Nintedanib'}, {'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2],2589
1,NCT02393755,Phase Ib/II,"Active, not recruiting","[{'id': 2589, 'therapyName': 'Capecitabine + Nintedanib'}]",Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer,2589
0,NCT02872116,Phase III,Recruiting,"[{'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Efficacy Study of Nivolumab Plus Ipilimumab Against Chemotherapy Standard of Care in Stomach Cancer or Stomach/Esophagus Junction Cancer (CheckMate649),1597
1,NCT02024607,Phase Ib/II,"Active, not recruiting","[{'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}, {'id': 2093, 'therapyName': 'BBI608 + Bevacizumab'}, {'id': 2094, 'therapyName': 'BBI608 + Regorafenib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2057, 'therapyName': 'BBI608'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer,1597
2,NCT02625610,Phase III,Recruiting,"[{'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}]",Avelumab in First-Line Gastric Cancer (JAVELIN Gastric 100),1597
3,NCT01191697,Phase II,"Active, not recruiting","[{'id': 1596, 'therapyName': 'Trastuzumab + Bevacizumab'}, {'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}]","CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer",1597
0,NCT00408772,Phase II,Withdrawn,"[{'id': 1601, 'therapyName': 'Capecitabine + Oxaliplatin + Bevacizumab'}]","Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Cannot Be Removed By Surgery",1601
1,NCT01006369,Phase II,Completed,"[{'id': 1316, 'therapyName': 'Hydroxychloroquine'}, {'id': 1601, 'therapyName': 'Capecitabine + Oxaliplatin + Bevacizumab'}, {'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}]","Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer",1601
2,NCT01208103,Phase II,"Active, not recruiting","[{'id': 1601, 'therapyName': 'Capecitabine + Oxaliplatin + Bevacizumab'}]",Bevacizumab With Capecitabine and Oxaliplatin in Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater,1601
0,NCT03111732,Phase II,Recruiting,"[{'id': 5549, 'therapyName': 'Capecitabine + Oxaliplatin + Pembrolizumab'}]","Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)",5549
0,NCT00967655,Phase II,Unknown status,"[{'id': 1960, 'therapyName': 'Capecitabine + Panitumumab'}, {'id': 1074, 'therapyName': 'Irinotecan'}]","Capecitabine, Panitumumab, and Radiation Therapy With or Without Irinotecan Hydrochloride in Treating Patients Undergoing Surgery for Localized Rectal Cancer",1960
0,NCT03257163,Phase II,Recruiting,"[{'id': 4022, 'therapyName': 'Capecitabine + Pembrolizumab'}]","Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer",4022
1,NCT02734290,Phase Ib/II,Recruiting,"[{'id': 4022, 'therapyName': 'Capecitabine + Pembrolizumab'}, {'id': 4021, 'therapyName': 'Paclitaxel + Pembrolizumab'}]",Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer,4022
2,NCT03044730,Phase II,Recruiting,"[{'id': 4022, 'therapyName': 'Capecitabine + Pembrolizumab'}]",Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery,4022
0,NCT02025803,Phase I,"Active, not recruiting","[{'id': 4335, 'therapyName': 'Capecitabine + TAS-114'}]","A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors",4335
0,NCT02213744,Phase II,Terminated,"[{'id': 1890, 'therapyName': 'Vinorelbine + Trastuzumab'}, {'id': 1409, 'therapyName': 'Capecitabine + Trastuzumab'}, {'id': 1889, 'therapyName': 'Gemcitabine + Trastuzumab'}, {'id': 1888, 'therapyName': 'MM-302 + Trastuzumab'}]",MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients,1409
1,NCT02614794,Phase II,Recruiting,"[{'id': 3340, 'therapyName': 'ARRY-380 + Capecitabine + Trastuzumab'}, {'id': 1409, 'therapyName': 'Capecitabine + Trastuzumab'}]",Study of ONT-380 vs Placebo in Combo w/ Capecitabine & Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer,1409
0,NCT03093870,Phase II,Not yet recruiting,"[{'id': 5543, 'therapyName': 'Capecitabine + Varlitinib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer,5543
0,NCT02921256,Phase II,Recruiting,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 4838, 'therapyName': 'Capecitabine + Veliparib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Veliparib and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer,4838
0,NCT02831179,Phase I,Withdrawn,"[{'id': 4463, 'therapyName': 'Capecitabine + Veliparib + Temozolomide'}]","Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor",4463
0,NCT02414139,Phase II,Recruiting,"[{'id': 1065, 'therapyName': 'Capmatinib'}]",Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With Advanced Non-small Cell Lung Cancer Who Have Received One or Two Prior Lines of Therapy,1065
1,NCT02468661,Phase Ib/II,Recruiting,"[{'id': 1065, 'therapyName': 'Capmatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]","A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification",1065
2,NCT02925104,Phase I,Recruiting,"[{'id': 1065, 'therapyName': 'Capmatinib'}]","A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.",1065
3,NCT03040973,FDA approved,Recruiting,"[{'id': 1065, 'therapyName': 'Capmatinib'}]",Roll-over Study for Patients With cMET-dependent Malignancies Who Previously Completed a Novartis Capmatinib Study,1065
4,NCT02520752,Phase I,"Active, not recruiting","[{'id': 2685, 'therapyName': 'Midazolam'}, {'id': 1065, 'therapyName': 'Capmatinib'}]",A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors,1065
5,NCT02626234,Phase I,Completed,"[{'id': 1065, 'therapyName': 'Capmatinib'}]",A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors,1065
6,NCT02019693,Phase II,Recruiting,"[{'id': 1065, 'therapyName': 'Capmatinib'}]",A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer,1065
7,NCT01324479,Phase I,Completed,"[{'id': 1065, 'therapyName': 'Capmatinib'}]",Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors,1065
8,NCT02750215,Phase II,"Active, not recruiting","[{'id': 1065, 'therapyName': 'Capmatinib'}]",A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor,1065
0,NCT01820364,Phase II,Terminated,"[{'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}, {'id': 1260, 'therapyName': 'Encorafenib + Ribociclib'}, {'id': 1337, 'therapyName': 'Encorafenib + BKM120'}, {'id': 1336, 'therapyName': 'BGJ398 + Encorafenib'}, {'id': 1338, 'therapyName': 'Capmatinib + Encorafenib'}]", LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma,1338
0,NCT01445418,Phase I,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer,1092
1,NCT01493843,Phase II,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 749, 'therapyName': 'GDC-0941'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer,1092
2,NCT01892046,Phase I,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 866, 'therapyName': 'SNX-5422'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors,1092
3,NCT02409342,Phase III,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Comparative Study of MPDL3280A (Anti-PDL1 Antibody) With Cisplatin or Carboplatin + Pemetrexed in Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC),1092
4,NCT02437812,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1031, 'therapyName': 'Metformin'}]","Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma",1092
5,NCT02199171,Phase I,Unknown status,"[{'id': 1092, 'therapyName': 'Carboplatin'}]","Heated Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Peritoneal Cancer",1092
6,NCT02477826,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, Trial of Nivolumab and Nivolumab Plus Ipilimumab Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC)",1092
7,NCT01344824,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}]","Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Who Are Light or Never Smokers",1092
8,NCT01281176,,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors,1092
9,NCT02389751,Phase I,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 745, 'therapyName': 'Ganetespib'}]",A Study of Ganetespib in Combination With Chemoradiation,1092
10,NCT01633541,Phase II,Recruiting,"[{'id': 644, 'therapyName': 'AT-101'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer,1092
11,NCT02409355,Phase III,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of MPDL3280A Compared With Gemcitabine + Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer,1092
12,NCT02009449,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2621, 'therapyName': 'AM0010 '}, {'id': 619, 'therapyName': 'Abraxane'}]",A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors,1092
13,NCT02309177,Phase I,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2489, 'therapyName': 'Abraxane + Nivolumab'}]","Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer",1092
14,NCT02470585,Phase III,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}]","Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1092
15,NCT02114229,Phase II,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2449, 'therapyName': 'Methotrexate + Cisplatin + Cyclophosphamide + Vincristine'}, {'id': 626, 'therapyName': 'Alisertib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 942, 'therapyName': 'Topotecan'}]",Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors,1092
16,NCT01187199,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 936, 'therapyName': 'Temsirolimus'}]","Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer",1092
17,NCT02581943,Phase II,Suspended,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer,1092
18,NCT00993655,Phase III,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}]"," Comparing Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",1092
19,NCT00254319,Phase II,Unknown status,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2114, 'therapyName': 'Bevacizumab + Pemetrexed'}]",Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC),1092
20,NCT01042522,Phase II,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1137, 'therapyName': 'Bleomycin'}]","Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors",1092
21,NCT00989651,Phase I,"Active, not recruiting","[{'id': 3047, 'therapyName': 'Bevacizumab + Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]","Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",1092
22,NCT02264990,Phase III,"Active, not recruiting","[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers,1092
23,NCT02605915,Phase I,Recruiting,"[{'id': 3250, 'therapyName': 'Atezolizumab + Trastuzumab'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 856, 'therapyName': 'Pertuzumab'}]",Safety and Pharmacokinetics of Atezolizumab in Combination With Trastuzumab Emtansine or With Trastuzumab and Pertuzumab in Participants With HER2-Positive Breast Cancer,1092
24,NCT03057106,Phase II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC,1092
25,NCT00303849,Phase Ib/II,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2562, 'therapyName': 'Etoposide + Melphalan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]",Combination Chemotherapy With BBBD Followed By Sodium Thiosulfate in Treating Patients With Anaplastic Oligodendroglioma or Oligoastrocytoma,1092
26,NCT01248949,Phase I,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1176, 'therapyName': 'MEDI3617'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors,1092
27,NCT02419495,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Selinexor in Combination With Standard Chemotherapy,1092
28,NCT02657434,Phase III,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer,1092
29,NCT02032277,Phase III,"Active, not recruiting","[{'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer,1092
30,NCT01459380,Phase I,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",1092
31,NCT01064479,Phase II,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Docetaxel And Cisplatin With or Without Erlotinib For Metastatic Or Recurrent Squamous Cell Carcinoma Of Head And Neck,1092
32,NCT01249443,Phase I,Terminated,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Vorinostat in Combination With Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection,1092
33,NCT01248962,Phase II,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}]","Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer",1092
34,NCT01928160,Phase II,Withdrawn,"[{'id': 1290, 'therapyName': 'Erlotinib + Pemetrexed'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1291, 'therapyName': 'Erlotinib + Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1292, 'therapyName': 'Erlotinib + Cisplatin'}]",Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib,1092
35,NCT03126916,Phase III,Not yet recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 5595, 'therapyName': 'Isotretinoin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 2286, 'therapyName': 'Dinutuximab  '}]",Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma,1092
36,NCT02855944,Phase III,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 906, 'therapyName': 'Rucaparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients",1092
37,NCT02606305,Phase I,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 3232, 'therapyName': 'IMGN853'}]","Study of IMGN853 in Comb. With Bevacizumab, Carboplatin or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer",1092
38,NCT01820754,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC),1092
39,NCT02446600,Phase III,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1001, 'therapyName': 'Cediranib'}]","Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1092
40,NCT01836029,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2000, 'therapyName': 'Fluorouracil + Cetuximab'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,1092
41,NCT02041533,Phase III,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)",1092
42,NCT02312804,Phase I,Withdrawn,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 674, 'therapyName': 'BGJ398'}]",Ph Ib/BGJ398/Cervix and Other Solid Tumors,1092
43,NCT02561832,Phase I,Completed,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","A Study to Assess the Safety, Tolerability and Efficacy of Olaparib in Combination With Carboplatin in Patients With HER-2 Negative Breast Cancer",1092
44,NCT01526603,Phase I,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1092, 'therapyName': 'Carboplatin'}]",High Dose Chemotherapy and Autologous Transplant for Neuroblastoma,1092
45,NCT02367794,Phase III,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC),1092
46,NCT02035345,FDA approved,Terminated,"[{'id': 1092, 'therapyName': 'Carboplatin'}]",Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment,1092
47,NCT02578680,Phase III,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Non-squamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189),1092
48,NCT02341456,Phase I,"Active, not recruiting","[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours,1092
49,NCT02531932,Phase II,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 735, 'therapyName': 'Everolimus'}]",Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer,1092
50,NCT02122770,Phase I,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1026, 'therapyName': 'Itraconazole'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1688, 'therapyName': 'MLN4924'}, {'id': 1689, 'therapyName': 'Fluconazole'}]","Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors",1092
51,NCT02358031,Phase III,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048),1092
52,NCT02142738,Phase III,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024),1092
53,NCT03206203,Phase II,Recruiting,"[{'id': 5983, 'therapyName': 'Atezolizumab + Carboplatin'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer,1092
54,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1092
55,NCT01366144,Phase I,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction",1092
56,NCT01664754,Phase I,"Active, not recruiting","[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 738, 'therapyName': 'Exemestane'}]","Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer",1092
57,NCT01859741,Phase Ib/II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2547, 'therapyName': 'Tarextumab'}]",A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Platinum Therapy in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE),1092
58,NCT01493505,Phase III,Terminated,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1218, 'therapyName': 'Trebananib'}]", TRINOVA-3,1092
59,NCT01653470,Phase I,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 2545, 'therapyName': 'BMS-906024'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors",1092
60,NCT01407562,Phase I,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}]","Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors",1092
61,NCT01437449,Phase II,"Active, not recruiting","[{'id': 1987, 'therapyName': 'Cisplatin + Docetaxel + Cetuximab'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","Weekly Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)",1092
62,NCT01450761,Phase III,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone,1092
63,NCT01898494,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer,1092
64,NCT01700400,Phase I,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]"," Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer",1092
65,NCT00565851,Phase III,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 3045, 'therapyName': 'Docetaxel + Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Carboplatin, Paclitaxel and Gemcitabine With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",1092
66,NCT01218048,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}]",ERBITUX; Followed by Adjuvant Treatment With Chemoradiation and ERBITUX; for Locally Advanced Head and Neck Squamous Cell Carcinoma,1092
67,NCT01454102,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)",1092
68,NCT02281955,Phase II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}]",De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC,1092
69,NCT01505569,Phase I,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2101, 'therapyName': 'Etoposide + Ifosfamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Auto Transplant for High Risk or Relapsed Solid or CNS Tumors,1092
70,NCT02574078,Phase I,Recruiting,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2114, 'therapyName': 'Bevacizumab + Pemetrexed'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",A Master Protocol Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate 370),1092
71,NCT02576574,Phase III,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100),1092
72,NCT02489903,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 3680, 'therapyName': 'RRx-001'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 619, 'therapyName': 'Abraxane'}]","RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens",1092
73,NCT01357161,Phase II,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 822, 'therapyName': 'MK-1775'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]", A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004),1092
74,NCT00492687,Phase II,Unknown status,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]","Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas",1092
75,NCT01927744,Phase II,Recruiting,"[{'id': 2474, 'therapyName': 'Erlotinib + Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","Study of Chemotherapy With Cisplatin/CarboplatinAstellas Pharma Inc, OSI Pharmaceuticals, Kadoorie Foundation, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection",1092
76,NCT01281150,Phase I,Completed,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors,1092
77,NCT00828009,Phase II,Unknown status,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 2142, 'therapyName': 'Emepepimut-S  '}, {'id': 1092, 'therapyName': 'Carboplatin'}]",BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery,1092
0,NCT03242915,Phase II,Not yet recruiting,"[{'id': 2105, 'therapyName': 'Carboplatin +  Pembrolizumab + Pemetrexed '}]",Pembrolizumab in Combination With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation and ALK Positive NSCLC (Non-Small Cell Lung Cancer) With Progressive Disease Following Prior Tyrosine Kinase Inhibitors (TKIs),2105
0,NCT02741570,Phase III,Recruiting,"[{'id': 4168, 'therapyName': 'Carboplatin + Cetuximab + Cisplatin + Fluorouracil'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,4168
0,NCT02124707,Phase II,Recruiting,"[{'id': 1989, 'therapyName': 'Carboplatin + Cetuximab + Paclitaxel'}]","Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN",1989
0,NCT03174275,Phase II,Not yet recruiting,"[{'id': 5873, 'therapyName': 'Carboplatin + Cisplatin + Durvalumab + Paclitaxel'}, {'id': 3997, 'therapyName': 'Carboplatin + Durvalumab + Paclitaxel'}]","Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma",5873
0,NCT02899728,Phase II,Suspended,"[{'id': 4728, 'therapyName': 'Carboplatin + Cisplatin + Etoposide'}, {'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]","Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer",4728
1,NCT03043872,Phase III,Recruiting,"[{'id': 5305, 'therapyName': 'MEDI4736 + Tremelimumab + Carboplatin + Cisplatin + Etoposide'}, {'id': 5306, 'therapyName': 'MEDI4736 + Carboplatin + Cisplatin + Etoposide'}, {'id': 4728, 'therapyName': 'Carboplatin + Cisplatin + Etoposide'}]",Durvalumab+/- Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (Caspian),4728
0,NCT02934503,Phase II,Recruiting,"[{'id': 6184, 'therapyName': 'Carboplatin + Cisplatin + Etoposide + Pembrolizumab'}]",Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC),6184
0,NCT03178552,Phase II,Recruiting,"[{'id': 4686, 'therapyName': 'Carboplatin + Cisplatin + Gemcitabine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 4616, 'therapyName': 'Carboplatin + Cisplatin + Pemetrexed'}, {'id': 698, 'therapyName': 'Alectinib'}]",A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST),4686
1,NCT02516241,Phase III,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 4686, 'therapyName': 'Carboplatin + Cisplatin + Gemcitabine'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer,4686
2,NCT02853305,Phase III,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 4686, 'therapyName': 'Carboplatin + Cisplatin + Gemcitabine'}]",Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361),4686
0,NCT03215706,Phase III,Recruiting,"[{'id': 6132, 'therapyName': 'Carboplatin + Cisplatin + Paclitaxel + Pemetrexed'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy by Itself as the First Treatment Given for Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 9LA),6132
0,NCT03178552,Phase II,Recruiting,"[{'id': 4686, 'therapyName': 'Carboplatin + Cisplatin + Gemcitabine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 4616, 'therapyName': 'Carboplatin + Cisplatin + Pemetrexed'}, {'id': 698, 'therapyName': 'Alectinib'}]",A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST),4616
1,NCT02864251,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 4616, 'therapyName': 'Carboplatin + Cisplatin + Pemetrexed'}]","A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Patients With EGFR Mutation, T790M Negative NSCLC Who Have Failed 1L EGFR TKI Therapy (CheckMate722)",4616
2,NCT02899299,Phase III,Recruiting,"[{'id': 4616, 'therapyName': 'Carboplatin + Cisplatin + Pemetrexed'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (CheckMate743),4616
0,NCT02703272,Phase III,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 4307, 'therapyName': 'Carboplatin + Dexamethasone + Etoposide + Ifosfamide + Rituximab'}, {'id': 4308, 'therapyName': 'Carboplatin + Dexamethasone + Idarubicin + Ifosfamide + Rituximab + Vincristine'}]",A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma,4307
0,NCT02703272,Phase III,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 4307, 'therapyName': 'Carboplatin + Dexamethasone + Etoposide + Ifosfamide + Rituximab'}, {'id': 4308, 'therapyName': 'Carboplatin + Dexamethasone + Idarubicin + Ifosfamide + Rituximab + Vincristine'}]",A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma,4308
0,NCT02565901,Phase Ib/II,Recruiting,"[{'id': 3111, 'therapyName': 'Carboplatin + Docetaxel + Sirolimus '}]","Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer",3111
0,NCT01281514,Phase I,Recruiting,"[{'id': 2168, 'therapyName': 'Carboplatin + Doxil + Everolimus'}]","Carboplatin, Pegylated Liposomal Doxorubicin Hydrochloride, and Everolimus in Treating Patients With Relapsed Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer",2168
0,NCT02098343,Phase Ib/II,Recruiting,"[{'id': 1953, 'therapyName': 'Carboplatin + Doxorubicin'}, {'id': 1952, 'therapyName': 'APR-246 + Carboplatin + Doxorubicin'}]","p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246",1953
0,NCT02726997,Phase Ib/II,Recruiting,"[{'id': 3997, 'therapyName': 'Carboplatin + Durvalumab + Paclitaxel'}]",Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer,3997
1,NCT02962063,Phase Ib/II,Recruiting,"[{'id': 3997, 'therapyName': 'Carboplatin + Durvalumab + Paclitaxel'}]","Durvalumab, an Anti-PD-L1 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer",3997
2,NCT03174275,Phase II,Not yet recruiting,"[{'id': 5873, 'therapyName': 'Carboplatin + Cisplatin + Durvalumab + Paclitaxel'}, {'id': 3997, 'therapyName': 'Carboplatin + Durvalumab + Paclitaxel'}]","Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma",3997
0,NCT02684227,Phase II,Recruiting,"[{'id': 3681, 'therapyName': 'Carboplatin + Enzalutamide + Paclitaxel'}]",Enzalutamide in Combination With Carboplatin and Paclitaxel in Endometrial Cancer,3681
0,NCT02017964,Phase II,Completed,"[{'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}, {'id': 2673, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine  '}]","Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-Metastatic Desmoplastic Medulloblastoma",1791
1,NCT02499770,Phase Ib/II,"Active, not recruiting","[{'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}, {'id': 3074, 'therapyName': 'Trilaciclib'}]",G1T28 (CDK 4/6 Inhibitor) in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC),1791
2,NCT02748889,Phase Ib/II,Terminated,"[{'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}, {'id': 4164, 'therapyName': 'Atezolizumab + Carboplatin + Etoposide'}]",Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer,1791
3,NCT02658214,Phase I,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors,1791
4,NCT02763579,Phase III,Recruiting,"[{'id': 4164, 'therapyName': 'Atezolizumab + Carboplatin + Etoposide'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer (IMpower133),1791
5,NCT01722292,Phase Ib/II,Terminated,"[{'id': 1587, 'therapyName': 'Taladegib'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Study of LY2940680 in Small Cell Lung Cancer,1791
6,NCT02130869,Phase I,Recruiting,"[{'id': 2378, 'therapyName': 'Bendamustine + Cytarabine + Etoposide'}, {'id': 2460, 'therapyName': 'Busulfan + Hu14.18K322A'}, {'id': 2459, 'therapyName': 'Aldesleukin + Melphalan + Sargramostim'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas,1791
7,NCT03066778,Phase III,Recruiting,"[{'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 5145, 'therapyName': 'Cisplatin + Etoposide + Pembrolizumab'}, {'id': 2604, 'therapyName': 'Carboplatin + Etoposide + Pembrolizumab'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604),1791
0,NCT01453205,Phase II,Completed,"[{'id': 2354, 'therapyName': 'Cisplatin + Cytarabine + Dexamethasone'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2407, 'therapyName': 'MEDI-551'}]","A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",2352
1,NCT02408042,Phase Ib/II,Withdrawn,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2486, 'therapyName': 'Brentuximab vedotin'}]",Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme),2352
2,NCT02018861,Phase I,"Active, not recruiting","[{'id': 2406, 'therapyName': 'INCB039110'}, {'id': 3097, 'therapyName': 'INCB039110 + INCB050465'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 3088, 'therapyName': 'INCB050465 '}]","A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies",2352
3,NCT01169636,Phase Ib/II,Completed,"[{'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}]","Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma",2352
4,NCT01959698,Phase Ib/II,Recruiting,"[{'id': 2351, 'therapyName': 'Carfilzomib + Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}]","Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma",2352
0,NCT02471911,Phase I,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3360, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide + Rituximab'}, {'id': 1749, 'therapyName': 'Selinexor'}]",KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma,3360
1,NCT02219737,Phase I,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3360, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide + Rituximab'}]",Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma,3360
0,NCT02116959,Phase I,Unknown status,"[{'id': 2559, 'therapyName': 'Carboplatin + Etoposide + Melphalan + Vincristine'}]",Alternating Systemic Chemotherapy and Intra-Arterial Melphalan Chemotherapy in Children With Intra-Ocular Retinoblastoma,2559
0,NCT03066778,Phase III,Recruiting,"[{'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 5145, 'therapyName': 'Cisplatin + Etoposide + Pembrolizumab'}, {'id': 2604, 'therapyName': 'Carboplatin + Etoposide + Pembrolizumab'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604),2604
1,NCT02402920,Phase I,Recruiting,"[{'id': 2604, 'therapyName': 'Carboplatin + Etoposide + Pembrolizumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Phase I Trial of MK-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung Cancer,2604
0,NCT02289690,Phase I,Recruiting,"[{'id': 1544, 'therapyName': 'Carboplatin + Etoposide + Veliparib'}]",Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer,1544
1,NCT01711541,Phase Ib/II,Suspended,"[{'id': 1544, 'therapyName': 'Carboplatin + Etoposide + Veliparib'}, {'id': 1849, 'therapyName': 'Cisplatin + Fluorouracil + Hydroxyurea'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer,1544
2,NCT01506609,Phase II,"Active, not recruiting","[{'id': 1193, 'therapyName': 'Veliparib + Temozolomide'}, {'id': 1544, 'therapyName': 'Carboplatin + Etoposide + Veliparib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer,1544
3,NCT01386385,Phase Ib/II,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1544, 'therapyName': 'Carboplatin + Etoposide + Veliparib'}]","Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery",1544
0,NCT00588770,Phase III,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1835, 'therapyName': 'Docetaxel + Cisplatin'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 1834, 'therapyName': 'Docetaxel + Carboplatin'}, {'id': 1832, 'therapyName': 'Carboplatin + Fluorouracil\t'}]",Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,1832
0,NCT01183559,Phase I,Unknown status,"[{'id': 2071, 'therapyName': 'Carboplatin + Fluorouracil + Paclitaxel + Vandetanib'}]","A Trial of ZD6474 (Zactima), Paclitaxel, Carboplatin, 5-Fluorouracil, and XRT Followed by Surgery",2071
0,NCT03206177,Phase I,Recruiting,"[{'id': 6265, 'therapyName': 'Carboplatin + Galunisertib + Paclitaxel'}]",Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary,6265
0,NCT02046421,Phase I,"Active, not recruiting","[{'id': 2603, 'therapyName': 'Mifepristone'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]","Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer",2667
1,NCT03164616,Phase III,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}]",Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON),2667
2,NCT02819518,Phase III,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355),2667
3,NCT02755272,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer,2667
4,NCT02542293,Phase III,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]",Study of 1st Line Therapy Study of MEDI4736 With Tremelimumab Versus SoC in Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE).,2667
5,NCT02658214,Phase I,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors,2667
6,NCT02412670,Phase II,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2668, 'therapyName': 'Aldoxorubicin + Cisplatin + Methotrexate + Vincristine'}]",Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer,2667
7,NCT02978716,Phase II,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 5737, 'therapyName': 'Carboplatin + Gemcitabine + Trilaciclib'}]","Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)",2667
8,NCT02627443,Phase II,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2879, 'therapyName': 'VX-970'}]","Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",2667
9,NCT02807636,Phase III,Recruiting,"[{'id': 4450, 'therapyName': 'Atezolizumab + Carboplatin + Gemcitabine'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",The Effect of Atezolizumab in Combination With Gemcitabine/Carboplatin and Gemcitabine/Carboplatin Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Therapy,2667
10,NCT01663857,Phase Ib/II,"Active, not recruiting","[{'id': 3296, 'therapyName': 'Ralimetinib'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",A Study of LY2228820 for Recurrent Ovarian Cancer,2667
11,NCT02435680,Phase II,"Active, not recruiting","[{'id': 2838, 'therapyName': 'MCS110'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC),2667
12,NCT03036098,Phase III,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care Chemotherapy in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer,2667
0,NCT02784795,Phase I,Recruiting,"[{'id': 4374, 'therapyName': 'Cisplatin + Gemcitabine + LY3039478'}, {'id': 4375, 'therapyName': 'Carboplatin + Gemcitabine + LY3039478'}, {'id': 4372, 'therapyName': 'LY3039478 + LY3023414'}, {'id': 4373, 'therapyName': 'Abemaciclib + LY3039478'}, {'id': 4371, 'therapyName': 'LY3039478 + Taladegib'}, {'id': 2958, 'therapyName': 'LY3039478'}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors,4375
0,NCT02978716,Phase II,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 5737, 'therapyName': 'Carboplatin + Gemcitabine + Trilaciclib'}]","Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)",5737
0,NCT01376310,Phase II,"Active, not recruiting","[{'id': 1264, 'therapyName': 'Docetaxel + Trametinib'}, {'id': 1265, 'therapyName': 'Erlotinib + Trametinib'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 1266, 'therapyName': 'Pemetrexed + GSK1120212'}, {'id': 1267, 'therapyName': 'Carboplatin + GSK1120212'}, {'id': 1268, 'therapyName': 'nab-paclitaxel + GSK1120212'}, {'id': 1269, 'therapyName': 'Gemcitabine + GSK1120212'}, {'id': 1271, 'therapyName': 'Everolimus + GSK1120212'}]",GSK1120212 Rollover Study,1267
0,NCT00983398,Phase Ib/II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2587, 'therapyName': 'Carboplatin + Melphalan'}]","Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors",2587
0,NCT00293475,Phase Ib/II,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 2669, 'therapyName': 'Carboplatin + Methotrexate + Rituximab'}]",Rituximab and Methotrexate Chemotherapy w/Blood-Brain Barrier Disruption (BBBD) &amp; Sodium Thiosulfate Chemoprotection for Patients With Newly Diagnosed PCNSL,2669
0,NCT02775435,Phase III,Recruiting,"[{'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407),2634
1,NCT02658214,Phase I,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors,2634
2,NCT02367781,Phase III,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}]",A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel in Patients With Non-Squamous Non-Small Cell Lung Cancer,2634
3,NCT02382406,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}]",Carboplatin/Nab-Paclitaxel and MK-3475 in NSCLC,2634
4,NCT03164616,Phase III,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}]",Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON),2634
0,NCT02392507,Phase II,Recruiting,"[{'id': 2599, 'therapyName': 'Carboplatin + nab-paclitaxel + Necitumumab'}]",A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC,2599
0,NCT03121352,Phase I,Recruiting,"[{'id': 5591, 'therapyName': 'Carboplatin + nab-paclitaxel + Pembrolizumab'}]","Pilot Study of Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer",5591
0,NCT03209401,Phase I,Not yet recruiting,"[{'id': 5984, 'therapyName': 'Carboplatin + Niraparib'}]",Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies,5984
0,NCT03256136,Phase II,Not yet recruiting,"[{'id': 6159, 'therapyName': 'Carboplatin + Nivolumab + Pemetrexed'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","A Phase II Study of Nivolumab in Combination With Carboplatin and Pemetrexed, or Nivolumab in Combination With Ipilimumab, in Patients With Advanced, EGFR-mutant or ALK-rearranged, Non-Small Cell Lung Cancer",6159
0,NCT02876107,Phase II,Recruiting,"[{'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 3386, 'therapyName': 'Carboplatin + Paclitaxel + Panitumumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Phase II Study of Using Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen (AC) for New Triple-Negative Inflammatory Breast Cancer (TN-IBC),3386
1,NCT02593175,Phase II,Recruiting,"[{'id': 3386, 'therapyName': 'Carboplatin + Paclitaxel + Panitumumab'}]","Women's Triple-Negative First-Line Study: A Phase II Trial of Panitumumab, Carboplatin and Paclitaxel (PaCT) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy",3386
0,NCT03064854,Phase I,Recruiting,"[{'id': 6027, 'therapyName': 'Carboplatin + Paclitaxel + PDR001'}, {'id': 6026, 'therapyName': 'Cisplatin + Pemetrexed + PDR001'}, {'id': 6025, 'therapyName': 'Cisplatin + Gemcitabine + PDR001'}, {'id': 6024, 'therapyName': 'Pemetrexed + PDR001 + Cisplatin + Carboplatin'}]","PDR001 in Combination With Platinum-doublet Chemotherapy in PD-L1 Unselected, Metastatic NSCLC Patients (ElevatION:NSCLC-101 Trial)",6027
0,NCT02621398,Phase I,Suspended,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]","Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer",2103
1,NCT02549209,Phase II,Recruiting,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]",Pembro/Carbo/Taxol in Endometrial Cancer,2103
2,NCT02039674,Phase Ib/II,"Active, not recruiting","[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}, {'id': 2104, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 2106, 'therapyName': 'Ipilimumab + Pembrolizumab '}, {'id': 2107, 'therapyName': 'Erlotinib + Pembrolizumab '}, {'id': 2108, 'therapyName': 'Gefitinib + Pembrolizumab '}]",A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021),2103
3,NCT02630823,Phase I,Recruiting,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]",MK-3475 Immunotherapy in Endometrial Carcinoma,2103
4,NCT02834975,Phase II,Recruiting,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]","Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).",2103
5,NCT02766582,Phase II,Recruiting,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]",Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer,2103
6,NCT03064490,Phase II,Recruiting,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]","Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)",2103
7,NCT02617849,Phase II,Recruiting,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]",Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma,2103
0,NCT02944396,Phase II,Recruiting,"[{'id': 5054, 'therapyName': 'Carboplatin + Paclitaxel + Pemetrexed + Veliparib'}, {'id': 5053, 'therapyName': 'Carboplatin + Paclitaxel + Pemetrexed + Nivolumab + Veliparib'}]",Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC),5053
0,NCT02944396,Phase II,Recruiting,"[{'id': 5054, 'therapyName': 'Carboplatin + Paclitaxel + Pemetrexed + Veliparib'}, {'id': 5053, 'therapyName': 'Carboplatin + Paclitaxel + Pemetrexed + Nivolumab + Veliparib'}]",Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC),5054
0,NCT03206645,Phase I,Recruiting,"[{'id': 6266, 'therapyName': 'Carboplatin + Paclitaxel + PTC596'}]",PTC-596 in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy,6266
0,NCT02269293,Phase I,Recruiting,"[{'id': 2640, 'therapyName': 'Carboplatin + Paclitaxel + Selinexor'}]","Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers",2640
0,NCT01912625,Phase I,Recruiting,"[{'id': 2196, 'therapyName': 'Carboplatin + Paclitaxel + Trametinib'}]","Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery",2196
0,NCT03194373,Phase II,Recruiting,"[{'id': 4735, 'therapyName': 'Carboplatin + Palbociclib'}]",Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma,4735
1,NCT02897375,Phase I,Recruiting,"[{'id': 4734, 'therapyName': 'Cisplatin + Palbociclib'}, {'id': 4735, 'therapyName': 'Carboplatin + Palbociclib'}]",Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,4735
0,NCT03029598,Phase Ib/II,Recruiting,"[{'id': 5265, 'therapyName': 'Carboplatin + Pembrolizumab'}]","Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",5265
1,NCT03095352,Phase II,Recruiting,"[{'id': 5265, 'therapyName': 'Carboplatin + Pembrolizumab'}]","A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease",5265
2,NCT03213041,Phase II,Recruiting,"[{'id': 5265, 'therapyName': 'Carboplatin + Pembrolizumab'}]",Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer,5265
0,NCT02259582,Phase II,"Active, not recruiting","[{'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 2007, 'therapyName': 'Demcizumab'}]","A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer",1602
1,NCT01803282,Phase I,Recruiting,"[{'id': 3320, 'therapyName': 'GS-5745'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Safety and Tolerability Study in Solid Tumors,1602
2,NCT02039674,Phase Ib/II,"Active, not recruiting","[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}, {'id': 2104, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 2106, 'therapyName': 'Ipilimumab + Pembrolizumab '}, {'id': 2107, 'therapyName': 'Erlotinib + Pembrolizumab '}, {'id': 2108, 'therapyName': 'Gefitinib + Pembrolizumab '}]",A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021),1602
3,NCT02591615,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]",Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC,1602
4,NCT03164616,Phase III,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}]",Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON),1602
5,NCT01263782,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 701, 'therapyName': 'Cixutumumab'}]",BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer,1602
6,NCT02468661,Phase Ib/II,Recruiting,"[{'id': 1065, 'therapyName': 'Capmatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]","A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification",1602
7,NCT02542293,Phase III,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]",Study of 1st Line Therapy Study of MEDI4736 With Tremelimumab Versus SoC in Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE).,1602
8,NCT02087241,Phase II,Terminated,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]",Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer,1602
0,NCT02789657,Phase II,Recruiting,"[{'id': 4235, 'therapyName': 'Carboplatin + Pertuzumab + Trastuzumab + Paclitaxel'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]",BrUOG 308: Efficacy of wPCbTP and Switching to an AC in Non-responding Patients as Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.,4235
0,NCT01690468,Phase Ib/II,Recruiting,"[{'id': 4566, 'therapyName': 'Carboplatin + Triciribine'}]",PTX-200 and Carboplatin in Ovarian Cancer,4566
0,NCT01107522,Phase I,"Active, not recruiting","[{'id': 1142, 'therapyName': 'CTO + Temozolomide'}, {'id': 999, 'therapyName': 'Carboxyamidotriazole Orotate'}]",Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar&#174; in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar&#174; and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas,999
1,NCT01989052,Phase Ib/II,Terminated,"[{'id': 2075, 'therapyName': 'Lomustine'}, {'id': 999, 'therapyName': 'Carboxyamidotriazole Orotate'}]",Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma,999
2,NCT01954030,Phase Ib/II,Terminated,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 999, 'therapyName': 'Carboxyamidotriazole Orotate'}]",Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure,999
0,NCT02512926,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children,1624
1,NCT03004287,Phase II,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy,1624
2,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1624
3,NCT01863550,Phase III,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,1624
4,NCT02235740,Phase I,Terminated,"[{'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1839, 'therapyName': 'Afuresertib + Carfilzomib'}]","A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)",1624
5,NCT02265510,Phase I,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2747, 'therapyName': 'INCB052793'}, {'id': 688, 'therapyName': 'Bortezomib'}]","An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies",1624
6,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,1624
7,NCT01998971,Phase I,Recruiting,"[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1475, 'therapyName': 'Thalidomide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 3323, 'therapyName': 'Montelukast'}]",A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma,1624
8,NCT02142530,Phase I,Recruiting,"[{'id': 1078, 'therapyName': 'Belinostat'}, {'id': 1624, 'therapyName': 'Carfilzomib'}]",Carfilzomib Plus Belinostat in Relapsed/Refractory NHL,1624
0,NCT02802163,Phase Ib/II,Withdrawn,"[{'id': 4367, 'therapyName': 'Carfilzomib + Dexamethasone + lenalidomide + Panobinostat'}]","Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat",4367
0,NCT03256045,Phase II,Not yet recruiting,"[{'id': 6289, 'therapyName': 'Carfilzomib + Dexamethasone + Panobinostat'}]","Panobinostat, Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma",6289
0,NCT02101944,Phase I,Recruiting,"[{'id': 2463, 'therapyName': 'Carfilzomib + Dexamethasone + Reolysin'}]","Viral Protein Production After Dexamethasone, Wild-Type Reovirus, and Carfilzomib in Treating Patients With Multiple Myeloma",2463
0,NCT02199665,Phase I,"Active, not recruiting","[{'id': 2985, 'therapyName': 'Carfilzomib + Dexamethasone + Selinexor'}]","Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma",2985
1,NCT02628704,Phase II,Withdrawn,"[{'id': 2985, 'therapyName': 'Carfilzomib + Dexamethasone + Selinexor'}]","Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma",2985
0,NCT02899052,Phase II,Recruiting,"[{'id': 5268, 'therapyName': 'Carfilzomib + Dexamethasone + Venetoclax'}]",Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM),5268
0,NCT02969837,Phase II,Recruiting,"[{'id': 5033, 'therapyName': 'Carfilzomib + Elotuzumab + Dexamethasone + lenalidomide'}]","Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma",5033
0,NCT03104270,Phase II,Recruiting,"[{'id': 5555, 'therapyName': 'Carfilzomib + Elotuzumab + Dexamethasone + Pomalidomide'}]",Combination Study for High Risk Multiple Myeloma Patients,5555
0,NCT01962792,Phase Ib/II,Recruiting,"[{'id': 3282, 'therapyName': 'Carfilzomib + Ibrutinib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]","Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Carfilzomib (Kyprolis), in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma",3282
1,NCT02269085,Phase Ib/II,"Active, not recruiting","[{'id': 3282, 'therapyName': 'Carfilzomib + Ibrutinib'}]",A Phase I/II Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma,3282
0,NCT01301807,Phase I,"Active, not recruiting","[{'id': 3438, 'therapyName': 'Carfilzomib + Panobinostat'}]",Carfilzomib Plus Panobinostat in Relapsed/Refractory Multiple Myeloma (MM),3438
0,NCT02073097,Phase Ib/II,Recruiting,"[{'id': 2351, 'therapyName': 'Carfilzomib + Rituximab'}, {'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}]","Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma",2351
1,NCT01959698,Phase Ib/II,Recruiting,"[{'id': 2351, 'therapyName': 'Carfilzomib + Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}]","Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma",2351
0,NCT02867618,Phase Ib/II,Recruiting,"[{'id': 4598, 'therapyName': 'Carfilzomib + TGR-1202'}]",Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma,4598
0,NCT02342782,Phase I,Recruiting,"[{'id': 2485, 'therapyName': '90Y basiliximab'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 2392, 'therapyName': 'Cytarabine + Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}]",Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma,1811
1,NCT02343666,Phase I,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 2556, 'therapyName': 'O6-benzylguanine'}]",HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection,1811
2,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1811
0,NCT02570542,Phase II,Recruiting,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 3359, 'therapyName': 'Carmustine + Cytarabine + Etoposide + Melphalan'}]",Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL),3359
1,NCT02443077,Phase III,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 3359, 'therapyName': 'Carmustine + Cytarabine + Etoposide + Melphalan'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma,3359
0,NCT00669669,Phase Ib/II,"Active, not recruiting","[{'id': 2556, 'therapyName': 'O6-benzylguanine'}, {'id': 2555, 'therapyName': 'Carmustine + Filgrastim + Plerixafor + Temozolomide'}]",Dose-Intensive Chemotherapy in Combination With Chemoprotected Autologous Stem Cells in Treating Patients With Malignant Gliomas,2555
0,NCT02935543,Phase II,Recruiting,"[{'id': 5999, 'therapyName': 'CART19 cells'}]",CART19 in Patient With ALL,5999
1,NCT02640209,Phase I,Recruiting,"[{'id': 5999, 'therapyName': 'CART19 cells'}]",Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL),5999
0,NCT02903914,Phase I,Recruiting,"[{'id': 4722, 'therapyName': 'CB-1158 + Nivolumab'}, {'id': 4721, 'therapyName': 'CB-1158'}]",Arginase Inhibitor CB-1158 in Patients With Solid Tumors,4721
0,NCT02903914,Phase I,Recruiting,"[{'id': 4722, 'therapyName': 'CB-1158 + Nivolumab'}, {'id': 4721, 'therapyName': 'CB-1158'}]",Arginase Inhibitor CB-1158 in Patients With Solid Tumors,4722
0,NCT02223598,Phase I,Terminated,"[{'id': 1944, 'therapyName': 'CB-5083'}, {'id': 4513, 'therapyName': 'CB-5083 + Dexamethasone'}]",A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies  (CLC-102),1944
1,NCT02243917,Phase I,"Active, not recruiting","[{'id': 1944, 'therapyName': 'CB-5083'}]",A Phase 1 Study Evaluating CB-5083 in Patients With Advanced Solid Tumors,1944
0,NCT02223598,Phase I,Terminated,"[{'id': 1944, 'therapyName': 'CB-5083'}, {'id': 4513, 'therapyName': 'CB-5083 + Dexamethasone'}]",A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies  (CLC-102),4513
0,NCT02071927,Phase I,Completed,"[{'id': 1667, 'therapyName': 'CB-839'}]",Study of the Glutaminase Inhibitor CB-839 in Leukemia,1667
1,NCT02071862,Phase I,Recruiting,"[{'id': 1667, 'therapyName': 'CB-839'}]",Study of the Glutaminase Inhibitor CB-839 in Solid Tumors,1667
0,NCT03263429,Phase Ib/II,Recruiting,"[{'id': 6158, 'therapyName': 'CB-839 + Irinotecan + Panitumumab'}]",Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer,6158
0,NCT02771626,Phase Ib/II,Recruiting,"[{'id': 4274, 'therapyName': 'CB-839 + Nivolumab'}]",Study CB-839 in Combination With Nivolumab in Patients With ccRCC and Other Solid Tumors,4274
0,NCT01905228,Phase I,Recruiting,"[{'id': 3940, 'therapyName': 'CBL0137 '}]",A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm or Refractory Lymphomas,3940
0,NCT03113188,Phase I,Recruiting,"[{'id': 6186, 'therapyName': 'CBP501 + Cisplatin + Nivolumab'}]","CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors",6186
0,NCT03175224,Phase I,Recruiting,"[{'id': 5963, 'therapyName': 'CBT-101'}]",CBT-101 Study for Advanced Solid Tumors and c-Met Dysregulation,5963
0,NCT02977780,Phase II,Recruiting,"[{'id': 1000, 'therapyName': 'CC-115'}, {'id': 5028, 'therapyName': 'Abemaciclib + Temozolomide'}, {'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 5029, 'therapyName': 'Neratinib + Temozolomide'}]",INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT),1000
1,NCT01353625,Phase I,"Active, not recruiting","[{'id': 1000, 'therapyName': 'CC-115'}]","Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.",1000
0,NCT02833883,Phase I,Recruiting,"[{'id': 4459, 'therapyName': 'CC-115 + Enzalutamide'}]","Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer",4459
0,NCT02406742,Phase Ib/II,Recruiting,"[{'id': 1646, 'therapyName': 'Obinutuzumab'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 2358, 'therapyName': 'CC-122'}]","A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Rituximab, Ibrutinib and Obinutuzumab in Subjects With Relapsed/Refractory CLL/SLL (ENHANCE)",2358
1,NCT01421524,Phase I,Recruiting,"[{'id': 2358, 'therapyName': 'CC-122'}]","Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma",2358
0,NCT02031419,Phase I,Recruiting,"[{'id': 2376, 'therapyName': 'CC-122 + CC-292'}, {'id': 2377, 'therapyName': 'CC-223 + CC-292'}, {'id': 2375, 'therapyName': 'CC-122 + CC-223'}, {'id': 897, 'therapyName': 'Rituximab'}]","Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma",2375
0,NCT02031419,Phase I,Recruiting,"[{'id': 2376, 'therapyName': 'CC-122 + CC-292'}, {'id': 2377, 'therapyName': 'CC-223 + CC-292'}, {'id': 2375, 'therapyName': 'CC-122 + CC-223'}, {'id': 897, 'therapyName': 'Rituximab'}]","Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma",2376
0,NCT02859324,Phase Ib/II,Recruiting,"[{'id': 4611, 'therapyName': 'CC-122 + Nivolumab'}]",A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC),4611
0,NCT01177397,Phase Ib/II,Completed,"[{'id': 693, 'therapyName': 'CC-223'}]","Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma",693
0,NCT02031419,Phase I,Recruiting,"[{'id': 2376, 'therapyName': 'CC-122 + CC-292'}, {'id': 2377, 'therapyName': 'CC-223 + CC-292'}, {'id': 2375, 'therapyName': 'CC-122 + CC-223'}, {'id': 897, 'therapyName': 'Rituximab'}]","Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma",2377
0,NCT02313012,Phase I,Terminated,"[{'id': 2874, 'therapyName': 'CC-90003'}]",Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors,2874
0,NCT01312376,Phase I,"Active, not recruiting","[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1227, 'therapyName': 'CD3/CD28 costimulated vaccine-primed autologous T-cells'}, {'id': 1222, 'therapyName': 'OC-DC vaccine'}]",Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer,1227
0,NCT02837991,Phase Ib/II,Recruiting,"[{'id': 5774, 'therapyName': 'CDX-014'}]","A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Advanced or Metastatic Renal Cell Carcinoma",5774
0,NCT02642016,Phase I,Recruiting,"[{'id': 4037, 'therapyName': 'CDX-0158'}]",A Study to Evaluate the Safety and Pharmacokinetics of KTN0158 in Adult Patients With Advanced Solid Tumors,4037
0,NCT02129075,Phase II,"Active, not recruiting","[{'id': 3006, 'therapyName': 'NeoVax melanoma vaccine'}, {'id': 3007, 'therapyName': 'CDX-301'}, {'id': 1324, 'therapyName': 'DEC-205-NY-ESO-1 fusion protein vaccine'}]",CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma,3007
1,NCT02200380,Phase II,Terminated,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 3007, 'therapyName': 'CDX-301'}]",A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs,3007
0,NCT01976585,Phase Ib/II,Recruiting,"[{'id': 4337, 'therapyName': 'CDX-301 + poly ICLC '}]",In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy,4337
0,NCT02014909,Phase I,Completed,"[{'id': 2054, 'therapyName': 'CDX-3379'}, {'id': 2063, 'therapyName': 'CDX-3379 + Vemurafenib'}, {'id': 2064, 'therapyName': 'CDX-3379 + Trastuzumab'}, {'id': 2061, 'therapyName': 'Cetuximab + CDX-3379'}, {'id': 2062, 'therapyName': 'CDX-3379 + Erlotinib'}]",A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors,2054
1,NCT02473731,Phase I,Completed,"[{'id': 2054, 'therapyName': 'CDX-3379'}]",A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients,2054
0,NCT02014909,Phase I,Completed,"[{'id': 2054, 'therapyName': 'CDX-3379'}, {'id': 2063, 'therapyName': 'CDX-3379 + Vemurafenib'}, {'id': 2064, 'therapyName': 'CDX-3379 + Trastuzumab'}, {'id': 2061, 'therapyName': 'Cetuximab + CDX-3379'}, {'id': 2062, 'therapyName': 'CDX-3379 + Erlotinib'}]",A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors,2062
0,NCT02014909,Phase I,Completed,"[{'id': 2054, 'therapyName': 'CDX-3379'}, {'id': 2063, 'therapyName': 'CDX-3379 + Vemurafenib'}, {'id': 2064, 'therapyName': 'CDX-3379 + Trastuzumab'}, {'id': 2061, 'therapyName': 'Cetuximab + CDX-3379'}, {'id': 2062, 'therapyName': 'CDX-3379 + Erlotinib'}]",A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors,2064
0,NCT02014909,Phase I,Completed,"[{'id': 2054, 'therapyName': 'CDX-3379'}, {'id': 2063, 'therapyName': 'CDX-3379 + Vemurafenib'}, {'id': 2064, 'therapyName': 'CDX-3379 + Trastuzumab'}, {'id': 2061, 'therapyName': 'Cetuximab + CDX-3379'}, {'id': 2062, 'therapyName': 'CDX-3379 + Erlotinib'}]",A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors,2063
1,NCT02456701,Phase I,Completed,"[{'id': 2063, 'therapyName': 'CDX-3379 + Vemurafenib'}]",Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379,2063
0,NCT00942877,Phase II,"Active, not recruiting","[{'id': 1001, 'therapyName': 'Cediranib'}]",Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma,1001
1,NCT01391962,Phase II,Recruiting,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1001, 'therapyName': 'Cediranib'}]",Sunitinib or Cediranib for Alveolar Soft Part Sarcoma,1001
2,NCT02502266,Phase II,Suspended,"[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1001, 'therapyName': 'Cediranib'}]","Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1001
3,NCT01208051,Phase Ib/II,"Active, not recruiting","[{'id': 2437, 'therapyName': 'Cediranib + Lenalidomide'}, {'id': 1001, 'therapyName': 'Cediranib'}]",Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer,1001
4,NCT02446600,Phase III,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1001, 'therapyName': 'Cediranib'}]","Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1001
0,NCT01064648,Phase Ib/II,"Active, not recruiting","[{'id': 2432, 'therapyName': 'Cediranib + Cisplatin + Pemetrexed'}]",Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma,2432
0,NCT02484404,Phase Ib/II,Recruiting,"[{'id': 2895, 'therapyName': 'Cediranib + Durvalumab'}, {'id': 2894, 'therapyName': 'Durvalumab + Olaparib'}]",Phase 1 and 2 Study of MEDI4736 in Combination With Olaparib or Cediranib for Advanced Solid Tumors and Recurrent Ovarian Cancer,2895
0,NCT01208051,Phase Ib/II,"Active, not recruiting","[{'id': 2437, 'therapyName': 'Cediranib + Lenalidomide'}, {'id': 1001, 'therapyName': 'Cediranib'}]",Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer,2437
0,NCT02345265,Phase II,"Active, not recruiting","[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]","Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer",1971
1,NCT02893917,Phase II,Recruiting,"[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}, {'id': 837, 'therapyName': 'Olaparib'}]",Olaparib With or Without Cediranib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,1971
2,NCT02498613,Phase II,Recruiting,"[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]",Cediranib Maleate and Olaparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,1971
3,NCT02340611,Phase II,Recruiting,"[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]",A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib,1971
4,NCT02681237,Phase I,Recruiting,"[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]",A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer,1971
5,NCT01116648,Phase Ib/II,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]","Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer",1971
6,NCT02899728,Phase II,Suspended,"[{'id': 4728, 'therapyName': 'Carboplatin + Cisplatin + Etoposide'}, {'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]","Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer",1971
7,NCT02889900,Phase II,Recruiting,"[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]",Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer (CONCERTO),1971
8,NCT02974621,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]",Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma,1971
0,NCT02030964,Phase I,"Active, not recruiting","[{'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}, {'id': 2124, 'therapyName': 'Celecoxib'}]",N2012-01 Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan,2124
1,NCT01356290,Phase II,Recruiting,"[{'id': 1475, 'therapyName': 'Thalidomide'}, {'id': 4418, 'therapyName': 'Fenofibrate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2124, 'therapyName': 'Celecoxib'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}]",Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma (MEMMAT),2124
2,NCT01729923,Phase II,Terminated,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 2124, 'therapyName': 'Celecoxib'}]",A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer,2124
0,NCT02574728,Phase II,Recruiting,"[{'id': 3143, 'therapyName': 'Celecoxib + Cyclophosphamide + Etoposide + Sirolimus'}]",Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors,3143
0,NCT00970502,Phase Ib/II,Completed,"[{'id': 2125, 'therapyName': 'Celecoxib + Erlotinib'}]","Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer",2125
0,NCT02401295,Phase I,Completed,"[{'id': 3433, 'therapyName': 'Celecoxib + Itraconazole + Tretinoin '}]","ATRA, Celecoxib, and Itraconazole as Maintenance",3433
0,NCT03052569,Expanded access,Temporarily not available,"[{'id': 1002, 'therapyName': 'CEP-32496'}]",Expanded Access to RXDX-105 for Cancers With RET Alterations,1002
1,NCT01877811,Phase Ib/II,"Active, not recruiting","[{'id': 1002, 'therapyName': 'CEP-32496'}]",CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and Advanced Melanoma and Metastatic Colorectal Cancer in Phase 2,1002
0,NCT01922752,Phase I,Completed,"[{'id': 2147, 'therapyName': 'CEP-37440'}]",To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors,2147
0,NCT01994382,Phase I,Recruiting,"[{'id': 2531, 'therapyName': 'Cerdulatinib'}]",Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma,2531
0,NCT02605746,Phase I,Recruiting,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis,789
1,NCT01742286,Phase I,Recruiting,"[{'id': 789, 'therapyName': 'Ceritinib'}]","Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)",789
2,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,789
3,NCT01772797,Phase I,Completed,"[{'id': 789, 'therapyName': 'Ceritinib'}, {'id': 647, 'therapyName': 'AUY922'}]",Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer,789
4,NCT02299505,Phase I,Recruiting,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC),789
5,NCT02321501,Phase I,Recruiting,"[{'id': 2295, 'therapyName': 'Ceritinib + Everolimus'}, {'id': 789, 'therapyName': 'Ceritinib'}]",Phase I/Ib Dose Escalation and Biomarker Study of Ceritinib (LDK378) + Everolimus for Locally Advanced or Metastatic Solid Tumors With an Expansion in Non-Small Cell Lung Cancer (NSCLC) Characterized by Abnormalities in Anaplastic Lymphoma Kinase (ALK) Expression,789
6,NCT01947608,Phase I,Available,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC,789
7,NCT02638909,Phase II,Recruiting,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies,789
8,NCT02186821,Phase II,Completed,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE),789
9,NCT02289144,Phase II,Recruiting,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Ceritinib (LDK378) in Mutation and Oncogene Directed Therapy in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer,789
10,NCT02343679,Phase II,Withdrawn,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies,789
11,NCT01828112,Phase III,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 789, 'therapyName': 'Ceritinib'}]",LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib,789
12,NCT02584933,FDA approved,Recruiting,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study,789
13,NCT02422589,Phase I,Recruiting,"[{'id': 2505, 'therapyName': 'Warfarin'}, {'id': 2685, 'therapyName': 'Midazolam'}, {'id': 789, 'therapyName': 'Ceritinib'}]","A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors",789
14,NCT02336451,Phase II,Recruiting,"[{'id': 789, 'therapyName': 'Ceritinib'}]",A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges,789
15,NCT02513667,Phase II,Recruiting,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma,789
0,NCT02321501,Phase I,Recruiting,"[{'id': 2295, 'therapyName': 'Ceritinib + Everolimus'}, {'id': 789, 'therapyName': 'Ceritinib'}]",Phase I/Ib Dose Escalation and Biomarker Study of Ceritinib (LDK378) + Everolimus for Locally Advanced or Metastatic Solid Tumors With an Expansion in Non-Small Cell Lung Cancer (NSCLC) Characterized by Abnormalities in Anaplastic Lymphoma Kinase (ALK) Expression,2295
0,NCT02227940,Phase I,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 2554, 'therapyName': 'Ceritinib + Gemcitabine'}]",Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer,2554
0,NCT02780128,Phase I,Recruiting,"[{'id': 2186, 'therapyName': 'HDM201'}, {'id': 2638, 'therapyName': 'Ceritinib + LEE011'}, {'id': 2, 'therapyName': 'Trametinib'}]",Next Generation Personalized Neuroblastoma Therapy,2638
1,NCT02292550,Phase Ib/II,"Active, not recruiting","[{'id': 2638, 'therapyName': 'Ceritinib + LEE011'}]",Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.,2638
0,NCT02393625,Phase I,Recruiting,"[{'id': 2565, 'therapyName': 'Ceritinib + Nivolumab'}]",Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer,2565
0,NCT03087448,Phase Ib/II,Recruiting,"[{'id': 6303, 'therapyName': 'Ceritinib + Trametinib'}]",Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC),6303
0,NCT00957853,Phase II,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 701, 'therapyName': 'Cixutumumab'}]",Preoperative Treatment With Cetuximab and/or IMC-A12,694
1,NCT01663259,Phase I,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}]",Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients,694
2,NCT01652482,Phase II,Completed,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 806, 'therapyName': 'MEHD7945A'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer,694
3,NCT01468896,Phase Ib/II,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}]","Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery",694
4,NCT00904345,Phase II,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}]",Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC),694
5,NCT02124850,Phase I,Recruiting,"[{'id': 694, 'therapyName': 'Cetuximab'}]",A Phase Ib Study of Neoadjuvant Immune Biomarker Modulation With ERBITUX&#174; (Cetuximab) and VTX-2337,694
6,NCT02800486,Phase II,Recruiting,"[{'id': 694, 'therapyName': 'Cetuximab'}]","Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA",694
7,NCT01309126,Phase III,Terminated,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 2065, 'therapyName': 'Cetuximab + Imprime PGG'}]",Study of Imprime PGG in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer,694
8,NCT02105636,Phase III,"Active, not recruiting","[{'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141),694
9,NCT01025089,Phase II,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1927, 'therapyName': 'Cisplatin + Doxorubicin + Cyclophosphamide'}]",Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma,694
10,NCT01524978,Phase II,"Active, not recruiting","[{'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Study of Zelboraf (Vemurafenib) in Patients With BRAF V600 Mutation-Positive Cancers,694
11,NCT01467115,Phase II,Completed,"[{'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1930, 'therapyName': 'Cisplatin + Docetaxel + Fluorouracil'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 694, 'therapyName': 'Cetuximab'}]",INDUCTION CHEMOTHERAPY FOLLOWED BY CETUXIMAB AND RADIATION THERAPY FOR HEAD AND NECK CANCER,694
12,NCT00292955,Phase II,Unknown status,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 700, 'therapyName': 'Cisplatin'}]","Cetuximab, Cisplatin, and Radiotherapy in Women With Locally Advanced Cervical Carcinoma",694
13,NCT01104922,Phase II,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}]",Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck,694
14,NCT02324608,Phase I,Recruiting,"[{'id': 694, 'therapyName': 'Cetuximab'}]",Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer,694
15,NCT01816984,Phase Ib/II,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 680, 'therapyName': 'BKM120'}]",PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,694
16,NCT01472016,Phase I,Completed,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1063, 'therapyName': 'ABT-700'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",Study of ABT-700 in Subjects With Advanced Solid Tumors,694
17,NCT01238237,Phase I,Completed,"[{'id': 694, 'therapyName': 'Cetuximab'}]",Super-Selective Intraarterial Cerebral Infusion of Cetuximab for the Treatment of Recurrent Glioblastoma Multiforme and Anaplastic Astrocytoma,694
18,NCT01979211,Phase II,Recruiting,"[{'id': 694, 'therapyName': 'Cetuximab'}]",Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck,694
19,NCT02563002,Phase III,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177),694
20,NCT02499120,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}]",Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer,694
21,NCT02555644,Phase I,Recruiting,"[{'id': 1651, 'therapyName': 'Prexasertib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Study of LY2606368 With Chemotherapy and Radiation in Participants With Head and Neck Cancer,694
22,NCT02693535,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 690, 'therapyName': 'Bosutinib'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer,694
23,NCT02599324,Phase Ib/II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors,694
24,NCT02057107,Phase II,Recruiting,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 720, 'therapyName': 'Docetaxel'}]","Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN)",694
25,NCT02358031,Phase III,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048),694
26,NCT01285037,Phase I,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1030, 'therapyName': 'LY2801653'}]",A Study of LY2801653 in Advanced Cancer,694
27,NCT03258554,Phase II,Not yet recruiting,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Stage III-IVB Head and Neck Cancer Who Cannot Take Cisplatin,694
28,NCT01577173,Phase II,Completed,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 806, 'therapyName': 'MEHD7945A'}]",A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck,694
29,NCT00956007,Phase III,Recruiting,"[{'id': 694, 'therapyName': 'Cetuximab'}]",Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer,694
30,NCT01540682,,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}]",MLN8237 in Head and Neck Cancer,694
31,NCT01218048,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}]",ERBITUX; Followed by Adjuvant Treatment With Chemoradiation and ERBITUX; for Locally Advanced Head and Neck Squamous Cell Carcinoma,694
32,NCT02252042,Phase III,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040),694
33,NCT02438722,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 694, 'therapyName': 'Cetuximab'}]","S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer",694
34,NCT02281955,Phase II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}]",De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC,694
35,NCT01744340,Phase Ib/II,Completed,"[{'id': 728, 'therapyName': 'Eribulin'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer,694
0,NCT02551159,Phase III,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1914, 'therapyName': 'Cetuximab + Carboplatin + Fluorouracil'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN,1914
1,NCT01063075,Phase II,Completed,"[{'id': 1914, 'therapyName': 'Cetuximab + Carboplatin + Fluorouracil'}]",A Study in Advanced Solid Tumors,1914
0,NCT03254927,Phase II,Not yet recruiting,"[{'id': 2061, 'therapyName': 'Cetuximab + CDX-3379'}]",A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma,2061
1,NCT02014909,Phase I,Completed,"[{'id': 2054, 'therapyName': 'CDX-3379'}, {'id': 2063, 'therapyName': 'CDX-3379 + Vemurafenib'}, {'id': 2064, 'therapyName': 'CDX-3379 + Trastuzumab'}, {'id': 2061, 'therapyName': 'Cetuximab + CDX-3379'}, {'id': 2062, 'therapyName': 'CDX-3379 + Erlotinib'}]",A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors,2061
0,NCT01099358,Phase II,Completed,"[{'id': 1915, 'therapyName': 'Cetuximab + Cisplatin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}]",Study in Advanced Solid Tumors,1915
1,NCT02177838,Phase II,Suspended,"[{'id': 1915, 'therapyName': 'Cetuximab + Cisplatin'}]",Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer,1915
0,NCT00316888,Phase II,"Active, not recruiting","[{'id': 1928, 'therapyName': 'Cetuximab + Cisplatin + Fluorouracil + Radiotherapy'}]","Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Anal Cancer",1928
0,NCT01133678,Phase II,"Active, not recruiting","[{'id': 1790, 'therapyName': 'Cetuximab + Cisplatin + Paclitaxel'}, {'id': 735, 'therapyName': 'Everolimus'}]",Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck,1790
0,NCT01488318,Phase II,Terminated,"[{'id': 1820, 'therapyName': 'Cetuximab + Dasatinib'}]",Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma,1820
0,NCT01719380,Phase Ib/II,"Active, not recruiting","[{'id': 1916, 'therapyName': 'Cetuximab + Encorafenib'}, {'id': 1917, 'therapyName': 'LGX818 + Cetuximab + BYL719'}]","Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer",1916
1,NCT02928224,Phase III,Recruiting,"[{'id': 1916, 'therapyName': 'Cetuximab + Encorafenib'}, {'id': 4886, 'therapyName': 'Binimetinib + Cetuximab + LGX818'}, {'id': 1874, 'therapyName': 'Cetuximab + Irinotecan'}, {'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}]",Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (BEACON CRC),1916
0,NCT03109158,Phase Ib/II,Recruiting,"[{'id': 5578, 'therapyName': 'Cetuximab + Fluorouracil + NC-6004'}]",NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,5578
0,NCT01442935,Phase II,"Active, not recruiting","[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}, {'id': 2181, 'therapyName': 'Bevacizumab + FOLFIRI'}, {'id': 2182, 'therapyName': 'Cetuximab + FOLFOX'}, {'id': 2183, 'therapyName': 'Bevacizumab + FOLFIRINOX'}, {'id': 2184, 'therapyName': 'Cetuximab + FOLFIRINOX'}]",Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases,2180
1,NCT02573220,Phase I,Withdrawn,"[{'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}]",Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer,2180
2,NCT02928224,Phase III,Recruiting,"[{'id': 1916, 'therapyName': 'Cetuximab + Encorafenib'}, {'id': 4886, 'therapyName': 'Binimetinib + Cetuximab + LGX818'}, {'id': 1874, 'therapyName': 'Cetuximab + Irinotecan'}, {'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}]",Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (BEACON CRC),2180
3,NCT01703390,Phase II,Unknown status,"[{'id': 2182, 'therapyName': 'Cetuximab + FOLFOX'}, {'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}]",Biomarker Directed Treatment in Metastatic Colorectal Cancer,2180
0,NCT01442935,Phase II,"Active, not recruiting","[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}, {'id': 2181, 'therapyName': 'Bevacizumab + FOLFIRI'}, {'id': 2182, 'therapyName': 'Cetuximab + FOLFOX'}, {'id': 2183, 'therapyName': 'Bevacizumab + FOLFIRINOX'}, {'id': 2184, 'therapyName': 'Cetuximab + FOLFIRINOX'}]",Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases,2184
0,NCT01442935,Phase II,"Active, not recruiting","[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}, {'id': 2181, 'therapyName': 'Bevacizumab + FOLFIRI'}, {'id': 2182, 'therapyName': 'Cetuximab + FOLFOX'}, {'id': 2183, 'therapyName': 'Bevacizumab + FOLFIRINOX'}, {'id': 2184, 'therapyName': 'Cetuximab + FOLFIRINOX'}]",Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases,2182
1,NCT01703390,Phase II,Unknown status,"[{'id': 2182, 'therapyName': 'Cetuximab + FOLFOX'}, {'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}]",Biomarker Directed Treatment in Metastatic Colorectal Cancer,2182
0,NCT02953782,Phase Ib/II,Recruiting,"[{'id': 4948, 'therapyName': 'Cetuximab + Hu5F9-G4'}]",Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer,4948
0,NCT01309126,Phase III,Terminated,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 2065, 'therapyName': 'Cetuximab + Imprime PGG'}]",Study of Imprime PGG in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer,2065
0,NCT02643550,Phase Ib/II,Recruiting,"[{'id': 3383, 'therapyName': 'Cetuximab + IPH2201'}]",Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,3383
0,NCT01860430,Phase I,"Active, not recruiting","[{'id': 1926, 'therapyName': 'Cetuximab + Ipilimumab'}]",A Phase Ib Trial of Concurrent Cetuximab (ERBITUX) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY) in Locally Advanced Head and Neck Cancer,1926
1,NCT01935921,Phase I,"Active, not recruiting","[{'id': 1926, 'therapyName': 'Cetuximab + Ipilimumab'}]","Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer",1926
0,NCT02292758,Phase II,Recruiting,"[{'id': 1923, 'therapyName': 'Bevacizumab + Cetuximab + Irinotecan'}, {'id': 1874, 'therapyName': 'Cetuximab + Irinotecan'}]","Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in KRAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer",1874
1,NCT02164916,Phase II,"Active, not recruiting","[{'id': 1874, 'therapyName': 'Cetuximab + Irinotecan'}, {'id': 1331, 'therapyName': 'Vemurafenib + Cetuximab + Irinotecan '}]",S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,1874
2,NCT02928224,Phase III,Recruiting,"[{'id': 1916, 'therapyName': 'Cetuximab + Encorafenib'}, {'id': 4886, 'therapyName': 'Binimetinib + Cetuximab + LGX818'}, {'id': 1874, 'therapyName': 'Cetuximab + Irinotecan'}, {'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}]",Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (BEACON CRC),1874
3,NCT01079780,Phase II,Unknown status,"[{'id': 1920, 'therapyName': 'Irinotecan + Cetuximab + Ramucirumab'}, {'id': 1874, 'therapyName': 'Cetuximab + Irinotecan'}]",Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy,1874
0,NCT03290937,Phase I,Not yet recruiting,"[{'id': 6288, 'therapyName': 'Cetuximab + Irinotecan + Utomilumab'}]","Clinical Trial Evaluating the Safety and Response With PF-05082566, Cetuximab and Irinotecan in Patients With Advanced Colorectal Cancer",6288
0,NCT02861898,Phase Ib/II,Recruiting,"[{'id': 4559, 'therapyName': 'Cetuximab + Mannitol'}]",Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma,4559
0,NCT02573493,Phase II,Recruiting,"[{'id': 3126, 'therapyName': 'Cisplatin + nab-paclitaxel'}, {'id': 3127, 'therapyName': 'Cetuximab + nab-paclitaxel'}]",Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC),3127
0,NCT01960023,Phase Ib/II,"Active, not recruiting","[{'id': 1118, 'therapyName': 'Cetuximab + Neratinib'}]",Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer,1118
0,NCT02764593,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 4760, 'therapyName': 'Cisplatin + Nivolumab'}, {'id': 4761, 'therapyName': 'Cetuximab + Nivolumab'}]",Chemotherapy +/- Nivolumab in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma,4761
0,NCT01316757,Phase II,"Active, not recruiting","[{'id': 1921, 'therapyName': 'Cetuximab + Paclitaxel + Carboplatin + Erlotinib'}]","Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer",1921
0,NCT02241187,Phase I,Completed,"[{'id': 2145, 'therapyName': 'Cetuximab + PEGPH20'}]",Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection,2145
0,NCT02124148,Phase I,Recruiting,"[{'id': 1994, 'therapyName': 'Cisplatin + Prexasertib'}, {'id': 1993, 'therapyName': 'Cetuximab + Prexasertib'}, {'id': 6248, 'therapyName': 'Pemetrexed + Prexasertib'}, {'id': 6247, 'therapyName': 'LY3023414 + Prexasertib'}, {'id': 6246, 'therapyName': 'Fluoruracil + Leucovorin + Prexasertib'}]",A Study of LY2606368 With Cisplatin or Cetuximab in Participants With Advanced Cancer,1993
0,NCT02630420,Phase I,Not yet recruiting,"[{'id': 3790, 'therapyName': 'Cetuximab + Savolitinib'}]",Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer,3790
0,NCT02110082,Phase I,Completed,"[{'id': 2066, 'therapyName': 'Cetuximab + Urelumab'}]",Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer,2066
0,NCT03187288,Phase I,Not yet recruiting,"[{'id': 4029, 'therapyName': 'CFI-400945'}]",A Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome,4029
1,NCT01954316,Phase I,Recruiting,"[{'id': 4029, 'therapyName': 'CFI-400945'}]",A Study of CFI-400945 Fumarate in Patients With Advanced Cancer,4029
0,NCT02792465,Phase I,Recruiting,"[{'id': 5853, 'therapyName': 'CFI-402257'}]",A Study of Investigational Drug CFI-402257 in Patients With Advanced Cancers,5853
0,NCT02365818,Phase II,"Active, not recruiting","[{'id': 2523, 'therapyName': 'CG0070'}]",Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade Non-Muscle Invasive Bladder Cancer After BCG Failure,2523
1,NCT01438112,,Terminated,"[{'id': 2524, 'therapyName': 'Gemcitabine + interferon + Mitomycin C + Valrubicin '}, {'id': 2523, 'therapyName': 'CG0070'}]",Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer,2523
0,NCT01760525,Phase I,"Active, not recruiting","[{'id': 2077, 'therapyName': 'CGM097'}]",A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors,2077
0,NCT02122809,Phase I,Completed,"[{'id': 1998, 'therapyName': 'Chiauranib'}]",Phase I Study of Chiauranib in Patients With Advanced Solid Tumors,1998
0,NCT02718066,Phase Ib/II,Recruiting,"[{'id': 4689, 'therapyName': 'Chidamide + Nivolumab'}]","Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer",4689
0,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,3035
1,NCT02475681,Phase III,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]","Elevate CLL TN: Study of Obinutuzumab + Chlorambucil, ACP-196 + Obinutuzumab, and ACP-196 in Subjects With Previously Untreated CLL",3035
0,NCT02100852,Phase I,"Active, not recruiting","[{'id': 2342, 'therapyName': 'Chlorambucil + Obinutuzumab + TGR-1202'}]","TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)",2342
0,NCT02955290,Phase Ib/II,Recruiting,"[{'id': 4941, 'therapyName': 'CIMAvax-EGF + Nivolumab'}]",CIMAvax Vaccine and Nivolumab in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer,4941
0,NCT02222688,Phase I,Recruiting,"[{'id': 4312, 'therapyName': 'Cirmtuzumab'}]",UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia,4312
1,NCT02860676,Phase I,Enrolling by invitation,"[{'id': 4312, 'therapyName': 'Cirmtuzumab'}]",Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961,4312
0,NCT03088878,Phase Ib/II,Not yet recruiting,"[{'id': 5480, 'therapyName': 'Cirmtuzumab + Ibrutinib'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies,5480
0,NCT02776917,Phase I,Not yet recruiting,"[{'id': 4313, 'therapyName': 'Cirmtuzumab + Paclitaxel'}]","Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer",4313
0,NCT02595905,Phase I,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 954, 'therapyName': 'Veliparib'}]",Cisplatin With or Without Veliparib in Treating Patients With Stage IV Triple-Negative and/or BRCA Mutation-Associated Breast Cancer,700
1,NCT02635360,Phase II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer,700
2,NCT02477826,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, Trial of Nivolumab and Nivolumab Plus Ipilimumab Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC)",700
3,NCT00993655,Phase III,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}]"," Comparing Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",700
4,NCT01128387,Phase Ib/II,Completed,"[{'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 845, 'therapyName': 'Panitumumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Trial of Panitumumab/Cisplatin/Fluorouracil With XRT in Esophageal Cancer,700
5,NCT02196168,Phase II,Terminated,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,700
6,NCT02009449,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2621, 'therapyName': 'AM0010 '}, {'id': 619, 'therapyName': 'Abraxane'}]",A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors,700
7,NCT00980954,Phase III,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy,700
8,NCT01982448,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Cisplatin vs Paclitaxel for Triple Neg,700
9,NCT01240590,Phase Ib/II,Completed,"[{'id': 1461, 'therapyName': 'Crolibulin + Cisplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC),700
10,NCT03040999,Phase III,Recruiting,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412),700
11,NCT01732640,Phase Ib/II,Completed,"[{'id': 2442, 'therapyName': 'Afatinib + Carboplatin + Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.,700
12,NCT01064921,Phase I,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma,700
13,NCT02394652,Phase II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1031, 'therapyName': 'Metformin'}]",The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer,700
14,NCT02657434,Phase III,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer,700
15,NCT02381535,Phase I,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 645, 'therapyName': 'AT13387'}]",Hsp90 Inhibitor AT13387 in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin,700
16,NCT01711515,Phase I,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Chemoradiation Therapy and Ipilimumab in Treating Patients With Locally Advanced Cervical Cancer,700
17,NCT01633541,Phase II,Recruiting,"[{'id': 644, 'therapyName': 'AT-101'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer,700
18,NCT02128906,Phase II,Recruiting,"[{'id': 1925, 'therapyName': 'Docetaxel + Cetuximab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC,700
19,NCT02409342,Phase III,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Comparative Study of MPDL3280A (Anti-PDL1 Antibody) With Cisplatin or Carboplatin + Pemetrexed in Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC),700
20,NCT02855944,Phase III,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 906, 'therapyName': 'Rucaparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients",700
21,NCT02429466,Phase I,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1949, 'therapyName': 'SGI-110'}]",Study of the Hypomethylating Drug SGI-110 Plus Cisplatin in Relapsed Refractory Germ Cell Tumors,700
22,NCT02157792,Phase I,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 2879, 'therapyName': 'VX-970'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy",700
23,NCT03107182,Phase II,Recruiting,"[{'id': 5581, 'therapyName': 'Dexamethasone + Diphenhydramine + Famotidine + 5FU + Hydroxyurea + Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 5303, 'therapyName': 'Nivolumab + Carboplatin + Paclitaxel'}]",Oropharyngeal Tumor Induction Chemotherapy and Response-stratified Locoregional Therapy Trial in Order to Minimize Long-term Adverse Events,700
24,NCT01553942,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Afatinib With CT and RT for EGFR-Mutant NSCLC,700
25,NCT00292955,Phase II,Unknown status,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 700, 'therapyName': 'Cisplatin'}]","Cetuximab, Cisplatin, and Radiotherapy in Women With Locally Advanced Cervical Carcinoma",700
26,NCT01064479,Phase II,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Docetaxel And Cisplatin With or Without Erlotinib For Metastatic Or Recurrent Squamous Cell Carcinoma Of Head And Neck,700
27,NCT02296684,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma,700
28,NCT02641093,Phase II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma,700
29,NCT02409355,Phase III,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of MPDL3280A Compared With Gemcitabine + Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer,700
30,NCT02555644,Phase I,Recruiting,"[{'id': 1651, 'therapyName': 'Prexasertib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Study of LY2606368 With Chemotherapy and Radiation in Participants With Head and Neck Cancer,700
31,NCT02201355,Phase I,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}]","Reduced-Volume Hypofractionated, PET-directed Intensity Modulated Radiotherapy Concurrent With Weekly Cisplatin Chemotherapy for Squamous Cell Carcinoma of the Head and Neck",700
32,NCT03057106,Phase II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC,700
33,NCT01285037,Phase I,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1030, 'therapyName': 'LY2801653'}]",A Study of LY2801653 in Advanced Cancer,700
34,NCT01820754,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC),700
35,NCT01336842,Phase I,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors,700
36,NCT01836029,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2000, 'therapyName': 'Fluorouracil + Cetuximab'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,700
37,NCT02041533,Phase III,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)",700
38,NCT02985658,Phase I,Available,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1685, 'therapyName': 'Vinorelbine'}]",Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer,700
39,NCT01810913,Phase II,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1925, 'therapyName': 'Docetaxel + Cetuximab'}]","Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",700
40,NCT01042522,Phase II,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1137, 'therapyName': 'Bleomycin'}]","Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors",700
41,NCT01737008,Phase I,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 714, 'therapyName': 'Dacomitinib'}]",Study of Dacomitinib With Radiotherapy With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck,700
42,NCT02537223,Phase I,Recruiting,"[{'id': 691, 'therapyName': 'BYL719'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer,700
43,NCT02264990,Phase III,"Active, not recruiting","[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers,700
44,NCT01928160,Phase II,Withdrawn,"[{'id': 1290, 'therapyName': 'Erlotinib + Pemetrexed'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1291, 'therapyName': 'Erlotinib + Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1292, 'therapyName': 'Erlotinib + Cisplatin'}]",Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib,700
45,NCT02551159,Phase III,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1914, 'therapyName': 'Cetuximab + Carboplatin + Fluorouracil'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN,700
46,NCT02227940,Phase I,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 2554, 'therapyName': 'Ceritinib + Gemcitabine'}]",Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer,700
47,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,700
48,NCT02365766,Phase Ib/II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Study of Neoadjuvant Pembrolizumab in Combination With Gemcitabine Based Therapy in Cis-eligible or -Ineligible Subjects With Urothelial Cancer,700
49,NCT02349958,Phase II,Recruiting,"[{'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy,700
50,NCT02578680,Phase III,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Non-squamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189),700
51,NCT02358031,Phase III,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048),700
52,NCT03126916,Phase III,Not yet recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 5595, 'therapyName': 'Isotretinoin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 2286, 'therapyName': 'Dinutuximab  '}]",Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma,700
53,NCT02142738,Phase III,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024),700
54,NCT01409174,Phase Ib/II,Terminated,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1299, 'therapyName': 'Interferon alfa-2b '}]",IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma,700
55,NCT01450761,Phase III,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone,700
56,NCT01711658,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2475, 'therapyName': 'Lapatinib + Cisplatin'}]",TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer,700
57,NCT01918306,Phase Ib/II,Terminated,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1554, 'therapyName': 'GDC-0941 + Cisplatin'}]",GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer,700
58,NCT02508246,Phase I,Recruiting,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]","AZD1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck",700
59,NCT03004287,Phase II,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy,700
60,NCT00989651,Phase I,"Active, not recruiting","[{'id': 3047, 'therapyName': 'Bevacizumab + Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]","Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",700
61,NCT01454102,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)",700
62,NCT01898494,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer,700
63,NCT02281955,Phase II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}]",De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC,700
64,NCT02532192,Phase I,Withdrawn,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1689, 'therapyName': 'Fluconazole'}, {'id': 1078, 'therapyName': 'Belinostat'}]","A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma",700
65,NCT02952586,Phase III,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 5052, 'therapyName': 'Avelumab + Cisplatin'}]",Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100),700
66,NCT02576574,Phase III,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100),700
67,NCT02314117,Phase III,"Active, not recruiting","[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer,700
68,NCT02489903,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 3680, 'therapyName': 'RRx-001'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 619, 'therapyName': 'Abraxane'}]","RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens",700
69,NCT02402920,Phase I,Recruiting,"[{'id': 2604, 'therapyName': 'Carboplatin + Etoposide + Pembrolizumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Phase I Trial of MK-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung Cancer,700
70,NCT01218048,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}]",ERBITUX; Followed by Adjuvant Treatment With Chemoradiation and ERBITUX; for Locally Advanced Head and Neck Squamous Cell Carcinoma,700
71,NCT02107235,Phase I,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1046, 'therapyName': 'rigosertib'}]",Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer,700
72,NCT01927744,Phase II,Recruiting,"[{'id': 2474, 'therapyName': 'Erlotinib + Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","Study of Chemotherapy With Cisplatin/CarboplatinAstellas Pharma Inc, OSI Pharmaceuticals, Kadoorie Foundation, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection",700
73,NCT02254278,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}]",Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer,700
74,NCT01859741,Phase Ib/II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2547, 'therapyName': 'Tarextumab'}]",A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Platinum Therapy in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE),700
75,NCT01014598,Phase I,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}]",Cisplatin in Treating Patients With Lung Cancer,700
0,NCT01453205,Phase II,Completed,"[{'id': 2354, 'therapyName': 'Cisplatin + Cytarabine + Dexamethasone'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2407, 'therapyName': 'MEDI-551'}]","A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",2354
0,NCT02436707,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3391, 'therapyName': 'Cisplatin + Dexamethasone + Gemcitabine + Rituximab'}]",Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma,3391
0,NCT01588431,Phase II,"Active, not recruiting","[{'id': 1987, 'therapyName': 'Cisplatin + Docetaxel + Cetuximab'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer,1987
1,NCT01437449,Phase II,"Active, not recruiting","[{'id': 1987, 'therapyName': 'Cisplatin + Docetaxel + Cetuximab'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","Weekly Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)",1987
0,NCT01467115,Phase II,Completed,"[{'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1930, 'therapyName': 'Cisplatin + Docetaxel + Fluorouracil'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 694, 'therapyName': 'Cetuximab'}]",INDUCTION CHEMOTHERAPY FOLLOWED BY CETUXIMAB AND RADIATION THERAPY FOR HEAD AND NECK CANCER,1930
1,NCT01914900,Phase II,Unknown status,"[{'id': 1930, 'therapyName': 'Cisplatin + Docetaxel + Fluorouracil'}]",Preoperative TPF Chemotherapy in a Population of Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer,1930
2,NCT03288350,Phase II,Not yet recruiting,"[{'id': 1930, 'therapyName': 'Cisplatin + Docetaxel + Fluorouracil'}, {'id': 3144, 'therapyName': 'Avelumab'}]",mDCF + Avelumab in Resectable Esophago-gastric Adenocarcinoma (EGA),1930
0,NCT02225405,Phase I,Recruiting,"[{'id': 2372, 'therapyName': 'Cisplatin + Docetaxel + Nintedanib'}]","Induction Study of Cisplatin, Docetaxel, and Nintedanib Stage IB-IIIA Non-Small Cell Lung Cancer (NCLC)",2372
0,NCT01025089,Phase II,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1927, 'therapyName': 'Cisplatin + Doxorubicin + Cyclophosphamide'}]",Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma,1927
0,NCT00734877,Phase III,Recruiting,"[{'id': 1851, 'therapyName': 'Cisplatin + Doxorubicin + Cyclophosphamide + Etoposide'}, {'id': 1852, 'therapyName': 'Melphalan + Bortezomib + Thalidomide + Dexamethasone'}]","UARK 2008-01, Total Therapy 4 - A Phase III Trial for Low Risk Myeloma",1851
0,NCT02899195,Phase II,Recruiting,"[{'id': 5630, 'therapyName': 'Cisplatin + Durvalumab + Pemetrexed'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma (PrE0505),5630
0,NCT02537418,Phase I,"Active, not recruiting","[{'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens,2585
1,NCT03066778,Phase III,Recruiting,"[{'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 5145, 'therapyName': 'Cisplatin + Etoposide + Pembrolizumab'}, {'id': 2604, 'therapyName': 'Carboplatin + Etoposide + Pembrolizumab'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604),2585
2,NCT02768558,Phase III,Recruiting,"[{'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 4922, 'therapyName': 'Cisplatin + Etoposide + Nivolumab'}]",Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC,2585
3,NCT01642251,Phase Ib/II,"Active, not recruiting","[{'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 954, 'therapyName': 'Veliparib'}]",Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer,2585
4,NCT01857934,Phase II,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 2627, 'therapyName': 'Levetiracetam'}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 2458, 'therapyName': 'Hu14.18K322A'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}]",Therapy for Children With Advanced Stage Neuroblastoma,2585
5,NCT01175356,Phase I,Completed,"[{'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}]","Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin",2585
0,NCT02768558,Phase III,Recruiting,"[{'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 4922, 'therapyName': 'Cisplatin + Etoposide + Nivolumab'}]",Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC,4922
0,NCT01822496,Phase II,Recruiting,"[{'id': 1375, 'therapyName': 'Cisplatin + Etoposide + Paclitaxel + Carboplatin + Erlotinib'}]",Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer,1375
0,NCT03066778,Phase III,Recruiting,"[{'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 5145, 'therapyName': 'Cisplatin + Etoposide + Pembrolizumab'}, {'id': 2604, 'therapyName': 'Carboplatin + Etoposide + Pembrolizumab'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604),5145
1,NCT02987998,Phase I,Recruiting,"[{'id': 5145, 'therapyName': 'Cisplatin + Etoposide + Pembrolizumab'}]",Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC,5145
0,NCT01579929,Phase I,Completed,"[{'id': 2504, 'therapyName': 'Cisplatin + Etoposide + Sonidegib'}]","Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)",2504
0,NCT01182168,Phase I,Completed,"[{'id': 2296, 'therapyName': 'Cisplatin + Everolimus + Gemcitabine'}]",Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies,2296
0,NCT03189719,Phase III,Recruiting,"[{'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 6051, 'therapyName': 'Cisplatin + Fluorouracil + Pembrolizumab'}]",First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590),1833
1,NCT00588770,Phase III,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1835, 'therapyName': 'Docetaxel + Cisplatin'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 1834, 'therapyName': 'Docetaxel + Carboplatin'}, {'id': 1832, 'therapyName': 'Carboplatin + Fluorouracil\t'}]",Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,1833
2,NCT03143153,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 5799, 'therapyName': 'Nivolumab + Cisplatin + Fluorouacil'}]",A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin (CheckMate 648),1833
3,NCT02494583,Phase III,"Active, not recruiting","[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062),1833
4,NCT02335411,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}]",A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059),1833
5,NCT02051868,Phase II,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}]",International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel (InterAACT),1833
6,NCT03221426,Phase III,Recruiting,"[{'id': 3999, 'therapyName': 'Capecitabine + Cisplatin'}, {'id': 6050, 'therapyName': 'Capecitabine + Cisplatin + Pembrolizumab'}, {'id': 6051, 'therapyName': 'Cisplatin + Fluorouracil + Pembrolizumab'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}]",Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585),1833
0,NCT01711541,Phase Ib/II,Suspended,"[{'id': 1544, 'therapyName': 'Carboplatin + Etoposide + Veliparib'}, {'id': 1849, 'therapyName': 'Cisplatin + Fluorouracil + Hydroxyurea'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer,1849
0,NCT03221426,Phase III,Recruiting,"[{'id': 3999, 'therapyName': 'Capecitabine + Cisplatin'}, {'id': 6050, 'therapyName': 'Capecitabine + Cisplatin + Pembrolizumab'}, {'id': 6051, 'therapyName': 'Cisplatin + Fluorouracil + Pembrolizumab'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}]",Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585),6051
1,NCT03189719,Phase III,Recruiting,"[{'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 6051, 'therapyName': 'Cisplatin + Fluorouracil + Pembrolizumab'}]",First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590),6051
0,NCT00980460,Phase III,Recruiting,"[{'id': 2298, 'therapyName': 'Irinotecan + Temsirolimus + Vincristine'}, {'id': 2297, 'therapyName': 'Cisplatin + Fluorouracil + Vincristine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer,2297
0,NCT02393248,Phase Ib/II,Recruiting,"[{'id': 4176, 'therapyName': 'Cisplatin + Gemcitabine + INCB054828'}, {'id': 4174, 'therapyName': 'Docetaxel + INCB054828'}, {'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}]","Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies",4176
0,NCT02784795,Phase I,Recruiting,"[{'id': 4374, 'therapyName': 'Cisplatin + Gemcitabine + LY3039478'}, {'id': 4375, 'therapyName': 'Carboplatin + Gemcitabine + LY3039478'}, {'id': 4372, 'therapyName': 'LY3039478 + LY3023414'}, {'id': 4373, 'therapyName': 'Abemaciclib + LY3039478'}, {'id': 4371, 'therapyName': 'LY3039478 + Taladegib'}, {'id': 2958, 'therapyName': 'LY3039478'}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors,4374
0,NCT02754726,Phase II,Recruiting,"[{'id': 4087, 'therapyName': 'Cisplatin + Gemcitabine + nab-paclitaxel + Nivolumab + Paricalcitol'}]",Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma,4087
0,NCT03101566,Phase II,Recruiting,"[{'id': 5511, 'therapyName': 'Cisplatin + Gemcitabine + Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer,5511
0,NCT03064854,Phase I,Recruiting,"[{'id': 6027, 'therapyName': 'Carboplatin + Paclitaxel + PDR001'}, {'id': 6026, 'therapyName': 'Cisplatin + Pemetrexed + PDR001'}, {'id': 6025, 'therapyName': 'Cisplatin + Gemcitabine + PDR001'}, {'id': 6024, 'therapyName': 'Pemetrexed + PDR001 + Cisplatin + Carboplatin'}]","PDR001 in Combination With Platinum-doublet Chemotherapy in PD-L1 Unselected, Metastatic NSCLC Patients (ElevatION:NSCLC-101 Trial)",6025
0,NCT02608684,Phase II,Recruiting,"[{'id': 3248, 'therapyName': 'Cisplatin + Gemcitabine + Pembrolizumab'}]",A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer,3248
1,NCT02690558,Phase II,Recruiting,"[{'id': 3248, 'therapyName': 'Cisplatin + Gemcitabine + Pembrolizumab'}]",Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy,3248
0,NCT02128282,Phase Ib/II,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 6091, 'therapyName': 'Cisplatin + Gemcitabine + Silmitasertib'}]",Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma,6091
0,NCT01938573,Phase Ib/II,Completed,"[{'id': 2289, 'therapyName': 'Cisplatin + Gemcitabine + Sirolimus '}]","Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer",2289
1,NCT01888302,Phase I,Completed,"[{'id': 2289, 'therapyName': 'Cisplatin + Gemcitabine + Sirolimus '}]","Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery",2289
0,NCT02567409,Phase II,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 3110, 'therapyName': 'Cisplatin + Gemcitabine + VX-970'}]",Cisplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Metastatic Urothelial Cancer,3110
0,NCT02949700,Phase Ib/II,Recruiting,"[{'id': 2205, 'therapyName': 'Cisplatin + Metformin'}]",Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma,2205
1,NCT02325401,Phase I,Recruiting,"[{'id': 2205, 'therapyName': 'Cisplatin + Metformin'}]",Dose-finding Study of Metformin With Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma,2205
0,NCT02573493,Phase II,Recruiting,"[{'id': 3126, 'therapyName': 'Cisplatin + nab-paclitaxel'}, {'id': 3127, 'therapyName': 'Cetuximab + nab-paclitaxel'}]",Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC),3126
1,NCT03193853,Phase II,Recruiting,"[{'id': 3126, 'therapyName': 'Cisplatin + nab-paclitaxel'}, {'id': 1283, 'therapyName': 'MLN1117 + Sapanisertib'}]",TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer,3126
0,NCT02764593,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 4760, 'therapyName': 'Cisplatin + Nivolumab'}, {'id': 4761, 'therapyName': 'Cetuximab + Nivolumab'}]",Chemotherapy +/- Nivolumab in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma,4760
0,NCT02124421,Phase II,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1812, 'therapyName': 'Cisplatin + Paclitaxel'}]","Outcomes in CRS/HIPEC as Initial Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Cancer",1812
0,NCT02121990,Phase I,"Active, not recruiting","[{'id': 1451, 'therapyName': 'Cisplatin + Paclitaxel + Bevacizumab + Olaparib '}]","Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer",1451
0,NCT02897375,Phase I,Recruiting,"[{'id': 4734, 'therapyName': 'Cisplatin + Palbociclib'}, {'id': 4735, 'therapyName': 'Carboplatin + Palbociclib'}]",Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,4734
0,NCT03040999,Phase III,Recruiting,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412),3256
1,NCT02759575,Phase Ib/II,Recruiting,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}]",A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma,3256
2,NCT02775812,Phase I,Recruiting,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}]","Cisplatin, Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma",3256
3,NCT02586207,Phase I,Recruiting,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}]",Pembrolizumab in Combination With CRT for LA-SCCHN,3256
4,NCT02777385,Phase II,Recruiting,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}]",Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer,3256
0,NCT02119650,Phase II,Terminated,"[{'id': 1856, 'therapyName': 'Ruxolitinib + Cisplatin + Pemetrexed'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}]",Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer,1857
1,NCT02784171,Phase II,Recruiting,"[{'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma,1857
2,NCT01907100,Phase III,Recruiting,"[{'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib (BIBF 1120) in Mesothelioma,1857
3,NCT02357147,Phase II,"Active, not recruiting","[{'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 3513, 'therapyName': 'Amatuximab'}]",Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM). (ARTEMIS),1857
4,NCT03164616,Phase III,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}]",Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON),1857
5,NCT01868022,Phase I,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 2899, 'therapyName': 'GSK3052230'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling",1857
6,NCT02468661,Phase Ib/II,Recruiting,"[{'id': 1065, 'therapyName': 'Capmatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]","A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification",1857
7,NCT02542293,Phase III,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]",Study of 1st Line Therapy Study of MEDI4736 With Tremelimumab Versus SoC in Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE).,1857
8,NCT02707666,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}]",A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma,1857
9,NCT02337530,Phase II,"Active, not recruiting","[{'id': 913, 'therapyName': 'Selumetinib'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}]",Selumetinib in Patients Receiving Pemetrexed and Cisplatin in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer,1857
0,NCT03064854,Phase I,Recruiting,"[{'id': 6027, 'therapyName': 'Carboplatin + Paclitaxel + PDR001'}, {'id': 6026, 'therapyName': 'Cisplatin + Pemetrexed + PDR001'}, {'id': 6025, 'therapyName': 'Cisplatin + Gemcitabine + PDR001'}, {'id': 6024, 'therapyName': 'Pemetrexed + PDR001 + Cisplatin + Carboplatin'}]","PDR001 in Combination With Platinum-doublet Chemotherapy in PD-L1 Unselected, Metastatic NSCLC Patients (ElevatION:NSCLC-101 Trial)",6026
0,NCT02124148,Phase I,Recruiting,"[{'id': 1994, 'therapyName': 'Cisplatin + Prexasertib'}, {'id': 1993, 'therapyName': 'Cetuximab + Prexasertib'}, {'id': 6248, 'therapyName': 'Pemetrexed + Prexasertib'}, {'id': 6247, 'therapyName': 'LY3023414 + Prexasertib'}, {'id': 6246, 'therapyName': 'Fluoruracil + Leucovorin + Prexasertib'}]",A Study of LY2606368 With Cisplatin or Cetuximab in Participants With Advanced Cancer,1994
0,NCT02393794,Phase Ib/II,"Active, not recruiting","[{'id': 2993, 'therapyName': 'Cisplatin + Romidepsin '}]",Romidepsin Plus Cisplatin in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC),2993
0,NCT00492505,Phase II,Unknown status,"[{'id': 2212, 'therapyName': 'Cisplatin + Sorafenib + Tamoxifen'}]","Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma",2212
0,NCT02723864,Phase I,Recruiting,"[{'id': 3993, 'therapyName': 'Cisplatin + Veliparib + VX-970'}]","Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors",3993
0,NCT02998528,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 5241, 'therapyName': 'Cisplatin + Vinorelbine + Gemcitabine + Docetaxel + Pemetrexed + Carboplatin'}]",A Neoadjuvant Study of Nivolumab and Ipilimumab Compared to Chemotherapy Doublet in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816),5241
0,NCT02567422,Phase I,Recruiting,"[{'id': 3109, 'therapyName': 'Cisplatin + VX-970'}]","VX-970, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced HPV-Negative Head and Neck Squamous Cell Carcinoma",3109
0,NCT02551185,Phase I,Recruiting,"[{'id': 3311, 'therapyName': 'Citarinostat'}]",ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors,3311
1,NCT02400242,Phase I,"Active, not recruiting","[{'id': 3311, 'therapyName': 'Citarinostat'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1622, 'therapyName': 'Pomalidomide'}]",Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma,3311
0,NCT01263782,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 701, 'therapyName': 'Cixutumumab'}]",BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer,701
1,NCT00957853,Phase II,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 701, 'therapyName': 'Cixutumumab'}]",Preoperative Treatment With Cetuximab and/or IMC-A12,701
0,NCT02926768,Phase Ib/II,Recruiting,"[{'id': 5329, 'therapyName': 'CK-101'}]",Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors,5329
0,NCT01515527,Phase II,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 650, 'therapyName': 'Decitabine'}]",Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS),1767
1,NCT02096055,Phase II,Recruiting,"[{'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1949, 'therapyName': 'SGI-110'}, {'id': 1022, 'therapyName': 'Idarubicin'}]",4-Arm Phase II Study of SGI-110 in Elderly Acute Myeloid Leukemia (AML),1767
2,NCT02756572,Phase I,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5215, 'therapyName': 'mitoxantrone hydrochloride'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myelodysplastic Syndrome or Acute Myeloid Leukemia,1767
3,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1767
4,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,1767
0,NCT02728050,Phase Ib/II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 4363, 'therapyName': 'Cladribine + Cytarabine + Filgrastim + Mitoxantrone'}]","Filgrastim, Cladribine, Cytarabine and Mitoxantrone With or Without Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome",4363
0,NCT02416908,Phase Ib/II,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}, {'id': 3178, 'therapyName': 'Cladribine + Cytarabine + Plerixafor'}]",Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia,3178
0,NCT02368886,Phase II,"Active, not recruiting","[{'id': 2350, 'therapyName': 'Clobetasol + Regorafenib'}]",Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer,2350
0,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,1746
1,NCT01252667,Phase II,Recruiting,"[{'id': 2272, 'therapyName': 'Cyclosporine + Mycophenolate mofetil'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant,1746
2,NCT02085408,Phase III,Recruiting,"[{'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}]",Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,1746
3,NCT01794702,Phase Ib/II,"Active, not recruiting","[{'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 650, 'therapyName': 'Decitabine'}]","Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia",1746
4,NCT03136146,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1090, 'therapyName': 'Ofatumumab'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]","Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)",1746
5,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1746
6,NCT03117751,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,1746
7,NCT02518750,Phase II,Recruiting,"[{'id': 1604, 'therapyName': 'Panobinostat + Bortezomib + Dexamethasone'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3217, 'therapyName': 'Cyclophosphamide + Etoposide'}, {'id': 3216, 'therapyName': 'Cytarabine + Methotrexate + Prednisone'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma,1746
8,NCT02883049,Phase III,Suspended,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations,1746
0,NCT00908167,Phase I,Completed,"[{'id': 2374, 'therapyName': 'Clofarabine + Cytarabine + Sorafenib'}]",Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies,2374
0,NCT00549848,Phase III,"Active, not recruiting","[{'id': 1781, 'therapyName': 'Vincristine + Pegaspargase + Daunorubicin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1782, 'therapyName': 'Clofarabine + Etoposide + Cyclophosphamide'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia,1782
0,NCT01885689,Phase II,Recruiting,"[{'id': 2236, 'therapyName': 'Clofarabine + Melphalan'}]",Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia or Acute Leukemia in Remission,2236
0,NCT02189174,Phase Ib/II,Terminated,"[{'id': 1464, 'therapyName': 'CLR457'}]",Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies,1464
0,NCT02346955,Phase I,Terminated,"[{'id': 4246, 'therapyName': 'CM-24'}, {'id': 4247, 'therapyName': 'CM-24 + Pembrolizumab'}]",Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001),4246
0,NCT02346955,Phase I,Terminated,"[{'id': 4246, 'therapyName': 'CM-24'}, {'id': 4247, 'therapyName': 'CM-24 + Pembrolizumab'}]",Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001),4247
0,NCT02387125,Phase I,Recruiting,"[{'id': 4318, 'therapyName': 'CMB305'}]","A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1",4318
0,NCT02186301,Phase II,Terminated,"[{'id': 1003, 'therapyName': 'CO1686'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR Mutant NSCLC Who Have Not Had Any Previous EGFR Directed Therapy,1003
1,NCT02705339,Phase II,Withdrawn,"[{'id': 1003, 'therapyName': 'CO1686'}]",Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC),1003
2,NCT01526928,Phase Ib/II,"Active, not recruiting","[{'id': 1003, 'therapyName': 'CO1686'}]","Study to Evaluate Safety, Pharmacokinetics, and Efficacy of CO-1686 in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients",1003
3,NCT02147990,Phase II,Unknown status,"[{'id': 1003, 'therapyName': 'CO1686'}]",Open Label Safety and Efficacy Study of Rociletinib (CO-1686) in Patients With T790M Positive NSCLC Who Have Failed One Previous EGFR-Directed TKI,1003
4,NCT02547675,Phase I,No longer available,"[{'id': 1003, 'therapyName': 'CO1686'}]",Rociletinib (CO-1686) USA Expanded Access Program,1003
5,NCT02322281,Phase III,"Active, not recruiting","[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1003, 'therapyName': 'CO1686'}]","TIGER-3 Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy",1003
6,NCT02580708,Phase Ib/II,Completed,"[{'id': 2, 'therapyName': 'Trametinib'}, {'id': 1003, 'therapyName': 'CO1686'}]",A Phase 1/2 Study of the Safety and Efficacy of Rociletinib When Administered in Combination With Trametinib in Patients With Activating EGFR Mutation-positive Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC),1003
0,NCT02427893,Phase III,Withdrawn,"[{'id': 1004, 'therapyName': 'Cobimetinib'}, {'id': 342, 'therapyName': 'Vemurafenib'}]",Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma,1004
1,NCT02457793,Phase I,Completed,"[{'id': 1004, 'therapyName': 'Cobimetinib'}, {'id': 2149, 'therapyName': 'GDC-0994'}]","A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors",1004
2,NCT02639546,Phase I,Recruiting,"[{'id': 1004, 'therapyName': 'Cobimetinib'}]",iMATRIXcobi: Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients With Previously Treated Solid Tumors,1004
3,NCT02322814,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1004, 'therapyName': 'Cobimetinib'}]",A Study of Cobimetinib in Combination With Paclitaxel as First-line Treatment for Patients With Metastatic Triple-negative Breast Cancer,1004
0,NCT02876224,Phase I,Recruiting,"[{'id': 4609, 'therapyName': 'Cobimetinib + Bevacizumab + Atezolizumab'}]",Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors,4609
0,NCT01562275,Phase I,Completed,"[{'id': 1160, 'therapyName': 'Cobimetinib + GDC-0068'}]"," A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors",1160
0,NCT03101254,Phase Ib/II,Recruiting,"[{'id': 5512, 'therapyName': 'Cobimetinib + LY3022855 + Vemurafenib'}]",LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma,5512
0,NCT02670044,Phase Ib/II,Recruiting,"[{'id': 4171, 'therapyName': 'Cobimetinib + Venetoclax'}, {'id': 4172, 'therapyName': 'RO5503781 + Venetoclax'}]",A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy,4171
0,NCT02721459,Phase I,Recruiting,"[{'id': 3995, 'therapyName': 'Cobimetinib + XL888 + Vemurafenib'}]",XL888 + Vemurafenib + Cobimetinib for Unresectable B Rapidly Accelerated Fibrosarcoma (BRAF) Mutated Stage III/IV Melanoma,3995
0,NCT01940172,Phase I,Completed,"[{'id': 1458, 'therapyName': 'Conatumumab'}, {'id': 2647, 'therapyName': 'Birinapant  '}]",Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer,1458
1,NCT01327612,Phase II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 746, 'therapyName': 'Ganitumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1458, 'therapyName': 'Conatumumab'}]",Open Label Extension Study of Conatumumab and AMG 479,1458
0,NCT02729701,Phase II,Recruiting,"[{'id': 5928, 'therapyName': 'Conjugated estrogens/bazedoxifene'}]",Pilot Study of the Effect of Duavee on Benign Breast Tissue Proliferation,5928
1,NCT02694809,Phase II,Recruiting,"[{'id': 5928, 'therapyName': 'Conjugated estrogens/bazedoxifene'}]",Conjugated Estrogens/Bazedoxifene in Treating Patients With Ductal Carcinoma in Situ Undergoing Surgery,5928
0,NCT02155582,Phase I,Completed,"[{'id': 995, 'therapyName': 'Copanlisib'}]",Copanlisib Pharmacodynamic Study,995
1,NCT02455297,Phase II,Terminated,"[{'id': 995, 'therapyName': 'Copanlisib'}]",Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL),995
2,NCT02391116,Phase II,"Active, not recruiting","[{'id': 995, 'therapyName': 'Copanlisib'}]",Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL),995
3,NCT02728258,Phase II,Suspended,"[{'id': 995, 'therapyName': 'Copanlisib'}]",Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer,995
4,NCT02626455,Phase III,Recruiting,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 3388, 'therapyName': 'Aldoxorubicin +Cyclophosphamide + Prednisone + Rituximab + Vincristine'}, {'id': 995, 'therapyName': 'Copanlisib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL),995
5,NCT01660451,Phase II,"Active, not recruiting","[{'id': 995, 'therapyName': 'Copanlisib'}]","Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas",995
6,NCT02369016,Phase III,"Active, not recruiting","[{'id': 995, 'therapyName': 'Copanlisib'}]",Phase III Copanlisib in Rituximab-refractory iNHL,995
7,NCT02253420,Phase I,Recruiting,"[{'id': 995, 'therapyName': 'Copanlisib'}, {'id': 1026, 'therapyName': 'Itraconazole'}]",COPANLISIB (BAY80-6946) Drug-drug Interaction Study in Advanced Solid Tumor Patients,995
8,NCT02367040,Phase III,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 995, 'therapyName': 'Copanlisib'}]",Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL),995
0,NCT03128619,Phase Ib/II,Recruiting,"[{'id': 5594, 'therapyName': 'Copanlisib + Palbociclib + Letrozole'}, {'id': 5593, 'therapyName': 'Copanlisib + Letrozole'}]","Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer",5593
0,NCT01411410,Phase I,Completed,"[{'id': 1276, 'therapyName': 'Copanlisib + Paclitaxel'}]",Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer,1276
0,NCT03128619,Phase Ib/II,Recruiting,"[{'id': 5594, 'therapyName': 'Copanlisib + Palbociclib + Letrozole'}, {'id': 5593, 'therapyName': 'Copanlisib + Letrozole'}]","Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer",5594
0,NCT02043665,Phase I,Recruiting,"[{'id': 2974, 'therapyName': 'coxsackievirus A21'}]",Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200) (STORM),2974
1,NCT02307149,Phase I,Recruiting,"[{'id': 2974, 'therapyName': 'coxsackievirus A21'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Study of Intratumoral CAVATAK (Coxsackievirus A21) and Ipilimumab in Patients With Advanced Melanoma,2974
0,NCT02565992,Phase I,Recruiting,"[{'id': 3136, 'therapyName': 'coxsackievirus A21 + Pembrolizumab'}]",Phase I Study of Intratumoral CAVATAK and Pembrolizumab in Subjects With Advanced Melanoma,3136
0,NCT02157636,Phase I,Recruiting,"[{'id': 2033, 'therapyName': 'CPI-0610'}]",A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma,2033
1,NCT01949883,Phase I,Recruiting,"[{'id': 2033, 'therapyName': 'CPI-0610'}]",A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma,2033
2,NCT02158858,Phase I,Recruiting,"[{'id': 2033, 'therapyName': 'CPI-0610'}]","A Phase 1 Study Evaluating CPI-0610 in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelodysplastic/Myeloproliferative Neoplasms",2033
0,NCT02395601,Phase I,Recruiting,"[{'id': 2733, 'therapyName': 'CPI-1205'}]",A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas,2733
0,NCT02655822,Phase I,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 3571, 'therapyName': 'CPI-444 '}]",Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers,3571
0,NCT02019069,Phase II,Recruiting,"[{'id': 4341, 'therapyName': 'CPX-351'}]",CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome,4341
1,NCT01804101,Phase I,"Active, not recruiting","[{'id': 4341, 'therapyName': 'CPX-351'}]",Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia,4341
2,NCT01943682,Phase I,Recruiting,"[{'id': 4341, 'therapyName': 'CPX-351'}]",Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma,4341
3,NCT02269579,Phase II,Recruiting,"[{'id': 4341, 'therapyName': 'CPX-351'}]",Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment,4341
4,NCT02286726,Phase II,Recruiting,"[{'id': 4341, 'therapyName': 'CPX-351'}]",Phase II CPX-351 in Acute Myeloid Leukemia (AML),4341
5,NCT02533115,Expanded access,Approved for marketing,"[{'id': 4341, 'therapyName': 'CPX-351'}]",EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML,4341
0,NCT02642965,Phase Ib/II,Recruiting,"[{'id': 4391, 'therapyName': 'CPX-351 + Cytarabine + Filgrastim + Fludarabine '}]","Liposomal Cytarabine-Daunorubicin CPX-351, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia",4391
0,NCT01657682,Phase II,Recruiting,"[{'id': 705, 'therapyName': 'Crenolanib'}]",A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations,705
1,NCT02626364,Phase II,Recruiting,"[{'id': 705, 'therapyName': 'Crenolanib'}]",Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification,705
2,NCT02400281,Phase Ib/II,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 705, 'therapyName': 'Crenolanib'}, {'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}]",Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients,705
3,NCT02847429,Phase III,Recruiting,"[{'id': 705, 'therapyName': 'Crenolanib'}]",Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST,705
4,NCT02400255,Phase II,Recruiting,"[{'id': 705, 'therapyName': 'Crenolanib'}]",Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients,705
0,NCT02283177,Phase II,Recruiting,"[{'id': 2637, 'therapyName': 'Crenolanib + Cytarabine + Daunorubicin'}]",A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations,2637
0,NCT02626338,Phase Ib/II,Recruiting,"[{'id': 4024, 'therapyName': 'Crenolanib + Cytarabine + Mitoxantrone'}]",Pilot Study of Crenolanib Combined With Cytarabine and Mitoxantrone in Subjects With R/R AML,4024
0,NCT03193918,Phase I,Recruiting,"[{'id': 5943, 'therapyName': 'Crenolanib + Paclitaxel + Ramucirumab'}]",Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma,5943
0,NCT02270788,Phase I,Completed,"[{'id': 1865, 'therapyName': 'Methotrexate + Cytarabine + Leucovorin'}, {'id': 1864, 'therapyName': 'Crenolanib + Sorafenib'}]",Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies,1864
0,NCT03194893,Phase III,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 698, 'therapyName': 'Alectinib'}]",A Roll Over Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer,706
1,NCT01712217,Phase Ib/II,"Active, not recruiting","[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 645, 'therapyName': 'AT13387'}]",A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib,706
2,NCT02201992,Phase III,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}]",Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial),706
3,NCT02559778,Phase I,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2629, 'therapyName': 'Eflornithine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 717, 'therapyName': 'Dasatinib'}]",Pediatric Precision Laboratory Advanced Neuroblastoma Therapy,706
4,NCT02465060,Phase II,Recruiting,"[{'id': 660, 'therapyName': 'AZD9291'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 958, 'therapyName': 'VS-6063'}, {'id': 765, 'therapyName': 'GSK2636771'}]",NCI-MATCH Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,706
5,NCT01576406,Phase I,Completed,"[{'id': 706, 'therapyName': 'Crizotinib'}]",Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients,706
6,NCT02473497,Expanded access,Available,"[{'id': 706, 'therapyName': 'Crizotinib'}]",Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients,706
7,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,706
8,NCT03052608,Phase III,Recruiting,"[{'id': 869, 'therapyName': 'PF-06463922'}, {'id': 706, 'therapyName': 'Crizotinib'}]",A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC,706
9,NCT00939770,Phase Ib/II,"Active, not recruiting","[{'id': 706, 'therapyName': 'Crizotinib'}]",Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma,706
10,NCT01970865,Phase Ib/II,Recruiting,"[{'id': 869, 'therapyName': 'PF-06463922'}, {'id': 706, 'therapyName': 'Crizotinib'}]",A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations,706
11,NCT02737501,Phase III,"Active, not recruiting","[{'id': 634, 'therapyName': 'AP26113'}, {'id': 706, 'therapyName': 'Crizotinib'}]",ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in ALK-positive Advanced Non-Small Cell Lung Cancer Patients,706
12,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,706
13,NCT02767804,Phase III,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 961, 'therapyName': 'X-396'}]",eXalt3: Study Comparing X-396 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients,706
14,NCT02612194,Phase II,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}]",LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer,706
15,NCT01531361,Phase I,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 1326, 'therapyName': 'Vemurafenib + Sorafenib'}]",Sorafenib or Crizotinib and Vemurafenib in Advanced Cancer,706
16,NCT03088930,Phase II,Not yet recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}]",Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer,706
17,NCT01606878,Phase I,Recruiting,"[{'id': 2952, 'therapyName': 'Dexamethasone + Doxorubicin + Vincristine'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}, {'id': 706, 'therapyName': 'Crizotinib'}]",Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma,706
18,NCT02584634,Phase I,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 869, 'therapyName': 'PF-06463922'}]","Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)",706
19,NCT00932451,Phase II,Completed,"[{'id': 706, 'therapyName': 'Crizotinib'}]","An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene",706
20,NCT02075840,Phase III,"Active, not recruiting","[{'id': 698, 'therapyName': 'Alectinib'}, {'id': 706, 'therapyName': 'Crizotinib'}]","ALEX Study: A Randomized, Phase III Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Patients",706
21,NCT02277457,Phase I,Withdrawn,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 4, 'therapyName': 'Erlotinib'}]","Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations",706
22,NCT02574078,Phase I,Recruiting,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2114, 'therapyName': 'Bevacizumab + Pemetrexed'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",A Master Protocol Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate 370),706
23,NCT02223819,Phase II,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}]",Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy,706
24,NCT02511184,Phase I,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Crizotinib Plus Pembrolizumab In Alk-positive Advanced Non Small Cell Lung Cancer Patients,706
25,NCT03126916,Phase III,Not yet recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 5595, 'therapyName': 'Isotretinoin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 2286, 'therapyName': 'Dinutuximab  '}]",Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma,706
26,NCT01121588,,"Active, not recruiting","[{'id': 706, 'therapyName': 'Crizotinib'}]","An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)",706
27,NCT02693535,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 690, 'therapyName': 'Bosutinib'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer,706
28,NCT01979536,Phase II,Suspended,"[{'id': 706, 'therapyName': 'Crizotinib'}]",Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma,706
29,NCT02761057,Phase II,Recruiting,"[{'id': 2161, 'therapyName': 'Savolitinib'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}]","Cabozantinib-S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer",706
0,NCT01744652,Phase I,"Active, not recruiting","[{'id': 1252, 'therapyName': 'Crizotinib + Dasatinib'}]",Dasatinib and Crizotinib in Advanced Cancer,1252
1,NCT01644773,Phase I,Recruiting,"[{'id': 1252, 'therapyName': 'Crizotinib + Dasatinib'}]",Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG),1252
0,NCT02207504,Phase I,"Active, not recruiting","[{'id': 2446, 'therapyName': 'Crizotinib + Enzalutamide'}]",Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer,2446
0,NCT00585195,Phase I,Recruiting,"[{'id': 1526, 'therapyName': 'Crizotinib + Itraconazole\t'}, {'id': 1483, 'therapyName': 'Crizotinib + Rifampin'}]","A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer",1526
0,NCT01548144,Phase I,"Active, not recruiting","[{'id': 1153, 'therapyName': 'Crizotinib + Pazopanib'}, {'id': 1151, 'therapyName': 'Crizotinib + Pemetrexed'}, {'id': 1156, 'therapyName': 'Pazopanib + Pemetrexed'}, {'id': 1155, 'therapyName': 'Crizotinib + Pazopanib + Pemetrexed'}]",Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer,1153
0,NCT01548144,Phase I,"Active, not recruiting","[{'id': 1153, 'therapyName': 'Crizotinib + Pazopanib'}, {'id': 1151, 'therapyName': 'Crizotinib + Pemetrexed'}, {'id': 1156, 'therapyName': 'Pazopanib + Pemetrexed'}, {'id': 1155, 'therapyName': 'Crizotinib + Pazopanib + Pemetrexed'}]",Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer,1155
0,NCT02134912,Phase II,Recruiting,"[{'id': 1151, 'therapyName': 'Crizotinib + Pemetrexed'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib,1151
1,NCT01548144,Phase I,"Active, not recruiting","[{'id': 1153, 'therapyName': 'Crizotinib + Pazopanib'}, {'id': 1151, 'therapyName': 'Crizotinib + Pemetrexed'}, {'id': 1156, 'therapyName': 'Pazopanib + Pemetrexed'}, {'id': 1155, 'therapyName': 'Crizotinib + Pazopanib + Pemetrexed'}]",Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer,1151
0,NCT00585195,Phase I,Recruiting,"[{'id': 1526, 'therapyName': 'Crizotinib + Itraconazole\t'}, {'id': 1483, 'therapyName': 'Crizotinib + Rifampin'}]","A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer",1483
0,NCT02648711,Phase I,"Active, not recruiting","[{'id': 708, 'therapyName': 'CRLX101'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Alternative Dosing for CRLX101 Alone and With Avastin in Advanced Solid Tumors,708
1,NCT01625936,Phase I,Unknown status,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 708, 'therapyName': 'CRLX101'}]",CRLX101 Plus Bevacizumab in Advanced RCC,708
0,NCT02187302,Phase II,Completed,"[{'id': 1213, 'therapyName': 'CRLX101 + Bevacizumab'}]",CRLX101 in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC),1213
1,NCT01652079,Phase II,"Active, not recruiting","[{'id': 1213, 'therapyName': 'CRLX101 + Bevacizumab'}]",CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer,1213
0,NCT02769962,Phase Ib/II,Recruiting,"[{'id': 4348, 'therapyName': 'CRLX101 + Olaparib'}]","Trial of CRLX101, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer",4348
0,NCT03094052,Phase II,Recruiting,"[{'id': 828, 'therapyName': 'Neratinib'}, {'id': 2700, 'therapyName': 'Loperamide'}, {'id': 5906, 'therapyName': 'Crofelemer'}, {'id': 4359, 'therapyName': 'Neratinib + Trastuzumab'}]","Diarrhea Prophylaxis in Patients With HER2+ Breast Cancer Treated With Trastuzumab and Neratinib, Followed by Neratinib Monotherapy",5906
0,NCT01240590,Phase Ib/II,Completed,"[{'id': 1461, 'therapyName': 'Crolibulin + Cisplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC),1461
0,NCT02575807,Phase Ib/II,Recruiting,"[{'id': 2575, 'therapyName': 'Epacadostat'}, {'id': 2641, 'therapyName': 'CRS-207'}]","Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian, or Peritoneal Cancer",2641
1,NCT02243371,Phase II,"Active, not recruiting","[{'id': 2642, 'therapyName': 'GVAX pancreatic cancer vaccine  '}, {'id': 2641, 'therapyName': 'CRS-207'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab,2641
0,NCT03006302,Phase II,Not yet recruiting,"[{'id': 5169, 'therapyName': 'CRS-207 + INCB024360 + Pembrolizumab'}, {'id': 5170, 'therapyName': 'CRS-207 + Cyclophosphamide + GVAX panc vaccine + INCB024360 + Pembrolizumab'}]","Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer",5170
0,NCT03006302,Phase II,Not yet recruiting,"[{'id': 5169, 'therapyName': 'CRS-207 + INCB024360 + Pembrolizumab'}, {'id': 5170, 'therapyName': 'CRS-207 + Cyclophosphamide + GVAX panc vaccine + INCB024360 + Pembrolizumab'}]","Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer",5169
0,NCT03122548,Phase II,Recruiting,"[{'id': 5716, 'therapyName': 'CRS-207 + Pembrolizumab'}]","Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers",5716
1,NCT03175172,Phase II,Recruiting,"[{'id': 5716, 'therapyName': 'CRS-207 + Pembrolizumab'}]",Evaluation of CRS-207 With Pembrolizumab in Previously Treated MPM,5716
0,NCT01107522,Phase I,"Active, not recruiting","[{'id': 1142, 'therapyName': 'CTO + Temozolomide'}, {'id': 999, 'therapyName': 'Carboxyamidotriazole Orotate'}]",Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar&#174; in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar&#174; and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas,1142
0,NCT02674750,Phase II,Recruiting,"[{'id': 4447, 'therapyName': 'CUDC-907 + Rituximab'}, {'id': 709, 'therapyName': 'CUDC-907'}]",Study to Evaluate the Efficacy and Safety of CUDC-907 With and Without Rituximab in Patients With RR MYC-Altered DLBCL,709
1,NCT01742988,Phase I,Recruiting,"[{'id': 709, 'therapyName': 'CUDC-907'}]","Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Patients With Lymphoma or Multiple Myeloma",709
2,NCT02307240,Phase I,Recruiting,"[{'id': 709, 'therapyName': 'CUDC-907'}]","Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors",709
3,NCT03002623,Phase II,Recruiting,"[{'id': 709, 'therapyName': 'CUDC-907'}]",CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer,709
4,NCT02909777,Phase I,Recruiting,"[{'id': 709, 'therapyName': 'CUDC-907'}]","Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma",709
0,NCT02674750,Phase II,Recruiting,"[{'id': 4447, 'therapyName': 'CUDC-907 + Rituximab'}, {'id': 709, 'therapyName': 'CUDC-907'}]",Study to Evaluate the Efficacy and Safety of CUDC-907 With and Without Rituximab in Patients With RR MYC-Altered DLBCL,4447
0,NCT01630733,Phase III,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 3648, 'therapyName': 'Custirsen + Docetaxel'}]","A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer",3648
0,NCT02840994,Phase Ib/II,Recruiting,"[{'id': 5244, 'therapyName': 'CV301 + Nivolumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Trial of CV301 in Combination With Nivolumab Versus Nivolumab in Subjects With Previously Treated Non-Small Cell Lung Cancer,5244
0,NCT02426723,Phase I,Recruiting,"[{'id': 3081, 'therapyName': 'CWP232291'}, {'id': 4036, 'therapyName': 'Dexamethasone + lenalidomide'}]",Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients,3081
1,NCT01398462,Phase I,Completed,"[{'id': 3081, 'therapyName': 'CWP232291'}]",Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients,3081
0,NCT03013491,Phase II,Recruiting,"[{'id': 5209, 'therapyName': 'CX-072 + Ipilimumab'}, {'id': 5210, 'therapyName': 'CX-072 + Vemurafenib'}, {'id': 5208, 'therapyName': 'CX-072'}]",A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas,5208
0,NCT03013491,Phase II,Recruiting,"[{'id': 5209, 'therapyName': 'CX-072 + Ipilimumab'}, {'id': 5210, 'therapyName': 'CX-072 + Vemurafenib'}, {'id': 5208, 'therapyName': 'CX-072'}]",A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas,5209
0,NCT03013491,Phase II,Recruiting,"[{'id': 5209, 'therapyName': 'CX-072 + Ipilimumab'}, {'id': 5210, 'therapyName': 'CX-072 + Vemurafenib'}, {'id': 5208, 'therapyName': 'CX-072'}]",A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas,5210
0,NCT03149549,Phase Ib/II,Recruiting,"[{'id': 5709, 'therapyName': 'CX-2009'}]",PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors,5709
0,NCT01707004,Phase I,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1206, 'therapyName': 'Busulfan'}]",Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,1148
1,NCT02512926,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children,1148
2,NCT03117751,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,1148
3,NCT00857389,Phase II,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies,1148
4,NCT01218867,Phase Ib/II,Completed,"[{'id': 984, 'therapyName': 'Anti-VEGFR2 CAR CD8 lymphocytes'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes,1148
5,NCT01966289,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1949, 'therapyName': 'SGI-110'}, {'id': 2977, 'therapyName': 'GVAX colorectal cancer vaccine'}]",SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC),1148
6,NCT03190941,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 6061, 'therapyName': 'anti-KRAS G12V mTCR cells'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*1101 Patients,1148
7,NCT02159495,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,1148
8,NCT02621021,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab,1148
9,NCT01253460,Phase II,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 3215, 'therapyName': 'Rituximab + sapacitabine'}]","Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)",1148
10,NCT01319981,Phase II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia,1148
11,NCT01993719,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Immunotherapy Using Tumor Infiltrating Lymphocytes Comparing 2 Different Conditioning Regimens for Patients With Metastatic Melanoma,1148
12,NCT02181478,Phase I,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Intra-Osseous Co-Transplant of UCB and hMSC,1148
13,NCT03126916,Phase III,Not yet recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 5595, 'therapyName': 'Isotretinoin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 2286, 'therapyName': 'Dinutuximab  '}]",Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma,1148
14,NCT00074490,Phase II,Completed,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,1148
15,NCT01351909,Phase Ib/II,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 954, 'therapyName': 'Veliparib'}]",Cyclophosphamide With or Without Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer,1148
16,NCT03136146,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1090, 'therapyName': 'Ofatumumab'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]","Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)",1148
17,NCT02118311,Phase II,Withdrawn,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",T Regulatory Cell for Suppression of Acute Graft-vs-Host-Disease After a Non-Myeloablative Umbilical Cord Blood Transplantation,1148
18,NCT01746849,Phase II,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 2373, 'therapyName': 'Palifermin'}]",Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation,1148
19,NCT03004287,Phase II,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy,1148
20,NCT00305682,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant,1148
21,NCT00971737,Phase II,Unknown status,"[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer,1148
22,NCT02118285,Phase I,Completed,"[{'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 2575, 'therapyName': 'Epacadostat'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}]","Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer",1148
23,NCT01338987,Phase II,"Active, not recruiting","[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Pilot Study of Lupron to Improve Immune Function After Allogeneic Bone Marrow Transplantation,1148
24,NCT03247088,Phase Ib/II,Recruiting,"[{'id': 6122, 'therapyName': 'Busulfan + Sorafenib + Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Study Of Sorafenib Added To Busulfan And Fludarabine Conditioning Regimen In Patients With Relapsed/Refractory AML Undergoing Stem Cell Transplantation,1148
25,NCT03215810,,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer,1148
26,NCT03007147,Phase III,Recruiting,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 5167, 'therapyName': 'Methylprednisolone'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 5168, 'therapyName': 'Prednisolone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,1148
27,NCT03147612,Phase II,Not yet recruiting,"[{'id': 5682, 'therapyName': 'Mesna'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Study of the Combination of Low-Intensity Chemotherapy and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),1148
28,NCT03023046,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}]","Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",1148
29,NCT00084695,Phase II,Unknown status,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases,1148
30,NCT02251821,Phase II,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 2006, 'therapyName': 'Pacritinib'}, {'id': 823, 'therapyName': 'Momelotinib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis,1148
31,NCT02446431,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1076, 'therapyName': 'Valproic acid'}]",Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence,1148
32,NCT02027935,Phase II,Recruiting,"[{'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4,1148
33,NCT00828009,Phase II,Unknown status,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 2142, 'therapyName': 'Emepepimut-S  '}, {'id': 1092, 'therapyName': 'Carboplatin'}]",BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery,1148
34,NCT01614197,Phase I,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma,1148
35,NCT02790515,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation,1148
36,NCT02234921,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Pilot Study of DRibble Vaccine for Prostate Cancer Patients,1148
37,NCT02004262,Phase II,Completed,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2383, 'therapyName': 'Capecitabine + Fluorouracil + Gemcitabine '}]",Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting,1148
38,NCT02210104,Phase I,Withdrawn,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Adoptive Therapy Using Antigen-Specific CD4 T-Cells,1148
39,NCT02472392,Phase I,Completed,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}]",Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma,1148
40,NCT01312376,Phase I,"Active, not recruiting","[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1227, 'therapyName': 'CD3/CD28 costimulated vaccine-primed autologous T-cells'}, {'id': 1222, 'therapyName': 'OC-DC vaccine'}]",Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer,1148
41,NCT02043587,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia &amp; Lymphoblastic Lymphoma,1148
42,NCT03020030,Phase III,Recruiting,"[{'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents,1148
43,NCT03197935,Phase III,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer (IMpassion031),1148
44,NCT02432274,Phase Ib/II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 792, 'therapyName': 'Lenvatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies,1148
45,NCT02793544,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide,1148
46,NCT01661400,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors,1148
47,NCT01822652,Phase I,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]","3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN",1148
48,NCT00902044,Phase I,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2940, 'therapyName': 'HER2 sensitized T-cells'}]",Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma,1148
49,NCT03136406,Phase Ib/II,Recruiting,"[{'id': 1018, 'therapyName': 'GI-4000'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 6163, 'therapyName': 'ETBX-011'}, {'id': 3060, 'therapyName': 'ALT-803'}]",QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy,1148
50,NCT02243371,Phase II,"Active, not recruiting","[{'id': 2642, 'therapyName': 'GVAX pancreatic cancer vaccine  '}, {'id': 2641, 'therapyName': 'CRS-207'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab,1148
51,NCT02792114,Phase I,Recruiting,"[{'id': 5992, 'therapyName': 'Rimiducid'}, {'id': 6029, 'therapyName': 'Mesothelin CAR-T cells'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",T-Cell Therapy for Advanced Breast Cancer,1148
52,NCT02112916,Phase III,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,1148
53,NCT02561832,Phase I,Completed,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","A Study to Assess the Safety, Tolerability and Efficacy of Olaparib in Combination With Carboplatin in Patients With HER-2 Negative Breast Cancer",1148
54,NCT01963481,Phase II,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 738, 'therapyName': 'Exemestane'}]",Exemestane and Cyclophosphamide for Metastatic Breast Cancer,1148
55,NCT02443077,Phase III,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 3359, 'therapyName': 'Carmustine + Cytarabine + Etoposide + Melphalan'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma,1148
56,NCT02553460,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I,1148
57,NCT01903330,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1873, 'therapyName': 'Sargramostim'}]",ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme,1148
58,NCT02419495,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Selinexor in Combination With Standard Chemotherapy,1148
59,NCT02425306,Phase Ib/II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2620, 'therapyName': '6MHP vaccine'}, {'id': 2595, 'therapyName': 'poly ICLC  '}]",Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma,1148
60,NCT02538926,Phase II,Not yet recruiting,"[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 3212, 'therapyName': 'Doxorubicin + Etoposide + Vincristine '}, {'id': 2206, 'therapyName': 'Asparaginase'}]","Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",1148
0,NCT01581970,Phase II,Completed,"[{'id': 1997, 'therapyName': 'Cyclophosphamide + Cetuximab'}]",Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head &amp; Neck Cancer,1997
0,NCT01878617,Phase II,Recruiting,"[{'id': 956, 'therapyName': 'Vismodegib'}, {'id': 1800, 'therapyName': 'Cyclophosphamide + Cisplatin + Vincristine '}, {'id': 1801, 'therapyName': 'Pemetrexed + Gemcitabine'}]",A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma,1800
0,NCT03150693,Phase III,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 3628, 'therapyName': 'Allopurinol'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]",Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia,1783
1,NCT01621477,Phase II,Terminated,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}]",T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant,1783
2,NCT01356290,Phase II,Recruiting,"[{'id': 1475, 'therapyName': 'Thalidomide'}, {'id': 4418, 'therapyName': 'Fenofibrate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2124, 'therapyName': 'Celecoxib'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}]",Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma (MEMMAT),1783
0,NCT02389309,Phase I,Recruiting,"[{'id': 2697, 'therapyName': 'Cyclophosphamide + Dasatinib + Temsirolimus'}]","A Trial of Dasatinib (PDGFR and SRC Inhibitor), Temsirolimus and Cyclophosphamide in Patients With Advanced Solid Tumors",2697
0,NCT02420717,Phase II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 2046, 'therapyName': 'Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine '}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 3194, 'therapyName': 'Mercaptopurine + Methotrexate + Prednisone + Vincristine'}]",Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL),2046
1,NCT01424982,Phase II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 2048, 'therapyName': 'Cytarabine + Methotrexate + Ponatinib'}, {'id': 2049, 'therapyName': 'Ponatinib + Vincristine'}, {'id': 2046, 'therapyName': 'Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine '}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),2046
0,NCT02636322,Phase II,Recruiting,"[{'id': 2482, 'therapyName': 'Cyclophosphamide + Doxorubicin + Etoposide + Vincristine '}, {'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}, {'id': 2188, 'therapyName': 'Prednisone'}]","A Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Dose Adjusted Chemotherapy For Patients With High Risk Diffuse Large B-Cell Lymphoma",2482
1,NCT02337985,Phase I,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 2482, 'therapyName': 'Cyclophosphamide + Doxorubicin + Etoposide + Vincristine '}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma,2482
0,NCT03285607,Phase I,Not yet recruiting,"[{'id': 6236, 'therapyName': 'Cyclophosphamide + Doxorubicin + Paclitaxel + MCS110'}]","MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer",6236
0,NCT02876302,Phase II,Recruiting,"[{'id': 4679, 'therapyName': 'Cyclophosphamide + Doxorubicin + Paclitaxel + Ruxolitinib'}]",Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer,4679
0,NCT01992653,Phase I,"Active, not recruiting","[{'id': 4248, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 4226, 'therapyName': 'Polatuzumab Vedotin'}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]","A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma",4248
0,NCT02531308,Phase II,Terminated,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}]",Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL),3266
1,NCT01855750,Phase III,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}]","A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma",3266
2,NCT01974440,Phase III,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}]","A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma",3266
3,NCT02596971,Phase I,Recruiting,"[{'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 1231, 'therapyName': 'Bendamustine'}]",Safety and Efficacy of MPDL3280A in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus CHOP in Patients With Follicular Lymphoma or Diffuse Large B-Cell Lymphoma,3266
4,NCT02055820,Phase I,"Active, not recruiting","[{'id': 1562, 'therapyName': 'Venetoclax'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]",A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma,3266
5,NCT02541565,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 897, 'therapyName': 'Rituximab'}]",Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma,3266
0,NCT02427620,Phase II,Recruiting,"[{'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 1642, 'therapyName': 'Leucovorin'}]",A Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma,2353
1,NCT01175356,Phase I,Completed,"[{'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}]","Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin",2353
2,NCT02073097,Phase Ib/II,Recruiting,"[{'id': 2351, 'therapyName': 'Carfilzomib + Rituximab'}, {'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}]","Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma",2353
0,NCT02323230,Phase II,"Active, not recruiting","[{'id': 4280, 'therapyName': 'Cyclophosphamide + DPX-Survivac'}]",A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL,4280
0,NCT02785250,Phase I,Recruiting,"[{'id': 4238, 'therapyName': 'Cyclophosphamide + DPX-Survivac + INCB024360 '}]",Study of DPX-Survivac Vaccine Therapy and Epacadostat in Patients With Recurrent Ovarian Cancer,4238
0,NCT02518750,Phase II,Recruiting,"[{'id': 1604, 'therapyName': 'Panobinostat + Bortezomib + Dexamethasone'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3217, 'therapyName': 'Cyclophosphamide + Etoposide'}, {'id': 3216, 'therapyName': 'Cytarabine + Methotrexate + Prednisone'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma,3217
0,NCT00602667,Phase I,"Active, not recruiting","[{'id': 2449, 'therapyName': 'Methotrexate + Cisplatin + Cyclophosphamide + Vincristine'}, {'id': 2450, 'therapyName': 'Cyclophosphamide + Etoposide + Topotecan'}, {'id': 2451, 'therapyName': 'Erlotinib + Cyclophosphamide + Topotecan'}]","Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma",2450
0,NCT00338377,Phase II,Recruiting,"[{'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization,2291
1,NCT01701674,Phase I,"Active, not recruiting","[{'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts,2291
2,NCT00003553,Phase II,Unknown status,"[{'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer,2291
3,NCT02153580,Phase I,"Active, not recruiting","[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1231, 'therapyName': 'Bendamustine'}]","Cellular Immunotherapy Following Cyclophosphamide in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia",2291
4,NCT01256398,Phase II,"Active, not recruiting","[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1824, 'therapyName': 'Vincristine + Methotrexate + Mercaptopurine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,2291
5,NCT00167180,Phase II,Completed,"[{'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}]",Post Transplant Donor Lymphocyte Infusion,2291
6,NCT01174121,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer,2291
7,NCT02356159,Phase Ib/II,Recruiting,"[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 2292, 'therapyName': 'Doxorubicin + Etoposide + Fludarabine + Vincristine '}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation,2291
0,NCT01804634,Phase II,Recruiting,"[{'id': 1373, 'therapyName': 'Cyclophosphamide + Fludarabine + Melphalan + Sirolimus'}]",A Phase II Trial of Reduced Intensity Conditioning and Haploidentical BMT for High-risk Solid Tumors,1373
0,NCT02556931,Phase II,Recruiting,"[{'id': 4228, 'therapyName': 'Cyclophosphamide + Fludarabine + Melphalan + Tacrolimus'}]","Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies",4228
0,NCT02722668,Phase II,Recruiting,"[{'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}]",UCB Transplant for Hematological DIseases Using a Non Myeloablative Prep,2281
1,NCT02423915,Phase Ib/II,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}, {'id': 917, 'therapyName': 'Sirolimus'}]",Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention,2281
2,NCT01203722,Phase Ib/II,Recruiting,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}]","Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies",2281
0,NCT02629809,Phase II,Recruiting,"[{'id': 3628, 'therapyName': 'Allopurinol'}, {'id': 3627, 'therapyName': 'Cyclophosphamide + Fludarabine + Obinutuzumab'}, {'id': 768, 'therapyName': 'Ibrutinib'}]","First-line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL)",3627
0,NCT02158091,Phase Ib/II,"Active, not recruiting","[{'id': 2339, 'therapyName': 'Cyclophosphamide + Fludarabine + Rituximab '}, {'id': 1024, 'therapyName': 'Duvelisib'}]","A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL",2339
0,NCT03056339,Phase Ib/II,Recruiting,"[{'id': 6217, 'therapyName': 'Cyclophosphamide + Fludarabine phosphate + iC9/CAR.19/IL15-Transduced CB-NK'}]",Umbilical & Cord Blood (CB)- Derived CAR-Engineered NK Cells for B Lymphoid Malignancies,6217
0,NCT02379520,Phase I,Recruiting,"[{'id': 5328, 'therapyName': 'Cyclophosphamide + Fludarabine phosphate + Nivolumab'}]","HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA (HESTIA)",5328
0,NCT02132949,Phase II,"Active, not recruiting","[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1895, 'therapyName': 'Cyclophosphamide + Fluorouracil + Docetaxel + Epirubicin  '}]","A Study Evaluating Perjeta (Pertuzumab) Combined With Herceptin (Trastuzumab) and Standard Anthracycline-based Chemotherapy in Patients With HER2-positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer.",1895
0,NCT02981524,Phase II,Recruiting,"[{'id': 5079, 'therapyName': 'Cyclophosphamide + GVAX colorectal cancer vaccine + Pembrolizumab'}]",Phase 2 Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer,5079
0,NCT02451982,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 3622, 'therapyName': 'Cyclophosphamide + GVAX pancreatic cancer vaccine '}]",Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab Trial for Surgically Resectable Pancreatic Cancer,3622
0,NCT03153410,Phase I,Not yet recruiting,"[{'id': 5778, 'therapyName': 'Cyclophosphamide + GVAX pancreatic cancer vaccine + LY3022855 + Pembrolizumab'}]","Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas",5778
0,NCT02648282,Phase II,Recruiting,"[{'id': 4473, 'therapyName': 'Cyclophosphamide + GVAX pancreatic cancer vaccine + Pembrolizumab'}]","Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer",4473
0,NCT02706405,Phase I,Recruiting,"[{'id': 4365, 'therapyName': 'Cyclophosphamide + JCAR014 + MEDI4736'}]",JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma,4365
0,NCT01955434,Phase II,Recruiting,"[{'id': 4019, 'therapyName': 'Cyclophosphamide + LCL161'}]",SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma,4019
0,NCT02017964,Phase II,Completed,"[{'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}, {'id': 2673, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine  '}]","Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-Metastatic Desmoplastic Medulloblastoma",2673
0,NCT00550992,Phase I,Unknown status,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia,1848
1,NCT02723994,Phase II,Recruiting,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 2346, 'therapyName': 'Mercaptopurine + Thioguanine'}, {'id': 2394, 'therapyName': 'Asparaginase + Cytarabine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}]",A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia,1848
0,NCT03003676,Phase I,Recruiting,"[{'id': 5173, 'therapyName': 'Cyclophosphamide + ONCOS-102 + Pembrolizumab'}]","A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade",5173
0,NCT01106898,Phase II,Unknown status,"[{'id': 1980, 'therapyName': 'Cyclophosphamide + Paclitaxel'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Treating Women With Stage I or Stage II Breast Cancer Who Have Undergone Surgery,1980
1,NCT01750073,Phase II,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1980, 'therapyName': 'Cyclophosphamide + Paclitaxel'}]",Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Stage I-III Breast Cancer,1980
0,NCT02654119,Phase II,Recruiting,"[{'id': 1898, 'therapyName': 'Cyclophosphamide + Paclitaxel + Trastuzumab '}]","Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Patients With Stage I-II HER2/Neu Positive Breast Cancer After Surgery",1898
0,NCT02948101,Phase II,Not yet recruiting,"[{'id': 5848, 'therapyName': 'Cyclophosphamide + PD 0360324'}]",Pre-Conditioning Effects of Anti-Macrophage Therapy Using PD 0360324 in Recurrent Platinum-Resistant Epithelial Ovarian Cancer,5848
0,NCT02650635,Phase I,"Active, not recruiting","[{'id': 3413, 'therapyName': 'Cyclophosphamide + Pegfilgrastim + VTX-2337'}]","TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors",3413
0,NCT02768701,Phase II,Recruiting,"[{'id': 4891, 'therapyName': 'Cyclophosphamide + Pembrolizumab'}]",Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer,4891
1,NCT03092453,Phase I,Recruiting,"[{'id': 4891, 'therapyName': 'Cyclophosphamide + Pembrolizumab'}]",Dendritic Cell Vaccination in Patients With Advanced Melamona,4891
0,NCT00923845,Phase II,Completed,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2308, 'therapyName': 'Cyclophosphamide + Pentostatin'}]",Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer,2308
0,NCT02873819,Phase II,Recruiting,"[{'id': 4614, 'therapyName': 'MAGE-A3 vaccine'}, {'id': 4615, 'therapyName': 'Cyclophosphamide + poly ICLC  + Sargramostim'}]",Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity,4615
0,NCT02343536,Phase I,Recruiting,"[{'id': 2488, 'therapyName': 'Cyclophosphamide + Prednisone + Rituximab + Vincristine'}, {'id': 651, 'therapyName': 'Azacitidine'}]","A Phase 1, Open-label,Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma",2488
0,NCT01925131,Phase I,Recruiting,"[{'id': 3221, 'therapyName': 'Cyclophosphamide + Prednisone + Vincristine'}, {'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]","S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia",3221
0,NCT02298348,Phase I,Recruiting,"[{'id': 2360, 'therapyName': 'Cyclophosphamide + Sorafenib + Topotecan'}]",Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma,2360
0,NCT02030964,Phase I,"Active, not recruiting","[{'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}, {'id': 2124, 'therapyName': 'Celecoxib'}]",N2012-01 Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan,2590
1,NCT01175356,Phase I,Completed,"[{'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}]","Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin",2590
2,NCT01606878,Phase I,Recruiting,"[{'id': 2952, 'therapyName': 'Dexamethasone + Doxorubicin + Vincristine'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}, {'id': 706, 'therapyName': 'Crizotinib'}]",Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma,2590
3,NCT01857934,Phase II,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 2627, 'therapyName': 'Levetiracetam'}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 2458, 'therapyName': 'Hu14.18K322A'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}]",Therapy for Children With Advanced Stage Neuroblastoma,2590
0,NCT01492673,Phase II,"Active, not recruiting","[{'id': 1479, 'therapyName': 'Cyclophosphamide + Topotecan + Bevacizumab'}]","Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma",1479
0,NCT00003553,Phase II,Unknown status,"[{'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer,1650
1,NCT02756572,Phase I,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5215, 'therapyName': 'mitoxantrone hydrochloride'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myelodysplastic Syndrome or Acute Myeloid Leukemia,1650
2,NCT00550992,Phase I,Unknown status,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia,1650
3,NCT00513474,Phase I,Completed,"[{'id': 2313, 'therapyName': 'Rasburicase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2314, 'therapyName': 'Busulfan + Cyclophosphamide + Etoposide'}]",Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant,1650
4,NCT02188264,Phase I,"Active, not recruiting","[{'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 913, 'therapyName': 'Selumetinib'}]",Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer,1650
5,NCT00074490,Phase II,Completed,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,1650
0,NCT03128034,Phase Ib/II,Recruiting,"[{'id': 5714, 'therapyName': 'Cyclosporine + Fludarabine phosphate + Mycophenolate mofetil + Sirolimus'}]","211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome",5714
0,NCT01252667,Phase II,Recruiting,"[{'id': 2272, 'therapyName': 'Cyclosporine + Mycophenolate mofetil'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant,2272
1,NCT01231412,Phase III,"Active, not recruiting","[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2272, 'therapyName': 'Cyclosporine + Mycophenolate mofetil'}]",Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant,2272
0,NCT01251575,Phase II,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2270, 'therapyName': 'Cyclosporine + Mycophenolate mofetil + Sirolimus'}]","Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant",2270
0,NCT02653196,Phase II,Terminated,"[{'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 3948, 'therapyName': 'Cyclosporine + Mycophenolate mofetil + Tacrolimus'}]",A Multi-Institutional Phase II Feasibility Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors,3948
0,NCT02349139,Phase Ib/II,"Active, not recruiting","[{'id': 2528, 'therapyName': 'CYP17 lyase inhibitor ASN001'}]","Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer",2528
0,NCT02412475,Phase I,"Active, not recruiting","[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 650, 'therapyName': 'Decitabine'}]",Epigenetic Reprogramming in Relapse AML,712
1,NCT01515527,Phase II,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 650, 'therapyName': 'Decitabine'}]",Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS),712
2,NCT02088541,Phase II,"Active, not recruiting","[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}]",Selinexor (KPT-330) in Older Patients With Relapsed AML,712
3,NCT02573363,Phase I,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia,712
4,NCT02203526,Phase I,Suspended,"[{'id': 1607, 'therapyName': 'Temozolomide + Etoposide + Doxil + Dexamethasone + Ibrutinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 897, 'therapyName': 'Rituximab'}]","Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma",712
5,NCT02920008,Phase III,Recruiting,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1949, 'therapyName': 'SGI-110'}]","Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia",712
6,NCT02043587,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia &amp; Lymphoblastic Lymphoma,712
7,NCT02348489,Phase III,"Active, not recruiting","[{'id': 1949, 'therapyName': 'SGI-110'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 650, 'therapyName': 'Decitabine'}]","SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction",712
8,NCT01794702,Phase Ib/II,"Active, not recruiting","[{'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 650, 'therapyName': 'Decitabine'}]","Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia",712
9,NCT03214562,,Recruiting,"[{'id': 1562, 'therapyName': 'Venetoclax'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive Acute Myeloid Leukemia (AML) Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML),712
10,NCT02421939,Phase III,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 3193, 'therapyName': 'Cytarabine + Fludarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2865, 'therapyName': 'Gilteritinib'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,712
11,NCT02488408,Phase I,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 2660, 'therapyName': 'BGB-324'}]",Multicenter Open-label Study of BGB324 as a Single Agent and in Combination With Cytarabine in Patients With AML,712
12,NCT03020030,Phase III,Recruiting,"[{'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents,712
13,NCT01870596,Phase II,Completed,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 2027, 'therapyName': 'MK-8776'}]",Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia,712
14,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,712
15,NCT03263936,Phase I,Recruiting,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Epigenetic Reprogramming in Relapse/Refractory AML,712
16,NCT02532192,Phase I,Withdrawn,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1689, 'therapyName': 'Fluconazole'}, {'id': 1078, 'therapyName': 'Belinostat'}]","A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma",712
17,NCT03164057,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia,712
18,NCT02351037,Phase II,Terminated,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 712, 'therapyName': 'Cytarabine'}]",A Multicenter Open-Label Phase 2a Study of Ibrutinib With or Without Cytarabine in Subjects With Acute Myeloid Leukemia,712
19,NCT02756962,Phase II,Recruiting,"[{'id': 810, 'therapyName': 'Midostaurin'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance,712
20,NCT03147612,Phase II,Not yet recruiting,"[{'id': 5682, 'therapyName': 'Mesna'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Study of the Combination of Low-Intensity Chemotherapy and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),712
21,NCT02419755,Phase II,Terminated,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies,712
22,NCT00549848,Phase III,"Active, not recruiting","[{'id': 1781, 'therapyName': 'Vincristine + Pegaspargase + Daunorubicin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1782, 'therapyName': 'Clofarabine + Etoposide + Cyclophosphamide'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia,712
23,NCT01892371,Phase Ib/II,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 882, 'therapyName': 'Quizartinib'}]",AC220 With 5-Aza or Low Dose Cytarabine,712
24,NCT03194932,Phase I,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}]",Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia,712
25,NCT02883049,Phase III,Suspended,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations,712
26,NCT01546038,Phase Ib/II,"Active, not recruiting","[{'id': 1748, 'therapyName': 'PF-04449913'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}]",A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,712
27,NCT02212561,Phase Ib/II,Completed,"[{'id': 1749, 'therapyName': 'Selinexor'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 2345, 'therapyName': 'Cytarabine + Dexamethasone+ Methotrexate '}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome,712
28,NCT03007147,Phase III,Recruiting,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 5167, 'therapyName': 'Methylprednisolone'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 5168, 'therapyName': 'Prednisolone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,712
29,NCT03069352,Phase III,Recruiting,"[{'id': 3182, 'therapyName': 'Cytarabine + GDC-0199'}, {'id': 712, 'therapyName': 'Cytarabine'}]",A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naïve Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy,712
30,NCT02535806,Phase II,Terminated,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults,712
31,NCT02907359,Phase III,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1949, 'therapyName': 'SGI-110'}]",Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs,712
32,NCT02666950,Phase II,Recruiting,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 712, 'therapyName': 'Cytarabine'}]",WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome,712
33,NCT02545283,Phase III,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 4395, 'therapyName': 'Cytarabine + Idasanutlin'}]",A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Patients With Relapsed or Refractory Acute Myeloid Leukemia,712
34,NCT02112916,Phase III,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,712
35,NCT01321346,Phase I,Completed,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1080, 'therapyName': 'Panobinostat'}]",A Study Of Panobinostat In Children With Refractory Hematologic Malignancies,712
36,NCT02756572,Phase I,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5215, 'therapyName': 'mitoxantrone hydrochloride'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myelodysplastic Syndrome or Acute Myeloid Leukemia,712
37,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,712
38,NCT01614197,Phase I,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma,712
39,NCT02577406,Phase III,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 2982, 'therapyName': 'Enasidenib'}]",An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation (IDHENTIFY),712
40,NCT01187810,Phase I,"Active, not recruiting","[{'id': 2731, 'therapyName': 'Fenretinide'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1639, 'therapyName': 'Methotrexate'}]","Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL",712
41,NCT02521493,Phase III,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 5912, 'therapyName': 'Asparaginase Erwinia chrysanthemi'}, {'id': 5215, 'therapyName': 'mitoxantrone hydrochloride'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2206, 'therapyName': 'Asparaginase'}]",Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome,712
42,NCT02553460,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I,712
43,NCT02560025,Phase II,"Active, not recruiting","[{'id': 626, 'therapyName': 'Alisertib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML,712
44,NCT03117751,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,712
0,NCT02680951,Phase I,Recruiting,"[{'id': 3731, 'therapyName': 'Cytarabine + Dasatinib + Fludarabine  + Idarubicin'}]",Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia,3731
0,NCT01371981,Phase III,"Active, not recruiting","[{'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2392, 'therapyName': 'Cytarabine + Etoposide'}, {'id': 2393, 'therapyName': 'Cytarabine + Mitoxantrone'}, {'id': 2394, 'therapyName': 'Asparaginase + Cytarabine'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,2391
1,NCT01256398,Phase II,"Active, not recruiting","[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1824, 'therapyName': 'Vincristine + Methotrexate + Mercaptopurine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,2391
0,NCT02632708,Phase I,Recruiting,"[{'id': 1491, 'therapyName': 'AG-120'}, {'id': 2982, 'therapyName': 'Enasidenib'}, {'id': 3431, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide + Mitoxantrone'}]",Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation,3431
0,NCT02668653,Phase III,Recruiting,"[{'id': 3543, 'therapyName': 'Cytarabine + Daunorubicin + Idarubicin'}, {'id': 882, 'therapyName': 'Quizartinib'}]",Quizartinib With Standard of Care Chemotherapy and as Maintenance Therapy in Patients With Newly Diagnosed FLT3-ITD (+) AML,3543
0,NCT02323607,Phase I,Suspended,"[{'id': 3219, 'therapyName': 'Cytarabine + Daunorubicin + Pacritinib'}, {'id': 3177, 'therapyName': 'Pacritinib + Decitabine'}]",Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations,3219
0,NCT01463046,Phase I,"Active, not recruiting","[{'id': 3185, 'therapyName': 'Cytarabine + Daunorubicin + Panobinostat'}]",Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome,3185
0,NCT02954653,Phase I,Recruiting,"[{'id': 6087, 'therapyName': 'PF-06747143'}, {'id': 6092, 'therapyName': 'Cytarabine + Daunorubicin + PF-06747143'}, {'id': 6093, 'therapyName': 'Azacitidine + Decitabine + PF-06747143'}]","A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia",6092
0,NCT03013998,Phase Ib/II,Recruiting,"[{'id': 4003, 'therapyName': 'Azacitidine + Enasidenib'}, {'id': 5539, 'therapyName': 'Azacitidine + Entospletinib'}, {'id': 5536, 'therapyName': 'Cytarabine + Daunorubicin + Samalizumab'}, {'id': 5538, 'therapyName': 'Azacitidine + BI 836858'}]",Study of Biomarker-Based Treatment of Acute Myeloid Leukemia,5536
0,NCT02339740,Phase III,Recruiting,"[{'id': 3686, 'therapyName': 'Cytarabine + Dexamethasone + Idarubicin + Mitoxantrone'}, {'id': 3685, 'therapyName': 'Arsenic trioxide + Gemtuzumab ozogamicin + Tretinoin'}]",Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia,3686
0,NCT02212561,Phase Ib/II,Completed,"[{'id': 1749, 'therapyName': 'Selinexor'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 2345, 'therapyName': 'Cytarabine + Dexamethasone+ Methotrexate '}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome,2345
1,NCT02101853,Phase III,Recruiting,"[{'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 2347, 'therapyName': 'Leucovorin + Pegaspargase  + Vincristine'}, {'id': 2346, 'therapyName': 'Mercaptopurine + Thioguanine'}, {'id': 2348, 'therapyName': 'Asparaginase + Cyclophosphamide + Etoposide'}, {'id': 2345, 'therapyName': 'Cytarabine + Dexamethasone+ Methotrexate '}]",Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia,2345
0,NCT01371981,Phase III,"Active, not recruiting","[{'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2392, 'therapyName': 'Cytarabine + Etoposide'}, {'id': 2393, 'therapyName': 'Cytarabine + Mitoxantrone'}, {'id': 2394, 'therapyName': 'Asparaginase + Cytarabine'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,2392
1,NCT02342782,Phase I,Recruiting,"[{'id': 2485, 'therapyName': '90Y basiliximab'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 2392, 'therapyName': 'Cytarabine + Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}]",Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma,2392
0,NCT02109627,Phase I,Recruiting,"[{'id': 3183, 'therapyName': 'Cytarabine + Ficlatuzumab'}]",Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML,3183
0,NCT02791919,Phase I,Withdrawn,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 4271, 'therapyName': 'Cytarabine + Filgrastim + Fludarabine'}]","Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia",4271
0,NCT02356159,Phase Ib/II,Recruiting,"[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 2292, 'therapyName': 'Doxorubicin + Etoposide + Fludarabine + Vincristine '}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation,2294
1,NCT00520130,Phase Ib/II,"Active, not recruiting","[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2305, 'therapyName': 'Alemtuzumab + Cyclosporine'}, {'id': 2306, 'therapyName': 'Rituximab + Fludarabine + EPOCH'}, {'id': 2307, 'therapyName': 'Fludarabine + EPOCH'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,2294
0,NCT02421939,Phase III,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 3193, 'therapyName': 'Cytarabine + Fludarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2865, 'therapyName': 'Gilteritinib'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,3193
1,NCT02039726,Phase III,"Active, not recruiting","[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 3193, 'therapyName': 'Cytarabine + Fludarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 882, 'therapyName': 'Quizartinib'}]",An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects,3193
0,NCT02676323,Phase Ib/II,Recruiting,"[{'id': 3732, 'therapyName': 'Cytarabine + Fludarabine + Leucovorin + Panobinostat'}]",Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome,3732
0,NCT02649764,Phase I,Recruiting,"[{'id': 3535, 'therapyName': 'Cytarabine + Fludarabine + Prexasertib'}]",LY2606368 in Combination With Cytarabine and Fludarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS),3535
0,NCT02287233,Phase I,"Active, not recruiting","[{'id': 3182, 'therapyName': 'Cytarabine + GDC-0199'}]",A Study Evaluating ABT-199 in Combination With Low-Dose Cytarabine in Treatment-Naïve Subjects With Acute Myelogenous Leukemia (AML),3182
1,NCT03069352,Phase III,Recruiting,"[{'id': 3182, 'therapyName': 'Cytarabine + GDC-0199'}, {'id': 712, 'therapyName': 'Cytarabine'}]",A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naïve Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy,3182
0,NCT01812252,Phase II,Recruiting,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 1798, 'therapyName': 'Decitabine + Azacitidine'}]",Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant,1606
1,NCT02236013,Phase I,Recruiting,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 2865, 'therapyName': 'Gilteritinib'}]",A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia,1606
2,NCT02835729,Phase Ib/II,Recruiting,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 4499, 'therapyName': 'Cytarabine + Idarubicin + indoximod'}]",A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia,1606
3,NCT02306291,Phase Ib/II,Recruiting,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 4402, 'therapyName': 'GMI-1271'}]","Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML",1606
4,NCT02665143,Phase Ib/II,Recruiting,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 831, 'therapyName': 'Nintedanib'}]",A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia,1606
5,NCT02779283,Phase I,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,1606
6,NCT02046122,Phase I,Recruiting,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}]",Adoptive Transfer of Haplo-identical DLI for AML and MDS,1606
7,NCT02400281,Phase Ib/II,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 705, 'therapyName': 'Crenolanib'}, {'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}]",Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients,1606
0,NCT01876953,Phase Ib/II,"Active, not recruiting","[{'id': 1850, 'therapyName': 'Cytarabine + Idarubicin + Dasatinib'}]","Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia",1850
0,NCT02635074,Phase I,Recruiting,"[{'id': 3573, 'therapyName': 'Cytarabine + Idarubicin + Ibrutinib'}]","Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",3573
0,NCT02835729,Phase Ib/II,Recruiting,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 4499, 'therapyName': 'Cytarabine + Idarubicin + indoximod'}]",A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia,4499
0,NCT02652871,Phase I,Recruiting,"[{'id': 3470, 'therapyName': 'Cytarabine + Idarubicin + LY2510924'}]","A Phase 1b, Open-label Study of LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia",3470
0,NCT02464657,Phase Ib/II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3192, 'therapyName': 'Cytarabine + Idarubicin + Nivolumab'}]",Nivolumab in Acute Myeloid Leukemia (AML),3192
0,NCT01822015,Phase I,"Active, not recruiting","[{'id': 2232, 'therapyName': 'Cytarabine + Idarubicin + Sirolimus'}]","Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",2232
0,NCT02527174,Phase I,Withdrawn,"[{'id': 3213, 'therapyName': 'Cytarabine + Idarubicin + Volasertib'}]",A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia (VIAC),3213
1,NCT02905994,Phase I,Withdrawn,"[{'id': 3213, 'therapyName': 'Cytarabine + Idarubicin + Volasertib'}]",Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia,3213
0,NCT02545283,Phase III,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 4395, 'therapyName': 'Cytarabine + Idasanutlin'}]",A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Patients With Relapsed or Refractory Acute Myeloid Leukemia,4395
0,NCT02420717,Phase II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 2046, 'therapyName': 'Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine '}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 3194, 'therapyName': 'Mercaptopurine + Methotrexate + Prednisone + Vincristine'}]",Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL),3195
1,NCT02427620,Phase II,Recruiting,"[{'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 1642, 'therapyName': 'Leucovorin'}]",A Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma,3195
2,NCT01769209,Phase II,"Active, not recruiting","[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 1830, 'therapyName': 'Vincristine + Dexamethasone + Pegaspargase + Doxorubicin'}]",Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,3195
0,NCT01424982,Phase II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 2048, 'therapyName': 'Cytarabine + Methotrexate + Ponatinib'}, {'id': 2049, 'therapyName': 'Ponatinib + Vincristine'}, {'id': 2046, 'therapyName': 'Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine '}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),2048
0,NCT02518750,Phase II,Recruiting,"[{'id': 1604, 'therapyName': 'Panobinostat + Bortezomib + Dexamethasone'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3217, 'therapyName': 'Cyclophosphamide + Etoposide'}, {'id': 3216, 'therapyName': 'Cytarabine + Methotrexate + Prednisone'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma,3216
0,NCT03207334,Phase II,Not yet recruiting,"[{'id': 6095, 'therapyName': 'Cytarabine + Midostaurin'}]",iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-BMT-AML-001),6095
0,NCT01371981,Phase III,"Active, not recruiting","[{'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2392, 'therapyName': 'Cytarabine + Etoposide'}, {'id': 2393, 'therapyName': 'Cytarabine + Mitoxantrone'}, {'id': 2394, 'therapyName': 'Asparaginase + Cytarabine'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,2393
1,NCT02520011,Phase II,Recruiting,"[{'id': 628, 'therapyName': 'Alvocidib'}, {'id': 2393, 'therapyName': 'Cytarabine + Mitoxantrone'}]",Alvocidib Biomarker-driven Phase 2 AML Study,2393
0,NCT02576301,Phase Ib/II,Recruiting,"[{'id': 3524, 'therapyName': 'OXi4503'}, {'id': 3887, 'therapyName': 'Cytarabine + OXi4503'}]",Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS,3887
0,NCT01606579,Phase Ib/II,Completed,"[{'id': 2466, 'therapyName': 'Cytarabine + Pri-724'}, {'id': 2465, 'therapyName': 'Dasatinib + Pri-724'}, {'id': 1083, 'therapyName': 'Pri-724'}]",Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies,2466
0,NCT02305563,Phase Ib/II,Recruiting,"[{'id': 6259, 'therapyName': 'Cytarabine + Ulocuplumab'}]",An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia,6259
0,NCT01880437,Phase II,Terminated,"[{'id': 1802, 'therapyName': 'Cytarabine + Vismodegib'}]",A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myleodysplastic Syndrome,1802
0,NCT02465060,Phase II,Recruiting,"[{'id': 660, 'therapyName': 'AZD9291'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 958, 'therapyName': 'VS-6063'}, {'id': 765, 'therapyName': 'GSK2636771'}]",NCI-MATCH Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,3
1,NCT01336634,Phase II,"Active, not recruiting","[{'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.,3
2,NCT01940809,Phase II,Recruiting,"[{'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 779, 'therapyName': 'Ipilimumab'}]","Ipilimumab With or Without Dabrafenib, and/or Trametinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery",3
3,NCT01682213,Phase II,"Active, not recruiting","[{'id': 3, 'therapyName': 'Dabrafenib'}]",Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation,3
4,NCT03091257,Phase I,Recruiting,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 2, 'therapyName': 'Trametinib'}]",A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma,3
5,NCT01907802,Phase I,"Active, not recruiting","[{'id': 3, 'therapyName': 'Dabrafenib'}]",Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction,3
6,NCT02367859,Phase I,Recruiting,"[{'id': 3, 'therapyName': 'Dabrafenib'}]",Dabrafenib in Treating Patients With BRAF Mutated Ameloblastoma,3
7,NCT01231594,Phase I,Recruiting,"[{'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 2, 'therapyName': 'Trametinib'}]",A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors,3
8,NCT01738451,Phase I,Completed,"[{'id': 3, 'therapyName': 'Dabrafenib'}]", A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors,3
9,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,3
10,NCT01701037,Phase II,Terminated,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}, {'id': 3, 'therapyName': 'Dabrafenib'}]", Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery,3
11,NCT01534897,Phase I,Completed,"[{'id': 3, 'therapyName': 'Dabrafenib'}]",Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436,3
12,NCT01677741,Phase I,Recruiting,"[{'id': 3, 'therapyName': 'Dabrafenib'}]"," The Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Pediatric Subjects",3
13,NCT01723202,Phase II,"Active, not recruiting","[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}, {'id': 3, 'therapyName': 'Dabrafenib'}]",Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer,3
14,NCT01978236,Phase II,Completed,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}, {'id': 3, 'therapyName': 'Dabrafenib'}]","Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites",3
15,NCT01721603,Phase II,Completed,"[{'id': 3, 'therapyName': 'Dabrafenib'}]", A Phase 2 Prospective Trial of Dabrafenib With Stereotactic Radiosurgery in BRAFV600E Melanoma Brain Metastases,3
0,NCT02915666,Phase I,Recruiting,"[{'id': 4778, 'therapyName': 'Dabrafenib + Digoxin + Trametinib'}]",A Clinical Trial of Patients With Melanoma,4778
0,NCT02027961,Phase Ib/II,"Active, not recruiting","[{'id': 1357, 'therapyName': 'Dabrafenib + Durvalumab + Trametinib'}, {'id': 1358, 'therapyName': 'Durvalumab + Trametinib'}]",Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone,1357
0,NCT01902173,Phase Ib/II,Suspended,"[{'id': 2, 'therapyName': 'Trametinib'}, {'id': 2200, 'therapyName': 'Dabrafenib + GSK2141795'}]","GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer",2200
0,NCT03272464,Phase I,Not yet recruiting,"[{'id': 6176, 'therapyName': 'Dabrafenib + INCB039110 + Trametinib'}]",Phase I Study of INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.,6176
0,NCT02200562,Phase Ib/II,Terminated,"[{'id': 1257, 'therapyName': 'Dabrafenib + Ipilimumab'}]",Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma,1257
1,NCT01767454,Phase I,Completed,"[{'id': 1258, 'therapyName': 'Dabrafenib + Ipilimumab + Trametinib'}, {'id': 1257, 'therapyName': 'Dabrafenib + Ipilimumab'}]",Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma,1257
0,NCT01767454,Phase I,Completed,"[{'id': 1258, 'therapyName': 'Dabrafenib + Ipilimumab + Trametinib'}, {'id': 1257, 'therapyName': 'Dabrafenib + Ipilimumab'}]",Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma,1258
0,NCT01947023,Phase I,Recruiting,"[{'id': 2478, 'therapyName': 'Dabrafenib + Lapatinib'}]",Dabrafenib and Lapatinib Ditosylate in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery,2478
0,NCT02910700,Phase II,Recruiting,"[{'id': 4753, 'therapyName': 'Nivolumab + Trametinib'}, {'id': 4754, 'therapyName': 'Dabrafenib + Nivolumab + Trametinib'}]",Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib in Patients With BRAF or NRAS-mutated Metastatic Melanoma,4754
0,NCT01713972,Phase I,"Active, not recruiting","[{'id': 1233, 'therapyName': 'Dabrafenib + Pazopanib'}]", Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors,1233
0,NCT01954043,Phase I,Completed,"[{'id': 1302, 'therapyName': 'Dabrafenib + Rabeprazole + Rifampin'}]",A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors,1302
0,NCT02082665,Phase I,Completed,"[{'id': 1388, 'therapyName': 'Dabrafenib + Rosuvastatin + Midazolam'}]",Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam,1388
0,NCT02143050,Phase Ib/II,Recruiting,"[{'id': 1443, 'therapyName': 'Dabrafenib + Trametinib + Metformin'}]","Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients",1443
0,NCT02967692,Phase III,Recruiting,"[{'id': 6023, 'therapyName': 'Dabrafenib + Trametinib + PDR001'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]","A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma",6023
0,NCT03026517,Phase I,Recruiting,"[{'id': 5270, 'therapyName': 'Dabrafenib + Trametinib + Phenformin'}]",Clinical Trial of Phenformin in Combination With Dabrafenib and Trametinib for Patients With BRAF-mutated Melanoma,5270
0,NCT01835145,Phase II,"Active, not recruiting","[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye,1154
1,NCT02678572,Phase III,Recruiting,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma,1154
2,NCT02049905,Phase III,Completed,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1440, 'therapyName': 'Aldoxorubicin'}, {'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}]",Phase 3 Study to Treat Patients With Soft Tissue Sarcomas,1154
3,NCT03070392,Phase II,Recruiting,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3847, 'therapyName': 'IMCgp100'}]",Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma,1154
4,NCT03233347,,Not yet recruiting,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 2486, 'therapyName': 'Brentuximab vedotin'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","Doxorubicin Hydrochloride, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma",1154
5,NCT01693068,Phase II,Completed,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 871, 'therapyName': 'Pimasertib'}]",Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma,1154
6,NCT01763164,Phase III,"Active, not recruiting","[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 807, 'therapyName': 'Binimetinib'}]",Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma,1154
7,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1154
8,NCT01132014,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1154, 'therapyName': 'Dacarbazine'}]",Autologous OC-DC Vaccine in Ovarian Cancer,1154
0,NCT03226249,Phase II,Not yet recruiting,"[{'id': 6157, 'therapyName': 'Dacarbazine + Doxorubicin + Pembrolizumab +Vinblastine'}]",PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma,6157
0,NCT03033914,Phase I,Recruiting,"[{'id': 5296, 'therapyName': 'Dacarbazine + Doxorubicin + Vinblastine + Nivolumab'}, {'id': 5295, 'therapyName': 'Bleomycin + Dacarbazine + Doxorubicin + Vinblastine + Nivolumab'}]",A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma,5296
0,NCT01465802,Phase II,Completed,"[{'id': 714, 'therapyName': 'Dacomitinib'}, {'id': 1392, 'therapyName': 'Alclometasone'}, {'id': 1391, 'therapyName': 'Doxycycline'}]",Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO,714
1,NCT02047747,Phase II,Terminated,"[{'id': 714, 'therapyName': 'Dacomitinib'}]",A Phase II Study of Dacomitinib in Progressive Brain Metastases,714
2,NCT01858389,Phase II,Completed,"[{'id': 714, 'therapyName': 'Dacomitinib'}]",A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer,714
3,NCT01737008,Phase I,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 714, 'therapyName': 'Dacomitinib'}]",Study of Dacomitinib With Radiotherapy With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck,714
4,NCT01112527,Phase II,"Active, not recruiting","[{'id': 714, 'therapyName': 'Dacomitinib'}]",PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma,714
0,NCT01535053,Phase III,"Active, not recruiting","[{'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Methotrexate or Dactinomycin in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia,2601
1,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,2601
0,NCT01323517,Phase II,Recruiting,"[{'id': 5900, 'therapyName': 'Dactinomycin + Ipilimumab + Melphalan'}]",Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity,5900
0,NCT01727336,Phase II,"Active, not recruiting","[{'id': 1245, 'therapyName': 'Dalantercept + Axitinib'}, {'id': 649, 'therapyName': 'Axitinib'}]", Study of Dalantercept in Patients With Advanced Renal Cell Carcinoma,1245
0,NCT02024087,Phase Ib/II,"Active, not recruiting","[{'id': 2364, 'therapyName': 'Dalantercept + Sorafenib'}]",Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma,2364
0,NCT02136134,Phase III,"Active, not recruiting","[{'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}]",Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma,1630
1,NCT02195479,Phase III,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 1207, 'therapyName': 'Melphalan'}]",A Study of Combination of Daratumumanb and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma,1630
2,NCT03011034,Phase II,Recruiting,"[{'id': 5809, 'therapyName': 'Talacotuzumab'}, {'id': 1630, 'therapyName': 'Daratumumab'}]",Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment,1630
3,NCT01998971,Phase I,Recruiting,"[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1475, 'therapyName': 'Thalidomide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 3323, 'therapyName': 'Montelukast'}]",A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma,1630
4,NCT03004287,Phase II,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy,1630
5,NCT02874742,Phase II,Recruiting,"[{'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}]","Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma",1630
0,NCT02807454,Phase Ib/II,"Active, not recruiting","[{'id': 4531, 'therapyName': 'Daratumumab + Dexamethasone + MEDI4736 + Pomalidomide'}, {'id': 4530, 'therapyName': 'Daratumumab + MEDI4736'}]",A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma (FUSIONMM-003),4531
0,NCT02807454,Phase Ib/II,"Active, not recruiting","[{'id': 4531, 'therapyName': 'Daratumumab + Dexamethasone + MEDI4736 + Pomalidomide'}, {'id': 4530, 'therapyName': 'Daratumumab + MEDI4736'}]",A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma (FUSIONMM-003),4530
1,NCT03000452,Phase II,"Active, not recruiting","[{'id': 4530, 'therapyName': 'Daratumumab + MEDI4736'}]",A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION-MM-005),4530
0,NCT03098550,Phase Ib/II,Recruiting,"[{'id': 5520, 'therapyName': 'Daratumumab + Nivolumab '}]",A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Advanced Solid Tumors or Tumors That Have Spread,5520
0,NCT03221634,Phase II,Not yet recruiting,"[{'id': 6115, 'therapyName': 'Daratumumab + Pembrolizumab'}]",Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668),6115
0,NCT03068351,Phase I,Recruiting,"[{'id': 937, 'therapyName': 'TEN-010'}, {'id': 5957, 'therapyName': 'Daratumumab + TEN-010'}]",Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma,5957
0,NCT01685125,Phase II,"Active, not recruiting","[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,717
1,NCT02779283,Phase I,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,717
2,NCT00700882,Phase II,Unknown status,"[{'id': 717, 'therapyName': 'Dasatinib'}]","Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery",717
3,NCT01471106,Phase II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}]",Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer,717
4,NCT01514864,Phase II,Terminated,"[{'id': 717, 'therapyName': 'Dasatinib'}]",Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation,717
5,NCT02268370,Phase II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}]",Treatment-free Remission Accomplished With Dasatinib in Patients With CML (TRAD),717
6,NCT02428855,Phase II,"Active, not recruiting","[{'id': 717, 'therapyName': 'Dasatinib'}]",Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma,717
7,NCT02709083,Phase II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 770, 'therapyName': 'Imatinib'}]","Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia",717
8,NCT01876212,Phase II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}]",Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma,717
9,NCT01850004,Phase II,"Active, not recruiting","[{'id': 717, 'therapyName': 'Dasatinib'}]",Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response,717
10,NCT01256398,Phase II,"Active, not recruiting","[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1824, 'therapyName': 'Vincristine + Methotrexate + Mercaptopurine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,717
11,NCT00918463,Phase II,Completed,"[{'id': 717, 'therapyName': 'Dasatinib'}]",A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),717
12,NCT02059265,Phase II,"Active, not recruiting","[{'id': 717, 'therapyName': 'Dasatinib'}]","Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",717
13,NCT01609816,Phase Ib/II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}]","Dasatinib in Treating Patients With Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Previously Treated With Autologous Stem Cell Transplant",717
14,NCT02043587,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia &amp; Lymphoblastic Lymphoma,717
15,NCT03023046,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}]","Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",717
16,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,717
17,NCT03020030,Phase III,Recruiting,"[{'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents,717
18,NCT02559778,Phase I,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2629, 'therapyName': 'Eflornithine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 717, 'therapyName': 'Dasatinib'}]",Pediatric Precision Laboratory Advanced Neuroblastoma Therapy,717
19,NCT01593254,Phase II,"Active, not recruiting","[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 717, 'therapyName': 'Dasatinib'}]",Phase IIb Study of Dasatinib Versus Imatinib in Patients With CML-CP Who Have Not Achieved an Early Optimal Response to Imatinib,717
20,NCT01643603,Phase Ib/II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}]",Dasatinib in Treating Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant,717
21,NCT02883049,Phase III,Suspended,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations,717
22,NCT02420717,Phase II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 2046, 'therapyName': 'Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine '}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 3194, 'therapyName': 'Mercaptopurine + Methotrexate + Prednisone + Vincristine'}]",Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL),717
23,NCT01482728,Phase I,Completed,"[{'id': 717, 'therapyName': 'Dasatinib'}]",Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer,717
24,NCT02015728,Phase I,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1804, 'therapyName': 'Temozolomide + Etoposide'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors,717
25,NCT00549848,Phase III,"Active, not recruiting","[{'id': 1781, 'therapyName': 'Vincristine + Pegaspargase + Daunorubicin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1782, 'therapyName': 'Clofarabine + Etoposide + Cyclophosphamide'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia,717
26,NCT01015222,Phase I,"Active, not recruiting","[{'id': 1032, 'therapyName': 'methylnaltrexone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies",717
27,NCT01620216,Phase II,Recruiting,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Validation of an in Vitro Assay to Predict Targeted Therapies for Acute Leukemia Patients,717
28,NCT01244750,Phase I,"Active, not recruiting","[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}]",Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting,717
29,NCT02720185,Phase II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}]",The Window of Opportunity of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR,717
30,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,717
31,NCT00777036,,"Active, not recruiting","[{'id': 717, 'therapyName': 'Dasatinib'}]",A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib,717
32,NCT01445509,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 717, 'therapyName': 'Dasatinib'}]",Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors,717
33,NCT02143414,Phase II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1824, 'therapyName': 'Vincristine + Methotrexate + Mercaptopurine'}]","Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",717
34,NCT02693535,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 690, 'therapyName': 'Bosutinib'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer,717
35,NCT00892190,Phase I,Completed,"[{'id': 717, 'therapyName': 'Dasatinib'}]",Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome,717
36,NCT01441882,Phase II,"Active, not recruiting","[{'id': 717, 'therapyName': 'Dasatinib'}]",A Study of Dasatinib in Chronic Lymphocytic Leukemia in Patients Who Exhibit in Vitro Dasatinib Sensitivity,717
37,NCT01990196,Phase II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 1815, 'therapyName': 'Degarelix + Enzalutamide'}]",Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer,717
38,NCT01660906,Phase III,Completed,"[{'id': 717, 'therapyName': 'Dasatinib'}]","This Study Will be a Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib",717
39,NCT03117751,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,717
40,NCT02689440,FDA approved,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}]",Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib,717
41,NCT01652976,Phase II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 717, 'therapyName': 'Dasatinib'}]","Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma",717
0,NCT01999985,Phase I,"Active, not recruiting","[{'id': 1351, 'therapyName': 'Dasatinib + Afatinib'}]",Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC),1351
0,NCT01498445,Phase Ib/II,Recruiting,"[{'id': 1760, 'therapyName': 'Dasatinib + Decitabine '}]",Phase I/II - Dasatinib and Decitabine,1760
0,NCT02494882,Phase I,Recruiting,"[{'id': 3218, 'therapyName': 'Dasatinib + Dexamethasone + Ruxolitinib'}]",Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older,3218
0,NCT03041701,Phase Ib/II,Recruiting,"[{'id': 5287, 'therapyName': 'Dasatinib + Ganitumab'}]",Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma,5287
0,NCT02815059,Phase I,Recruiting,"[{'id': 4438, 'therapyName': 'Dasatinib + Ibrutinib + Prednisone'}]","Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone",4438
0,NCT01643278,Phase I,Completed,"[{'id': 1803, 'therapyName': 'Dasatinib + Ipilimumab'}]",Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic,1803
0,NCT00829647,Phase Ib/II,Withdrawn,"[{'id': 1825, 'therapyName': 'Dasatinib + lenalidomide'}]",A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia,1825
0,NCT02819804,Phase I,Recruiting,"[{'id': 1813, 'therapyName': 'Dasatinib + Nivolumab'}]",Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,1813
1,NCT02750514,Phase II,Recruiting,"[{'id': 1813, 'therapyName': 'Dasatinib + Nivolumab'}, {'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Study to Test Combination Treatments in People With Advanced Non-Small Cell Lung Cancer,1813
2,NCT02011945,Phase I,"Active, not recruiting","[{'id': 1813, 'therapyName': 'Dasatinib + Nivolumab'}]",A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia,1813
0,NCT02954523,Phase Ib/II,Recruiting,"[{'id': 4946, 'therapyName': 'Dasatinib + Osimertinib'}]",Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations,4946
0,NCT01440998,Phase I,"Active, not recruiting","[{'id': 1819, 'therapyName': 'Dasatinib + Paclitaxel + Carboplatin'}]","Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer",1819
0,NCT01606579,Phase Ib/II,Completed,"[{'id': 2466, 'therapyName': 'Cytarabine + Pri-724'}, {'id': 2465, 'therapyName': 'Dasatinib + Pri-724'}, {'id': 1083, 'therapyName': 'Pri-724'}]",Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies,2465
0,NCT01173679,Phase II,Terminated,"[{'id': 1821, 'therapyName': 'Dasatinib + Rituximab + Fludarabine'}]",Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL),1821
0,NCT03164057,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia,1006
1,NCT02560025,Phase II,"Active, not recruiting","[{'id': 626, 'therapyName': 'Alisertib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML,1006
2,NCT03117751,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,1006
3,NCT00550992,Phase I,Unknown status,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia,1006
4,NCT02112916,Phase III,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,1006
5,NCT03007147,Phase III,Recruiting,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 5167, 'therapyName': 'Methylprednisolone'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 5168, 'therapyName': 'Prednisolone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,1006
6,NCT02412475,Phase I,"Active, not recruiting","[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 650, 'therapyName': 'Decitabine'}]",Epigenetic Reprogramming in Relapse AML,1006
7,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,1006
8,NCT03150693,Phase III,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 3628, 'therapyName': 'Allopurinol'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]",Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia,1006
9,NCT02043587,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia &amp; Lymphoblastic Lymphoma,1006
10,NCT02521493,Phase III,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 5912, 'therapyName': 'Asparaginase Erwinia chrysanthemi'}, {'id': 5215, 'therapyName': 'mitoxantrone hydrochloride'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2206, 'therapyName': 'Asparaginase'}]",Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome,1006
11,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1006
0,NCT01806571,Phase II,Recruiting,"[{'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}]","Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",1738
1,NCT02403310,Phase I,"Active, not recruiting","[{'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}, {'id': 1749, 'therapyName': 'Selinexor'}]",A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML,1738
2,NCT01546038,Phase Ib/II,"Active, not recruiting","[{'id': 1748, 'therapyName': 'PF-04449913'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}]",A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,1738
3,NCT02085408,Phase III,Recruiting,"[{'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}]",Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,1738
4,NCT02343939,Phase Ib/II,Recruiting,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}, {'id': 2522, 'therapyName': 'Entospletinib  '}]",Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),1738
5,NCT01627041,Phase II,"Active, not recruiting","[{'id': 1739, 'therapyName': 'Daunorubicin + Cytarabine + Decitabine'}, {'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}]","Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia",1738
0,NCT01627041,Phase II,"Active, not recruiting","[{'id': 1739, 'therapyName': 'Daunorubicin + Cytarabine + Decitabine'}, {'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}]","Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia",1739
0,NCT03059485,Phase II,Recruiting,"[{'id': 5369, 'therapyName': 'DC/AML Vaccine'}, {'id': 5370, 'therapyName': 'DC/AML Vaccine + MEDI4736'}]",DC/AML Fusion Cell Vaccine vs DC/AML Fusion Cell Vaccine Plus Durvalumab vs Observation in Patients Who Achieve a Chemotherapy-induced Remission,5369
0,NCT03059485,Phase II,Recruiting,"[{'id': 5369, 'therapyName': 'DC/AML Vaccine'}, {'id': 5370, 'therapyName': 'DC/AML Vaccine + MEDI4736'}]",DC/AML Fusion Cell Vaccine vs DC/AML Fusion Cell Vaccine Plus Durvalumab vs Observation in Patients Who Achieve a Chemotherapy-induced Remission,5370
0,NCT02571036,Phase I,Recruiting,"[{'id': 4316, 'therapyName': 'DCC-2618'}]","A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies",4316
0,NCT03069469,Phase I,Recruiting,"[{'id': 5760, 'therapyName': 'DCC-3014'}]",Study of DCC-3014 in Patients With Advanced Malignancies,5760
0,NCT02314052,Phase Ib/II,Terminated,"[{'id': 3122, 'therapyName': 'DCR-MYC'}]","Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma",3122
1,NCT02110563,Phase I,Terminated,"[{'id': 3122, 'therapyName': 'DCR-MYC'}]","Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma",3122
0,NCT03014804,Phase II,Not yet recruiting,"[{'id': 5205, 'therapyName': 'DCVax-L'}, {'id': 5206, 'therapyName': 'DCVax-L + Nivolumab'}]",Dendritic Cell-Autologous Lung Tumor Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma,5205
1,NCT02146066,Expanded access,Available,"[{'id': 5205, 'therapyName': 'DCVax-L'}]",Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221,5205
0,NCT03014804,Phase II,Not yet recruiting,"[{'id': 5205, 'therapyName': 'DCVax-L'}, {'id': 5206, 'therapyName': 'DCVax-L + Nivolumab'}]",Dendritic Cell-Autologous Lung Tumor Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma,5206
0,NCT01834248,Phase I,Completed,"[{'id': 1795, 'therapyName': 'DEC-205-NY-ESO-1 + Decitabine '}]",DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia,1795
0,NCT02129075,Phase II,"Active, not recruiting","[{'id': 3006, 'therapyName': 'NeoVax melanoma vaccine'}, {'id': 3007, 'therapyName': 'CDX-301'}, {'id': 1324, 'therapyName': 'DEC-205-NY-ESO-1 fusion protein vaccine'}]",CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma,1324
1,NCT02413827,Phase Ib/II,Terminated,"[{'id': 2526, 'therapyName': 'Nivolumab + Varlilumab'}, {'id': 1324, 'therapyName': 'DEC-205-NY-ESO-1 fusion protein vaccine'}, {'id': 2595, 'therapyName': 'poly ICLC  '}]",A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma,1324
2,NCT02166905,Phase Ib/II,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 1324, 'therapyName': 'DEC-205-NY-ESO-1 fusion protein vaccine'}, {'id': 2575, 'therapyName': 'Epacadostat'}]","DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission",1324
3,NCT01522820,Phase I,Completed,"[{'id': 1324, 'therapyName': 'DEC-205-NY-ESO-1 fusion protein vaccine'}, {'id': 917, 'therapyName': 'Sirolimus'}]",Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors,1324
0,NCT02920008,Phase III,Recruiting,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1949, 'therapyName': 'SGI-110'}]","Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia",650
1,NCT01720225,Phase II,"Active, not recruiting","[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk,650
2,NCT02332889,Phase Ib/II,Terminated,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 2595, 'therapyName': 'poly ICLC  '}]",Phase I/II Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs,650
3,NCT02088541,Phase II,"Active, not recruiting","[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}]",Selinexor (KPT-330) in Older Patients With Relapsed AML,650
4,NCT02073838,Phase II,Recruiting,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 3179, 'therapyName': 'Vismodegib + Ribavirin'}]",Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML,650
5,NCT01786343,Phase II,Recruiting,"[{'id': 650, 'therapyName': 'Decitabine'}]",Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML),650
6,NCT02348489,Phase III,"Active, not recruiting","[{'id': 1949, 'therapyName': 'SGI-110'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 650, 'therapyName': 'Decitabine'}]","SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction",650
7,NCT01241162,Phase I,Completed,"[{'id': 650, 'therapyName': 'Decitabine'}]",Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma,650
8,NCT02343939,Phase Ib/II,Recruiting,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}, {'id': 2522, 'therapyName': 'Entospletinib  '}]",Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),650
9,NCT02412475,Phase I,"Active, not recruiting","[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 650, 'therapyName': 'Decitabine'}]",Epigenetic Reprogramming in Relapse AML,650
10,NCT01515527,Phase II,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 650, 'therapyName': 'Decitabine'}]",Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS),650
11,NCT01794702,Phase Ib/II,"Active, not recruiting","[{'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 650, 'therapyName': 'Decitabine'}]","Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia",650
12,NCT02469415,Phase II,Terminated,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2006, 'therapyName': 'Pacritinib'}]",Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS),650
13,NCT01593670,Phase II,Terminated,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes,650
14,NCT03263936,Phase I,Recruiting,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Epigenetic Reprogramming in Relapse/Refractory AML,650
15,NCT01729845,Phase Ib/II,"Active, not recruiting","[{'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 650, 'therapyName': 'Decitabine'}]","Decitabine Followed By Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes",650
16,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,650
17,NCT03164057,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia,650
18,NCT02632721,Phase II,Recruiting,"[{'id': 5540, 'therapyName': 'BI 836858 + Decitabine'}, {'id': 650, 'therapyName': 'Decitabine'}]",A Study to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML),650
19,NCT01483274,Phase I,Withdrawn,"[{'id': 650, 'therapyName': 'Decitabine'}]",Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation,650
20,NCT01546038,Phase Ib/II,"Active, not recruiting","[{'id': 1748, 'therapyName': 'PF-04449913'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}]",A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,650
21,NCT01303796,Phase III,Unknown status,"[{'id': 1747, 'therapyName': 'Decitabine + Sapacitabine'}, {'id': 650, 'therapyName': 'Decitabine'}]",A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (SEAMLESS),650
22,NCT01707004,Phase I,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1206, 'therapyName': 'Busulfan'}]",Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,650
23,NCT02188706,Phase II,"Active, not recruiting","[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 1608, 'therapyName': 'Decitabine + Carboplatin'}, {'id': 1609, 'therapyName': 'Decitabine + Arsenic trioxide '}]","A Leukemia SPORE Phase II Clinical Trial Comparing Decitabine Versus Decitabine/Carboplatin and Decitabine/Arsenic for the Treatment of Relapsed, Refractory, and Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)",650
24,NCT01687400,Phase II,"Active, not recruiting","[{'id': 650, 'therapyName': 'Decitabine'}]",Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes,650
25,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,650
26,NCT02472145,Phase III,"Active, not recruiting","[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 5909, 'therapyName': 'Decitabine + Talacotuzumab'}]",An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy,650
27,NCT01483690,Phase Ib/II,Terminated,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}]",A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL,650
28,NCT01993641,Phase II,Completed,"[{'id': 1758, 'therapyName': 'Pracinostat'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 650, 'therapyName': 'Decitabine'}]",Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA,650
0,NCT02190695,Phase II,Recruiting,"[{'id': 1608, 'therapyName': 'Decitabine + Carboplatin'}, {'id': 1609, 'therapyName': 'Decitabine + Arsenic trioxide '}]","A Safety and Efficacy Study Using Decitabine, Decitabine/Carboplatin, Decitabine/Arsenic for the Treatment of Relapsed, Refractory, and Elderly Acute Myeloid Leukemia , Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia",1609
1,NCT02188706,Phase II,"Active, not recruiting","[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 1608, 'therapyName': 'Decitabine + Carboplatin'}, {'id': 1609, 'therapyName': 'Decitabine + Arsenic trioxide '}]","A Leukemia SPORE Phase II Clinical Trial Comparing Decitabine Versus Decitabine/Carboplatin and Decitabine/Arsenic for the Treatment of Relapsed, Refractory, and Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)",1609
0,NCT01812252,Phase II,Recruiting,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 1798, 'therapyName': 'Decitabine + Azacitidine'}]",Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant,1798
0,NCT02190695,Phase II,Recruiting,"[{'id': 1608, 'therapyName': 'Decitabine + Carboplatin'}, {'id': 1609, 'therapyName': 'Decitabine + Arsenic trioxide '}]","A Safety and Efficacy Study Using Decitabine, Decitabine/Carboplatin, Decitabine/Arsenic for the Treatment of Relapsed, Refractory, and Elderly Acute Myeloid Leukemia , Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia",1608
1,NCT02188706,Phase II,"Active, not recruiting","[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 1608, 'therapyName': 'Decitabine + Carboplatin'}, {'id': 1609, 'therapyName': 'Decitabine + Arsenic trioxide '}]","A Leukemia SPORE Phase II Clinical Trial Comparing Decitabine Versus Decitabine/Carboplatin and Decitabine/Arsenic for the Treatment of Relapsed, Refractory, and Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)",1608
0,NCT01829503,Phase II,"Active, not recruiting","[{'id': 1736, 'therapyName': 'Decitabine + Cytarabine'}]",Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),1736
1,NCT03092674,Phase II,Not yet recruiting,"[{'id': 1736, 'therapyName': 'Decitabine + Cytarabine'}, {'id': 2471, 'therapyName': 'Azacitidine + Midostaurin'}, {'id': 3196, 'therapyName': 'Azacitidine + Nivolumab'}, {'id': 651, 'therapyName': 'Azacitidine'}]","Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",1736
2,NCT02121418,Phase I,"Active, not recruiting","[{'id': 1736, 'therapyName': 'Decitabine + Cytarabine'}]","Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm",1736
0,NCT02890329,Phase I,Recruiting,"[{'id': 5738, 'therapyName': 'Decitabine + Ipilimumab'}]",Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia,5738
0,NCT02634827,Phase II,Recruiting,"[{'id': 1769, 'therapyName': 'Decitabine + Midostaurin'}]",Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation,1769
1,NCT01846624,Phase II,"Active, not recruiting","[{'id': 1769, 'therapyName': 'Decitabine + Midostaurin'}]",Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,1769
0,NCT03009240,Phase I,Recruiting,"[{'id': 5214, 'therapyName': 'Decitabine + MLN4924'}]",Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia,5214
0,NCT02664181,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 5910, 'therapyName': 'Decitabine + Nivolumab + Tetrahydrouridine'}]",Pharmacologically Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With Non-Small Cell Lung Cancer (PRECISE),5910
0,NCT03063944,Phase I,"Active, not recruiting","[{'id': 5794, 'therapyName': 'Decitabine + OPB-111077'}]",STAT Inhibitor OPB-111077 and Decitabine in Treating Patients With Acute Myeloid Leukemia That Is Refractory or Newly Diagnosed and Ineligible for Intensive Chemotherapy,5794
0,NCT02109744,Phase Ib/II,Recruiting,"[{'id': 1796, 'therapyName': 'Decitabine + Sirolimus'}, {'id': 1797, 'therapyName': 'Decitabine + Ribavirin'}]",Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients,1797
0,NCT01303796,Phase III,Unknown status,"[{'id': 1747, 'therapyName': 'Decitabine + Sapacitabine'}, {'id': 650, 'therapyName': 'Decitabine'}]",A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (SEAMLESS),1747
0,NCT02093403,Phase I,"Active, not recruiting","[{'id': 1768, 'therapyName': 'Decitabine + Selinexor'}]",Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,1768
0,NCT02109744,Phase Ib/II,Recruiting,"[{'id': 1796, 'therapyName': 'Decitabine + Sirolimus'}, {'id': 1797, 'therapyName': 'Decitabine + Ribavirin'}]",Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients,1796
0,NCT02472145,Phase III,"Active, not recruiting","[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 5909, 'therapyName': 'Decitabine + Talacotuzumab'}]",An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy,5909
0,NCT02878785,Phase Ib/II,Recruiting,"[{'id': 5531, 'therapyName': 'Decitabine + Talazoparib'}]",Decitabine and Talazoparib in Untreated AML and R/R AML (1565GCC) ,5531
0,NCT00925132,Phase Ib/II,Terminated,"[{'id': 1737, 'therapyName': 'Decitabine + Temozolomide + Panobinostat'}]","Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat",1737
0,NCT02839694,Phase I,Withdrawn,"[{'id': 3567, 'therapyName': 'Decitabine + Tetrahydrouridine'}, {'id': 4592, 'therapyName': 'Decitabine + Tetrahydrouridine + Celecoxib'}]",Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy,3567
1,NCT02846935,Phase 0,Recruiting,"[{'id': 3567, 'therapyName': 'Decitabine + Tetrahydrouridine'}]",p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies,3567
2,NCT02847000,Phase 0,Recruiting,"[{'id': 3567, 'therapyName': 'Decitabine + Tetrahydrouridine'}]",p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer,3567
0,NCT02839694,Phase I,Withdrawn,"[{'id': 3567, 'therapyName': 'Decitabine + Tetrahydrouridine'}, {'id': 4592, 'therapyName': 'Decitabine + Tetrahydrouridine + Celecoxib'}]",Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy,4592
0,NCT01893320,Phase Ib/II,"Active, not recruiting","[{'id': 1766, 'therapyName': 'Decitabine + Vosaroxin'}]",Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome,1766
0,NCT02546531,Phase I,Recruiting,"[{'id': 3083, 'therapyName': 'Defactinib + Gemcitabine + Pembrolizumab'}]",Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer,3083
0,NCT02494713,Phase II,Recruiting,"[{'id': 1814, 'therapyName': 'Degarelix'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 2858, 'therapyName': 'Ketoconazole'}]",Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer,1814
1,NCT02560051,Phase II,Recruiting,"[{'id': 1814, 'therapyName': 'Degarelix'}, {'id': 3087, 'therapyName': 'Aldoxorubicin + Docetaxel + Estramustine + Ketoconazole'}]",Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,1814
2,NCT01786265,Phase II,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1814, 'therapyName': 'Degarelix'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone,1814
3,NCT02346253,Phase Ib/II,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 1814, 'therapyName': 'Degarelix'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 759, 'therapyName': 'Goserelin'}]",High-Dose Brachytherapy in Treating Patients With Prostate Cancer,1814
4,NCT02020070,Phase II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1814, 'therapyName': 'Degarelix'}]","Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy",1814
5,NCT01751451,Phase II,"Active, not recruiting","[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1814, 'therapyName': 'Degarelix'}]","3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy",1814
6,NCT02472275,Phase I,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 874, 'therapyName': 'PLX3397'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 1814, 'therapyName': 'Degarelix'}]","PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer",1814
7,NCT03009981,Phase III,Recruiting,"[{'id': 5523, 'therapyName': 'Abiraterone + ARN-509 + Degarelix + Prednisone'}, {'id': 5524, 'therapyName': 'ARN-509 + Degarelix'}, {'id': 1814, 'therapyName': 'Degarelix'}]",A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer,1814
8,NCT01674270,Phase II,Completed,"[{'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 1814, 'therapyName': 'Degarelix'}]",Degarelix Neo-Adjuvant Radical Prostatectomy Trial,1814
9,NCT02278185,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1814, 'therapyName': 'Degarelix'}, {'id': 2047, 'therapyName': 'Histrelin acetate'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer,1814
10,NCT02489357,Phase I,"Active, not recruiting","[{'id': 1814, 'therapyName': 'Degarelix'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer",1814
11,NCT02663908,Phase III,Recruiting,"[{'id': 1814, 'therapyName': 'Degarelix'}, {'id': 795, 'therapyName': 'Leuprolide'}]",A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease,1814
12,NCT02403505,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1814, 'therapyName': 'Degarelix'}]",Discovery Stage Clinical Study About Oncology Drugs and Single Nucleotide Polymorphisms,1814
0,NCT01990196,Phase II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 1815, 'therapyName': 'Degarelix + Enzalutamide'}]",Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer,1815
0,NCT01952249,Phase Ib/II,Completed,"[{'id': 2007, 'therapyName': 'Demcizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian,2007
1,NCT02259582,Phase II,"Active, not recruiting","[{'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 2007, 'therapyName': 'Demcizumab'}]","A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer",2007
0,NCT02289898,Phase II,"Active, not recruiting","[{'id': 2639, 'therapyName': 'Demcizumab + Gemcitabine + nab-paclitaxel'}]","Study of Gemcitabine, Abraxane Plus Placebo Versus Gemcitabine, Abraxane Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma",2639
0,NCT02722954,Phase I,"Active, not recruiting","[{'id': 3994, 'therapyName': 'Demcizumab + Pembrolizumab'}]",A Study of Demcizumab Plus Pembrolizumab +/- Chemotherapy,3994
0,NCT01345019,Phase III,"Active, not recruiting","[{'id': 1198, 'therapyName': 'Denosumab'}, {'id': 2971, 'therapyName': 'Zoledronic acid'}]",Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma,1198
1,NCT01952054,Phase II,Recruiting,"[{'id': 1198, 'therapyName': 'Denosumab'}]",Denosumab for Breast Cancer With Bone Mets,1198
2,NCT00680992,Phase II,"Active, not recruiting","[{'id': 1198, 'therapyName': 'Denosumab'}]",Study of Denosumab in Subjects With Giant Cell Tumor of Bone,1198
3,NCT02833610,Phase II,Recruiting,"[{'id': 1198, 'therapyName': 'Denosumab'}]",A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency,1198
4,NCT02366130,Phase II,Recruiting,"[{'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}, {'id': 1198, 'therapyName': 'Denosumab'}]",Phase II Trial of Ra-223 Dichloride and Hormonal Treatment,1198
5,NCT03070002,Phase II,Recruiting,"[{'id': 1198, 'therapyName': 'Denosumab'}]","Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells",1198
6,NCT01545648,Phase II,"Active, not recruiting","[{'id': 1198, 'therapyName': 'Denosumab'}]",Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer,1198
7,NCT02470091,Phase II,Recruiting,"[{'id': 1198, 'therapyName': 'Denosumab'}]",Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma,1198
8,NCT02900469,Phase 0,Recruiting,"[{'id': 1198, 'therapyName': 'Denosumab'}]",Safety Study of Denosumab to Treat Breast Cancer,1198
0,NCT02758132,Phase I,Terminated,"[{'id': 4182, 'therapyName': 'Abiraterone + Denosumab + Enzalutamide + Prednisone'}, {'id': 4183, 'therapyName': 'Denosumab + Enzalutamide'}]","Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases",4183
0,NCT02721433,FDA approved,Recruiting,"[{'id': 4784, 'therapyName': 'Denosumab + pamidronate + Zoledronic acid'}]",4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases (REaCT-BTA),4784
0,NCT02036502,Phase I,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3322, 'therapyName': 'lenalidomide + Pembrolizumab'}]",A Study of Pembrolizumab (MK-3475) in Combination With Lenalidomide and Dexamethasone in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023),1390
1,NCT02427620,Phase II,Recruiting,"[{'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 1642, 'therapyName': 'Leucovorin'}]",A Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma,1390
2,NCT02265510,Phase I,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2747, 'therapyName': 'INCB052793'}, {'id': 688, 'therapyName': 'Bortezomib'}]","An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies",1390
3,NCT02589145,Phase Ib/II,Recruiting,"[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 3278, 'therapyName': 'Enoxaparin'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}]",Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype,1390
4,NCT01846611,Phase III,Recruiting,"[{'id': 1008, 'therapyName': 'Doxil'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]","A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",1390
5,NCT02420860,Phase II,Recruiting,"[{'id': 5972, 'therapyName': 'Famotidine'}, {'id': 3430, 'therapyName': 'Elotuzumab + lenalidomide'}, {'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Study of Elotuzumab With Lenalidomide as Maintenance After Autologous Stem Cell Transplant (ASCT),1390
6,NCT00549848,Phase III,"Active, not recruiting","[{'id': 1781, 'therapyName': 'Vincristine + Pegaspargase + Daunorubicin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1782, 'therapyName': 'Clofarabine + Etoposide + Cyclophosphamide'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia,1390
7,NCT02211014,Phase I,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]","An Open-Label, Phase 1b Study of ACP-196 With and Without Dexamethasone in Subjects With Multiple Myeloma",1390
8,NCT01863550,Phase III,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,1390
9,NCT02490878,Phase II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases,1390
10,NCT02520115,Phase I,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1076, 'therapyName': 'Valproic acid'}]",Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer,1390
11,NCT03117751,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,1390
12,NCT02112916,Phase III,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,1390
13,NCT03007147,Phase III,Recruiting,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 5167, 'therapyName': 'Methylprednisolone'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 5168, 'therapyName': 'Prednisolone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,1390
14,NCT01319981,Phase II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia,1390
15,NCT03150693,Phase III,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 3628, 'therapyName': 'Allopurinol'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]",Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia,1390
16,NCT01729091,Phase Ib/II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3343, 'therapyName': 'Elotuzumab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1164, 'therapyName': 'lenalidomide'}]",Study of Umbilical Cord Blood-derived Natural Killer Cells in Conjunction With High Dose Chemotherapy and Autologous Stem Cell Transplant for Patients With Multiple Myeloma,1390
17,NCT02506959,Phase II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma,1390
18,NCT01363817,Phase I,"Active, not recruiting","[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2545, 'therapyName': 'BMS-906024'}]",Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma,1390
19,NCT01459211,Phase II,Completed,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}]",Pilot Study to Establish Safety and Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL),1390
20,NCT02471911,Phase I,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3360, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide + Rituximab'}, {'id': 1749, 'therapyName': 'Selinexor'}]",KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma,1390
21,NCT03147612,Phase II,Not yet recruiting,"[{'id': 5682, 'therapyName': 'Mesna'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Study of the Combination of Low-Intensity Chemotherapy and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),1390
22,NCT02491411,Phase I,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel,1390
23,NCT02906332,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM),1390
24,NCT02685826,Phase I,Suspended,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3934, 'therapyName': 'lenalidomide + MEDI4736'}]",A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Subjects With Newly Diagnosed Multiple Myeloma,1390
25,NCT02279394,Phase II,"Active, not recruiting","[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3430, 'therapyName': 'Elotuzumab + lenalidomide'}]",Trial of Combination of Elotuzumab and Lenalidomide +/- Dexamethasone in High-Risk Smoldering Multiple Myeloma,1390
26,NCT02532192,Phase I,Withdrawn,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1689, 'therapyName': 'Fluconazole'}, {'id': 1078, 'therapyName': 'Belinostat'}]","A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma",1390
27,NCT01428492,Phase I,Completed,"[{'id': 625, 'therapyName': 'Afuresertib'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma,1390
28,NCT02419755,Phase II,Terminated,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies,1390
29,NCT02605356,Phase Ib/II,Withdrawn,"[{'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma,1390
30,NCT01483690,Phase Ib/II,Terminated,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}]",A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL,1390
31,NCT01422746,,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]", Effect of Metformin on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess,1390
32,NCT02576977,Phase III,Suspended,"[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183),1390
33,NCT02518113,Phase Ib/II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2958, 'therapyName': 'LY3039478'}]",A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL,1390
34,NCT02553460,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I,1390
35,NCT02464657,Phase Ib/II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3192, 'therapyName': 'Cytarabine + Idarubicin + Nivolumab'}]",Nivolumab in Acute Myeloid Leukemia (AML),1390
36,NCT03259503,Phase Ib/II,Not yet recruiting,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas,1390
37,NCT02579863,Phase III,Suspended,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}]",Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185),1390
38,NCT03004287,Phase II,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy,1390
39,NCT02030483,Phase I,Terminated,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}]",Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma,1390
40,NCT02352558,Phase I,"Active, not recruiting","[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 2057, 'therapyName': 'BBI608'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]","A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies",1390
41,NCT01455389,Phase Ib/II,Recruiting,"[{'id': 1313, 'therapyName': 'DOTAP:chol-Fus1'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer,1390
42,NCT01256398,Phase II,"Active, not recruiting","[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1824, 'therapyName': 'Vincristine + Methotrexate + Mercaptopurine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,1390
43,NCT02400242,Phase I,"Active, not recruiting","[{'id': 3311, 'therapyName': 'Citarinostat'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1622, 'therapyName': 'Pomalidomide'}]",Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma,1390
44,NCT01983969,Phase Ib/II,"Active, not recruiting","[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2557, 'therapyName': 'Azacitidine + Gemcitabine + vorinostat'}]",Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma,1390
45,NCT03020030,Phase III,Recruiting,"[{'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents,1390
46,NCT01962792,Phase Ib/II,Recruiting,"[{'id': 3282, 'therapyName': 'Carfilzomib + Ibrutinib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]","Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Carfilzomib (Kyprolis), in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma",1390
47,NCT02419495,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Selinexor in Combination With Standard Chemotherapy,1390
48,NCT02616640,Phase I,"Active, not recruiting","[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma,1390
0,NCT03107182,Phase II,Recruiting,"[{'id': 5581, 'therapyName': 'Dexamethasone + Diphenhydramine + Famotidine + 5FU + Hydroxyurea + Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 5303, 'therapyName': 'Nivolumab + Carboplatin + Paclitaxel'}]",Oropharyngeal Tumor Induction Chemotherapy and Response-stratified Locoregional Therapy Trial in Order to Minimize Long-term Adverse Events,5581
0,NCT02861573,Phase I,Recruiting,"[{'id': 5343, 'therapyName': 'Dexamethasone + Docetaxel + Pembrolizumab + Prednisone'}, {'id': 5342, 'therapyName': 'Olaparib + Pembrolizumab'}, {'id': 2666, 'therapyName': 'Enzalutamide + Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365),5343
0,NCT02883049,Phase III,Suspended,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations,4685
1,NCT02723994,Phase II,Recruiting,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 2346, 'therapyName': 'Mercaptopurine + Thioguanine'}, {'id': 2394, 'therapyName': 'Asparaginase + Cytarabine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}]",A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia,4685
0,NCT01606878,Phase I,Recruiting,"[{'id': 2952, 'therapyName': 'Dexamethasone + Doxorubicin + Vincristine'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}, {'id': 706, 'therapyName': 'Crizotinib'}]",Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma,2952
0,NCT03227432,Phase II,Not yet recruiting,"[{'id': 6118, 'therapyName': 'Dexamethasone + Elotuzumab + Nivolumab + Pomalidomide'}, {'id': 6117, 'therapyName': 'Elotuzumab + Nivolumab'}]",An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma,6118
0,NCT02961816,Phase II,Withdrawn,"[{'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 4976, 'therapyName': 'Busulfan + Gemcitabine + Melphalan + Panobinostat'}, {'id': 4977, 'therapyName': 'Dexamethasone + Filgrastim + Palifermin + Rituximab'}]",Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma,4977
0,NCT02633059,Phase Ib/II,Recruiting,"[{'id': 4392, 'therapyName': 'Dexamethasone + Idasanutlin + Ixazomib'}]","Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma",4392
0,NCT02057640,Phase Ib/II,"Active, not recruiting","[{'id': 4565, 'therapyName': 'Dexamethasone + Ixazomib + Panobinostat'}]",MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma,4565
0,NCT02831686,Phase I,Recruiting,"[{'id': 4500, 'therapyName': 'Dexamethasone + Ixazomib + Selinexor'}]","A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma",4500
0,NCT02952573,Phase II,Recruiting,"[{'id': 4950, 'therapyName': 'Dexamethasone + JNJ-42756493'}]",Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement,4950
0,NCT02426723,Phase I,Recruiting,"[{'id': 3081, 'therapyName': 'CWP232291'}, {'id': 4036, 'therapyName': 'Dexamethasone + lenalidomide'}]",Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients,4036
0,NCT02880228,Phase II,"Active, not recruiting","[{'id': 4612, 'therapyName': 'Dexamethasone + lenalidomide + Pembrolizumab'}]","Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant",4612
0,NCT02666209,Phase I,No longer available,"[{'id': 3556, 'therapyName': 'Bortezomib + Dexamethasone + Ulocuplumab'}, {'id': 3555, 'therapyName': 'Dexamethasone + lenalidomide + Ulocuplumab'}]",Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma,3555
0,NCT02780609,Phase Ib/II,Recruiting,"[{'id': 4221, 'therapyName': 'Dexamethasone + Melphalan + Selinexor'}]",Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma,4221
0,NCT02186834,Phase Ib/II,"Active, not recruiting","[{'id': 3356, 'therapyName': 'Dexamethasone + pegylated liposomal-doxorubicin + Selinexor'}]",Selinexor (KPT-330) and Pegylated Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma,3356
0,NCT02289222,Phase Ib/II,"Active, not recruiting","[{'id': 3344, 'therapyName': 'Dexamethasone + Pembrolizumab + Pomalidomide'}]",Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma,3344
0,NCT02726581,Phase III,"Active, not recruiting","[{'id': 3343, 'therapyName': 'Elotuzumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 3792, 'therapyName': 'Dexamethasone + Pomalidomide'}]","Study of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Multiple Myeloma",3792
1,NCT02548962,Phase Ib/II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3792, 'therapyName': 'Dexamethasone + Pomalidomide'}]",Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma,3792
2,NCT02654132,Phase II,"Active, not recruiting","[{'id': 3792, 'therapyName': 'Dexamethasone + Pomalidomide'}, {'id': 3343, 'therapyName': 'Elotuzumab'}]",Trial of Elotuzumab With or Without Pomalidomide and Low-dose Dexamethasone to Treat Refractory and Relapsed and Refractory Multiple Myeloma,3792
0,NCT02343042,Phase Ib/II,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 2479, 'therapyName': 'Dexamethasone + Selinexor'}, {'id': 1622, 'therapyName': 'Pomalidomide'}]",Phase 1b/2 Study of Selinexor (KPT-330) in Combination w/ Backbone Treatments for Resistant/Refractory Multiple Myeloma,2479
1,NCT02336815,Phase II,Recruiting,"[{'id': 2479, 'therapyName': 'Dexamethasone + Selinexor'}]",Phase 2b Open-Label Single-Arm Selinexor (KPT-330) + Low-Dose Dexamethasone in Patients w/ Multiple Myeloma Quad-refractory to Previous Therapies,2479
0,NCT01471054,Phase II,Terminated,"[{'id': 1480, 'therapyName': 'Dexamethasone intravitreal implant'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma,1480
0,NCT03164057,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia,5153
1,NCT03126916,Phase III,Not yet recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 5595, 'therapyName': 'Isotretinoin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 2286, 'therapyName': 'Dinutuximab  '}]",Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma,5153
2,NCT03020030,Phase III,Recruiting,"[{'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents,5153
3,NCT02584309,Phase II,Recruiting,"[{'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 4140, 'therapyName': 'Doxorubicin + Olaratumab'}]",Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma,5153
4,NCT03007147,Phase III,Recruiting,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 5167, 'therapyName': 'Methylprednisolone'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 5168, 'therapyName': 'Prednisolone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,5153
0,NCT01783171,Phase I,Completed,"[{'id': 2193, 'therapyName': 'Dinaciclib + MK2206'}]",Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed By Surgery,2193
0,NCT02684617,Phase I,Recruiting,"[{'id': 4225, 'therapyName': 'Dinaciclib + Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies  (MK-3475-155) (KEYNOTE-155),4225
1,NCT01676753,Phase Ib/II,Recruiting,"[{'id': 4225, 'therapyName': 'Dinaciclib + Pembrolizumab'}]",Phase 1b Dose De-escalation Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer,4225
0,NCT01767194,Phase II,Suspended,"[{'id': 2286, 'therapyName': 'Dinutuximab  '}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1462, 'therapyName': 'Temozolomide + Irinotecan'}]",Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Monoclonal Antibody Ch14.18 in Treating Younger Patients With Refractory or Relapsed Neuroblastoma,2286
1,NCT03126916,Phase III,Not yet recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 5595, 'therapyName': 'Isotretinoin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 2286, 'therapyName': 'Dinutuximab  '}]",Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma,2286
0,NCT01392183,Phase II,"Active, not recruiting","[{'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC),1275
1,NCT02420860,Phase II,Recruiting,"[{'id': 5972, 'therapyName': 'Famotidine'}, {'id': 3430, 'therapyName': 'Elotuzumab + lenalidomide'}, {'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Study of Elotuzumab With Lenalidomide as Maintenance After Autologous Stem Cell Transplant (ASCT),1275
2,NCT01455389,Phase Ib/II,Recruiting,"[{'id': 1313, 'therapyName': 'DOTAP:chol-Fus1'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer,1275
3,NCT01998971,Phase I,Recruiting,"[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1475, 'therapyName': 'Thalidomide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 3323, 'therapyName': 'Montelukast'}]",A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma,1275
0,NCT02013154,Phase I,Recruiting,"[{'id': 6254, 'therapyName': 'DKN-01 + Paclitaxel'}]",A Study of DKN-01 in Combination With Paclitaxel,6254
0,NCT01991210,Phase II,Terminated,"[{'id': 1345, 'therapyName': 'DNIB0600A'}, {'id': 1008, 'therapyName': 'Doxil'}]",A Randomized Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer,1345
0,NCT01995188,Phase I,Completed,"[{'id': 1347, 'therapyName': 'DNIB0600A + Carboplatin + Bevacizumab'}, {'id': 1346, 'therapyName': 'DNIB0600A + Carboplatin'}]",A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Patients With Ovarian Cancer,1346
0,NCT01995188,Phase I,Completed,"[{'id': 1347, 'therapyName': 'DNIB0600A + Carboplatin + Bevacizumab'}, {'id': 1346, 'therapyName': 'DNIB0600A + Carboplatin'}]",A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Patients With Ovarian Cancer,1347
0,NCT02197169,Phase I,"Active, not recruiting","[{'id': 4407, 'therapyName': 'DNX-2401'}, {'id': 4444, 'therapyName': 'DNX-2401 + interferon gamma '}]",DNX-2401 With Interferon Gamma (IFN-gamma) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors (TARGET-I),4407
0,NCT02197169,Phase I,"Active, not recruiting","[{'id': 4407, 'therapyName': 'DNX-2401'}, {'id': 4444, 'therapyName': 'DNX-2401 + interferon gamma '}]",DNX-2401 With Interferon Gamma (IFN-gamma) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors (TARGET-I),4444
0,NCT02798406,Phase II,Recruiting,"[{'id': 4408, 'therapyName': 'DNX-2401 + Pembrolizumab'}]",Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE),4408
0,NCT01472016,Phase I,Completed,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1063, 'therapyName': 'ABT-700'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",Study of ABT-700 in Subjects With Advanced Solid Tumors,720
1,NCT02283320,Phase II,Completed,"[{'id': 720, 'therapyName': 'Docetaxel'}]",A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer,720
2,NCT01810913,Phase II,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1925, 'therapyName': 'Docetaxel + Cetuximab'}]","Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",720
3,NCT03137771,Phase II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}]",Maintenance Chemotherapy With or Without Stereotactic Body Radiation Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,720
4,NCT02494713,Phase II,Recruiting,"[{'id': 1814, 'therapyName': 'Degarelix'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 2858, 'therapyName': 'Ketoconazole'}]",Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer,720
5,NCT02117024,Phase II,"Active, not recruiting","[{'id': 2472, 'therapyName': 'HS-110 + Cyclophosphamide'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer,720
6,NCT02387216,Phase II,Recruiting,"[{'id': 820, 'therapyName': 'Seribantumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC,720
7,NCT02605915,Phase I,Recruiting,"[{'id': 3250, 'therapyName': 'Atezolizumab + Trastuzumab'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 856, 'therapyName': 'Pertuzumab'}]",Safety and Pharmacokinetics of Atezolizumab in Combination With Trastuzumab Emtansine or With Trastuzumab and Pertuzumab in Participants With HER2-Positive Breast Cancer,720
8,NCT01780545,Phase II,Completed,"[{'id': 1807, 'therapyName': 'OGX-427'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer,720
9,NCT02009449,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2621, 'therapyName': 'AM0010 '}, {'id': 619, 'therapyName': 'Abraxane'}]",A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors,720
10,NCT02426125,Phase III,"Active, not recruiting","[{'id': 886, 'therapyName': 'Ramucirumab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer,720
11,NCT02401542,Phase II,Recruiting,"[{'id': 2934, 'therapyName': 'B-701'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Phase 2 Study of B-701 in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma,720
12,NCT02366494,Phase I,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Micro RNAs to Predict Response to Androgen Deprivation Therapy,720
13,NCT02252042,Phase III,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040),720
14,NCT03056599,,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1733, 'therapyName': 'interferon gamma '}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 3420, 'therapyName': 'trabectedin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma,720
15,NCT01641939,Phase III,Terminated,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer,720
16,NCT02551055,Phase I,Terminated,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 626, 'therapyName': 'Alisertib'}, {'id': 3146, 'therapyName': 'TAK-659'}, {'id': 1033, 'therapyName': 'MLN1117'}]","MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma",720
17,NCT01572038,Phase III,"Active, not recruiting","[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE),720
18,NCT01911325,Phase Ib/II,Terminated,"[{'id': 680, 'therapyName': 'BKM120'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients,720
19,NCT02105636,Phase III,"Active, not recruiting","[{'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141),720
20,NCT02257619,Phase II,Terminated,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 2406, 'therapyName': 'INCB039110'}]",Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer,720
21,NCT02057107,Phase II,Recruiting,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 720, 'therapyName': 'Docetaxel'}]","Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN)",720
22,NCT02229149,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1105, 'therapyName': 'Capecitabine'}]","Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer",720
23,NCT01708993,Phase II,Completed,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1110, 'therapyName': 'Reolysin + Pemetrexed'}, {'id': 1111, 'therapyName': 'Reolysin + Docetaxel'}]"," Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy",720
24,NCT01792050,Phase II,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 2976, 'therapyName': 'indoximod'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer,720
25,NCT02182622,Phase I,Unknown status,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1428, 'therapyName': 'Sonidegib'}]",LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel,720
26,NCT01750281,Phase II,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1117, 'therapyName': 'Selumetinib + Docetaxel'}]",Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.,720
27,NCT01798485,Phase III,Terminated,"[{'id': 745, 'therapyName': 'Ganetespib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC,720
28,NCT01783587,Phase I,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer,720
29,NCT01646125,,Terminated,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 647, 'therapyName': 'AUY922'}, {'id': 854, 'therapyName': 'Pemetrexed'}]"," An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations",720
30,NCT02154490,Phase II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 1016, 'therapyName': 'GDC-0032'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 629, 'therapyName': 'AMG102'}]",Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,720
31,NCT01879085,Phase Ib/II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Phase 1b/2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma,720
32,NCT01779050,Phase II,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1087, 'therapyName': 'Epirubicin + Cyclophosphamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}, {'id': 1834, 'therapyName': 'Docetaxel + Carboplatin'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}]",Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells,720
33,NCT01064479,Phase II,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Docetaxel And Cisplatin With or Without Erlotinib For Metastatic Or Recurrent Squamous Cell Carcinoma Of Head And Neck,720
34,NCT02437370,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer,720
35,NCT02122770,Phase I,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1026, 'therapyName': 'Itraconazole'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1688, 'therapyName': 'MLN4924'}, {'id': 1689, 'therapyName': 'Fluconazole'}]","Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors",720
36,NCT01362374,Phase I,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 747, 'therapyName': 'Ipatasertib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]","Safety and Pharmacology Of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors",720
37,NCT01630733,Phase III,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 3648, 'therapyName': 'Custirsen + Docetaxel'}]","A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer",720
38,NCT02231164,Phase III,Terminated,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 831, 'therapyName': 'Nintedanib'}]",LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research,720
39,NCT01828112,Phase III,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 789, 'therapyName': 'Ceritinib'}]",LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib,720
40,NCT01927744,Phase II,Recruiting,"[{'id': 2474, 'therapyName': 'Erlotinib + Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","Study of Chemotherapy With Cisplatin/CarboplatinAstellas Pharma Inc, OSI Pharmaceuticals, Kadoorie Foundation, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection",720
41,NCT01868022,Phase I,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 2899, 'therapyName': 'GSK3052230'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling",720
42,NCT02504489,Phase III,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 3679, 'therapyName': 'Docetaxel + Plinabulin'}]",Plinabulin (P) + Docetaxel (D) vs D as 2nd-Line Chemo in Patients With Advanced NSCLC With at Least 1 Large Lung Lesion,720
43,NCT02331251,Phase Ib/II,"Active, not recruiting","[{'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 619, 'therapyName': 'Abraxane'}]",Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus),720
44,NCT02008227,Phase III,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Randomized Phase 3 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - OAK,720
45,NCT02302807,Phase III,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Study of MPDL3280A Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer,720
46,NCT01633541,Phase II,Recruiting,"[{'id': 644, 'therapyName': 'AT-101'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer,720
47,NCT02395172,Phase III,"Active, not recruiting","[{'id': 3144, 'therapyName': 'Avelumab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200),720
48,NCT02508246,Phase I,Recruiting,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]","AZD1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck",720
49,NCT02599324,Phase Ib/II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors,720
50,NCT02450539,Phase II,"Active, not recruiting","[{'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer,720
51,NCT02536495,Phase Ib/II,Withdrawn,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer,720
52,NCT02322281,Phase III,"Active, not recruiting","[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1003, 'therapyName': 'CO1686'}]","TIGER-3 Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy",720
53,NCT02574078,Phase I,Recruiting,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2114, 'therapyName': 'Bevacizumab + Pemetrexed'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",A Master Protocol Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate 370),720
54,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,720
55,NCT03041181,Phase II,Recruiting,"[{'id': 5288, 'therapyName': 'Docetaxel + Nivolumab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Docetaxel Plus Nivolumab or Docetaxel Alone in Patients With Advanced Non-squamous NSCLC Previously Treated With Nivolumab,720
0,NCT00588770,Phase III,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1835, 'therapyName': 'Docetaxel + Cisplatin'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 1834, 'therapyName': 'Docetaxel + Carboplatin'}, {'id': 1832, 'therapyName': 'Carboplatin + Fluorouracil\t'}]",Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,1834
1,NCT01779050,Phase II,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1087, 'therapyName': 'Epirubicin + Cyclophosphamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}, {'id': 1834, 'therapyName': 'Docetaxel + Carboplatin'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}]",Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells,1834
0,NCT02128906,Phase II,Recruiting,"[{'id': 1925, 'therapyName': 'Docetaxel + Cetuximab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC,1925
1,NCT01794845,Phase II,Terminated,"[{'id': 1925, 'therapyName': 'Docetaxel + Cetuximab'}]",Phase II Trial Using Erbitux+ Taxotere With Low Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma,1925
2,NCT01810913,Phase II,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1925, 'therapyName': 'Docetaxel + Cetuximab'}]","Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",1925
0,NCT00588770,Phase III,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1835, 'therapyName': 'Docetaxel + Cisplatin'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 1834, 'therapyName': 'Docetaxel + Carboplatin'}, {'id': 1832, 'therapyName': 'Carboplatin + Fluorouracil\t'}]",Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,1835
1,NCT02358863,Phase I,Terminated,"[{'id': 4311, 'therapyName': 'Docetaxel + Irinotecan'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1835, 'therapyName': 'Docetaxel + Cisplatin'}, {'id': 1406, 'therapyName': 'Camptosar + Cisplatin'}, {'id': 4310, 'therapyName': 'Epirubicin + Docetaxel'}, {'id': 4309, 'therapyName': 'Capecitabine + Docetaxel'}]",Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach (mEGA),1835
0,NCT01275677,Phase III,"Active, not recruiting","[{'id': 1503, 'therapyName': 'Paclitaxel + Trastuzumab + Doxorubicin + Cyclophosphamide'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}, {'id': 1882, 'therapyName': 'Docetaxel + Cyclophosphamide + Trastuzumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}]",Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,1881
1,NCT01501487,FDA approved,"Active, not recruiting","[{'id': 1902, 'therapyName': 'Docetaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1485, 'therapyName': 'Trastuzumab + Docetaxel + Carboplatin'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]",MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I,1881
2,NCT01779050,Phase II,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1087, 'therapyName': 'Epirubicin + Cyclophosphamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}, {'id': 1834, 'therapyName': 'Docetaxel + Carboplatin'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}]",Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells,1881
0,NCT01275677,Phase III,"Active, not recruiting","[{'id': 1503, 'therapyName': 'Paclitaxel + Trastuzumab + Doxorubicin + Cyclophosphamide'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}, {'id': 1882, 'therapyName': 'Docetaxel + Cyclophosphamide + Trastuzumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}]",Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,1882
0,NCT01501487,FDA approved,"Active, not recruiting","[{'id': 1902, 'therapyName': 'Docetaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1485, 'therapyName': 'Trastuzumab + Docetaxel + Carboplatin'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]",MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I,1902
0,NCT03211117,Phase II,Recruiting,"[{'id': 6040, 'therapyName': 'Docetaxel + Doxorubicin + Pembrolizumab'}]","Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer",6040
0,NCT02685267,Phase II,"Active, not recruiting","[{'id': 4681, 'therapyName': 'Docetaxel + Enzalutamide + Prednisone'}, {'id': 2462, 'therapyName': 'Docetaxel + Prednisone'}]",Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer (Doce/Enza),4681
0,NCT02494921,Phase Ib/II,Recruiting,"[{'id': 3113, 'therapyName': 'Docetaxel + Filgrastim + Prednisone + Ribociclib'}]",LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC,3113
0,NCT01862081,Phase I,Completed,"[{'id': 2321, 'therapyName': 'Docetaxel + GDC-0032 '}, {'id': 2322, 'therapyName': 'GDC-0032 + Paclitaxel'}]","A Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer",2321
0,NCT00936936,Phase II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2101, 'therapyName': 'Etoposide + Ifosfamide'}, {'id': 2100, 'therapyName': 'Docetaxel + Gemcitabine + Melphalan'}, {'id': 2074, 'therapyName': 'Bevacizumab + Carboplatin'}]",High-dose Chemotherapy for Poor-prognosis Relapsed Germ-Cell Tumors,2100
0,NCT02393248,Phase Ib/II,Recruiting,"[{'id': 4176, 'therapyName': 'Cisplatin + Gemcitabine + INCB054828'}, {'id': 4174, 'therapyName': 'Docetaxel + INCB054828'}, {'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}]","Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies",4174
0,NCT02460367,Phase Ib/II,Recruiting,"[{'id': 3578, 'therapyName': 'Docetaxel + Indoximod'}]",Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer,3578
0,NCT02358863,Phase I,Terminated,"[{'id': 4311, 'therapyName': 'Docetaxel + Irinotecan'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1835, 'therapyName': 'Docetaxel + Cisplatin'}, {'id': 1406, 'therapyName': 'Camptosar + Cisplatin'}, {'id': 4310, 'therapyName': 'Epirubicin + Docetaxel'}, {'id': 4309, 'therapyName': 'Capecitabine + Docetaxel'}]",Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach (mEGA),4311
0,NCT01822613,Phase Ib/II,Completed,"[{'id': 2282, 'therapyName': 'Docetaxel + Irinotecan + Paclitaxel'}, {'id': 2283, 'therapyName': 'BYL719 + LJM716'}]",Study of Safety and Efficacy of the Combination of LJM716 and BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC),2282
1,NCT02564263,Phase III,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2282, 'therapyName': 'Docetaxel + Irinotecan + Paclitaxel'}]",Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181),2282
0,NCT01935947,Phase II,Terminated,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2645, 'therapyName': 'Azacitidine + Entinostat'}, {'id': 2646, 'therapyName': 'Docetaxel + Irinotecan + Pemetrexed '}]",Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer,2646
0,NCT02834403,Phase Ib/II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 6123, 'therapyName': 'Docetaxel + L-NMMA'}, {'id': 6096, 'therapyName': 'L-NMMA'}]",L-NMMA Plus Docetaxel in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients,6123
0,NCT01837667,Phase I,Completed,"[{'id': 3683, 'therapyName': 'Docetaxel + LB-100'}]",Phase I Study of LB-100 With Docetaxel in Solid Tumors,3683
0,NCT03228186,Phase II,Not yet recruiting,"[{'id': 6033, 'therapyName': 'Docetaxel + MLN4924'}]",Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer,6033
0,NCT03041181,Phase II,Recruiting,"[{'id': 5288, 'therapyName': 'Docetaxel + Nivolumab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Docetaxel Plus Nivolumab or Docetaxel Alone in Patients With Advanced Non-squamous NSCLC Previously Treated With Nivolumab,5288
0,NCT02799602,Phase III,Recruiting,"[{'id': 836, 'therapyName': 'ODM-201'}, {'id': 4921, 'therapyName': 'Docetaxel + ODM-201'}]",ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer (ARASENS),4921
0,NCT02569242,Phase III,"Active, not recruiting","[{'id': 3045, 'therapyName': 'Docetaxel + Paclitaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer,3045
1,NCT00565851,Phase III,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 3045, 'therapyName': 'Docetaxel + Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Carboplatin, Paclitaxel and Gemcitabine With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",3045
0,NCT01385228,Phase I,Completed,"[{'id': 2042, 'therapyName': 'Docetaxel + Pazopanib + Pegfilgrastim'}]","Pazopanib, Docetaxel, Prednisone Prostate",2042
0,NCT03083808,Phase II,Recruiting,"[{'id': 5497, 'therapyName': 'Pembrolizumab + Gemcitabine'}, {'id': 5496, 'therapyName': 'Docetaxel + Pembrolizumab'}, {'id': 5498, 'therapyName': 'Pemetrexed + Pembrolizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Phase II Trial of Continuation Therapy in Advanced NSCLC,5496
0,NCT02654587,Phase III,"Active, not recruiting","[{'id': 4327, 'therapyName': 'OSE 2101 '}, {'id': 4328, 'therapyName': 'Docetaxel + Pemetrexed'}]",Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC (ATALANTE 1),4328
0,NCT02504489,Phase III,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 3679, 'therapyName': 'Docetaxel + Plinabulin'}]",Plinabulin (P) + Docetaxel (D) vs D as 2nd-Line Chemo in Patients With Advanced NSCLC With at Least 1 Large Lung Lesion,3679
0,NCT01619813,Phase II,Completed,"[{'id': 2462, 'therapyName': 'Docetaxel + Prednisone'}, {'id': 893, 'therapyName': 'Reolysin'}]",Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer,2462
1,NCT02685267,Phase II,"Active, not recruiting","[{'id': 4681, 'therapyName': 'Docetaxel + Enzalutamide + Prednisone'}, {'id': 2462, 'therapyName': 'Docetaxel + Prednisone'}]",Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer (Doce/Enza),2462
0,NCT03095612,Phase Ib/II,Not yet recruiting,"[{'id': 5534, 'therapyName': 'Docetaxel + Selinexor'}]",Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC),5534
0,NCT02793219,Phase II,Not yet recruiting,"[{'id': 4270, 'therapyName': 'Docetaxel + Sipuleucel-T'}]",Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer,4270
1,NCT02793765,Phase II,Not yet recruiting,"[{'id': 4270, 'therapyName': 'Docetaxel + Sipuleucel-T'}]",Docetaxel Followed by Provenge in Metastatic Prostate Cancer,4270
0,NCT00589420,Phase II,Unknown status,"[{'id': 2390, 'therapyName': 'Docetaxel + Sorafenib'}]",Sorafenib and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy,2390
0,NCT00781612,Phase II,Recruiting,"[{'id': 5471, 'therapyName': 'Trastuzumab + trastuzumab emtansine'}, {'id': 5470, 'therapyName': 'Paclitaxel + trastuzumab emtansine'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 3930, 'therapyName': 'Docetaxel + T-DM1'}, {'id': 1976, 'therapyName': 'trastuzumab emtansine + Capecitabine'}, {'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}]",A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies,3930
0,NCT01376310,Phase II,"Active, not recruiting","[{'id': 1264, 'therapyName': 'Docetaxel + Trametinib'}, {'id': 1265, 'therapyName': 'Erlotinib + Trametinib'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 1266, 'therapyName': 'Pemetrexed + GSK1120212'}, {'id': 1267, 'therapyName': 'Carboplatin + GSK1120212'}, {'id': 1268, 'therapyName': 'nab-paclitaxel + GSK1120212'}, {'id': 1269, 'therapyName': 'Gemcitabine + GSK1120212'}, {'id': 1271, 'therapyName': 'Everolimus + GSK1120212'}]",GSK1120212 Rollover Study,1264
1,NCT02642042,Phase II,Recruiting,"[{'id': 1264, 'therapyName': 'Docetaxel + Trametinib'}]",Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV Non-small Cell Lung Cancer,1264
0,NCT01957007,Phase I,Completed,"[{'id': 4413, 'therapyName': 'Docetaxel + Vantictumab'}]",A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC,4413
0,NCT01455389,Phase Ib/II,Recruiting,"[{'id': 1313, 'therapyName': 'DOTAP:chol-Fus1'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer,1313
0,NCT01769547,Phase II,Terminated,"[{'id': 721, 'therapyName': 'Dovitinib'}]",A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy,721
1,NCT01831726,Phase II,Completed,"[{'id': 721, 'therapyName': 'Dovitinib'}]",Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib,721
2,NCT01497392,Phase I,Completed,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 721, 'therapyName': 'Dovitinib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]"," Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers",721
3,NCT01266070,,Terminated,"[{'id': 721, 'therapyName': 'Dovitinib'}]", TKI 258 in Von Hippel-Lindau Syndrome (VHL),721
4,NCT01484041,Phase Ib/II,Terminated,"[{'id': 721, 'therapyName': 'Dovitinib'}]",Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer,721
5,NCT02108782,Phase II,Withdrawn,"[{'id': 721, 'therapyName': 'Dovitinib'}]",Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors,721
6,NCT01753713,Phase II,"Active, not recruiting","[{'id': 721, 'therapyName': 'Dovitinib'}]",Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma,721
7,NCT01888965,Phase II,Terminated,"[{'id': 721, 'therapyName': 'Dovitinib'}]",Maintenance Dovitinib for Colorectal and Pancreas Cancer,721
8,NCT01994590,Phase II,Terminated,"[{'id': 721, 'therapyName': 'Dovitinib'}]",Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC),721
9,NCT02048943,Phase I,Withdrawn,"[{'id': 1372, 'therapyName': 'Dovitinib + Gemcitabine + Abraxane'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 721, 'therapyName': 'Dovitinib'}]","Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer",721
10,NCT01443481,Phase I,Completed,"[{'id': 721, 'therapyName': 'Dovitinib'}]",Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function,721
11,NCT01676714,Phase II,Completed,"[{'id': 721, 'therapyName': 'Dovitinib'}]",Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer,721
12,NCT01678105,,Completed,"[{'id': 721, 'therapyName': 'Dovitinib'}]", A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands,721
13,NCT01262027,Phase II,"Active, not recruiting","[{'id': 721, 'therapyName': 'Dovitinib'}]", TKI258 for Metastatic Inflammatory Breast Cancer Patients,721
14,NCT02116803,Phase III,Completed,"[{'id': 721, 'therapyName': 'Dovitinib'}]",An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective,721
0,NCT01700270,Phase I,Completed,"[{'id': 1232, 'therapyName': 'Dovitinib + Fluvoxamine'}]", Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.,1232
0,NCT02048943,Phase I,Withdrawn,"[{'id': 1372, 'therapyName': 'Dovitinib + Gemcitabine + Abraxane'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 721, 'therapyName': 'Dovitinib'}]","Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer",1372
0,NCT01815294,Phase I,Completed,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1008, 'therapyName': 'Doxil'}]", A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer,1008
1,NCT01990352,Phase II,Suspended,"[{'id': 1008, 'therapyName': 'Doxil'}]",Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy,1008
2,NCT01991210,Phase II,Terminated,"[{'id': 1345, 'therapyName': 'DNIB0600A'}, {'id': 1008, 'therapyName': 'Doxil'}]",A Randomized Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer,1008
3,NCT00092222,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1187, 'therapyName': 'Alpha 2 Interferon'}, {'id': 2211, 'therapyName': 'EPOCH'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1008, 'therapyName': 'Doxil'}]",Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity,1008
4,NCT02081495,Phase I,Completed,"[{'id': 1008, 'therapyName': 'Doxil'}]",A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer,1008
5,NCT01846611,Phase III,Recruiting,"[{'id': 1008, 'therapyName': 'Doxil'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]","A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",1008
0,NCT02839707,Phase II,Recruiting,"[{'id': 4496, 'therapyName': 'Atezolizumab + Bevacizumab + Doxil'}, {'id': 4495, 'therapyName': 'Atezolizumab + Doxil'}, {'id': 1673, 'therapyName': 'Doxil + Bevacizamub'}]","Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1673
1,NCT00923936,Phase II,"Active, not recruiting","[{'id': 1673, 'therapyName': 'Doxil + Bevacizamub'}]",Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma,1673
0,NCT02101788,Phase II,Recruiting,"[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 2173, 'therapyName': 'Doxil + Letrozole + Tamoxifen + Paclitaxel'}, {'id': 2, 'therapyName': 'Trametinib'}]",Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,2173
0,NCT02631876,Phase II,Recruiting,"[{'id': 3574, 'therapyName': 'Doxil + Paclitaxel'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3232, 'therapyName': 'IMGN853'}]","PH2 Study of IMGN853 vs Investigator's Choice of Chemo in Adults With FRa+ Adv. EOC, Primary Peritoneal or Primary Fallopian Tube Cancer",3574
0,NCT02865811,Phase II,"Active, not recruiting","[{'id': 4558, 'therapyName': 'Doxil + Pembrolizumab'}]","Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer",4558
0,NCT02188368,Phase II,Recruiting,"[{'id': 1625, 'therapyName': 'Bortezomib + Carfilzomib + Clarithromycin'}, {'id': 1674, 'therapyName': 'Doxil + Pomalidomide'}, {'id': 1622, 'therapyName': 'Pomalidomide'}]",Pomalidomide for Lenalidomide for Failures,1674
0,NCT01902225,Phase I,Unknown status,"[{'id': 3393, 'therapyName': 'Doxil + romidepsin '}]",Phase I Dose-finding and Preliminary Efficacy Study of the Istodax in Combination With Doxil for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma,3393
0,NCT03126916,Phase III,Not yet recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 5595, 'therapyName': 'Isotretinoin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 2286, 'therapyName': 'Dinutuximab  '}]",Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma,1009
1,NCT01459380,Phase I,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",1009
2,NCT01015833,Phase III,"Active, not recruiting","[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,1009
3,NCT02502266,Phase II,Suspended,"[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1001, 'therapyName': 'Cediranib'}]","Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1009
4,NCT03197935,Phase III,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer (IMpassion031),1009
5,NCT02349958,Phase II,Recruiting,"[{'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy,1009
6,NCT03117751,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,1009
7,NCT00074490,Phase II,Completed,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,1009
8,NCT00549848,Phase III,"Active, not recruiting","[{'id': 1781, 'therapyName': 'Vincristine + Pegaspargase + Daunorubicin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1782, 'therapyName': 'Clofarabine + Etoposide + Cyclophosphamide'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia,1009
9,NCT02648477,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer,1009
10,NCT01750073,Phase II,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1980, 'therapyName': 'Cyclophosphamide + Paclitaxel'}]",Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Stage I-III Breast Cancer,1009
11,NCT01815294,Phase I,Completed,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1008, 'therapyName': 'Doxil'}]", A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer,1009
12,NCT01857934,Phase II,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 2627, 'therapyName': 'Levetiracetam'}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 2458, 'therapyName': 'Hu14.18K322A'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}]",Therapy for Children With Advanced Stage Neuroblastoma,1009
13,NCT03145558,Phase II,Not yet recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 3028, 'therapyName': 'tirapazamine'}]",TATE Versus TACE in Intermediate Stage HCC (TATE),1009
14,NCT03150693,Phase III,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 3628, 'therapyName': 'Allopurinol'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]",Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia,1009
15,NCT02580058,Phase III,"Active, not recruiting","[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 3144, 'therapyName': 'Avelumab'}]",A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer,1009
16,NCT02331251,Phase Ib/II,"Active, not recruiting","[{'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 619, 'therapyName': 'Abraxane'}]",Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus),1009
17,NCT02446600,Phase III,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1001, 'therapyName': 'Cediranib'}]","Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1009
18,NCT02451943,Phase III,"Active, not recruiting","[{'id': 3269, 'therapyName': 'Olaratumab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma,1009
19,NCT02312245,Phase II,Recruiting,"[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",1009
20,NCT02460991,Phase I,Terminated,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma,1009
21,NCT01319981,Phase II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia,1009
22,NCT02112916,Phase III,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,1009
23,NCT01655693,Phase III,"Active, not recruiting","[{'id': 1009, 'therapyName': 'Doxorubicin'}]",Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma (ReLive),1009
24,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1009
25,NCT03007147,Phase III,Recruiting,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 5167, 'therapyName': 'Methylprednisolone'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 5168, 'therapyName': 'Prednisolone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,1009
26,NCT02049905,Phase III,Completed,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1440, 'therapyName': 'Aldoxorubicin'}, {'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}]",Phase 3 Study to Treat Patients With Soft Tissue Sarcomas,1009
27,NCT02483247,Phase Ib/II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1945, 'therapyName': 'BBI503'}]",A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer,1009
28,NCT02677116,Phase I,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 3618, 'therapyName': 'Irinotecan + Vincristine'}, {'id': 3269, 'therapyName': 'Olaratumab'}]",A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,1009
29,NCT02494713,Phase II,Recruiting,"[{'id': 1814, 'therapyName': 'Degarelix'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 2858, 'therapyName': 'Ketoconazole'}]",Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer,1009
30,NCT01523977,Phase I,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL,1009
31,NCT02456857,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 936, 'therapyName': 'Temsirolimus'}]","Liposomal Doxorubicin, Bevacizumab and Temsirolimus (DAT) in Triple-Negative Breast Cancer (TNBC) Insensitive to Standard Neoadjuvant Chemotherapy",1009
32,NCT02606305,Phase I,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 3232, 'therapyName': 'IMGN853'}]","Study of IMGN853 in Comb. With Bevacizumab, Carboplatin or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer",1009
33,NCT00980460,Phase III,Recruiting,"[{'id': 2298, 'therapyName': 'Irinotecan + Temsirolimus + Vincristine'}, {'id': 2297, 'therapyName': 'Cisplatin + Fluorouracil + Vincristine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer,1009
34,NCT03004287,Phase II,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy,1009
35,NCT02094872,Phase II,"Active, not recruiting","[{'id': 1009, 'therapyName': 'Doxorubicin'}]",Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic,1009
36,NCT03023046,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}]","Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",1009
37,NCT03056599,,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1733, 'therapyName': 'interferon gamma '}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 3420, 'therapyName': 'trabectedin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma,1009
38,NCT02419755,Phase II,Terminated,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies,1009
39,NCT03020030,Phase III,Recruiting,"[{'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents,1009
40,NCT01375699,Phase I,"Active, not recruiting","[{'id': 1009, 'therapyName': 'Doxorubicin'}]","Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers",1009
41,NCT02192021,Phase I,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}]",Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL),1009
42,NCT02419495,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Selinexor in Combination With Standard Chemotherapy,1009
0,NCT01746238,Phase I,"Active, not recruiting","[{'id': 1473, 'therapyName': 'Doxorubicin + Bevacizumab'}]",Bevacizumab/Doxorubicin/Radiation for Sarcoma,1473
0,NCT01796197,Phase II,"Active, not recruiting","[{'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa,1977
1,NCT02876107,Phase II,Recruiting,"[{'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 3386, 'therapyName': 'Carboplatin + Paclitaxel + Panitumumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Phase II Study of Using Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen (AC) for New Triple-Negative Inflammatory Breast Cancer (TN-IBC),1977
2,NCT01897441,Phase I,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]",Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer,1977
3,NCT03036488,Phase III,Recruiting,"[{'id': 1087, 'therapyName': 'Epirubicin + Cyclophosphamide'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522),1977
4,NCT01501487,FDA approved,"Active, not recruiting","[{'id': 1902, 'therapyName': 'Docetaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1485, 'therapyName': 'Trastuzumab + Docetaxel + Carboplatin'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]",MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I,1977
5,NCT02489448,Phase Ib/II,Recruiting,"[{'id': 3100, 'therapyName': 'MEDI4736 + nab-paclitaxel'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]",Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer,1977
6,NCT02032277,Phase III,"Active, not recruiting","[{'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer,1977
7,NCT01697293,Phase Ib/II,Recruiting,"[{'id': 3054, 'therapyName': 'Paclitaxel + Triciribine'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]","Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer",1977
8,NCT02789657,Phase II,Recruiting,"[{'id': 4235, 'therapyName': 'Carboplatin + Pertuzumab + Trastuzumab + Paclitaxel'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]",BrUOG 308: Efficacy of wPCbTP and Switching to an AC in Non-responding Patients as Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.,1977
9,NCT00574587,Phase Ib/II,Unknown status,"[{'id': 1983, 'therapyName': 'vorinostat + Paclitaxel'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]","Trial for Locally Advanced Her2 Positive Breast Cancer Using Paclitaxel, Trastuzumab, Doxorubicin and Cyclophasmide on a Weekly Basis",1977
0,NCT02957968,Phase II,Recruiting,"[{'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 5729, 'therapyName': 'Doxorubicin + Cyclophosphamide + Paclitaxel + Carboplatin'}]",Neoadj Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca,5729
0,NCT02356159,Phase Ib/II,Recruiting,"[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 2292, 'therapyName': 'Doxorubicin + Etoposide + Fludarabine + Vincristine '}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation,2292
0,NCT02538926,Phase II,Not yet recruiting,"[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 3212, 'therapyName': 'Doxorubicin + Etoposide + Vincristine '}, {'id': 2206, 'therapyName': 'Asparaginase'}]","Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",3212
0,NCT01446809,Phase I,"Active, not recruiting","[{'id': 1472, 'therapyName': 'Doxorubicin + Ifosfamide'}, {'id': 1471, 'therapyName': 'Pazopanib + Doxorubicin + Ifosfamide'}]",Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma,1472
1,NCT02180867,Phase II,Recruiting,"[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1472, 'therapyName': 'Doxorubicin + Ifosfamide'}]",Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can be Removed by Surgery (PAZNTIS),1472
0,NCT03283696,Phase I,Not yet recruiting,"[{'id': 6292, 'therapyName': 'Doxorubicin + Ifosfamide + Mesna + Olaratumab'}]","A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma",6292
0,NCT02584309,Phase II,Recruiting,"[{'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 4140, 'therapyName': 'Doxorubicin + Olaratumab'}]",Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma,4140
1,NCT02783599,Phase I,Recruiting,"[{'id': 4140, 'therapyName': 'Doxorubicin + Olaratumab'}]",A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma,4140
0,NCT03056001,Phase II,Recruiting,"[{'id': 4690, 'therapyName': 'Doxorubicin + Pembrolizumab'}]","Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma",4690
1,NCT02888665,Phase Ib/II,Recruiting,"[{'id': 4690, 'therapyName': 'Doxorubicin + Pembrolizumab'}]",Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery,4690
0,NCT03009201,Phase I,Recruiting,"[{'id': 5179, 'therapyName': 'Doxorubicin + Ribociclib'}]",Ribociclib and Doxorubicin Hydrochloride in Treating Patients Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery,5179
0,NCT01840592,Phase II,"Active, not recruiting","[{'id': 2363, 'therapyName': 'Doxorubicin + Sorafenib'}]",Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib,2363
0,NCT01874860,Phase I,Recruiting,"[{'id': 1391, 'therapyName': 'Doxycycline'}]",Skin Rash Study Before Chemotherapy in Colorectal &amp; Head and Neck Cancer Patients,1391
1,NCT03076281,Phase II,Recruiting,"[{'id': 1391, 'therapyName': 'Doxycycline'}, {'id': 4610, 'therapyName': 'Metformin + Doxycycline'}, {'id': 1031, 'therapyName': 'Metformin'}]",Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery,1391
2,NCT01465802,Phase II,Completed,"[{'id': 714, 'therapyName': 'Dacomitinib'}, {'id': 1392, 'therapyName': 'Alclometasone'}, {'id': 1391, 'therapyName': 'Doxycycline'}]",Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO,1391
0,NCT01288430,Phase I,Terminated,"[{'id': 1181, 'therapyName': 'DS-2248'}]","A Study of DS-2248, in Subjects With Advanced Solid Tumors",1181
0,NCT02579824,Phase I,Recruiting,"[{'id': 2079, 'therapyName': 'DS-3032b'}]",DS-3032b for Relapsed and/or Refractory (RR) Myeloma,2079
1,NCT01877382,Phase I,Recruiting,"[{'id': 2079, 'therapyName': 'DS-3032b'}]","A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral Murine Double Minute 2 (MDM2) Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas",2079
2,NCT02319369,Phase I,Recruiting,"[{'id': 2079, 'therapyName': 'DS-3032b'}]","Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-3032b in Hematological Malignancies",2079
0,NCT01588678,Phase I,Completed,"[{'id': 1010, 'therapyName': 'DS-3078a'}]"," A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas",1010
0,NCT03110354,Phase I,Recruiting,"[{'id': 5691, 'therapyName': 'DS-3201b'}]",DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL),5691
0,NCT02564900,Phase I,Recruiting,"[{'id': 4844, 'therapyName': 'DS-8201a'}]",Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors,4844
1,NCT03248492,Phase II,Recruiting,"[{'id': 4844, 'therapyName': 'DS-8201a'}]",DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,4844
0,NCT02991196,Phase I,Terminated,"[{'id': 5078, 'therapyName': 'DS-8273a + Nivolumab'}]",Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer,5078
1,NCT02983006,Phase I,Recruiting,"[{'id': 5078, 'therapyName': 'DS-8273a + Nivolumab'}]",Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma,5078
0,NCT02279433,Phase I,"Active, not recruiting","[{'id': 4343, 'therapyName': 'DS6051b'}]","A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b",4343
0,NCT02498665,Phase I,Recruiting,"[{'id': 4320, 'therapyName': 'DSP-7888'}]",A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies,4320
0,NCT02273375,Phase III,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC,1356
1,NCT02886065,Phase I,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 5082, 'therapyName': 'PVX-410 + MEDI4736'}, {'id': 5081, 'therapyName': 'PVX-410 + MEDI4736 + lenalidomide'}]","A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Durvalumab (Anti-PDL1) With and Without Lenalidomide for Patients With Smoldering Multiple Myeloma",1356
2,NCT03015129,Phase II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer,1356
3,NCT03038477,Phase II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",A Study of Durvalumab in Patients With Borderline Resectable Pancreas Adenocarcinoma Following Neoadjuvant Therapy and Successful Surgical Resection,1356
4,NCT02793466,Phase I,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab in Pediatric and Adolescent Patients,1356
5,NCT02527434,Phase II,"Active, not recruiting","[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of Tremelimumab in Patients With Advanced Solid Tumors,1356
6,NCT03084471,Phase III,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies. (STRONG)",1356
7,NCT03298451,Phase III,Not yet recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma,1356
8,NCT02516241,Phase III,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 4686, 'therapyName': 'Carboplatin + Cisplatin + Gemcitabine'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer,1356
9,NCT03196401,Phase I,Suspended,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",A Study of Immunotherapy Plus Radiation Therapy to Stimulate Immunity in Solitary Bone Plasmacytoma,1356
10,NCT02319044,Phase II,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck",1356
11,NCT02558894,Phase II,Completed,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma,1356
12,NCT02899195,Phase II,Recruiting,"[{'id': 5630, 'therapyName': 'Cisplatin + Durvalumab + Pemetrexed'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma (PrE0505),1356
13,NCT02207530,Phase II,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}]",Phase II Study of MEDI4736 Monotherapy in the Treatment of Patients With Recurrent or Metastatic SCCHN.,1356
14,NCT02788773,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer,1356
15,NCT03206073,Phase Ib/II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer,1356
16,NCT02369874,Phase III,"Active, not recruiting","[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer,1356
17,NCT02879617,Phase II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients,1356
18,NCT02340975,Phase Ib/II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma",1356
19,NCT03011814,Phase Ib/II,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3934, 'therapyName': 'lenalidomide + MEDI4736'}]",Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma,1356
20,NCT02227667,Phase II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer,1356
21,NCT02966587,Phase II,Not yet recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,1356
22,NCT02891161,Phase Ib/II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder,1356
23,NCT02901548,Phase II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder,1356
24,NCT02549651,Phase I,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3098, 'therapyName': 'AZD9150 + MEDI4736'}]",MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Diffuse Large B-cell Lymphoma (D4190C00023),1356
25,NCT03235869,Phase I,Not yet recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma,1356
26,NCT02205333,Phase Ib/II,Terminated,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1653, 'therapyName': 'MEDI6469'}, {'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies,1356
27,NCT02551159,Phase III,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1914, 'therapyName': 'Cetuximab + Carboplatin + Fluorouracil'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN,1356
28,NCT02904954,Phase II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage IB and II Non-small Cell Lung Cancer,1356
29,NCT02221960,Phase I,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3119, 'therapyName': 'MEDI6383'}]",A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors,1356
30,NCT03007407,Phase II,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy,1356
31,NCT02592551,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma,1356
32,NCT03150836,Phase II,Not yet recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer",1356
33,NCT02291055,Phase Ib/II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3090, 'therapyName': 'ADXS11-001'}]",Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head &amp; Neck Cancer,1356
34,NCT02154490,Phase II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 1016, 'therapyName': 'GDC-0032'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 629, 'therapyName': 'AMG102'}]",Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,1356
35,NCT02179671,Phase II,Completed,"[{'id': 1117, 'therapyName': 'Selumetinib + Docetaxel'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 660, 'therapyName': 'AZD9291'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer",1356
36,NCT02087423,Phase II,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}]",A Global Study to Assess the Effects of MEDI4736 in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ATLANTIC),1356
37,NCT02262741,Phase I,"Active, not recruiting","[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 With Tremelimumab or Tremelimumab Alone in Head and Neck Cancer",1356
38,NCT02454933,Phase III,"Active, not recruiting","[{'id': 660, 'therapyName': 'AZD9291'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours,1356
39,NCT02639065,Phase II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",A Study of Durvalumab (MEDI4736) in Esophageal Cancer,1356
40,NCT03164616,Phase III,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}]",Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON),1356
41,NCT02503774,Phase I,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3089, 'therapyName': 'MEDI9447'}]",MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors,1356
42,NCT02301130,Phase I,"Active, not recruiting","[{'id': 2968, 'therapyName': 'Mogamulizumab '}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Study of Mogamulizumab + MEDI4736 and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors,1356
43,NCT02537418,Phase I,"Active, not recruiting","[{'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens,1356
44,NCT02352948,Phase III,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2438, 'therapyName': 'Erlotinib + Gemcitabine + Vinorelbine'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer",1356
45,NCT02546661,Phase I,Recruiting,"[{'id': 654, 'therapyName': 'AZD4547'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer",1356
46,NCT02088112,Phase I,"Active, not recruiting","[{'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC),1356
47,NCT02519348,Phase II,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","A Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Unresectable Hepatocellular Carcinoma",1356
48,NCT03026062,Phase II,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab and Tremelimumab in Combo Versus Sequential,1356
49,NCT01693562,Phase Ib/II,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}]",A Phase 1/2 Study to Evaluate MEDI4736,1356
50,NCT02733042,Phase Ib/II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 4278, 'therapyName': 'lenalidomide + MEDI4736 + Rituximab'}, {'id': 4279, 'therapyName': 'Bendamustine + MEDI4736 + Rituximab'}, {'id': 2573, 'therapyName': 'Ibrutinib + MEDI4736'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia (FUSION NHL 001)",1356
51,NCT02616640,Phase I,"Active, not recruiting","[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma,1356
52,NCT03277482,Phase I,Not yet recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer",1356
53,NCT02453282,Phase III,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC).,1356
54,NCT03144778,Phase I,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Checkpoint Inhibitors Assessment in Oropharynx Carcinoma (CIAO),1356
55,NCT02336165,Phase II,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2117, 'therapyName': 'Bevacizumab + MEDI4736'}]",Phase 2 Study of MEDI4736 in Patients With Glioblastoma,1356
56,NCT03199040,Phase I,Not yet recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy,1356
57,NCT02868632,Phase I,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer",1356
58,NCT03258554,Phase II,Not yet recruiting,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Stage III-IVB Head and Neck Cancer Who Cannot Take Cisplatin,1356
59,NCT03283943,Phase I,Not yet recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.,1356
60,NCT03245541,Phase Ib/II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Study of Durvalumab and Stereotactive Ablative Body Radiotherapy in Advanced Pancreatic Adenocarcinoma (DurvaRad),1356
61,NCT02827838,Phase I,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer,1356
62,NCT02311361,Phase I,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer,1356
63,NCT02535078,Phase Ib/II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3847, 'therapyName': 'IMCgp100'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Cutaneous Melanoma,1356
64,NCT03215095,Phase I,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers,1356
65,NCT02125461,Phase III,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}]",A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC),1356
66,NCT02499328,Phase Ib/II,Recruiting,"[{'id': 3098, 'therapyName': 'AZD9150 + MEDI4736'}, {'id': 3099, 'therapyName': 'AZD5069 + MEDI4736'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2782, 'therapyName': 'AZD9150 '}]",Study to Assess Combination of MEDI4736 With Either AZD9150 or AZD5069 in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck,1356
67,NCT02669914,Phase II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors,1356
68,NCT02794883,Phase II,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma,1356
0,NCT03162224,Phase Ib/II,Recruiting,"[{'id': 5791, 'therapyName': 'Durvalumab + MEDI0457'}]",Safety and Efficacy of MEDI0457 and Durvalumab in Patients With HPV Associated Recurrent/Metastatic Head and Neck Cancer,5791
0,NCT02734004,Phase Ib/II,"Active, not recruiting","[{'id': 2894, 'therapyName': 'Durvalumab + Olaparib'}]",A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA),2894
1,NCT02484404,Phase Ib/II,Recruiting,"[{'id': 2895, 'therapyName': 'Cediranib + Durvalumab'}, {'id': 2894, 'therapyName': 'Durvalumab + Olaparib'}]",Phase 1 and 2 Study of MEDI4736 in Combination With Olaparib or Cediranib for Advanced Solid Tumors and Recurrent Ovarian Cancer,2894
0,NCT03258593,Phase I,Not yet recruiting,"[{'id': 6291, 'therapyName': 'Durvalumab + Oportuzumab monatox'}]",Durvalumab and Vicinium in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG),6291
0,NCT03161223,Phase Ib/II,Not yet recruiting,"[{'id': 5882, 'therapyName': 'Durvalumab + Romidepsin'}, {'id': 4178, 'therapyName': 'Azacitidine + MEDI4736'}, {'id': 5881, 'therapyName': 'Azacitidine + Durvalumab + Romidepsin'}, {'id': 5880, 'therapyName': 'Durvalumab + Pralatrexate + Romidepsin'}]","Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma",5880
0,NCT03161223,Phase Ib/II,Not yet recruiting,"[{'id': 5882, 'therapyName': 'Durvalumab + Romidepsin'}, {'id': 4178, 'therapyName': 'Azacitidine + MEDI4736'}, {'id': 5881, 'therapyName': 'Azacitidine + Durvalumab + Romidepsin'}, {'id': 5880, 'therapyName': 'Durvalumab + Pralatrexate + Romidepsin'}]","Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma",5882
0,NCT03257761,Phase I,Not yet recruiting,"[{'id': 6146, 'therapyName': 'Durvalumab + SGI-110'}]","Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer",6146
0,NCT02027961,Phase Ib/II,"Active, not recruiting","[{'id': 1357, 'therapyName': 'Dabrafenib + Durvalumab + Trametinib'}, {'id': 1358, 'therapyName': 'Durvalumab + Trametinib'}]",Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone,1358
0,NCT03084471,Phase III,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies. (STRONG)",2439
1,NCT03164616,Phase III,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}]",Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON),2439
2,NCT03298451,Phase III,Not yet recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma,2439
3,NCT02000947,Phase Ib/II,"Active, not recruiting","[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer,2439
4,NCT02938793,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors,2439
5,NCT02812420,Phase I,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Neoadjuvant Chemotherapy",2439
6,NCT03130764,Phase II,Not yet recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC,2439
7,NCT03005002,Phase I,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver,2439
8,NCT03150836,Phase II,Not yet recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer",2439
9,NCT03158064,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors",2439
10,NCT03277482,Phase I,Not yet recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer",2439
11,NCT02542293,Phase III,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]",Study of 1st Line Therapy Study of MEDI4736 With Tremelimumab Versus SoC in Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE).,2439
12,NCT02868632,Phase I,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer",2439
13,NCT02879162,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours,2439
14,NCT03122509,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer",2439
15,NCT02879318,Phase II,Recruiting,"[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Pancreatic Adenocarcinoma",2439
16,NCT03122496,Phase I,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer,2439
17,NCT02815995,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes,2439
18,NCT02639026,Phase I,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers",2439
19,NCT03026062,Phase II,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab and Tremelimumab in Combo Versus Sequential,2439
20,NCT02352948,Phase III,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2438, 'therapyName': 'Erlotinib + Gemcitabine + Vinorelbine'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer",2439
21,NCT03275597,Phase I,Not yet recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition,2439
22,NCT02369874,Phase III,"Active, not recruiting","[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer,2439
23,NCT02788773,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer,2439
24,NCT02870920,Phase II,"Active, not recruiting","[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients With Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies,2439
25,NCT03144778,Phase I,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Checkpoint Inhibitors Assessment in Oropharynx Carcinoma (CIAO),2439
26,NCT03015129,Phase II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer,2439
27,NCT03206073,Phase Ib/II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer,2439
28,NCT03132467,Phase I,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 Antibody (Tremelimumab) in HR+/HER2- Breast Cancer,2439
29,NCT03057106,Phase II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC,2439
30,NCT03204812,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Tremelimumab + Durvalumab Chemotherapy Naive CRPC,2439
31,NCT02716805,Phase I,"Active, not recruiting","[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Phase 1 Study to Assess Safety & Tolerability of Tremelimumab & Durvalumab, Administered With High Dose Chemotherapy and Autologous Stem Cell Transplant",2439
32,NCT02592551,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma,2439
33,NCT02516241,Phase III,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 4686, 'therapyName': 'Carboplatin + Cisplatin + Gemcitabine'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer,2439
34,NCT02549651,Phase I,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3098, 'therapyName': 'AZD9150 + MEDI4736'}]",MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Diffuse Large B-cell Lymphoma (D4190C00023),2439
35,NCT02527434,Phase II,"Active, not recruiting","[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of Tremelimumab in Patients With Advanced Solid Tumors,2439
36,NCT01975831,Phase I,"Active, not recruiting","[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab,2439
37,NCT02536794,Phase II,Suspended,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer,2439
38,NCT02658214,Phase I,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors,2439
39,NCT02888743,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer,2439
40,NCT02261220,Phase I,"Active, not recruiting","[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors,2439
41,NCT02762006,Phase I,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma,2439
42,NCT02794883,Phase II,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma,2439
43,NCT03075527,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma,2439
44,NCT03283605,Phase Ib/II,Not yet recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas,2439
45,NCT02821754,Phase Ib/II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC),2439
0,NCT01342367,Phase I,Recruiting,"[{'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 2643, 'therapyName': 'Dutasteride'}, {'id': 2644, 'therapyName': 'Finasteride'}]",Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer,2643
0,NCT02213107,Phase II,"Active, not recruiting","[{'id': 3067, 'therapyName': 'Dutasteride + Enzalutamide'}]",Enzalutamide & Dutasteride as 1st Line Treatment for Patients =/&gt; 65 Years Old With Prostate Cancer.,3067
0,NCT02004522,Phase III,"Active, not recruiting","[{'id': 1024, 'therapyName': 'Duvelisib'}, {'id': 1090, 'therapyName': 'Ofatumumab'}]",A Phase 3 Study of IPI-145 Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO),1024
1,NCT02204982,Phase III,Terminated,"[{'id': 1024, 'therapyName': 'Duvelisib'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of IPI-145 in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma (DYNAMO + R),1024
2,NCT01871675,Phase I,Completed,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1024, 'therapyName': 'Duvelisib'}, {'id': 1231, 'therapyName': 'Bendamustine'}]","Phase Ib Study of IPI-145 in Combination With Bendamustine, Rituximab or Bendamustine/Rituximab in Hematologic Malignancies",1024
3,NCT01882803,Phase II,"Active, not recruiting","[{'id': 1024, 'therapyName': 'Duvelisib'}]",A Phase 2 Study of IPI-145 in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO),1024
4,NCT02158091,Phase Ib/II,"Active, not recruiting","[{'id': 2339, 'therapyName': 'Cyclophosphamide + Fludarabine + Rituximab '}, {'id': 1024, 'therapyName': 'Duvelisib'}]","A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL",1024
5,NCT02049515,Phase III,Enrolling by invitation,"[{'id': 1090, 'therapyName': 'Ofatumumab'}, {'id': 1024, 'therapyName': 'Duvelisib'}]",A Phase 3 Extension Study of IPI-145 and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07,1024
6,NCT02576275,Phase III,Withdrawn,"[{'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 1024, 'therapyName': 'Duvelisib'}]",A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA),1024
0,NCT02292225,Phase I,Terminated,"[{'id': 2341, 'therapyName': 'Duvelisib + Obinutuzumab'}]",IPI-145 With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi,2341
0,NCT02605694,Phase II,Withdrawn,"[{'id': 3389, 'therapyName': 'Duvelisib + Rituximab'}, {'id': 2195, 'therapyName': 'R-CHOP'}]",Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO),3389
0,NCT02783625,Phase I,Recruiting,"[{'id': 4240, 'therapyName': 'Bortezomib + Duvelisib'}, {'id': 4239, 'therapyName': 'Duvelisib + romidepsin '}]",Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas,4239
0,NCT02418000,Phase Ib/II,Terminated,"[{'id': 1011, 'therapyName': 'E6201'}]",A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 Mutation,1011
0,NCT02540291,Phase I,Recruiting,"[{'id': 5694, 'therapyName': 'E7046'}]",Study of E7046 in Subjects With Selected Advanced Malignancies,5694
0,NCT03152370,Phase I,Recruiting,"[{'id': 5798, 'therapyName': 'E7046 + mFOLFOX-6'}, {'id': 5805, 'therapyName': 'Capecitabine + E7046'}]",Preoperative Radiotherapy and E7046 in Rectum Cancer (PRAER 1),5798
0,NCT01570036,Phase II,Recruiting,"[{'id': 3766, 'therapyName': 'E75'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax,3766
1,NCT01479244,Phase III,Completed,"[{'id': 3766, 'therapyName': 'E75'}, {'id': 1873, 'therapyName': 'Sargramostim'}]",Efficacy and Safety Study of NeuVax (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence,3766
2,NCT02297698,Phase II,Recruiting,"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 3766, 'therapyName': 'E75'}]",Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients,3766
0,NCT01498484,Phase II,"Active, not recruiting","[{'id': 5057, 'therapyName': 'EB-VST cells'}]",Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies,5057
0,NCT02973113,Phase I,Recruiting,"[{'id': 5058, 'therapyName': 'EB-VST cells + Nivolumab'}]","Nivolumab With Epstein Barr Virus Specific T Cells (EB-VSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) (PREVALE)",5058
0,NCT01999738,Phase I,"Active, not recruiting","[{'id': 1603, 'therapyName': 'EC1456'}]",Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors,1603
0,NCT02576496,Phase I,Recruiting,"[{'id': 6104, 'therapyName': 'EDO-S101'}]","Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies",6104
0,NCT02139397,Phase Ib/II,Recruiting,"[{'id': 2629, 'therapyName': 'Eflornithine'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Study of DFMO in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma,2629
1,NCT02559778,Phase I,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2629, 'therapyName': 'Eflornithine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 717, 'therapyName': 'Dasatinib'}]",Pediatric Precision Laboratory Advanced Neuroblastoma Therapy,2629
0,NCT02605083,Phase Ib/II,Recruiting,"[{'id': 4005, 'therapyName': 'eFT508'}]",A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors,4005
1,NCT02937675,Phase Ib/II,Recruiting,"[{'id': 4005, 'therapyName': 'eFT508'}]",A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies,4005
2,NCT03258398,Phase II,Recruiting,"[{'id': 6238, 'therapyName': 'Avelumab + eFT508'}, {'id': 4005, 'therapyName': 'eFT508'}]",A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer,4005
0,NCT02108964,Phase Ib/II,Recruiting,"[{'id': 1309, 'therapyName': 'EGF816'}]","A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies",1309
0,NCT03292133,Phase II,Not yet recruiting,"[{'id': 6287, 'therapyName': 'EGF816 + Gefitinib'}]",A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer,6287
0,NCT02335944,Phase Ib/II,Recruiting,"[{'id': 2445, 'therapyName': 'EGF816 + INC280'}]",Study of Safety and Efficacy of EGF816 in Combination With INC280 in Non-small Cell Lung Cancer Patients With EGFR Mutation.,2445
0,NCT02323126,Phase II,Recruiting,"[{'id': 2443, 'therapyName': 'EGF816 + Nivolumab'}, {'id': 2444, 'therapyName': 'INC280 + Nivolumab'}]",Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer,2443
0,NCT00903461,Phase Ib/II,Terminated,"[{'id': 2130, 'therapyName': 'EGFR Antisense DNA'}]",Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma,2130
0,NCT02766699,Phase I,Recruiting,"[{'id': 5331, 'therapyName': 'EGFR(V)-EDV-Dox'}]","A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM) (CerebralEDV)",5331
0,NCT02521090,Phase Ib/II,Withdrawn,"[{'id': 1012, 'therapyName': 'EGFRBi-armed autologous activated T cells'}]",EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma,1012
1,NCT01081808,Phase I,Terminated,"[{'id': 1012, 'therapyName': 'EGFRBi-armed autologous activated T cells'}]","Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors",1012
2,NCT01420874,Phase I,"Active, not recruiting","[{'id': 1012, 'therapyName': 'EGFRBi-armed autologous activated T cells'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Anti-CD3 x Anti-Erbitux Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer),1012
3,NCT00569296,,Terminated,"[{'id': 1012, 'therapyName': 'EGFRBi-armed autologous activated T cells'}]"," Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer",1012
0,NCT01729091,Phase Ib/II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3343, 'therapyName': 'Elotuzumab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1164, 'therapyName': 'lenalidomide'}]",Study of Umbilical Cord Blood-derived Natural Killer Cells in Conjunction With High Dose Chemotherapy and Autologous Stem Cell Transplant for Patients With Multiple Myeloma,3343
1,NCT02726581,Phase III,"Active, not recruiting","[{'id': 3343, 'therapyName': 'Elotuzumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 3792, 'therapyName': 'Dexamethasone + Pomalidomide'}]","Study of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Multiple Myeloma",3343
2,NCT01668719,Phase Ib/II,Recruiting,"[{'id': 3343, 'therapyName': 'Elotuzumab'}, {'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}]","S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",3343
3,NCT02654132,Phase II,"Active, not recruiting","[{'id': 3792, 'therapyName': 'Dexamethasone + Pomalidomide'}, {'id': 3343, 'therapyName': 'Elotuzumab'}]",Trial of Elotuzumab With or Without Pomalidomide and Low-dose Dexamethasone to Treat Refractory and Relapsed and Refractory Multiple Myeloma,3343
4,NCT02252263,Phase I,"Active, not recruiting","[{'id': 2055, 'therapyName': 'Urelumab'}, {'id': 2583, 'therapyName': 'Lirilumab '}, {'id': 3343, 'therapyName': 'Elotuzumab'}]",A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma,3343
5,NCT02375555,Phase II,"Active, not recruiting","[{'id': 3343, 'therapyName': 'Elotuzumab'}, {'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}]","Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM",3343
0,NCT02159365,Phase II,"Active, not recruiting","[{'id': 3353, 'therapyName': 'Elotuzumab + Dexamethasone + Lenalidomide'}]",Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients,3353
1,NCT03168100,Phase II,Recruiting,"[{'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}, {'id': 3353, 'therapyName': 'Elotuzumab + Dexamethasone + Lenalidomide'}]","2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma",3353
2,NCT02368301,Phase I,Approved for marketing,"[{'id': 3353, 'therapyName': 'Elotuzumab + Dexamethasone + Lenalidomide'}]",Expanded Access Treatment Protocol CA204-143,3353
3,NCT02843074,Phase II,Recruiting,"[{'id': 3353, 'therapyName': 'Elotuzumab + Dexamethasone + Lenalidomide'}]","Elotuzumab, Lenalidomide and Dexamethasone (ERd) in the Induction, Consolidation and Maintenance Treatment of Transplant-Eligible, Newly Diagnosed Multiple Myeloma Patients",3353
0,NCT02612779,Phase II,"Active, not recruiting","[{'id': 3355, 'therapyName': 'Elotuzumab + Dexamethasone + Pomalidomide'}]",A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone (EPd) in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide,3355
1,NCT03030261,Phase II,Not yet recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 3355, 'therapyName': 'Elotuzumab + Dexamethasone + Pomalidomide'}]","Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma",3355
0,NCT02420860,Phase II,Recruiting,"[{'id': 5972, 'therapyName': 'Famotidine'}, {'id': 3430, 'therapyName': 'Elotuzumab + lenalidomide'}, {'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Study of Elotuzumab With Lenalidomide as Maintenance After Autologous Stem Cell Transplant (ASCT),3430
1,NCT02279394,Phase II,"Active, not recruiting","[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3430, 'therapyName': 'Elotuzumab + lenalidomide'}]",Trial of Combination of Elotuzumab and Lenalidomide +/- Dexamethasone in High-Risk Smoldering Multiple Myeloma,3430
2,NCT02655458,Phase I,Completed,"[{'id': 3430, 'therapyName': 'Elotuzumab + lenalidomide'}]",Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma,3430
0,NCT03227432,Phase II,Not yet recruiting,"[{'id': 6118, 'therapyName': 'Dexamethasone + Elotuzumab + Nivolumab + Pomalidomide'}, {'id': 6117, 'therapyName': 'Elotuzumab + Nivolumab'}]",An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma,6117
0,NCT02010645,Phase II,"Active, not recruiting","[{'id': 1763, 'therapyName': 'Eltrombopag + Decitabine'}]",Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS),1763
0,NCT01494688,Phase I,"Active, not recruiting","[{'id': 2843, 'therapyName': 'Emactuzumab'}, {'id': 4249, 'therapyName': 'Emactuzumab + Paclitaxel'}]",A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Patients With Advanced Solid Tumors,2843
0,NCT01494688,Phase I,"Active, not recruiting","[{'id': 2843, 'therapyName': 'Emactuzumab'}, {'id': 4249, 'therapyName': 'Emactuzumab + Paclitaxel'}]",A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Patients With Advanced Solid Tumors,4249
0,NCT02760797,Phase I,Recruiting,"[{'id': 4181, 'therapyName': 'Emactuzumab + RO7009789'}]",A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors,4181
0,NCT01014936,,Completed,"[{'id': 726, 'therapyName': 'EMD 1214063'}]"," First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors",726
0,NCT00828009,Phase II,Unknown status,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 2142, 'therapyName': 'Emepepimut-S  '}, {'id': 1092, 'therapyName': 'Carboplatin'}]",BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery,2142
0,NCT01900652,Phase II,Completed,"[{'id': 1179, 'therapyName': 'Emibetuzumab + Erlotinib'}, {'id': 803, 'therapyName': 'Emibetuzumab'}]",A Study of LY2875358 in Non Small Cell Lung Cancer (NSCLC) Participants,803
1,NCT01287546,Phase I,Completed,"[{'id': 1179, 'therapyName': 'Emibetuzumab + Erlotinib'}, {'id': 1180, 'therapyName': 'Emibetuzumab + Trametinib'}, {'id': 803, 'therapyName': 'Emibetuzumab'}]",A Study of LY2875358 in Participants With Advanced Cancer,803
0,NCT01900652,Phase II,Completed,"[{'id': 1179, 'therapyName': 'Emibetuzumab + Erlotinib'}, {'id': 803, 'therapyName': 'Emibetuzumab'}]",A Study of LY2875358 in Non Small Cell Lung Cancer (NSCLC) Participants,1179
1,NCT01287546,Phase I,Completed,"[{'id': 1179, 'therapyName': 'Emibetuzumab + Erlotinib'}, {'id': 1180, 'therapyName': 'Emibetuzumab + Trametinib'}, {'id': 803, 'therapyName': 'Emibetuzumab'}]",A Study of LY2875358 in Participants With Advanced Cancer,1179
0,NCT02082210,Phase Ib/II,"Active, not recruiting","[{'id': 1387, 'therapyName': 'Emibetuzumab + Ramucirumab'}]",A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer,1387
0,NCT01287546,Phase I,Completed,"[{'id': 1179, 'therapyName': 'Emibetuzumab + Erlotinib'}, {'id': 1180, 'therapyName': 'Emibetuzumab + Trametinib'}, {'id': 803, 'therapyName': 'Emibetuzumab'}]",A Study of LY2875358 in Participants With Advanced Cancer,1180
0,NCT02636036,Phase I,Recruiting,"[{'id': 3620, 'therapyName': 'Enadenotucirev + Pembrolizumab'}]",Study of Enadenotucirev and Pembrolizumab in Subjects With Metastatic or Advanced Epithelial Tumors,3620
0,NCT02273739,Phase Ib/II,Completed,"[{'id': 2982, 'therapyName': 'Enasidenib'}]","Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation",2982
1,NCT02632708,Phase I,Recruiting,"[{'id': 1491, 'therapyName': 'AG-120'}, {'id': 2982, 'therapyName': 'Enasidenib'}, {'id': 3431, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide + Mitoxantrone'}]",Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation,2982
2,NCT01915498,Phase I,"Active, not recruiting","[{'id': 2982, 'therapyName': 'Enasidenib'}]",Phase 1 Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation,2982
3,NCT02577406,Phase III,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 2982, 'therapyName': 'Enasidenib'}]",An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation (IDHENTIFY),2982
0,NCT01894672,Phase II,Completed,"[{'id': 796, 'therapyName': 'Encorafenib'}]","BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation",796
1,NCT01777776,Phase Ib/II,Terminated,"[{'id': 796, 'therapyName': 'Encorafenib'}, {'id': 1260, 'therapyName': 'Encorafenib + Ribociclib'}]",Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.,796
2,NCT01981187,Phase II,Completed,"[{'id': 796, 'therapyName': 'Encorafenib'}]",LGX818 for Patients With BRAFV600 Mutated Tumors,796
3,NCT01909453,Phase III,"Active, not recruiting","[{'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 796, 'therapyName': 'Encorafenib'}, {'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}]",Study Comparing Combination of LGX818 Plus MEK162 and LGX818 Monotherapy Versus Vemurafenib in BRAF Mutant Melanoma,796
4,NCT01436656,Phase I,"Active, not recruiting","[{'id': 796, 'therapyName': 'Encorafenib'}]",A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma,796
0,NCT01820364,Phase II,Terminated,"[{'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}, {'id': 1260, 'therapyName': 'Encorafenib + Ribociclib'}, {'id': 1337, 'therapyName': 'Encorafenib + BKM120'}, {'id': 1336, 'therapyName': 'BGJ398 + Encorafenib'}, {'id': 1338, 'therapyName': 'Capmatinib + Encorafenib'}]", LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma,1337
0,NCT01777776,Phase Ib/II,Terminated,"[{'id': 796, 'therapyName': 'Encorafenib'}, {'id': 1260, 'therapyName': 'Encorafenib + Ribociclib'}]",Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.,1260
1,NCT01820364,Phase II,Terminated,"[{'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}, {'id': 1260, 'therapyName': 'Encorafenib + Ribociclib'}, {'id': 1337, 'therapyName': 'Encorafenib + BKM120'}, {'id': 1336, 'therapyName': 'BGJ398 + Encorafenib'}, {'id': 1338, 'therapyName': 'Capmatinib + Encorafenib'}]", LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma,1260
0,NCT03219333,Phase II,Recruiting,"[{'id': 4125, 'therapyName': 'Enfortumab vedotin'}]",A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (EV-201),4125
0,NCT02234986,Phase II,"Active, not recruiting","[{'id': 727, 'therapyName': 'ENMD-2076'}]","A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma",727
1,NCT01719744,,Completed,"[{'id': 727, 'therapyName': 'ENMD-2076'}]", Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma,727
2,NCT01914510,Phase II,Recruiting,"[{'id': 727, 'therapyName': 'ENMD-2076'}]",A Study of ENMD-2076 in Ovarian Clear Cell Cancers,727
3,NCT01639248,,Completed,"[{'id': 727, 'therapyName': 'ENMD-2076'}]", A Phase II Study of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced and Metastatic Triple-Negative Breast Cancer,727
0,NCT02746328,Phase II,"Active, not recruiting","[{'id': 5026, 'therapyName': 'enobosarm'}]",Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass,5026
1,NCT02463032,Phase II,"Active, not recruiting","[{'id': 5026, 'therapyName': 'enobosarm'}]",Efficacy and Safety of GTx-024 in Patients With ER+/AR+ Breast Cancer,5026
2,NCT02368691,Phase II,Terminated,"[{'id': 5026, 'therapyName': 'enobosarm'}]",Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC),5026
0,NCT02971761,Phase II,Recruiting,"[{'id': 5027, 'therapyName': 'enobosarm + Pembrolizumab'}]",Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer,5027
0,NCT02589145,Phase Ib/II,Recruiting,"[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 3278, 'therapyName': 'Enoxaparin'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}]",Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype,3278
0,NCT01038778,Phase Ib/II,"Active, not recruiting","[{'id': 1541, 'therapyName': 'Entinostat'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer,1541
1,NCT02453620,Phase I,Recruiting,"[{'id': 1541, 'therapyName': 'Entinostat'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer",1541
2,NCT03211988,Phase II,Not yet recruiting,"[{'id': 1541, 'therapyName': 'Entinostat'}]",Entinostat Neuroendocrine (NE) Tumor,1541
3,NCT01928576,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1541, 'therapyName': 'Entinostat'}, {'id': 651, 'therapyName': 'Azacitidine'}]",Phase II Anti-PD1 Epigenetic Priming Study in NSCLC.,1541
4,NCT02780804,Phase I,Recruiting,"[{'id': 1541, 'therapyName': 'Entinostat'}]",Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors,1541
5,NCT02897778,Phase I,Completed,"[{'id': 1541, 'therapyName': 'Entinostat'}]",Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors,1541
6,NCT02115282,Phase III,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1541, 'therapyName': 'Entinostat'}, {'id': 738, 'therapyName': 'Exemestane'}]",Exemestane With or Without Entinostat in Treating Postmenopausal Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,1541
0,NCT03024437,Phase Ib/II,"Active, not recruiting","[{'id': 5129, 'therapyName': 'Entinostat + Atezolizumab'}, {'id': 5235, 'therapyName': 'Atezolizumab + Entinostat + Bevacizumab'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma,5129
1,NCT02708680,Phase Ib/II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 5129, 'therapyName': 'Entinostat + Atezolizumab'}]",Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In,5129
0,NCT02820961,Phase I,Recruiting,"[{'id': 4437, 'therapyName': 'Entinostat + Exemestane'}]",Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer,4437
0,NCT03215264,Phase Ib/II,Not yet recruiting,"[{'id': 6052, 'therapyName': 'Entinostat + Hydroxychloroquine + Regorafenib'}]","Phase I/II Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer",6052
0,NCT01434303,Phase I,"Active, not recruiting","[{'id': 1542, 'therapyName': 'Entinostat + Lapatinib + Trastuzumab'}]","Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only",1542
0,NCT03250273,Phase II,Not yet recruiting,"[{'id': 6114, 'therapyName': 'Entinostat + Nivolumab'}]",A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma,6114
0,NCT02936752,Phase I,Recruiting,"[{'id': 3354, 'therapyName': 'Entinostat + Pembrolizumab'}]",Entinostat and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome After DNMTi Therapy Failure,3354
1,NCT02909452,Phase I,Recruiting,"[{'id': 3354, 'therapyName': 'Entinostat + Pembrolizumab'}]",Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors,3354
2,NCT02437136,Phase Ib/II,Recruiting,"[{'id': 3354, 'therapyName': 'Entinostat + Pembrolizumab'}]",Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma,3354
3,NCT03179930,Phase II,Recruiting,"[{'id': 3354, 'therapyName': 'Entinostat + Pembrolizumab'}]",Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas,3354
0,NCT01799889,Phase II,"Active, not recruiting","[{'id': 2522, 'therapyName': 'Entospletinib  '}]",A Phase 2 of Entospletinib in Subjects With Relapsed or Refractory Hematologic Malignancies,2522
1,NCT02343939,Phase Ib/II,Recruiting,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}, {'id': 2522, 'therapyName': 'Entospletinib  '}]",Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),2522
0,NCT02097810,Phase Ib/II,Recruiting,"[{'id': 1455, 'therapyName': 'Entrectinib'}]","A Phase 1/2a Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer; Study Targeting ALK, ROS1, or TRKA/B/C",1455
1,NCT02650401,Phase I,Recruiting,"[{'id': 1455, 'therapyName': 'Entrectinib'}]",Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors,1455
2,NCT03066661,Expanded access,Available,"[{'id': 1455, 'therapyName': 'Entrectinib'}]","Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions",1455
3,NCT02568267,Phase II,Recruiting,"[{'id': 1455, 'therapyName': 'Entrectinib'}]","Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements  (STARTRK-2)",1455
0,NCT02003924,Phase III,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer,1262
1,NCT02028988,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide + External Beam Rt For Prostate,1262
2,NCT02457910,Phase Ib/II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1016, 'therapyName': 'GDC-0032'}]",Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer,1262
3,NCT02203695,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy,1262
4,NCT02403505,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1814, 'therapyName': 'Degarelix'}]",Discovery Stage Clinical Study About Oncology Drugs and Single Nucleotide Polymorphisms,1262
5,NCT02023463,Phase I,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 795, 'therapyName': 'Leuprolide'}]","Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer",1262
6,NCT02676986,Phase II,Recruiting,"[{'id': 6183, 'therapyName': 'Enzalutamide + Exemestane'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]","Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer (ARB)",1262
7,NCT02446405,Phase III,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer,1262
8,NCT02555189,Phase Ib/II,Recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]","Enzalutamide With and Without Ribociclib for Metastatic, Castrate-Resistant, Chemotherapy-Naive Prostate Cancer That Retains RB Expression",1262
9,NCT02199197,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Radium Ra 223 With Enzalutamide in Men With Metastatic Castration Refractory Prostate Cancer,1262
10,NCT02438007,Phase III,Terminated,"[{'id': 1508, 'therapyName': 'galeterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC,1262
11,NCT02407054,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer,1262
12,NCT02489123,Phase I,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma,1262
13,NCT02204072,Phase I,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2916, 'therapyName': 'Xentuzumab'}]",BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC),1262
14,NCT02353715,Phase I,Recruiting,"[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2648, 'therapyName': 'Sipuleucel-T'}]","Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge), Abiraterone Acetate (Zytiga) or Enzalutamide (Xtandi) Undergoing Cardiopulmonary EXercise Testing",1262
15,NCT02125357,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",Sequencing Abiraterone and Enzalutamide in mCRPC,1262
16,NCT02929576,Phase III,Withdrawn,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 3725, 'therapyName': 'Enzalutamide + Paclitaxel'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]","Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer (ENDEAR)",1262
17,NCT03016312,Phase III,Recruiting,"[{'id': 5204, 'therapyName': 'Atezolizumab + Enzalutamide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]","IMbassador250: A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen",1262
18,NCT02254785,Phase II,Recruiting,"[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}]",Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer,1262
19,NCT02491411,Phase I,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel,1262
20,NCT02429193,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}]",Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA (BARRIER-P),1262
21,NCT02012296,Phase Ib/II,Recruiting,"[{'id': 2603, 'therapyName': 'Mifepristone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer,1262
22,NCT02057939,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM),1262
23,NCT02286921,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2591, 'therapyName': 'Andriol'}]","Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance",1262
24,NCT02268175,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate,1262
25,NCT02685397,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Management of Castration-Resistant Prostate Cancer With Oligometastases,1262
26,NCT02607228,Phase Ib/II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 3561, 'therapyName': 'GS-5829 + Exemestane'}]","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer",1262
27,NCT01927627,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide in Patients With High-risk Prostate Cancer,1262
28,NCT01974765,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]","Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies",1262
29,NCT02749903,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers,1262
30,NCT02300610,Phase I,"Active, not recruiting","[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer,1262
31,NCT01942837,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer With Correlative Assessment of Androgen Receptor Signaling,1262
32,NCT02532114,Phase I,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 3072, 'therapyName': 'Niclosamide'}]","Niclosamide and Enzalutamide in Treating Patients With Androgen Receptor Splice Variant-Positive, Castration-Resistant, Metastatic Prostate Cancer",1262
33,NCT02605863,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide for Bladder Cancer Chemoprevention,1262
34,NCT02677896,Phase III,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC),1262
35,NCT01977651,FDA approved,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}]",A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide,1262
36,NCT02007512,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 738, 'therapyName': 'Exemestane'}]",Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer,1262
37,NCT02452008,Phase II,Recruiting,"[{'id': 2409, 'therapyName': 'Galunisertib'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Study of TGF-Beta Receptor Inhibitor LY2157299 and Enzalutamide in Metastatic Castration-resistant Prostate Cancer,1262
38,NCT02384382,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}]",A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC),1262
39,NCT02446444,Phase III,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]","Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer",1262
40,NCT02799745,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance (ENACT) (ENACT),1262
41,NCT02379390,Phase II,Terminated,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}]",Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enz (PRIMCAB),1262
42,NCT02500901,Phase I,"Active, not recruiting","[{'id': 832, 'therapyName': 'Niraparib'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC),1262
43,NCT02319837,Phase III,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK),1262
44,NCT02215096,Phase I,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 765, 'therapyName': 'GSK2636771'}]",Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer,1262
45,NCT02090114,Phase II,Recruiting,"[{'id': 2591, 'therapyName': 'Andriol'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistant (The RESTORE Study),1262
46,NCT02278185,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1814, 'therapyName': 'Degarelix'}, {'id': 2047, 'therapyName': 'Histrelin acetate'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer,1262
47,NCT02507570,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}]",Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis,1262
48,NCT02138383,Phase I,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer,1262
49,NCT02528643,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}]",A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma,1262
50,NCT02750358,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer,1262
51,NCT02987543,Phase III,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",Study of Olaparib (Lynparza) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study),1262
52,NCT02058706,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 795, 'therapyName': 'Leuprolide'}]",LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer,1262
53,NCT01867333,Phase II,"Active, not recruiting","[{'id': 3069, 'therapyName': 'PROSTVAC-F/TRICOM '}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer,1262
54,NCT02064582,Phase II,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]","Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer",1262
55,NCT02034552,Phase II,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC),1262
56,NCT02960022,Phase II,Recruiting,"[{'id': 5371, 'therapyName': 'Enzalutamide + Abiraterone + Prednisone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study,1262
57,NCT01362374,Phase I,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 747, 'therapyName': 'Ipatasertib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]","Safety and Pharmacology Of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors",1262
58,NCT02885649,Phase 0,Not yet recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide Before Surgery in Treating Patients With Kidney Cancer,1262
59,NCT02642913,Phase Ib/II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients,1262
60,NCT01949337,Phase III,"Active, not recruiting","[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,1262
61,NCT03016741,FDA approved,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}]",Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer,1262
62,NCT02256111,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",EXTEND Exercise Trial,1262
63,NCT02441517,FDA approved,Terminated,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel Treatment in Patients Who Have Previously Received Enzalutamide,1262
0,NCT02960022,Phase II,Recruiting,"[{'id': 5371, 'therapyName': 'Enzalutamide + Abiraterone + Prednisone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study,5371
0,NCT02125084,Phase I,"Active, not recruiting","[{'id': 2264, 'therapyName': 'Enzalutamide + Everolimus'}]",Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer,2264
0,NCT02676986,Phase II,Recruiting,"[{'id': 6183, 'therapyName': 'Enzalutamide + Exemestane'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]","Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer (ARB)",6183
0,NCT02953860,Phase II,Recruiting,"[{'id': 4940, 'therapyName': 'Enzalutamide + Fulvestrant'}]",Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer,4940
1,NCT02955394,Phase II,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 4940, 'therapyName': 'Enzalutamide + Fulvestrant'}]",Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer,4940
0,NCT03150056,Phase I,Recruiting,"[{'id': 6034, 'therapyName': 'Abiraterone + GSK525762'}, {'id': 6035, 'therapyName': 'Enzalutamide + GSK525762'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer,6035
0,NCT02935205,Phase Ib/II,Not yet recruiting,"[{'id': 4876, 'therapyName': 'Enzalutamide + Indomethacin'}]",Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer,4876
0,NCT02508636,Phase II,Recruiting,"[{'id': 3180, 'therapyName': 'Enzalutamide + Leuprolide'}]",Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate,3180
0,NCT02991911,Phase I,Recruiting,"[{'id': 5217, 'therapyName': 'Enzalutamide + MEDI3726'}, {'id': 5216, 'therapyName': 'MEDI3726'}]",A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer,5217
0,NCT02339168,Phase I,Recruiting,"[{'id': 2202, 'therapyName': 'Enzalutamide + Metformin'}]",Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer,2202
0,NCT02689427,Phase II,Recruiting,"[{'id': 3725, 'therapyName': 'Enzalutamide + Paclitaxel'}]",Phase IIB Neoadjuvant Enzalutamide (ZT) Plus Taxol for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer (AR+ TNBC),3725
1,NCT02929576,Phase III,Withdrawn,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 3725, 'therapyName': 'Enzalutamide + Paclitaxel'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]","Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer (ENDEAR)",3725
0,NCT02312557,Phase II,Recruiting,"[{'id': 2666, 'therapyName': 'Enzalutamide + Pembrolizumab'}]",Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide,2666
1,NCT02861573,Phase I,Recruiting,"[{'id': 5343, 'therapyName': 'Dexamethasone + Docetaxel + Pembrolizumab + Prednisone'}, {'id': 5342, 'therapyName': 'Olaparib + Pembrolizumab'}, {'id': 2666, 'therapyName': 'Enzalutamide + Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365),2666
0,NCT01875250,Phase II,"Active, not recruiting","[{'id': 4884, 'therapyName': 'Enzalutamide + PROSTVAC-F/TRICOM + PROSTVAC-V/TRICOM'}]",Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer,4884
0,NCT01885949,Phase II,"Active, not recruiting","[{'id': 2395, 'therapyName': 'Enzalutamide + Tivozanib'}]",Tivozanib + Enzalutamide in Adv Prostate Cancer,2395
0,NCT02091960,Phase II,"Active, not recruiting","[{'id': 1878, 'therapyName': 'Enzalutamide + Trastuzumab'}]","A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Subjects With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) and Estrogen Receptor Negative (ER-) Metastatic or Locally Advanced Breast Cancer",1878
0,NCT02711956,Phase I,Recruiting,"[{'id': 4033, 'therapyName': 'Enzalutamide + ZEN003694'}]",A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer,4033
0,NCT03263026,Phase III,Not yet recruiting,"[{'id': 2195, 'therapyName': 'R-CHOP'}, {'id': 1682, 'therapyName': 'Enzastaurin'}]",Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1,1682
0,NCT02118285,Phase I,Completed,"[{'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 2575, 'therapyName': 'Epacadostat'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}]","Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer",2575
1,NCT02575807,Phase Ib/II,Recruiting,"[{'id': 2575, 'therapyName': 'Epacadostat'}, {'id': 2641, 'therapyName': 'CRS-207'}]","Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian, or Peritoneal Cancer",2575
2,NCT01961115,Phase II,"Active, not recruiting","[{'id': 2575, 'therapyName': 'Epacadostat'}, {'id': 3016, 'therapyName': 'MELITAC 12.1 Peptide Vaccine '}]",INCB024360 and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma,2575
3,NCT02042430,Phase I,"Active, not recruiting","[{'id': 2575, 'therapyName': 'Epacadostat'}]","INCB024360 Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",2575
4,NCT02178722,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2575, 'therapyName': 'Epacadostat'}]","A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors and Advanced NSCLC (INCB 24360-202 / MK-3475-037 / KEYNOTE-037)",2575
5,NCT02166905,Phase Ib/II,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 1324, 'therapyName': 'DEC-205-NY-ESO-1 fusion protein vaccine'}, {'id': 2575, 'therapyName': 'Epacadostat'}]","DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission",2575
0,NCT03277352,Phase Ib/II,Not yet recruiting,"[{'id': 6277, 'therapyName': 'Epacadostat + INCAGN01876 + Pembrolizumab'}]",INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies,6277
0,NCT02752074,Phase III,"Active, not recruiting","[{'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma,4088
1,NCT03196232,Phase II,Recruiting,"[{'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}]",Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer,4088
2,NCT03291054,Phase II,Not yet recruiting,"[{'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}]",Epacadostat and Pembrolizumab in Patients With GIST,4088
3,NCT02393248,Phase Ib/II,Recruiting,"[{'id': 4176, 'therapyName': 'Cisplatin + Gemcitabine + INCB054828'}, {'id': 4174, 'therapyName': 'Docetaxel + INCB054828'}, {'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}]","Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies",4088
4,NCT03238638,Phase II,Not yet recruiting,"[{'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}]","A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy",4088
0,NCT02606123,Phase Ib/II,"Active, not recruiting","[{'id': 5611, 'therapyName': 'EPI-506'}]",Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer,5611
0,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1013
0,NCT01901146,Phase III,Completed,"[{'id': 1087, 'therapyName': 'Epirubicin + Cyclophosphamide'}, {'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}]",Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Subjects With HER2 Positive Early Breast Cancer (Lilac),1087
1,NCT03036488,Phase III,Recruiting,"[{'id': 1087, 'therapyName': 'Epirubicin + Cyclophosphamide'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522),1087
2,NCT01779050,Phase II,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1087, 'therapyName': 'Epirubicin + Cyclophosphamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}, {'id': 1834, 'therapyName': 'Docetaxel + Carboplatin'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}]",Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells,1087
0,NCT02358863,Phase I,Terminated,"[{'id': 4311, 'therapyName': 'Docetaxel + Irinotecan'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1835, 'therapyName': 'Docetaxel + Cisplatin'}, {'id': 1406, 'therapyName': 'Camptosar + Cisplatin'}, {'id': 4310, 'therapyName': 'Epirubicin + Docetaxel'}, {'id': 4309, 'therapyName': 'Capecitabine + Docetaxel'}]",Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach (mEGA),4310
0,NCT02050919,Phase II,Recruiting,"[{'id': 2365, 'therapyName': 'Epirubicin + Ifosfamide + Sorafenib'}]","Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma",2365
0,NCT00092222,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1187, 'therapyName': 'Alpha 2 Interferon'}, {'id': 2211, 'therapyName': 'EPOCH'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1008, 'therapyName': 'Doxil'}]",Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity,2211
0,NCT02141828,Phase I,Completed,"[{'id': 2855, 'therapyName': 'EPZ-5676'}]",A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene,2855
0,NCT01401959,Phase II,"Active, not recruiting","[{'id': 728, 'therapyName': 'Eribulin'}, {'id': 1981, 'therapyName': 'Eribulin + Trastuzumab'}]",Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy,728
1,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,728
2,NCT03051659,Phase II,Recruiting,"[{'id': 728, 'therapyName': 'Eribulin'}, {'id': 3080, 'therapyName': 'Eribulin + Pembrolizumab'}]",A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer,728
3,NCT01945775,Phase III,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 682, 'therapyName': 'Talazoparib'}, {'id': 728, 'therapyName': 'Eribulin'}]","A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)",728
4,NCT02481050,Phase II,"Active, not recruiting","[{'id': 728, 'therapyName': 'Eribulin'}]",Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer,728
5,NCT02492711,Phase III,Recruiting,"[{'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 808, 'therapyName': 'MGAH22'}]",Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer,728
6,NCT01744340,Phase Ib/II,Completed,"[{'id': 728, 'therapyName': 'Eribulin'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer,728
7,NCT02555657,Phase III,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119),728
8,NCT01596751,Phase Ib/II,"Active, not recruiting","[{'id': 728, 'therapyName': 'Eribulin'}, {'id': 874, 'therapyName': 'PLX3397'}]",Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer,728
9,NCT02000622,Phase III,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.,728
10,NCT03056599,,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1733, 'therapyName': 'interferon gamma '}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 3420, 'therapyName': 'trabectedin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma,728
11,NCT02419495,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Selinexor in Combination With Standard Chemotherapy,728
12,NCT01912963,Phase II,"Active, not recruiting","[{'id': 728, 'therapyName': 'Eribulin'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 947, 'therapyName': 'Trastuzumab'}]","Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer",728
0,NCT02120469,Phase I,Recruiting,"[{'id': 2252, 'therapyName': 'Eribulin + Everolimus'}]",Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer,2252
0,NCT02640508,Phase II,Recruiting,"[{'id': 3352, 'therapyName': 'Eribulin + Lenvatinib'}]",Eribulin and Lenvatinib in Advanced Solid Tumors,3352
0,NCT02014337,Phase I,"Active, not recruiting","[{'id': 3053, 'therapyName': 'Eribulin + Mifepristone'}]",Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors,3053
0,NCT02513472,Phase Ib/II,"Active, not recruiting","[{'id': 3080, 'therapyName': 'Eribulin + Pembrolizumab'}]",Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC),3080
1,NCT03051659,Phase II,Recruiting,"[{'id': 728, 'therapyName': 'Eribulin'}, {'id': 3080, 'therapyName': 'Eribulin + Pembrolizumab'}]",A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer,3080
0,NCT02824575,Phase I,Recruiting,"[{'id': 4433, 'therapyName': 'Paclitaxel + Rebastinib'}, {'id': 4434, 'therapyName': 'Eribulin + Rebastinib'}]",Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer,4434
0,NCT01401959,Phase II,"Active, not recruiting","[{'id': 728, 'therapyName': 'Eribulin'}, {'id': 1981, 'therapyName': 'Eribulin + Trastuzumab'}]",Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy,1981
0,NCT02468661,Phase Ib/II,Recruiting,"[{'id': 1065, 'therapyName': 'Capmatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]","A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification",4
1,NCT00054496,Phase II,Unknown status,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme,4
2,NCT02296125,Phase III,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 660, 'therapyName': 'AZD9291'}, {'id': 751, 'therapyName': 'Gefitinib'}]",AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer,4
3,NCT02770014,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer,4
4,NCT02186301,Phase II,Terminated,"[{'id': 1003, 'therapyName': 'CO1686'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR Mutant NSCLC Who Have Not Had Any Previous EGFR Directed Therapy,4
5,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,4
6,NCT02961374,Phase II,Not yet recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer,4
7,NCT01344824,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}]","Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Who Are Light or Never Smokers",4
8,NCT02193282,Phase III,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),4
9,NCT03137771,Phase II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}]",Maintenance Chemotherapy With or Without Stereotactic Body Radiation Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,4
10,NCT02015728,Phase I,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1804, 'therapyName': 'Temozolomide + Etoposide'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors,4
11,NCT02134886,Phase I,Terminated,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection,4
12,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,4
13,NCT02134015,Phase III,Terminated,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2530, 'therapyName': 'Patritumab + Erlotinib'}]",Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung),4
14,NCT01455389,Phase Ib/II,Recruiting,"[{'id': 1313, 'therapyName': 'DOTAP:chol-Fus1'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer,4
15,NCT00301418,Phase Ib/II,Completed,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma,4
16,NCT02588261,Phase III,"Active, not recruiting","[{'id': 1082, 'therapyName': 'ASP8273'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations,4
17,NCT01472016,Phase I,Completed,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1063, 'therapyName': 'ABT-700'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",Study of ABT-700 in Subjects With Advanced Solid Tumors,4
18,NCT01197170,Phase I,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Hormone Blockade in Combination With Targeted Agents,4
19,NCT01857271,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer,4
20,NCT01592383,Phase II,Completed,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma,4
21,NCT01233687,Phase Ib/II,Completed,"[{'id': 629, 'therapyName': 'AMG102'}, {'id': 4, 'therapyName': 'Erlotinib'}]",AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer,4
22,NCT02091141,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 698, 'therapyName': 'Alectinib'}, {'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]","My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors",4
23,NCT02450591,Phase I,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations,4
24,NCT02004262,Phase II,Completed,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2383, 'therapyName': 'Capecitabine + Fluorouracil + Gemcitabine '}]",Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting,4
25,NCT01454102,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)",4
26,NCT01532089,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib With or Without Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer With EGFR Mutations,4
27,NCT02277457,Phase I,Withdrawn,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 4, 'therapyName': 'Erlotinib'}]","Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations",4
28,NCT02574078,Phase I,Recruiting,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2114, 'therapyName': 'Bevacizumab + Pemetrexed'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",A Master Protocol Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate 370),4
29,NCT00997334,Phase II,Completed,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC,4
30,NCT01306045,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 816, 'therapyName': 'MK2206'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 913, 'therapyName': 'Selumetinib'}]","Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies",4
31,NCT02411448,Phase III,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Participants With EGFR Mutation-Positive Metastatic NSCLC,4
32,NCT01064479,Phase II,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Docetaxel And Cisplatin With or Without Erlotinib For Metastatic Or Recurrent Squamous Cell Carcinoma Of Head And Neck,4
33,NCT01471964,Phase Ib/II,Suspended,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 626, 'therapyName': 'Alisertib'}]","Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer",4
34,NCT02318368,Phase II,Terminated,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2169, 'therapyName': 'Ficlatuzumab + Erlotinib'}]","A Phase 2, Multicenter, Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label",4
35,NCT02355431,Phase II,Withdrawn,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2406, 'therapyName': 'INCB039110'}]",INCB039110 in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations,4
36,NCT00547105,Phase II,Unknown status,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib and Stereotactic Body Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Non-Small Call Lung Cancer,4
37,NCT01248247,Phase I,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1098, 'therapyName': 'MK2206 + Selumetinib'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1097, 'therapyName': 'Erlotinib + MK2206'}]",BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study,4
38,NCT01116336,Phase I,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Phase I Chemoprevention Trial With Green Tea Polyphenon E and Erlotinib in Patients With Premalignant Lesions of the Head and Neck,4
39,NCT02152631,Phase III,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 802, 'therapyName': 'Abemaciclib'}]",A Study of LY2835219 in Participants With Previously Treated Lung Cancer,4
40,NCT01967095,Phase I,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}]",Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer,4
41,NCT02169284,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery,4
42,NCT02117024,Phase II,"Active, not recruiting","[{'id': 2472, 'therapyName': 'HS-110 + Cyclophosphamide'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer,4
43,NCT01801111,Phase II,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 698, 'therapyName': 'Alectinib'}]",A Study of RO5424802 in Patients With Non-Small Cell Lung Cancer Who Have ALK Mutation and Failed Crizotinib Treatment,4
44,NCT01573702,Phase II,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}]",Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR),4
45,NCT01456325,Phase III,Completed,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 838, 'therapyName': 'Onartuzumab'}]",A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung),4
46,NCT02154490,Phase II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 1016, 'therapyName': 'GDC-0032'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 629, 'therapyName': 'AMG102'}]",Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,4
47,NCT02693535,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 690, 'therapyName': 'Bosutinib'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer,4
0,NCT01683422,Phase II,Recruiting,"[{'id': 2473, 'therapyName': 'Erlotinib + Capecitabine + Gemcitabine'}]",Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer,2473
0,NCT01928160,Phase II,Withdrawn,"[{'id': 1290, 'therapyName': 'Erlotinib + Pemetrexed'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1291, 'therapyName': 'Erlotinib + Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1292, 'therapyName': 'Erlotinib + Cisplatin'}]",Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib,1291
0,NCT01545947,Phase I,Completed,"[{'id': 1149, 'therapyName': 'Azacitidine + CC-223'}, {'id': 1147, 'therapyName': 'Erlotinib + CC-223'}]"," Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer",1147
0,NCT01928160,Phase II,Withdrawn,"[{'id': 1290, 'therapyName': 'Erlotinib + Pemetrexed'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1291, 'therapyName': 'Erlotinib + Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1292, 'therapyName': 'Erlotinib + Cisplatin'}]",Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib,1292
0,NCT00602667,Phase I,"Active, not recruiting","[{'id': 2449, 'therapyName': 'Methotrexate + Cisplatin + Cyclophosphamide + Vincristine'}, {'id': 2450, 'therapyName': 'Cyclophosphamide + Etoposide + Topotecan'}, {'id': 2451, 'therapyName': 'Erlotinib + Cyclophosphamide + Topotecan'}]","Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma",2451
0,NCT01927744,Phase II,Recruiting,"[{'id': 2474, 'therapyName': 'Erlotinib + Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","Study of Chemotherapy With Cisplatin/CarboplatinAstellas Pharma Inc, OSI Pharmaceuticals, Kadoorie Foundation, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection",2474
0,NCT02321293,Phase I,Unknown status,"[{'id': 2379, 'therapyName': 'Erlotinib + Gefitinib'}]",A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC,2379
0,NCT02154737,Phase I,Recruiting,"[{'id': 2381, 'therapyName': 'Erlotinib + Gemcitabine'}]",Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer,2381
1,NCT01013649,Phase II,Recruiting,"[{'id': 2381, 'therapyName': 'Erlotinib + Gemcitabine'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,2381
0,NCT02352948,Phase III,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2438, 'therapyName': 'Erlotinib + Gemcitabine + Vinorelbine'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer",2438
0,NCT02991651,Phase I,Recruiting,"[{'id': 5135, 'therapyName': 'Erlotinib + IRX4204'}]",Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC,5135
0,NCT02942095,Phase I,Recruiting,"[{'id': 4885, 'therapyName': 'Erlotinib + Ixazomib'}]",Phase I Study of Ixazomib and Erlotinib in Solid Tumors,4885
0,NCT01248247,Phase I,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1098, 'therapyName': 'MK2206 + Selumetinib'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1097, 'therapyName': 'Erlotinib + MK2206'}]",BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study,1097
0,NCT02206763,Phase I,Terminated,"[{'id': 2380, 'therapyName': 'Erlotinib + Momelotinib'}]",Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC),2380
0,NCT02535338,Phase Ib/II,Suspended,"[{'id': 3071, 'therapyName': 'Erlotinib + Onalespib'}]",Erlotinib Hydrochloride and Hsp90 Inhibitor AT13387 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer,3071
0,NCT02342353,Phase Ib/II,Recruiting,"[{'id': 2382, 'therapyName': 'Erlotinib + Pacritinib'}]",Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI),2382
0,NCT02039674,Phase Ib/II,"Active, not recruiting","[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}, {'id': 2104, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 2106, 'therapyName': 'Ipilimumab + Pembrolizumab '}, {'id': 2107, 'therapyName': 'Erlotinib + Pembrolizumab '}, {'id': 2108, 'therapyName': 'Gefitinib + Pembrolizumab '}]",A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021),2107
0,NCT01928160,Phase II,Withdrawn,"[{'id': 1290, 'therapyName': 'Erlotinib + Pemetrexed'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1291, 'therapyName': 'Erlotinib + Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1292, 'therapyName': 'Erlotinib + Cisplatin'}]",Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib,1290
1,NCT00573989,Phase Ib/II,Terminated,"[{'id': 1290, 'therapyName': 'Erlotinib + Pemetrexed'}]","Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer",1290
2,NCT00950365,Phase II,Unknown status,"[{'id': 1290, 'therapyName': 'Erlotinib + Pemetrexed'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Pharmacodynamic Separation of Pemetrexed and Erlotinib as Second-line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC),1290
0,NCT01532011,Phase I,Completed,"[{'id': 1328, 'therapyName': 'Erlotinib + Pralatrexate'}]",Erlotinib in Combination With Pralatrexate in Advanced Malignancies,1328
0,NCT01839955,Phase Ib/II,Completed,"[{'id': 1237, 'therapyName': 'Erlotinib + Quinacrine'}]",Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer,1237
0,NCT01962896,Phase II,Recruiting,"[{'id': 2253, 'therapyName': 'Erlotinib + Sirolimus'}]",A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors,2253
0,NCT02689336,Phase II,Recruiting,"[{'id': 3726, 'therapyName': 'Erlotinib + Temozolomide'}]",Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors,3726
0,NCT02080078,Phase I,Recruiting,"[{'id': 2436, 'therapyName': 'Erlotinib + Theophylline'}]",A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline,2436
0,NCT01376310,Phase II,"Active, not recruiting","[{'id': 1264, 'therapyName': 'Docetaxel + Trametinib'}, {'id': 1265, 'therapyName': 'Erlotinib + Trametinib'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 1266, 'therapyName': 'Pemetrexed + GSK1120212'}, {'id': 1267, 'therapyName': 'Carboplatin + GSK1120212'}, {'id': 1268, 'therapyName': 'nab-paclitaxel + GSK1120212'}, {'id': 1269, 'therapyName': 'Gemcitabine + GSK1120212'}, {'id': 1271, 'therapyName': 'Everolimus + GSK1120212'}]",GSK1120212 Rollover Study,1265
1,NCT03076164,Phase Ib/II,Recruiting,"[{'id': 1265, 'therapyName': 'Erlotinib + Trametinib'}]",A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib,1265
0,NCT02381080,Phase I,Completed,"[{'id': 3793, 'therapyName': 'Erythromycin + Ibrutinib + Voriconazole'}]",Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy,3793
0,NCT02188745,Phase II,Recruiting,"[{'id': 738, 'therapyName': 'Exemestane'}, {'id': 1643, 'therapyName': 'Estradiol'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}]",ER Reactivation Therapy for Breast Cancer,1643
0,NCT02494713,Phase II,Recruiting,"[{'id': 1814, 'therapyName': 'Degarelix'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 2858, 'therapyName': 'Ketoconazole'}]",Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer,2950
1,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,2950
0,NCT03136406,Phase Ib/II,Recruiting,"[{'id': 1018, 'therapyName': 'GI-4000'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 6163, 'therapyName': 'ETBX-011'}, {'id': 3060, 'therapyName': 'ALT-803'}]",QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy,6163
0,NCT03126916,Phase III,Not yet recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 5595, 'therapyName': 'Isotretinoin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 2286, 'therapyName': 'Dinutuximab  '}]",Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma,1136
1,NCT01356290,Phase II,Recruiting,"[{'id': 1475, 'therapyName': 'Thalidomide'}, {'id': 4418, 'therapyName': 'Fenofibrate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2124, 'therapyName': 'Celecoxib'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}]",Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma (MEMMAT),1136
2,NCT01526603,Phase I,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1092, 'therapyName': 'Carboplatin'}]",High Dose Chemotherapy and Autologous Transplant for Neuroblastoma,1136
3,NCT01042522,Phase II,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1137, 'therapyName': 'Bleomycin'}]","Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors",1136
4,NCT02512926,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children,1136
5,NCT00074490,Phase II,Completed,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,1136
6,NCT02883049,Phase III,Suspended,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations,1136
7,NCT01450761,Phase III,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone,1136
8,NCT02432274,Phase Ib/II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 792, 'therapyName': 'Lenvatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies,1136
9,NCT03117751,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,1136
10,NCT02112916,Phase III,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,1136
11,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1136
12,NCT03007147,Phase III,Recruiting,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 5167, 'therapyName': 'Methylprednisolone'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 5168, 'therapyName': 'Prednisolone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,1136
13,NCT01614197,Phase I,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma,1136
14,NCT02153580,Phase I,"Active, not recruiting","[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1231, 'therapyName': 'Bendamustine'}]","Cellular Immunotherapy Following Cyclophosphamide in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia",1136
15,NCT02489903,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 3680, 'therapyName': 'RRx-001'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 619, 'therapyName': 'Abraxane'}]","RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens",1136
16,NCT03164057,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia,1136
17,NCT02521493,Phase III,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 5912, 'therapyName': 'Asparaginase Erwinia chrysanthemi'}, {'id': 5215, 'therapyName': 'mitoxantrone hydrochloride'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2206, 'therapyName': 'Asparaginase'}]",Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome,1136
18,NCT02653196,Phase II,Terminated,"[{'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 3948, 'therapyName': 'Cyclosporine + Mycophenolate mofetil + Tacrolimus'}]",A Multi-Institutional Phase II Feasibility Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors,1136
19,NCT02553460,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I,1136
20,NCT03136146,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1090, 'therapyName': 'Ofatumumab'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]","Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)",1136
21,NCT02114229,Phase II,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2449, 'therapyName': 'Methotrexate + Cisplatin + Cyclophosphamide + Vincristine'}, {'id': 626, 'therapyName': 'Alisertib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 942, 'therapyName': 'Topotecan'}]",Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors,1136
22,NCT03004287,Phase II,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy,1136
23,NCT02815592,Phase Ib/II,"Active, not recruiting","[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 4563, 'therapyName': 'BMS-986012 + Cisplatin + Etoposide'}, {'id': 4564, 'therapyName': 'BMS-986012 + Carboplatin + Etoposide'}]",Trial of BMS-986012 in Combination With Platinum and Etoposide,1136
24,NCT03023046,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}]","Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",1136
25,NCT02299518,Phase I,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}]",Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,1136
26,NCT02157792,Phase I,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 2879, 'therapyName': 'VX-970'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy",1136
27,NCT00936936,Phase II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2101, 'therapyName': 'Etoposide + Ifosfamide'}, {'id': 2100, 'therapyName': 'Docetaxel + Gemcitabine + Melphalan'}, {'id': 2074, 'therapyName': 'Bevacizumab + Carboplatin'}]",High-dose Chemotherapy for Poor-prognosis Relapsed Germ-Cell Tumors,1136
28,NCT03020030,Phase III,Recruiting,"[{'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents,1136
29,NCT01859741,Phase Ib/II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2547, 'therapyName': 'Tarextumab'}]",A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Platinum Therapy in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE),1136
30,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,1136
31,NCT02043587,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia &amp; Lymphoblastic Lymphoma,1136
0,NCT01408043,Phase I,Terminated,"[{'id': 3222, 'therapyName': 'Etoposide + Filgrastim + Plerixafor'}]","Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma",3222
0,NCT00936936,Phase II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2101, 'therapyName': 'Etoposide + Ifosfamide'}, {'id': 2100, 'therapyName': 'Docetaxel + Gemcitabine + Melphalan'}, {'id': 2074, 'therapyName': 'Bevacizumab + Carboplatin'}]",High-dose Chemotherapy for Poor-prognosis Relapsed Germ-Cell Tumors,2101
1,NCT01505569,Phase I,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2101, 'therapyName': 'Etoposide + Ifosfamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Auto Transplant for High Risk or Relapsed Solid or CNS Tumors,2101
0,NCT00303849,Phase Ib/II,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2562, 'therapyName': 'Etoposide + Melphalan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]",Combination Chemotherapy With BBBD Followed By Sodium Thiosulfate in Treating Patients With Anaplastic Oligodendroglioma or Oligoastrocytoma,2562
0,NCT02504892,Phase II,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}]",Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer,735
1,NCT02560012,Phase II,Terminated,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Personalized Targeted Inhibitors Treatment in Renal Cell Cancer,735
2,NCT02236572,Phase II,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}]","Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score",735
3,NCT01334502,Phase I,Completed,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 2195, 'therapyName': 'R-CHOP'}]","Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma",735
4,NCT01827384,Phase II,Recruiting,"[{'id': 1194, 'therapyName': 'MK-1775 + Carboplatin '}, {'id': 1193, 'therapyName': 'Veliparib + Temozolomide'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 2, 'therapyName': 'Trametinib'}]",Molecular Profiling-Based Targeted Therapy in Treating Patients With Advanced Solid Tumors,735
5,NCT01931163,Phase II,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}]",NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer,735
6,NCT01674140,Phase III,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}]",S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,735
7,NCT01215136,Phase II,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma,735
8,NCT01523977,Phase I,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL,735
9,NCT01665768,Phase II,"Active, not recruiting","[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 735, 'therapyName': 'Everolimus'}]",Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma,735
10,NCT01197170,Phase I,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Hormone Blockade in Combination With Targeted Agents,735
11,NCT01270321,Phase II,"Active, not recruiting","[{'id': 2260, 'therapyName': 'Pasireotide'}, {'id': 735, 'therapyName': 'Everolimus'}]",A Trial of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer,735
12,NCT02205515,Phase Ib/II,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}]","An Open Label, Single-Centre, Phase II Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis",735
13,NCT01548807,Phase I,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}]",Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy,735
14,NCT02332902,Phase II,Completed,"[{'id': 735, 'therapyName': 'Everolimus'}]",Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T,735
15,NCT01797523,Phase II,"Active, not recruiting","[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1031, 'therapyName': 'Metformin'}]",RAD/Letrozole/Metformin,735
16,NCT00610948,Phase I,Completed,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 845, 'therapyName': 'Panitumumab'}]","Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Solid Tumors That Did Not Respond to Treatment",735
17,NCT02269670,Phase II,"Active, not recruiting","[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1869, 'therapyName': 'Megestrol'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 633, 'therapyName': 'Anastrozole'}]",Everolimus and Hormone Therapy in Treating Patients With Advanced Hormone Receptor Positive Breast Cancer That Has Progressed or Recurred on Everolimus and Exemestane Therapy,735
18,NCT02531932,Phase II,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 735, 'therapyName': 'Everolimus'}]",Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer,735
19,NCT02724020,Phase II,Recruiting,"[{'id': 1283, 'therapyName': 'MLN1117 + Sapanisertib'}, {'id': 1282, 'therapyName': 'Sapanisertib'}, {'id': 735, 'therapyName': 'Everolimus'}]",MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma,735
20,NCT01120249,Phase III,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}]","S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",735
21,NCT02089334,Phase Ib/II,Recruiting,"[{'id': 2262, 'therapyName': 'Everolimus + RX-0201'}, {'id': 735, 'therapyName': 'Everolimus'}]","Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer",735
22,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,735
23,NCT01218555,Phase I,"Active, not recruiting","[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 735, 'therapyName': 'Everolimus'}]",Study of Everolimus (RAD001)in Combination With Lenalidomide,735
24,NCT01880749,Phase I,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}]",Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas,735
25,NCT03032406,Phase II,Recruiting,"[{'id': 2231, 'therapyName': 'Everolimus + Hydroxychloroquine'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1316, 'therapyName': 'Hydroxychloroquine'}]","CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer",735
26,NCT01133678,Phase II,"Active, not recruiting","[{'id': 1790, 'therapyName': 'Cetuximab + Cisplatin + Paclitaxel'}, {'id': 735, 'therapyName': 'Everolimus'}]",Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck,735
27,NCT01508104,Phase Ib/II,Terminated,"[{'id': 1321, 'therapyName': 'BEZ235 + Everolimus'}, {'id': 735, 'therapyName': 'Everolimus'}]",Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors,735
28,NCT02520063,Phase Ib/II,Recruiting,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 1242, 'therapyName': 'TRC105'}, {'id': 735, 'therapyName': 'Everolimus'}]","Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer",735
29,NCT02273752,Phase II,Terminated,"[{'id': 735, 'therapyName': 'Everolimus'}]","Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer",735
30,NCT01345136,Phase II,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}]",Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma,735
31,NCT00912340,Phase II,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Randomized Phase II Trial of Trastuzumab or EVEROLIMUS in Hormone-refractory Metastatic Breast Cancer,735
32,NCT01700400,Phase I,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]"," Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer",735
33,NCT02599324,Phase Ib/II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors,735
34,NCT00976573,,Completed,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma",735
35,NCT02450175,Phase I,Unknown status,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 735, 'therapyName': 'Everolimus'}]","Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls",735
36,NCT02143726,Phase II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 735, 'therapyName': 'Everolimus'}]","Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Thyroid Cancer",735
37,NCT02201212,Phase II,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}]",Everolimus for Cancer With TSC1 or TSC2 Mutation,735
38,NCT01087554,Phase I,"Active, not recruiting","[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer,735
39,NCT02397083,Phase II,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}]",Phase II Study of Intrauterine Device (IUD) Alone or in Combination With Everolimus in Endometrial Cancer,735
40,NCT02254239,Phase I,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}]",Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma,735
41,NCT00831480,Phase II,Terminated,"[{'id': 735, 'therapyName': 'Everolimus'}]",Everolimus(RAD001) For Advanced Renal Cell Carcinoma(RCC)Before Kidney Removal,735
42,NCT00823459,Phase II,Completed,"[{'id': 735, 'therapyName': 'Everolimus'}]",Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma,735
43,NCT01734512,Phase II,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}]",PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children,735
44,NCT02081755,,Recruiting,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 735, 'therapyName': 'Everolimus'}]",Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer,735
45,NCT02315625,Phase II,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery,735
46,NCT01603004,Phase I,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Potential Imaging and Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors,735
47,NCT02031536,Phase II,Terminated,"[{'id': 735, 'therapyName': 'Everolimus'}]",Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery,735
48,NCT01637090,Phase II,Terminated,"[{'id': 735, 'therapyName': 'Everolimus'}]",Everolimus in Treating Cutaneous T-cell Lymphoma,735
49,NCT01865747,Phase III,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}]",A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma,735
50,NCT02539459,Phase II,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}]",Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus,735
51,NCT01217931,Phase II,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy,735
52,NCT02155920,Phase II,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}]",Everolimus for Children With Recurrent or Progressive Ependymomaildren With Recurrent or Progressive Ependymoma,735
53,NCT02015728,Phase I,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1804, 'therapyName': 'Temozolomide + Etoposide'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors,735
54,NCT01111058,Phase II,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}]",Everolimus Versus Placebo in Head and Neck Cancer,735
55,NCT02023905,Phase II,Recruiting,"[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 735, 'therapyName': 'Everolimus'}]",Everolimus With and Without Temozolomide in Adult Low Grade Glioma,735
56,NCT02352844,Phase II,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}]","Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations",735
0,NCT01122199,Phase I,Completed,"[{'id': 1145, 'therapyName': 'Everolimus + AMG479'}]",Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors,1145
0,NCT01661283,Phase II,"Active, not recruiting","[{'id': 1120, 'therapyName': 'Everolimus + Bevacizumab'}]",Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors,1120
1,NCT01031381,Phase II,Completed,"[{'id': 1120, 'therapyName': 'Everolimus + Bevacizumab'}]","Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer",1120
2,NCT00756340,Phase I,Completed,"[{'id': 1120, 'therapyName': 'Everolimus + Bevacizumab'}]",A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors,1120
3,NCT01399918,Phase II,"Active, not recruiting","[{'id': 1120, 'therapyName': 'Everolimus + Bevacizumab'}]",Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC),1120
0,NCT01624766,Phase I,Recruiting,"[{'id': 1199, 'therapyName': 'Everolimus + Denosumab'}, {'id': 1192, 'therapyName': 'Anakinra + Everolimus'}]",Anakinra or Denosumab and Everolimus in Advanced Cancer,1199
0,NCT02057133,Phase I,Recruiting,"[{'id': 2254, 'therapyName': 'Abemaciclib + Letrozole'}, {'id': 2257, 'therapyName': 'Abemaciclib + Exemestane'}, {'id': 2258, 'therapyName': 'Everolimus + Exemestane + LY2835219'}, {'id': 2255, 'therapyName': 'Abemaciclib + Anastrozole'}, {'id': 2256, 'therapyName': 'Abemaciclib + Tamoxifen'}, {'id': 2259, 'therapyName': 'Abemaciclib + Trastuzumab'}]",A Study of LY2835219 in Combination With Hormone Therapies for Breast Cancer That Has Spread,2258
0,NCT03014297,Phase I,Recruiting,"[{'id': 5207, 'therapyName': 'Everolimus + Fosbretabulin'}]",Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression,5207
0,NCT01259063,Phase Ib/II,Completed,"[{'id': 2279, 'therapyName': 'Everolimus + Gemcitabine'}]",RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder,2279
0,NCT01376310,Phase II,"Active, not recruiting","[{'id': 1264, 'therapyName': 'Docetaxel + Trametinib'}, {'id': 1265, 'therapyName': 'Erlotinib + Trametinib'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 1266, 'therapyName': 'Pemetrexed + GSK1120212'}, {'id': 1267, 'therapyName': 'Carboplatin + GSK1120212'}, {'id': 1268, 'therapyName': 'nab-paclitaxel + GSK1120212'}, {'id': 1269, 'therapyName': 'Gemcitabine + GSK1120212'}, {'id': 1271, 'therapyName': 'Everolimus + GSK1120212'}]",GSK1120212 Rollover Study,1271
0,NCT03032406,Phase II,Recruiting,"[{'id': 2231, 'therapyName': 'Everolimus + Hydroxychloroquine'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1316, 'therapyName': 'Hydroxychloroquine'}]","CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer",2231
1,NCT01510119,Phase Ib/II,"Active, not recruiting","[{'id': 2231, 'therapyName': 'Everolimus + Hydroxychloroquine'}]",Autophagy Inhibition to Augment mTOR Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine in Patients With Previously Treated Renal Cell Carcinoma,2231
0,NCT01188889,Phase Ib/II,Withdrawn,"[{'id': 2198, 'therapyName': 'Everolimus + Imatinib'}]",RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease,2198
0,NCT01283789,Phase II,"Active, not recruiting","[{'id': 1539, 'therapyName': 'Everolimus + Lapatinib'}]",Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer,1539
0,NCT02811861,Phase III,Recruiting,"[{'id': 1713, 'therapyName': 'Everolimus + Lenvatinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 4782, 'therapyName': 'Lenvatinib + Pembrolizumab'}]",Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma,1713
1,NCT03173560,Phase II,Recruiting,"[{'id': 1713, 'therapyName': 'Everolimus + Lenvatinib'}]",Trial to Assess Safety and Efficacy of Lenvatinib in Combination With Everolimus in Participants With Renal Cell Carcinoma,1713
2,NCT03245151,Phase Ib/II,Not yet recruiting,"[{'id': 1713, 'therapyName': 'Everolimus + Lenvatinib'}]","Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors",1713
3,NCT02915783,Phase II,Recruiting,"[{'id': 1713, 'therapyName': 'Everolimus + Lenvatinib'}]",A Phase 2 Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease,1713
4,NCT03139747,Phase II,Recruiting,"[{'id': 1713, 'therapyName': 'Everolimus + Lenvatinib'}]",UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone,1713
0,NCT02228681,Phase II,"Active, not recruiting","[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 2401, 'therapyName': 'Medroxyprogesterone'}, {'id': 1621, 'therapyName': 'Everolimus + Letrozole'}]",Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer,1621
1,NCT02291913,Phase II,"Active, not recruiting","[{'id': 2267, 'therapyName': 'Everolimus + Tamoxifen'}, {'id': 2268, 'therapyName': 'Anastrozole + Everolimus'}, {'id': 1589, 'therapyName': 'Fulvestrant + Everolimus'}, {'id': 1621, 'therapyName': 'Everolimus + Letrozole'}, {'id': 2269, 'therapyName': 'Everolimus + Toremifene'}, {'id': 1966, 'therapyName': 'Exemestane + Everolimus'}]",Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer,1621
2,NCT02188550,Phase II,Unknown status,"[{'id': 1621, 'therapyName': 'Everolimus + Letrozole'}]",Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer,1621
3,NCT02283658,Phase II,"Active, not recruiting","[{'id': 1621, 'therapyName': 'Everolimus + Letrozole'}]","Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer",1621
4,NCT01698918,Phase II,"Active, not recruiting","[{'id': 1966, 'therapyName': 'Exemestane + Everolimus'}, {'id': 1621, 'therapyName': 'Everolimus + Letrozole'}]","Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer",1621
0,NCT02152943,Phase I,Recruiting,"[{'id': 1591, 'therapyName': 'Everolimus + Letrozole + Trastuzumab'}]","Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients",1591
0,NCT01490749,Phase I,"Active, not recruiting","[{'id': 1924, 'therapyName': 'Everolimus + Paclitaxel + Carboplatin + Cetuximab'}]",Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer,1924
0,NCT01252251,Phase II,Completed,"[{'id': 2261, 'therapyName': 'Everolimus + Pasireotide'}]",RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma,2261
1,NCT01313559,Phase II,Terminated,"[{'id': 2261, 'therapyName': 'Everolimus + Pasireotide'}, {'id': 2260, 'therapyName': 'Pasireotide'}]","Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer",2261
0,NCT01184326,Phase I,Completed,"[{'id': 1806, 'therapyName': 'everolimus + pazopanib'}]",An Expanded Phase I Study of Pazopanib and Everolimus in Patients With Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer,1806
0,NCT02089334,Phase Ib/II,Recruiting,"[{'id': 2262, 'therapyName': 'Everolimus + RX-0201'}, {'id': 735, 'therapyName': 'Everolimus'}]","Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer",2262
0,NCT01789281,Phase III,Recruiting,"[{'id': 1333, 'therapyName': 'Everolimus + Sandostatin LAR Depot'}]",Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.,1333
0,NCT02138929,Phase I,"Active, not recruiting","[{'id': 1871, 'therapyName': 'Everolimus + Sonidegib'}]",LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma,1871
0,NCT01434602,Phase Ib/II,Recruiting,"[{'id': 2299, 'therapyName': 'Everolimus + Sorafenib'}]",Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas,2299
1,NCT01263951,Phase II,"Active, not recruiting","[{'id': 2299, 'therapyName': 'Everolimus + Sorafenib'}]",Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone,2299
0,NCT02291913,Phase II,"Active, not recruiting","[{'id': 2267, 'therapyName': 'Everolimus + Tamoxifen'}, {'id': 2268, 'therapyName': 'Anastrozole + Everolimus'}, {'id': 1589, 'therapyName': 'Fulvestrant + Everolimus'}, {'id': 1621, 'therapyName': 'Everolimus + Letrozole'}, {'id': 2269, 'therapyName': 'Everolimus + Toremifene'}, {'id': 1966, 'therapyName': 'Exemestane + Everolimus'}]",Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer,2267
0,NCT02291913,Phase II,"Active, not recruiting","[{'id': 2267, 'therapyName': 'Everolimus + Tamoxifen'}, {'id': 2268, 'therapyName': 'Anastrozole + Everolimus'}, {'id': 1589, 'therapyName': 'Fulvestrant + Everolimus'}, {'id': 1621, 'therapyName': 'Everolimus + Letrozole'}, {'id': 2269, 'therapyName': 'Everolimus + Toremifene'}, {'id': 1966, 'therapyName': 'Exemestane + Everolimus'}]",Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer,2269
0,NCT01522872,Phase Ib/II,"Active, not recruiting","[{'id': 1317, 'therapyName': 'Evofosfamide'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma,1317
1,NCT01403610,Phase II,Completed,"[{'id': 2144, 'therapyName': 'Bevacizumab + Evofosfamide'}, {'id': 1317, 'therapyName': 'Evofosfamide'}]",Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab,1317
0,NCT03098160,Phase I,Recruiting,"[{'id': 5745, 'therapyName': 'Evofosfamide + Ipilimumab'}]",Immunotherapy Study of Evofosfamide in Combination With Ipilimumab,5745
0,NCT01485042,Phase I,Completed,"[{'id': 1318, 'therapyName': 'Evofosfamide + Pazopanib'}]",Dose Escalation Study of Pazopanib Plus TH-302,1318
0,NCT01497444,Phase Ib/II,Suspended,"[{'id': 1320, 'therapyName': 'Evofosfamide + Sorafenib'}]",Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery,1320
0,NCT02040857,Phase II,"Active, not recruiting","[{'id': 738, 'therapyName': 'Exemestane'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}]",Palbociclib + Endocrine Therapy for HR + BrCa,738
1,NCT02753686,Phase I,Recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 1966, 'therapyName': 'Exemestane + Everolimus'}]",Treatment of Canadian Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy (Treat ER+ight),738
2,NCT02598557,Phase II,Recruiting,"[{'id': 738, 'therapyName': 'Exemestane'}]",Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer,738
3,NCT03238703,FDA approved,Not yet recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}]","Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer",738
4,NCT02983604,Phase Ib/II,Recruiting,"[{'id': 738, 'therapyName': 'Exemestane'}, {'id': 5074, 'therapyName': 'GS-5829 + Fulvestrant'}, {'id': 3561, 'therapyName': 'GS-5829 + Exemestane'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",GS-5829 in Combination With Exemestane or Fulvestrant Comparing With Exemestane or Fulvestrant Alone in Women With Advanced Estrogen Receptor Positive HER2- Breast Cancer,738
5,NCT03300557,Phase II,Not yet recruiting,"[{'id': 738, 'therapyName': 'Exemestane'}]",Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Grade 1 Endometrial Cancer,738
6,NCT02947685,Phase III,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 947, 'therapyName': 'Trastuzumab'}]","Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (PATINA)",738
7,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,738
8,NCT02115282,Phase III,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1541, 'therapyName': 'Entinostat'}, {'id': 738, 'therapyName': 'Exemestane'}]",Exemestane With or Without Entinostat in Treating Postmenopausal Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,738
9,NCT01160211,Phase III,"Active, not recruiting","[{'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 738, 'therapyName': 'Exemestane'}]","A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer",738
10,NCT01674140,Phase III,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}]",S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,738
11,NCT02007512,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 738, 'therapyName': 'Exemestane'}]",Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer,738
12,NCT02666105,Phase II,Recruiting,"[{'id': 738, 'therapyName': 'Exemestane'}]",Exemestane in Post-Menopausal Women With NSCLC,738
13,NCT01664754,Phase I,"Active, not recruiting","[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 738, 'therapyName': 'Exemestane'}]","Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer",738
14,NCT01963481,Phase II,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 738, 'therapyName': 'Exemestane'}]",Exemestane and Cyclophosphamide for Metastatic Breast Cancer,738
15,NCT02188745,Phase II,Recruiting,"[{'id': 738, 'therapyName': 'Exemestane'}, {'id': 1643, 'therapyName': 'Estradiol'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}]",ER Reactivation Therapy for Breast Cancer,738
16,NCT02204098,Phase I,Recruiting,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]",Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy,738
17,NCT02648477,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer,738
18,NCT02689921,Phase II,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 738, 'therapyName': 'Exemestane'}]",NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (NEOADAPT),738
19,NCT01272037,Phase III,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}]","Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",738
20,NCT02476786,Phase II,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}]",Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score,738
0,NCT01698918,Phase II,"Active, not recruiting","[{'id': 1966, 'therapyName': 'Exemestane + Everolimus'}, {'id': 1621, 'therapyName': 'Everolimus + Letrozole'}]","Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer",1966
1,NCT02258451,Phase II,Recruiting,"[{'id': 1966, 'therapyName': 'Exemestane + Everolimus'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}]",Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane / Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer,1966
2,NCT01857193,Phase Ib/II,Recruiting,"[{'id': 2265, 'therapyName': 'LEE011 + Everolimus + Exemestane'}, {'id': 1966, 'therapyName': 'Exemestane + Everolimus'}, {'id': 2266, 'therapyName': 'LEE011 + Exemestane'}]",Phase Ib/II Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of ER+ Her2- Advanced Breast Cancer,1966
3,NCT02753686,Phase I,Recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 1966, 'therapyName': 'Exemestane + Everolimus'}]",Treatment of Canadian Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy (Treat ER+ight),1966
4,NCT02291913,Phase II,"Active, not recruiting","[{'id': 2267, 'therapyName': 'Everolimus + Tamoxifen'}, {'id': 2268, 'therapyName': 'Anastrozole + Everolimus'}, {'id': 1589, 'therapyName': 'Fulvestrant + Everolimus'}, {'id': 1621, 'therapyName': 'Everolimus + Letrozole'}, {'id': 2269, 'therapyName': 'Everolimus + Toremifene'}, {'id': 1966, 'therapyName': 'Exemestane + Everolimus'}]",Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer,1966
0,NCT02871791,Phase Ib/II,Recruiting,"[{'id': 4597, 'therapyName': 'Exemestane + Everolimus + Palbociclib'}]",Palbociclib With Everolimus + Exemestane In BC,4597
0,NCT02564614,Phase I,"Active, not recruiting","[{'id': 3612, 'therapyName': 'EZN-2968'}]","A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)",3612
0,NCT02620800,Phase Ib/II,Recruiting,"[{'id': 3621, 'therapyName': 'FABLOx'}]","Study of 5-fluorouracil (5-FU), Nab-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer",3621
0,NCT02420860,Phase II,Recruiting,"[{'id': 5972, 'therapyName': 'Famotidine'}, {'id': 3430, 'therapyName': 'Elotuzumab + lenalidomide'}, {'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Study of Elotuzumab With Lenalidomide as Maintenance After Autologous Stem Cell Transplant (ASCT),5972
0,NCT02511132,Phase II,"Active, not recruiting","[{'id': 1157, 'therapyName': 'FANG vaccine'}, {'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}]",Randomized Phase IIb Trial of Vigil Versus Gemcitabine + Docetaxel for Ewing's Sarcoma,1157
1,NCT02574533,Phase I,Completed,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1157, 'therapyName': 'FANG vaccine'}]",Pilot Study of Vigil + Pembrolizumab for Advanced Melanoma,1157
2,NCT02346747,Phase II,"Active, not recruiting","[{'id': 1157, 'therapyName': 'FANG vaccine'}]",Phase II/III Trial of Maintenance Vigil for High Risk Stage III/IV Ovarian Cancer (VITAL),1157
0,NCT01551745,Phase II,Completed,"[{'id': 1158, 'therapyName': 'FANG vaccine + Bevacizumab'}]", Salvage Ovarian FANG Vaccine + Bevacizumab,1158
0,NCT02725489,Phase II,Recruiting,"[{'id': 4388, 'therapyName': 'FANG vaccine + MEDI4736'}]",Pilot Study of Durvalumab (MEDI4736) in Combination With Vigil in Advanced Breast Cancer,4388
0,NCT02639234,Phase II,Withdrawn,"[{'id': 3572, 'therapyName': 'FANG vaccine + Nivolumab'}]",Vigil + Nivolumab in Advanced Non-Small Cell Lung Cancer,3572
0,NCT02289950,Phase II,Recruiting,"[{'id': 3230, 'therapyName': 'Farletuzumab'}]",A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA125 Platinum-Sensitive Ovarian Cancer,3230
0,NCT02936102,Phase I,Recruiting,"[{'id': 4971, 'therapyName': 'FAZ053'}, {'id': 4972, 'therapyName': 'FAZ053 + PDR001'}]",A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.,4971
0,NCT02936102,Phase I,Recruiting,"[{'id': 4971, 'therapyName': 'FAZ053'}, {'id': 4972, 'therapyName': 'FAZ053 + PDR001'}]",A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.,4972
0,NCT01534598,Phase I,Recruiting,"[{'id': 3789, 'therapyName': 'FdCyd + THU'}]",FdCyd and THU for Advanced Solid Tumors,3789
1,NCT00978250,Phase II,Recruiting,"[{'id': 3789, 'therapyName': 'FdCyd + THU'}]",A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU),3789
0,NCT01356290,Phase II,Recruiting,"[{'id': 1475, 'therapyName': 'Thalidomide'}, {'id': 4418, 'therapyName': 'Fenofibrate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2124, 'therapyName': 'Celecoxib'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}]",Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma (MEMMAT),4418
0,NCT02495415,Phase II,Recruiting,"[{'id': 2731, 'therapyName': 'Fenretinide'}]",Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas,2731
1,NCT01187810,Phase I,"Active, not recruiting","[{'id': 2731, 'therapyName': 'Fenretinide'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1639, 'therapyName': 'Methotrexate'}]","Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL",2731
2,NCT01535157,Phase Ib/II,"Active, not recruiting","[{'id': 2858, 'therapyName': 'Ketoconazole'}, {'id': 2731, 'therapyName': 'Fenretinide'}]",Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer,2731
3,NCT02163356,Phase I,Recruiting,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 2731, 'therapyName': 'Fenretinide'}, {'id': 2858, 'therapyName': 'Ketoconazole'}]",Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma,2731
4,NCT02075177,Phase I,Available,"[{'id': 2858, 'therapyName': 'Ketoconazole'}, {'id': 2731, 'therapyName': 'Fenretinide'}]",Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma,2731
5,NCT01553071,Phase I,Recruiting,"[{'id': 1049, 'therapyName': 'Safingol'}, {'id': 2731, 'therapyName': 'Fenretinide'}]",Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies,2731
0,NCT02454010,Phase I,Recruiting,"[{'id': 3833, 'therapyName': 'FF-21101(90Y)'}]",A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer,3833
0,NCT01948297,Phase I,Recruiting,"[{'id': 1014, 'therapyName': 'FF-284'}]",Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations,1014
0,NCT02325739,Phase Ib/II,Recruiting,"[{'id': 2031, 'therapyName': 'FGF401'}]",Safety and Efficacy of FGF401 in Patients With Solid Malignancies,2031
0,NCT02090127,Phase I,No longer available,"[{'id': 740, 'therapyName': 'Ficlatuzumab'}]",Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient,740
0,NCT02277197,Phase I,"Active, not recruiting","[{'id': 1959, 'therapyName': 'Ficlatuzumab + Cetuximab'}]",Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC),1959
0,NCT02277184,Phase I,Terminated,"[{'id': 1955, 'therapyName': 'Ficlatuzumab + Cisplatin'}]","Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma",1955
0,NCT02318368,Phase II,Terminated,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2169, 'therapyName': 'Ficlatuzumab + Erlotinib'}]","A Phase 2, Multicenter, Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label",2169
0,NCT01857934,Phase II,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 2627, 'therapyName': 'Levetiracetam'}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 2458, 'therapyName': 'Hu14.18K322A'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}]",Therapy for Children With Advanced Stage Neuroblastoma,1632
1,NCT02039726,Phase III,"Active, not recruiting","[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 3193, 'therapyName': 'Cytarabine + Fludarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 882, 'therapyName': 'Quizartinib'}]",An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects,1632
2,NCT00303849,Phase Ib/II,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2562, 'therapyName': 'Etoposide + Melphalan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]",Combination Chemotherapy With BBBD Followed By Sodium Thiosulfate in Treating Patients With Anaplastic Oligodendroglioma or Oligoastrocytoma,1632
3,NCT00983398,Phase Ib/II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2587, 'therapyName': 'Carboplatin + Melphalan'}]","Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors",1632
4,NCT02337985,Phase I,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 2482, 'therapyName': 'Cyclophosphamide + Doxorubicin + Etoposide + Vincristine '}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma,1632
5,NCT00513474,Phase I,Completed,"[{'id': 2313, 'therapyName': 'Rasburicase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2314, 'therapyName': 'Busulfan + Cyclophosphamide + Etoposide'}]",Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant,1632
6,NCT01467115,Phase II,Completed,"[{'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1930, 'therapyName': 'Cisplatin + Docetaxel + Fluorouracil'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 694, 'therapyName': 'Cetuximab'}]",INDUCTION CHEMOTHERAPY FOLLOWED BY CETUXIMAB AND RADIATION THERAPY FOR HEAD AND NECK CANCER,1632
7,NCT03247088,Phase Ib/II,Recruiting,"[{'id': 6122, 'therapyName': 'Busulfan + Sorafenib + Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Study Of Sorafenib Added To Busulfan And Fludarabine Conditioning Regimen In Patients With Relapsed/Refractory AML Undergoing Stem Cell Transplantation,1632
8,NCT02343666,Phase I,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 2556, 'therapyName': 'O6-benzylguanine'}]",HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection,1632
9,NCT00293475,Phase Ib/II,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 2669, 'therapyName': 'Carboplatin + Methotrexate + Rituximab'}]",Rituximab and Methotrexate Chemotherapy w/Blood-Brain Barrier Disruption (BBBD) &amp; Sodium Thiosulfate Chemoprotection for Patients With Newly Diagnosed PCNSL,1632
10,NCT01729091,Phase Ib/II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3343, 'therapyName': 'Elotuzumab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1164, 'therapyName': 'lenalidomide'}]",Study of Umbilical Cord Blood-derived Natural Killer Cells in Conjunction With High Dose Chemotherapy and Autologous Stem Cell Transplant for Patients With Multiple Myeloma,1632
11,NCT02104427,Phase II,Completed,"[{'id': 2853, 'therapyName': 'TG-0054'}, {'id': 1632, 'therapyName': 'Filgrastim'}]","PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients",1632
12,NCT03214562,,Recruiting,"[{'id': 1562, 'therapyName': 'Venetoclax'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive Acute Myeloid Leukemia (AML) Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML),1632
13,NCT02356159,Phase Ib/II,Recruiting,"[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 2292, 'therapyName': 'Doxorubicin + Etoposide + Fludarabine + Vincristine '}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation,1632
14,NCT02412475,Phase I,"Active, not recruiting","[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 650, 'therapyName': 'Decitabine'}]",Epigenetic Reprogramming in Relapse AML,1632
15,NCT01526603,Phase I,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1092, 'therapyName': 'Carboplatin'}]",High Dose Chemotherapy and Autologous Transplant for Neuroblastoma,1632
16,NCT01823198,Phase Ib/II,Recruiting,"[{'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1846, 'therapyName': 'Busulfan + Fludarabine + anti-thymocyte globulin'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies,1632
17,NCT02756572,Phase I,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5215, 'therapyName': 'mitoxantrone hydrochloride'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myelodysplastic Syndrome or Acute Myeloid Leukemia,1632
18,NCT02790515,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation,1632
19,NCT01526096,Phase I,Recruiting,"[{'id': 5985, 'therapyName': 'Basiliximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 1207, 'therapyName': 'Melphalan'}]",Stem Cell Transplantation for Patients With Multiple Myeloma,1632
20,NCT01707004,Phase I,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1206, 'therapyName': 'Busulfan'}]",Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,1632
21,NCT01256398,Phase II,"Active, not recruiting","[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1824, 'therapyName': 'Vincristine + Methotrexate + Mercaptopurine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,1632
22,NCT00857389,Phase II,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies,1632
23,NCT02421939,Phase III,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 3193, 'therapyName': 'Cytarabine + Fludarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2865, 'therapyName': 'Gilteritinib'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,1632
24,NCT03197935,Phase III,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer (IMpassion031),1632
25,NCT01319981,Phase II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia,1632
26,NCT01177683,Phase Ib/II,"Active, not recruiting","[{'id': 3349, 'therapyName': 'Bendamustine + Bortezomib + pegylated liposomal-doxorubicin'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma,1632
27,NCT02098109,Phase II,Completed,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma,1632
28,NCT00520130,Phase Ib/II,"Active, not recruiting","[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2305, 'therapyName': 'Alemtuzumab + Cyclosporine'}, {'id': 2306, 'therapyName': 'Rituximab + Fludarabine + EPOCH'}, {'id': 2307, 'therapyName': 'Fludarabine + EPOCH'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,1632
29,NCT03164057,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia,1632
30,NCT01505569,Phase I,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2101, 'therapyName': 'Etoposide + Ifosfamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Auto Transplant for High Risk or Relapsed Solid or CNS Tumors,1632
31,NCT01547806,Phase II,"Active, not recruiting","[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1756, 'therapyName': 'Plerixafor'}]",Collection of Transplant Stem Cells for Plasma Cell Myeloma,1632
32,NCT02423915,Phase Ib/II,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}, {'id': 917, 'therapyName': 'Sirolimus'}]",Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention,1632
33,NCT02427620,Phase II,Recruiting,"[{'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 1642, 'therapyName': 'Leucovorin'}]",A Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma,1632
34,NCT01701986,Phase Ib/II,Recruiting,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 3992, 'therapyName': 'Busulfan + Clofarabine + Gemcitabine'}]",Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas,1632
35,NCT03147612,Phase II,Not yet recruiting,"[{'id': 5682, 'therapyName': 'Mesna'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Study of the Combination of Low-Intensity Chemotherapy and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),1632
36,NCT01858883,Phase I,Completed,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2406, 'therapyName': 'INCB039110'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Safety Study of INCB039110 in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors,1632
37,NCT00074490,Phase II,Completed,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,1632
38,NCT02130869,Phase I,Recruiting,"[{'id': 2378, 'therapyName': 'Bendamustine + Cytarabine + Etoposide'}, {'id': 2460, 'therapyName': 'Busulfan + Hu14.18K322A'}, {'id': 2459, 'therapyName': 'Aldesleukin + Melphalan + Sargramostim'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas,1632
39,NCT03263936,Phase I,Recruiting,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Epigenetic Reprogramming in Relapse/Refractory AML,1632
0,NCT02703779,Phase II,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 3933, 'therapyName': 'Filgrastim + Plerixafor'}]",Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM),3933
1,NCT03240861,Phase I,Not yet recruiting,"[{'id': 6116, 'therapyName': 'Busulfan + Fludarabine'}, {'id': 3933, 'therapyName': 'Filgrastim + Plerixafor'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer (NYESO SCT),3933
0,NCT01342367,Phase I,Recruiting,"[{'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 2643, 'therapyName': 'Dutasteride'}, {'id': 2644, 'therapyName': 'Finasteride'}]",Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer,2644
0,NCT02490930,Phase I,Completed,"[{'id': 3610, 'therapyName': 'Fingolimod'}]",A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma,3610
0,NCT03069950,Phase II,Recruiting,"[{'id': 5476, 'therapyName': 'Floxiuridine + Panitumumab + Dexamethasone + FOLFIRI'}]",Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver,5476
0,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1941
1,NCT01312857,Phase II,Recruiting,"[{'id': 845, 'therapyName': 'Panitumumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1941, 'therapyName': 'Floxuridine'}]","Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type KRAS Who Have Resected Hepatic Metastases From Colorectal Cancer",1941
0,NCT01749397,Phase I,Recruiting,"[{'id': 2009, 'therapyName': 'Floxuridine + Veliparib'}]","Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer",2009
0,NCT02222922,Phase I,Recruiting,"[{'id': 1689, 'therapyName': 'Fluconazole'}, {'id': 4421, 'therapyName': 'PF-06647020'}]",A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors,1689
1,NCT02532192,Phase I,Withdrawn,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1689, 'therapyName': 'Fluconazole'}, {'id': 1078, 'therapyName': 'Belinostat'}]","A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma",1689
2,NCT02122770,Phase I,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1026, 'therapyName': 'Itraconazole'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1688, 'therapyName': 'MLN4924'}, {'id': 1689, 'therapyName': 'Fluconazole'}]","Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors",1689
0,NCT00084695,Phase II,Unknown status,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases,1166
1,NCT03164057,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia,1166
2,NCT00902044,Phase I,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2940, 'therapyName': 'HER2 sensitized T-cells'}]",Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma,1166
3,NCT03214562,,Recruiting,"[{'id': 1562, 'therapyName': 'Venetoclax'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive Acute Myeloid Leukemia (AML) Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML),1166
4,NCT01625351,Phase I,"Active, not recruiting","[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}]",A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas,1166
5,NCT01822652,Phase I,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]","3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN",1166
6,NCT02412475,Phase I,"Active, not recruiting","[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 650, 'therapyName': 'Decitabine'}]",Epigenetic Reprogramming in Relapse AML,1166
7,NCT01231412,Phase III,"Active, not recruiting","[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2272, 'therapyName': 'Cyclosporine + Mycophenolate mofetil'}]",Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant,1166
8,NCT02251821,Phase II,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 2006, 'therapyName': 'Pacritinib'}, {'id': 823, 'therapyName': 'Momelotinib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis,1166
9,NCT01218867,Phase Ib/II,Completed,"[{'id': 984, 'therapyName': 'Anti-VEGFR2 CAR CD8 lymphocytes'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes,1166
10,NCT02621021,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab,1166
11,NCT03215810,,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer,1166
12,NCT01993719,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Immunotherapy Using Tumor Infiltrating Lymphocytes Comparing 2 Different Conditioning Regimens for Patients With Metastatic Melanoma,1166
13,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,1166
14,NCT02181478,Phase I,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Intra-Osseous Co-Transplant of UCB and hMSC,1166
15,NCT02118311,Phase II,Withdrawn,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",T Regulatory Cell for Suppression of Acute Graft-vs-Host-Disease After a Non-Myeloablative Umbilical Cord Blood Transplantation,1166
16,NCT02790515,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation,1166
17,NCT03263936,Phase I,Recruiting,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Epigenetic Reprogramming in Relapse/Refractory AML,1166
18,NCT00305682,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant,1166
19,NCT02212561,Phase Ib/II,Completed,"[{'id': 1749, 'therapyName': 'Selinexor'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 2345, 'therapyName': 'Cytarabine + Dexamethasone+ Methotrexate '}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome,1166
20,NCT02118285,Phase I,Completed,"[{'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 2575, 'therapyName': 'Epacadostat'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}]","Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer",1166
21,NCT00074490,Phase II,Completed,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,1166
22,NCT02756572,Phase I,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5215, 'therapyName': 'mitoxantrone hydrochloride'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myelodysplastic Syndrome or Acute Myeloid Leukemia,1166
23,NCT01312376,Phase I,"Active, not recruiting","[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1227, 'therapyName': 'CD3/CD28 costimulated vaccine-primed autologous T-cells'}, {'id': 1222, 'therapyName': 'OC-DC vaccine'}]",Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer,1166
24,NCT02472392,Phase I,Completed,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}]",Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma,1166
25,NCT01707004,Phase I,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1206, 'therapyName': 'Busulfan'}]",Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,1166
26,NCT01659151,Phase II,"Active, not recruiting","[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 342, 'therapyName': 'Vemurafenib'}]", Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer &amp; High Dose IL-2 Metastatic Melanoma,1166
27,NCT03190941,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 6061, 'therapyName': 'anti-KRAS G12V mTCR cells'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*1101 Patients,1166
28,NCT01529827,Phase II,"Active, not recruiting","[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1166, 'therapyName': 'Fludarabine'}]","Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies",1166
29,NCT02793544,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide,1166
30,NCT01251575,Phase II,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2270, 'therapyName': 'Cyclosporine + Mycophenolate mofetil + Sirolimus'}]","Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant",1166
31,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1166
0,NCT00520130,Phase Ib/II,"Active, not recruiting","[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2305, 'therapyName': 'Alemtuzumab + Cyclosporine'}, {'id': 2306, 'therapyName': 'Rituximab + Fludarabine + EPOCH'}, {'id': 2307, 'therapyName': 'Fludarabine + EPOCH'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,2307
0,NCT02514083,Phase II,Recruiting,"[{'id': 3633, 'therapyName': 'Fludarabine + Ibrutinib'}]",A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL),3633
0,NCT03204188,Phase II,Recruiting,"[{'id': 6154, 'therapyName': 'Fludarabine + Ibrutinib + Pembrolizumab'}]","Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",6154
0,NCT01453101,Phase II,"Active, not recruiting","[{'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma,2237
1,NCT02771197,Phase II,Recruiting,"[{'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant,2237
2,NCT02440464,Phase II,Recruiting,"[{'id': 3321, 'therapyName': 'Tacrolimus + Methotrexate'}, {'id': 1359, 'therapyName': 'Ixazomib'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302),2237
3,NCT02508038,Phase I,Recruiting,"[{'id': 2971, 'therapyName': 'Zoledronic acid'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}]", Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa,2237
4,NCT02528877,Phase I,Withdrawn,"[{'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 3181, 'therapyName': 'Ruxolitinib + Sirolimus + Tacrolimus'}]","Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis",2237
5,NCT02333162,Phase I,Recruiting,"[{'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}]","Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant",2237
6,NCT00577278,Phase II,"Active, not recruiting","[{'id': 767, 'therapyName': 'Ibritumomab'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}]","Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma",2237
7,NCT02653196,Phase II,Terminated,"[{'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 3948, 'therapyName': 'Cyclosporine + Mycophenolate mofetil + Tacrolimus'}]",A Multi-Institutional Phase II Feasibility Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors,2237
0,NCT01760655,Phase II,Recruiting,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1842, 'therapyName': 'Fludarabine + Thiotepa + Cyclophosphamide'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}]",Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies,1842
0,NCT02083653,Phase II,"Active, not recruiting","[{'id': 931, 'therapyName': 'SYM004'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer,1715
1,NCT02620423,Phase I,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 893, 'therapyName': 'Reolysin'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab With REOLYSIN and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma,1715
2,NCT02314117,Phase III,"Active, not recruiting","[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer,1715
3,NCT01750918,Phase II,"Active, not recruiting","[{'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1718, 'therapyName': 'Panitumumab + Dabrafenib'}, {'id': 1992, 'therapyName': 'Panitumumab + Trametinib + Dabrafenib'}, {'id': 1991, 'therapyName': 'Panitumumab + Trametinib'}]",BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC),1715
4,NCT02358031,Phase III,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048),1715
5,NCT01128387,Phase Ib/II,Completed,"[{'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 845, 'therapyName': 'Panitumumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Trial of Panitumumab/Cisplatin/Fluorouracil With XRT in Esophageal Cancer,1715
6,NCT01775501,Phase II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Sorafenib + mFOLFOX for Hepatocellular Carcinoma,1715
7,NCT02138617,Phase II,Recruiting,"[{'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1715, 'therapyName': 'Fluorouracil'}]",Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer,1715
8,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1715
9,NCT02688712,Phase II,Recruiting,"[{'id': 5788, 'therapyName': 'Capecitabine + Galunisertib'}, {'id': 5789, 'therapyName': 'Fluorouracil + Galunisertib'}, {'id': 2409, 'therapyName': 'Galunisertib'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer,1715
10,NCT01099358,Phase II,Completed,"[{'id': 1915, 'therapyName': 'Cetuximab + Cisplatin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}]",Study in Advanced Solid Tumors,1715
11,NCT03136406,Phase Ib/II,Recruiting,"[{'id': 1018, 'therapyName': 'GI-4000'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 6163, 'therapyName': 'ETBX-011'}, {'id': 3060, 'therapyName': 'ALT-803'}]",QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy,1715
0,NCT03050814,Phase II,Suspended,"[{'id': 1524, 'therapyName': 'Fluorouracil + Bevacizumab + Capecitabine + Leucovorin + Oxaliplatin'}, {'id': 5336, 'therapyName': 'Ad-CEA + Bevacizumab + FOLFOX'}]",Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer,1524
0,NCT01765582,Phase II,Terminated,"[{'id': 1523, 'therapyName': 'Fluorouracil + Capecitabine + Irinotecan + Leucovorin + Oxaliplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}]",STEAM: A Study of Sequential and Concurrent FOLFOXIRI/Avastin (Bevacizumab) Regimens Versus FOLFOX/Avastin in First-Line in Patients With Metastatic Colorectal Cancer,1523
0,NCT01836029,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2000, 'therapyName': 'Fluorouracil + Cetuximab'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,2000
0,NCT01501487,FDA approved,"Active, not recruiting","[{'id': 1902, 'therapyName': 'Docetaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1485, 'therapyName': 'Trastuzumab + Docetaxel + Carboplatin'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]",MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I,1982
1,NCT01036087,Phase II,"Active, not recruiting","[{'id': 1984, 'therapyName': 'Panitumumab + Abraxane + Carboplatin'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}]","Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer",1982
2,NCT01779050,Phase II,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1087, 'therapyName': 'Epirubicin + Cyclophosphamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}, {'id': 1834, 'therapyName': 'Docetaxel + Carboplatin'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}]",Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells,1982
0,NCT02688712,Phase II,Recruiting,"[{'id': 5788, 'therapyName': 'Capecitabine + Galunisertib'}, {'id': 5789, 'therapyName': 'Fluorouracil + Galunisertib'}, {'id': 2409, 'therapyName': 'Galunisertib'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer,5789
0,NCT02785068,Phase I,Withdrawn,"[{'id': 4532, 'therapyName': 'Fluorouracil + Irinotecan + Leucovorin + MM-151'}]",Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer,4532
0,NCT02448810,Phase II,Terminated,"[{'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}, {'id': 2996, 'therapyName': 'Imalumab'}, {'id': 845, 'therapyName': 'Panitumumab'}]",Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer,2278
1,NCT02042443,Phase II,Completed,"[{'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 2, 'therapyName': 'Trametinib'}]",Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery,2278
2,NCT02620865,Phase Ib/II,Suspended,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}]",Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer,2278
3,NCT01959672,Phase II,Recruiting,"[{'id': 827, 'therapyName': 'Nelfinavir'}, {'id': 1189, 'therapyName': 'Oregovomab'}, {'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Combination Chemotherapy With or Without Oregovomab Followed by Stereotactic Body Radiation Therapy and Nelfinavir Mesylate in Treating Patients With Locally Advanced Pancreatic Cancer,2278
0,NCT01383538,Phase I,Completed,"[{'id': 2498, 'therapyName': 'Fluorouracil + Leucovorin + Irinotecan + Oxaliplatin + Saridegib'}]",FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma,2498
0,NCT02124148,Phase I,Recruiting,"[{'id': 1994, 'therapyName': 'Cisplatin + Prexasertib'}, {'id': 1993, 'therapyName': 'Cetuximab + Prexasertib'}, {'id': 6248, 'therapyName': 'Pemetrexed + Prexasertib'}, {'id': 6247, 'therapyName': 'LY3023414 + Prexasertib'}, {'id': 6246, 'therapyName': 'Fluoruracil + Leucovorin + Prexasertib'}]",A Study of LY2606368 With Cisplatin or Cetuximab in Participants With Advanced Cancer,6246
0,NCT00936390,Phase III,"Active, not recruiting","[{'id': 742, 'therapyName': 'Flutamide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,742
1,NCT00223665,Phase II,Unknown status,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 742, 'therapyName': 'Flutamide'}]",Intermittent Hormone Therapy in Men With Localized Prostate Cancer After Radiation Therapy or Radical Prostatectomy,742
0,NCT02335814,Phase I,Terminated,"[{'id': 2529, 'therapyName': 'FLX925  '}]",First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia,2529
0,NCT01814501,Phase II,Recruiting,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 845, 'therapyName': 'Panitumumab'}]",Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab,1315
1,NCT02046538,Phase II,Withdrawn,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 624, 'therapyName': 'Aflibercept'}]",Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer,1315
2,NCT02482441,Phase I,Recruiting,"[{'id': 4401, 'therapyName': 'Rosmantuzumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]","A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10",1315
3,NCT01312857,Phase II,Recruiting,"[{'id': 845, 'therapyName': 'Panitumumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1941, 'therapyName': 'Floxuridine'}]","Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type KRAS Who Have Resected Hepatic Metastases From Colorectal Cancer",1315
4,NCT01488552,Phase Ib/II,Completed,"[{'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1031, 'therapyName': 'Metformin'}]",Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer,1315
5,NCT01274624,Phase I,"Active, not recruiting","[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 2099, 'therapyName': 'Bevacizumab + Reolysin'}]",Study of REOLYSIN; in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer,1315
6,NCT02024607,Phase Ib/II,"Active, not recruiting","[{'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}, {'id': 2093, 'therapyName': 'BBI608 + Bevacizumab'}, {'id': 2094, 'therapyName': 'BBI608 + Regorafenib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2057, 'therapyName': 'BBI608'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer,1315
7,NCT01260415,Phase II,Completed,"[{'id': 845, 'therapyName': 'Panitumumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases,1315
8,NCT02605044,Phase III,Recruiting,"[{'id': 804, 'therapyName': 'Masitinib'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",Study to Compare the Efficacy and Safety of Masitinib in Combination With FOLFIRI to Placebo in Combination With FOLFIRI in Second Line Treatment of Patients With Metastatic Colorectal Cancer,1315
9,NCT02753127,Phase III,Recruiting,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 2057, 'therapyName': 'BBI608'}]",A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CanStem303C),1315
10,NCT02305758,Phase II,Completed,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 954, 'therapyName': 'Veliparib'}]",Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer,1315
11,NCT02508077,Phase II,Terminated,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 845, 'therapyName': 'Panitumumab'}]",FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer,1315
12,NCT01803282,Phase I,Recruiting,"[{'id': 3320, 'therapyName': 'GS-5745'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Safety and Tolerability Study in Solid Tumors,1315
13,NCT01298570,Phase II,"Active, not recruiting","[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer,1315
14,NCT01653470,Phase I,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 2545, 'therapyName': 'BMS-906024'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors",1315
15,NCT01937715,Phase II,Terminated,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1040, 'therapyName': 'PF-05212384'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer,1315
16,NCT02890355,,Recruiting,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer,1315
17,NCT02563002,Phase III,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177),1315
18,NCT02213289,Phase Ib/II,Recruiting,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1913, 'therapyName': 'FOLTAX'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 629, 'therapyName': 'AMG102'}]",PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression,1315
19,NCT01472016,Phase I,Completed,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1063, 'therapyName': 'ABT-700'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",Study of ABT-700 in Subjects With Advanced Solid Tumors,1315
20,NCT01652482,Phase II,Completed,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 806, 'therapyName': 'MEHD7945A'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer,1315
0,NCT03035253,Phase I,Recruiting,"[{'id': 5297, 'therapyName': 'FOLFIRI + OMP-305B83'}]",A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer,5297
0,NCT02568046,Phase Ib/II,"Active, not recruiting","[{'id': 3949, 'therapyName': 'FOLFIRI + SYM004'}]",Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients,3949
0,NCT01485744,Phase I,"Active, not recruiting","[{'id': 1903, 'therapyName': 'FOLFIRINOX'}, {'id': 1428, 'therapyName': 'Sonidegib'}]","LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer",1903
1,NCT01821729,Phase II,Recruiting,"[{'id': 1903, 'therapyName': 'FOLFIRINOX'}, {'id': 2998, 'therapyName': 'Losartan'}]",Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer,1903
2,NCT01928290,Phase II,Recruiting,"[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1903, 'therapyName': 'FOLFIRINOX'}]","Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer",1903
3,NCT01896869,Phase II,Suspended,"[{'id': 1903, 'therapyName': 'FOLFIRINOX'}, {'id': 779, 'therapyName': 'Ipilimumab'}]","A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab With Allogenic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer",1903
4,NCT02581215,Phase II,Recruiting,"[{'id': 886, 'therapyName': 'Ramucirumab'}, {'id': 1903, 'therapyName': 'FOLFIRINOX'}]",Phase II Randomized Trial of FOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer,1903
0,NCT02213289,Phase Ib/II,Recruiting,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1913, 'therapyName': 'FOLTAX'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 629, 'therapyName': 'AMG102'}]",PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression,1913
0,NCT01305213,Phase Ib/II,Completed,"[{'id': 1186, 'therapyName': 'Fosbretabulin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Bevacizumab With or Without Fosbretabulin Tromethamine in Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer",1186
0,NCT02611063,Phase I,Recruiting,"[{'id': 1528, 'therapyName': 'Fostamatinib'}]",Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell Transplant,1528
0,NCT02526017,Phase I,Recruiting,"[{'id': 2840, 'therapyName': 'FPA008'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers,2840
1,NCT02471716,Phase Ib/II,Recruiting,"[{'id': 2840, 'therapyName': 'FPA008'}]",Study of FPA008 in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor,2840
0,NCT02318329,Phase I,Recruiting,"[{'id': 2933, 'therapyName': 'FPA144'}]","Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors",2933
0,NCT02581787,Phase Ib/II,Recruiting,"[{'id': 2707, 'therapyName': 'fresolimumab'}]",SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer,2707
0,NCT02719574,Phase I,Recruiting,"[{'id': 4336, 'therapyName': 'FT-2102'}, {'id': 4449, 'therapyName': 'FT-2102 + Azacitidine'}]",Dose-Escalation Study of FT-2102 as a Single Agent and in Combination With Azacitidine in Patients With AML or MDS With an IDH1 Mutation,4336
0,NCT02719574,Phase I,Recruiting,"[{'id': 4336, 'therapyName': 'FT-2102'}, {'id': 4449, 'therapyName': 'FT-2102 + Azacitidine'}]",Dose-Escalation Study of FT-2102 as a Single Agent and in Combination With Azacitidine in Patients With AML or MDS With an IDH1 Mutation,4449
0,NCT02947685,Phase III,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 947, 'therapyName': 'Trastuzumab'}]","Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (PATINA)",744
1,NCT02384239,Phase II,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]",A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer,744
2,NCT02476786,Phase II,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}]",Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score,744
3,NCT01296555,Phase I,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1016, 'therapyName': 'GDC-0032'}, {'id': 794, 'therapyName': 'Letrozole'}]",A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors And in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer,744
4,NCT02964507,Phase II,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 5242, 'therapyName': 'GSK525762 + Fulvestrant'}]",Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Estrogen Receptor Positive (ER+) Breast Cancer,744
5,NCT02684032,Phase I,Recruiting,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 4034, 'therapyName': 'Gedatolisib + Palbociclib'}]",A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer,744
6,NCT02756364,Phase II,Recruiting,"[{'id': 1581, 'therapyName': 'MLN0128 + Fulvestrant'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",MLN0128 in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy,744
7,NCT02374099,Phase II,"Active, not recruiting","[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant,744
8,NCT02569801,Phase II,"Active, not recruiting","[{'id': 2150, 'therapyName': 'GDC-0810'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",A Study of GDC-0810 Versus Fulvestrant in Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy,744
9,NCT01219699,Phase I,"Active, not recruiting","[{'id': 691, 'therapyName': 'BYL719'}, {'id': 744, 'therapyName': 'Fulvestrant'}]"," A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene",744
10,NCT02936206,Phase I,Recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Examination of Breast Cancer Cells of Pre-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.,744
11,NCT03241810,,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 820, 'therapyName': 'Seribantumab'}]",Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer,744
12,NCT02675231,Phase II,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 744, 'therapyName': 'Fulvestrant'}]","A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer",744
13,NCT02626507,Phase I,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1040, 'therapyName': 'PF-05212384'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer,744
14,NCT01633060,Phase III,"Active, not recruiting","[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1546, 'therapyName': 'Fulvestrant + BKM120'}]","A Phase III Study of BKM120 With Fulvestrant in Patients With HR+, HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi",744
15,NCT02137837,Phase III,"Active, not recruiting","[{'id': 1589, 'therapyName': 'Fulvestrant + Everolimus'}, {'id': 1590, 'therapyName': 'Fulvestrant + Everolimus + Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}]","S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer",744
16,NCT02983604,Phase Ib/II,Recruiting,"[{'id': 738, 'therapyName': 'Exemestane'}, {'id': 5074, 'therapyName': 'GS-5829 + Fulvestrant'}, {'id': 3561, 'therapyName': 'GS-5829 + Exemestane'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",GS-5829 in Combination With Exemestane or Fulvestrant Comparing With Exemestane or Fulvestrant Alone in Women With Advanced Estrogen Receptor Positive HER2- Breast Cancer,744
17,NCT02260661,Phase I,Completed,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 2013, 'therapyName': 'AZD8835'}]","Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours",744
18,NCT02422615,Phase III,"Active, not recruiting","[{'id': 790, 'therapyName': 'Ribociclib'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.,744
19,NCT02630693,Phase II,"Active, not recruiting","[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]","Study Comparing Two Different Schedules of Palbociclib Plus Second Line Endocrine Therapy in Women With Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer",744
20,NCT01437566,Phase II,Completed,"[{'id': 750, 'therapyName': 'GDC-0980'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 749, 'therapyName': 'GDC-0941'}]",Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy,744
21,NCT02107703,Phase III,"Active, not recruiting","[{'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer,744
22,NCT01610284,Phase III,"Active, not recruiting","[{'id': 1546, 'therapyName': 'Fulvestrant + BKM120'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor,744
23,NCT03280563,Phase Ib/II,Not yet recruiting,"[{'id': 6269, 'therapyName': 'Atezolizumab + Ipatasertib'}, {'id': 6270, 'therapyName': 'Atezolizumab + Bevacizumab + Exemestane'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 6271, 'therapyName': 'Atezolizumab + Bevacizumab + Fulvestrant'}, {'id': 6272, 'therapyName': 'Atezolizumab + Bevacizumab + Tamoxifen'}, {'id': 6273, 'therapyName': 'Atezolizumab + Ipatasertib + Fulvestrant'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 6268, 'therapyName': 'Atezolizumab + Fulvestrant'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer,744
24,NCT02913430,Phase II,Recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Phase II Treatment of Metastatic Breast Cancer With Fulvestrant or Tamoxifen,744
25,NCT02437318,Phase III,Recruiting,"[{'id': 691, 'therapyName': 'BYL719'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.,744
26,NCT01953588,Phase III,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,744
27,NCT02955394,Phase II,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 4940, 'therapyName': 'Enzalutamide + Fulvestrant'}]",Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer,744
28,NCT01560416,Phase II,"Active, not recruiting","[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 745, 'therapyName': 'Ganetespib'}]",Fulvestrant With or Without Ganetespib in HR+ Breast Cancer,744
29,NCT02219789,Phase I,"Active, not recruiting","[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 626, 'therapyName': 'Alisertib'}]",Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery,744
30,NCT02540330,Phase II,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}]",PK Study of Pre-Surgical Intramuscular and Intraductal Fulvestrant in Women With Invasive Breast Cancer or DCIS Undergoing Mastectomy,744
31,NCT02345772,Phase I,Terminated,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]","Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Taxotere, Trastuzumab and Pertuzumab) in Patients With HER2-positive and ER-Positive Breast Cancer",744
32,NCT02753686,Phase I,Recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 1966, 'therapyName': 'Exemestane + Everolimus'}]",Treatment of Canadian Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy (Treat ER+ight),744
33,NCT02206984,Phase I,Recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Endocrine Response in Women With Invasive Lobular Breast Cancer,744
34,NCT01797120,Phase II,Completed,"[{'id': 1589, 'therapyName': 'Fulvestrant + Everolimus'}, {'id': 744, 'therapyName': 'Fulvestrant'}]","Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI",744
35,NCT01528345,Phase II,Terminated,"[{'id': 2189, 'therapyName': 'Fulvestrant + Dovitinib'}, {'id': 744, 'therapyName': 'Fulvestrant'}]","Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer",744
36,NCT02632045,Phase II,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 790, 'therapyName': 'Ribociclib'}]",Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ H2N- Advanced Breast Cancer,744
37,NCT02340221,Phase III,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1016, 'therapyName': 'GDC-0032'}]",SANDPIPER Study: A Study Of Taselisib + Fulvestrant Versus Placebo + Fulvestrant In Patients With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy,744
38,NCT02269670,Phase II,"Active, not recruiting","[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1869, 'therapyName': 'Megestrol'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 633, 'therapyName': 'Anastrozole'}]",Everolimus and Hormone Therapy in Treating Patients With Advanced Hormone Receptor Positive Breast Cancer That Has Progressed or Recurred on Everolimus and Exemestane Therapy,744
39,NCT00921115,Phase II,"Active, not recruiting","[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.,744
40,NCT03147287,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 3205, 'therapyName': 'Fulvestrant + Palbociclib'}, {'id': 5684, 'therapyName': 'Fulvestrant + Palbociclib + Avelumab'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Palbociclib After CDK and Endocrine Therapy (PACE),744
0,NCT01610284,Phase III,"Active, not recruiting","[{'id': 1546, 'therapyName': 'Fulvestrant + BKM120'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor,1546
1,NCT01633060,Phase III,"Active, not recruiting","[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1546, 'therapyName': 'Fulvestrant + BKM120'}]","A Phase III Study of BKM120 With Fulvestrant in Patients With HR+, HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi",1546
0,NCT01528345,Phase II,Terminated,"[{'id': 2189, 'therapyName': 'Fulvestrant + Dovitinib'}, {'id': 744, 'therapyName': 'Fulvestrant'}]","Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer",2189
0,NCT02137837,Phase III,"Active, not recruiting","[{'id': 1589, 'therapyName': 'Fulvestrant + Everolimus'}, {'id': 1590, 'therapyName': 'Fulvestrant + Everolimus + Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}]","S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer",1589
1,NCT02291913,Phase II,"Active, not recruiting","[{'id': 2267, 'therapyName': 'Everolimus + Tamoxifen'}, {'id': 2268, 'therapyName': 'Anastrozole + Everolimus'}, {'id': 1589, 'therapyName': 'Fulvestrant + Everolimus'}, {'id': 1621, 'therapyName': 'Everolimus + Letrozole'}, {'id': 2269, 'therapyName': 'Everolimus + Toremifene'}, {'id': 1966, 'therapyName': 'Exemestane + Everolimus'}]",Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer,1589
2,NCT01797120,Phase II,Completed,"[{'id': 1589, 'therapyName': 'Fulvestrant + Everolimus'}, {'id': 744, 'therapyName': 'Fulvestrant'}]","Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI",1589
0,NCT02137837,Phase III,"Active, not recruiting","[{'id': 1589, 'therapyName': 'Fulvestrant + Everolimus'}, {'id': 1590, 'therapyName': 'Fulvestrant + Everolimus + Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}]","S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer",1590
0,NCT02384746,Phase I,Recruiting,"[{'id': 2568, 'therapyName': 'Fulvestrant + Ixazomib'}]",Phase I Study of the Combination of MLN9708 and Fulvestrant,2568
0,NCT02088684,Phase Ib/II,"Active, not recruiting","[{'id': 2315, 'therapyName': 'BKM120 + Fulvestrant + LEE011'}, {'id': 2316, 'therapyName': 'Fulvestrant + LEE011'}, {'id': 2317, 'therapyName': 'BYL719 + Fulvestrant + LEE011'}]",Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer,2316
0,NCT03289039,,Not yet recruiting,"[{'id': 828, 'therapyName': 'Neratinib'}, {'id': 5705, 'therapyName': 'Fulvestrant + Neratinib'}]","A Phase 2 Study of Neratinib With or Without Fulvestrant in HER2-Positive, ER-Positive Metastatic Breast Cancer",5705
0,NCT02599714,Phase Ib/II,Recruiting,"[{'id': 3205, 'therapyName': 'Fulvestrant + Palbociclib'}, {'id': 991, 'therapyName': 'Vistusertib'}]",Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer (PASTOR),3205
1,NCT03007979,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 3205, 'therapyName': 'Fulvestrant + Palbociclib'}, {'id': 2922, 'therapyName': 'Palbociclib + Letrozole'}]",Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer,3205
2,NCT02760030,Phase II,Recruiting,"[{'id': 3205, 'therapyName': 'Fulvestrant + Palbociclib'}]",Fulvestrant and Palbociclib in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery,3205
3,NCT02738866,Phase II,Recruiting,"[{'id': 3205, 'therapyName': 'Fulvestrant + Palbociclib'}]",Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor,3205
4,NCT03147287,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 3205, 'therapyName': 'Fulvestrant + Palbociclib'}, {'id': 5684, 'therapyName': 'Fulvestrant + Palbociclib + Avelumab'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Palbociclib After CDK and Endocrine Therapy (PACE),3205
0,NCT03147287,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 3205, 'therapyName': 'Fulvestrant + Palbociclib'}, {'id': 5684, 'therapyName': 'Fulvestrant + Palbociclib + Avelumab'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Palbociclib After CDK and Endocrine Therapy (PACE),5684
0,NCT03294694,Phase I,Not yet recruiting,"[{'id': 6285, 'therapyName': 'Fulvestrant + PDR001 + Ribociclib'}, {'id': 6284, 'therapyName': 'PDR001 + Ribociclib'}]",Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer,6285
0,NCT02609984,Phase II,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 3273, 'therapyName': 'G305 + ID-LV305'}]",Trial of CMB305 and Atezolizumab in Patients With Sarcoma,3273
0,NCT02438007,Phase III,Terminated,"[{'id': 1508, 'therapyName': 'galeterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC,1508
1,NCT01709734,Phase II,"Active, not recruiting","[{'id': 1508, 'therapyName': 'galeterone'}]","A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer",1508
0,NCT02906397,Phase I,Recruiting,"[{'id': 2409, 'therapyName': 'Galunisertib'}]",A Phase I Study of Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Patients With Advanced Hepatocellular Carcinoma (HCC),2409
1,NCT02452008,Phase II,Recruiting,"[{'id': 2409, 'therapyName': 'Galunisertib'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Study of TGF-Beta Receptor Inhibitor LY2157299 and Enzalutamide in Metastatic Castration-resistant Prostate Cancer,2409
2,NCT02688712,Phase II,Recruiting,"[{'id': 5788, 'therapyName': 'Capecitabine + Galunisertib'}, {'id': 5789, 'therapyName': 'Fluorouracil + Galunisertib'}, {'id': 2409, 'therapyName': 'Galunisertib'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer,2409
3,NCT02423343,Phase Ib/II,Recruiting,"[{'id': 2409, 'therapyName': 'Galunisertib'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioma",2409
4,NCT02304419,Phase I,Completed,"[{'id': 2409, 'therapyName': 'Galunisertib'}]",A Study of Galunisertib on the Immune System in Participants With Cancer,2409
5,NCT01246986,Phase II,"Active, not recruiting","[{'id': 2421, 'therapyName': 'Galunisertib + Sorafenib'}, {'id': 2409, 'therapyName': 'Galunisertib'}]",A Study of LY2157299 in Participants With Hepatocellular Carcinoma,2409
0,NCT02734160,Phase I,Recruiting,"[{'id': 4211, 'therapyName': 'Galunisertib + MEDI4736'}]",A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer,4211
0,NCT02672475,Phase I,Recruiting,"[{'id': 3541, 'therapyName': 'Galunisertib + Paclitaxel'}]",Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer,3541
0,NCT01246986,Phase II,"Active, not recruiting","[{'id': 2421, 'therapyName': 'Galunisertib + Sorafenib'}, {'id': 2409, 'therapyName': 'Galunisertib'}]",A Study of LY2157299 in Participants With Hepatocellular Carcinoma,2421
0,NCT01798485,Phase III,Terminated,"[{'id': 745, 'therapyName': 'Ganetespib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC,745
1,NCT02334319,Phase I,Terminated,"[{'id': 745, 'therapyName': 'Ganetespib'}]",Ganetespib Window of Opportunity Study in Head and Neck Cancers,745
2,NCT01200238,Phase II,"Active, not recruiting","[{'id': 745, 'therapyName': 'Ganetespib'}]",STA-9090(Ganetespib) in Metastatic Ocular Melanoma,745
3,NCT01560416,Phase II,"Active, not recruiting","[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 745, 'therapyName': 'Ganetespib'}]",Fulvestrant With or Without Ganetespib in HR+ Breast Cancer,745
4,NCT01962948,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 745, 'therapyName': 'Ganetespib'}]","Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",745
5,NCT02637375,Phase I,Withdrawn,"[{'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 745, 'therapyName': 'Ganetespib'}]",A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer,745
6,NCT02389751,Phase I,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 745, 'therapyName': 'Ganetespib'}]",A Study of Ganetespib in Combination With Chemoradiation,745
0,NCT02192541,Phase I,Completed,"[{'id': 1665, 'therapyName': 'Ganetespib + Aflibercept'}]","Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas",1665
0,NCT01579994,Phase I,"Active, not recruiting","[{'id': 2190, 'therapyName': 'Ganetespib + Crizotinib'}]",Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers,2190
0,NCT02060253,Phase I,"Active, not recruiting","[{'id': 1579, 'therapyName': 'Ganetespib + Paclitaxel + Trastuzumab'}]","Ganetespib, Paclitaxel and Trastuzumab for Advanced or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer",1579
0,NCT02008877,Phase Ib/II,"Active, not recruiting","[{'id': 2271, 'therapyName': 'Ganetespib + Sirolimus'}]",A Trial of Ganetespib Plus Sirolimus: Phase 1 Includes Multiple Sarcoma Subtypes and Phase 2 MPNST,2271
0,NCT01327612,Phase II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 746, 'therapyName': 'Ganitumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1458, 'therapyName': 'Conatumumab'}]",Open Label Extension Study of Conatumumab and AMG 479,746
1,NCT01042379,Phase II,Recruiting,"[{'id': 1218, 'therapyName': 'Trebananib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 746, 'therapyName': 'Ganitumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1494, 'therapyName': 'MK2206 + Trastuzumab'}, {'id': 1493, 'therapyName': 'Trebananib + Trastuzumab'}, {'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}]",I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer,746
2,NCT02306161,Phase II,Recruiting,"[{'id': 1433, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide'}, {'id': 746, 'therapyName': 'Ganitumab'}]",Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma,746
0,NCT02785913,Phase II,"Active, not recruiting","[{'id': 1016, 'therapyName': 'GDC-0032'}]",Lung-MAP: Taselisib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches,1016
1,NCT02273973,Phase II,Completed,"[{'id': 1016, 'therapyName': 'GDC-0032'}]",Study of Neoadjuvant Letrozole + GDC-0032 Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI),1016
2,NCT02457910,Phase Ib/II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1016, 'therapyName': 'GDC-0032'}]",Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer,1016
3,NCT01296555,Phase I,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1016, 'therapyName': 'GDC-0032'}, {'id': 794, 'therapyName': 'Letrozole'}]",A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors And in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer,1016
4,NCT02154490,Phase II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 1016, 'therapyName': 'GDC-0032'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 629, 'therapyName': 'AMG102'}]",Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,1016
5,NCT02390427,Phase I,Recruiting,"[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 1016, 'therapyName': 'GDC-0032'}]",Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer,1016
6,NCT02340221,Phase III,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1016, 'therapyName': 'GDC-0032'}]",SANDPIPER Study: A Study Of Taselisib + Fulvestrant Versus Placebo + Fulvestrant In Patients With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy,1016
0,NCT01862081,Phase I,Completed,"[{'id': 2321, 'therapyName': 'Docetaxel + GDC-0032 '}, {'id': 2322, 'therapyName': 'GDC-0032 + Paclitaxel'}]","A Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer",2322
0,NCT03006172,Phase I,Recruiting,"[{'id': 5182, 'therapyName': 'GDC-0077 + Letrozole + Palbociclib'}, {'id': 5181, 'therapyName': 'GDC-0077'}, {'id': 5184, 'therapyName': 'GDC-0077 + Fulvestrant'}, {'id': 5183, 'therapyName': 'GDC-0077 + Letrozole'}]","To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer",5181
0,NCT03006172,Phase I,Recruiting,"[{'id': 5182, 'therapyName': 'GDC-0077 + Letrozole + Palbociclib'}, {'id': 5181, 'therapyName': 'GDC-0077'}, {'id': 5184, 'therapyName': 'GDC-0077 + Fulvestrant'}, {'id': 5183, 'therapyName': 'GDC-0077 + Letrozole'}]","To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer",5184
0,NCT03006172,Phase I,Recruiting,"[{'id': 5182, 'therapyName': 'GDC-0077 + Letrozole + Palbociclib'}, {'id': 5181, 'therapyName': 'GDC-0077'}, {'id': 5184, 'therapyName': 'GDC-0077 + Fulvestrant'}, {'id': 5183, 'therapyName': 'GDC-0077 + Letrozole'}]","To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer",5183
0,NCT03006172,Phase I,Recruiting,"[{'id': 5182, 'therapyName': 'GDC-0077 + Letrozole + Palbociclib'}, {'id': 5181, 'therapyName': 'GDC-0077'}, {'id': 5184, 'therapyName': 'GDC-0077 + Fulvestrant'}, {'id': 5183, 'therapyName': 'GDC-0077 + Letrozole'}]","To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer",5182
0,NCT01547546,Phase I,Completed,"[{'id': 2018, 'therapyName': 'GDC-0084'}]",A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma,2018
0,NCT02203773,Phase I,"Active, not recruiting","[{'id': 1636, 'therapyName': 'GDC-0199 + Decitabine'}, {'id': 1637, 'therapyName': 'GDC-0199 + Azacitidine'}]",Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo),1637
1,NCT02993523,Phase III,Recruiting,"[{'id': 1637, 'therapyName': 'GDC-0199 + Azacitidine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Elderly Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy,1637
2,NCT02966782,Phase I,Recruiting,"[{'id': 1637, 'therapyName': 'GDC-0199 + Azacitidine'}, {'id': 1562, 'therapyName': 'Venetoclax'}]",A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure,1637
3,NCT02942290,Phase II,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 1637, 'therapyName': 'GDC-0199 + Azacitidine'}]",A Study Evaluating Venetoclax in Combination With Azacitidine Compared With Azacitidine Alone in Participants With Previously Untreated Higher-Risk Myelodysplastic Syndromes (MDS),1637
0,NCT02203773,Phase I,"Active, not recruiting","[{'id': 1636, 'therapyName': 'GDC-0199 + Decitabine'}, {'id': 1637, 'therapyName': 'GDC-0199 + Azacitidine'}]",Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo),1636
0,NCT02640833,Phase I,Withdrawn,"[{'id': 3624, 'therapyName': 'GDC-0199 + Duvelisib'}]","A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor",3624
0,NCT02910583,Phase II,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3392, 'therapyName': 'GDC-0199 + Ibrutinib'}]",Ibrutinib Plus Venetoclax in Patients With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma,3392
1,NCT02419560,Phase I,Suspended,"[{'id': 3392, 'therapyName': 'GDC-0199 + Ibrutinib'}]",Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL,3392
2,NCT03045328,Phase Ib/II,Recruiting,"[{'id': 3392, 'therapyName': 'GDC-0199 + Ibrutinib'}]",Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL,3392
3,NCT02756897,Phase II,Recruiting,"[{'id': 3392, 'therapyName': 'GDC-0199 + Ibrutinib'}]",Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL),3392
4,NCT02956382,Phase Ib/II,Recruiting,"[{'id': 3392, 'therapyName': 'GDC-0199 + Ibrutinib'}]",Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma,3392
5,NCT03112174,Phase III,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3392, 'therapyName': 'GDC-0199 + Ibrutinib'}]",Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO),3392
0,NCT02427451,Phase Ib/II,"Active, not recruiting","[{'id': 3472, 'therapyName': 'GDC-0199 + Ibrutinib + Obinutuzumab'}]","Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia",3472
0,NCT02242942,Phase III,"Active, not recruiting","[{'id': 1648, 'therapyName': 'Obinutuzumab + Chlorambucil'}, {'id': 3636, 'therapyName': 'GDC-0199 + Obinutuzumab'}]",A Study to Compare the Efficacy and Safety of Obinutuzumab + GDC-0199 Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia,3636
1,NCT01685892,Phase I,"Active, not recruiting","[{'id': 3636, 'therapyName': 'GDC-0199 + Obinutuzumab'}]",A Study of Venetoclax (GDC-0199; ABT-199) in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia,3636
0,NCT02187861,Phase II,"Active, not recruiting","[{'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 3637, 'therapyName': 'Bendamustine + GDC-0199 + Rituximab'}, {'id': 3937, 'therapyName': 'GDC-0199 + Rituximab'}]",A Study Evaluating the Safety and Efficacy of GDC-0199 (ABT-199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or GDC-0199 Plus Rituximab in Patients With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma,3937
0,NCT01564251,Phase I,"Active, not recruiting","[{'id': 2113, 'therapyName': 'GDC-0575 + Gemcitabine'}, {'id': 2024, 'therapyName': 'GDC-0575'}]",A Study of GDC-0575 Alone And in Combination With Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma,2024
0,NCT01564251,Phase I,"Active, not recruiting","[{'id': 2113, 'therapyName': 'GDC-0575 + Gemcitabine'}, {'id': 2024, 'therapyName': 'GDC-0575'}]",A Study of GDC-0575 Alone And in Combination With Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma,2113
0,NCT01106599,Phase I,Completed,"[{'id': 748, 'therapyName': 'GDC-0623'}]","A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advanced or Metastatic Solid Tumors",748
0,NCT02569801,Phase II,"Active, not recruiting","[{'id': 2150, 'therapyName': 'GDC-0810'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",A Study of GDC-0810 Versus Fulvestrant in Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy,2150
1,NCT01823835,Phase II,"Active, not recruiting","[{'id': 2150, 'therapyName': 'GDC-0810'}]",A Study of ARN-810 (GDC-0810) in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer,2150
0,NCT01908413,Phase I,Terminated,"[{'id': 3639, 'therapyName': 'GDC-0917'}]","Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma",3639
0,NCT02471846,Phase I,"Active, not recruiting","[{'id': 2888, 'therapyName': 'GDC-0919'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors,2888
1,NCT02048709,Phase I,Completed,"[{'id': 2888, 'therapyName': 'GDC-0919'}]",IDO Inhibitor in Advanced Solid Tumors,2888
0,NCT01493843,Phase II,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 749, 'therapyName': 'GDC-0941'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer,749
1,NCT01437566,Phase II,Completed,"[{'id': 750, 'therapyName': 'GDC-0980'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 749, 'therapyName': 'GDC-0941'}]",Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy,749
0,NCT01918306,Phase Ib/II,Terminated,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1554, 'therapyName': 'GDC-0941 + Cisplatin'}]",GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer,1554
0,NCT01437566,Phase II,Completed,"[{'id': 750, 'therapyName': 'GDC-0980'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 749, 'therapyName': 'GDC-0941'}]",Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy,750
1,NCT01485861,Phase II,"Active, not recruiting","[{'id': 750, 'therapyName': 'GDC-0980'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 747, 'therapyName': 'Ipatasertib'}]",Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy,750
2,NCT00854152,,Completed,"[{'id': 750, 'therapyName': 'GDC-0980'}]", A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma,750
0,NCT01875705,Phase I,Completed,"[{'id': 2149, 'therapyName': 'GDC-0994'}]",A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors,2149
1,NCT02457793,Phase I,Completed,"[{'id': 1004, 'therapyName': 'Cobimetinib'}, {'id': 2149, 'therapyName': 'GDC-0994'}]","A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors",2149
0,NCT02920450,Phase Ib/II,Recruiting,"[{'id': 4785, 'therapyName': 'Gedatolisib + Paclitaxel + Carboplatin'}]","Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC",4785
0,NCT03065062,Phase I,Recruiting,"[{'id': 4034, 'therapyName': 'Gedatolisib + Palbociclib'}]","Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors",4034
1,NCT02684032,Phase I,Recruiting,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 4034, 'therapyName': 'Gedatolisib + Palbociclib'}]",A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer,4034
0,NCT03243331,Phase I,Not yet recruiting,"[{'id': 6110, 'therapyName': 'Gedatolisib + PF-06647020'}]",An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer,6110
0,NCT02179671,Phase II,Completed,"[{'id': 1117, 'therapyName': 'Selumetinib + Docetaxel'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 660, 'therapyName': 'AZD9291'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer",751
1,NCT02588261,Phase III,"Active, not recruiting","[{'id': 1082, 'therapyName': 'ASP8273'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations,751
2,NCT02088112,Phase I,"Active, not recruiting","[{'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC),751
3,NCT02296125,Phase III,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 660, 'therapyName': 'AZD9291'}, {'id': 751, 'therapyName': 'Gefitinib'}]",AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer,751
4,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,751
5,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,751
0,NCT03122717,Phase I,Recruiting,"[{'id': 5616, 'therapyName': 'Gefitinib + Osimertinib'}]",Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer,5616
0,NCT02039674,Phase Ib/II,"Active, not recruiting","[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}, {'id': 2104, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 2106, 'therapyName': 'Ipilimumab + Pembrolizumab '}, {'id': 2107, 'therapyName': 'Erlotinib + Pembrolizumab '}, {'id': 2108, 'therapyName': 'Gefitinib + Pembrolizumab '}]",A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021),2108
0,NCT01945775,Phase III,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 682, 'therapyName': 'Talazoparib'}, {'id': 728, 'therapyName': 'Eribulin'}]","A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)",755
1,NCT03191786,Phase III,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}]",A Study of Atezolizumab Compared With Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Containing Therapy,755
2,NCT03057106,Phase II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC,755
3,NCT02492711,Phase III,Recruiting,"[{'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 808, 'therapyName': 'MGAH22'}]",Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer,755
4,NCT02620865,Phase Ib/II,Suspended,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}]",Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer,755
5,NCT02422381,Phase Ib/II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC),755
6,NCT01013649,Phase II,Recruiting,"[{'id': 2381, 'therapyName': 'Erlotinib + Gemcitabine'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,755
7,NCT02589145,Phase Ib/II,Recruiting,"[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 3278, 'therapyName': 'Enoxaparin'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}]",Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype,755
8,NCT01959672,Phase II,Recruiting,"[{'id': 827, 'therapyName': 'Nelfinavir'}, {'id': 1189, 'therapyName': 'Oregovomab'}, {'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Combination Chemotherapy With or Without Oregovomab Followed by Stereotactic Body Radiation Therapy and Nelfinavir Mesylate in Treating Patients With Locally Advanced Pancreatic Cancer,755
9,NCT02265510,Phase I,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2747, 'therapyName': 'INCB052793'}, {'id': 688, 'therapyName': 'Bortezomib'}]","An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies",755
10,NCT00565851,Phase III,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 3045, 'therapyName': 'Docetaxel + Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Carboplatin, Paclitaxel and Gemcitabine With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",755
11,NCT01532687,Phase II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1478, 'therapyName': 'Gemcitabine + Pazopanib'}]",Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma,755
12,NCT02142738,Phase III,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024),755
13,NCT01454102,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)",755
14,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,755
15,NCT02574078,Phase I,Recruiting,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2114, 'therapyName': 'Bevacizumab + Pemetrexed'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",A Master Protocol Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate 370),755
16,NCT01497392,Phase I,Completed,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 721, 'therapyName': 'Dovitinib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]"," Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers",755
17,NCT01586611,Phase III,Unknown status,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer,755
18,NCT01879085,Phase Ib/II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Phase 1b/2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma,755
19,NCT03257267,Phase III,Recruiting,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 5656, 'therapyName': 'REGN2810'}, {'id': 942, 'therapyName': 'Topotecan'}]",Study of REGN2810 in Adults With Cervical Cancer,755
20,NCT02437370,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer,755
21,NCT02506959,Phase II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma,755
22,NCT02079636,Phase I,Recruiting,"[{'id': 1069, 'therapyName': 'LY3023414'}, {'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC),755
23,NCT01164228,Phase II,Recruiting,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery,755
24,NCT02237157,Phase I,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}]",A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer,755
25,NCT02981342,Phase II,Recruiting,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 5175, 'therapyName': 'Abemaciclib + LY3023414'}, {'id': 5176, 'therapyName': 'Abemaciclib + Galunisertib'}]",A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma,755
26,NCT02275039,Phase I,"Active, not recruiting","[{'id': 1038, 'therapyName': 'MVAp53'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer,755
27,NCT03137771,Phase II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}]",Maintenance Chemotherapy With or Without Stereotactic Body Radiation Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,755
28,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,755
29,NCT02309177,Phase I,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2489, 'therapyName': 'Abraxane + Nivolumab'}]","Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer",755
30,NCT02009449,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2621, 'therapyName': 'AM0010 '}, {'id': 619, 'therapyName': 'Abraxane'}]",A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors,755
31,NCT02399137,Phase II,"Active, not recruiting","[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1073, 'therapyName': 'MM-141'}]",A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer,755
32,NCT02595892,Phase II,Recruiting,"[{'id': 2879, 'therapyName': 'VX-970'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","Gemcitabine Hydrochloride Alone or With VX-970 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",755
33,NCT01647828,Phase Ib/II,Completed,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2547, 'therapyName': 'Tarextumab'}]",A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer,755
34,NCT02576574,Phase III,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100),755
35,NCT02620423,Phase I,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 893, 'therapyName': 'Reolysin'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab With REOLYSIN and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma,755
36,NCT02555657,Phase III,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119),755
37,NCT02101775,Phase II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1279, 'therapyName': 'MK-1775 + Gemcitabine'}]","Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",755
38,NCT02322281,Phase III,"Active, not recruiting","[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1003, 'therapyName': 'CO1686'}]","TIGER-3 Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy",755
39,NCT02331251,Phase Ib/II,"Active, not recruiting","[{'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 619, 'therapyName': 'Abraxane'}]",Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus),755
40,NCT02701673,Phase Ib/II,Withdrawn,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1078, 'therapyName': 'Belinostat'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}]",Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma,755
41,NCT02621151,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder",755
42,NCT01506973,Phase Ib/II,Recruiting,"[{'id': 1316, 'therapyName': 'Hydroxychloroquine'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer,755
43,NCT02312245,Phase II,Recruiting,"[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",755
44,NCT02477826,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, Trial of Nivolumab and Nivolumab Plus Ipilimumab Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC)",755
45,NCT02631876,Phase II,Recruiting,"[{'id': 3574, 'therapyName': 'Doxil + Paclitaxel'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3232, 'therapyName': 'IMGN853'}]","PH2 Study of IMGN853 vs Investigator's Choice of Chemo in Adults With FRa+ Adv. EOC, Primary Peritoneal or Primary Fallopian Tube Cancer",755
46,NCT02117024,Phase II,"Active, not recruiting","[{'id': 2472, 'therapyName': 'HS-110 + Cyclophosphamide'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer,755
47,NCT02446600,Phase III,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1001, 'therapyName': 'Cediranib'}]","Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",755
48,NCT02855944,Phase III,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 906, 'therapyName': 'Rucaparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients",755
49,NCT01956812,Phase III,Terminated,"[{'id': 3000, 'therapyName': 'Y90 clivatuzumab tetraxetan'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer (PANCRIT-1),755
50,NCT02157792,Phase I,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 2879, 'therapyName': 'VX-970'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy",755
51,NCT02138383,Phase I,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer,755
52,NCT02194829,Phase Ib/II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 822, 'therapyName': 'MK-1775'}]",Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery,755
53,NCT01908478,Phase I,"Active, not recruiting","[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","A Phase I Study of Veliparib (ABT-888) in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Locally Advanced, Unresectable Pancreatic Cancer",755
54,NCT01610206,Phase II,"Active, not recruiting","[{'id': 1478, 'therapyName': 'Gemcitabine + Pazopanib'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer,755
55,NCT01858883,Phase I,Completed,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2406, 'therapyName': 'INCB039110'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Safety Study of INCB039110 in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors,755
56,NCT02041533,Phase III,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)",755
57,NCT03056599,,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1733, 'therapyName': 'interferon gamma '}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 3420, 'therapyName': 'trabectedin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma,755
58,NCT02565758,Phase I,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 3846, 'therapyName': 'ABBV-085'}]","ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors",755
59,NCT03259503,Phase Ib/II,Not yet recruiting,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas,755
60,NCT00936936,Phase II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2101, 'therapyName': 'Etoposide + Ifosfamide'}, {'id': 2100, 'therapyName': 'Docetaxel + Gemcitabine + Melphalan'}, {'id': 2074, 'therapyName': 'Bevacizumab + Carboplatin'}]",High-dose Chemotherapy for Poor-prognosis Relapsed Germ-Cell Tumors,755
61,NCT01935947,Phase II,Terminated,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2645, 'therapyName': 'Azacitidine + Entinostat'}, {'id': 2646, 'therapyName': 'Docetaxel + Irinotecan + Pemetrexed '}]",Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer,755
62,NCT01248949,Phase I,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1176, 'therapyName': 'MEDI3617'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors,755
63,NCT02409355,Phase III,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of MPDL3280A Compared With Gemcitabine + Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer,755
64,NCT02365766,Phase Ib/II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Study of Neoadjuvant Pembrolizumab in Combination With Gemcitabine Based Therapy in Cis-eligible or -Ineligible Subjects With Urothelial Cancer,755
0,NCT01936974,Phase II,Terminated,"[{'id': 1295, 'therapyName': 'Gemcitabine + Bevacizumab + Cisplatin'}, {'id': 1296, 'therapyName': 'Gemcitabine + Bevacizumab + Oxaliplatin'}, {'id': 1294, 'therapyName': 'Gemcitabine + Bevacizumab + Carboplatin'}, {'id': 1297, 'therapyName': 'Gemcitabine + Bevacizumab'}]","(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma",1297
1,NCT00602602,Phase II,"Active, not recruiting","[{'id': 2102, 'therapyName': 'Bevacizumab + Fluorouracil + Oxaliplatin'}, {'id': 1296, 'therapyName': 'Gemcitabine + Bevacizumab + Oxaliplatin'}, {'id': 1297, 'therapyName': 'Gemcitabine + Bevacizumab'}]","Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer",1297
0,NCT01936974,Phase II,Terminated,"[{'id': 1295, 'therapyName': 'Gemcitabine + Bevacizumab + Cisplatin'}, {'id': 1296, 'therapyName': 'Gemcitabine + Bevacizumab + Oxaliplatin'}, {'id': 1294, 'therapyName': 'Gemcitabine + Bevacizumab + Carboplatin'}, {'id': 1297, 'therapyName': 'Gemcitabine + Bevacizumab'}]","(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma",1294
1,NCT00150657,Phase II,Unknown status,"[{'id': 1294, 'therapyName': 'Gemcitabine + Bevacizumab + Carboplatin'}]",Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer,1294
0,NCT01936974,Phase II,Terminated,"[{'id': 1295, 'therapyName': 'Gemcitabine + Bevacizumab + Cisplatin'}, {'id': 1296, 'therapyName': 'Gemcitabine + Bevacizumab + Oxaliplatin'}, {'id': 1294, 'therapyName': 'Gemcitabine + Bevacizumab + Carboplatin'}, {'id': 1297, 'therapyName': 'Gemcitabine + Bevacizumab'}]","(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma",1295
1,NCT00942331,Phase III,"Active, not recruiting","[{'id': 1295, 'therapyName': 'Gemcitabine + Bevacizumab + Cisplatin'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,1295
0,NCT01936974,Phase II,Terminated,"[{'id': 1295, 'therapyName': 'Gemcitabine + Bevacizumab + Cisplatin'}, {'id': 1296, 'therapyName': 'Gemcitabine + Bevacizumab + Oxaliplatin'}, {'id': 1294, 'therapyName': 'Gemcitabine + Bevacizumab + Carboplatin'}, {'id': 1297, 'therapyName': 'Gemcitabine + Bevacizumab'}]","(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma",1296
1,NCT00602602,Phase II,"Active, not recruiting","[{'id': 2102, 'therapyName': 'Bevacizumab + Fluorouracil + Oxaliplatin'}, {'id': 1296, 'therapyName': 'Gemcitabine + Bevacizumab + Oxaliplatin'}, {'id': 1297, 'therapyName': 'Gemcitabine + Bevacizumab'}]","Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer",1296
0,NCT01916109,Phase II,Terminated,"[{'id': 1943, 'therapyName': 'Gemcitabine + Carboplatin + Panitumumab'}]","Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer",1943
0,NCT02542293,Phase III,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]",Study of 1st Line Therapy Study of MEDI4736 With Tremelimumab Versus SoC in Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE).,1467
1,NCT01585805,Phase II,Recruiting,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer,1467
2,NCT02567409,Phase II,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 3110, 'therapyName': 'Cisplatin + Gemcitabine + VX-970'}]",Cisplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Metastatic Urothelial Cancer,1467
3,NCT02177695,Phase II,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2564, 'therapyName': 'Aldoxorubicin + Cisplatin + Filgrastim + Methotrexate + Vinblastine'}]","S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer",1467
4,NCT00942331,Phase III,"Active, not recruiting","[{'id': 1295, 'therapyName': 'Gemcitabine + Bevacizumab + Cisplatin'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,1467
5,NCT02300610,Phase I,"Active, not recruiting","[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer,1467
6,NCT02537561,Phase I,Withdrawn,"[{'id': 682, 'therapyName': 'Talazoparib'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors,1467
7,NCT03036098,Phase III,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care Chemotherapy in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer,1467
8,NCT02711553,Phase II,"Active, not recruiting","[{'id': 886, 'therapyName': 'Ramucirumab'}, {'id': 1030, 'therapyName': 'LY2801653'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer,1467
9,NCT02453282,Phase III,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC).,1467
10,NCT02128282,Phase Ib/II,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 6091, 'therapyName': 'Cisplatin + Gemcitabine + Silmitasertib'}]",Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma,1467
11,NCT03164616,Phase III,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}]",Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON),1467
12,NCT02452970,Phase II,"Active, not recruiting","[{'id': 3680, 'therapyName': 'RRx-001'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy (EPIC),1467
0,NCT01660971,Phase I,"Active, not recruiting","[{'id': 1816, 'therapyName': 'Gemcitabine + Dasatinib + Erlotinib'}]","Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery",1816
0,NCT02049905,Phase III,Completed,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1440, 'therapyName': 'Aldoxorubicin'}, {'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}]",Phase 3 Study to Treat Patients With Soft Tissue Sarcomas,1439
1,NCT01593748,Phase II,"Active, not recruiting","[{'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}, {'id': 1478, 'therapyName': 'Gemcitabine + Pazopanib'}]",A Treatment Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma,1439
2,NCT02659020,Phase Ib/II,Recruiting,"[{'id': 3269, 'therapyName': 'Olaratumab'}, {'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}]",A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma,1439
3,NCT02511132,Phase II,"Active, not recruiting","[{'id': 1157, 'therapyName': 'FANG vaccine'}, {'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}]",Randomized Phase IIb Trial of Vigil Versus Gemcitabine + Docetaxel for Ewing's Sarcoma,1439
4,NCT02045446,Phase II,"Active, not recruiting","[{'id': 1146, 'therapyName': 'Bevacizumab + Erlotinib'}, {'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}]",Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC),1439
0,NCT01719302,Phase Ib/II,Completed,"[{'id': 1470, 'therapyName': 'Gemcitabine + Docetaxel + Pazopanib'}]","Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma",1470
1,NCT01418001,Phase Ib/II,Terminated,"[{'id': 1470, 'therapyName': 'Gemcitabine + Docetaxel + Pazopanib'}]",Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS),1470
0,NCT01376310,Phase II,"Active, not recruiting","[{'id': 1264, 'therapyName': 'Docetaxel + Trametinib'}, {'id': 1265, 'therapyName': 'Erlotinib + Trametinib'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 1266, 'therapyName': 'Pemetrexed + GSK1120212'}, {'id': 1267, 'therapyName': 'Carboplatin + GSK1120212'}, {'id': 1268, 'therapyName': 'nab-paclitaxel + GSK1120212'}, {'id': 1269, 'therapyName': 'Gemcitabine + GSK1120212'}, {'id': 1271, 'therapyName': 'Everolimus + GSK1120212'}]",GSK1120212 Rollover Study,1269
0,NCT02562898,Phase Ib/II,Recruiting,"[{'id': 3259, 'therapyName': 'Gemcitabine + Ibrutinib + Paclitaxel'}]",Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer,3259
0,NCT01438112,,Terminated,"[{'id': 2524, 'therapyName': 'Gemcitabine + interferon + Mitomycin C + Valrubicin '}, {'id': 2523, 'therapyName': 'CG0070'}]",Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer,2524
0,NCT01473940,Phase I,"Active, not recruiting","[{'id': 2970, 'therapyName': 'Gemcitabine + Ipilimumab'}]",Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery,2970
0,NCT02583477,Phase Ib/II,Recruiting,"[{'id': 3099, 'therapyName': 'AZD5069 + MEDI4736'}, {'id': 3163, 'therapyName': 'Gemcitabine + MEDI4736 + nab-paclitaxel'}]",Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma,3163
0,NCT02105350,Phase I,Suspended,"[{'id': 2210, 'therapyName': 'Gemcitabine + MEK162 + Oxaliplatin'}]",A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer,2210
0,NCT02303262,Phase II,Completed,"[{'id': 3128, 'therapyName': 'Gemcitabine + Mocetinostat'}]",A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma,3128
0,NCT03193190,Phase Ib/II,Recruiting,"[{'id': 5942, 'therapyName': 'Atezolizumab + BKT140'}, {'id': 5940, 'therapyName': 'Gemcitabine + Nab-Paclitaxel + mFOLFOX-6'}, {'id': 5941, 'therapyName': 'Atezolizumab + PEGPH20'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC),5940
0,NCT03214250,Phase Ib/II,Recruiting,"[{'id': 6047, 'therapyName': 'Gemcitabine + nab-paclitaxel + Nivolumab'}, {'id': 6048, 'therapyName': 'APX005M + Gemcitabine + nab-paclitaxel'}, {'id': 6049, 'therapyName': 'APX005M + Gemcitabine + nab-paclitaxel + Nivolumab'}]",Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma,6047
0,NCT02732938,Phase I,"Active, not recruiting","[{'id': 4340, 'therapyName': 'Gemcitabine + nab-paclitaxel + PF-04136309'}]",Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients (CCR2i),4340
0,NCT02178436,Phase Ib/II,Suspended,"[{'id': 2560, 'therapyName': 'Gemcitabine + nab-paclitaxel + Selinexor'}]","Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Pancreatic Cancer",2560
0,NCT01431794,Phase Ib/II,"Active, not recruiting","[{'id': 2497, 'therapyName': 'Gemcitabine + nab-paclitaxel + Sonidegib'}]",Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma,2497
0,NCT02005315,Phase I,"Active, not recruiting","[{'id': 4412, 'therapyName': 'Gemcitabine + nab-paclitaxel + Vantictumab'}]",A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer,4412
0,NCT02651727,Phase I,Terminated,"[{'id': 4342, 'therapyName': 'Gemcitabine + nab-paclitaxel + VS-4718'}]","Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects",4342
0,NCT02240238,Phase Ib/II,Recruiting,"[{'id': 5626, 'therapyName': 'Gemcitabine + NC-6004'}]","Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer",5626
0,NCT03302247,Phase II,Not yet recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 6297, 'therapyName': 'Gemcitabine + Nivolumab'}]",Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy,6297
0,NCT02181218,Phase I,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1611, 'therapyName': 'Gemcitabine + Oxaliplatin + Dexamethasone'}]","Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas",1611
0,NCT02951156,Phase III,Recruiting,"[{'id': 5088, 'therapyName': 'Avelumab + Azacitidine + Utomilumab'}, {'id': 5087, 'therapyName': 'Avelumab + Rituximab + Utomilumab'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 5090, 'therapyName': 'Gemcitabine + Oxaliplatin + Rituximab'}, {'id': 5089, 'therapyName': 'Avelumab + Bendamustine + Rituximab'}]","Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)",5090
0,NCT01593748,Phase II,"Active, not recruiting","[{'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}, {'id': 1478, 'therapyName': 'Gemcitabine + Pazopanib'}]",A Treatment Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma,1478
1,NCT01610206,Phase II,"Active, not recruiting","[{'id': 1478, 'therapyName': 'Gemcitabine + Pazopanib'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer,1478
2,NCT01532687,Phase II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1478, 'therapyName': 'Gemcitabine + Pazopanib'}]",Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma,1478
0,NCT01764477,Phase I,Completed,"[{'id': 2566, 'therapyName': 'Gemcitabine + Pri-724'}]",Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma,2566
0,NCT02383433,Phase II,"Active, not recruiting","[{'id': 2491, 'therapyName': 'Gemcitabine + Regorafenib'}]",Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer,2491
0,NCT02414724,Phase I,Terminated,"[{'id': 2898, 'therapyName': 'Gemcitabine + Ribociclib'}]",Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma,2898
1,NCT03237390,Phase I,Recruiting,"[{'id': 2898, 'therapyName': 'Gemcitabine + Ribociclib'}]",Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors,2898
0,NCT02954406,Phase I,Recruiting,"[{'id': 5150, 'therapyName': 'Lenalidomide + TAK-659'}, {'id': 5149, 'therapyName': 'Ibrutinib + TAK-659'}, {'id': 5148, 'therapyName': 'Gemcitabine + TAK-659'}, {'id': 5147, 'therapyName': 'Bendamustine + Rituximab + TAK-659'}, {'id': 5146, 'therapyName': 'Bendamustine + TAK-659'}]","A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma",5148
0,NCT02213744,Phase II,Terminated,"[{'id': 1890, 'therapyName': 'Vinorelbine + Trastuzumab'}, {'id': 1409, 'therapyName': 'Capecitabine + Trastuzumab'}, {'id': 1889, 'therapyName': 'Gemcitabine + Trastuzumab'}, {'id': 1888, 'therapyName': 'MM-302 + Trastuzumab'}]",MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients,1889
0,NCT02139358,Phase Ib/II,"Active, not recruiting","[{'id': 1592, 'therapyName': 'Gemcitabine + Trastuzumab + Pertuzumab'}]",Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer,1592
1,NCT02252887,Phase II,"Active, not recruiting","[{'id': 1592, 'therapyName': 'Gemcitabine + Trastuzumab + Pertuzumab'}]","Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab-Based Therapy, TDM-1, and TDM-1 + Pertuzumab",1592
0,NCT01869803,Phase I,Suspended,"[{'id': 756, 'therapyName': 'Gemtuzumab ozogamicin'}]",Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia,756
1,NCT02117297,Phase II,Recruiting,"[{'id': 756, 'therapyName': 'Gemtuzumab ozogamicin'}]",SCT Plus Immune Therapy in Average Risk AML/MDS,756
0,NCT02624388,Phase II,Recruiting,"[{'id': 757, 'therapyName': 'Genistein'}]",Study of Genistein in Pediatric Oncology Patients (UVA-Gen001),757
1,NCT01985763,Phase Ib/II,Completed,"[{'id': 757, 'therapyName': 'Genistein'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Genistein in Treatment of Metastatic Colorectal Cancer,757
2,NCT02766478,Phase II,Recruiting,"[{'id': 757, 'therapyName': 'Genistein'}]",Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing Androgen Deprivation Therapy for Prostate Cancer,757
3,NCT01489813,Phase II,Recruiting,"[{'id': 757, 'therapyName': 'Genistein'}]",Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment,757
0,NCT02499861,Phase Ib/II,Recruiting,"[{'id': 1734, 'therapyName': 'Genistein + Decitabine'}]",Phase I/II a Study of Decitabine in Combination With Genistein in Pediatric Relapsed or Refractory Malignancies,1734
1,NCT01628471,Phase Ib/II,Completed,"[{'id': 1734, 'therapyName': 'Genistein + Decitabine'}]","MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer",1734
0,NCT03136406,Phase Ib/II,Recruiting,"[{'id': 1018, 'therapyName': 'GI-4000'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 6163, 'therapyName': 'ETBX-011'}, {'id': 3060, 'therapyName': 'ALT-803'}]",QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy,1018
0,NCT02752035,Phase II,Recruiting,"[{'id': 2865, 'therapyName': 'Gilteritinib'}, {'id': 651, 'therapyName': 'Azacitidine'}]","A Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation in Patients Not Eligible for Intensive Induction Chemotherapy",2865
1,NCT02236013,Phase I,Recruiting,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 2865, 'therapyName': 'Gilteritinib'}]",A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia,2865
2,NCT02456883,Phase I,Completed,"[{'id': 2865, 'therapyName': 'Gilteritinib'}]","Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors",2865
3,NCT02421939,Phase III,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 3193, 'therapyName': 'Cytarabine + Fludarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2865, 'therapyName': 'Gilteritinib'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,2865
4,NCT02561455,Phase Ib/II,"Active, not recruiting","[{'id': 2865, 'therapyName': 'Gilteritinib'}]",Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial,2865
5,NCT02927262,Phase III,Recruiting,"[{'id': 2865, 'therapyName': 'Gilteritinib'}]","A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission",2865
6,NCT03070093,Expanded access,Available,"[{'id': 2865, 'therapyName': 'Gilteritinib'}]",Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD),2865
0,NCT00717587,Phase II,Unknown status,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 2129, 'therapyName': 'girentuximab'}, {'id': 2128, 'therapyName': 'motexafin gadolinium'}]",Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer,2129
0,NCT02180698,Phase I,Recruiting,"[{'id': 3576, 'therapyName': 'GLA-SE'}]",TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery,3576
0,NCT02320305,Phase I,"Active, not recruiting","[{'id': 3787, 'therapyName': 'MART-1 antigen'}, {'id': 3889, 'therapyName': 'GLA-SE + MART-1 antigen'}]",MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery,3889
0,NCT02501473,Phase Ib/II,Recruiting,"[{'id': 3577, 'therapyName': 'GLA-SE + Pembrolizumab'}]",Study of Intratumoral G100 Therapy in Patients With Or Without Pembrolizumab With Follicular Non-Hodgkin's Lymphoma,3577
0,NCT02713828,Phase Ib/II,Recruiting,"[{'id': 3597, 'therapyName': 'Glembatumumab vedotin'}]","Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung",3597
1,NCT01997333,Phase II,"Active, not recruiting","[{'id': 3597, 'therapyName': 'Glembatumumab vedotin'}, {'id': 1105, 'therapyName': 'Capecitabine'}]","Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer",3597
2,NCT02487979,Phase II,"Active, not recruiting","[{'id': 3597, 'therapyName': 'Glembatumumab vedotin'}]",Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma,3597
3,NCT02302339,Phase II,Recruiting,"[{'id': 3597, 'therapyName': 'Glembatumumab vedotin'}]",A Study of Glembatumumab Vedotin in Patients With Advanced Melanoma,3597
4,NCT02363283,Phase II,Recruiting,"[{'id': 3597, 'therapyName': 'Glembatumumab vedotin'}]",Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma,3597
0,NCT02306291,Phase Ib/II,Recruiting,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 4402, 'therapyName': 'GMI-1271'}]","Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML",4402
0,NCT02204085,Phase Ib/II,Recruiting,"[{'id': 3426, 'therapyName': 'GO-203-2C'}]","A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia",3426
0,NCT01433991,Phase Ib/II,"Active, not recruiting","[{'id': 1019, 'therapyName': 'Golvatinib'}, {'id': 792, 'therapyName': 'Lenvatinib'}]",E7050 in Combination With E7080 in Subjects With Advanced Solid Tumors (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2),1019
0,NCT01786265,Phase II,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1814, 'therapyName': 'Degarelix'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone,759
1,NCT00541047,Phase III,"Active, not recruiting","[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS),759
2,NCT02476786,Phase II,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}]",Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score,759
3,NCT02003209,Phase III,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1879, 'therapyName': 'Pertuzumab + Trastuzumab + Carboplatin + Docetaxel'}]","Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",759
4,NCT02346253,Phase Ib/II,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 1814, 'therapyName': 'Degarelix'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 759, 'therapyName': 'Goserelin'}]",High-Dose Brachytherapy in Treating Patients With Prostate Cancer,759
5,NCT02278185,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1814, 'therapyName': 'Degarelix'}, {'id': 2047, 'therapyName': 'Histrelin acetate'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer,759
6,NCT02059213,Phase II,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 795, 'therapyName': 'Leuprolide'}]", A Phase II Study of Androgen Deprivation Therapy With or Without PD 0332991 in RB-Positive Metastatic Prostate Cancer,759
7,NCT03279250,Phase II,Not yet recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1947, 'therapyName': 'ARN-509'}]",Effects of Apalutamide Plus LHRH Agonist or Apalutamide Plus Abiraterone Acetate Plus LHRH Agonist for Six Months for Prostate Cancer Patients at High Risk for Recurrence,759
8,NCT02626507,Phase I,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1040, 'therapyName': 'PF-05212384'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer,759
9,NCT02064036,Phase I,Recruiting,"[{'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate,759
10,NCT02594072,Phase I,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}]",Androgen Suppression With Stereotactic Body or External Beam Radiation Therapy (ASSERT) (ASSERT),759
11,NCT02586675,Phase I,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 3175, 'therapyName': 'LEE001 + Tamoxifen'}]",TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer,759
12,NCT02907918,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 4756, 'therapyName': 'Letrozole + Palbociclib + Trastuzumab'}]",Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer (PALTAN),759
13,NCT00936390,Phase III,"Active, not recruiting","[{'id': 742, 'therapyName': 'Flutamide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,759
14,NCT01674140,Phase III,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}]",S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,759
15,NCT02366494,Phase I,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Micro RNAs to Predict Response to Androgen Deprivation Therapy,759
16,NCT01717053,Phase II,"Active, not recruiting","[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 759, 'therapyName': 'Goserelin'}]","Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer",759
17,NCT01723774,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 759, 'therapyName': 'Goserelin'}]",PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer,759
18,NCT02278120,Phase III,"Active, not recruiting","[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 790, 'therapyName': 'Ribociclib'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 633, 'therapyName': 'Anastrozole'}]","Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer",759
19,NCT03007979,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 3205, 'therapyName': 'Fulvestrant + Palbociclib'}, {'id': 2922, 'therapyName': 'Palbociclib + Letrozole'}]",Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer,759
20,NCT02023463,Phase I,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 795, 'therapyName': 'Leuprolide'}]","Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer",759
21,NCT02058706,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 795, 'therapyName': 'Leuprolide'}]",LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer,759
22,NCT02430480,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}]",Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer,759
23,NCT02204098,Phase I,Recruiting,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]",Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy,759
24,NCT02472275,Phase I,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 874, 'therapyName': 'PLX3397'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 1814, 'therapyName': 'Degarelix'}]","PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer",759
25,NCT02115282,Phase III,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1541, 'therapyName': 'Entinostat'}, {'id': 738, 'therapyName': 'Exemestane'}]",Exemestane With or Without Entinostat in Treating Postmenopausal Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,759
26,NCT02685397,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Management of Castration-Resistant Prostate Cancer With Oligometastases,759
27,NCT00002651,Phase III,Completed,"[{'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 759, 'therapyName': 'Goserelin'}]",Hormone Therapy in Treating Men With Stage IV Prostate Cancer,759
0,NCT01776008,Phase II,"Active, not recruiting","[{'id': 1548, 'therapyName': 'Goserelin + MK2206'}]",Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer,1548
0,NCT02267083,Phase II,Completed,"[{'id': 2041, 'therapyName': 'GPX-150'}]",Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma,2041
0,NCT02575404,Phase I,Recruiting,"[{'id': 2975, 'therapyName': 'GR-MD-02'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",GR-MD-02 Plus Pembrolizumab in Melanoma Patients,2975
1,NCT02117362,Phase I,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2975, 'therapyName': 'GR-MD-02'}]",Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma,2975
0,NCT01967810,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2053, 'therapyName': 'GRN1005'}]",ANG1005 in Patients With Recurrent High-Grade Glioma,2053
1,NCT02048059,Phase II,Completed,"[{'id': 2053, 'therapyName': 'GRN1005'}]",ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases,2053
0,NCT01803282,Phase I,Recruiting,"[{'id': 3320, 'therapyName': 'GS-5745'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Safety and Tolerability Study in Solid Tumors,3320
1,NCT02545504,Phase III,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 3320, 'therapyName': 'GS-5745'}]",GS-5745 With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma,3320
0,NCT02864381,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 4736, 'therapyName': 'GS-5745 + Nivolumab'}]",GS-5745 Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma,4736
0,NCT02392611,Phase I,"Active, not recruiting","[{'id': 3561, 'therapyName': 'GS-5829 + Exemestane'}]","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 in Adults With Advanced Solid Tumors and Lymphomas",3561
1,NCT02607228,Phase Ib/II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 3561, 'therapyName': 'GS-5829 + Exemestane'}]","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer",3561
2,NCT02983604,Phase Ib/II,Recruiting,"[{'id': 738, 'therapyName': 'Exemestane'}, {'id': 5074, 'therapyName': 'GS-5829 + Fulvestrant'}, {'id': 3561, 'therapyName': 'GS-5829 + Exemestane'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",GS-5829 in Combination With Exemestane or Fulvestrant Comparing With Exemestane or Fulvestrant Alone in Women With Advanced Estrogen Receptor Positive HER2- Breast Cancer,3561
0,NCT02983604,Phase Ib/II,Recruiting,"[{'id': 738, 'therapyName': 'Exemestane'}, {'id': 5074, 'therapyName': 'GS-5829 + Fulvestrant'}, {'id': 3561, 'therapyName': 'GS-5829 + Exemestane'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",GS-5829 in Combination With Exemestane or Fulvestrant Comparing With Exemestane or Fulvestrant Alone in Women With Advanced Estrogen Receptor Positive HER2- Breast Cancer,5074
0,NCT01619774,Phase II,Completed,"[{'id': 1191, 'therapyName': 'GSK1120212 + Dabrafenib'}]", An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor,1191
0,NCT01138085,Phase I,Completed,"[{'id': 1150, 'therapyName': 'GSK1120212 + GSK2141795'}]","Safety, Pharmacokinetics (PK) of AKT and MEK Combination",1150
1,NCT01958112,Phase II,Terminated,"[{'id': 1150, 'therapyName': 'GSK1120212 + GSK2141795'}]",GSK1120212+GSK2141795 for Cervical Cancer,1150
0,NCT02523014,Phase II,Recruiting,"[{'id': 3078, 'therapyName': 'GSK2256098'}, {'id': 956, 'therapyName': 'Vismodegib'}]",A Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas,3078
0,NCT02428270,Phase II,Recruiting,"[{'id': 4205, 'therapyName': 'GSK2256098 + Trametinib'}]",A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer,4205
0,NCT01458067,Phase I,Completed,"[{'id': 765, 'therapyName': 'GSK2636771'}]"," A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency",765
1,NCT02465060,Phase II,Recruiting,"[{'id': 660, 'therapyName': 'AZD9291'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 958, 'therapyName': 'VS-6063'}, {'id': 765, 'therapyName': 'GSK2636771'}]",NCI-MATCH Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,765
2,NCT02215096,Phase I,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 765, 'therapyName': 'GSK2636771'}]",Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer,765
0,NCT03131908,Phase Ib/II,Recruiting,"[{'id': 3518, 'therapyName': 'GSK2636771 + Pembrolizumab'}]",Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss,3518
0,NCT02082977,Phase I,Terminated,"[{'id': 2734, 'therapyName': 'GSK2816126'}]","A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell and Transformed Follicular Lymphoma",2734
0,NCT01966445,Phase I,"Active, not recruiting","[{'id': 2919, 'therapyName': 'GSK2849330'}]","Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors",2919
0,NCT02177812,Phase I,Recruiting,"[{'id': 3014, 'therapyName': 'GSK2879552 '}]",A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML),3014
1,NCT02034123,Phase I,Terminated,"[{'id': 3014, 'therapyName': 'GSK2879552 '}]",Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma,3014
0,NCT01868022,Phase I,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 2899, 'therapyName': 'GSK3052230'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling",2899
0,NCT02528357,Phase I,Recruiting,"[{'id': 5177, 'therapyName': 'GSK3174998'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors,5177
0,NCT02723955,Phase I,Recruiting,"[{'id': 4409, 'therapyName': 'GSK3359609'}, {'id': 4410, 'therapyName': 'GSK3359609 + Pembrolizumab'}]",Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1),4409
0,NCT02723955,Phase I,Recruiting,"[{'id': 4409, 'therapyName': 'GSK3359609'}, {'id': 4410, 'therapyName': 'GSK3359609 + Pembrolizumab'}]",Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1),4410
0,NCT01943851,Phase I,Recruiting,"[{'id': 784, 'therapyName': 'GSK525762'}]","A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies",784
1,NCT01587703,Phase I,Recruiting,"[{'id': 784, 'therapyName': 'GSK525762'}]","A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers",784
0,NCT02964507,Phase II,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 5242, 'therapyName': 'GSK525762 + Fulvestrant'}]",Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Estrogen Receptor Positive (ER+) Breast Cancer,5242
0,NCT01966289,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1949, 'therapyName': 'SGI-110'}, {'id': 2977, 'therapyName': 'GVAX colorectal cancer vaccine'}]",SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC),2977
0,NCT02243371,Phase II,"Active, not recruiting","[{'id': 2642, 'therapyName': 'GVAX pancreatic cancer vaccine  '}, {'id': 2641, 'therapyName': 'CRS-207'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab,2642
0,NCT02740270,Phase I,Recruiting,"[{'id': 4469, 'therapyName': 'GWN 323 + PDR001'}, {'id': 4468, 'therapyName': 'GWN 323'}]",Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas,4468
0,NCT02740270,Phase I,Recruiting,"[{'id': 4469, 'therapyName': 'GWN 323 + PDR001'}, {'id': 4468, 'therapyName': 'GWN 323'}]",Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas,4469
0,NCT03250676,Phase Ib/II,Recruiting,"[{'id': 6150, 'therapyName': 'H3B-6545'}]","Trial of H3B-6545, a Covalent Antagonist of Estrogen Receptor Alpha, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer",6150
0,NCT02780128,Phase I,Recruiting,"[{'id': 2186, 'therapyName': 'HDM201'}, {'id': 2638, 'therapyName': 'Ceritinib + LEE011'}, {'id': 2, 'therapyName': 'Trametinib'}]",Next Generation Personalized Neuroblastoma Therapy,2186
1,NCT02143635,Phase I,Recruiting,"[{'id': 2186, 'therapyName': 'HDM201'}]",Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt,2186
0,NCT02343172,Phase Ib/II,Recruiting,"[{'id': 2481, 'therapyName': 'HDM201 + LEE011'}]",Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma,2481
0,NCT01922921,Phase Ib/II,"Active, not recruiting","[{'id': 1556, 'therapyName': 'HER-2/neu intracellular domain protein + Trastuzumab '}, {'id': 1558, 'therapyName': 'HER-2/neu intracellular domain protein + Trastuzumab + Polysaccharide-K'}]",Vaccine Therapy and Trastuzumab With or Without Polysaccharide-K in Treating Patients With Stage IV HER2 Positive Breast Cancer,1556
0,NCT01922921,Phase Ib/II,"Active, not recruiting","[{'id': 1556, 'therapyName': 'HER-2/neu intracellular domain protein + Trastuzumab '}, {'id': 1558, 'therapyName': 'HER-2/neu intracellular domain protein + Trastuzumab + Polysaccharide-K'}]",Vaccine Therapy and Trastuzumab With or Without Polysaccharide-K in Treating Patients With Stage IV HER2 Positive Breast Cancer,1558
0,NCT02442297,Phase I,Recruiting,"[{'id': 2940, 'therapyName': 'HER2 sensitized T-cells'}]",T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With Glioblastoma,2940
1,NCT00902044,Phase I,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2940, 'therapyName': 'HER2 sensitized T-cells'}]",Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma,2940
0,NCT01730118,Phase I,Recruiting,"[{'id': 1404, 'therapyName': 'HER2 Vaccine'}]",Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing,1404
1,NCT01376505,Phase I,Recruiting,"[{'id': 1404, 'therapyName': 'HER2 Vaccine'}]",Vaccine Therapy in Treating Patients With Metastatic Solid Tumors,1404
0,NCT02336984,Phase Ib/II,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 5222, 'therapyName': 'HER2-pulsed DC1 vaccine'}]",A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS,5222
1,NCT02063724,Phase I,"Active, not recruiting","[{'id': 5222, 'therapyName': 'HER2-pulsed DC1 vaccine'}]",HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer (Adjuvant),5222
2,NCT02061332,Phase Ib/II,"Active, not recruiting","[{'id': 5222, 'therapyName': 'HER2-pulsed DC1 vaccine'}]",DC Vaccine for Patients With Ductal Carcinoma In Situ,5222
0,NCT02272855,Phase II,"Active, not recruiting","[{'id': 2003, 'therapyName': 'HF10 + Ipilimumab'}]",A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma,2003
0,NCT03259425,Phase II,Not yet recruiting,"[{'id': 6149, 'therapyName': 'HF10 + Nivolumab'}]","Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma",6149
0,NCT02278185,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1814, 'therapyName': 'Degarelix'}, {'id': 2047, 'therapyName': 'Histrelin acetate'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer,2047
0,NCT02648490,Phase I,Recruiting,"[{'id': 3939, 'therapyName': 'Acetaminophen + Dexamethasone + Diphenhydramine + Ondansetron'}, {'id': 3938, 'therapyName': 'HLX07'}]","An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers",3938
0,NCT02485652,Phase II,"Active, not recruiting","[{'id': 2137, 'therapyName': 'HM61713'}]",Phase II Trial of HM61713 (BI 1482694) for the Treatment of >2nd Line T790M Mutation Positive Adenocarcinoma of the Lung (NSCLC),2137
0,NCT02981108,Phase Ib/II,Recruiting,"[{'id': 5830, 'therapyName': 'HS-10296'}]","A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC",5830
0,NCT02439450,Phase I,Recruiting,"[{'id': 2457, 'therapyName': 'HS-110'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer,2457
0,NCT02117024,Phase II,"Active, not recruiting","[{'id': 2472, 'therapyName': 'HS-110 + Cyclophosphamide'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer,2472
0,NCT01857934,Phase II,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 2627, 'therapyName': 'Levetiracetam'}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 2458, 'therapyName': 'Hu14.18K322A'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}]",Therapy for Children With Advanced Stage Neuroblastoma,2458
0,NCT02216409,Phase I,Recruiting,"[{'id': 4947, 'therapyName': 'Hu5F9-G4'}]","Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody",4947
1,NCT03248479,Phase I,Not yet recruiting,"[{'id': 6133, 'therapyName': 'Azacitidine + Hu5F9-G4'}, {'id': 4947, 'therapyName': 'Hu5F9-G4'}]",Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination With Azacitidine in Patients With Hematological Malignancies,4947
0,NCT02953509,Phase Ib/II,Recruiting,"[{'id': 4955, 'therapyName': 'Hu5F9-G4 + Rituximab'}]",Trial of Hu5F9-G4 in Combination With Rituximab in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma,4955
0,NCT02988817,Phase Ib/II,Recruiting,"[{'id': 5864, 'therapyName': 'HuMax-Axl-ADC'}]",HuMax-AXL-ADC Safety Study in Patients With Solid Tumors,5864
0,NCT01006369,Phase II,Completed,"[{'id': 1316, 'therapyName': 'Hydroxychloroquine'}, {'id': 1601, 'therapyName': 'Capecitabine + Oxaliplatin + Bevacizumab'}, {'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}]","Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer",1316
1,NCT02232243,Phase I,Recruiting,"[{'id': 1316, 'therapyName': 'Hydroxychloroquine'}]",HCQ on PAR-4 Levels in Patients With Resectable Solid Tumors,1316
2,NCT02316340,Phase II,Recruiting,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1316, 'therapyName': 'Hydroxychloroquine'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer,1316
3,NCT01828476,Phase II,Terminated,"[{'id': 1316, 'therapyName': 'Hydroxychloroquine'}, {'id': 2597, 'therapyName': 'Abiraterone + Navitoclax'}]",Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer,1316
4,NCT01206530,Phase Ib/II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1316, 'therapyName': 'Hydroxychloroquine'}]",FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer,1316
5,NCT03032406,Phase II,Recruiting,"[{'id': 2231, 'therapyName': 'Everolimus + Hydroxychloroquine'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1316, 'therapyName': 'Hydroxychloroquine'}]","CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer",1316
6,NCT01506973,Phase Ib/II,Recruiting,"[{'id': 1316, 'therapyName': 'Hydroxychloroquine'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer,1316
0,NCT03081702,Phase Ib/II,Not yet recruiting,"[{'id': 5495, 'therapyName': 'Hydroxychloroquine + Itraconazole'}]","A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian Cancer",5495
0,NCT00909831,Phase I,"Active, not recruiting","[{'id': 2302, 'therapyName': 'Hydroxychloroquine + Temsirolimus '}]",Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment,2302
0,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,1750
1,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1750
2,NCT02088541,Phase II,"Active, not recruiting","[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}]",Selinexor (KPT-330) in Older Patients With Relapsed AML,1750
0,NCT03291938,Phase I,Not yet recruiting,"[{'id': 6267, 'therapyName': 'IACS-010759'}]",Study to Evaluate the Safety and Tolerability of IACS-010759 in Subjects With Advanced Solid Tumors and Lymphoma,6267
1,NCT02882321,Phase I,Recruiting,"[{'id': 6267, 'therapyName': 'IACS-010759'}]",Study of IACS-010759 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML),6267
0,NCT00577278,Phase II,"Active, not recruiting","[{'id': 767, 'therapyName': 'Ibritumomab'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}]","Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma",767
0,NCT02662296,Phase II,Withdrawn,"[{'id': 1023, 'therapyName': 'Idelalisib'}, {'id': 768, 'therapyName': 'Ibrutinib'}]","Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant",768
1,NCT02207062,Phase I,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma,768
2,NCT03088878,Phase Ib/II,Not yet recruiting,"[{'id': 5480, 'therapyName': 'Cirmtuzumab + Ibrutinib'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies,768
3,NCT02219737,Phase I,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3360, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide + Rituximab'}]",Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma,768
4,NCT03207555,Phase II,Not yet recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL),768
5,NCT02436707,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3391, 'therapyName': 'Cisplatin + Dexamethasone + Gemcitabine + Rituximab'}]",Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma,768
6,NCT02910583,Phase II,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3392, 'therapyName': 'GDC-0199 + Ibrutinib'}]",Ibrutinib Plus Venetoclax in Patients With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma,768
7,NCT02315326,Phase Ib/II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]","Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)",768
8,NCT02575300,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors,768
9,NCT02824029,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma,768
10,NCT02943473,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients,768
11,NCT02801578,Phase I,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}]",A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL),768
12,NCT02599324,Phase Ib/II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors,768
13,NCT01804686,Phase III,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",A Long-term Extension Study of PCI-32765 (Ibrutinib),768
14,NCT02007044,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 897, 'therapyName': 'Rituximab'}]",Ibrutinib Versus Ibrutinib + Rituximab (i vs iR) in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL),768
15,NCT02272686,Phase II,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma,768
16,NCT03219047,Phase I,Not yet recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",The EXPLORE Trial: Study Evaluating Xenografts to Personalize Therapies (PDX) in Relapsed Mantle Cell Lymphoma to Optimize Response,768
17,NCT02436668,Phase II,"Active, not recruiting","[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 768, 'therapyName': 'Ibrutinib'}]","Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma",768
18,NCT02703272,Phase III,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 4307, 'therapyName': 'Carboplatin + Dexamethasone + Etoposide + Ifosfamide + Rituximab'}, {'id': 4308, 'therapyName': 'Carboplatin + Dexamethasone + Idarubicin + Ifosfamide + Rituximab + Vincristine'}]",A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma,768
19,NCT03267186,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant,768
20,NCT02415608,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis,768
21,NCT02966730,Phase I,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy,768
22,NCT02649387,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy (MERIT),768
23,NCT02912754,Phase Ib/II,Not yet recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 4768, 'therapyName': 'Ibrutinib + Ruxolitinib'}]",Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients,768
24,NCT02643667,Phase Ib/II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",A Study of Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer,768
25,NCT02129062,Phase II,Terminated,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia,768
26,NCT02581930,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Treating Patients With Refractory Stage IV Cutaneous Melanoma,768
27,NCT02629809,Phase II,Recruiting,"[{'id': 3628, 'therapyName': 'Allopurinol'}, {'id': 3627, 'therapyName': 'Cyclophosphamide + Fludarabine + Obinutuzumab'}, {'id': 768, 'therapyName': 'Ibrutinib'}]","First-line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL)",768
28,NCT02351037,Phase II,Terminated,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 712, 'therapyName': 'Cytarabine'}]",A Multicenter Open-Label Phase 2a Study of Ibrutinib With or Without Cytarabine in Subjects With Acute Myeloid Leukemia,768
29,NCT02604511,Phase II,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}]","Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing",768
30,NCT03229200,FDA approved,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.,768
31,NCT02406742,Phase Ib/II,Recruiting,"[{'id': 1646, 'therapyName': 'Obinutuzumab'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 2358, 'therapyName': 'CC-122'}]","A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Rituximab, Ibrutinib and Obinutuzumab in Subjects With Relapsed/Refractory CLL/SLL (ENHANCE)",768
32,NCT02947347,Phase III,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3280, 'therapyName': 'Ibrutinib + Rituximab'}]",Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma,768
33,NCT02518555,Phase II,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}]","Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",768
34,NCT01974440,Phase III,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}]","A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma",768
35,NCT02006485,Phase I,Recruiting,"[{'id': 2319, 'therapyName': 'TGR-1202 + Ublituximab'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",Ublituximab in Combination With TGR-1202 in Patients With B-cell Malignancies,768
36,NCT01841723,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia,768
37,NCT01855750,Phase III,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}]","A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma",768
38,NCT03053440,Phase III,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 2544, 'therapyName': 'BGB-3111'}]",A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM),768
39,NCT02301156,Phase III,"Active, not recruiting","[{'id': 2287, 'therapyName': 'Ublituximab'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL),768
40,NCT02443077,Phase III,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 3359, 'therapyName': 'Carmustine + Cytarabine + Etoposide + Melphalan'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma,768
41,NCT02869633,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant,768
42,NCT03282396,Phase II,Not yet recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Newly Diagnosed Mantle Cell Lymphoma With Low-Risk Disease,768
43,NCT02309580,Phase I,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma,768
44,NCT02321540,Phase Ib/II,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}]",A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer,768
45,NCT02548962,Phase Ib/II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3792, 'therapyName': 'Dexamethasone + Pomalidomide'}]",Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma,768
46,NCT02352558,Phase I,"Active, not recruiting","[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 2057, 'therapyName': 'BBI608'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]","A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies",768
47,NCT02477696,Phase III,Recruiting,"[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",Elevate CLL R/R: Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia,768
48,NCT03112174,Phase III,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3392, 'therapyName': 'GDC-0199 + Ibrutinib'}]",Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO),768
49,NCT02242097,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma,768
0,NCT02760485,Phase Ib/II,Recruiting,"[{'id': 5151, 'therapyName': 'Ibrutinib + INCB039110'}]",A Study of INCB039110 in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma,5151
0,NCT02743546,Phase I,Withdrawn,"[{'id': 4167, 'therapyName': 'Ibrutinib + JNJ-64052781'}]","Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of JNJ-64052781 Plus Ibrutinib in Lymphoma",4167
0,NCT01955499,Phase I,"Active, not recruiting","[{'id': 3580, 'therapyName': 'Ibrutinib + lenalidomide'}]",Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma,3580
1,NCT01886859,Phase I,"Active, not recruiting","[{'id': 3580, 'therapyName': 'Ibrutinib + lenalidomide'}]",Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,3580
0,NCT03015792,Phase Ib/II,Recruiting,"[{'id': 5240, 'therapyName': 'Ibrutinib + Lenalidomide + Dexamethasone'}]","Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant",5240
0,NCT03223610,Phase I,Not yet recruiting,"[{'id': 6189, 'therapyName': 'Ibrutinib + Lenalidomide + Obinutuzumab + Prednisone + Venetoclax'}]","Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma",6189
0,NCT02403271,Phase Ib/II,Completed,"[{'id': 2573, 'therapyName': 'Ibrutinib + MEDI4736'}]",A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors,2573
1,NCT02401048,Phase Ib/II,"Active, not recruiting","[{'id': 2573, 'therapyName': 'Ibrutinib + MEDI4736'}]",A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas,2573
2,NCT02733042,Phase Ib/II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 4278, 'therapyName': 'lenalidomide + MEDI4736 + Rituximab'}, {'id': 4279, 'therapyName': 'Bendamustine + MEDI4736 + Rituximab'}, {'id': 2573, 'therapyName': 'Ibrutinib + MEDI4736'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia (FUSION NHL 001)",2573
0,NCT02005289,Phase II,Recruiting,"[{'id': 5843, 'therapyName': 'Lenalidomide + MOR208'}, {'id': 5847, 'therapyName': 'Ibrutinib + MOR208'}]","Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL",5847
0,NCT02329847,Phase Ib/II,Recruiting,"[{'id': 3198, 'therapyName': 'Ibrutinib + Nivolumab'}]",Pharmacokinetic and Pharmacodynamic Study to Evaluate Safety and Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies,3198
1,NCT02940301,Phase II,Recruiting,"[{'id': 3198, 'therapyName': 'Ibrutinib + Nivolumab'}]",Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma,3198
2,NCT02420912,Phase II,Recruiting,"[{'id': 3198, 'therapyName': 'Ibrutinib + Nivolumab'}]","Nivolumab With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)",3198
3,NCT02899078,Phase Ib/II,Recruiting,"[{'id': 3198, 'therapyName': 'Ibrutinib + Nivolumab'}]",Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer,3198
4,NCT02950038,Phase II,Withdrawn,"[{'id': 3198, 'therapyName': 'Ibrutinib + Nivolumab'}]",Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC),3198
0,NCT02315768,Phase Ib/II,Recruiting,"[{'id': 3476, 'therapyName': 'Ibrutinib + Obinutuzumab'}]",Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.,3476
1,NCT02736617,Phase II,Recruiting,"[{'id': 3476, 'therapyName': 'Ibrutinib + Obinutuzumab'}]",Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma,3476
2,NCT02611908,Phase I,Recruiting,"[{'id': 3476, 'therapyName': 'Ibrutinib + Obinutuzumab'}]",Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.,3476
3,NCT02537613,Phase I,Recruiting,"[{'id': 3476, 'therapyName': 'Ibrutinib + Obinutuzumab'}]",A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,3476
0,NCT01644253,Phase I,Recruiting,"[{'id': 4745, 'therapyName': 'Idelalisib + Otlertuzumab + Rituximab'}, {'id': 4742, 'therapyName': 'Otlertuzumab + Rituximab'}, {'id': 4743, 'therapyName': 'Obinutuzumab + Otlertuzumab'}, {'id': 4744, 'therapyName': 'Ibrutinib + Otlertuzumab'}]","Phase 1b Safety and Efficacy Study of TRU-016 and Rituximab, Obinutuzumab, Idelalisib, or Ibrutinib in Chronic Lymphocytic Leukemia",4744
0,NCT02677948,Phase Ib/II,Withdrawn,"[{'id': 3623, 'therapyName': 'Ibrutinib + Pacritinib'}]",Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL),3623
0,NCT02159755,Phase I,"Active, not recruiting","[{'id': 1729, 'therapyName': 'ibrutinib + palbociclib'}]",Ibrutinib and Palbociclib Isethionate in Treating Patients With Previously Treated Mantle Cell Lymphoma,1729
0,NCT01880567,Phase II,Recruiting,"[{'id': 3280, 'therapyName': 'Ibrutinib + Rituximab'}]",Phase 2 Ibrutinib + Rituximab in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL),3280
1,NCT02947347,Phase III,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3280, 'therapyName': 'Ibrutinib + Rituximab'}]",Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma,3280
0,NCT02251548,Phase II,Recruiting,"[{'id': 2185, 'therapyName': 'Ibrutinib + Rituximab + Cyclophosphamide + Fludarabine'}]","A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia",2185
0,NCT03136497,Phase I,Recruiting,"[{'id': 5777, 'therapyName': 'Ibrutinib + Rituximab + Venetoclax'}]",A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL),5777
0,NCT02912754,Phase Ib/II,Not yet recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 4768, 'therapyName': 'Ibrutinib + Ruxolitinib'}]",Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients,4768
0,NCT02927964,Phase Ib/II,Recruiting,"[{'id': 4828, 'therapyName': 'Ibrutinib + SD-101 + Radiotherapy'}]","TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma",4828
0,NCT02303392,Phase I,Recruiting,"[{'id': 3579, 'therapyName': 'Ibrutinib + Selinexor'}]",Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma,3579
0,NCT02973399,Phase I,Recruiting,"[{'id': 4780, 'therapyName': 'Ibrutinib + SNX-5422'}]",Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL,4780
1,NCT02914327,Phase I,Recruiting,"[{'id': 4780, 'therapyName': 'Ibrutinib + SNX-5422'}]",Safety and Activity of SNX-5422 Plus Ibrutinib in CLL,4780
0,NCT02954406,Phase I,Recruiting,"[{'id': 5150, 'therapyName': 'Lenalidomide + TAK-659'}, {'id': 5149, 'therapyName': 'Ibrutinib + TAK-659'}, {'id': 5148, 'therapyName': 'Gemcitabine + TAK-659'}, {'id': 5147, 'therapyName': 'Bendamustine + Rituximab + TAK-659'}, {'id': 5146, 'therapyName': 'Bendamustine + TAK-659'}]","A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma",5149
0,NCT02874404,Phase II,Recruiting,"[{'id': 2044, 'therapyName': 'Ibrutinib + TGR-1202'}]",TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma,2044
1,NCT02268851,Phase I,Recruiting,"[{'id': 2044, 'therapyName': 'Ibrutinib + TGR-1202'}]",A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL,2044
0,NCT02033148,Phase I,Withdrawn,"[{'id': 769, 'therapyName': 'Icotinib'}]",Icotinib Hydrochloride in Treating Patients With Advanced Cancers,769
0,NCT02122861,Phase I,"Active, not recruiting","[{'id': 3271, 'therapyName': 'ID-LV305'}]","A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1",3271
0,NCT03164057,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia,1022
1,NCT01794702,Phase Ib/II,"Active, not recruiting","[{'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 650, 'therapyName': 'Decitabine'}]","Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia",1022
2,NCT03214562,,Recruiting,"[{'id': 1562, 'therapyName': 'Venetoclax'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive Acute Myeloid Leukemia (AML) Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML),1022
3,NCT02560025,Phase II,"Active, not recruiting","[{'id': 626, 'therapyName': 'Alisertib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML,1022
4,NCT03117751,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,1022
5,NCT02096055,Phase II,Recruiting,"[{'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1949, 'therapyName': 'SGI-110'}, {'id': 1022, 'therapyName': 'Idarubicin'}]",4-Arm Phase II Study of SGI-110 in Elderly Acute Myeloid Leukemia (AML),1022
6,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1022
0,NCT02624986,Phase Ib/II,Recruiting,"[{'id': 4393, 'therapyName': 'Idasanutlin + Obinutuzumab'}]",A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL),4393
0,NCT03135262,Phase Ib/II,Recruiting,"[{'id': 5646, 'therapyName': 'Idasanutlin + Rituximab + Venetoclax'}, {'id': 5644, 'therapyName': 'Idasanutlin + Obinutuzumab + Venetoclax'}, {'id': 5645, 'therapyName': 'Idasanutlin + Obinutuzumab + Rituximab + Venetoclax'}]",A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL),5645
0,NCT03135262,Phase Ib/II,Recruiting,"[{'id': 5646, 'therapyName': 'Idasanutlin + Rituximab + Venetoclax'}, {'id': 5644, 'therapyName': 'Idasanutlin + Obinutuzumab + Venetoclax'}, {'id': 5645, 'therapyName': 'Idasanutlin + Obinutuzumab + Rituximab + Venetoclax'}]",A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL),5644
0,NCT03135262,Phase Ib/II,Recruiting,"[{'id': 5646, 'therapyName': 'Idasanutlin + Rituximab + Venetoclax'}, {'id': 5644, 'therapyName': 'Idasanutlin + Obinutuzumab + Venetoclax'}, {'id': 5645, 'therapyName': 'Idasanutlin + Obinutuzumab + Rituximab + Venetoclax'}]",A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL),5646
0,NCT01732913,Phase III,Terminated,"[{'id': 1023, 'therapyName': 'Idelalisib'}, {'id': 897, 'therapyName': 'Rituximab'}]",Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas,1023
1,NCT02662296,Phase II,Withdrawn,"[{'id': 1023, 'therapyName': 'Idelalisib'}, {'id': 768, 'therapyName': 'Ibrutinib'}]","Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant",1023
2,NCT03133221,Phase II,Not yet recruiting,"[{'id': 1023, 'therapyName': 'Idelalisib'}]",1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation,1023
3,NCT01732926,Phase III,Terminated,"[{'id': 1023, 'therapyName': 'Idelalisib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}]",Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas,1023
4,NCT01306643,Phase Ib/II,Completed,"[{'id': 1023, 'therapyName': 'Idelalisib'}]","Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma",1023
5,NCT03126019,Phase II,Recruiting,"[{'id': 3088, 'therapyName': 'INCB050465 '}, {'id': 1023, 'therapyName': 'Idelalisib'}]","An Open-Label, Randomized Study Comparing INCB050465 to Idelalisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)",1023
0,NCT02639910,Phase II,Recruiting,"[{'id': 5785, 'therapyName': 'MOR208 + Venetoclax'}, {'id': 5784, 'therapyName': 'Idelalisib + MOR208'}]",Study to Evaluate Efficacy and Safety of MOR208 With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (COSMOS),5784
0,NCT01980875,Phase III,Terminated,"[{'id': 1647, 'therapyName': 'Idelalisib + Obinutuzumab'}, {'id': 1648, 'therapyName': 'Obinutuzumab + Chlorambucil'}]",Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia,1647
0,NCT02135133,Phase II,Suspended,"[{'id': 2326, 'therapyName': 'Idelalisib + Ofatumumab'}]","A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL",2326
0,NCT01644253,Phase I,Recruiting,"[{'id': 4745, 'therapyName': 'Idelalisib + Otlertuzumab + Rituximab'}, {'id': 4742, 'therapyName': 'Otlertuzumab + Rituximab'}, {'id': 4743, 'therapyName': 'Obinutuzumab + Otlertuzumab'}, {'id': 4744, 'therapyName': 'Ibrutinib + Otlertuzumab'}]","Phase 1b Safety and Efficacy Study of TRU-016 and Rituximab, Obinutuzumab, Idelalisib, or Ibrutinib in Chronic Lymphocytic Leukemia",4745
0,NCT03257722,Phase Ib/II,Recruiting,"[{'id': 6145, 'therapyName': 'Idelalisib + Pembrolizumab'}]",Pembrolizumab + Idelalisib for Lung Cancer Study,6145
0,NCT02044822,Phase II,Terminated,"[{'id': 2325, 'therapyName': 'Idelalisib + Rituximab'}]",Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion,2325
0,NCT02381886,Phase I,Suspended,"[{'id': 2981, 'therapyName': 'IDH305'}]",A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations,2981
1,NCT02977689,Phase II,Not yet recruiting,"[{'id': 2981, 'therapyName': 'IDH305'}]",Trial of IDH305 in IDH1 Mutant Grade II or III Glioma,2981
0,NCT02584829,Phase Ib/II,Suspended,"[{'id': 3156, 'therapyName': 'IFN-B'}, {'id': 3144, 'therapyName': 'Avelumab'}]",Localized Radiation Therapy or Recombinant Interferon Beta and MSB0010718C With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma,3156
0,NCT02049905,Phase III,Completed,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1440, 'therapyName': 'Aldoxorubicin'}, {'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}]",Phase 3 Study to Treat Patients With Soft Tissue Sarcomas,1441
1,NCT00936936,Phase II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2101, 'therapyName': 'Etoposide + Ifosfamide'}, {'id': 2100, 'therapyName': 'Docetaxel + Gemcitabine + Melphalan'}, {'id': 2074, 'therapyName': 'Bevacizumab + Carboplatin'}]",High-dose Chemotherapy for Poor-prognosis Relapsed Germ-Cell Tumors,1441
2,NCT02677116,Phase I,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 3618, 'therapyName': 'Irinotecan + Vincristine'}, {'id': 3269, 'therapyName': 'Olaratumab'}]",A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,1441
3,NCT02112916,Phase III,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,1441
4,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1441
5,NCT03007147,Phase III,Recruiting,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 5167, 'therapyName': 'Methylprednisolone'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 5168, 'therapyName': 'Prednisolone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,1441
0,NCT02507583,Phase I,Recruiting,"[{'id': 4325, 'therapyName': 'IGF-1R/AS ODN'}]",Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma,4325
0,NCT02493361,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2990, 'therapyName': 'IL-12 gene'}]",Trial of pIL-12/MK-3475 in Metastatic Melanoma,2990
0,NCT02924038,Phase I,Recruiting,"[{'id': 4835, 'therapyName': 'IMA950 + poly ICLC '}, {'id': 2525, 'therapyName': 'Varlilumab'}]",A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG),4835
0,NCT02540356,Phase Ib/II,Terminated,"[{'id': 2996, 'therapyName': 'Imalumab'}]",Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer,2996
1,NCT02448810,Phase II,Terminated,"[{'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}, {'id': 2996, 'therapyName': 'Imalumab'}, {'id': 845, 'therapyName': 'Panitumumab'}]",Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer,2996
0,NCT03023046,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}]","Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",770
1,NCT01319981,Phase II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia,770
2,NCT00812240,Phase III,Unknown status,"[{'id': 804, 'therapyName': 'Masitinib'}, {'id': 770, 'therapyName': 'Imatinib'}]",A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment,770
3,NCT01593254,Phase II,"Active, not recruiting","[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 717, 'therapyName': 'Dasatinib'}]",Phase IIb Study of Dasatinib Versus Imatinib in Patients With CML-CP Who Have Not Achieved an Early Optimal Response to Imatinib,770
4,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,770
5,NCT03007147,Phase III,Recruiting,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 5167, 'therapyName': 'Methylprednisolone'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 5168, 'therapyName': 'Prednisolone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,770
6,NCT02177825,Phase II,Recruiting,"[{'id': 770, 'therapyName': 'Imatinib'}]",Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas,770
7,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,770
8,NCT01244750,Phase I,"Active, not recruiting","[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}]",Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting,770
9,NCT02130557,Phase III,"Active, not recruiting","[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 770, 'therapyName': 'Imatinib'}]","A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia",770
10,NCT02352558,Phase I,"Active, not recruiting","[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 2057, 'therapyName': 'BBI608'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]","A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies",770
11,NCT00290485,Phase II,Unknown status,"[{'id': 770, 'therapyName': 'Imatinib'}]",Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST),770
12,NCT00718263,Phase III,Recruiting,"[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}]",Efficacy and Safety of Nilotinib Patients With Newly Diagnosed CML - CP (Chronic Myelogenous Leukemia - Chronic Phase),770
13,NCT02538926,Phase II,Not yet recruiting,"[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 3212, 'therapyName': 'Doxorubicin + Etoposide + Vincristine '}, {'id': 2206, 'therapyName': 'Asparaginase'}]","Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",770
14,NCT02709083,Phase II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 770, 'therapyName': 'Imatinib'}]","Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia",770
0,NCT00573378,Phase II,Withdrawn,"[{'id': 2467, 'therapyName': 'Imatinib + Interferon alfa-2b '}, {'id': 2468, 'therapyName': 'Interferon alfa-2b + Nilotinib '}]",Imatinib or Nilotinib With Pegylated Interferon-alpha2b in Chronic Myeloid Leukemia,2467
0,NCT02812693,Phase Ib/II,Recruiting,"[{'id': 4376, 'therapyName': 'Imatinib + Pembrolizumab'}]",Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification,4376
0,NCT02570308,Phase I,Recruiting,"[{'id': 3847, 'therapyName': 'IMCgp100'}]",A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma,3847
1,NCT02535078,Phase Ib/II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3847, 'therapyName': 'IMCgp100'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Cutaneous Melanoma,3847
2,NCT02889861,Phase Ib/II,Recruiting,"[{'id': 3847, 'therapyName': 'IMCgp100'}]",IMCgp100-401 Rollover Study,3847
3,NCT03070392,Phase II,Recruiting,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3847, 'therapyName': 'IMCgp100'}]",Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma,3847
0,NCT02598661,Phase III,Recruiting,"[{'id': 3710, 'therapyName': 'Imetelstat'}]",Study to Evaluate Imetelstat (JNJ-63935937) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS),3710
0,NCT01609556,Phase I,"Active, not recruiting","[{'id': 3232, 'therapyName': 'IMGN853'}]","First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors",3232
1,NCT03106077,Phase II,Recruiting,"[{'id': 3232, 'therapyName': 'IMGN853'}]",Mirvetuximab Soravtansine in Localized Triple-Negative Breast Cancer (TNBC),3232
2,NCT02606305,Phase I,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 3232, 'therapyName': 'IMGN853'}]","Study of IMGN853 in Comb. With Bevacizumab, Carboplatin or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer",3232
3,NCT02631876,Phase II,Recruiting,"[{'id': 3574, 'therapyName': 'Doxil + Paclitaxel'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3232, 'therapyName': 'IMGN853'}]","PH2 Study of IMGN853 vs Investigator's Choice of Chemo in Adults With FRa+ Adv. EOC, Primary Peritoneal or Primary Fallopian Tube Cancer",3232
4,NCT02996825,Phase I,Recruiting,"[{'id': 3232, 'therapyName': 'IMGN853'}]","Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRa-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer",3232
0,NCT03276832,Phase I,Not yet recruiting,"[{'id': 6220, 'therapyName': 'Imiquimod + Pembrolizumab'}]",Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma,6220
0,NCT03052205,Phase I,Recruiting,"[{'id': 4243, 'therapyName': 'IMO-2125'}]",A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors,4243
0,NCT02644967,Phase Ib/II,Recruiting,"[{'id': 4244, 'therapyName': 'IMO-2125 + Ipilimumab'}, {'id': 4245, 'therapyName': 'IMO-2125 + Pembrolizumab'}]",A Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab or Pembrolizumab in Patients With Metastatic Melanoma,4244
0,NCT02644967,Phase Ib/II,Recruiting,"[{'id': 4244, 'therapyName': 'IMO-2125 + Ipilimumab'}, {'id': 4245, 'therapyName': 'IMO-2125 + Pembrolizumab'}]",A Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab or Pembrolizumab in Patients With Metastatic Melanoma,4245
0,NCT02252146,Phase Ib/II,Completed,"[{'id': 2866, 'therapyName': 'IMO-8400'}]",Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88L265P Mutation,2866
1,NCT02092909,Phase Ib/II,"Active, not recruiting","[{'id': 2866, 'therapyName': 'IMO-8400'}]",Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia (8400-401),2866
0,NCT02981303,Phase II,Recruiting,"[{'id': 5174, 'therapyName': 'Imprime PGG + Pembrolizumab'}]",Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer,5174
1,NCT03003468,Phase Ib/II,Recruiting,"[{'id': 5174, 'therapyName': 'Imprime PGG + Pembrolizumab'}]",Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Chemotherapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017,5174
0,NCT02205398,Phase Ib/II,Terminated,"[{'id': 1618, 'therapyName': 'INC280 + Cetuximab '}]","Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy",1618
0,NCT02323126,Phase II,Recruiting,"[{'id': 2443, 'therapyName': 'EGF816 + Nivolumab'}, {'id': 2444, 'therapyName': 'INC280 + Nivolumab'}]",Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer,2444
0,NCT02795429,Phase Ib/II,Recruiting,"[{'id': 2659, 'therapyName': 'PDR001'}, {'id': 4492, 'therapyName': 'INC280 + PDR001'}]",Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC,4492
0,NCT02697591,Phase Ib/II,Recruiting,"[{'id': 4321, 'therapyName': 'INCAGN01876'}]","An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors",4321
0,NCT03126110,Phase Ib/II,Recruiting,"[{'id': 5599, 'therapyName': 'INCAGN01876 + Nivolumab + Ipilimumab'}, {'id': 5598, 'therapyName': 'INCAGN01876 + Nivolumab'}, {'id': 5597, 'therapyName': 'INCAGN01876 + Ipilimumab'}]","Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies",5597
0,NCT03126110,Phase Ib/II,Recruiting,"[{'id': 5599, 'therapyName': 'INCAGN01876 + Nivolumab + Ipilimumab'}, {'id': 5598, 'therapyName': 'INCAGN01876 + Nivolumab'}, {'id': 5597, 'therapyName': 'INCAGN01876 + Ipilimumab'}]","Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies",5598
0,NCT03126110,Phase Ib/II,Recruiting,"[{'id': 5599, 'therapyName': 'INCAGN01876 + Nivolumab + Ipilimumab'}, {'id': 5598, 'therapyName': 'INCAGN01876 + Nivolumab'}, {'id': 5597, 'therapyName': 'INCAGN01876 + Ipilimumab'}]","Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies",5599
0,NCT02923349,Phase Ib/II,Recruiting,"[{'id': 5831, 'therapyName': 'INCAGN01949'}]","A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors",5831
0,NCT03241173,Phase Ib/II,Not yet recruiting,"[{'id': 6120, 'therapyName': 'INCAGN01949 + Ipilimumab'}, {'id': 6119, 'therapyName': 'INCAGN01949 + Nivolumab'}, {'id': 6121, 'therapyName': 'INCAGN01949 + Ipilimumab + Nivolumab'}]",A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies,6120
0,NCT03241173,Phase Ib/II,Not yet recruiting,"[{'id': 6120, 'therapyName': 'INCAGN01949 + Ipilimumab'}, {'id': 6119, 'therapyName': 'INCAGN01949 + Nivolumab'}, {'id': 6121, 'therapyName': 'INCAGN01949 + Ipilimumab + Nivolumab'}]",A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies,6121
0,NCT03241173,Phase Ib/II,Not yet recruiting,"[{'id': 6120, 'therapyName': 'INCAGN01949 + Ipilimumab'}, {'id': 6119, 'therapyName': 'INCAGN01949 + Nivolumab'}, {'id': 6121, 'therapyName': 'INCAGN01949 + Ipilimumab + Nivolumab'}]",A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies,6119
0,NCT02318277,Phase Ib/II,Recruiting,"[{'id': 3015, 'therapyName': 'INCB024360 + MEDI4736'}]",A Study of INCB024360 in Combination With MEDI4736 in Subjects With Selected Advanced Solid Tumors,3015
0,NCT02327078,Phase Ib/II,Recruiting,"[{'id': 3059, 'therapyName': 'INCB024360 + Nivolumab'}]","A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers",3059
0,NCT03085914,Phase Ib/II,Recruiting,"[{'id': 5483, 'therapyName': 'INCB024360 + Nivolumab + mFOLFOX6'}, {'id': 5484, 'therapyName': 'INCB024360 + Nivolumab + Gemcitabine + nab-paclitaxel'}, {'id': 5485, 'therapyName': 'INCB024360 + Pembrolizumab + Carboplatin + Paclitaxel'}, {'id': 5486, 'therapyName': 'INCB024360 + Pembrolizumab + Carboplatin + Pemetrexed'}, {'id': 5487, 'therapyName': 'INCB024360 + Pembrolizumab + Cyclophosphamide'}]",A Study of Epacadostat in Combination With a PD-1 Inhibitor and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207),5484
0,NCT03085914,Phase Ib/II,Recruiting,"[{'id': 5483, 'therapyName': 'INCB024360 + Nivolumab + mFOLFOX6'}, {'id': 5484, 'therapyName': 'INCB024360 + Nivolumab + Gemcitabine + nab-paclitaxel'}, {'id': 5485, 'therapyName': 'INCB024360 + Pembrolizumab + Carboplatin + Paclitaxel'}, {'id': 5486, 'therapyName': 'INCB024360 + Pembrolizumab + Carboplatin + Pemetrexed'}, {'id': 5487, 'therapyName': 'INCB024360 + Pembrolizumab + Cyclophosphamide'}]",A Study of Epacadostat in Combination With a PD-1 Inhibitor and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207),5483
0,NCT03085914,Phase Ib/II,Recruiting,"[{'id': 5483, 'therapyName': 'INCB024360 + Nivolumab + mFOLFOX6'}, {'id': 5484, 'therapyName': 'INCB024360 + Nivolumab + Gemcitabine + nab-paclitaxel'}, {'id': 5485, 'therapyName': 'INCB024360 + Pembrolizumab + Carboplatin + Paclitaxel'}, {'id': 5486, 'therapyName': 'INCB024360 + Pembrolizumab + Carboplatin + Pemetrexed'}, {'id': 5487, 'therapyName': 'INCB024360 + Pembrolizumab + Cyclophosphamide'}]",A Study of Epacadostat in Combination With a PD-1 Inhibitor and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207),5485
0,NCT03085914,Phase Ib/II,Recruiting,"[{'id': 5483, 'therapyName': 'INCB024360 + Nivolumab + mFOLFOX6'}, {'id': 5484, 'therapyName': 'INCB024360 + Nivolumab + Gemcitabine + nab-paclitaxel'}, {'id': 5485, 'therapyName': 'INCB024360 + Pembrolizumab + Carboplatin + Paclitaxel'}, {'id': 5486, 'therapyName': 'INCB024360 + Pembrolizumab + Carboplatin + Pemetrexed'}, {'id': 5487, 'therapyName': 'INCB024360 + Pembrolizumab + Cyclophosphamide'}]",A Study of Epacadostat in Combination With a PD-1 Inhibitor and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207),5486
0,NCT03085914,Phase Ib/II,Recruiting,"[{'id': 5483, 'therapyName': 'INCB024360 + Nivolumab + mFOLFOX6'}, {'id': 5484, 'therapyName': 'INCB024360 + Nivolumab + Gemcitabine + nab-paclitaxel'}, {'id': 5485, 'therapyName': 'INCB024360 + Pembrolizumab + Carboplatin + Paclitaxel'}, {'id': 5486, 'therapyName': 'INCB024360 + Pembrolizumab + Carboplatin + Pemetrexed'}, {'id': 5487, 'therapyName': 'INCB024360 + Pembrolizumab + Cyclophosphamide'}]",A Study of Epacadostat in Combination With a PD-1 Inhibitor and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207),5487
0,NCT01911507,Phase I,Recruiting,"[{'id': 1284, 'therapyName': 'INCB028060 + Erlotinib'}]",INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer,1284
0,NCT02018861,Phase I,"Active, not recruiting","[{'id': 2406, 'therapyName': 'INCB039110'}, {'id': 3097, 'therapyName': 'INCB039110 + INCB050465'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 3088, 'therapyName': 'INCB050465 '}]","A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies",2406
1,NCT02355431,Phase II,Withdrawn,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2406, 'therapyName': 'INCB039110'}]",INCB039110 in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations,2406
2,NCT01858883,Phase I,Completed,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2406, 'therapyName': 'INCB039110'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Safety Study of INCB039110 in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors,2406
3,NCT02646748,Phase I,Recruiting,"[{'id': 3088, 'therapyName': 'INCB050465 '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2406, 'therapyName': 'INCB039110'}]",Pembrolizumab Combined With INCB039110 and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors,2406
4,NCT02257619,Phase II,Terminated,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 2406, 'therapyName': 'INCB039110'}]",Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer,2406
0,NCT02559492,Phase I,"Active, not recruiting","[{'id': 3096, 'therapyName': 'INCB039110 + INCB024360'}, {'id': 3097, 'therapyName': 'INCB039110 + INCB050465'}]",INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors,3096
0,NCT01905813,Phase I,"Active, not recruiting","[{'id': 2420, 'therapyName': 'INCB039110 + INCB040093'}, {'id': 2021, 'therapyName': 'INCB040093'}]",Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies,2420
0,NCT02018861,Phase I,"Active, not recruiting","[{'id': 2406, 'therapyName': 'INCB039110'}, {'id': 3097, 'therapyName': 'INCB039110 + INCB050465'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 3088, 'therapyName': 'INCB050465 '}]","A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies",3097
1,NCT02559492,Phase I,"Active, not recruiting","[{'id': 3096, 'therapyName': 'INCB039110 + INCB024360'}, {'id': 3097, 'therapyName': 'INCB039110 + INCB050465'}]",INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors,3097
0,NCT02917993,Phase Ib/II,Recruiting,"[{'id': 4777, 'therapyName': 'INCB039110 + Osimertinib'}]",An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer,4777
0,NCT01905813,Phase I,"Active, not recruiting","[{'id': 2420, 'therapyName': 'INCB039110 + INCB040093'}, {'id': 2021, 'therapyName': 'INCB040093'}]",Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies,2021
0,NCT02646748,Phase I,Recruiting,"[{'id': 3088, 'therapyName': 'INCB050465 '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2406, 'therapyName': 'INCB039110'}]",Pembrolizumab Combined With INCB039110 and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors,3088
1,NCT02018861,Phase I,"Active, not recruiting","[{'id': 2406, 'therapyName': 'INCB039110'}, {'id': 3097, 'therapyName': 'INCB039110 + INCB050465'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 3088, 'therapyName': 'INCB050465 '}]","A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies",3088
2,NCT03126019,Phase II,Recruiting,"[{'id': 3088, 'therapyName': 'INCB050465 '}, {'id': 1023, 'therapyName': 'Idelalisib'}]","An Open-Label, Randomized Study Comparing INCB050465 to Idelalisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)",3088
3,NCT02998476,Phase II,Recruiting,"[{'id': 3088, 'therapyName': 'INCB050465 '}]",A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202),3088
4,NCT03144674,Phase II,Recruiting,"[{'id': 3088, 'therapyName': 'INCB050465 '}]",A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204),3088
0,NCT02718300,Phase II,Recruiting,"[{'id': 4224, 'therapyName': 'INCB050465 + Ruxolitinib'}]",A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis,4224
0,NCT02265510,Phase I,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2747, 'therapyName': 'INCB052793'}, {'id': 688, 'therapyName': 'Bortezomib'}]","An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies",2747
0,NCT02587598,Phase Ib/II,Recruiting,"[{'id': 3696, 'therapyName': 'INCB053914'}]",Study of INCB053914 in Subjects With Advanced Malignancies,3696
0,NCT02431260,Phase I,"Active, not recruiting","[{'id': 2812, 'therapyName': 'INCB054329'}]","An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies",2812
0,NCT02872714,Phase II,Recruiting,"[{'id': 4173, 'therapyName': 'INCB054828'}]",A Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Urothelial Carcinoma,4173
1,NCT03011372,Phase II,Recruiting,"[{'id': 4173, 'therapyName': 'INCB054828'}]",A Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement,4173
2,NCT02924376,Phase II,Recruiting,"[{'id': 4173, 'therapyName': 'INCB054828'}]",Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy,4173
0,NCT02711137,Phase Ib/II,Recruiting,"[{'id': 4319, 'therapyName': 'INCB057643 '}]","A Phase 1/2, Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies",4319
0,NCT02712905,Phase Ib/II,Recruiting,"[{'id': 5464, 'therapyName': 'INCB059872'}]","An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies",5464
0,NCT03144661,Phase I,Recruiting,"[{'id': 5832, 'therapyName': 'INCB062079'}]",An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies,5832
0,NCT01792050,Phase II,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 2976, 'therapyName': 'indoximod'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer,2976
1,NCT02502708,Phase I,Recruiting,"[{'id': 2976, 'therapyName': 'indoximod'}, {'id': 1141, 'therapyName': 'Temozolomide'}]","Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Primary Malignant Brain Tumors",2976
2,NCT02077881,Phase Ib/II,Recruiting,"[{'id': 2976, 'therapyName': 'indoximod'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer,2976
3,NCT02052648,Phase Ib/II,Recruiting,"[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 2976, 'therapyName': 'indoximod'}]",Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors,2976
4,NCT02073123,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2976, 'therapyName': 'indoximod'}]",Study of IDO Inhibitor in Combination With Ipilimumab for Adult Patients With Metastatic Melanoma,2976
0,NCT01593228,Phase III,Completed,"[{'id': 1173, 'therapyName': 'Iniparib + doxorubicin + carboplatin'}, {'id': 1172, 'therapyName': 'Iniparib + Paclitaxel'}, {'id': 1171, 'therapyName': 'Iniparib + Irinotecan'}, {'id': 1170, 'therapyName': 'Iniparib + Topotecan'}, {'id': 1169, 'therapyName': 'Iniparib + Gemcitabine + Carboplatin'}, {'id': 1168, 'therapyName': 'Iniparib'}]", Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial,1168
0,NCT01593228,Phase III,Completed,"[{'id': 1173, 'therapyName': 'Iniparib + doxorubicin + carboplatin'}, {'id': 1172, 'therapyName': 'Iniparib + Paclitaxel'}, {'id': 1171, 'therapyName': 'Iniparib + Irinotecan'}, {'id': 1170, 'therapyName': 'Iniparib + Topotecan'}, {'id': 1169, 'therapyName': 'Iniparib + Gemcitabine + Carboplatin'}, {'id': 1168, 'therapyName': 'Iniparib'}]", Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial,1173
0,NCT01593228,Phase III,Completed,"[{'id': 1173, 'therapyName': 'Iniparib + doxorubicin + carboplatin'}, {'id': 1172, 'therapyName': 'Iniparib + Paclitaxel'}, {'id': 1171, 'therapyName': 'Iniparib + Irinotecan'}, {'id': 1170, 'therapyName': 'Iniparib + Topotecan'}, {'id': 1169, 'therapyName': 'Iniparib + Gemcitabine + Carboplatin'}, {'id': 1168, 'therapyName': 'Iniparib'}]", Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial,1169
0,NCT01593228,Phase III,Completed,"[{'id': 1173, 'therapyName': 'Iniparib + doxorubicin + carboplatin'}, {'id': 1172, 'therapyName': 'Iniparib + Paclitaxel'}, {'id': 1171, 'therapyName': 'Iniparib + Irinotecan'}, {'id': 1170, 'therapyName': 'Iniparib + Topotecan'}, {'id': 1169, 'therapyName': 'Iniparib + Gemcitabine + Carboplatin'}, {'id': 1168, 'therapyName': 'Iniparib'}]", Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial,1171
0,NCT01593228,Phase III,Completed,"[{'id': 1173, 'therapyName': 'Iniparib + doxorubicin + carboplatin'}, {'id': 1172, 'therapyName': 'Iniparib + Paclitaxel'}, {'id': 1171, 'therapyName': 'Iniparib + Irinotecan'}, {'id': 1170, 'therapyName': 'Iniparib + Topotecan'}, {'id': 1169, 'therapyName': 'Iniparib + Gemcitabine + Carboplatin'}, {'id': 1168, 'therapyName': 'Iniparib'}]", Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial,1172
0,NCT01593228,Phase III,Completed,"[{'id': 1173, 'therapyName': 'Iniparib + doxorubicin + carboplatin'}, {'id': 1172, 'therapyName': 'Iniparib + Paclitaxel'}, {'id': 1171, 'therapyName': 'Iniparib + Irinotecan'}, {'id': 1170, 'therapyName': 'Iniparib + Topotecan'}, {'id': 1169, 'therapyName': 'Iniparib + Gemcitabine + Carboplatin'}, {'id': 1168, 'therapyName': 'Iniparib'}]", Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial,1170
0,NCT02960594,Phase I,Recruiting,"[{'id': 5844, 'therapyName': 'INO-1400 + INO-9012'}, {'id': 5807, 'therapyName': 'INO-1400'}]",hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse,5807
0,NCT02960594,Phase I,Recruiting,"[{'id': 5844, 'therapyName': 'INO-1400 + INO-9012'}, {'id': 5807, 'therapyName': 'INO-1400'}]",hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse,5844
0,NCT02241369,Phase I,Recruiting,"[{'id': 5846, 'therapyName': 'INO-3106 + INO-9012'}]",Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies,5846
0,NCT02981628,Phase II,Recruiting,"[{'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]",Inotuzumab Ozogamicin in Treating Younger Patients With Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia,3199
1,NCT03094611,Phase II,Not yet recruiting,"[{'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]",Study of Low Dose Inotuzumab Ozogamicin in Patients With Relapsed and Refractory CD22 Positive Acute Lymphocytic Leukemia,3199
2,NCT03104491,Phase Ib/II,Recruiting,"[{'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]",Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia,3199
3,NCT01925131,Phase I,Recruiting,"[{'id': 3221, 'therapyName': 'Cyclophosphamide + Prednisone + Vincristine'}, {'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]","S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia",3199
4,NCT03150693,Phase III,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 3628, 'therapyName': 'Allopurinol'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]",Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia,3199
0,NCT03056599,,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1733, 'therapyName': 'interferon gamma '}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 3420, 'therapyName': 'trabectedin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma,1299
1,NCT02339324,Phase I,"Active, not recruiting","[{'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b,1299
2,NCT02737046,Phase II,Recruiting,"[{'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 2624, 'therapyName': 'peginterferon alfa-2b'}, {'id': 4361, 'therapyName': 'Belinostat + Zidovudine'}]",Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma,1299
3,NCT01708941,Phase II,"Active, not recruiting","[{'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,1299
4,NCT02506153,Phase III,"Active, not recruiting","[{'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery,1299
5,NCT01409174,Phase Ib/II,Terminated,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1299, 'therapyName': 'Interferon alfa-2b '}]",IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma,1299
6,NCT01274338,Phase III,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1299, 'therapyName': 'Interferon alfa-2b '}]",Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,1299
0,NCT00573378,Phase II,Withdrawn,"[{'id': 2467, 'therapyName': 'Imatinib + Interferon alfa-2b '}, {'id': 2468, 'therapyName': 'Interferon alfa-2b + Nilotinib '}]",Imatinib or Nilotinib With Pegylated Interferon-alpha2b in Chronic Myeloid Leukemia,2468
0,NCT03056599,,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1733, 'therapyName': 'interferon gamma '}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 3420, 'therapyName': 'trabectedin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma,1733
1,NCT02614456,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1733, 'therapyName': 'interferon gamma '}]",Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors,1733
0,NCT03112590,Phase Ib/II,Recruiting,"[{'id': 5548, 'therapyName': 'Interferon gamma + Paclitaxel + Pertuzumab + Trastuzumab'}]",Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer,5548
0,NCT02948426,Phase I,Recruiting,"[{'id': 4975, 'therapyName': 'interferon gamma + peginterferon alfa-2b'}]","Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer",4975
0,NCT02542124,Phase II,Recruiting,"[{'id': 5262, 'therapyName': 'Interleukin-12'}]",NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT),5262
0,NCT02069145,Phase I,Completed,"[{'id': 2413, 'therapyName': 'Ipafricept + Sorafenib'}]",Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer,2413
0,NCT01362374,Phase I,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 747, 'therapyName': 'Ipatasertib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]","Safety and Pharmacology Of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors",747
1,NCT01896531,Phase II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 747, 'therapyName': 'Ipatasertib'}]",A Study of GDC-0068 in Combination With Fluoropyrimidine Plus Oxaliplatin in Patients With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer,747
2,NCT01485861,Phase II,"Active, not recruiting","[{'id': 750, 'therapyName': 'GDC-0980'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 747, 'therapyName': 'Ipatasertib'}]",Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy,747
3,NCT02301988,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 747, 'therapyName': 'Ipatasertib'}]",A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Patients With Early Stage Triple Negative Breast Cancer,747
0,NCT02162719,Phase II,"Active, not recruiting","[{'id': 1588, 'therapyName': 'Ipatasertib + Paclitaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Front-line Treatment for Patients With Metastatic Triple-Negative Breast Cancer,1588
0,NCT02459301,Phase I,"Active, not recruiting","[{'id': 3382, 'therapyName': 'IPH2201'}]","Dose-Ranging Study of IPH2201 in Patients With High Grade Serious CA of Ovarian, Fallopian Tube or Peritoneal Origin",3382
1,NCT02557516,Phase Ib/II,Recruiting,"[{'id': 3382, 'therapyName': 'IPH2201'}]",Combination Study of IPH2201 With Ibrutinib in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia,3382
0,NCT02637531,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3363, 'therapyName': 'IPI-549'}]","A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549",3363
0,NCT02117362,Phase I,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2975, 'therapyName': 'GR-MD-02'}]",Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma,779
1,NCT01804465,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",A Randomized Phase 2 Trial of Combining Sipuleucel-T With Immediate vs. Delayed CTLA-4 Blockade for Prostate Cancer,779
2,NCT01592370,Phase I,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2583, 'therapyName': 'Lirilumab '}]",Safety Study in Nivolumab Alone and in Combination With Ipilimumab or Lirilumab in Lymphoma and Multiple Myeloma,779
3,NCT01950195,Phase I,Terminated,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",SRS (Stereotactic Radiosurgery) Plus Ipilimumab,779
4,NCT02538666,Phase III,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy (CheckMate 451)",779
5,NCT03110107,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 5552, 'therapyName': 'BMS-986218 + Nivolumab'}, {'id': 5551, 'therapyName': 'BMS-986218'}]",First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Patients With Advanced Solid Tumors,779
6,NCT02530463,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS),779
7,NCT02115243,Phase I,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}]",Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma,779
8,NCT01176474,Phase I,"Active, not recruiting","[{'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma,779
9,NCT01896869,Phase II,Suspended,"[{'id': 1903, 'therapyName': 'FOLFIRINOX'}, {'id': 779, 'therapyName': 'Ipilimumab'}]","A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab With Allogenic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer",779
10,NCT02239900,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors,779
11,NCT02731729,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy,779
12,NCT02073123,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2976, 'therapyName': 'indoximod'}]",Study of IDO Inhibitor in Combination With Ipilimumab for Adult Patients With Metastatic Melanoma,779
13,NCT02009397,Phase Ib/II,Recruiting,"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients,779
14,NCT02452281,Phase Ib/II,Withdrawn,"[{'id': 2973, 'therapyName': 'Vitespen'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma,779
15,NCT02060188,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142),779
16,NCT01530984,Phase II,Withdrawn,"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Ipilimumab and GMCSF Immunotherapy for Prostate Cancer,779
17,NCT01928394,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors",779
18,NCT02259231,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 3062, 'therapyName': 'RTA 408'}]",RTA 408 Capsules in Patients With Melanoma - REVEAL,779
19,NCT01585194,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma,779
20,NCT01740297,Phase Ib/II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2695, 'therapyName': 'talimogene laherparepvec '}]",Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma,779
21,NCT01450761,Phase III,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone,779
22,NCT02307149,Phase I,Recruiting,"[{'id': 2974, 'therapyName': 'coxsackievirus A21'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Study of Intratumoral CAVATAK (Coxsackievirus A21) and Ipilimumab in Patients With Advanced Melanoma,779
23,NCT01449279,Phase I,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}]",Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy,779
24,NCT01688492,Phase Ib/II,"Active, not recruiting","[{'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-na&#239;ve Patients With Progressive Metastatic Castration-resistant Prostate Cancer,779
25,NCT02339571,Phase II,Suspended,"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,779
26,NCT02027935,Phase II,Recruiting,"[{'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4,779
27,NCT02054520,Phase II,Unknown status,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",Immunotherapy Study for Patients With Stage IV Melanoma,779
28,NCT02089685,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2624, 'therapyName': 'peginterferon alfa-2b'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29),779
29,NCT01454102,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)",779
30,NCT01565837,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma,779
31,NCT01970527,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma,779
32,NCT02737475,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 4030, 'therapyName': 'BMS-986178'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Study of BMS-986178 Monotherapy or in Combination With Nivolumab or Ipilimumab in Subjects With Advanced Solid Tumors,779
33,NCT02388906,Phase III,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238),779
34,NCT01696045,Phase II,Terminated,"[{'id': 779, 'therapyName': 'Ipilimumab'}]","Phase 2 Study of Ipilimumab in Children and Adolescents (12 to <18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma",779
35,NCT01940809,Phase II,Recruiting,"[{'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 779, 'therapyName': 'Ipilimumab'}]","Ipilimumab With or Without Dabrafenib, and/or Trametinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery",779
36,NCT02107755,Phase II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}]",Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma,779
37,NCT01621490,Phase I,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma (PD-1),779
38,NCT01711515,Phase I,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Chemoradiation Therapy and Ipilimumab in Treating Patients With Locally Advanced Cervical Cancer,779
39,NCT02519322,Phase II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma,779
40,NCT02279862,Phase II,Completed,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive,779
41,NCT01701674,Phase I,"Active, not recruiting","[{'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts,779
42,NCT01703507,Phase I,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}]",Ipilimumab and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Melanoma With Brain Metastases,779
43,NCT03271047,,Recruiting,"[{'id': 807, 'therapyName': 'Binimetinib'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation,779
44,NCT01689974,Phase II,Terminated,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma,779
45,NCT01708941,Phase II,"Active, not recruiting","[{'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,779
46,NCT02703623,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}, {'id': 3844, 'therapyName': 'Cabazitaxel + Carboplatin'}]",A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer (DynaMO),779
47,NCT02950766,,Not yet recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}]","A Study Combining NeoVax, a Personalized NeoAntigen Cancer Vaccine, With Ipilimumab to Treat High-risk Renal Cell Carcinoma",779
48,NCT02500797,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma,779
49,NCT03056599,,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1733, 'therapyName': 'interferon gamma '}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 3420, 'therapyName': 'trabectedin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma,779
50,NCT02097732,Phase II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}]",Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery,779
51,NCT02678572,Phase III,Recruiting,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma,779
52,NCT02812524,Phase I,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",Ipilimumab for Head and Neck Cancer Patients,779
53,NCT03070392,Phase II,Recruiting,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3847, 'therapyName': 'IMCgp100'}]",Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma,779
54,NCT03305445,,Not yet recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL,779
55,NCT02553642,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260),779
56,NCT02113657,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer,779
57,NCT01810016,Phase I,Terminated,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}]",NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma,779
58,NCT02020070,Phase II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1814, 'therapyName': 'Degarelix'}]","Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy",779
59,NCT01409174,Phase Ib/II,Terminated,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1299, 'therapyName': 'Interferon alfa-2b '}]",IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma,779
60,NCT02846376,Phase I,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002),779
61,NCT01498978,Phase II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}]",Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,779
62,NCT01820754,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC),779
63,NCT02696993,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Phase I/II Trial of Nivolumab With Radiation or Nivolumab and Ipilimumab With Radiation for the Treatment of Intracranial Metastases From Non-small Cell Lung Cancer,779
64,NCT02032810,Phase I,"Active, not recruiting","[{'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma,779
65,NCT02221739,Phase II,Completed,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC),779
66,NCT02210104,Phase I,Withdrawn,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Adoptive Therapy Using Antigen-Specific CD4 T-Cells,779
67,NCT02498600,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",779
68,NCT02496208,Phase I,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2067, 'therapyName': 'Cabozantinib + Nivolumab'}]",Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors,779
69,NCT01274338,Phase III,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1299, 'therapyName': 'Interferon alfa-2b '}]",Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,779
70,NCT02506114,Phase II,Recruiting,"[{'id': 4892, 'therapyName': 'PROSTVAC-V/F'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 4895, 'therapyName': 'PROSTVAC-V/F + Ipilimumab'}]",Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer,779
71,NCT01950390,Phase II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1301, 'therapyName': 'Ipilimumab + Bevacizumab'}]",Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot be Removed by Surgery,779
72,NCT02477826,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, Trial of Nivolumab and Nivolumab Plus Ipilimumab Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC)",779
73,NCT03033576,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That is Stage IV or Stage III and Cannot Be Removed by Surgery,779
74,NCT01497808,Phase Ib/II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}]",RADVAX: A Stratified Phase I/II Dose Escalation Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Metastatic Melanoma,779
75,NCT02311920,Phase I,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Temozolomide in Combination With Ipilimumab and/or Nivolumab in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma,779
76,NCT02158520,Phase II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1261, 'therapyName': 'Bevacizumab + Abraxane'}]",Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery,779
77,NCT02467361,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2057, 'therapyName': 'BBI608'}]",A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers,779
78,NCT03068455,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study of Nivolumab in Combination With Ipilimumab Compared to Nivolumab or Ipilimumab Alone in Treatment of Patients After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915),779
79,NCT02385669,Phase Ib/II,Recruiting,"[{'id': 2620, 'therapyName': '6MHP vaccine'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma,779
0,NCT01950390,Phase II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1301, 'therapyName': 'Ipilimumab + Bevacizumab'}]",Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot be Removed by Surgery,1301
0,NCT01998126,Phase I,"Active, not recruiting","[{'id': 1348, 'therapyName': 'Ipilimumab + Erlotinib'}, {'id': 1349, 'therapyName': 'Ipilimumab + Crizotinib'}]",Ipilimumab Plus Targeted Inhibitor (Erlotinib or Crizotinib) for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer: Phase Ib With Expansion Cohorts,1349
0,NCT01998126,Phase I,"Active, not recruiting","[{'id': 1348, 'therapyName': 'Ipilimumab + Erlotinib'}, {'id': 1349, 'therapyName': 'Ipilimumab + Crizotinib'}]",Ipilimumab Plus Targeted Inhibitor (Erlotinib or Crizotinib) for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer: Phase Ib With Expansion Cohorts,1348
0,NCT01738139,Phase I,Recruiting,"[{'id': 1250, 'therapyName': 'Ipilimumab + Imatinib Mesylate'}]",Ipilimumab and Imatinib Mesylate in Advanced Cancer,1250
0,NCT01750983,Phase I,"Active, not recruiting","[{'id': 2992, 'therapyName': 'Ipilimumab + lenalidomide'}]",Ipilimumab and Lenalidomide in Advanced Cancer,2992
0,NCT02381314,Phase I,Recruiting,"[{'id': 3058, 'therapyName': 'Ipilimumab + MGA271'}]",Safety Study of MGA271 in Combination With Ipilimumab in Refractory Cancer,3058
0,NCT01827111,Phase II,"Active, not recruiting","[{'id': 2978, 'therapyName': 'Ipilimumab + nab-paclitaxel'}]",Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma,2978
0,NCT02723006,Phase I,Recruiting,"[{'id': 4198, 'therapyName': 'MLN2480 + Nivolumab'}, {'id': 4200, 'therapyName': 'MLN1202 + Nivolumab'}, {'id': 4202, 'therapyName': 'Ipilimumab + Nivolumab + Vedolizumab '}]","Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma",4202
0,NCT03302234,Phase III,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2106, 'therapyName': 'Ipilimumab + Pembrolizumab '}]",Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer (MK-3475-598/KEYNOTE-598),2106
1,NCT02743819,Phase II,Recruiting,"[{'id': 2106, 'therapyName': 'Ipilimumab + Pembrolizumab '}]",Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody,2106
2,NCT02039674,Phase Ib/II,"Active, not recruiting","[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}, {'id': 2104, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 2106, 'therapyName': 'Ipilimumab + Pembrolizumab '}, {'id': 2107, 'therapyName': 'Erlotinib + Pembrolizumab '}, {'id': 2108, 'therapyName': 'Gefitinib + Pembrolizumab '}]",A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021),2106
0,NCT02254772,Phase Ib/II,Completed,"[{'id': 3848, 'therapyName': 'Ipilimumab + SD-101'}]","TLR9 Agonist SD-101, Ipilimumab, and Radiation Therapy in Treating Patients With Low-Grade Recurrent B-cell Lymphoma",3848
0,NCT02668770,Phase I,Recruiting,"[{'id': 5741, 'therapyName': 'Ipilumumab + Lefitolimod'}]",Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies,5741
0,NCT00940316,Phase II,"Active, not recruiting","[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1940, 'therapyName': 'Panitumumab + Erlotinib'}]",Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer,1074
1,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,1074
2,NCT03257267,Phase III,Recruiting,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 5656, 'therapyName': 'REGN2810'}, {'id': 942, 'therapyName': 'Topotecan'}]",Study of REGN2810 in Adults With Cervical Cancer,1074
3,NCT00576654,Phase I,Recruiting,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 954, 'therapyName': 'Veliparib'}]",Irinotecan Hydrochloride and Veliparib in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery,1074
4,NCT00730158,Phase II,Suspended,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1699, 'therapyName': 'KD018'}]","A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer",1074
5,NCT02579226,Phase I,Recruiting,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 3547, 'therapyName': 'AZD2811'}]","A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors",1074
6,NCT02138617,Phase II,Recruiting,"[{'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1715, 'therapyName': 'Fluorouracil'}]",Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer,1074
7,NCT01520389,Phase I,Completed,"[{'id': 821, 'therapyName': 'MM-151'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment,1074
8,NCT02423954,Phase Ib/II,"Active, not recruiting","[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus),1074
9,NCT01916447,Phase I,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2426, 'therapyName': 'trifluridine/tipiracil hydrochloride'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.,1074
10,NCT00967655,Phase II,Unknown status,"[{'id': 1960, 'therapyName': 'Capecitabine + Panitumumab'}, {'id': 1074, 'therapyName': 'Irinotecan'}]","Capecitabine, Panitumumab, and Radiation Therapy With or Without Irinotecan Hydrochloride in Treating Patients Undergoing Surgery for Localized Rectal Cancer",1074
11,NCT02567435,Phase III,Suspended,"[{'id': 1435, 'therapyName': 'Vincristine + Dactinomycin + Cyclophosphamide'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Combination Chemotherapy and Irinotecan Hydrochloride or Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma,1074
12,NCT02004262,Phase II,Completed,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2383, 'therapyName': 'Capecitabine + Fluorouracil + Gemcitabine '}]",Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting,1074
13,NCT02620423,Phase I,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 893, 'therapyName': 'Reolysin'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab With REOLYSIN and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma,1074
14,NCT02331251,Phase Ib/II,"Active, not recruiting","[{'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 619, 'therapyName': 'Abraxane'}]",Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus),1074
15,NCT01347866,Phase I,Terminated,"[{'id': 1040, 'therapyName': 'PF-05212384'}, {'id': 849, 'therapyName': 'PD-0325901'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer,1074
16,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1074
17,NCT02625623,Phase III,"Active, not recruiting","[{'id': 3144, 'therapyName': 'Avelumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300),1074
0,NCT01923337,Phase I,"Active, not recruiting","[{'id': 1288, 'therapyName': 'Irinotecan + Alisertib'}]",Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer,1288
0,NCT01079780,Phase II,Unknown status,"[{'id': 1920, 'therapyName': 'Irinotecan + Cetuximab + Ramucirumab'}, {'id': 1874, 'therapyName': 'Cetuximab + Irinotecan'}]",Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy,1920
0,NCT00871169,Phase II,Completed,"[{'id': 1919, 'therapyName': 'Irinotecan + Oxaliplatin + Cetuximab'}]","Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer",1919
0,NCT03136055,Phase II,Recruiting,"[{'id': 5643, 'therapyName': 'Irinotecan + Pembrolizumab'}, {'id': 4021, 'therapyName': 'Paclitaxel + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas,5643
0,NCT03141034,Phase II,Not yet recruiting,"[{'id': 5633, 'therapyName': 'Irinotecan + Ramucirumab'}]",Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma,5633
0,NCT02801097,Phase I,Recruiting,"[{'id': 4323, 'therapyName': 'Irinotecan + RRx-001'}]","A Phase I, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer  (PAYLOAD) (PAYLOAD)",4323
0,NCT02283359,Phase I,Terminated,"[{'id': 2588, 'therapyName': 'Irinotecan + Selinexor'}]",Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus,2588
0,NCT02392793,Phase I,Recruiting,"[{'id': 1378, 'therapyName': 'Irinotecan + Talazoparib'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies,1378
1,NCT02049593,Phase I,"Active, not recruiting","[{'id': 1377, 'therapyName': 'Talazoparib + Temozolomide'}, {'id': 1378, 'therapyName': 'Irinotecan + Talazoparib'}]",PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors,1378
0,NCT00980460,Phase III,Recruiting,"[{'id': 2298, 'therapyName': 'Irinotecan + Temsirolimus + Vincristine'}, {'id': 2297, 'therapyName': 'Cisplatin + Fluorouracil + Vincristine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer,2298
0,NCT02631733,Phase I,Recruiting,"[{'id': 3314, 'therapyName': 'Irinotecan + Veliparib'}]",Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,3314
0,NCT02677116,Phase I,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 3618, 'therapyName': 'Irinotecan + Vincristine'}, {'id': 3269, 'therapyName': 'Olaratumab'}]",A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,3618
0,NCT03258008,Phase II,Not yet recruiting,"[{'id': 6148, 'therapyName': 'ISA101b + Utomilumab'}]",Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer,6148
0,NCT03126916,Phase III,Not yet recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 5595, 'therapyName': 'Isotretinoin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 2286, 'therapyName': 'Dinutuximab  '}]",Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma,5595
0,NCT02735356,Phase I,"Active, not recruiting","[{'id': 1026, 'therapyName': 'Itraconazole'}]",Topical Itraconazole in Treating Patients With Basal Cell Cancer,1026
1,NCT01787331,Phase II,"Active, not recruiting","[{'id': 1026, 'therapyName': 'Itraconazole'}]",A Phase II Study of Itraconazole in Biochemical Relapse,1026
2,NCT02122770,Phase I,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1026, 'therapyName': 'Itraconazole'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1688, 'therapyName': 'MLN4924'}, {'id': 1689, 'therapyName': 'Fluconazole'}]","Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors",1026
3,NCT02749513,Phase I,Recruiting,"[{'id': 1026, 'therapyName': 'Itraconazole'}]",Itraconazole as a Targeted Therapy for Inhibiting Hedgehog Pathway Signaling in Esophageal Cancer Patients,1026
4,NCT02120677,Phase I,Recruiting,"[{'id': 1026, 'therapyName': 'Itraconazole'}]",Topical Itraconazole in the Treatment of Basal Cell Carcinoma,1026
5,NCT02259010,Phase I,"Active, not recruiting","[{'id': 626, 'therapyName': 'Alisertib'}, {'id': 1026, 'therapyName': 'Itraconazole'}]",A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma,1026
6,NCT02157883,Phase I,"Active, not recruiting","[{'id': 1026, 'therapyName': 'Itraconazole'}, {'id': 660, 'therapyName': 'AZD9291'}]","Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)",1026
7,NCT02253420,Phase I,Recruiting,"[{'id': 995, 'therapyName': 'Copanlisib'}, {'id': 1026, 'therapyName': 'Itraconazole'}]",COPANLISIB (BAY80-6946) Drug-drug Interaction Study in Advanced Solid Tumor Patients,1026
8,NCT02457351,Phase I,Completed,"[{'id': 663, 'therapyName': 'BAY1000394'}, {'id': 1026, 'therapyName': 'Itraconazole'}]",Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study,1026
9,NCT02357836,Phase I,Recruiting,"[{'id': 1026, 'therapyName': 'Itraconazole'}]",Neoadjuvant Itraconazole in Non-small Cell Lung Cancer,1026
0,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,781
1,NCT03093155,Phase II,Recruiting,"[{'id': 1122, 'therapyName': 'Bevacizumab + Ixabepilone'}, {'id': 781, 'therapyName': 'Ixabepilone'}]",Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab,781
0,NCT01375829,Phase I,"Active, not recruiting","[{'id': 1263, 'therapyName': 'ixabepilone + temsirolimus'}]",Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,1263
0,NCT02440464,Phase II,Recruiting,"[{'id': 3321, 'therapyName': 'Tacrolimus + Methotrexate'}, {'id': 1359, 'therapyName': 'Ixazomib'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302),1359
0,NCT02042989,Phase I,"Active, not recruiting","[{'id': 1360, 'therapyName': 'Ixazomib + Vorinostat'}]",MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies,1360
0,NCT02631044,Phase I,Recruiting,"[{'id': 5980, 'therapyName': 'JCAR017'}]",Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL),5980
0,NCT02365597,Phase II,Recruiting,"[{'id': 1028, 'therapyName': 'JNJ-42756493'}]",An Efficacy and Safety Study of JNJ-42756493 in Participants With Urothelial Cancer,1028
1,NCT03210714,Phase II,Not yet recruiting,"[{'id': 1028, 'therapyName': 'JNJ-42756493'}]","Pediatric MATCH: Pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations",1028
2,NCT01703481,Phase I,"Active, not recruiting","[{'id': 1028, 'therapyName': 'JNJ-42756493'}]","A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Patients With Advanced or Refractory Solid Tumors or Lymphoma",1028
0,NCT03238196,Phase I,Recruiting,"[{'id': 6099, 'therapyName': 'JNJ-42756493 + Fulvestrant + Palbociclib'}]","Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer",6099
0,NCT02671955,Phase I,Terminated,"[{'id': 3614, 'therapyName': 'JNJ-61610588 '}]","A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer",3614
0,NCT03145181,Phase I,Recruiting,"[{'id': 5708, 'therapyName': 'JNJ-64007957'}]","Dose Escalation Study of JNJ-64007957, a Humanized BCMA CD3 DuoBody® Antibody, in Participants With Relapsed or Refractory Multiple Myeloma",5708
0,NCT02625857,Phase I,"Active, not recruiting","[{'id': 4889, 'therapyName': 'JNJ-64041809'}]","Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer",4889
0,NCT02454270,Phase II,"Active, not recruiting","[{'id': 4166, 'therapyName': 'JNJ-64052781'}]",A Dose Escalation Study of JNJ-64052781 in Participants With Relapsed or Refractory B-cell Malignancies,4166
0,NCT02904226,Phase Ib/II,Recruiting,"[{'id': 4720, 'therapyName': 'JTX-2011 + Nivolumab'}, {'id': 4719, 'therapyName': 'JTX-2011'}]",Dose Escalation and Expansion of JTX-2011 Alone or in Combination With Anti-PD-1 in Subjects With Advanced Solid Tumors (ICONIC),4719
0,NCT02904226,Phase Ib/II,Recruiting,"[{'id': 4720, 'therapyName': 'JTX-2011 + Nivolumab'}, {'id': 4719, 'therapyName': 'JTX-2011'}]",Dose Escalation and Expansion of JTX-2011 Alone or in Combination With Anti-PD-1 in Subjects With Advanced Solid Tumors (ICONIC),4720
0,NCT02562755,Phase III,Recruiting,"[{'id': 3341, 'therapyName': 'JX-594'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone,3341
0,NCT00730158,Phase II,Suspended,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1699, 'therapyName': 'KD018'}]","A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer",1699
1,NCT02178644,Phase I,Recruiting,"[{'id': 1699, 'therapyName': 'KD018'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Pilot Trial of KD018 With Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Rectal Cancer,1699
0,NCT02075177,Phase I,Available,"[{'id': 2858, 'therapyName': 'Ketoconazole'}, {'id': 2731, 'therapyName': 'Fenretinide'}]",Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma,2858
1,NCT00859781,Phase II,Recruiting,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 2858, 'therapyName': 'Ketoconazole'}]",177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer,2858
2,NCT01535157,Phase Ib/II,"Active, not recruiting","[{'id': 2858, 'therapyName': 'Ketoconazole'}, {'id': 2731, 'therapyName': 'Fenretinide'}]",Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer,2858
3,NCT02163356,Phase I,Recruiting,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 2731, 'therapyName': 'Fenretinide'}, {'id': 2858, 'therapyName': 'Ketoconazole'}]",Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma,2858
4,NCT02494713,Phase II,Recruiting,"[{'id': 1814, 'therapyName': 'Degarelix'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 2858, 'therapyName': 'Ketoconazole'}]",Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer,2858
5,NCT00536991,Phase Ib/II,Terminated,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 2889, 'therapyName': 'calcitriol'}, {'id': 2858, 'therapyName': 'Ketoconazole'}]","Calcitriol, Ketoconazole, and Hydrocortisone in Treating Patients With Advanced or Recurrent Prostate Cancer",2858
0,NCT03139370,Phase I,Recruiting,"[{'id': 5803, 'therapyName': 'KITE-718'}]",A Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced Cancers,5803
0,NCT02827968,Phase I,Recruiting,"[{'id': 6140, 'therapyName': 'KN035'}]",Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors,6140
0,NCT03051035,Phase I,Recruiting,"[{'id': 5747, 'therapyName': 'KO-947'}]",First-in-Human Study of KO-947 in Non-Hematological Malignancies,5747
0,NCT02649790,Phase Ib/II,Recruiting,"[{'id': 5687, 'therapyName': 'KPT-8602'}]","Study of the Safety, Tolerability and Efficacy of KPT-8602 in Patients With Relapsed/Refractory Multiple Myeloma",5687
0,NCT02702492,Phase I,Recruiting,"[{'id': 4662, 'therapyName': 'KPT-9274'}, {'id': 4688, 'therapyName': 'KPT-9274 + Niacin'}]",PAK4 and NAMPT in Patients With Solid MAlignancies or NHL (PANAMA) (PANAMA),4662
0,NCT02702492,Phase I,Recruiting,"[{'id': 4662, 'therapyName': 'KPT-9274'}, {'id': 4688, 'therapyName': 'KPT-9274 + Niacin'}]",PAK4 and NAMPT in Patients With Solid MAlignancies or NHL (PANAMA) (PANAMA),4688
0,NCT02625480,Phase Ib/II,Recruiting,"[{'id': 4829, 'therapyName': 'KTE-C19'}]",A Multi-Center Study Evaluating KTE-C19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-4),4829
1,NCT02614066,Phase Ib/II,Recruiting,"[{'id': 4829, 'therapyName': 'KTE-C19'}]",A Study Evaluating KTE-C19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3) (ZUMA-3),4829
2,NCT03105336,Phase II,Recruiting,"[{'id': 4829, 'therapyName': 'KTE-C19'}]",A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5),4829
3,NCT02348216,Phase Ib/II,Recruiting,"[{'id': 4829, 'therapyName': 'KTE-C19'}]",A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1),4829
0,NCT03153462,Expanded access,Available,"[{'id': 5098, 'therapyName': 'KTE-C19 + Fludarabine phosphate + Cyclophosphamide'}]",Axicabtagene Ciloleucel Expanded Access Study,5098
1,NCT02601313,Phase II,Recruiting,"[{'id': 5098, 'therapyName': 'KTE-C19 + Fludarabine phosphate + Cyclophosphamide'}]",A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2),5098
0,NCT02834403,Phase Ib/II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 6123, 'therapyName': 'Docetaxel + L-NMMA'}, {'id': 6096, 'therapyName': 'L-NMMA'}]",L-NMMA Plus Docetaxel in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients,6096
0,NCT03236935,Phase I,Not yet recruiting,"[{'id': 6097, 'therapyName': 'L-NMMA + Pembrolizumab'}]",Phase Ib of L-NMMA and Pembrolizumab,6097
0,NCT02460224,Phase Ib/II,Recruiting,"[{'id': 2887, 'therapyName': 'LAG525'}, {'id': 2659, 'therapyName': 'PDR001'}]",Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies,2887
0,NCT03289741,FDA approved,Recruiting,"[{'id': 6279, 'therapyName': 'Lanreotide Depot + Octreotide'}]",A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide,6279
0,NCT03043664,Phase Ib/II,Recruiting,"[{'id': 6129, 'therapyName': 'Lanreotide Depot + Pembrolizumab'}]",Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors (PLANET),6129
0,NCT01328054,,Completed,"[{'id': 787, 'therapyName': 'Lapatinib'}]",A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval,787
1,NCT01427322,,Terminated,"[{'id': 787, 'therapyName': 'Lapatinib'}]",Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease,787
2,NCT01306045,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 816, 'therapyName': 'MK2206'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 913, 'therapyName': 'Selumetinib'}]","Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies",787
3,NCT01622868,Phase II,Recruiting,"[{'id': 787, 'therapyName': 'Lapatinib'}]",Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer,787
4,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,787
5,NCT00863122,Phase I,Unknown status,"[{'id': 787, 'therapyName': 'Lapatinib'}]",Concentration and Activity of Lapatinib in Vestibular Schwannomas,787
6,NCT01868503,Phase II,Terminated,"[{'id': 787, 'therapyName': 'Lapatinib'}]",Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer,787
7,NCT00790816,Phase I,Completed,"[{'id': 1410, 'therapyName': 'Lapatinib + Paclitaxel'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 1399, 'therapyName': 'Lapatinib + Capecitabine'}, {'id': 1497, 'therapyName': 'Lapatinib + Letrozole'}, {'id': 1498, 'therapyName': 'Lapatinib + Oxaliplatin + Capecitabine'}, {'id': 1499, 'therapyName': 'Lapatinib + Gemcitabine'}, {'id': 1500, 'therapyName': 'Lapatinib + Docetaxel'}, {'id': 1501, 'therapyName': 'Lapatinib + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 1502, 'therapyName': 'Lapatinib + Irinotecan + Leucovorin + Fluorouracil'}]",Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents,787
8,NCT00759642,Phase II,"Active, not recruiting","[{'id': 787, 'therapyName': 'Lapatinib'}]",Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy,787
9,NCT02559778,Phase I,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2629, 'therapyName': 'Eflornithine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 717, 'therapyName': 'Dasatinib'}]",Pediatric Precision Laboratory Advanced Neuroblastoma Therapy,787
10,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,787
11,NCT02101905,Phase I,Recruiting,"[{'id': 787, 'therapyName': 'Lapatinib'}]",Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma,787
12,NCT01160211,Phase III,"Active, not recruiting","[{'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 738, 'therapyName': 'Exemestane'}]","A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer",787
13,NCT00939523,Phase II,Recruiting,"[{'id': 787, 'therapyName': 'Lapatinib'}]",Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy,787
0,NCT01497626,Phase I,Terminated,"[{'id': 1394, 'therapyName': 'Lapatinib + bortezomib'}]",Lapatinib and Bortezomib in Patients With Advanced Malignancies,1394
0,NCT00790816,Phase I,Completed,"[{'id': 1410, 'therapyName': 'Lapatinib + Paclitaxel'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 1399, 'therapyName': 'Lapatinib + Capecitabine'}, {'id': 1497, 'therapyName': 'Lapatinib + Letrozole'}, {'id': 1498, 'therapyName': 'Lapatinib + Oxaliplatin + Capecitabine'}, {'id': 1499, 'therapyName': 'Lapatinib + Gemcitabine'}, {'id': 1500, 'therapyName': 'Lapatinib + Docetaxel'}, {'id': 1501, 'therapyName': 'Lapatinib + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 1502, 'therapyName': 'Lapatinib + Irinotecan + Leucovorin + Fluorouracil'}]",Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents,1399
1,NCT02650752,Phase I,Recruiting,"[{'id': 1399, 'therapyName': 'Lapatinib + Capecitabine'}]",Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases,1399
2,NCT01808573,Phase III,"Active, not recruiting","[{'id': 1399, 'therapyName': 'Lapatinib + Capecitabine'}, {'id': 1543, 'therapyName': 'Capecitabine + Neratinib'}]",A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting,1399
0,NCT01783756,Phase Ib/II,"Active, not recruiting","[{'id': 1552, 'therapyName': 'Lapatinib + Capecitabine + Everolimus'}]","Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis",1552
0,NCT01612351,Phase II,"Active, not recruiting","[{'id': 2477, 'therapyName': 'Lapatinib + Carboplatin + Cisplatin + Paclitaxel'}, {'id': 2476, 'therapyName': 'Lapatinib + Carboplatin + Paclitaxel'}]",Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery,2477
0,NCT01612351,Phase II,"Active, not recruiting","[{'id': 2477, 'therapyName': 'Lapatinib + Carboplatin + Cisplatin + Paclitaxel'}, {'id': 2476, 'therapyName': 'Lapatinib + Carboplatin + Paclitaxel'}]",Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery,2476
0,NCT01711658,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2475, 'therapyName': 'Lapatinib + Cisplatin'}]",TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer,2475
0,NCT00790816,Phase I,Completed,"[{'id': 1410, 'therapyName': 'Lapatinib + Paclitaxel'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 1399, 'therapyName': 'Lapatinib + Capecitabine'}, {'id': 1497, 'therapyName': 'Lapatinib + Letrozole'}, {'id': 1498, 'therapyName': 'Lapatinib + Oxaliplatin + Capecitabine'}, {'id': 1499, 'therapyName': 'Lapatinib + Gemcitabine'}, {'id': 1500, 'therapyName': 'Lapatinib + Docetaxel'}, {'id': 1501, 'therapyName': 'Lapatinib + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 1502, 'therapyName': 'Lapatinib + Irinotecan + Leucovorin + Fluorouracil'}]",Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents,1500
0,NCT00790816,Phase I,Completed,"[{'id': 1410, 'therapyName': 'Lapatinib + Paclitaxel'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 1399, 'therapyName': 'Lapatinib + Capecitabine'}, {'id': 1497, 'therapyName': 'Lapatinib + Letrozole'}, {'id': 1498, 'therapyName': 'Lapatinib + Oxaliplatin + Capecitabine'}, {'id': 1499, 'therapyName': 'Lapatinib + Gemcitabine'}, {'id': 1500, 'therapyName': 'Lapatinib + Docetaxel'}, {'id': 1501, 'therapyName': 'Lapatinib + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 1502, 'therapyName': 'Lapatinib + Irinotecan + Leucovorin + Fluorouracil'}]",Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents,1499
0,NCT00790816,Phase I,Completed,"[{'id': 1410, 'therapyName': 'Lapatinib + Paclitaxel'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 1399, 'therapyName': 'Lapatinib + Capecitabine'}, {'id': 1497, 'therapyName': 'Lapatinib + Letrozole'}, {'id': 1498, 'therapyName': 'Lapatinib + Oxaliplatin + Capecitabine'}, {'id': 1499, 'therapyName': 'Lapatinib + Gemcitabine'}, {'id': 1500, 'therapyName': 'Lapatinib + Docetaxel'}, {'id': 1501, 'therapyName': 'Lapatinib + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 1502, 'therapyName': 'Lapatinib + Irinotecan + Leucovorin + Fluorouracil'}]",Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents,1502
0,NCT00790816,Phase I,Completed,"[{'id': 1410, 'therapyName': 'Lapatinib + Paclitaxel'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 1399, 'therapyName': 'Lapatinib + Capecitabine'}, {'id': 1497, 'therapyName': 'Lapatinib + Letrozole'}, {'id': 1498, 'therapyName': 'Lapatinib + Oxaliplatin + Capecitabine'}, {'id': 1499, 'therapyName': 'Lapatinib + Gemcitabine'}, {'id': 1500, 'therapyName': 'Lapatinib + Docetaxel'}, {'id': 1501, 'therapyName': 'Lapatinib + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 1502, 'therapyName': 'Lapatinib + Irinotecan + Leucovorin + Fluorouracil'}]",Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents,1497
0,NCT01087983,Phase I,Completed,"[{'id': 1139, 'therapyName': 'Lapatinib + Sirolimus'}, {'id': 1140, 'therapyName': 'Lapatinib + Metformin'}]",Lapatinib With Sirolimus or Metformin,1140
0,NCT00790816,Phase I,Completed,"[{'id': 1410, 'therapyName': 'Lapatinib + Paclitaxel'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 1399, 'therapyName': 'Lapatinib + Capecitabine'}, {'id': 1497, 'therapyName': 'Lapatinib + Letrozole'}, {'id': 1498, 'therapyName': 'Lapatinib + Oxaliplatin + Capecitabine'}, {'id': 1499, 'therapyName': 'Lapatinib + Gemcitabine'}, {'id': 1500, 'therapyName': 'Lapatinib + Docetaxel'}, {'id': 1501, 'therapyName': 'Lapatinib + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 1502, 'therapyName': 'Lapatinib + Irinotecan + Leucovorin + Fluorouracil'}]",Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents,1498
0,NCT00790816,Phase I,Completed,"[{'id': 1410, 'therapyName': 'Lapatinib + Paclitaxel'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 1399, 'therapyName': 'Lapatinib + Capecitabine'}, {'id': 1497, 'therapyName': 'Lapatinib + Letrozole'}, {'id': 1498, 'therapyName': 'Lapatinib + Oxaliplatin + Capecitabine'}, {'id': 1499, 'therapyName': 'Lapatinib + Gemcitabine'}, {'id': 1500, 'therapyName': 'Lapatinib + Docetaxel'}, {'id': 1501, 'therapyName': 'Lapatinib + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 1502, 'therapyName': 'Lapatinib + Irinotecan + Leucovorin + Fluorouracil'}]",Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents,1501
0,NCT00790816,Phase I,Completed,"[{'id': 1410, 'therapyName': 'Lapatinib + Paclitaxel'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 1399, 'therapyName': 'Lapatinib + Capecitabine'}, {'id': 1497, 'therapyName': 'Lapatinib + Letrozole'}, {'id': 1498, 'therapyName': 'Lapatinib + Oxaliplatin + Capecitabine'}, {'id': 1499, 'therapyName': 'Lapatinib + Gemcitabine'}, {'id': 1500, 'therapyName': 'Lapatinib + Docetaxel'}, {'id': 1501, 'therapyName': 'Lapatinib + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 1502, 'therapyName': 'Lapatinib + Irinotecan + Leucovorin + Fluorouracil'}]",Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents,1410
0,NCT01087983,Phase I,Completed,"[{'id': 1139, 'therapyName': 'Lapatinib + Sirolimus'}, {'id': 1140, 'therapyName': 'Lapatinib + Metformin'}]",Lapatinib With Sirolimus or Metformin,1139
0,NCT01591577,Phase II,Recruiting,"[{'id': 2440, 'therapyName': 'Lapatinib + Temozolomide'}]",Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme,2440
0,NCT02158507,Phase I,"Active, not recruiting","[{'id': 2543, 'therapyName': 'Lapatinib + Veliparib'}]","Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer",2543
0,NCT03027388,Phase I,Not yet recruiting,"[{'id': 3514, 'therapyName': 'LB-100'}]","Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma",3514
0,NCT02649673,Phase Ib/II,Recruiting,"[{'id': 3845, 'therapyName': 'LCL161 + Topotecan'}]",LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies,3845
0,NCT02586675,Phase I,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 3175, 'therapyName': 'LEE001 + Tamoxifen'}]",TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer,3175
0,NCT02154776,Phase I,Completed,"[{'id': 1594, 'therapyName': 'LEE011 + BKM120 + Letrozole'}]","Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer. (LeeBLet)",1594
0,NCT01872260,Phase Ib/II,Recruiting,"[{'id': 1553, 'therapyName': 'Letrozole + BYL719'}, {'id': 1569, 'therapyName': 'LEE011 + BYL719 + Letrozole'}, {'id': 1568, 'therapyName': 'LEE011 + Letrozole'}]","Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer",1569
0,NCT03056833,Phase I,Recruiting,"[{'id': 5333, 'therapyName': 'LEE011 + Carboplatin + Paclitaxel'}]",Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer,5333
0,NCT01857193,Phase Ib/II,Recruiting,"[{'id': 2265, 'therapyName': 'LEE011 + Everolimus + Exemestane'}, {'id': 1966, 'therapyName': 'Exemestane + Everolimus'}, {'id': 2266, 'therapyName': 'LEE011 + Exemestane'}]",Phase Ib/II Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of ER+ Her2- Advanced Breast Cancer,2265
1,NCT02732119,Phase Ib/II,Recruiting,"[{'id': 2265, 'therapyName': 'LEE011 + Everolimus + Exemestane'}]",Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. (TRINITI-1),2265
0,NCT01857193,Phase Ib/II,Recruiting,"[{'id': 2265, 'therapyName': 'LEE011 + Everolimus + Exemestane'}, {'id': 1966, 'therapyName': 'Exemestane + Everolimus'}, {'id': 2266, 'therapyName': 'LEE011 + Exemestane'}]",Phase Ib/II Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of ER+ Her2- Advanced Breast Cancer,2266
0,NCT03050398,Phase III,Recruiting,"[{'id': 1568, 'therapyName': 'LEE011 + Letrozole'}]",A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib,1568
1,NCT01872260,Phase Ib/II,Recruiting,"[{'id': 1553, 'therapyName': 'Letrozole + BYL719'}, {'id': 1569, 'therapyName': 'LEE011 + BYL719 + Letrozole'}, {'id': 1568, 'therapyName': 'LEE011 + Letrozole'}]","Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer",1568
2,NCT02657928,Phase II,Recruiting,"[{'id': 1568, 'therapyName': 'LEE011 + Letrozole'}]","Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal or Endometrial Cancer",1568
3,NCT02712723,Phase II,Recruiting,"[{'id': 1568, 'therapyName': 'LEE011 + Letrozole'}]","Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer",1568
0,NCT01218555,Phase I,"Active, not recruiting","[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 735, 'therapyName': 'Everolimus'}]",Study of Everolimus (RAD001)in Combination With Lenalidomide,1164
1,NCT01604031,Phase Ib/II,Terminated,"[{'id': 1164, 'therapyName': 'lenalidomide'}]",Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide,1164
2,NCT01954784,Phase I,Terminated,"[{'id': 3434, 'therapyName': 'Bortezomib + Cyclosporine + Mycophenolate'}, {'id': 1164, 'therapyName': 'lenalidomide'}]",Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma,1164
3,NCT02589145,Phase Ib/II,Recruiting,"[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 3278, 'therapyName': 'Enoxaparin'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}]",Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype,1164
4,NCT01827137,Phase I,"Active, not recruiting","[{'id': 2893, 'therapyName': 'WT1 vaccine'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1873, 'therapyName': 'Sargramostim'}]",WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation,1164
5,NCT03004287,Phase II,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy,1164
6,NCT01216683,Phase II,Unknown status,"[{'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1164, 'therapyName': 'lenalidomide'}]","Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma",1164
7,NCT02265510,Phase I,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2747, 'therapyName': 'INCB052793'}, {'id': 688, 'therapyName': 'Bortezomib'}]","An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies",1164
8,NCT02431208,Phase I,Suspended,"[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of Atezolizumab (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) Administered With or Without Lenalidomide in Participants With Multiple Myeloma (MM),1164
9,NCT02331368,Phase II,"Active, not recruiting","[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma,1164
10,NCT02579863,Phase III,Suspended,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}]",Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185),1164
11,NCT01459211,Phase II,Completed,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}]",Pilot Study to Establish Safety and Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL),1164
12,NCT01729091,Phase Ib/II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3343, 'therapyName': 'Elotuzumab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1164, 'therapyName': 'lenalidomide'}]",Study of Umbilical Cord Blood-derived Natural Killer Cells in Conjunction With High Dose Chemotherapy and Autologous Stem Cell Transplant for Patients With Multiple Myeloma,1164
13,NCT02030483,Phase I,Terminated,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}]",Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma,1164
14,NCT01863550,Phase III,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,1164
15,NCT01919086,Phase II,"Active, not recruiting","[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}]",Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma,1164
16,NCT01415752,Phase II,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1164, 'therapyName': 'lenalidomide'}]","Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",1164
17,NCT01998971,Phase I,Recruiting,"[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1475, 'therapyName': 'Thalidomide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 3323, 'therapyName': 'Montelukast'}]",A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma,1164
18,NCT01556776,Phase III,Terminated,"[{'id': 1164, 'therapyName': 'lenalidomide'}]",A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy,1164
19,NCT02126553,Phase II,Recruiting,"[{'id': 1164, 'therapyName': 'lenalidomide'}]",Lenalidomide Maintenance With High Risk (HR) Acute Myeloid Leukemia (AML) in Remission,1164
0,NCT01619761,Phase I,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1847, 'therapyName': 'lenalidomide + Fludarabine + Melphalan'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1843, 'therapyName': 'Tacrolimus'}]",Natural Killer (NK) Cells in Cord Blood Transplantation,1847
0,NCT03011814,Phase Ib/II,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3934, 'therapyName': 'lenalidomide + MEDI4736'}]",Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma,3934
1,NCT02685826,Phase I,Suspended,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3934, 'therapyName': 'lenalidomide + MEDI4736'}]",A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Subjects With Newly Diagnosed Multiple Myeloma,3934
0,NCT02733042,Phase Ib/II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 4278, 'therapyName': 'lenalidomide + MEDI4736 + Rituximab'}, {'id': 4279, 'therapyName': 'Bendamustine + MEDI4736 + Rituximab'}, {'id': 2573, 'therapyName': 'Ibrutinib + MEDI4736'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia (FUSION NHL 001)",4278
0,NCT02399085,Phase II,Recruiting,"[{'id': 5843, 'therapyName': 'Lenalidomide + MOR208'}]",A Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL,5843
1,NCT02005289,Phase II,Recruiting,"[{'id': 5843, 'therapyName': 'Lenalidomide + MOR208'}, {'id': 5847, 'therapyName': 'Ibrutinib + MOR208'}]","Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL",5843
0,NCT03015896,Phase Ib/II,Suspended,"[{'id': 5239, 'therapyName': 'Lenalidomide + Nivolumab'}]",Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma,5239
0,NCT03269669,Phase II,Recruiting,"[{'id': 6257, 'therapyName': 'Obinutuzumab + CHOP'}, {'id': 6302, 'therapyName': 'Lenalidomide + Obinutuzumab\t'}, {'id': 6301, 'therapyName': 'Obinutuzumab + TGR-1202'}, {'id': 2188, 'therapyName': 'Prednisone'}]","Obinutuzumab With or Without PI3K-delta Inhibitor TGR-1202, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma",6302
0,NCT02600897,Phase Ib/II,Recruiting,"[{'id': 4394, 'therapyName': 'lenalidomide + Obinutuzumab + Polatuzumab Vedotin'}]","A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",4394
0,NCT02992522,Phase I,Recruiting,"[{'id': 5133, 'therapyName': 'Lenalidomide + Obinutuzumab + Venetoclax'}]","Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",5133
0,NCT02875067,Phase Ib/II,Recruiting,"[{'id': 3322, 'therapyName': 'lenalidomide + Pembrolizumab'}]","Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma",3322
1,NCT02963610,Phase Ib/II,Recruiting,"[{'id': 3322, 'therapyName': 'lenalidomide + Pembrolizumab'}]",Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer,3322
2,NCT02036502,Phase I,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3322, 'therapyName': 'lenalidomide + Pembrolizumab'}]",A Study of Pembrolizumab (MK-3475) in Combination With Lenalidomide and Dexamethasone in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023),3322
0,NCT02077959,Phase Ib/II,"Active, not recruiting","[{'id': 3357, 'therapyName': 'lenalidomide + Pidilizumab'}]",Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma,3357
0,NCT02281279,Phase Ib/II,Withdrawn,"[{'id': 2349, 'therapyName': 'Lenalidomide + Rituximab + Romidepsin '}]","Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma",2349
0,NCT02086552,Phase II,Recruiting,"[{'id': 4445, 'therapyName': 'lenalidomide + Sonidegib'}]",Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma,4445
0,NCT02954406,Phase I,Recruiting,"[{'id': 5150, 'therapyName': 'Lenalidomide + TAK-659'}, {'id': 5149, 'therapyName': 'Ibrutinib + TAK-659'}, {'id': 5148, 'therapyName': 'Gemcitabine + TAK-659'}, {'id': 5147, 'therapyName': 'Bendamustine + Rituximab + TAK-659'}, {'id': 5146, 'therapyName': 'Bendamustine + TAK-659'}]","A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma",5150
0,NCT03050450,Phase I,Recruiting,"[{'id': 5337, 'therapyName': 'Lenalidomide + Vorinostat'}]",Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors,5337
0,NCT02846766,Phase II,Not yet recruiting,"[{'id': 792, 'therapyName': 'Lenvatinib'}]",Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling,792
1,NCT02780310,Phase II,"Active, not recruiting","[{'id': 792, 'therapyName': 'Lenvatinib'}]",Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma,792
2,NCT01433991,Phase Ib/II,"Active, not recruiting","[{'id': 1019, 'therapyName': 'Golvatinib'}, {'id': 792, 'therapyName': 'Lenvatinib'}]",E7050 in Combination With E7080 in Subjects With Advanced Solid Tumors (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2),792
3,NCT02501096,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 792, 'therapyName': 'Lenvatinib'}]",Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors,792
4,NCT01877083,Phase II,"Active, not recruiting","[{'id': 792, 'therapyName': 'Lenvatinib'}]",Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung,792
5,NCT01761266,Phase III,"Active, not recruiting","[{'id': 792, 'therapyName': 'Lenvatinib'}, {'id': 920, 'therapyName': 'Sorafenib'}]","A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma",792
6,NCT02211222,Phase I,Approved for marketing,"[{'id': 792, 'therapyName': 'Lenvatinib'}]",An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer,792
7,NCT02432274,Phase Ib/II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 792, 'therapyName': 'Lenvatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies,792
8,NCT02657369,Phase II,Recruiting,"[{'id': 792, 'therapyName': 'Lenvatinib'}]",A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC),792
9,NCT03008369,Phase II,Recruiting,"[{'id': 792, 'therapyName': 'Lenvatinib'}]",Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery,792
10,NCT02702388,Phase II,Recruiting,"[{'id': 792, 'therapyName': 'Lenvatinib'}]","Phase 2 Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 20 mg or 14 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile",792
0,NCT02686164,Phase I,"Active, not recruiting","[{'id': 3730, 'therapyName': 'Lenvatinib + Midazolam'}]",Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors,3730
0,NCT02788708,Phase I,Recruiting,"[{'id': 4236, 'therapyName': 'Lenvatinib + Paclitaxel'}]",Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer,4236
0,NCT02973997,Phase II,Not yet recruiting,"[{'id': 4782, 'therapyName': 'Lenvatinib + Pembrolizumab'}]",Pembrolizumab and Lenvatinib in Treating Metastatic or Recurrent Differentiated Thyroid Cancer That Cannot Be Removed by Surgery,4782
1,NCT02811861,Phase III,Recruiting,"[{'id': 1713, 'therapyName': 'Everolimus + Lenvatinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 4782, 'therapyName': 'Lenvatinib + Pembrolizumab'}]",Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma,4782
2,NCT03006926,Phase I,Recruiting,"[{'id': 4782, 'therapyName': 'Lenvatinib + Pembrolizumab'}]",A Trial of Lenvatinib Plus Pembrolizumab in Subjects With Hepatocellular Carcinoma,4782
0,NCT02450175,Phase I,Unknown status,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 735, 'therapyName': 'Everolimus'}]","Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls",794
1,NCT01674140,Phase III,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}]",S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,794
2,NCT01296555,Phase I,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1016, 'therapyName': 'GDC-0032'}, {'id': 794, 'therapyName': 'Letrozole'}]",A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors And in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer,794
3,NCT02278120,Phase III,"Active, not recruiting","[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 790, 'therapyName': 'Ribociclib'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 633, 'therapyName': 'Anastrozole'}]","Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer",794
4,NCT01923168,Phase II,Completed,"[{'id': 1570, 'therapyName': 'BKM120 + Letrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 1553, 'therapyName': 'Letrozole + BYL719'}]","Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women",794
5,NCT02619669,Phase I,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}, {'id': 794, 'therapyName': 'Letrozole'}]",Neoadjuvant Run-In Study With TAK-228 (MLN0128) Followed by Letrozole/TAK-228 (MLN0128) in Women With High-Risk ER+/HER2- Breast Cancer,794
6,NCT01669343,Phase I,"Active, not recruiting","[{'id': 794, 'therapyName': 'Letrozole'}]",Aromatase Inhibitor Host Factors Study,794
7,NCT02296801,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 794, 'therapyName': 'Letrozole'}]",A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer,794
8,NCT02115048,Phase II,"Active, not recruiting","[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 794, 'therapyName': 'Letrozole'}]",Clinical Study for the Treatment of Breast Cancer the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone,794
9,NCT02188745,Phase II,Recruiting,"[{'id': 738, 'therapyName': 'Exemestane'}, {'id': 1643, 'therapyName': 'Estradiol'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}]",ER Reactivation Therapy for Breast Cancer,794
10,NCT01035099,Phase I,Recruiting,"[{'id': 794, 'therapyName': 'Letrozole'}]",RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF,794
11,NCT02204098,Phase I,Recruiting,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]",Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy,794
12,NCT01491737,Phase II,"Active, not recruiting","[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]","A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer",794
13,NCT01272037,Phase III,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}]","Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",794
14,NCT02095184,Phase I,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}]",GCC 1366 Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients,794
15,NCT02764541,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]",Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS),794
16,NCT01797523,Phase II,"Active, not recruiting","[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1031, 'therapyName': 'Metformin'}]",RAD/Letrozole/Metformin,794
17,NCT00651976,Phase I,Suspended,"[{'id': 794, 'therapyName': 'Letrozole'}]","Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery",794
18,NCT01160211,Phase III,"Active, not recruiting","[{'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 738, 'therapyName': 'Exemestane'}]","A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer",794
19,NCT02648477,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer,794
20,NCT02689921,Phase II,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 738, 'therapyName': 'Exemestane'}]",NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (NEOADAPT),794
21,NCT00461773,Phase II,Unknown status,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer,794
22,NCT02753686,Phase I,Recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 1966, 'therapyName': 'Exemestane + Everolimus'}]",Treatment of Canadian Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy (Treat ER+ight),794
23,NCT02269670,Phase II,"Active, not recruiting","[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1869, 'therapyName': 'Megestrol'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 633, 'therapyName': 'Anastrozole'}]",Everolimus and Hormone Therapy in Treating Patients With Advanced Hormone Receptor Positive Breast Cancer That Has Progressed or Recurred on Everolimus and Exemestane Therapy,794
24,NCT03122197,Phase I,Recruiting,"[{'id': 794, 'therapyName': 'Letrozole'}]",Study of Letrozole in Recurrent Gliomas,794
25,NCT02947685,Phase III,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 947, 'therapyName': 'Trastuzumab'}]","Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (PATINA)",794
26,NCT02684032,Phase I,Recruiting,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 4034, 'therapyName': 'Gedatolisib + Palbociclib'}]",A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer,794
27,NCT02040857,Phase II,"Active, not recruiting","[{'id': 738, 'therapyName': 'Exemestane'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}]",Palbociclib + Endocrine Therapy for HR + BrCa,794
28,NCT02520063,Phase Ib/II,Recruiting,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 1242, 'therapyName': 'TRC105'}, {'id': 735, 'therapyName': 'Everolimus'}]","Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer",794
29,NCT01958021,Phase III,"Active, not recruiting","[{'id': 790, 'therapyName': 'Ribociclib'}, {'id': 794, 'therapyName': 'Letrozole'}]",Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2),794
30,NCT03238703,FDA approved,Not yet recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}]","Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer",794
31,NCT02010021,Phase I,"Active, not recruiting","[{'id': 794, 'therapyName': 'Letrozole'}]",Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer.,794
0,NCT01870505,Phase I,"Active, not recruiting","[{'id': 2318, 'therapyName': 'BYL719 + Exemestane'}, {'id': 1553, 'therapyName': 'Letrozole + BYL719'}]",BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer,1553
1,NCT01872260,Phase Ib/II,Recruiting,"[{'id': 1553, 'therapyName': 'Letrozole + BYL719'}, {'id': 1569, 'therapyName': 'LEE011 + BYL719 + Letrozole'}, {'id': 1568, 'therapyName': 'LEE011 + Letrozole'}]","Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer",1553
2,NCT03056755,Phase II,Recruiting,"[{'id': 5929, 'therapyName': 'Alpelisib + Fulvestrant'}, {'id': 1553, 'therapyName': 'Letrozole + BYL719'}]","Efficacy and Safety of Treatment With Alpelisib Plus Endocrine Therapy in Patients With HR+, HER2-negative aBC, With PIK3CA Mutations, Whose Disease Has Progressed on or After CDK 4/6 Treatment With an Aromatase Inhibitor (AI) or Fulvestrant",1553
3,NCT01791478,Phase I,"Active, not recruiting","[{'id': 1553, 'therapyName': 'Letrozole + BYL719'}]",BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer,1553
4,NCT01923168,Phase II,Completed,"[{'id': 1570, 'therapyName': 'BKM120 + Letrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 1553, 'therapyName': 'Letrozole + BYL719'}]","Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women",1553
0,NCT02778685,Phase II,Recruiting,"[{'id': 4222, 'therapyName': 'Letrozole + Palbociclib + Pembrolizumab'}]","Pembrolizumab, Letrozole, and Palbociclib in Treating Patients With Stage IV Estrogen Receptor Positive Breast Cancer With Stable Disease That Has Not Responded to Letrozole and Palbociclib",4222
0,NCT02907918,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 4756, 'therapyName': 'Letrozole + Palbociclib + Trastuzumab'}]",Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer (PALTAN),4756
0,NCT02138617,Phase II,Recruiting,"[{'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1715, 'therapyName': 'Fluorouracil'}]",Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer,1642
1,NCT01535053,Phase III,"Active, not recruiting","[{'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Methotrexate or Dactinomycin in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia,1642
2,NCT03136406,Phase Ib/II,Recruiting,"[{'id': 1018, 'therapyName': 'GI-4000'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 6163, 'therapyName': 'ETBX-011'}, {'id': 3060, 'therapyName': 'ALT-803'}]",QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy,1642
3,NCT03007147,Phase III,Recruiting,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 5167, 'therapyName': 'Methylprednisolone'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 5168, 'therapyName': 'Prednisolone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,1642
4,NCT02883049,Phase III,Suspended,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations,1642
5,NCT01424982,Phase II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 2048, 'therapyName': 'Cytarabine + Methotrexate + Ponatinib'}, {'id': 2049, 'therapyName': 'Ponatinib + Vincristine'}, {'id': 2046, 'therapyName': 'Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine '}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),1642
6,NCT02723994,Phase II,Recruiting,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 2346, 'therapyName': 'Mercaptopurine + Thioguanine'}, {'id': 2394, 'therapyName': 'Asparaginase + Cytarabine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}]",A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia,1642
7,NCT02620423,Phase I,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 893, 'therapyName': 'Reolysin'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab With REOLYSIN and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma,1642
8,NCT01256398,Phase II,"Active, not recruiting","[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1824, 'therapyName': 'Vincristine + Methotrexate + Mercaptopurine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,1642
9,NCT01775501,Phase II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Sorafenib + mFOLFOX for Hepatocellular Carcinoma,1642
10,NCT01467115,Phase II,Completed,"[{'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1930, 'therapyName': 'Cisplatin + Docetaxel + Fluorouracil'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 694, 'therapyName': 'Cetuximab'}]",INDUCTION CHEMOTHERAPY FOLLOWED BY CETUXIMAB AND RADIATION THERAPY FOR HEAD AND NECK CANCER,1642
11,NCT02112916,Phase III,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,1642
12,NCT02043587,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia &amp; Lymphoblastic Lymphoma,1642
13,NCT02427620,Phase II,Recruiting,"[{'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 1642, 'therapyName': 'Leucovorin'}]",A Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma,1642
14,NCT00267865,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma,1642
15,NCT00293475,Phase Ib/II,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 2669, 'therapyName': 'Carboplatin + Methotrexate + Rituximab'}]",Rituximab and Methotrexate Chemotherapy w/Blood-Brain Barrier Disruption (BBBD) &amp; Sodium Thiosulfate Chemoprotection for Patients With Newly Diagnosed PCNSL,1642
16,NCT00550992,Phase I,Unknown status,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia,1642
17,NCT02553460,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I,1642
18,NCT03020030,Phase III,Recruiting,"[{'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents,1642
0,NCT02101853,Phase III,Recruiting,"[{'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 2347, 'therapyName': 'Leucovorin + Pegaspargase  + Vincristine'}, {'id': 2346, 'therapyName': 'Mercaptopurine + Thioguanine'}, {'id': 2348, 'therapyName': 'Asparaginase + Cyclophosphamide + Etoposide'}, {'id': 2345, 'therapyName': 'Cytarabine + Dexamethasone+ Methotrexate '}]",Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia,2347
0,NCT02268175,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate,795
1,NCT02366494,Phase I,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Micro RNAs to Predict Response to Androgen Deprivation Therapy,795
2,NCT01717053,Phase II,"Active, not recruiting","[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 759, 'therapyName': 'Goserelin'}]","Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer",795
3,NCT00936390,Phase III,"Active, not recruiting","[{'id': 742, 'therapyName': 'Flutamide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,795
4,NCT02064582,Phase II,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]","Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer",795
5,NCT00223665,Phase II,Unknown status,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 742, 'therapyName': 'Flutamide'}]",Intermittent Hormone Therapy in Men With Localized Prostate Cancer After Radiation Therapy or Radical Prostatectomy,795
6,NCT01674140,Phase III,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}]",S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,795
7,NCT02064036,Phase I,Recruiting,"[{'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate,795
8,NCT02811809,Phase II,Not yet recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 4207, 'therapyName': 'ARN-509 + Leuprolide'}]",Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer,795
9,NCT02472275,Phase I,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 874, 'therapyName': 'PLX3397'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 1814, 'therapyName': 'Degarelix'}]","PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer",795
10,NCT02736435,Phase III,Not yet recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}]",Treatment of Uterine Fibroids With Magnetic Resonance Guided High Intensity Focused Ultrasound,795
11,NCT03085095,Phase III,Recruiting,"[{'id': 5492, 'therapyName': 'Relugolix'}, {'id': 795, 'therapyName': 'Leuprolide'}]",A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer (HERO),795
12,NCT02023463,Phase I,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 795, 'therapyName': 'Leuprolide'}]","Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer",795
13,NCT02058706,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 795, 'therapyName': 'Leuprolide'}]",LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer,795
14,NCT02685397,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Management of Castration-Resistant Prostate Cancer With Oligometastases,795
15,NCT02663908,Phase III,Recruiting,"[{'id': 1814, 'therapyName': 'Degarelix'}, {'id': 795, 'therapyName': 'Leuprolide'}]",A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease,795
16,NCT02234115,Phase III,Completed,"[{'id': 795, 'therapyName': 'Leuprolide'}]","Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma",795
17,NCT03093272,Phase II,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 5521, 'therapyName': 'ARN-509 + Docetaxel'}]",A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer,795
18,NCT03261999,Phase III,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}]","Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer",795
19,NCT00541047,Phase III,"Active, not recruiting","[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS),795
20,NCT02689921,Phase II,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 738, 'therapyName': 'Exemestane'}]",NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (NEOADAPT),795
21,NCT02278185,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1814, 'therapyName': 'Degarelix'}, {'id': 2047, 'therapyName': 'Histrelin acetate'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer,795
22,NCT02319837,Phase III,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK),795
23,NCT02346253,Phase Ib/II,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 1814, 'therapyName': 'Degarelix'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 759, 'therapyName': 'Goserelin'}]",High-Dose Brachytherapy in Treating Patients With Prostate Cancer,795
24,NCT01746849,Phase II,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 2373, 'therapyName': 'Palifermin'}]",Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation,795
25,NCT01338987,Phase II,"Active, not recruiting","[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Pilot Study of Lupron to Improve Immune Function After Allogeneic Bone Marrow Transplantation,795
26,NCT02057939,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM),795
27,NCT02059213,Phase II,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 795, 'therapyName': 'Leuprolide'}]", A Phase II Study of Androgen Deprivation Therapy With or Without PD 0332991 in RB-Positive Metastatic Prostate Cancer,795
28,NCT01786265,Phase II,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1814, 'therapyName': 'Degarelix'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone,795
29,NCT03279250,Phase II,Not yet recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1947, 'therapyName': 'ARN-509'}]",Effects of Apalutamide Plus LHRH Agonist or Apalutamide Plus Abiraterone Acetate Plus LHRH Agonist for Six Months for Prostate Cancer Patients at High Risk for Recurrence,795
0,NCT01857934,Phase II,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 2627, 'therapyName': 'Levetiracetam'}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 2458, 'therapyName': 'Hu14.18K322A'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}]",Therapy for Children With Advanced Stage Neuroblastoma,2627
0,NCT02144038,Phase Ib/II,Completed,"[{'id': 2419, 'therapyName': 'BYL719 + LGH447'}, {'id': 2402, 'therapyName': 'LGH447 '}]",Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma,2402
1,NCT01456689,Phase I,"Active, not recruiting","[{'id': 2685, 'therapyName': 'Midazolam'}, {'id': 2402, 'therapyName': 'LGH447 '}]",A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma,2402
2,NCT02078609,Phase I,Recruiting,"[{'id': 2402, 'therapyName': 'LGH447 '}]",A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS),2402
0,NCT02649530,Phase II,Withdrawn,"[{'id': 1937, 'therapyName': 'LGK974'}]","An Open Label, Non-randomized Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma",1937
1,NCT01351103,Phase I,Recruiting,"[{'id': 1937, 'therapyName': 'LGK974'}]",A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands,1937
0,NCT02278133,Phase Ib/II,Completed,"[{'id': 2008, 'therapyName': 'LGK974 + LGX818 + Cetuximab'}]",Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations,2008
0,NCT01719380,Phase Ib/II,"Active, not recruiting","[{'id': 1916, 'therapyName': 'Cetuximab + Encorafenib'}, {'id': 1917, 'therapyName': 'LGX818 + Cetuximab + BYL719'}]","Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer",1917
0,NCT02159066,Phase II,"Active, not recruiting","[{'id': 1101, 'therapyName': 'Binimetinib + Encorafenib + Ribociclib'}, {'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}, {'id': 2216, 'therapyName': 'LGX818 + MEK162 + INC280'}, {'id': 2215, 'therapyName': 'LGX818 + MEK162 + BKM120'}, {'id': 2214, 'therapyName': 'LGX818 + MEK162 + BGJ398'}]","LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma",2214
0,NCT02159066,Phase II,"Active, not recruiting","[{'id': 1101, 'therapyName': 'Binimetinib + Encorafenib + Ribociclib'}, {'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}, {'id': 2216, 'therapyName': 'LGX818 + MEK162 + INC280'}, {'id': 2215, 'therapyName': 'LGX818 + MEK162 + BKM120'}, {'id': 2214, 'therapyName': 'LGX818 + MEK162 + BGJ398'}]","LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma",2215
0,NCT02159066,Phase II,"Active, not recruiting","[{'id': 1101, 'therapyName': 'Binimetinib + Encorafenib + Ribociclib'}, {'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}, {'id': 2216, 'therapyName': 'LGX818 + MEK162 + INC280'}, {'id': 2215, 'therapyName': 'LGX818 + MEK162 + BKM120'}, {'id': 2214, 'therapyName': 'LGX818 + MEK162 + BGJ398'}]","LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma",2216
0,NCT03301896,Phase I,Not yet recruiting,"[{'id': 6299, 'therapyName': 'LHC165 + PDR001'}, {'id': 6298, 'therapyName': 'LHC165'}]",Phase I/Ib Study of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies,6298
0,NCT03301896,Phase I,Not yet recruiting,"[{'id': 6299, 'therapyName': 'LHC165 + PDR001'}, {'id': 6298, 'therapyName': 'LHC165'}]",Phase I/Ib Study of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies,6299
0,NCT01672736,Phase Ib/II,"Active, not recruiting","[{'id': 1831, 'therapyName': 'Linsitinib + Bortezomib + Dexamethasone'}]",A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma,1831
0,NCT01182285,Phase II,Completed,"[{'id': 2674, 'therapyName': 'liothyronine sodium  '}, {'id': 1076, 'therapyName': 'Valproic acid'}]",A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin,2674
0,NCT02252263,Phase I,"Active, not recruiting","[{'id': 2055, 'therapyName': 'Urelumab'}, {'id': 2583, 'therapyName': 'Lirilumab '}, {'id': 3343, 'therapyName': 'Elotuzumab'}]",A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma,2583
1,NCT01592370,Phase I,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2583, 'therapyName': 'Lirilumab '}]",Safety Study in Nivolumab Alone and in Combination With Ipilimumab or Lirilumab in Lymphoma and Multiple Myeloma,2583
2,NCT02599649,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2583, 'therapyName': 'Lirilumab '}]",Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS),2583
0,NCT01714739,Phase I,Recruiting,"[{'id': 2584, 'therapyName': 'Lirilumab + Nivolumab'}]",A Phase I Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors,2584
0,NCT01602406,Phase I,Completed,"[{'id': 2037, 'therapyName': 'LJM716 + Trastuzumab'}]",Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer,2037
0,NCT03030417,Phase I,Recruiting,"[{'id': 5749, 'therapyName': 'LMP744'}]",Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas,5749
0,NCT02343406,Phase II,Recruiting,"[{'id': 2075, 'therapyName': 'Lomustine'}, {'id': 976, 'therapyName': 'ABT-414'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma,2075
1,NCT02414165,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 3211, 'therapyName': 'Toca 511 + Toca FC'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA (Toca5),2075
2,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,2075
3,NCT01989052,Phase Ib/II,Terminated,"[{'id': 2075, 'therapyName': 'Lomustine'}, {'id': 999, 'therapyName': 'Carboxyamidotriazole Orotate'}]",Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma,2075
4,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,2075
5,NCT01860638,Phase III,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2075, 'therapyName': 'Lomustine'}]",A Comparison of Continuous Avastin (Bevacizumab) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Patients With Glioblastoma,2075
0,NCT02126579,Phase Ib/II,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 3009, 'therapyName': 'Long peptide vaccine 7'}]",Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists,3009
0,NCT03094052,Phase II,Recruiting,"[{'id': 828, 'therapyName': 'Neratinib'}, {'id': 2700, 'therapyName': 'Loperamide'}, {'id': 5906, 'therapyName': 'Crofelemer'}, {'id': 4359, 'therapyName': 'Neratinib + Trastuzumab'}]","Diarrhea Prophylaxis in Patients With HER2+ Breast Cancer Treated With Trastuzumab and Neratinib, Followed by Neratinib Monotherapy",2700
1,NCT02441946,Phase II,Completed,"[{'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 2700, 'therapyName': 'Loperamide'}, {'id': 633, 'therapyName': 'Anastrozole'}]","A Phase 2 Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer",2700
0,NCT01821729,Phase II,Recruiting,"[{'id': 1903, 'therapyName': 'FOLFIRINOX'}, {'id': 2998, 'therapyName': 'Losartan'}]",Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer,2998
0,NCT03155620,Phase II,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}, {'id': 2650, 'therapyName': 'LOXO-101'}, {'id': 1069, 'therapyName': 'LY3023414'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 913, 'therapyName': 'Selumetinib'}, {'id': 961, 'therapyName': 'X-396'}]",Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Advanced Refractory Solid Tumors or Lymphomas,2650
1,NCT02122913,Phase I,Recruiting,"[{'id': 2650, 'therapyName': 'LOXO-101'}]",Oral TRK Inhibitor LOXO-101 for Treatment of Advanced Adult Solid Tumors,2650
2,NCT02576431,Phase II,Recruiting,"[{'id': 2650, 'therapyName': 'LOXO-101'}]",Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors,2650
3,NCT02637687,Phase I,Recruiting,"[{'id': 2650, 'therapyName': 'LOXO-101'}]",Oral TRK Inhibitor LOXO-101 for Treatment of Advanced Pediatric Solid or Primary Central Nervous System Tumors,2650
4,NCT03213704,Phase II,Recruiting,"[{'id': 2650, 'therapyName': 'LOXO-101'}]","Pediatric MATCH: Trk Inhibitor LOXO-101 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions",2650
0,NCT03215511,Phase Ib/II,Recruiting,"[{'id': 5917, 'therapyName': 'LOXO-195'}]",Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusions or Non-fusion NTRK Cancers,5917
0,NCT03157128,Phase I,Recruiting,"[{'id': 5702, 'therapyName': 'LOXO-292'}]","Phase 1 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET-Fusion Lung Cancer and Medullary Thyroid Cancer",5702
0,NCT02734615,Phase I,Recruiting,"[{'id': 4441, 'therapyName': 'Alpelisib + LSZ 102'}, {'id': 4440, 'therapyName': 'LSZ 102 + Ribociclib'}, {'id': 4439, 'therapyName': 'LSZ 102'}]",Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers,4439
0,NCT02734615,Phase I,Recruiting,"[{'id': 4441, 'therapyName': 'Alpelisib + LSZ 102'}, {'id': 4440, 'therapyName': 'LSZ 102 + Ribociclib'}, {'id': 4439, 'therapyName': 'LSZ 102'}]",Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers,4440
0,NCT01283945,Phase Ib/II,Completed,"[{'id': 1029, 'therapyName': 'Lucitanib'}]","Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors",1029
1,NCT02202746,Phase II,"Active, not recruiting","[{'id': 1029, 'therapyName': 'Lucitanib'}]","A Study to Assess the Safety and Efficacy of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With FGF Aberrant Metastatic Breast Cancer",1029
2,NCT02747797,Phase II,Withdrawn,"[{'id': 1029, 'therapyName': 'Lucitanib'}]","Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations",1029
3,NCT02053636,Phase II,Completed,"[{'id': 1029, 'therapyName': 'Lucitanib'}]",A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer,1029
4,NCT02109016,Phase II,Completed,"[{'id': 1029, 'therapyName': 'Lucitanib'}]","A Study to Assess the Efficacy of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With FGFR1-driven Lung Cancer",1029
0,NCT01405391,Phase I,Completed,"[{'id': 1195, 'therapyName': 'Lurbinectedin'}]",Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks,1195
1,NCT01525589,Phase II,Recruiting,"[{'id': 1195, 'therapyName': 'Lurbinectedin'}]",A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer,1195
2,NCT02454972,Phase II,Recruiting,"[{'id': 1195, 'therapyName': 'Lurbinectedin'}]",Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors,1195
0,NCT01831089,Phase I,Completed,"[{'id': 1196, 'therapyName': 'Lurbinectedin + Paclitaxel + Bevacizumab'}, {'id': 1197, 'therapyName': 'Lurbinectedin + Paclitaxel'}]","Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors",1197
0,NCT01831089,Phase I,Completed,"[{'id': 1196, 'therapyName': 'Lurbinectedin + Paclitaxel + Bevacizumab'}, {'id': 1197, 'therapyName': 'Lurbinectedin + Paclitaxel'}]","Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors",1196
0,NCT02607813,Phase I,Recruiting,"[{'id': 4443, 'therapyName': 'LXH 254 + PDR001'}, {'id': 4442, 'therapyName': 'LXH 254'}]",Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations,4442
0,NCT02607813,Phase I,Recruiting,"[{'id': 4443, 'therapyName': 'LXH 254 + PDR001'}, {'id': 4442, 'therapyName': 'LXH 254'}]",Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations,4443
0,NCT02737072,Phase I,"Active, not recruiting","[{'id': 4210, 'therapyName': 'LY2510924 + MEDI4736'}]",A Study of LY2510924 and Durvalumab in Participants With Solid Tumors,4210
0,NCT02711553,Phase II,"Active, not recruiting","[{'id': 886, 'therapyName': 'Ramucirumab'}, {'id': 1030, 'therapyName': 'LY2801653'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer,1030
1,NCT01285037,Phase I,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1030, 'therapyName': 'LY2801653'}]",A Study of LY2801653 in Advanced Cancer,1030
2,NCT02920996,Phase II,Recruiting,"[{'id': 1030, 'therapyName': 'LY2801653'}]",Merestinib In Non-Small Cell Lung Cancer And Solid Tumors,1030
0,NCT03125239,Phase I,Recruiting,"[{'id': 5744, 'therapyName': 'LY2801653 + LY2874455'}]",Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia,5744
0,NCT02745769,Phase I,Recruiting,"[{'id': 4208, 'therapyName': 'LY2801653 + Ramucirumab'}, {'id': 4209, 'therapyName': 'Abemaciclib + Ramucirumab'}]",A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents,4208
0,NCT02632448,Phase Ib/II,Recruiting,"[{'id': 4420, 'therapyName': 'LY2880070 + Gemcitabine'}, {'id': 4315, 'therapyName': 'LY2880070'}]",A Study of LY2880070 in Patients With Advanced or Metastatic Cancer,4315
0,NCT02632448,Phase Ib/II,Recruiting,"[{'id': 4420, 'therapyName': 'LY2880070 + Gemcitabine'}, {'id': 4315, 'therapyName': 'LY2880070'}]",A Study of LY2880070 in Patients With Advanced or Metastatic Cancer,4420
0,NCT02014116,Phase I,"Active, not recruiting","[{'id': 3268, 'therapyName': 'LY3009120'}]",A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body,3268
0,NCT02265536,Phase I,Recruiting,"[{'id': 2004, 'therapyName': 'LY3022855'}]",A Study of LY3022855 In Participants With Breast or Prostate Cancer,2004
1,NCT02323191,Phase I,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 2004, 'therapyName': 'LY3022855'}]",A Study of RO5509554 and MPDL3280A Administered in Combination in Patients With Advanced Solid Tumors,2004
2,NCT01346358,Phase I,"Active, not recruiting","[{'id': 2004, 'therapyName': 'LY3022855'}]",A Study of IMC-CS4 in Subjects With Advanced Solid Tumors,2004
0,NCT02718911,Phase I,Recruiting,"[{'id': 4216, 'therapyName': 'LY3022855 + Tremelimumab'}, {'id': 4215, 'therapyName': 'LY3022855 + MEDI4736'}]",A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors,4215
0,NCT02718911,Phase I,Recruiting,"[{'id': 4216, 'therapyName': 'LY3022855 + Tremelimumab'}, {'id': 4215, 'therapyName': 'LY3022855 + MEDI4736'}]",A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors,4216
0,NCT03155620,Phase II,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}, {'id': 2650, 'therapyName': 'LOXO-101'}, {'id': 1069, 'therapyName': 'LY3023414'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 913, 'therapyName': 'Selumetinib'}, {'id': 961, 'therapyName': 'X-396'}]",Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Advanced Refractory Solid Tumors or Lymphomas,1069
1,NCT02549989,Phase II,Recruiting,"[{'id': 1069, 'therapyName': 'LY3023414'}]",Study of LY3023414 for the Treatment of Recurrent,1069
2,NCT03213678,Phase II,Recruiting,"[{'id': 1069, 'therapyName': 'LY3023414'}]","Pediatric MATCH: PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations",1069
3,NCT02079636,Phase I,Recruiting,"[{'id': 1069, 'therapyName': 'LY3023414'}, {'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC),1069
4,NCT02443337,Phase II,"Active, not recruiting","[{'id': 826, 'therapyName': 'Necitumumab'}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of LY3023414 and Necitumumab in Squamous Lung Cancer,1069
5,NCT02784795,Phase I,Recruiting,"[{'id': 4374, 'therapyName': 'Cisplatin + Gemcitabine + LY3039478'}, {'id': 4375, 'therapyName': 'Carboplatin + Gemcitabine + LY3039478'}, {'id': 4372, 'therapyName': 'LY3039478 + LY3023414'}, {'id': 4373, 'therapyName': 'Abemaciclib + LY3039478'}, {'id': 4371, 'therapyName': 'LY3039478 + Taladegib'}, {'id': 2958, 'therapyName': 'LY3039478'}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors,1069
6,NCT01655225,Phase I,Recruiting,"[{'id': 1214, 'therapyName': 'LY3023414 + Midazolam '}, {'id': 1215, 'therapyName': ' LY3023414 + Letrozole '}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of LY3023414 in Participants With Advanced Cancer,1069
7,NCT02407054,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer,1069
0,NCT01655225,Phase I,Recruiting,"[{'id': 1214, 'therapyName': 'LY3023414 + Midazolam '}, {'id': 1215, 'therapyName': ' LY3023414 + Letrozole '}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of LY3023414 in Participants With Advanced Cancer,1214
0,NCT02124148,Phase I,Recruiting,"[{'id': 1994, 'therapyName': 'Cisplatin + Prexasertib'}, {'id': 1993, 'therapyName': 'Cetuximab + Prexasertib'}, {'id': 6248, 'therapyName': 'Pemetrexed + Prexasertib'}, {'id': 6247, 'therapyName': 'LY3023414 + Prexasertib'}, {'id': 6246, 'therapyName': 'Fluoruracil + Leucovorin + Prexasertib'}]",A Study of LY2606368 With Cisplatin or Cetuximab in Participants With Advanced Cancer,6247
0,NCT02518113,Phase Ib/II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2958, 'therapyName': 'LY3039478'}]",A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL,2958
1,NCT01695005,Phase I,Recruiting,"[{'id': 2958, 'therapyName': 'LY3039478'}]",A Study of LY3039478 in Participants With Advanced Cancer,2958
2,NCT02784795,Phase I,Recruiting,"[{'id': 4374, 'therapyName': 'Cisplatin + Gemcitabine + LY3039478'}, {'id': 4375, 'therapyName': 'Carboplatin + Gemcitabine + LY3039478'}, {'id': 4372, 'therapyName': 'LY3039478 + LY3023414'}, {'id': 4373, 'therapyName': 'Abemaciclib + LY3039478'}, {'id': 4371, 'therapyName': 'LY3039478 + Taladegib'}, {'id': 2958, 'therapyName': 'LY3039478'}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors,2958
0,NCT02784795,Phase I,Recruiting,"[{'id': 4374, 'therapyName': 'Cisplatin + Gemcitabine + LY3039478'}, {'id': 4375, 'therapyName': 'Carboplatin + Gemcitabine + LY3039478'}, {'id': 4372, 'therapyName': 'LY3039478 + LY3023414'}, {'id': 4373, 'therapyName': 'Abemaciclib + LY3039478'}, {'id': 4371, 'therapyName': 'LY3039478 + Taladegib'}, {'id': 2958, 'therapyName': 'LY3039478'}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors,4372
0,NCT02784795,Phase I,Recruiting,"[{'id': 4374, 'therapyName': 'Cisplatin + Gemcitabine + LY3039478'}, {'id': 4375, 'therapyName': 'Carboplatin + Gemcitabine + LY3039478'}, {'id': 4372, 'therapyName': 'LY3039478 + LY3023414'}, {'id': 4373, 'therapyName': 'Abemaciclib + LY3039478'}, {'id': 4371, 'therapyName': 'LY3039478 + Taladegib'}, {'id': 2958, 'therapyName': 'LY3039478'}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors,4371
0,NCT02529553,Phase I,Recruiting,"[{'id': 3164, 'therapyName': 'LY3076226'}]",A Study of LY3076226 in Participants With Advanced or Metastatic Cancer,3164
0,NCT02597036,Phase I,"Active, not recruiting","[{'id': 3562, 'therapyName': 'LY3127804 '}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors,3562
0,NCT02221882,Phase I,Completed,"[{'id': 1969, 'therapyName': 'LY3164530'}]",A Study of LY3164530 in Participants With Cancer,1969
0,NCT02937272,Phase I,Recruiting,"[{'id': 5811, 'therapyName': 'LY3200882'}]",A Study of LY3200882 in Participants With Solid Tumors,5811
0,NCT02857270,Phase I,Recruiting,"[{'id': 4588, 'therapyName': 'LY3214996'}, {'id': 4590, 'therapyName': 'LY3214996 + nab-paclitaxel + Gemcitabine'}, {'id': 4589, 'therapyName': 'LY3214996 + Midazolam'}, {'id': 4591, 'therapyName': 'LY3214996 + Abemaciclib'}]",A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer,4588
0,NCT02857270,Phase I,Recruiting,"[{'id': 4588, 'therapyName': 'LY3214996'}, {'id': 4590, 'therapyName': 'LY3214996 + nab-paclitaxel + Gemcitabine'}, {'id': 4589, 'therapyName': 'LY3214996 + Midazolam'}, {'id': 4591, 'therapyName': 'LY3214996 + Abemaciclib'}]",A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer,4591
0,NCT02857270,Phase I,Recruiting,"[{'id': 4588, 'therapyName': 'LY3214996'}, {'id': 4590, 'therapyName': 'LY3214996 + nab-paclitaxel + Gemcitabine'}, {'id': 4589, 'therapyName': 'LY3214996 + Midazolam'}, {'id': 4591, 'therapyName': 'LY3214996 + Abemaciclib'}]",A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer,4589
0,NCT02857270,Phase I,Recruiting,"[{'id': 4588, 'therapyName': 'LY3214996'}, {'id': 4590, 'therapyName': 'LY3214996 + nab-paclitaxel + Gemcitabine'}, {'id': 4589, 'therapyName': 'LY3214996 + Midazolam'}, {'id': 4591, 'therapyName': 'LY3214996 + Abemaciclib'}]",A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer,4590
0,NCT02791334,Phase I,Recruiting,"[{'id': 4370, 'therapyName': 'LY3300054 + Necitumumab'}, {'id': 4369, 'therapyName': 'LY3300054 + Ramucirumab'}, {'id': 4368, 'therapyName': 'LY3300054'}]",A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors  (PACT),4368
0,NCT03099109,Phase I,Recruiting,"[{'id': 5556, 'therapyName': 'LY3321367'}, {'id': 5557, 'therapyName': 'LY3300054 + LY3321367'}]",A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors,5557
0,NCT02791334,Phase I,Recruiting,"[{'id': 4370, 'therapyName': 'LY3300054 + Necitumumab'}, {'id': 4369, 'therapyName': 'LY3300054 + Ramucirumab'}, {'id': 4368, 'therapyName': 'LY3300054'}]",A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors  (PACT),4370
0,NCT02791334,Phase I,Recruiting,"[{'id': 4370, 'therapyName': 'LY3300054 + Necitumumab'}, {'id': 4369, 'therapyName': 'LY3300054 + Ramucirumab'}, {'id': 4368, 'therapyName': 'LY3300054'}]",A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors  (PACT),4369
0,NCT03099109,Phase I,Recruiting,"[{'id': 5556, 'therapyName': 'LY3321367'}, {'id': 5557, 'therapyName': 'LY3300054 + LY3321367'}]",A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors,5556
0,NCT02929862,Phase Ib/II,Recruiting,"[{'id': 5812, 'therapyName': 'LYC-55716'}]",Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer,5812
0,NCT03286296,Phase I,Recruiting,"[{'id': 6281, 'therapyName': 'LZM009'}]",LZM009 to Treat Patients With Advanced Solid Tumors,6281
0,NCT03225105,Phase I,Recruiting,"[{'id': 6059, 'therapyName': 'M3541'}]",M3541 in Combination With Radiotherapy in Subjects With Solid Tumors,6059
0,NCT02517398,Phase I,Recruiting,"[{'id': 5860, 'therapyName': 'M7824'}]",MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors,5860
0,NCT02873819,Phase II,Recruiting,"[{'id': 4614, 'therapyName': 'MAGE-A3 vaccine'}, {'id': 4615, 'therapyName': 'Cyclophosphamide + poly ICLC  + Sargramostim'}]",Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity,4614
0,NCT02320305,Phase I,"Active, not recruiting","[{'id': 3787, 'therapyName': 'MART-1 antigen'}, {'id': 3889, 'therapyName': 'GLA-SE + MART-1 antigen'}]",MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery,3787
0,NCT01470131,Phase III,Unknown status,"[{'id': 804, 'therapyName': 'Masitinib'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}]",A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma,804
1,NCT00812240,Phase III,Unknown status,"[{'id': 804, 'therapyName': 'Masitinib'}, {'id': 770, 'therapyName': 'Imatinib'}]",A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment,804
2,NCT00814073,Phase III,Unknown status,"[{'id': 804, 'therapyName': 'Masitinib'}]","A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap",804
3,NCT02605044,Phase III,Recruiting,"[{'id': 804, 'therapyName': 'Masitinib'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",Study to Compare the Efficacy and Safety of Masitinib in Combination With FOLFIRI to Placebo in Combination With FOLFIRI in Second Line Treatment of Patients With Metastatic Colorectal Cancer,804
0,NCT02608268,Phase Ib/II,Recruiting,"[{'id': 2659, 'therapyName': 'PDR001'}, {'id': 3560, 'therapyName': 'MBG453'}]",Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies,3560
0,NCT01643850,Phase II,Recruiting,"[{'id': 2838, 'therapyName': 'MCS110'}]",MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCTTS),2838
1,NCT02435680,Phase II,"Active, not recruiting","[{'id': 2838, 'therapyName': 'MCS110'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC),2838
0,NCT02807844,Phase Ib/II,Recruiting,"[{'id': 5072, 'therapyName': 'MCS110 + PDR001'}]",Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies,5072
0,NCT02100007,Phase Ib/II,Terminated,"[{'id': 2174, 'therapyName': 'ME-344 + Topotecan'}]",ME-344 Given in Combination With Hycamtin in Patients With Solid Tumors,2174
0,NCT01837862,Phase Ib/II,Recruiting,"[{'id': 2134, 'therapyName': 'Mebendazole + Vincristine + Carboplatin + Temozolomide'}, {'id': 2133, 'therapyName': 'Mebendazole + Bevacizumab + Irinotecan'}]",A Phase I/II Study of Mebendazole for the Treatment of Pediatric Gliomas,2133
0,NCT01837862,Phase Ib/II,Recruiting,"[{'id': 2134, 'therapyName': 'Mebendazole + Vincristine + Carboplatin + Temozolomide'}, {'id': 2133, 'therapyName': 'Mebendazole + Bevacizumab + Irinotecan'}]",A Phase I/II Study of Mebendazole for the Treatment of Pediatric Gliomas,2134
0,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,4303
0,NCT01453205,Phase II,Completed,"[{'id': 2354, 'therapyName': 'Cisplatin + Cytarabine + Dexamethasone'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2407, 'therapyName': 'MEDI-551'}]","A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",2407
0,NCT02520791,Phase I,Recruiting,"[{'id': 4762, 'therapyName': 'MEDI-570'}]",Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma,4762
0,NCT02318394,Phase I,"Active, not recruiting","[{'id': 3838, 'therapyName': 'MEDI0562'}]",A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors,3838
0,NCT02705482,Phase I,Recruiting,"[{'id': 3840, 'therapyName': 'MEDI0562 + Tremelimumab'}, {'id': 3839, 'therapyName': 'MEDI0562 + MEDI4736'}]",A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors,3839
0,NCT02705482,Phase I,Recruiting,"[{'id': 3840, 'therapyName': 'MEDI0562 + Tremelimumab'}, {'id': 3839, 'therapyName': 'MEDI0562 + MEDI4736'}]",A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors,3840
1,NCT02701400,Phase II,Recruiting,"[{'id': 3840, 'therapyName': 'MEDI0562 + Tremelimumab'}]",Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer,3840
0,NCT01577745,Phase I,Completed,"[{'id': 2546, 'therapyName': 'MEDI0639'}]","A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors",2546
0,NCT02013804,Phase I,Completed,"[{'id': 3120, 'therapyName': 'MEDI0680'}]",A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies,3120
0,NCT02118337,Phase I,Recruiting,"[{'id': 3121, 'therapyName': 'MEDI0680 + MEDI4736'}]","A Phase 1, Open-label Study to Evaluate the Safety and Tolerability of MEDI0680 (AMP-514) in Combination With MEDI4736 in Subjects With Advanced Malignancies",3121
0,NCT02141542,Phase I,"Active, not recruiting","[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 1176, 'therapyName': 'MEDI3617'}]",Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma,1176
1,NCT01248949,Phase I,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1176, 'therapyName': 'MEDI3617'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors,1176
0,NCT02991911,Phase I,Recruiting,"[{'id': 5217, 'therapyName': 'Enzalutamide + MEDI3726'}, {'id': 5216, 'therapyName': 'MEDI3726'}]",A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer,5216
0,NCT03019003,Phase Ib/II,Recruiting,"[{'id': 5199, 'therapyName': 'MEDI4736 + Azacitidine + Tremelimumab'}]","A Phase IB/II Study With Azacitidine, Durvalumab, and Tremelimumab in Recurrent and/or Metastatic Head and Neck Cancer Patients",5199
0,NCT03043872,Phase III,Recruiting,"[{'id': 5305, 'therapyName': 'MEDI4736 + Tremelimumab + Carboplatin + Cisplatin + Etoposide'}, {'id': 5306, 'therapyName': 'MEDI4736 + Carboplatin + Cisplatin + Etoposide'}, {'id': 4728, 'therapyName': 'Carboplatin + Cisplatin + Etoposide'}]",Durvalumab+/- Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (Caspian),5306
0,NCT03089645,Phase I,Recruiting,"[{'id': 5588, 'therapyName': 'MEDI5083'}, {'id': 5589, 'therapyName': 'MEDI4736 + MEDI5083'}]",MEDI5083 Alone and in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors,5589
0,NCT02900157,Phase I,"Active, not recruiting","[{'id': 4727, 'therapyName': 'MEDI4736 + MEDI9090'}]",Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors,4727
0,NCT02617277,Phase I,Recruiting,"[{'id': 3414, 'therapyName': 'MEDI4736 + MK-1775'}]","Safety, Tolerability and Pharmacokinetics of AZD1775 Plus MEDI4736 in Patients With Advanced Solid Tumours",3414
0,NCT02805660,Phase Ib/II,Recruiting,"[{'id': 4378, 'therapyName': 'MEDI4736 + Mocetinostat'}]",Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC,4378
1,NCT02993991,Phase I,Not yet recruiting,"[{'id': 4378, 'therapyName': 'MEDI4736 + Mocetinostat'}]",Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity,4378
0,NCT02489448,Phase Ib/II,Recruiting,"[{'id': 3100, 'therapyName': 'MEDI4736 + nab-paclitaxel'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]",Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer,3100
0,NCT02953457,Phase Ib/II,Recruiting,"[{'id': 4949, 'therapyName': 'MEDI4736 + Olaparib + Tremelimumab'}]","Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRAC2 Mutation",4949
0,NCT02643303,Phase Ib/II,Recruiting,"[{'id': 3385, 'therapyName': 'MEDI4736 + poly ICLC '}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers",3385
0,NCT02826434,Phase I,Recruiting,"[{'id': 4466, 'therapyName': 'MEDI4736 + PVX-410 + poly ICLC '}]",Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer,4466
0,NCT03003520,Phase II,Recruiting,"[{'id': 5350, 'therapyName': 'MEDI4736 + R2-CHOP'}, {'id': 5349, 'therapyName': 'MEDI4736 + Rituximab + Doxorubicin + Vincristine + Cyclophosphamide + Prednisone'}]",A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,5350
0,NCT02572687,Phase I,Recruiting,"[{'id': 3257, 'therapyName': 'MEDI4736 + Ramucirumab'}]",A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies,3257
0,NCT03003520,Phase II,Recruiting,"[{'id': 5350, 'therapyName': 'MEDI4736 + R2-CHOP'}, {'id': 5349, 'therapyName': 'MEDI4736 + Rituximab + Doxorubicin + Vincristine + Cyclophosphamide + Prednisone'}]",A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,5349
0,NCT03004105,Phase II,Not yet recruiting,"[{'id': 3162, 'therapyName': 'MEDI4736 + Selumetinib'}]",MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC),3162
1,NCT02586987,Phase I,Recruiting,"[{'id': 3162, 'therapyName': 'MEDI4736 + Selumetinib'}]","A Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 in Patients With Advanced Solid Tumours",3162
0,NCT02764333,Phase II,Recruiting,"[{'id': 4180, 'therapyName': 'MEDI4736 + TPIV 200'}]",TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer,4180
0,NCT02649686,Phase I,"Active, not recruiting","[{'id': 4218, 'therapyName': 'MEDI4736 + Trastuzumab'}]",Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab,4218
0,NCT03043872,Phase III,Recruiting,"[{'id': 5305, 'therapyName': 'MEDI4736 + Tremelimumab + Carboplatin + Cisplatin + Etoposide'}, {'id': 5306, 'therapyName': 'MEDI4736 + Carboplatin + Cisplatin + Etoposide'}, {'id': 4728, 'therapyName': 'Carboplatin + Cisplatin + Etoposide'}]",Durvalumab+/- Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (Caspian),5305
0,NCT02898116,Phase Ib/II,Recruiting,"[{'id': 4730, 'therapyName': 'MEDI4736 + X-396'}, {'id': 961, 'therapyName': 'X-396'}]","A Study of ALK Inhibitor, Ensartinib, and Anti-PD-L1, Durvalumab, in Subjects With ALK-rearranged Non-small Cell Lung Cancer",4730
0,NCT03089645,Phase I,Recruiting,"[{'id': 5588, 'therapyName': 'MEDI5083'}, {'id': 5589, 'therapyName': 'MEDI4736 + MEDI5083'}]",MEDI5083 Alone and in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors,5588
0,NCT02221960,Phase I,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3119, 'therapyName': 'MEDI6383'}]",A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors,3119
0,NCT02559024,Phase I,"Active, not recruiting","[{'id': 1653, 'therapyName': 'MEDI6469'}]",Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer,1653
1,NCT02205333,Phase Ib/II,Terminated,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1653, 'therapyName': 'MEDI6469'}, {'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies,1653
2,NCT01862900,Phase Ib/II,"Active, not recruiting","[{'id': 1653, 'therapyName': 'MEDI6469'}]",Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions,1653
0,NCT03106428,Phase I,Recruiting,"[{'id': 5762, 'therapyName': 'MEDI7247'}]",A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies,5762
0,NCT02556463,Phase I,Recruiting,"[{'id': 5457, 'therapyName': 'MEDI9197'}, {'id': 5458, 'therapyName': 'MEDI9197 + MEDI4736'}]",A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and Palliative Radiation in Subjects With Solid Tumors,5457
0,NCT02556463,Phase I,Recruiting,"[{'id': 5457, 'therapyName': 'MEDI9197'}, {'id': 5458, 'therapyName': 'MEDI9197 + MEDI4736'}]",A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and Palliative Radiation in Subjects With Solid Tumors,5458
0,NCT02503774,Phase I,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3089, 'therapyName': 'MEDI9447'}]",MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors,3089
0,NCT03018249,Phase II,Recruiting,"[{'id': 2401, 'therapyName': 'Medroxyprogesterone'}, {'id': 5203, 'therapyName': 'Medroxyprogesterone + Entinostat'}]",Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer,2401
1,NCT02228681,Phase II,"Active, not recruiting","[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 2401, 'therapyName': 'Medroxyprogesterone'}, {'id': 1621, 'therapyName': 'Everolimus + Letrozole'}]",Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer,2401
2,NCT02335203,Phase II,"Active, not recruiting","[{'id': 2401, 'therapyName': 'Medroxyprogesterone'}]",The Effect of Neoadjuvant DMPA on Glandular Cellularity in Women Awaiting Hysterectomy,2401
0,NCT03018249,Phase II,Recruiting,"[{'id': 2401, 'therapyName': 'Medroxyprogesterone'}, {'id': 5203, 'therapyName': 'Medroxyprogesterone + Entinostat'}]",Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer,5203
0,NCT01430351,Phase I,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1784, 'therapyName': 'Memantine'}, {'id': 1031, 'therapyName': 'Metformin'}, {'id': 1785, 'therapyName': 'Mefloquine'}]","Phase I Factorial Trial of Temozolomide, Memantine, Mefloquine, and Metformin for Post-Radiation Therapy (RT) Glioblastoma Multiforme (GBM)",1785
0,NCT02269670,Phase II,"Active, not recruiting","[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1869, 'therapyName': 'Megestrol'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 633, 'therapyName': 'Anastrozole'}]",Everolimus and Hormone Therapy in Treating Patients With Advanced Hormone Receptor Positive Breast Cancer That Has Progressed or Recurred on Everolimus and Exemestane Therapy,1869
0,NCT01577173,Phase II,Completed,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 806, 'therapyName': 'MEHD7945A'}]",A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck,806
1,NCT01652482,Phase II,Completed,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 806, 'therapyName': 'MEHD7945A'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer,806
0,NCT01986166,Phase I,Completed,"[{'id': 1342, 'therapyName': 'MEHD7945A + Cobimetinib'}]",A Study of MEHD7945A and Cobimetinib (GDC-0973) in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS,1342
0,NCT01801358,Phase Ib/II,Terminated,"[{'id': 807, 'therapyName': 'Binimetinib'}, {'id': 1114, 'therapyName': 'MEK162 + AEB071'}]", A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma,1114
0,NCT02185690,Phase I,Not yet recruiting,"[{'id': 2213, 'therapyName': 'MEK162 + Carboplatin + Pemetrexed'}]","A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung",2213
0,NCT01859026,Phase I,Recruiting,"[{'id': 1253, 'therapyName': 'MEK162 + Erlotinib'}]",A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation,1253
0,NCT02041481,Phase I,"Active, not recruiting","[{'id': 2217, 'therapyName': 'MEK162 + FOLFOX'}]","MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer",2217
0,NCT01828034,Phase Ib/II,"Active, not recruiting","[{'id': 2218, 'therapyName': 'MEK162 + Gemcitabine + Cisplatin'}]","First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma",2218
0,NCT02049801,Phase I,"Active, not recruiting","[{'id': 2220, 'therapyName': 'MEK162 + Idarubicin + Cytarabine'}]","MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",2220
0,NCT01991379,Phase Ib/II,Recruiting,"[{'id': 1430, 'therapyName': 'MEK162 + Imatinib mesylate'}]",MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST),1430
0,NCT02225574,Phase Ib/II,Completed,"[{'id': 2219, 'therapyName': 'MEK162 + Nilotinib'}]","An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)",2219
0,NCT01649336,Phase I,Completed,"[{'id': 2010, 'therapyName': 'MEK162 + Paclitaxel'}]","A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer",2010
0,NCT02334735,Phase II,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 3012, 'therapyName': 'Melan-A/MART-1 peptide vaccine'}, {'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}]",A Comparison of Matured Dendritic Cells and Montanide&#174; in Study Subjects With High Risk of Melanoma Recurrence,3012
0,NCT01961115,Phase II,"Active, not recruiting","[{'id': 2575, 'therapyName': 'Epacadostat'}, {'id': 3016, 'therapyName': 'MELITAC 12.1 Peptide Vaccine '}]",INCB024360 and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma,3016
0,NCT02097134,Phase I,"Active, not recruiting","[{'id': 1207, 'therapyName': 'Melphalan'}]",Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma,1207
1,NCT01453088,Phase II,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older,1207
2,NCT01998971,Phase I,Recruiting,"[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1475, 'therapyName': 'Thalidomide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 3323, 'therapyName': 'Montelukast'}]",A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma,1207
3,NCT03126916,Phase III,Not yet recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 5595, 'therapyName': 'Isotretinoin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 2286, 'therapyName': 'Dinutuximab  '}]",Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma,1207
4,NCT02756572,Phase I,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5215, 'therapyName': 'mitoxantrone hydrochloride'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myelodysplastic Syndrome or Acute Myeloid Leukemia,1207
5,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1207
6,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,1207
7,NCT02790515,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation,1207
8,NCT02472392,Phase I,Completed,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}]",Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma,1207
9,NCT01526096,Phase I,Recruiting,"[{'id': 5985, 'therapyName': 'Basiliximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 1207, 'therapyName': 'Melphalan'}]",Stem Cell Transplantation for Patients With Multiple Myeloma,1207
10,NCT02678572,Phase III,Recruiting,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma,1207
11,NCT02508038,Phase I,Recruiting,"[{'id': 2971, 'therapyName': 'Zoledronic acid'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}]", Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa,1207
12,NCT03030261,Phase II,Not yet recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 3355, 'therapyName': 'Elotuzumab + Dexamethasone + Pomalidomide'}]","Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma",1207
13,NCT02701673,Phase Ib/II,Withdrawn,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1078, 'therapyName': 'Belinostat'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}]",Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma,1207
14,NCT01529827,Phase II,"Active, not recruiting","[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1166, 'therapyName': 'Fludarabine'}]","Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies",1207
15,NCT00550992,Phase I,Unknown status,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia,1207
16,NCT03004287,Phase II,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy,1207
17,NCT02342782,Phase I,Recruiting,"[{'id': 2485, 'therapyName': '90Y basiliximab'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 2392, 'therapyName': 'Cytarabine + Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}]",Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma,1207
18,NCT02195479,Phase III,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 1207, 'therapyName': 'Melphalan'}]",A Study of Combination of Daratumumanb and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma,1207
19,NCT02251821,Phase II,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 2006, 'therapyName': 'Pacritinib'}, {'id': 823, 'therapyName': 'Momelotinib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis,1207
20,NCT01625351,Phase I,"Active, not recruiting","[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}]",A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas,1207
21,NCT01526603,Phase I,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1092, 'therapyName': 'Carboplatin'}]",High Dose Chemotherapy and Autologous Transplant for Neuroblastoma,1207
22,NCT02406508,Phase II,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC,1207
23,NCT03259503,Phase Ib/II,Not yet recruiting,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas,1207
24,NCT00936936,Phase II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2101, 'therapyName': 'Etoposide + Ifosfamide'}, {'id': 2100, 'therapyName': 'Docetaxel + Gemcitabine + Melphalan'}, {'id': 2074, 'therapyName': 'Bevacizumab + Carboplatin'}]",High-dose Chemotherapy for Poor-prognosis Relapsed Germ-Cell Tumors,1207
25,NCT01256398,Phase II,"Active, not recruiting","[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1824, 'therapyName': 'Vincristine + Methotrexate + Mercaptopurine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,1207
26,NCT01729091,Phase Ib/II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3343, 'therapyName': 'Elotuzumab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1164, 'therapyName': 'lenalidomide'}]",Study of Umbilical Cord Blood-derived Natural Killer Cells in Conjunction With High Dose Chemotherapy and Autologous Stem Cell Transplant for Patients With Multiple Myeloma,1207
27,NCT02331368,Phase II,"Active, not recruiting","[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma,1207
0,NCT00734877,Phase III,Recruiting,"[{'id': 1851, 'therapyName': 'Cisplatin + Doxorubicin + Cyclophosphamide + Etoposide'}, {'id': 1852, 'therapyName': 'Melphalan + Bortezomib + Thalidomide + Dexamethasone'}]","UARK 2008-01, Total Therapy 4 - A Phase III Trial for Low Risk Myeloma",1852
1,NCT01849783,Phase II,Recruiting,"[{'id': 1852, 'therapyName': 'Melphalan + Bortezomib + Thalidomide + Dexamethasone'}, {'id': 3435, 'therapyName': 'Aldoxorubicin + Cisplatin + Cyclophosphamide + Dexamethasone + Etoposide'}]",Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma,1852
0,NCT02700841,Phase II,Recruiting,"[{'id': 5344, 'therapyName': 'Melphalan + PVX-410'}]",Enhancing Anti-Myeloma Vaccine Response After Autologous Stem Cell Transplantation,5344
0,NCT01430351,Phase I,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1784, 'therapyName': 'Memantine'}, {'id': 1031, 'therapyName': 'Metformin'}, {'id': 1785, 'therapyName': 'Mefloquine'}]","Phase I Factorial Trial of Temozolomide, Memantine, Mefloquine, and Metformin for Post-Radiation Therapy (RT) Glioblastoma Multiforme (GBM)",1784
0,NCT03020030,Phase III,Recruiting,"[{'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents,1640
1,NCT00550992,Phase I,Unknown status,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia,1640
2,NCT02112916,Phase III,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,1640
3,NCT02419755,Phase II,Terminated,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies,1640
4,NCT00549848,Phase III,"Active, not recruiting","[{'id': 1781, 'therapyName': 'Vincristine + Pegaspargase + Daunorubicin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1782, 'therapyName': 'Clofarabine + Etoposide + Cyclophosphamide'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia,1640
5,NCT02518750,Phase II,Recruiting,"[{'id': 1604, 'therapyName': 'Panobinostat + Bortezomib + Dexamethasone'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3217, 'therapyName': 'Cyclophosphamide + Etoposide'}, {'id': 3216, 'therapyName': 'Cytarabine + Methotrexate + Prednisone'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma,1640
6,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1640
7,NCT02883049,Phase III,Suspended,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations,1640
8,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,1640
9,NCT03007147,Phase III,Recruiting,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 5167, 'therapyName': 'Methylprednisolone'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 5168, 'therapyName': 'Prednisolone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,1640
10,NCT03150693,Phase III,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 3628, 'therapyName': 'Allopurinol'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]",Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia,1640
11,NCT03117751,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,1640
0,NCT02420717,Phase II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 2046, 'therapyName': 'Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine '}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 3194, 'therapyName': 'Mercaptopurine + Methotrexate + Prednisone + Vincristine'}]",Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL),3194
0,NCT02101853,Phase III,Recruiting,"[{'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 2347, 'therapyName': 'Leucovorin + Pegaspargase  + Vincristine'}, {'id': 2346, 'therapyName': 'Mercaptopurine + Thioguanine'}, {'id': 2348, 'therapyName': 'Asparaginase + Cyclophosphamide + Etoposide'}, {'id': 2345, 'therapyName': 'Cytarabine + Dexamethasone+ Methotrexate '}]",Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia,2346
1,NCT02723994,Phase II,Recruiting,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 2346, 'therapyName': 'Mercaptopurine + Thioguanine'}, {'id': 2394, 'therapyName': 'Asparaginase + Cytarabine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}]",A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia,2346
0,NCT03147612,Phase II,Not yet recruiting,"[{'id': 5682, 'therapyName': 'Mesna'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Study of the Combination of Low-Intensity Chemotherapy and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),5682
1,NCT02793544,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide,5682
2,NCT02790515,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation,5682
0,NCT02792114,Phase I,Recruiting,"[{'id': 5992, 'therapyName': 'Rimiducid'}, {'id': 6029, 'therapyName': 'Mesothelin CAR-T cells'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",T-Cell Therapy for Advanced Breast Cancer,6029
0,NCT01996696,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]","A Study With or Without Metformin to Determine if Metformin Can Prevent Weight Gain and Other Problems (i.e. Diabetes, Increased Cholesterol, Etc.) That Can Arise From the Use of Hormonal Therapy in Combination With Radiation Therapy When Treating Aggressive Localized Prostate Cancer.",1031
1,NCT02402348,Phase I,Terminated,"[{'id': 1031, 'therapyName': 'Metformin'}]","Pilot Study of Metformin in HNSCC to Investigate the Effects of MF, Tumor Genotype and MF-genotype Interactions, on Tumor Metabolism and Anoikis",1031
2,NCT01877564,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women,1031
3,NCT02376166,Phase I,Completed,"[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin for Rising PSA Remote Trial,1031
4,NCT02531308,Phase II,Terminated,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}]",Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL),1031
5,NCT01324180,Phase I,Completed,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1830, 'therapyName': 'Vincristine + Dexamethasone + Pegaspargase + Doxorubicin'}]","Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)",1031
6,NCT01528046,Phase I,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1826, 'therapyName': 'Vincristine + Irinotecan + Temozolomide '}]",Metformin in Children With Relapsed or Refractory Solid Tumors,1031
7,NCT01310231,Phase II,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}]",A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer,1031
8,NCT03086733,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",Phase II Lung Metcore - Preoperative Metformin for Lung Cancer (Metcore),1031
9,NCT01302379,Phase I,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}]",Reach for Health Study: Obesity-related Mechanisms and Mortality in Breast Cancer Survivors,1031
10,NCT02122185,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1827, 'therapyName': 'Paclitaxel + Carboplatin + Docetaxel'}]","Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1031
11,NCT01620593,Phase II,Completed,"[{'id': 1031, 'therapyName': 'Metformin'}]",Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer,1031
12,NCT02040376,Phase III,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}]",Placebo Controlled Double Blind Crossover Trial of Metformin for Brain Repair in Children With Cranial-Spinal Radiation for Medulloblastoma,1031
13,NCT02048384,Phase Ib/II,Recruiting,"[{'id': 1593, 'therapyName': 'Sirolimus + Metformin'}, {'id': 1031, 'therapyName': 'Metformin'}]",A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer,1031
14,NCT02278965,Phase I,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer,1031
15,NCT01340300,Phase II,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}]",Exercise and Metformin in Colorectal and Breast Cancer Survivors,1031
16,NCT01578551,Phase II,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",A Randomized Phase II Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma.,1031
17,NCT02019979,Phase II,Terminated,"[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC) (METRO),1031
18,NCT02176161,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin Prostate Cancer Adjuvant Trial,1031
19,NCT01430351,Phase I,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1784, 'therapyName': 'Memantine'}, {'id': 1031, 'therapyName': 'Metformin'}, {'id': 1785, 'therapyName': 'Mefloquine'}]","Phase I Factorial Trial of Temozolomide, Memantine, Mefloquine, and Metformin for Post-Radiation Therapy (RT) Glioblastoma Multiforme (GBM)",1031
20,NCT02815397,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma,1031
21,NCT01717482,Phase II,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer,1031
22,NCT01666730,Phase II,Recruiting,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1031, 'therapyName': 'Metformin'}]",Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer,1031
23,NCT02978547,Phase II,Not yet recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma (Metformin 001),1031
24,NCT02035787,Phase I,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients,1031
25,NCT02437812,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1031, 'therapyName': 'Metformin'}]","Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma",1031
26,NCT01750567,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL,1031
27,NCT01579812,Phase II,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}]","Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients",1031
28,NCT01697566,Phase III,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}]",An Endometrial Cancer Chemoprevention Study of Metformin,1031
29,NCT02186847,Phase II,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer,1031
30,NCT02285855,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin in Non Small Cell Lung Cancer (NSCLC),1031
31,NCT02614859,Phase II,Recruiting,"[{'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 1031, 'therapyName': 'Metformin'}]",Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients,1031
32,NCT01954732,Phase I,Withdrawn,"[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin Hydrochloride in Treating Patients With Pancreatic Cancer That Can be Removed by Surgery,1031
33,NCT02394652,Phase II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1031, 'therapyName': 'Metformin'}]",The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer,1031
34,NCT03076281,Phase II,Recruiting,"[{'id': 1391, 'therapyName': 'Doxycycline'}, {'id': 4610, 'therapyName': 'Metformin + Doxycycline'}, {'id': 1031, 'therapyName': 'Metformin'}]",Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery,1031
35,NCT01797523,Phase II,"Active, not recruiting","[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1031, 'therapyName': 'Metformin'}]",RAD/Letrozole/Metformin,1031
36,NCT01864096,Phase III,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",The Metformin Active Surveillance Trial (MAST) Study,1031
37,NCT02153450,Phase I,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",Stereotactic Radiosurgery and Metformin Hydrochloride in Treating Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer,1031
38,NCT01422746,,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]", Effect of Metformin on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess,1031
39,NCT01793948,Phase I,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin Hydrochloride vs. Placebo in Overweight or Obese Patients at Elevated Risk for Breast Cancer,1031
40,NCT03053544,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin With Neoadjuvant Chemoradiation to Improve Pathologic Responses in Rectal Cancer,1031
41,NCT02083692,,Completed,"[{'id': 1031, 'therapyName': 'Metformin'}]",Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling,1031
42,NCT02042495,Phase II,Withdrawn,"[{'id': 1031, 'therapyName': 'Metformin'}]",Endometrial Cancer Biomarker Changes Following Exposure to Metformin,1031
43,NCT02420652,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy,1031
44,NCT02780024,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]","Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM",1031
45,NCT01981525,,Completed,"[{'id': 1031, 'therapyName': 'Metformin'}]",A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome,1031
46,NCT01488552,Phase Ib/II,Completed,"[{'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1031, 'therapyName': 'Metformin'}]",Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer,1031
47,NCT03109873,Phase I,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin Hydrochloride in Affecting Cytokines and Exosomes in Patients With Head and Neck Cancer,1031
48,NCT02115464,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",Advanced Lung Cancer Treatment With Metformin and Chemo-Radiotherapy,1031
0,NCT01849276,Phase I,"Active, not recruiting","[{'id': 1792, 'therapyName': 'Metformin + Cytarabine'}]",Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML,1792
0,NCT02874430,Phase II,Recruiting,"[{'id': 4610, 'therapyName': 'Metformin + Doxycycline'}]",Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer,4610
1,NCT03076281,Phase II,Recruiting,"[{'id': 1391, 'therapyName': 'Doxycycline'}, {'id': 4610, 'therapyName': 'Metformin + Doxycycline'}, {'id': 1031, 'therapyName': 'Metformin'}]",Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery,4610
0,NCT01650506,Phase I,Completed,"[{'id': 1828, 'therapyName': 'Metformin + Erlotinib'}]",Study of Erlotinib and Metformin in Triple Negative Breast Cancer,1828
0,NCT03048500,Phase II,Not yet recruiting,"[{'id': 5302, 'therapyName': 'Metformin + Nivolumab'}]",Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery,5302
0,NCT03238495,Phase II,Recruiting,"[{'id': 1879, 'therapyName': 'Pertuzumab + Trastuzumab + Carboplatin + Docetaxel'}, {'id': 6101, 'therapyName': 'Metformin + Pertuzumab + Trastuzumab + Carboplatin + Docetaxel'}]",Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer,6101
0,NCT02948283,Phase 0,Recruiting,"[{'id': 4919, 'therapyName': 'Metformin + Ritonavir'}]",Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia,4919
0,NCT02360618,Phase II,Recruiting,"[{'id': 1829, 'therapyName': 'Metformin + Simvastatin'}]",Metformin and Simvastatin Use in Bladder Cancer,1829
1,NCT01561482,Phase II,Withdrawn,"[{'id': 1829, 'therapyName': 'Metformin + Simvastatin'}]",Study of Metformin With Simvastatin for Men With Prostate Carcinoma,1829
0,NCT02495103,Phase Ib/II,Recruiting,"[{'id': 2959, 'therapyName': 'Metformin + Vandetanib'}]",Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma,2959
0,NCT03007147,Phase III,Recruiting,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 5167, 'therapyName': 'Methylprednisolone'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 5168, 'therapyName': 'Prednisolone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,1639
1,NCT00513474,Phase I,Completed,"[{'id': 2313, 'therapyName': 'Rasburicase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2314, 'therapyName': 'Busulfan + Cyclophosphamide + Etoposide'}]",Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant,1639
2,NCT02105636,Phase III,"Active, not recruiting","[{'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141),1639
3,NCT02419755,Phase II,Terminated,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies,1639
4,NCT01535053,Phase III,"Active, not recruiting","[{'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Methotrexate or Dactinomycin in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia,1639
5,NCT02076997,Phase I,Recruiting,"[{'id': 1639, 'therapyName': 'Methotrexate'}]",Individualized High Dose Methotrexate to Treat Cancer in Children Who Have a Significant Risk for Side Effects to Methotrexate,1639
6,NCT00030264,Phase II,Completed,"[{'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas,1639
7,NCT00549848,Phase III,"Active, not recruiting","[{'id': 1781, 'therapyName': 'Vincristine + Pegaspargase + Daunorubicin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1782, 'therapyName': 'Clofarabine + Etoposide + Cyclophosphamide'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia,1639
8,NCT03150693,Phase III,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 3628, 'therapyName': 'Allopurinol'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]",Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia,1639
9,NCT02535806,Phase II,Terminated,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults,1639
10,NCT02458339,Phase I,Recruiting,"[{'id': 1639, 'therapyName': 'Methotrexate'}]",Methotrexate Infusion Into Fourth Ventricle in Children With Recurrent Malignant Fourth Ventricular Brain Tumors,1639
11,NCT01529827,Phase II,"Active, not recruiting","[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1166, 'therapyName': 'Fludarabine'}]","Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies",1639
12,NCT02112916,Phase III,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,1639
13,NCT01483690,Phase Ib/II,Terminated,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}]",A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL,1639
14,NCT00621036,Phase II,Unknown status,"[{'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1873, 'therapyName': 'Sargramostim'}]",Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma,1639
15,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1639
16,NCT01614197,Phase I,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma,1639
17,NCT01187810,Phase I,"Active, not recruiting","[{'id': 2731, 'therapyName': 'Fenretinide'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1639, 'therapyName': 'Methotrexate'}]","Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL",1639
18,NCT03117751,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,1639
19,NCT02553460,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I,1639
20,NCT00003553,Phase II,Unknown status,"[{'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer,1639
21,NCT01823198,Phase Ib/II,Recruiting,"[{'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1846, 'therapyName': 'Busulfan + Fludarabine + anti-thymocyte globulin'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies,1639
22,NCT00267865,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma,1639
23,NCT02043587,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia &amp; Lymphoblastic Lymphoma,1639
24,NCT01338987,Phase II,"Active, not recruiting","[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Pilot Study of Lupron to Improve Immune Function After Allogeneic Bone Marrow Transplantation,1639
25,NCT01790568,Phase II,"Active, not recruiting","[{'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant,1639
26,NCT00857389,Phase II,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies,1639
27,NCT03020030,Phase III,Recruiting,"[{'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents,1639
28,NCT02252042,Phase III,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040),1639
29,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,1639
30,NCT02251821,Phase II,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 2006, 'therapyName': 'Pacritinib'}, {'id': 823, 'therapyName': 'Momelotinib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis,1639
31,NCT02883049,Phase III,Suspended,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations,1639
32,NCT03147612,Phase II,Not yet recruiting,"[{'id': 5682, 'therapyName': 'Mesna'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Study of the Combination of Low-Intensity Chemotherapy and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),1639
0,NCT02114229,Phase II,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2449, 'therapyName': 'Methotrexate + Cisplatin + Cyclophosphamide + Vincristine'}, {'id': 626, 'therapyName': 'Alisertib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 942, 'therapyName': 'Topotecan'}]",Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors,2449
1,NCT00602667,Phase I,"Active, not recruiting","[{'id': 2449, 'therapyName': 'Methotrexate + Cisplatin + Cyclophosphamide + Vincristine'}, {'id': 2450, 'therapyName': 'Cyclophosphamide + Etoposide + Topotecan'}, {'id': 2451, 'therapyName': 'Erlotinib + Cyclophosphamide + Topotecan'}]","Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma",2449
0,NCT02270788,Phase I,Completed,"[{'id': 1865, 'therapyName': 'Methotrexate + Cytarabine + Leucovorin'}, {'id': 1864, 'therapyName': 'Crenolanib + Sorafenib'}]",Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies,1865
0,NCT01015222,Phase I,"Active, not recruiting","[{'id': 1032, 'therapyName': 'methylnaltrexone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies",1032
0,NCT03007147,Phase III,Recruiting,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 5167, 'therapyName': 'Methylprednisolone'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 5168, 'therapyName': 'Prednisolone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,5167
0,NCT03110822,Phase I,Recruiting,"[{'id': 5550, 'therapyName': 'Methylprednisolone + Lenalidomide + Ruxolitinib'}]","A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients",5550
0,NCT02923921,Phase III,Recruiting,"[{'id': 5849, 'therapyName': 'AM0010 + mFOLFOX-6'}, {'id': 5850, 'therapyName': 'mFOLFOX-6'}]",Study of AM0010 With FOLFOX Compared to FOLFOX Alone Second-line Tx in Pts With Metastatic Pancreatic Cancer,5850
1,NCT03281369,Phase Ib/II,Not yet recruiting,"[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 6274, 'therapyName': 'mFOLFOX-6 + Atezolizumab + Cobimetinib'}, {'id': 6275, 'therapyName': 'mFOLFOX-6 + Atezolizumab'}, {'id': 6276, 'therapyName': 'Atezolizumab + Linagliptin'}, {'id': 5941, 'therapyName': 'Atezolizumab + PEGPH20'}, {'id': 5942, 'therapyName': 'Atezolizumab + BKT140'}, {'id': 1721, 'therapyName': 'Ramucirumab + Paclitaxel'}, {'id': 5850, 'therapyName': 'mFOLFOX-6'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (UMBRELLA),5850
0,NCT03281369,Phase Ib/II,Not yet recruiting,"[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 6274, 'therapyName': 'mFOLFOX-6 + Atezolizumab + Cobimetinib'}, {'id': 6275, 'therapyName': 'mFOLFOX-6 + Atezolizumab'}, {'id': 6276, 'therapyName': 'Atezolizumab + Linagliptin'}, {'id': 5941, 'therapyName': 'Atezolizumab + PEGPH20'}, {'id': 5942, 'therapyName': 'Atezolizumab + BKT140'}, {'id': 1721, 'therapyName': 'Ramucirumab + Paclitaxel'}, {'id': 5850, 'therapyName': 'mFOLFOX-6'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (UMBRELLA),6275
0,NCT03281369,Phase Ib/II,Not yet recruiting,"[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 6274, 'therapyName': 'mFOLFOX-6 + Atezolizumab + Cobimetinib'}, {'id': 6275, 'therapyName': 'mFOLFOX-6 + Atezolizumab'}, {'id': 6276, 'therapyName': 'Atezolizumab + Linagliptin'}, {'id': 5941, 'therapyName': 'Atezolizumab + PEGPH20'}, {'id': 5942, 'therapyName': 'Atezolizumab + BKT140'}, {'id': 1721, 'therapyName': 'Ramucirumab + Paclitaxel'}, {'id': 5850, 'therapyName': 'mFOLFOX-6'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (UMBRELLA),6274
0,NCT01206530,Phase Ib/II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1316, 'therapyName': 'Hydroxychloroquine'}]",FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer,1161
1,NCT02213289,Phase Ib/II,Recruiting,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1913, 'therapyName': 'FOLTAX'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 629, 'therapyName': 'AMG102'}]",PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression,1161
2,NCT02046538,Phase II,Withdrawn,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 624, 'therapyName': 'Aflibercept'}]",Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer,1161
3,NCT02730546,Phase Ib/II,Suspended,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery",1161
4,NCT01662869,Phase III,Completed,"[{'id': 838, 'therapyName': 'Onartuzumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric),1161
5,NCT02024607,Phase Ib/II,"Active, not recruiting","[{'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}, {'id': 2093, 'therapyName': 'BBI608 + Bevacizumab'}, {'id': 2094, 'therapyName': 'BBI608 + Regorafenib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2057, 'therapyName': 'BBI608'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer,1161
6,NCT02625610,Phase III,Recruiting,"[{'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}]",Avelumab in First-Line Gastric Cancer (JAVELIN Gastric 100),1161
7,NCT01260415,Phase II,Completed,"[{'id': 845, 'therapyName': 'Panitumumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases,1161
8,NCT02912559,Phase III,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair or Microsatellite Instability,1161
9,NCT01586611,Phase III,Unknown status,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer,1161
10,NCT02268825,Phase Ib/II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase I/IIA Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers,1161
11,NCT02413853,Phase II,Withdrawn,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1083, 'therapyName': 'Pri-724'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer,1161
12,NCT01985763,Phase Ib/II,Completed,"[{'id': 757, 'therapyName': 'Genistein'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Genistein in Treatment of Metastatic Colorectal Cancer,1161
13,NCT02344810,Phase Ib/II,Unknown status,"[{'id': 1064, 'therapyName': 'AMG 337'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]","C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer",1161
14,NCT01327612,Phase II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 746, 'therapyName': 'Ganitumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1458, 'therapyName': 'Conatumumab'}]",Open Label Extension Study of Conatumumab and AMG 479,1161
15,NCT02009449,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2621, 'therapyName': 'AM0010 '}, {'id': 619, 'therapyName': 'Abraxane'}]",A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors,1161
16,NCT02921256,Phase II,Recruiting,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 4838, 'therapyName': 'Capecitabine + Veliparib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Veliparib and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer,1161
17,NCT01896531,Phase II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 747, 'therapyName': 'Ipatasertib'}]",A Study of GDC-0068 in Combination With Fluoropyrimidine Plus Oxaliplatin in Patients With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer,1161
18,NCT02574663,Phase I,"Active, not recruiting","[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2022, 'therapyName': 'TGR-1202'}]",TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors,1161
19,NCT02943603,Phase II,Withdrawn,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach,1161
20,NCT01362374,Phase I,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 747, 'therapyName': 'Ipatasertib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]","Safety and Pharmacology Of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors",1161
21,NCT01747551,Phase II,"Active, not recruiting","[{'id': 624, 'therapyName': 'Aflibercept'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer,1161
22,NCT02141295,Phase II,Completed,"[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 1598, 'therapyName': 'RO5520985'}, {'id': 1599, 'therapyName': 'Bevacizumab + Fluorouracil + Leucovorin'}, {'id': 1600, 'therapyName': 'RO5520985 + Leucovorin + Fluorouracil'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study Comparing the Efficacy and Safety of RO5520985 and FOLFOX With Bevacizumab and FOLFOX in Patients With Untreated Metastatic Colorectal Cancer (McCAVE),1161
23,NCT00602329,Phase II,Unknown status,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer,1161
24,NCT02358863,Phase I,Terminated,"[{'id': 4311, 'therapyName': 'Docetaxel + Irinotecan'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1835, 'therapyName': 'Docetaxel + Cisplatin'}, {'id': 1406, 'therapyName': 'Camptosar + Cisplatin'}, {'id': 4310, 'therapyName': 'Epirubicin + Docetaxel'}, {'id': 4309, 'therapyName': 'Capecitabine + Docetaxel'}]",Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach (mEGA),1161
25,NCT01516216,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Study of Vitamin D in Untreated Metastatic Colorectal Cancer,1161
26,NCT01489865,Phase Ib/II,Recruiting,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 954, 'therapyName': 'Veliparib'}]",ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer,1161
27,NCT02375672,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer,1161
28,NCT01571024,Phase I,Completed,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 680, 'therapyName': 'BKM120'}]", BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer,1161
29,NCT01420874,Phase I,"Active, not recruiting","[{'id': 1012, 'therapyName': 'EGFRBi-armed autologous activated T cells'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Anti-CD3 x Anti-Erbitux Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer),1161
30,NCT02715531,Phase I,Recruiting,"[{'id': 3947, 'therapyName': 'Atezolizumab + Gemcitabine + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors,1161
31,NCT02872116,Phase III,Recruiting,"[{'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Efficacy Study of Nivolumab Plus Ipilimumab Against Chemotherapy Standard of Care in Stomach Cancer or Stomach/Esophagus Junction Cancer (CheckMate649),1161
32,NCT01666730,Phase II,Recruiting,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1031, 'therapyName': 'Metformin'}]",Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer,1161
33,NCT01803282,Phase I,Recruiting,"[{'id': 3320, 'therapyName': 'GS-5745'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Safety and Tolerability Study in Solid Tumors,1161
34,NCT02319018,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 626, 'therapyName': 'Alisertib'}]",Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors,1161
35,NCT02658214,Phase I,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors,1161
36,NCT01652976,Phase II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 717, 'therapyName': 'Dasatinib'}]","Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma",1161
37,NCT02545504,Phase III,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 3320, 'therapyName': 'GS-5745'}]",GS-5745 With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma,1161
38,NCT02563002,Phase III,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177),1161
0,NCT03059823,Phase I,Recruiting,"[{'id': 5813, 'therapyName': 'MGA012'}]",A Phase 1 Study of MGA012 in Patients With Advanced Solid Tumors,5813
0,NCT02982941,Phase I,Recruiting,"[{'id': 2863, 'therapyName': 'MGA271'}]",Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors,2863
1,NCT01391143,Phase I,Recruiting,"[{'id': 2863, 'therapyName': 'MGA271'}]",Safety Study of MGA271 in Refractory Cancer,2863
2,NCT02923180,Phase I,Recruiting,"[{'id': 2863, 'therapyName': 'MGA271'}]",Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer,2863
0,NCT02475213,Phase I,Recruiting,"[{'id': 2864, 'therapyName': 'MGA271 + Pembrolizumab'}]",Safety Study of MGA271 in Combination With Pembrolizumab in Refractory Cancer,2864
0,NCT01148849,Phase I,"Active, not recruiting","[{'id': 808, 'therapyName': 'MGAH22'}]",Safety Study of MGAH22 in HER2-positive Carcinomas,808
1,NCT01828021,Phase II,Completed,"[{'id': 808, 'therapyName': 'MGAH22'}]",Phase 2 Study of the Monoclonal Antibody MGAH22(Margetuximab)in Patients With Relapsed or Refractory Advanced Breast Cancer,808
2,NCT02492711,Phase III,Recruiting,"[{'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 808, 'therapyName': 'MGAH22'}]",Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer,808
0,NCT02689284,Phase Ib/II,Recruiting,"[{'id': 3728, 'therapyName': 'MGAH22 + Pembrolizumab'}]","Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer",3728
0,NCT00697632,Phase I,Recruiting,"[{'id': 809, 'therapyName': 'MGCD265'}]",Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies,809
1,NCT02544633,Phase II,Recruiting,"[{'id': 809, 'therapyName': 'MGCD265'}]",Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET,809
0,NCT00975767,Phase Ib/II,Terminated,"[{'id': 1127, 'therapyName': 'MGCD265 + Docetaxel'}, {'id': 1126, 'therapyName': 'MGCD265 + Erlotinib'}]",A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer,1127
0,NCT00975767,Phase Ib/II,Terminated,"[{'id': 1127, 'therapyName': 'MGCD265 + Docetaxel'}, {'id': 1126, 'therapyName': 'MGCD265 + Erlotinib'}]",A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer,1126
0,NCT02954991,Phase II,Recruiting,"[{'id': 4943, 'therapyName': 'MGCD516 + Nivolumab'}, {'id': 4944, 'therapyName': 'Mocetinostat + Nivolumab'}, {'id': 4942, 'therapyName': 'MGCD265 + Nivolumab'}]","Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer",4942
0,NCT02978859,Phase II,Recruiting,"[{'id': 1655, 'therapyName': 'MGCD516'}]",MGCD516 in Advanced Liposarcoma and Other Soft Tissue Sarcomas,1655
1,NCT02219711,Phase I,Recruiting,"[{'id': 1655, 'therapyName': 'MGCD516'}]",Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer,1655
0,NCT02954991,Phase II,Recruiting,"[{'id': 4943, 'therapyName': 'MGCD516 + Nivolumab'}, {'id': 4944, 'therapyName': 'Mocetinostat + Nivolumab'}, {'id': 4942, 'therapyName': 'MGCD265 + Nivolumab'}]","Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer",4943
1,NCT03015740,Phase Ib/II,Recruiting,"[{'id': 4943, 'therapyName': 'MGCD516 + Nivolumab'}]",MGCD516 Combined With Nivolumab in Renal Cell Cancer (RCC),4943
0,NCT02248805,Phase I,Recruiting,"[{'id': 3093, 'therapyName': 'MGD007'}]",Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma,3093
0,NCT03219268,Phase I,Recruiting,"[{'id': 6060, 'therapyName': 'MGD013'}]",A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms,6060
0,NCT02422589,Phase I,Recruiting,"[{'id': 2505, 'therapyName': 'Warfarin'}, {'id': 2685, 'therapyName': 'Midazolam'}, {'id': 789, 'therapyName': 'Ceritinib'}]","A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors",2685
1,NCT02520752,Phase I,"Active, not recruiting","[{'id': 2685, 'therapyName': 'Midazolam'}, {'id': 1065, 'therapyName': 'Capmatinib'}]",A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors,2685
2,NCT01456689,Phase I,"Active, not recruiting","[{'id': 2685, 'therapyName': 'Midazolam'}, {'id': 2402, 'therapyName': 'LGH447 '}]",A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma,2685
0,NCT00866281,Phase Ib/II,Terminated,"[{'id': 810, 'therapyName': 'Midostaurin'}]",A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia,810
1,NCT02756962,Phase II,Recruiting,"[{'id': 810, 'therapyName': 'Midostaurin'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance,810
2,NCT02723435,Phase II,Not yet recruiting,"[{'id': 810, 'therapyName': 'Midostaurin'}]",Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant,810
3,NCT01282502,Phase I,"Active, not recruiting","[{'id': 810, 'therapyName': 'Midostaurin'}]",Midostaurin (PKC412) for Locally Advanced Rectal Cancer,810
4,NCT01883362,Phase II,Recruiting,"[{'id': 810, 'therapyName': 'Midostaurin'}]",Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML,810
5,NCT02624570,Phase I,Available,"[{'id': 810, 'therapyName': 'Midostaurin'}]",Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy.,810
0,NCT02012296,Phase Ib/II,Recruiting,"[{'id': 2603, 'therapyName': 'Mifepristone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer,2603
1,NCT02046421,Phase I,"Active, not recruiting","[{'id': 2603, 'therapyName': 'Mifepristone'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]","Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer",2603
2,NCT02642939,Phase II,Recruiting,"[{'id': 2603, 'therapyName': 'Mifepristone'}]",Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer,2603
0,NCT02788981,Phase II,Recruiting,"[{'id': 4350, 'therapyName': 'Mifepristone + Nab-paclitaxel'}, {'id': 619, 'therapyName': 'Abraxane'}]","A Trial of Nanoparticle Albumin-Bound Paclitaxel (Nab-Paclitaxel, Abraxane) With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer",4350
0,NCT03225547,Phase II,Not yet recruiting,"[{'id': 6030, 'therapyName': 'Mifepristone + Pembrolizumab'}]",Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer,6030
0,NCT02992483,Phase I,Recruiting,"[{'id': 5814, 'therapyName': 'MIK665'}]","Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma",5814
0,NCT01139723,Phase I,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1616, 'therapyName': 'MINT1526A'}]","A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors",1616
0,NCT02876003,Phase II,Withdrawn,"[{'id': 4338, 'therapyName': 'mipsagargin'}]",Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma,4338
1,NCT02607553,Phase II,Completed,"[{'id': 4338, 'therapyName': 'mipsagargin'}]",Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA,4338
2,NCT02067156,Phase II,Completed,"[{'id': 4338, 'therapyName': 'mipsagargin'}]","Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma",4338
3,NCT02381236,Phase II,Completed,"[{'id': 4338, 'therapyName': 'mipsagargin'}]",G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer,4338
0,NCT01610570,Phase Ib/II,Terminated,"[{'id': 1397, 'therapyName': 'Mithramycin'}]",Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma,1397
0,NCT01580410,Phase II,"Active, not recruiting","[{'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}]",Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix,1133
1,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1133
2,NCT02349958,Phase II,Recruiting,"[{'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy,1133
0,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,4302
0,NCT02553460,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I,1740
1,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1740
2,NCT02573363,Phase I,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia,1740
3,NCT02518750,Phase II,Recruiting,"[{'id': 1604, 'therapyName': 'Panobinostat + Bortezomib + Dexamethasone'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3217, 'therapyName': 'Cyclophosphamide + Etoposide'}, {'id': 3216, 'therapyName': 'Cytarabine + Methotrexate + Prednisone'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma,1740
4,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,1740
5,NCT03164057,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia,1740
6,NCT02419755,Phase II,Terminated,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies,1740
7,NCT01483690,Phase Ib/II,Terminated,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}]",A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL,1740
8,NCT02535806,Phase II,Terminated,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults,1740
0,NCT02421939,Phase III,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 3193, 'therapyName': 'Cytarabine + Fludarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2865, 'therapyName': 'Gilteritinib'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,1752
1,NCT00550992,Phase I,Unknown status,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia,1752
2,NCT01729845,Phase Ib/II,"Active, not recruiting","[{'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 650, 'therapyName': 'Decitabine'}]","Decitabine Followed By Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes",1752
3,NCT01222143,Phase Ib/II,Terminated,"[{'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}]","Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia",1752
4,NCT02306291,Phase Ib/II,Recruiting,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 4402, 'therapyName': 'GMI-1271'}]","Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML",1752
5,NCT02299518,Phase I,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}]",Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,1752
6,NCT02039726,Phase III,"Active, not recruiting","[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 3193, 'therapyName': 'Cytarabine + Fludarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 882, 'therapyName': 'Quizartinib'}]",An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects,1752
7,NCT02583893,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}]",Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia,1752
0,NCT02521493,Phase III,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 5912, 'therapyName': 'Asparaginase Erwinia chrysanthemi'}, {'id': 5215, 'therapyName': 'mitoxantrone hydrochloride'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2206, 'therapyName': 'Asparaginase'}]",Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome,5215
1,NCT02756572,Phase I,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5215, 'therapyName': 'mitoxantrone hydrochloride'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myelodysplastic Syndrome or Acute Myeloid Leukemia,5215
0,NCT03172936,Phase I,Recruiting,"[{'id': 6219, 'therapyName': 'MIW815 + PDR001'}]",Study of the Safety and Efficacy of MIW815 With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas,6219
0,NCT03179436,Phase I,Recruiting,"[{'id': 6039, 'therapyName': 'MK-1308 + Pembrolizumab'}]","Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab in Advanced Solid Tumors (MK-1308-001)",6039
0,NCT03010176,Phase I,Recruiting,"[{'id': 5348, 'therapyName': 'MK-1454 + Pembrolizumab'}, {'id': 5347, 'therapyName': 'MK-1454'}]",Study of MK-1454 Alone or in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001),5347
0,NCT03010176,Phase I,Recruiting,"[{'id': 5348, 'therapyName': 'MK-1454 + Pembrolizumab'}, {'id': 5347, 'therapyName': 'MK-1454'}]",Study of MK-1454 Alone or in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001),5348
0,NCT02511795,Phase I,Recruiting,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 837, 'therapyName': 'Olaparib'}]",AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors,822
1,NCT02659241,Phase I,Recruiting,"[{'id': 822, 'therapyName': 'MK-1775'}]",A Pilot Study of Induction Wee1 Inhibition in Ovarian Cancer,822
2,NCT01357161,Phase II,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 822, 'therapyName': 'MK-1775'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]", A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004),822
3,NCT02087176,Phase II,Terminated,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]",A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer,822
4,NCT02087241,Phase II,Terminated,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]",Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer,822
5,NCT02610075,Phase I,Recruiting,"[{'id': 822, 'therapyName': 'MK-1775'}]",Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.,822
6,NCT03253679,Phase II,Not yet recruiting,"[{'id': 822, 'therapyName': 'MK-1775'}]",WEE1 Inhibitor AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification,822
7,NCT02194829,Phase Ib/II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 822, 'therapyName': 'MK-1775'}]",Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery,822
8,NCT02791919,Phase I,Withdrawn,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 4271, 'therapyName': 'Cytarabine + Filgrastim + Fludarabine'}]","Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia",822
9,NCT01748825,Phase I,Recruiting,"[{'id': 822, 'therapyName': 'MK-1775'}]",MK-1775 for Advanced Solid Tumors,822
10,NCT02341456,Phase I,"Active, not recruiting","[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours,822
11,NCT02508246,Phase I,Recruiting,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]","AZD1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck",822
12,NCT01922076,Phase I,Recruiting,"[{'id': 822, 'therapyName': 'MK-1775'}]",WEE1 Inhibitor MK-1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas,822
13,NCT02196168,Phase II,Terminated,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,822
14,NCT02513563,Phase II,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 822, 'therapyName': 'MK-1775'}]",AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer,822
15,NCT02666950,Phase II,Recruiting,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 712, 'therapyName': 'Cytarabine'}]",WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome,822
0,NCT01827384,Phase II,Recruiting,"[{'id': 1194, 'therapyName': 'MK-1775 + Carboplatin '}, {'id': 1193, 'therapyName': 'Veliparib + Temozolomide'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 2, 'therapyName': 'Trametinib'}]",Molecular Profiling-Based Targeted Therapy in Treating Patients With Advanced Solid Tumors,1194
1,NCT02272790,Phase II,Recruiting,"[{'id': 1194, 'therapyName': 'MK-1775 + Carboplatin '}, {'id': 1279, 'therapyName': 'MK-1775 + Gemcitabine'}, {'id': 1567, 'therapyName': 'MK-1775 + Paclitaxel'}]","A Phase II Study Comparing AZD1775 + Chemotherapy Versus Chemotherapy Alone in Patients to Treat Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.",1194
0,NCT02585973,Phase I,Recruiting,"[{'id': 1725, 'therapyName': 'MK-1775 + Cisplatin'}]",Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC,1725
1,NCT01958658,Phase I,Suspended,"[{'id': 1725, 'therapyName': 'MK-1775 + Cisplatin'}]","AZD1775, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer",1725
2,NCT03012477,Phase II,Recruiting,"[{'id': 1725, 'therapyName': 'MK-1775 + Cisplatin'}]",CISPLATIN + AZD-1775 In Breast Cancer,1725
0,NCT02037230,Phase Ib/II,Recruiting,"[{'id': 1279, 'therapyName': 'MK-1775 + Gemcitabine'}]",Dose Escalation Trial of MK1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas,1279
1,NCT02101775,Phase II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1279, 'therapyName': 'MK-1775 + Gemcitabine'}]","Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",1279
2,NCT02272790,Phase II,Recruiting,"[{'id': 1194, 'therapyName': 'MK-1775 + Carboplatin '}, {'id': 1279, 'therapyName': 'MK-1775 + Gemcitabine'}, {'id': 1567, 'therapyName': 'MK-1775 + Paclitaxel'}]","A Phase II Study Comparing AZD1775 + Chemotherapy Versus Chemotherapy Alone in Patients to Treat Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.",1279
0,NCT02095132,Phase Ib/II,Recruiting,"[{'id': 1361, 'therapyName': 'MK-1775 + Irinotecan'}]",WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors,1361
1,NCT02906059,Phase I,Recruiting,"[{'id': 1361, 'therapyName': 'MK-1775 + Irinotecan'}]","Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer",1361
0,NCT02576444,Phase II,Recruiting,"[{'id': 3140, 'therapyName': 'MK-1775 + Olaparib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 3141, 'therapyName': 'Olaparib + Vistusertib'}, {'id': 3139, 'therapyName': 'AZD5363 + Olaparib'}]",OLAParib COmbinations,3140
0,NCT02272790,Phase II,Recruiting,"[{'id': 1194, 'therapyName': 'MK-1775 + Carboplatin '}, {'id': 1279, 'therapyName': 'MK-1775 + Gemcitabine'}, {'id': 1567, 'therapyName': 'MK-1775 + Paclitaxel'}]","A Phase II Study Comparing AZD1775 + Chemotherapy Versus Chemotherapy Alone in Patients to Treat Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.",1567
0,NCT01849146,Phase I,Recruiting,"[{'id': 2713, 'therapyName': 'MK-1775 + Temozolomide'}]","WEE1 Inhibitor MK-1775, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme",2713
0,NCT02731742,Phase I,Recruiting,"[{'id': 4471, 'therapyName': 'MK-1966 + SD-101'}]",Dose Evaluation of MK-1966 in Combination With SD-101 in Participants With Advanced Malignancies (MK-1966-001),4471
0,NCT03249792,Phase I,Recruiting,"[{'id': 6131, 'therapyName': 'MK-2118 + Pembrolizumab'}, {'id': 6130, 'therapyName': 'MK-2118'}]",Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) in the Treatment of Adults With Advance/Metastatic Solid Tumors or Lymphomas (MK-2118-001),6130
0,NCT03249792,Phase I,Recruiting,"[{'id': 6131, 'therapyName': 'MK-2118 + Pembrolizumab'}, {'id': 6130, 'therapyName': 'MK-2118'}]",Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) in the Treatment of Adults With Advance/Metastatic Solid Tumors or Lymphomas (MK-2118-001),6131
0,NCT02132754,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2829, 'therapyName': 'MK-4166'}]",Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001),2829
0,NCT02720068,Phase I,Recruiting,"[{'id': 4213, 'therapyName': 'MK-4280 + Pembrolizumab'}, {'id': 4212, 'therapyName': 'MK-4280'}]",Study of MK-4280 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-4280-001),4212
0,NCT02720068,Phase I,Recruiting,"[{'id': 4213, 'therapyName': 'MK-4280 + Pembrolizumab'}, {'id': 4212, 'therapyName': 'MK-4280'}]",Study of MK-4280 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-4280-001),4213
0,NCT02964013,Phase I,Recruiting,"[{'id': 5218, 'therapyName': 'MK-7684'}, {'id': 5219, 'therapyName': 'MK-7684 + Pembrolizumab'}]",Study of MK-7684 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001),5218
0,NCT02964013,Phase I,Recruiting,"[{'id': 5218, 'therapyName': 'MK-7684'}, {'id': 5219, 'therapyName': 'MK-7684 + Pembrolizumab'}]",Study of MK-7684 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001),5219
0,NCT02972034,Phase I,Recruiting,"[{'id': 5269, 'therapyName': 'MK-8353 + Pembrolizumab'}]",Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013),5269
0,NCT01870596,Phase II,Completed,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 2027, 'therapyName': 'MK-8776'}]",Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia,2027
0,NCT01306045,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 816, 'therapyName': 'MK2206'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 913, 'therapyName': 'Selumetinib'}]","Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies",816
1,NCT01802320,Phase II,"Active, not recruiting","[{'id': 816, 'therapyName': 'MK2206'}]",Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery,816
0,NCT01480154,Phase I,"Active, not recruiting","[{'id': 1393, 'therapyName': 'MK2206 + hydroxychloroquine'}]","Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer",1393
0,NCT01248247,Phase I,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1098, 'therapyName': 'MK2206 + Selumetinib'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1097, 'therapyName': 'Erlotinib + MK2206'}]",BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study,1098
0,NCT01042379,Phase II,Recruiting,"[{'id': 1218, 'therapyName': 'Trebananib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 746, 'therapyName': 'Ganitumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1494, 'therapyName': 'MK2206 + Trastuzumab'}, {'id': 1493, 'therapyName': 'Trebananib + Trastuzumab'}, {'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}]",I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer,1494
0,NCT02142803,Phase I,Recruiting,"[{'id': 1444, 'therapyName': 'MLN0128 + Bevacizumab'}]",MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors,1444
0,NCT02049957,Phase Ib/II,Recruiting,"[{'id': 1581, 'therapyName': 'MLN0128 + Fulvestrant'}, {'id': 1580, 'therapyName': 'MLN0128 + Exemestane'}]",Safety and Efficacy Study of MLN0128 in Combination With Exemestane or Fulvestrant in Postmenopausal Women With ER/PR+ Metastatic Breast Cancer,1580
0,NCT02756364,Phase II,Recruiting,"[{'id': 1581, 'therapyName': 'MLN0128 + Fulvestrant'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",MLN0128 in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy,1581
1,NCT02049957,Phase Ib/II,Recruiting,"[{'id': 1581, 'therapyName': 'MLN0128 + Fulvestrant'}, {'id': 1580, 'therapyName': 'MLN0128 + Exemestane'}]",Safety and Efficacy Study of MLN0128 in Combination With Exemestane or Fulvestrant in Postmenopausal Women With ER/PR+ Metastatic Breast Cancer,1581
0,NCT03017833,Phase I,Not yet recruiting,"[{'id': 5197, 'therapyName': 'MLN0128 + Metformin'}]",Study of TAK-228 (MLN0128) in Combination With Metformin in Patients With Advanced Cancers,5197
0,NCT02327169,Phase I,Recruiting,"[{'id': 2175, 'therapyName': 'MLN0128 + MLN2480'}, {'id': 2176, 'therapyName': 'MLN2480 + Alisertib'}, {'id': 2177, 'therapyName': 'MLN2480 + Paclitaxel'}]",A Phase 1B Study of MLN2480 in Combination With MLN0128 or Alisertib or Paclitaxel in Adult Patients With Advanced Nonhematologic Malignancies,2175
0,NCT02988986,Phase II,Recruiting,"[{'id': 5141, 'therapyName': 'MLN0128 + Tamoxifen'}]","TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer",5141
0,NCT01449370,Phase I,Completed,"[{'id': 1033, 'therapyName': 'MLN1117'}]",Dose Escalation Study of MLN1117 in Subjects With Advanced Cancer,1033
1,NCT02551055,Phase I,Terminated,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 626, 'therapyName': 'Alisertib'}, {'id': 3146, 'therapyName': 'TAK-659'}, {'id': 1033, 'therapyName': 'MLN1117'}]","MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma",1033
0,NCT02724020,Phase II,Recruiting,"[{'id': 1283, 'therapyName': 'MLN1117 + Sapanisertib'}, {'id': 1282, 'therapyName': 'Sapanisertib'}, {'id': 735, 'therapyName': 'Everolimus'}]",MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma,1283
1,NCT01899053,Phase I,"Active, not recruiting","[{'id': 1283, 'therapyName': 'MLN1117 + Sapanisertib'}]",Phase 1b Study of MLN0128 in Combination With MLN1117 in Adult Patients With Advanced Nonhematologic Malignancies,1283
2,NCT02725268,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1282, 'therapyName': 'Sapanisertib'}, {'id': 1283, 'therapyName': 'MLN1117 + Sapanisertib'}]","Phase 2 Study of MLN0128, Combination of MLN0128 With MLN1117, Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial Cancer",1283
3,NCT03193853,Phase II,Recruiting,"[{'id': 3126, 'therapyName': 'Cisplatin + nab-paclitaxel'}, {'id': 1283, 'therapyName': 'MLN1117 + Sapanisertib'}]",TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer,1283
0,NCT02723006,Phase I,Recruiting,"[{'id': 4198, 'therapyName': 'MLN2480 + Nivolumab'}, {'id': 4200, 'therapyName': 'MLN1202 + Nivolumab'}, {'id': 4202, 'therapyName': 'Ipilimumab + Nivolumab + Vedolizumab '}]","Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma",4200
0,NCT01425008,Phase I,"Active, not recruiting","[{'id': 1034, 'therapyName': 'MLN2480'}]",Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma,1034
0,NCT02327169,Phase I,Recruiting,"[{'id': 2175, 'therapyName': 'MLN0128 + MLN2480'}, {'id': 2176, 'therapyName': 'MLN2480 + Alisertib'}, {'id': 2177, 'therapyName': 'MLN2480 + Paclitaxel'}]",A Phase 1B Study of MLN2480 in Combination With MLN0128 or Alisertib or Paclitaxel in Adult Patients With Advanced Nonhematologic Malignancies,2176
0,NCT02723006,Phase I,Recruiting,"[{'id': 4198, 'therapyName': 'MLN2480 + Nivolumab'}, {'id': 4200, 'therapyName': 'MLN1202 + Nivolumab'}, {'id': 4202, 'therapyName': 'Ipilimumab + Nivolumab + Vedolizumab '}]","Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma",4198
0,NCT02327169,Phase I,Recruiting,"[{'id': 2175, 'therapyName': 'MLN0128 + MLN2480'}, {'id': 2176, 'therapyName': 'MLN2480 + Alisertib'}, {'id': 2177, 'therapyName': 'MLN2480 + Paclitaxel'}]",A Phase 1B Study of MLN2480 in Combination With MLN0128 or Alisertib or Paclitaxel in Adult Patients With Advanced Nonhematologic Malignancies,2177
0,NCT01814826,Phase I,"Active, not recruiting","[{'id': 1688, 'therapyName': 'MLN4924'}, {'id': 651, 'therapyName': 'Azacitidine'}]",Study of MLN4924 Plus Azacitidine in Treatment-Naïve Patients With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older,1688
1,NCT02122770,Phase I,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1026, 'therapyName': 'Itraconazole'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1688, 'therapyName': 'MLN4924'}, {'id': 1689, 'therapyName': 'Fluconazole'}]","Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors",1688
2,NCT02610777,Phase II,"Active, not recruiting","[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 1688, 'therapyName': 'MLN4924'}]","An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)",1688
0,NCT01733004,Phase I,Completed,"[{'id': 1248, 'therapyName': 'MM-141 + Everolimus'}, {'id': 1073, 'therapyName': 'MM-141'}, {'id': 1249, 'therapyName': 'MM-141 + Abraxane + Gemcitabine'}]",A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors,1073
1,NCT02399137,Phase II,"Active, not recruiting","[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1073, 'therapyName': 'MM-141'}]",A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer,1073
0,NCT01733004,Phase I,Completed,"[{'id': 1248, 'therapyName': 'MM-141 + Everolimus'}, {'id': 1073, 'therapyName': 'MM-141'}, {'id': 1249, 'therapyName': 'MM-141 + Abraxane + Gemcitabine'}]",A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors,1249
0,NCT01733004,Phase I,Completed,"[{'id': 1248, 'therapyName': 'MM-141 + Everolimus'}, {'id': 1073, 'therapyName': 'MM-141'}, {'id': 1249, 'therapyName': 'MM-141 + Abraxane + Gemcitabine'}]",A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors,1248
0,NCT01520389,Phase I,Completed,"[{'id': 821, 'therapyName': 'MM-151'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment,821
1,NCT02538627,Phase I,Terminated,"[{'id': 820, 'therapyName': 'Seribantumab'}, {'id': 821, 'therapyName': 'MM-151'}]",Phase 1 Combination Study of MM-151 and MM-121,821
0,NCT02213744,Phase II,Terminated,"[{'id': 1890, 'therapyName': 'Vinorelbine + Trastuzumab'}, {'id': 1409, 'therapyName': 'Capecitabine + Trastuzumab'}, {'id': 1889, 'therapyName': 'Gemcitabine + Trastuzumab'}, {'id': 1888, 'therapyName': 'MM-302 + Trastuzumab'}]",MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients,1888
0,NCT03076372,Phase I,Recruiting,"[{'id': 5758, 'therapyName': 'MM-310'}]",A Study Evaluating MM-310 in Patients With Solid Tumors,5758
0,NCT02236195,Phase II,Completed,"[{'id': 3002, 'therapyName': 'Mocetinostat'}]",Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes,3002
1,NCT02282358,Phase Ib/II,"Active, not recruiting","[{'id': 3002, 'therapyName': 'Mocetinostat'}]",Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma,3002
0,NCT02954991,Phase II,Recruiting,"[{'id': 4943, 'therapyName': 'MGCD516 + Nivolumab'}, {'id': 4944, 'therapyName': 'Mocetinostat + Nivolumab'}, {'id': 4942, 'therapyName': 'MGCD265 + Nivolumab'}]","Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer",4944
0,NCT03220477,Phase I,Recruiting,"[{'id': 6042, 'therapyName': 'Mocetinostat + Pembrolizumab + SGI-110'}]",Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.,6042
0,NCT02301130,Phase I,"Active, not recruiting","[{'id': 2968, 'therapyName': 'Mogamulizumab '}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Study of Mogamulizumab + MEDI4736 and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors,2968
0,NCT02705105,Phase Ib/II,Recruiting,"[{'id': 3843, 'therapyName': 'Mogamulizumab + Nivolumab'}]",Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors,3843
0,NCT02258607,Phase I,Terminated,"[{'id': 823, 'therapyName': 'Momelotinib'}, {'id': 1860, 'therapyName': 'Momelotinib + Trametinib'}]",Efficacy and Safety of Momelotinib and Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase,823
1,NCT02101021,Phase II,Terminated,"[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 823, 'therapyName': 'Momelotinib'}]",Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma,823
2,NCT02251821,Phase II,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 2006, 'therapyName': 'Pacritinib'}, {'id': 823, 'therapyName': 'Momelotinib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis,823
3,NCT02244489,Phase I,Terminated,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 823, 'therapyName': 'Momelotinib'}]",Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma,823
0,NCT02258607,Phase I,Terminated,"[{'id': 823, 'therapyName': 'Momelotinib'}, {'id': 1860, 'therapyName': 'Momelotinib + Trametinib'}]",Efficacy and Safety of Momelotinib and Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase,1860
0,NCT01998971,Phase I,Recruiting,"[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1475, 'therapyName': 'Thalidomide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 3323, 'therapyName': 'Montelukast'}]",A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma,3323
0,NCT02639910,Phase II,Recruiting,"[{'id': 5785, 'therapyName': 'MOR208 + Venetoclax'}, {'id': 5784, 'therapyName': 'Idelalisib + MOR208'}]",Study to Evaluate Efficacy and Safety of MOR208 With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (COSMOS),5785
0,NCT02262910,Phase I,Recruiting,"[{'id': 4651, 'therapyName': 'MOR209/ES414'}]",Study of MOR209/ES414 in Metastatic Castration-Resistant Prostate Cancer,4651
0,NCT00717587,Phase II,Unknown status,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 2129, 'therapyName': 'girentuximab'}, {'id': 2128, 'therapyName': 'motexafin gadolinium'}]",Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer,2128
0,NCT02410512,Phase I,Recruiting,"[{'id': 2729, 'therapyName': 'MOXR0916'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and MPDL3280A in Patients With Locally Advanced or Metastatic Solid Tumors,2729
1,NCT02219724,Phase I,"Active, not recruiting","[{'id': 2729, 'therapyName': 'MOXR0916'}]","A Phase I, Open-Label Study of MOXR0916 in Patients With Locally Advanced or Metastatic Solid Tumors",2729
0,NCT01829971,Phase I,Terminated,"[{'id': 1035, 'therapyName': 'MRX34'}]","A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection",1035
0,NCT02864992,Phase II,Recruiting,"[{'id': 1398, 'therapyName': 'MSC2156119J'}]",Tepotinib Phase II Study in Lung Adenocarcinoma Harbouring MET Exon 14 (METex14) Skipping Alterations,1398
0,NCT01971515,Phase I,Recruiting,"[{'id': 1037, 'therapyName': 'MSC2363318A'}]",First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies,1037
0,NCT02516813,Phase I,Recruiting,"[{'id': 3616, 'therapyName': 'MSC2490484A '}]","Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy",3616
1,NCT03116971,Phase Ib/II,Recruiting,"[{'id': 5546, 'therapyName': 'MSC2490484A  + Cisplatin + Etoposide'}, {'id': 3616, 'therapyName': 'MSC2490484A '}]",Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED),3616
0,NCT03116971,Phase Ib/II,Recruiting,"[{'id': 5546, 'therapyName': 'MSC2490484A  + Cisplatin + Etoposide'}, {'id': 3616, 'therapyName': 'MSC2490484A '}]",Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED),5546
0,NCT02794571,Phase I,Recruiting,"[{'id': 4269, 'therapyName': 'Atezolizumab + MTIG7192A '}, {'id': 4268, 'therapyName': 'MTIG7192A '}]",Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors,4268
0,NCT02192775,Phase II,Recruiting,"[{'id': 6125, 'therapyName': 'MV-NIS'}]",UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus,6125
0,NCT02919449,Phase I,Recruiting,"[{'id': 6127, 'therapyName': 'MV-NIS + Atezolizumab'}]",Trial of Measles Virotherapy in Combination With Atezolizumab in Patients With Metastatic Non-Small Cell Lung Cancer,6127
0,NCT01383148,Phase Ib/II,Terminated,"[{'id': 1273, 'therapyName': 'MVA-MUC1-IL2 vaccine'}]",Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer,1273
0,NCT02823990,Phase II,Recruiting,"[{'id': 4435, 'therapyName': 'MVA-MUC1-IL2 vaccine + Nivolumab'}]",TG4010 and Nivolumab in Patients With Lung Cancer,4435
0,NCT02275039,Phase I,"Active, not recruiting","[{'id': 1038, 'therapyName': 'MVAp53'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer,1038
1,NCT02432963,Phase I,Recruiting,"[{'id': 1038, 'therapyName': 'MVAp53'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy,1038
0,NCT03113487,Phase II,Not yet recruiting,"[{'id': 5547, 'therapyName': 'MVAp53 + Pembrolizumab'}]","P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",5547
0,NCT03118349,Phase I,Recruiting,"[{'id': 5801, 'therapyName': 'MVT-1075 + MVT-5873'}]",Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy,5801
0,NCT02672917,Phase I,Recruiting,"[{'id': 5712, 'therapyName': 'MVT-5873'}]",Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies,5712
0,NCT00305682,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant,1845
1,NCT02756572,Phase I,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5215, 'therapyName': 'mitoxantrone hydrochloride'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myelodysplastic Syndrome or Acute Myeloid Leukemia,1845
2,NCT02333162,Phase I,Recruiting,"[{'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}]","Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant",1845
3,NCT01529827,Phase II,"Active, not recruiting","[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1166, 'therapyName': 'Fludarabine'}]","Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies",1845
4,NCT02251821,Phase II,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 2006, 'therapyName': 'Pacritinib'}, {'id': 823, 'therapyName': 'Momelotinib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis,1845
5,NCT01621477,Phase II,Terminated,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}]",T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant,1845
6,NCT02793544,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide,1845
7,NCT01701986,Phase Ib/II,Recruiting,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 3992, 'therapyName': 'Busulfan + Clofarabine + Gemcitabine'}]",Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas,1845
8,NCT00003553,Phase II,Unknown status,"[{'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer,1845
9,NCT01619761,Phase I,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1847, 'therapyName': 'lenalidomide + Fludarabine + Melphalan'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1843, 'therapyName': 'Tacrolimus'}]",Natural Killer (NK) Cells in Cord Blood Transplantation,1845
10,NCT01760655,Phase II,Recruiting,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1842, 'therapyName': 'Fludarabine + Thiotepa + Cyclophosphamide'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}]",Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies,1845
11,NCT02508038,Phase I,Recruiting,"[{'id': 2971, 'therapyName': 'Zoledronic acid'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}]", Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa,1845
0,NCT02366143,Phase III,"Active, not recruiting","[{'id': 2370, 'therapyName': 'Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel'}, {'id': 1489, 'therapyName': 'Nab-paclitaxel + Carboplatin + Bevacizumab'}, {'id': 1203, 'therapyName': 'Atezolizumab + Carboplatin + Paclitaxel'}]",TBAA Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer,1489
1,NCT00618657,Phase II,"Active, not recruiting","[{'id': 1490, 'therapyName': 'Nab-paclitaxel + Carboplatin + Trastuzumab'}, {'id': 1489, 'therapyName': 'Nab-paclitaxel + Carboplatin + Bevacizumab'}]","Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting",1489
0,NCT00618657,Phase II,"Active, not recruiting","[{'id': 1490, 'therapyName': 'Nab-paclitaxel + Carboplatin + Trastuzumab'}, {'id': 1489, 'therapyName': 'Nab-paclitaxel + Carboplatin + Bevacizumab'}]","Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting",1490
0,NCT02574663,Phase I,"Active, not recruiting","[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2022, 'therapyName': 'TGR-1202'}]",TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors,1779
1,NCT02109445,Phase II,Terminated,"[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 859, 'therapyName': 'PF-03084014'}]",Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies,1779
2,NCT02879318,Phase II,Recruiting,"[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Pancreatic Adenocarcinoma",1779
3,NCT01803282,Phase I,Recruiting,"[{'id': 3320, 'therapyName': 'GS-5745'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Safety and Tolerability Study in Solid Tumors,1779
4,NCT01921751,Phase II,Terminated,"[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery,1779
5,NCT03086369,Phase Ib/II,Recruiting,"[{'id': 5482, 'therapyName': 'Olaratumab + nab-paclitaxel + Gemcitabine'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer,1779
6,NCT01804530,Phase I,"Active, not recruiting","[{'id': 2651, 'therapyName': 'PLX7486'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",Phase 1 Study of PLX7486 as Single Agent and With Gemcitabine Plus Nab-Paclitaxel in Patients With Advanced Solid Tumors,1779
7,NCT02570711,Phase II,Terminated,"[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",Study of Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Previously Untreated Metastatic Pancreatic Cancer,1779
8,NCT02077881,Phase Ib/II,Recruiting,"[{'id': 2976, 'therapyName': 'indoximod'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer,1779
9,NCT02101021,Phase II,Terminated,"[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 823, 'therapyName': 'Momelotinib'}]",Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma,1779
10,NCT02340117,Phase II,Recruiting,"[{'id': 2518, 'therapyName': 'SGT-53'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer,1779
11,NCT01621243,Phase Ib/II,Terminated,"[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 4251, 'therapyName': 'Necuparanib'}]",M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer,1779
12,NCT02436668,Phase II,"Active, not recruiting","[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 768, 'therapyName': 'Ibrutinib'}]","Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma",1779
13,NCT01488552,Phase Ib/II,Completed,"[{'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1031, 'therapyName': 'Metformin'}]",Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer,1779
14,NCT02993731,Phase III,Recruiting,"[{'id': 2630, 'therapyName': 'BBI608 + Gemcitabine + nab-paclitaxel'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma (CanStem111P),1779
0,NCT01376310,Phase II,"Active, not recruiting","[{'id': 1264, 'therapyName': 'Docetaxel + Trametinib'}, {'id': 1265, 'therapyName': 'Erlotinib + Trametinib'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 1266, 'therapyName': 'Pemetrexed + GSK1120212'}, {'id': 1267, 'therapyName': 'Carboplatin + GSK1120212'}, {'id': 1268, 'therapyName': 'nab-paclitaxel + GSK1120212'}, {'id': 1269, 'therapyName': 'Gemcitabine + GSK1120212'}, {'id': 1271, 'therapyName': 'Everolimus + GSK1120212'}]",GSK1120212 Rollover Study,1268
1,NCT02300935,Phase I,Withdrawn,"[{'id': 1268, 'therapyName': 'nab-paclitaxel + GSK1120212'}]",Study of Trametinib and Nab-paclitaxel in Patients With Melanoma,1268
0,NCT02501902,Phase I,Recruiting,"[{'id': 3112, 'therapyName': 'nab-paclitaxel + Palbociclib'}]",Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC,3112
0,NCT02733250,Phase Ib/II,Recruiting,"[{'id': 4023, 'therapyName': 'nab-paclitaxel + Pembrolizumab'}]",Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer (URCOH-PMS-001),4023
1,NCT02752685,Phase II,Recruiting,"[{'id': 4023, 'therapyName': 'nab-paclitaxel + Pembrolizumab'}]",Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer,4023
2,NCT03240016,Phase II,Not yet recruiting,"[{'id': 4023, 'therapyName': 'nab-paclitaxel + Pembrolizumab'}]",Abraxane With Anti-PD1/PDL1 in Cisplatin-ineligible Patients With Advanced Urothelial Cancer,4023
0,NCT02494570,Phase II,Recruiting,"[{'id': 3380, 'therapyName': 'Nab-Rapamycin'}]",A Phase 2 Study of ABI-009 in Patients With Advanced Malignant PEComa,3380
1,NCT02646319,Phase II,"Active, not recruiting","[{'id': 3380, 'therapyName': 'Nab-Rapamycin'}]",Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations,3380
0,NCT03190174,Phase Ib/II,Recruiting,"[{'id': 5931, 'therapyName': 'Nab-Rapamycin + Nivolumab'}]",Nivolumab (Opdivo) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma,5931
0,NCT02975882,Phase I,Recruiting,"[{'id': 5030, 'therapyName': 'Nab-Rapamycin + Temozolomide + Irinotecan'}]","Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors",5030
0,NCT02520778,Phase I,Recruiting,"[{'id': 3065, 'therapyName': 'Navitoclax + Osimertinib'}]",EGFR Inhibitor AZD9291 and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer,3065
0,NCT02143401,Phase I,Recruiting,"[{'id': 1872, 'therapyName': 'Navitoclax + Sorafenib'}]",Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors,1872
0,NCT03181126,Phase I,Not yet recruiting,"[{'id': 6187, 'therapyName': 'Navitoclax + Venetoclax'}]",A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed Acute Lymphoblastic Leukemia,6187
0,NCT02496663,Phase I,Recruiting,"[{'id': 826, 'therapyName': 'Necitumumab'}, {'id': 660, 'therapyName': 'AZD9291'}]",EGFR Inhibitor AZD9291 and Necitumumab in Treating Patients With EGFR-Positive Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor,826
1,NCT01624467,Phase II,Completed,"[{'id': 826, 'therapyName': 'Necitumumab'}]",A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors,826
2,NCT01769391,Phase II,"Active, not recruiting","[{'id': 826, 'therapyName': 'Necitumumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer,826
3,NCT02443337,Phase II,"Active, not recruiting","[{'id': 826, 'therapyName': 'Necitumumab'}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of LY3023414 and Necitumumab in Squamous Lung Cancer,826
4,NCT02451930,Phase I,"Active, not recruiting","[{'id': 826, 'therapyName': 'Necitumumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC,826
0,NCT02941601,Phase II,Withdrawn,"[{'id': 4973, 'therapyName': 'Necitumumab + Gemcitabine + Carboplatin'}]",A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC),4973
0,NCT01788566,Phase II,Completed,"[{'id': 2882, 'therapyName': 'Necitumumab + Gemcitabine + Cisplatin'}]",A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Lung Cancer,2882
0,NCT02789345,Phase I,Recruiting,"[{'id': 4379, 'therapyName': 'Osimertinib + Ramucirumab'}, {'id': 4380, 'therapyName': 'Necitumumab + Osimertinib'}]",A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer,4380
0,NCT01621243,Phase Ib/II,Terminated,"[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 4251, 'therapyName': 'Necuparanib'}]",M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer,4251
0,NCT03020030,Phase III,Recruiting,"[{'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents,3160
1,NCT02518750,Phase II,Recruiting,"[{'id': 1604, 'therapyName': 'Panobinostat + Bortezomib + Dexamethasone'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3217, 'therapyName': 'Cyclophosphamide + Etoposide'}, {'id': 3216, 'therapyName': 'Cytarabine + Methotrexate + Prednisone'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma,3160
2,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,3160
0,NCT01959672,Phase II,Recruiting,"[{'id': 827, 'therapyName': 'Nelfinavir'}, {'id': 1189, 'therapyName': 'Oregovomab'}, {'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Combination Chemotherapy With or Without Oregovomab Followed by Stereotactic Body Radiation Therapy and Nelfinavir Mesylate in Treating Patients With Locally Advanced Pancreatic Cancer,827
0,NCT03050060,Phase II,Recruiting,"[{'id': 5301, 'therapyName': 'Nelfinavir + Nivolumab'}]","Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, and Nivolumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer",5301
0,NCT02636582,Phase II,Recruiting,"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 5152, 'therapyName': 'Nelipepimut-S Plus GM-CSF'}]",Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer,5152
0,NCT02897765,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 4733, 'therapyName': 'NEO-PV-01 + poly ICLC'}]","A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer",4733
0,NCT02129075,Phase II,"Active, not recruiting","[{'id': 3006, 'therapyName': 'NeoVax melanoma vaccine'}, {'id': 3007, 'therapyName': 'CDX-301'}, {'id': 1324, 'therapyName': 'DEC-205-NY-ESO-1 fusion protein vaccine'}]",CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma,3006
1,NCT01970358,Phase I,Recruiting,"[{'id': 3006, 'therapyName': 'NeoVax melanoma vaccine'}]",A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma,3006
0,NCT01670877,Phase II,Recruiting,"[{'id': 828, 'therapyName': 'Neratinib'}]",Neratinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer,828
1,NCT03094052,Phase II,Recruiting,"[{'id': 828, 'therapyName': 'Neratinib'}, {'id': 2700, 'therapyName': 'Loperamide'}, {'id': 5906, 'therapyName': 'Crofelemer'}, {'id': 4359, 'therapyName': 'Neratinib + Trastuzumab'}]","Diarrhea Prophylaxis in Patients With HER2+ Breast Cancer Treated With Trastuzumab and Neratinib, Followed by Neratinib Monotherapy",828
2,NCT03289039,,Not yet recruiting,"[{'id': 828, 'therapyName': 'Neratinib'}, {'id': 5705, 'therapyName': 'Fulvestrant + Neratinib'}]","A Phase 2 Study of Neratinib With or Without Fulvestrant in HER2-Positive, ER-Positive Metastatic Breast Cancer",828
3,NCT01953926,Phase II,Recruiting,"[{'id': 828, 'therapyName': 'Neratinib'}]","An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification",828
4,NCT02400476,Phase II,Recruiting,"[{'id': 828, 'therapyName': 'Neratinib'}]",A Study Looking the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide,828
5,NCT01494662,Phase II,"Active, not recruiting","[{'id': 1543, 'therapyName': 'Capecitabine + Neratinib'}, {'id': 828, 'therapyName': 'Neratinib'}]",HKI-272 for HER2-Positive Breast Cancer and Brain Metastases,828
6,NCT02673398,Phase II,Recruiting,"[{'id': 828, 'therapyName': 'Neratinib'}]",Neratinib in Treating Older Patients With Locally Advanced or Metastatic HER2-Positive Breast Cancer,828
7,NCT02932280,Phase Ib/II,Recruiting,"[{'id': 828, 'therapyName': 'Neratinib'}]",Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment,828
0,NCT03065387,Phase I,Not yet recruiting,"[{'id': 5401, 'therapyName': 'Neratinib + Everolimus'}, {'id': 5402, 'therapyName': 'Neratinib + Palbociclib'}, {'id': 5403, 'therapyName': 'Neratinib + Trametinib'}]","Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification or HER3/4 Mutation",5401
0,NCT03101748,Phase Ib/II,Not yet recruiting,"[{'id': 3187, 'therapyName': 'Neratinib + Paclitaxel + Pertuzumab + Trastuzumab'}, {'id': 1505, 'therapyName': 'Paclitaxel + Neratinib + Doxorubicin + Cyclophosphamide'}]",3HT With Taxol for Metastatic Breast Cancer,3187
1,NCT02593708,Phase I,Unknown status,"[{'id': 3187, 'therapyName': 'Neratinib + Paclitaxel + Pertuzumab + Trastuzumab'}]","Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+",3187
0,NCT03065387,Phase I,Not yet recruiting,"[{'id': 5401, 'therapyName': 'Neratinib + Everolimus'}, {'id': 5402, 'therapyName': 'Neratinib + Palbociclib'}, {'id': 5403, 'therapyName': 'Neratinib + Trametinib'}]","Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification or HER3/4 Mutation",5402
0,NCT02977780,Phase II,Recruiting,"[{'id': 1000, 'therapyName': 'CC-115'}, {'id': 5028, 'therapyName': 'Abemaciclib + Temozolomide'}, {'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 5029, 'therapyName': 'Neratinib + Temozolomide'}]",INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT),5029
0,NCT03065387,Phase I,Not yet recruiting,"[{'id': 5401, 'therapyName': 'Neratinib + Everolimus'}, {'id': 5402, 'therapyName': 'Neratinib + Palbociclib'}, {'id': 5403, 'therapyName': 'Neratinib + Trametinib'}]","Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification or HER3/4 Mutation",5403
0,NCT03094052,Phase II,Recruiting,"[{'id': 828, 'therapyName': 'Neratinib'}, {'id': 2700, 'therapyName': 'Loperamide'}, {'id': 5906, 'therapyName': 'Crofelemer'}, {'id': 4359, 'therapyName': 'Neratinib + Trastuzumab'}]","Diarrhea Prophylaxis in Patients With HER2+ Breast Cancer Treated With Trastuzumab and Neratinib, Followed by Neratinib Monotherapy",4359
0,NCT02236000,Phase Ib/II,Recruiting,"[{'id': 1906, 'therapyName': 'Neratinib + trastuzumab emtansine'}]",A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer,1906
0,NCT00906516,Phase II,Unknown status,"[{'id': 2146, 'therapyName': 'Neuradiab + Bevacizumab'}]",Neuradiab Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme,2146
0,NCT02687009,Phase I,Recruiting,"[{'id': 3072, 'therapyName': 'Niclosamide'}]",A Study of Niclosamide in Patients With Resectable Colon Cancer,3072
1,NCT02532114,Phase I,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 3072, 'therapyName': 'Niclosamide'}]","Niclosamide and Enzalutamide in Treating Patients With Androgen Receptor Splice Variant-Positive, Castration-Resistant, Metastatic Prostate Cancer",3072
0,NCT03123978,Phase I,Recruiting,"[{'id': 5607, 'therapyName': 'Niclosamide + Enzalutamide'}]",Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer,5607
0,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,829
1,NCT01407198,Phase I,"Active, not recruiting","[{'id': 829, 'therapyName': 'Nilotinib'}]",Nilotinib With Radiation for High Risk Chordoma,829
2,NCT02081378,Phase I,Recruiting,"[{'id': 2484, 'therapyName': 'ABL001'}, {'id': 829, 'therapyName': 'Nilotinib'}]","A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)",829
3,NCT01201538,Phase II,Terminated,"[{'id': 829, 'therapyName': 'Nilotinib'}]",A Study of Nilotinib in Growing Vestibular Schwannomas,829
4,NCT01698905,Phase II,"Active, not recruiting","[{'id': 829, 'therapyName': 'Nilotinib'}]",Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop),829
5,NCT01140568,Phase II,Recruiting,"[{'id': 829, 'therapyName': 'Nilotinib'}]",Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas,829
6,NCT01784068,Phase II,"Active, not recruiting","[{'id': 829, 'therapyName': 'Nilotinib'}]",Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients,829
7,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,829
8,NCT01207492,Phase II,"Active, not recruiting","[{'id': 829, 'therapyName': 'Nilotinib'}]",Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor,829
9,NCT01844765,Phase II,"Active, not recruiting","[{'id': 829, 'therapyName': 'Nilotinib'}]","Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.",829
10,NCT02779283,Phase I,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,829
11,NCT01028222,Phase II,Completed,"[{'id': 829, 'therapyName': 'Nilotinib'}]",A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation,829
12,NCT01806571,Phase II,Recruiting,"[{'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}]","Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",829
13,NCT01744665,Phase II,"Active, not recruiting","[{'id': 829, 'therapyName': 'Nilotinib'}]",Safety and Efficacy of CML Patients Who Switch to Nilotinib and Stop Treatment After Achieving and Sustaining MR4.5.,829
14,NCT00129740,Phase II,"Active, not recruiting","[{'id': 829, 'therapyName': 'Nilotinib'}]",Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML),829
15,NCT02709083,Phase II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 770, 'therapyName': 'Imatinib'}]","Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia",829
16,NCT01620216,Phase II,Recruiting,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Validation of an in Vitro Assay to Predict Targeted Therapies for Acute Leukemia Patients,829
17,NCT02353728,Phase II,Not yet recruiting,"[{'id': 829, 'therapyName': 'Nilotinib'}]",Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy,829
18,NCT01244750,Phase I,"Active, not recruiting","[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}]",Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting,829
19,NCT00718263,Phase III,Recruiting,"[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}]",Efficacy and Safety of Nilotinib Patients With Newly Diagnosed CML - CP (Chronic Myelogenous Leukemia - Chronic Phase),829
20,NCT01222143,Phase Ib/II,Terminated,"[{'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}]","Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia",829
21,NCT01077544,Phase I,Completed,"[{'id': 829, 'therapyName': 'Nilotinib'}]",A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL),829
0,NCT01871311,Phase I,Recruiting,"[{'id': 1929, 'therapyName': 'Nilotinib + Cetuximab'}]",A Phase I Study of the BCR-ABL Tyrosine Kinase Inhibitor Nilontinib and Cetuximab in Patients With Solid Tumors That Can be Treated With Cetuximab,1929
0,NCT02947386,Phase Ib/II,Recruiting,"[{'id': 4920, 'therapyName': 'Nimotuzumab + Nivolumab'}]",Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer,4920
0,NCT02452463,Phase II,Recruiting,"[{'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy,831
1,NCT02496585,Phase II,Recruiting,"[{'id': 831, 'therapyName': 'Nintedanib'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis,831
2,NCT02780700,Phase II,Terminated,"[{'id': 2589, 'therapyName': 'Capecitabine + Nintedanib'}, {'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2],831
3,NCT01907100,Phase III,Recruiting,"[{'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib (BIBF 1120) in Mesothelioma,831
4,NCT02231164,Phase III,Terminated,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 831, 'therapyName': 'Nintedanib'}]",LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research,831
5,NCT02568449,Phase II,Recruiting,"[{'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent,831
6,NCT02152059,Phase II,Withdrawn,"[{'id': 831, 'therapyName': 'Nintedanib'}]",A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy,831
7,NCT01948141,Phase II,Completed,"[{'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens,831
8,NCT02389764,Phase II,Recruiting,"[{'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib For HER2-negative Metastatic Inflammatory Breast Cancer (MIBC),831
9,NCT02149108,Phase III,Completed,"[{'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib (BIBF 1120) vs Placebo in Refractory Colorectal Cancer,831
10,NCT01669798,Phase II,Recruiting,"[{'id': 831, 'therapyName': 'Nintedanib'}]","BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer",831
11,NCT02399215,Phase II,Recruiting,"[{'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors,831
12,NCT02902484,Phase Ib/II,Not yet recruiting,"[{'id': 4723, 'therapyName': 'Nintedanib + Gemcitabine + nab-paclitaxel'}, {'id': 831, 'therapyName': 'Nintedanib'}]",Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer,831
13,NCT02299141,Phase I,Recruiting,"[{'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer,831
14,NCT02665143,Phase Ib/II,Recruiting,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 831, 'therapyName': 'Nintedanib'}]",A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia,831
15,NCT02234596,Phase II,"Active, not recruiting","[{'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib in Patients With Advanced Esophagogastric Cancer,831
0,NCT02902484,Phase Ib/II,Not yet recruiting,"[{'id': 4723, 'therapyName': 'Nintedanib + Gemcitabine + nab-paclitaxel'}, {'id': 831, 'therapyName': 'Nintedanib'}]",Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer,4723
0,NCT01847274,Phase III,Completed,"[{'id': 832, 'therapyName': 'Niraparib'}]",A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer,832
1,NCT03016338,Phase II,Not yet recruiting,"[{'id': 832, 'therapyName': 'Niraparib'}]",Study of Niraparib in Recurrent Endometrial Cancer,832
2,NCT01905592,Phase III,"Active, not recruiting","[{'id': 832, 'therapyName': 'Niraparib'}]","A Phase III Trial of Niraparib Versus Physician's Choice in Her2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients",832
3,NCT02854436,Phase II,Suspended,"[{'id': 832, 'therapyName': 'Niraparib'}]",An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies,832
4,NCT03307785,,Not yet recruiting,"[{'id': 832, 'therapyName': 'Niraparib'}]",Study of Niraparib or Carboplatin-Paclitaxel in Combination With TSR-042,832
5,NCT02500901,Phase I,"Active, not recruiting","[{'id': 832, 'therapyName': 'Niraparib'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC),832
6,NCT03207347,Phase II,Not yet recruiting,"[{'id': 832, 'therapyName': 'Niraparib'}]",A Trial of Niraparib in BAP1 and Other DNA Double-Strand Break Repair Deficient Neoplasms (UF-STO-ETI-001),832
7,NCT02354131,Phase Ib/II,Recruiting,"[{'id': 832, 'therapyName': 'Niraparib'}, {'id': 4254, 'therapyName': 'Bevacizumab + Niraparib'}]",Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer (AVANOVA),832
8,NCT02655016,Phase III,Recruiting,"[{'id': 832, 'therapyName': 'Niraparib'}]",A Study of Niraparib Maintenance Treatment in Patients With HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy,832
9,NCT02354586,Phase II,Recruiting,"[{'id': 832, 'therapyName': 'Niraparib'}]",A Study of Niraparib in Patients With Ovarian Cancer Who Have Received at Least Three Previous Chemotherapy Regimens,832
0,NCT03154281,Phase I,Not yet recruiting,"[{'id': 5732, 'therapyName': 'Niraparib + Everolimus'}]",Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Ovarian and Breast,5732
0,NCT02657889,Phase Ib/II,Recruiting,"[{'id': 3935, 'therapyName': 'Niraparib + Pembrolizumab'}]",Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Triple-negative Breast Cancer or Ovarian Cancer (KEYNOTE-162),3935
0,NCT03076203,Phase I,Recruiting,"[{'id': 5436, 'therapyName': 'Niraparib + radium Ra 223 dichloride'}]",Radium Ra 223 Dichloride and Niraparib in Treating Patients With Hormone- Resistant Prostate Cancer Metastatic to the Bone,5436
0,NCT02044120,Phase I,Recruiting,"[{'id': 1437, 'therapyName': 'Niraparib + Temozolomide'}]","ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide in Patients With Previously Treated, Incurable Ewing Sarcoma",1437
0,NCT02947165,Phase I,Recruiting,"[{'id': 5632, 'therapyName': 'NIS793 + PDR001'}, {'id': 5631, 'therapyName': 'NIS793'}]",Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.,5631
0,NCT02947165,Phase I,Recruiting,"[{'id': 5632, 'therapyName': 'NIS793 + PDR001'}, {'id': 5631, 'therapyName': 'NIS793'}]",Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.,5632
0,NCT01210378,Phase II,Completed,"[{'id': 2924, 'therapyName': 'Nitroglycerin'}]",Nitroglycerin in Non-small Cell Lung Cancer,2924
0,NCT02314169,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Treating Patients With Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal,1312
1,NCT02992964,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers,1312
2,NCT02775292,Phase I,Recruiting,"[{'id': 3409, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine '}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}]","Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1",1312
3,NCT03259867,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Combination of TATE and PD-1 Inhibitor in Liver Cancer,1312
4,NCT02569242,Phase III,"Active, not recruiting","[{'id': 3045, 'therapyName': 'Docetaxel + Paclitaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer,1312
5,NCT02526017,Phase I,Recruiting,"[{'id': 2840, 'therapyName': 'FPA008'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers,1312
6,NCT02857426,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL) (CheckMate 647),1312
7,NCT02731729,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy,1312
8,NCT01592370,Phase I,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2583, 'therapyName': 'Lirilumab '}]",Safety Study in Nivolumab Alone and in Combination With Ipilimumab or Lirilumab in Lymphoma and Multiple Myeloma,1312
9,NCT02617589,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1141, 'therapyName': 'Temozolomide'}]","Study of Nivolumab Versus Temozolomide, Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate 498)",1312
10,NCT02311920,Phase I,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Temozolomide in Combination With Ipilimumab and/or Nivolumab in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma,1312
11,NCT03241745,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study of Nivolumab in Selected Uterine Cancer Patients,1312
12,NCT02743494,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal or Gastroesophageal Junction Cancer (CheckMate 577),1312
13,NCT03106610,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy,1312
14,NCT02596035,FDA approved,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374),1312
15,NCT03285321,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC),1312
16,NCT03080974,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma,1312
17,NCT03021993,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer,1312
18,NCT02575222,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma,1312
19,NCT02736123,Phase Ib/II,Withdrawn,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone,1312
20,NCT02017717,Phase III,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Randomized Study of Nivolumab Versus Bevacizumab and a Safety Study of Nivolumab in Adult Subjects With Recurrent Glioblastoma (GBM) (CheckMate 143),1312
21,NCT02565758,Phase I,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 3846, 'therapyName': 'ABBV-085'}]","ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors",1312
22,NCT02532231,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Acute Myeloid Leukemia (AML) in Remission at High Risk for Relapse,1312
23,NCT02781506,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab and Stereotactic Ablative Radiation Therapy Versus Nivolumab Alone for Metastatic Renal Cancer,1312
24,NCT02475382,Expanded access,No longer available,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen (CheckMate 169),1312
25,NCT03025256,Phase I,Not yet recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Concurrent Intravenous and Intrathecal Nivolumab for Patients With Leptomeningeal Disease (LMD),1312
26,NCT02785952,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers,1312
27,NCT02553642,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260),1312
28,NCT02919683,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity,1312
29,NCT03203304,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Stereotactic Body Radiotherapy (SBRT) Followed by Nivolumab or Ipilimumab With Nivolumab in Unresectable Hepatocellular Carcinoma,1312
30,NCT02598960,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 3559, 'therapyName': 'BMS-986156'}]",A Study of BMS-986156 Given Alone and in Combination With Nivolumab in Subjects With Advanced Solid Tumors,1312
31,NCT02483247,Phase Ib/II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1945, 'therapyName': 'BBI503'}]",A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer,1312
32,NCT02530463,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS),1312
33,NCT03121417,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Biomarker-Driven Phase 2 Study of Nivolumab in Advanced Metastatic Non-small Cell Lung Cancer,1312
34,NCT02897765,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 4733, 'therapyName': 'NEO-PV-01 + poly ICLC'}]","A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer",1312
35,NCT01658878,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]","Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab in Subjects With Advanced Liver Cancer Anti-PD-1 HCC (Anti-Programmed-Death-1 Hepatocellular Carcinoma)",1312
36,NCT02439450,Phase I,Recruiting,"[{'id': 2457, 'therapyName': 'HS-110'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer,1312
37,NCT01928394,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors",1312
38,NCT01454102,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)",1312
39,NCT01928576,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1541, 'therapyName': 'Entinostat'}, {'id': 651, 'therapyName': 'Azacitidine'}]",Phase II Anti-PD1 Epigenetic Priming Study in NSCLC.,1312
40,NCT03203473,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study),1312
41,NCT02631746,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma,1312
42,NCT02142218,Phase I,No longer available,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Expanded Access Program With Nivolumab to Treat Melanoma,1312
43,NCT02864381,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 4736, 'therapyName': 'GS-5745 + Nivolumab'}]",GS-5745 Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma,1312
44,NCT02840994,Phase Ib/II,Recruiting,"[{'id': 5244, 'therapyName': 'CV301 + Nivolumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Trial of CV301 in Combination With Nivolumab Versus Nivolumab in Subjects With Previously Treated Non-Small Cell Lung Cancer,1312
45,NCT02477826,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, Trial of Nivolumab and Nivolumab Plus Ipilimumab Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC)",1312
46,NCT03075553,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma,1312
47,NCT02664181,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 5910, 'therapyName': 'Decitabine + Nivolumab + Tetrahydrouridine'}]",Pharmacologically Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With Non-Small Cell Lung Cancer (PRECISE),1312
48,NCT02451982,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 3622, 'therapyName': 'Cyclophosphamide + GVAX pancreatic cancer vaccine '}]",Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab Trial for Surgically Resectable Pancreatic Cancer,1312
49,NCT02466568,Phase Ib/II,Not yet recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung,1312
50,NCT03068455,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study of Nivolumab in Combination With Ipilimumab Compared to Nivolumab or Ipilimumab Alone in Treatment of Patients After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915),1312
51,NCT02257528,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]","Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer",1312
52,NCT03158129,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study Of Induction Checkpoint Blockade For Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable For Surgical Resection,1312
53,NCT02837029,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer,1312
54,NCT02529072,Phase I,Terminated,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab With DC Vaccines for Recurrent Brain Tumors,1312
55,NCT02599402,Phase III,"Active, not recruiting","[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma,1312
56,NCT02105636,Phase III,"Active, not recruiting","[{'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141),1312
57,NCT02750514,Phase II,Recruiting,"[{'id': 1813, 'therapyName': 'Dasatinib + Nivolumab'}, {'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Study to Test Combination Treatments in People With Advanced Non-Small Cell Lung Cancer,1312
58,NCT03115801,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers,1312
59,NCT02467361,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2057, 'therapyName': 'BBI608'}]",A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers,1312
60,NCT02472977,Phase Ib/II,Terminated,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 2847, 'therapyName': 'Ulocuplumab'}]",Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors,1312
61,NCT02864251,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 4616, 'therapyName': 'Carboplatin + Cisplatin + Pemetrexed'}]","A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Patients With EGFR Mutation, T790M Negative NSCLC Who Have Failed 1L EGFR TKI Therapy (CheckMate722)",1312
62,NCT02339558,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer,1312
63,NCT02823574,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,1312
64,NCT03215810,,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer,1312
65,NCT02428192,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Treating Patients With Advanced Uterine Leiomyosarcoma,1312
66,NCT03055013,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy (PROSPER),1312
67,NCT03126331,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Intermittent Nivolumab in Metastatic Renal Cell Carcinoma Patients,1312
68,NCT02041533,Phase III,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)",1312
69,NCT02696993,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Phase I/II Trial of Nivolumab With Radiation or Nivolumab and Ipilimumab With Radiation for the Treatment of Intracranial Metastases From Non-small Cell Lung Cancer,1312
70,NCT02978404,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases,1312
71,NCT02764593,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 4760, 'therapyName': 'Cisplatin + Nivolumab'}, {'id': 4761, 'therapyName': 'Cetuximab + Nivolumab'}]",Chemotherapy +/- Nivolumab in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma,1312
72,NCT02538666,Phase III,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy (CheckMate 451)",1312
73,NCT02426892,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors,1312
74,NCT02469701,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]",BrUOG 317: Nivolumab and Ablation For Patients With Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease,1312
75,NCT03224871,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC.,1312
76,NCT02387996,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer,1312
77,NCT02599649,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2583, 'therapyName': 'Lirilumab '}]",Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS),1312
78,NCT03149120,Phase II,Withdrawn,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 5681, 'therapyName': 'Nivolumab + Pazopanib'}]",Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas,1312
79,NCT03238365,Phase I,Recruiting,"[{'id': 6100, 'therapyName': 'Nivolumab + Tadalafil'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab With or Without Tadalafil in Treating Patients With Recurrent Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery,1312
80,NCT03038672,Phase II,Not yet recruiting,"[{'id': 2526, 'therapyName': 'Nivolumab + Varlilumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas,1312
81,NCT03130959,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies (CheckMate 908),1312
82,NCT02576509,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 920, 'therapyName': 'Sorafenib'}]",A Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma,1312
83,NCT02985554,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies,1312
84,NCT02713867,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]","A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks (CheckMate 384)",1312
85,NCT03143270,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer,1312
86,NCT03233347,,Not yet recruiting,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 2486, 'therapyName': 'Brentuximab vedotin'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","Doxorubicin Hydrochloride, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma",1312
87,NCT02339571,Phase II,Suspended,"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,1312
88,NCT03171025,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer (NEXT),1312
89,NCT02684253,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]","Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)",1312
90,NCT02066636,Phase III,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153),1312
91,NCT02060188,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142),1312
92,NCT02962804,Phase II,Not yet recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC),1312
93,NCT02350764,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Evaluate the Mediators of Sensitivity and Resistance to Nivolumab in Patients With Advanced NSCLCs,1312
94,NCT03090737,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer (CheckMate 907),1312
95,NCT03117309,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma,1312
96,NCT01176474,Phase I,"Active, not recruiting","[{'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma,1312
97,NCT02652455,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 3409, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine '}, {'id': 2055, 'therapyName': 'Urelumab'}]","Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma",1312
98,NCT03110978,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I or Isolated Lung Parenchymal Recurrent Non-small Cell Lung Cancer: I-SABR,1312
99,NCT02924233,Phase Ib/II,Withdrawn,"[{'id': 4833, 'therapyName': 'Nivolumab + SYM004'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer,1312
100,NCT02716948,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Stereotactic Radiosurgery and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine,1312
101,NCT02829918,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers,1312
102,NCT03173950,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers,1312
103,NCT02388906,Phase III,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238),1312
104,NCT02156804,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]","A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)",1312
105,NCT02614456,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1733, 'therapyName': 'interferon gamma '}]",Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors,1312
106,NCT03222076,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable and Potentially Resectable Hepatocellular Carcinoma (HCC) (CA209-956),1312
107,NCT02259231,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 3062, 'therapyName': 'RTA 408'}]",RTA 408 Capsules in Patients With Melanoma - REVEAL,1312
108,NCT02275533,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Eliminating Minimal Residual Disease and Preventing Relapse in Patients With Acute Myeloid Leukemia in Remission After Chemotherapy,1312
109,NCT02574078,Phase I,Recruiting,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2114, 'therapyName': 'Bevacizumab + Pemetrexed'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",A Master Protocol Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate 370),1312
110,NCT02720484,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer,1312
111,NCT02648997,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma,1312
112,NCT02829931,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Hypofractionated Stereotactic Irradiation With Nivolumab in Patients With Recurrent High Grade Gliomas,1312
113,NCT02595918,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Treating Patients With HIgh-Risk Non-Metastatic Kidney Cancer,1312
114,NCT02726581,Phase III,"Active, not recruiting","[{'id': 3343, 'therapyName': 'Elotuzumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 3792, 'therapyName': 'Dexamethasone + Pomalidomide'}]","Study of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Multiple Myeloma",1312
115,NCT03302247,Phase II,Not yet recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 6297, 'therapyName': 'Gemcitabine + Nivolumab'}]",Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy,1312
116,NCT02846376,Phase I,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002),1312
117,NCT02880020,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery,1312
118,NCT01621490,Phase I,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma (PD-1),1312
119,NCT02737475,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 4030, 'therapyName': 'BMS-986178'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Study of BMS-986178 Monotherapy or in Combination With Nivolumab or Ipilimumab in Subjects With Advanced Solid Tumors,1312
120,NCT02989636,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]","Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma",1312
121,NCT03271047,,Recruiting,"[{'id': 807, 'therapyName': 'Binimetinib'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation,1312
122,NCT01585194,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma,1312
123,NCT02519322,Phase II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma,1312
124,NCT03233711,Phase II,Not yet recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer,1312
125,NCT02488759,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358),1312
126,NCT02498600,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",1312
127,NCT02481830,Phase III,"Active, not recruiting","[{'id': 2951, 'therapyName': 'Amrubicin'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 942, 'therapyName': 'Topotecan'}]",Efficacy Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer,1312
128,NCT02500797,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma,1312
129,NCT03305445,,Not yet recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL,1312
130,NCT02210117,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 2111, 'therapyName': 'Bevacizumab + Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab vs Nivolumab + Bevacizumab vs Nivolumab + Ipilimumab in Metastatic Renal Cell Carcinoma (mRCC),1312
131,NCT02259621,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]","Neoadjuvant Anti-PD-1, Nivolumab in Resectable NSCLC",1312
132,NCT03168464,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632),1312
133,NCT02632409,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study of Adjuvant Nivolumab Versus Placebo Post-Surgical Removal of High Risk Invasive Urothelial Carcinoma,1312
134,NCT02038946,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140),1312
135,NCT02181738,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Nivolumab in Subjects With Hodgkin's Lymphoma (Registrational) (CheckMate 205),1312
136,NCT02423954,Phase Ib/II,"Active, not recruiting","[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus),1312
137,NCT03247712,Phase Ib/II,Not yet recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Neoadjuvant Immunoradiotherapy in Head & Neck Cancer,1312
138,NCT02518958,Phase I,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]","A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab",1312
139,NCT02864316,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure,1312
140,NCT02595944,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (ANVIL),1312
141,NCT02423343,Phase Ib/II,Recruiting,"[{'id': 2409, 'therapyName': 'Galunisertib'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioma",1312
0,NCT03107182,Phase II,Recruiting,"[{'id': 5581, 'therapyName': 'Dexamethasone + Diphenhydramine + Famotidine + 5FU + Hydroxyurea + Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 5303, 'therapyName': 'Nivolumab + Carboplatin + Paclitaxel'}]",Oropharyngeal Tumor Induction Chemotherapy and Response-stratified Locoregional Therapy Trial in Order to Minimize Long-term Adverse Events,5303
1,NCT03245892,Phase I,Recruiting,"[{'id': 5303, 'therapyName': 'Nivolumab + Carboplatin + Paclitaxel'}]",A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab in Patients With Ovarian Cancer,5303
2,NCT03044613,Phase I,Recruiting,"[{'id': 5304, 'therapyName': 'Nivolumab + Ipilimumab + Carboplatin + Paclitaxel'}, {'id': 5303, 'therapyName': 'Nivolumab + Carboplatin + Paclitaxel'}]",Nivolumab or Nivolumab/Ipilimumab Prior to Chemoradiation Plus Nivolumab With II/III Gastro/Esophageal Cancer,5303
0,NCT03143153,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 5799, 'therapyName': 'Nivolumab + Cisplatin + Fluorouacil'}]",A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin (CheckMate 648),5799
0,NCT03016871,Phase II,Recruiting,"[{'id': 5198, 'therapyName': 'Nivolumab + Etoposide + Ifosfamide + Carboplatin'}]","Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed Hodgkin Lymphoma",5198
0,NCT03146650,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Metastatic Recurrent Major or Minor Salivary Gland Cancer,1627
1,NCT02231749,Phase III,"Active, not recruiting","[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214),1627
2,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,1627
3,NCT03043599,Phase Ib/II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer,1627
4,NCT03065179,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Trial of SBRT in Combination With Nivolumab/Ipilimumab in RCC / Kidney Cancer Patients,1627
5,NCT03143153,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 5799, 'therapyName': 'Nivolumab + Cisplatin + Fluorouacil'}]",A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin (CheckMate 648),1627
6,NCT03033576,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That is Stage IV or Stage III and Cannot Be Removed by Surgery,1627
7,NCT02935634,Phase II,Recruiting,"[{'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer (FRACTION-GC),1627
8,NCT02186249,Phase III,No longer available,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Anti-CTLA-4 Treatment-Naïve Subjects With Unresectable or Metastatic Melanoma (CheckMate 218),1627
9,NCT02846376,Phase I,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002),1627
10,NCT02978443,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab,1627
11,NCT02714218,Phase III,"Active, not recruiting","[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma",1627
12,NCT02681302,Phase Ib/II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence (CPIT001),1627
13,NCT03203473,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study),1627
14,NCT02899299,Phase III,Recruiting,"[{'id': 4616, 'therapyName': 'Carboplatin + Cisplatin + Pemetrexed'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (CheckMate743),1627
15,NCT03162731,Phase I,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage IVA-B Head and Neck Cancer",1627
16,NCT03223155,Phase I,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","Evaluate Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV Non-Small Cell Lung Cancer",1627
17,NCT02599402,Phase III,"Active, not recruiting","[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma,1627
18,NCT03068455,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study of Nivolumab in Combination With Ipilimumab Compared to Nivolumab or Ipilimumab Alone in Treatment of Patients After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915),1627
19,NCT03274258,Phase II,Not yet recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma,1627
20,NCT02880020,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery,1627
21,NCT03158129,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study Of Induction Checkpoint Blockade For Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable For Surgical Resection,1627
22,NCT03101566,Phase II,Recruiting,"[{'id': 5511, 'therapyName': 'Cisplatin + Gemcitabine + Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer,1627
23,NCT02320058,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects With Melanoma Metastatic to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy (CheckMate 204),1627
24,NCT02210117,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 2111, 'therapyName': 'Bevacizumab + Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab vs Nivolumab + Bevacizumab vs Nivolumab + Ipilimumab in Metastatic Renal Cell Carcinoma (mRCC),1627
25,NCT03001882,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC),1627
26,NCT03104439,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer,1627
27,NCT03149159,Phase II,Not yet recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab",1627
28,NCT03256136,Phase II,Not yet recruiting,"[{'id': 6159, 'therapyName': 'Carboplatin + Nivolumab + Pemetrexed'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","A Phase II Study of Nivolumab in Combination With Carboplatin and Pemetrexed, or Nivolumab in Combination With Ipilimumab, in Patients With Advanced, EGFR-mutant or ALK-rearranged, Non-Small Cell Lung Cancer",1627
29,NCT02864251,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 4616, 'therapyName': 'Carboplatin + Cisplatin + Pemetrexed'}]","A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Patients With EGFR Mutation, T790M Negative NSCLC Who Have Failed 1L EGFR TKI Therapy (CheckMate722)",1627
30,NCT03029780,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma,1627
31,NCT02823574,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,1627
32,NCT03215706,Phase III,Recruiting,"[{'id': 6132, 'therapyName': 'Carboplatin + Cisplatin + Paclitaxel + Pemetrexed'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy by Itself as the First Treatment Given for Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 9LA),1627
33,NCT02996110,Phase II,Recruiting,"[{'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (FRACTION-RCC),1627
34,NCT03036098,Phase III,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care Chemotherapy in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer,1627
35,NCT02998528,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 5241, 'therapyName': 'Cisplatin + Vinorelbine + Gemcitabine + Docetaxel + Pemetrexed + Carboplatin'}]",A Neoadjuvant Study of Nivolumab and Ipilimumab Compared to Chemotherapy Doublet in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816),1627
36,NCT03138512,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Participants With Localized Renal Cell Carcinoma (CheckMate 914),1627
37,NCT02304458,Phase Ib/II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas,1627
38,NCT02659540,Phase I,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma,1627
39,NCT02741570,Phase III,Recruiting,"[{'id': 4168, 'therapyName': 'Carboplatin + Cetuximab + Cisplatin + Fluorouracil'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,1627
40,NCT03071406,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma,1627
41,NCT02970981,Phase II,Not yet recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma,1627
42,NCT02982954,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer (CHECKMATE 920),1627
43,NCT02869789,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Safety Study of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers,1627
44,NCT03126461,Phase II,Not yet recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients,1627
45,NCT03130959,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies (CheckMate 908),1627
46,NCT02601014,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7,1627
47,NCT03285321,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC),1627
48,NCT02736123,Phase Ib/II,Withdrawn,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone,1627
49,NCT02453620,Phase I,Recruiting,"[{'id': 1541, 'therapyName': 'Entinostat'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer",1627
50,NCT02659059,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab Plus Ipilimumab to Treat First Line Stage IV Non-Small Cell Lung Cancer (CheckMate568),1627
51,NCT02892734,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer,1627
52,NCT02939300,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab and Nivolumab in Leptomeningeal Metastases From Melanoma,1627
53,NCT02985957,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study to Evaluate Preliminary Safety and Efficacy of Nivolumab Plus Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer,1627
54,NCT03048136,Phase III,Not yet recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer (CheckMate 955),1627
55,NCT03117309,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma,1627
56,NCT03222076,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable and Potentially Resectable Hepatocellular Carcinoma (HCC) (CA209-956),1627
57,NCT02872116,Phase III,Recruiting,"[{'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Efficacy Study of Nivolumab Plus Ipilimumab Against Chemotherapy Standard of Care in Stomach Cancer or Stomach/Esophagus Junction Cancer (CheckMate649),1627
58,NCT02919683,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity,1627
59,NCT03203304,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Stereotactic Body Radiotherapy (SBRT) Followed by Nivolumab or Ipilimumab With Nivolumab in Unresectable Hepatocellular Carcinoma,1627
60,NCT03220009,Phase II,Not yet recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma",1627
61,NCT03172624,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer,1627
62,NCT02224781,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma,1627
63,NCT02408861,Phase I,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Advanced HIV Associated Solid Tumors,1627
64,NCT01822509,Phase I,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant,1627
65,NCT02785952,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers,1627
66,NCT02017717,Phase III,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Randomized Study of Nivolumab Versus Bevacizumab and a Safety Study of Nivolumab in Adult Subjects With Recurrent Glioblastoma (GBM) (CheckMate 143),1627
67,NCT02833233,Phase I,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer,1627
68,NCT03262779,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.,1627
69,NCT02656706,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",BrUOG 324: Adjuvant Nivolumab and Low Dose Ipilimumab for Stage III and Resected Stage IV Melanoma: A Phase II Brown University Oncology Research Group Trial,1627
70,NCT03246958,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab Plus Ipilimumab in Thyroid Cancer,1627
0,NCT03044613,Phase I,Recruiting,"[{'id': 5304, 'therapyName': 'Nivolumab + Ipilimumab + Carboplatin + Paclitaxel'}, {'id': 5303, 'therapyName': 'Nivolumab + Carboplatin + Paclitaxel'}]",Nivolumab or Nivolumab/Ipilimumab Prior to Chemoradiation Plus Nivolumab With II/III Gastro/Esophageal Cancer,5304
0,NCT02903381,Phase II,Recruiting,"[{'id': 5128, 'therapyName': 'Nivolumab + Lenalidomide + Dexamethasone'}]",Nivolumab + Lenalidomide + Dexamethasone In SMM,5128
0,NCT03149120,Phase II,Withdrawn,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 5681, 'therapyName': 'Nivolumab + Pazopanib'}]",Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas,5681
0,NCT02949843,Phase II,Recruiting,"[{'id': 4918, 'therapyName': 'Nivolumab + Pembrolizumab'}]",Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations,4918
0,NCT03229278,Phase I,Not yet recruiting,"[{'id': 6055, 'therapyName': 'Nivolumab + Pembrolizumab + Trigriluzole'}]",Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma,6055
0,NCT02812667,Phase I,Recruiting,"[{'id': 4512, 'therapyName': 'Nivolumab + Plinabulin'}]",Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC),4512
1,NCT02846792,Phase Ib/II,Recruiting,"[{'id': 4512, 'therapyName': 'Nivolumab + Plinabulin'}]","Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer",4512
0,NCT03121677,Phase I,Not yet recruiting,"[{'id': 5592, 'therapyName': 'Nivolumab + poly ICLC + Rituximab'}]",Personalized Synthetic Long Peptide Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma,5592
0,NCT02400385,Phase II,Withdrawn,"[{'id': 2626, 'therapyName': 'Nivolumab + Sunitinib'}]",A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma,2626
0,NCT02924233,Phase Ib/II,Withdrawn,"[{'id': 4833, 'therapyName': 'Nivolumab + SYM004'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer,4833
0,NCT03238365,Phase I,Recruiting,"[{'id': 6100, 'therapyName': 'Nivolumab + Tadalafil'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab With or Without Tadalafil in Treating Patients With Recurrent Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery,6100
0,NCT02834247,Phase I,Recruiting,"[{'id': 4680, 'therapyName': 'Nivolumab + TAK-659'}]",A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors,4680
0,NCT02667587,Phase II,Recruiting,"[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 3724, 'therapyName': 'Nivolumab + Temozolomide'}]","Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer).",3724
0,NCT02910700,Phase II,Recruiting,"[{'id': 4753, 'therapyName': 'Nivolumab + Trametinib'}, {'id': 4754, 'therapyName': 'Dabrafenib + Nivolumab + Trametinib'}]",Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib in Patients With BRAF or NRAS-mutated Metastatic Melanoma,4753
0,NCT02860546,Phase II,"Active, not recruiting","[{'id': 4560, 'therapyName': 'Nivolumab + trifluridine/tipiracil hydrochloride'}]",A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC,4560
0,NCT02253992,Phase Ib/II,Recruiting,"[{'id': 2567, 'therapyName': 'Nivolumab + Urelumab'}]",Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkins Lymphoma,2567
1,NCT02845323,Phase II,Recruiting,"[{'id': 2055, 'therapyName': 'Urelumab'}, {'id': 2567, 'therapyName': 'Nivolumab + Urelumab'}]",Neoadjuvant Nivolumab With and Without Urelumab in Patients With Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma of the Bladder,2567
0,NCT02648633,Phase I,Terminated,"[{'id': 4219, 'therapyName': 'Nivolumab + Valproic acid'}]",Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma,4219
0,NCT03038672,Phase II,Not yet recruiting,"[{'id': 2526, 'therapyName': 'Nivolumab + Varlilumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas,2526
1,NCT02413827,Phase Ib/II,Terminated,"[{'id': 2526, 'therapyName': 'Nivolumab + Varlilumab'}, {'id': 1324, 'therapyName': 'DEC-205-NY-ESO-1 fusion protein vaccine'}, {'id': 2595, 'therapyName': 'poly ICLC  '}]",A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma,2526
2,NCT02335918,Phase Ib/II,Recruiting,"[{'id': 2526, 'therapyName': 'Nivolumab + Varlilumab'}]",A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors,2526
0,NCT02737787,Phase I,Recruiting,"[{'id': 4020, 'therapyName': 'Nivolumab + WT1 vaccine'}]",A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer,4020
0,NCT02923531,Phase Ib/II,Recruiting,"[{'id': 4837, 'therapyName': 'Nivolumab + X4P-001'}]",Addition of X4P-001 to Nivolumab Treatment in Patients With Renal Cell Carcinoma,4837
0,NCT03018405,Phase I,Recruiting,"[{'id': 5998, 'therapyName': 'NKR-2 cells'}]",A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK),5998
0,NCT02869295,Phase I,Recruiting,"[{'id': 5075, 'therapyName': 'NKTR-214'}]",A Phase 1 Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors,5075
0,NCT03282344,Phase II,Recruiting,"[{'id': 5076, 'therapyName': 'NKTR-214 + Nivolumab'}]",A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma,5076
1,NCT02983045,Phase Ib/II,Recruiting,"[{'id': 5076, 'therapyName': 'NKTR-214 + Nivolumab'}]",A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors (PIVOT-02),5076
0,NCT03138889,Phase I,Recruiting,"[{'id': 5625, 'therapyName': 'NKTR-214 + Pembrolizumab'}]",A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Metastatic Urothelial Bladder Cancer or Metastatic Non-Small Cell Lung Cancer,5625
0,NCT03164603,Phase I,Recruiting,"[{'id': 5815, 'therapyName': 'NLG802'}]","NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors",5815
0,NCT01176474,Phase I,"Active, not recruiting","[{'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma,2696
1,NCT02334735,Phase II,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 3012, 'therapyName': 'Melan-A/MART-1 peptide vaccine'}, {'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}]",A Comparison of Matured Dendritic Cells and Montanide&#174; in Study Subjects With High Risk of Melanoma Recurrence,2696
2,NCT02070406,Phase I,Recruiting,"[{'id': 3409, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine '}, {'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}]","Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies",2696
3,NCT02833506,Phase I,Not yet recruiting,"[{'id': 4460, 'therapyName': 'NY-ESO-1 peptide vaccine + Sirolimus'}, {'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}]","Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",2696
4,NCT01810016,Phase I,Terminated,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}]",NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma,2696
5,NCT02775292,Phase I,Recruiting,"[{'id': 3409, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine '}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}]","Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1",2696
0,NCT02833506,Phase I,Not yet recruiting,"[{'id': 4460, 'therapyName': 'NY-ESO-1 peptide vaccine + Sirolimus'}, {'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}]","Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",4460
0,NCT01343043,Phase Ib/II,Recruiting,"[{'id': 5877, 'therapyName': 'NY-ESO-1-c259T'}]",A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1c259T in HLA-A2+ Patients With Synovial Sarcoma  (NY-ESO-1),5877
1,NCT03168438,Phase I,Recruiting,"[{'id': 5877, 'therapyName': 'NY-ESO-1-c259T'}, {'id': 5878, 'therapyName': 'NY-ESO-1-c259T + Pembrolizumab'}]",NY-ESO-1-c259T Alone and in Combination With Pembrolizumab for Multiple Myeloma,5877
0,NCT03168438,Phase I,Recruiting,"[{'id': 5877, 'therapyName': 'NY-ESO-1-c259T'}, {'id': 5878, 'therapyName': 'NY-ESO-1-c259T + Pembrolizumab'}]",NY-ESO-1-c259T Alone and in Combination With Pembrolizumab for Multiple Myeloma,5878
0,NCT00669669,Phase Ib/II,"Active, not recruiting","[{'id': 2556, 'therapyName': 'O6-benzylguanine'}, {'id': 2555, 'therapyName': 'Carmustine + Filgrastim + Plerixafor + Temozolomide'}]",Dose-Intensive Chemotherapy in Combination With Chemoprotected Autologous Stem Cells in Treating Patients With Malignant Gliomas,2556
1,NCT02343666,Phase I,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 2556, 'therapyName': 'O6-benzylguanine'}]",HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection,2556
0,NCT01269424,Phase I,Suspended,"[{'id': 2972, 'therapyName': 'O6-benzylguanine + Temozolomide'}]",O6-Benzylguanine and Temozolomide With MGMTP140K Genetically Modified Blood Stem Cells in Untreated Glioblastoma,2972
0,NCT02406742,Phase Ib/II,Recruiting,"[{'id': 1646, 'therapyName': 'Obinutuzumab'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 2358, 'therapyName': 'CC-122'}]","A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Rituximab, Ibrutinib and Obinutuzumab in Subjects With Relapsed/Refractory CLL/SLL (ENHANCE)",1646
1,NCT01992653,Phase I,"Active, not recruiting","[{'id': 4248, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 4226, 'therapyName': 'Polatuzumab Vedotin'}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]","A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma",1646
2,NCT02257567,Phase Ib/II,"Active, not recruiting","[{'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 4226, 'therapyName': 'Polatuzumab Vedotin'}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]",A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma,1646
3,NCT02055820,Phase I,"Active, not recruiting","[{'id': 1562, 'therapyName': 'Venetoclax'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]",A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma,1646
4,NCT02475681,Phase III,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]","Elevate CLL TN: Study of Obinutuzumab + Chlorambucil, ACP-196 + Obinutuzumab, and ACP-196 in Subjects With Previously Untreated CLL",1646
0,NCT02242942,Phase III,"Active, not recruiting","[{'id': 1648, 'therapyName': 'Obinutuzumab + Chlorambucil'}, {'id': 3636, 'therapyName': 'GDC-0199 + Obinutuzumab'}]",A Study to Compare the Efficacy and Safety of Obinutuzumab + GDC-0199 Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia,1648
1,NCT01980875,Phase III,Terminated,"[{'id': 1647, 'therapyName': 'Idelalisib + Obinutuzumab'}, {'id': 1648, 'therapyName': 'Obinutuzumab + Chlorambucil'}]",Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia,1648
2,NCT02612311,Phase III,Recruiting,"[{'id': 2287, 'therapyName': 'Ublituximab'}, {'id': 1648, 'therapyName': 'Obinutuzumab + Chlorambucil'}, {'id': 2022, 'therapyName': 'TGR-1202'}]",Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia,1648
0,NCT03269669,Phase II,Recruiting,"[{'id': 6257, 'therapyName': 'Obinutuzumab + CHOP'}, {'id': 6302, 'therapyName': 'Lenalidomide + Obinutuzumab\t'}, {'id': 6301, 'therapyName': 'Obinutuzumab + TGR-1202'}, {'id': 2188, 'therapyName': 'Prednisone'}]","Obinutuzumab With or Without PI3K-delta Inhibitor TGR-1202, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma",6257
0,NCT01644253,Phase I,Recruiting,"[{'id': 4745, 'therapyName': 'Idelalisib + Otlertuzumab + Rituximab'}, {'id': 4742, 'therapyName': 'Otlertuzumab + Rituximab'}, {'id': 4743, 'therapyName': 'Obinutuzumab + Otlertuzumab'}, {'id': 4744, 'therapyName': 'Ibrutinib + Otlertuzumab'}]","Phase 1b Safety and Efficacy Study of TRU-016 and Rituximab, Obinutuzumab, Idelalisib, or Ibrutinib in Chronic Lymphocytic Leukemia",4743
0,NCT01691898,Phase Ib/II,"Active, not recruiting","[{'id': 4415, 'therapyName': 'Obinutuzumab + Pinatuzumab Vedotin + Rituximab'}, {'id': 4416, 'therapyName': 'Polatuzumab Vedotin + Pinatuzumab Vedotin + Rituximab'}, {'id': 4417, 'therapyName': 'Obinutuzumab + Polatuzumab Vedotin'}]",A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (ROMULUS),4415
0,NCT01691898,Phase Ib/II,"Active, not recruiting","[{'id': 4415, 'therapyName': 'Obinutuzumab + Pinatuzumab Vedotin + Rituximab'}, {'id': 4416, 'therapyName': 'Polatuzumab Vedotin + Pinatuzumab Vedotin + Rituximab'}, {'id': 4417, 'therapyName': 'Obinutuzumab + Polatuzumab Vedotin'}]",A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (ROMULUS),4417
0,NCT02611323,Phase Ib/II,Recruiting,"[{'id': 4227, 'therapyName': 'Obinutuzumab + Polatuzumab Vedotin + Venetoclax'}]","A Study of Obinutuzumab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",4227
0,NCT03075696,Phase I,Recruiting,"[{'id': 6162, 'therapyName': 'Obinutuzumab + RO7082859 + Tocilizumab'}]","A Dose Escalation Study of RO7082859, Administered After a Fixed, Single Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma",6162
0,NCT03269669,Phase II,Recruiting,"[{'id': 6257, 'therapyName': 'Obinutuzumab + CHOP'}, {'id': 6302, 'therapyName': 'Lenalidomide + Obinutuzumab\t'}, {'id': 6301, 'therapyName': 'Obinutuzumab + TGR-1202'}, {'id': 2188, 'therapyName': 'Prednisone'}]","Obinutuzumab With or Without PI3K-delta Inhibitor TGR-1202, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma",6301
0,NCT02414516,Phase I,Unknown status,"[{'id': 2906, 'therapyName': 'OBP-801'}]",A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors,2906
0,NCT01312376,Phase I,"Active, not recruiting","[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1227, 'therapyName': 'CD3/CD28 costimulated vaccine-primed autologous T-cells'}, {'id': 1222, 'therapyName': 'OC-DC vaccine'}]",Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer,1222
0,NCT02452775,Phase I,Recruiting,"[{'id': 3008, 'therapyName': 'OC-L'}]",Autologous OC-L Vaccine and Ovarian Cancer,3008
0,NCT02795858,Phase II,Recruiting,"[{'id': 4266, 'therapyName': 'Octreotide + Ramucirumab'}]","A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors",4266
0,NCT02200614,Phase III,Recruiting,"[{'id': 836, 'therapyName': 'ODM-201'}]",Efficacy and Safety Study of ODM-201 in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer,836
1,NCT02799602,Phase III,Recruiting,"[{'id': 836, 'therapyName': 'ODM-201'}, {'id': 4921, 'therapyName': 'Docetaxel + ODM-201'}]",ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer (ARASENS),836
2,NCT03004534,Phase 0,Recruiting,"[{'id': 836, 'therapyName': 'ODM-201'}]",A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of ODM-201,836
0,NCT02004522,Phase III,"Active, not recruiting","[{'id': 1024, 'therapyName': 'Duvelisib'}, {'id': 1090, 'therapyName': 'Ofatumumab'}]",A Phase 3 Study of IPI-145 Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO),1090
1,NCT02049515,Phase III,Enrolling by invitation,"[{'id': 1090, 'therapyName': 'Ofatumumab'}, {'id': 1024, 'therapyName': 'Duvelisib'}]",A Phase 3 Extension Study of IPI-145 and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07,1090
2,NCT03136146,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1090, 'therapyName': 'Ofatumumab'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]","Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)",1090
0,NCT01532700,Phase II,"Active, not recruiting","[{'id': 1091, 'therapyName': 'Ofatumumab + GSK2110183'}]", An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL),1091
0,NCT01780545,Phase II,Completed,"[{'id': 1807, 'therapyName': 'OGX-427'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer,1807
1,NCT01681433,Phase II,Terminated,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1807, 'therapyName': 'OGX-427'}]",OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone,1807
2,NCT00959868,Phase I,Unknown status,"[{'id': 1807, 'therapyName': 'OGX-427'}]",A Study for Treatment of Superficial Bladder Cancer Using OGX-427,1807
0,NCT03259503,Phase Ib/II,Not yet recruiting,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas,837
1,NCT03212274,Phase II,Not yet recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]","Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations",837
2,NCT01445418,Phase I,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer,837
3,NCT01844986,Phase III,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.,837
4,NCT03233204,Phase II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]","Pediatric MATCH: Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes",837
5,NCT02893917,Phase II,Recruiting,"[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}, {'id': 837, 'therapyName': 'Olaparib'}]",Olaparib With or Without Cediranib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,837
6,NCT02588105,Phase I,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 3557, 'therapyName': 'AZD0156'}]",Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer,837
7,NCT02032823,Phase III,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,837
8,NCT03263650,Phase II,Recruiting,"[{'id': 3844, 'therapyName': 'Cabazitaxel + Carboplatin'}, {'id': 837, 'therapyName': 'Olaparib'}]",Randomized Phase II Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC,837
9,NCT02392676,Phase III,Withdrawn,"[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations,837
10,NCT02485990,Phase Ib/II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)",837
11,NCT03022409,Phase I,Not yet recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 2881, 'therapyName': 'AZD6738'}]",A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC),837
12,NCT02576444,Phase II,Recruiting,"[{'id': 3140, 'therapyName': 'MK-1775 + Olaparib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 3141, 'therapyName': 'Olaparib + Vistusertib'}, {'id': 3139, 'therapyName': 'AZD5363 + Olaparib'}]",OLAParib COmbinations,837
13,NCT03047135,Phase II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]","Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis",837
14,NCT02502266,Phase II,Suspended,"[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1001, 'therapyName': 'Cediranib'}]","Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",837
15,NCT03155620,Phase II,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}, {'id': 2650, 'therapyName': 'LOXO-101'}, {'id': 1069, 'therapyName': 'LY3023414'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 913, 'therapyName': 'Selumetinib'}, {'id': 961, 'therapyName': 'X-396'}]",Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Advanced Refractory Solid Tumors or Lymphomas,837
16,NCT01874353,Phase III,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy,837
17,NCT02282020,Phase III,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib Treatment in Relapsed Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments.,837
18,NCT03012321,Phase II,Recruiting,"[{'id': 5226, 'therapyName': 'Abiraterone + Prednisone + Olaparib'}, {'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}, {'id': 837, 'therapyName': 'Olaparib'}]","Abiraterone Acetate, Olaparib, and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer With DNA Repair Defects",837
19,NCT02000622,Phase III,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.,837
20,NCT02446704,Phase Ib/II,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy,837
21,NCT02489006,Phase II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]","A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer",837
22,NCT03085147,,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]",A Dye for the Detection of Cancer of the Tongue and Mouth,837
23,NCT01972217,Phase II,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 837, 'therapyName': 'Olaparib'}]",Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer,837
24,NCT02184195,Phase III,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy,837
25,NCT02983799,Phase II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status,837
26,NCT02987543,Phase III,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",Study of Olaparib (Lynparza) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study),837
27,NCT02511795,Phase I,Recruiting,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 837, 'therapyName': 'Olaparib'}]",AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors,837
28,NCT02677038,Phase II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]",Ph II Olaparib for BRCAness Phenotype in Pancreatic Cancer,837
29,NCT03079687,Expanded access,Approved for marketing,"[{'id': 837, 'therapyName': 'Olaparib'}]","Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.",837
30,NCT01116648,Phase Ib/II,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]","Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer",837
31,NCT02208375,Phase Ib/II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 655, 'therapyName': 'AZD5363'}, {'id': 991, 'therapyName': 'Vistusertib'}]",mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Cancer,837
32,NCT02446600,Phase III,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1001, 'therapyName': 'Cediranib'}]","Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",837
33,NCT02693535,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 690, 'therapyName': 'Bosutinib'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer,837
34,NCT02476968,FDA approved,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]",To Assess Efficacy of Olaparib Maintenance Monotherapy at Preventing or Delaying the Return of the Cancer,837
35,NCT02561832,Phase I,Completed,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","A Study to Assess the Safety, Tolerability and Efficacy of Olaparib in Combination With Carboplatin in Patients With HER-2 Negative Breast Cancer",837
36,NCT02571725,Phase Ib/II,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 837, 'therapyName': 'Olaparib'}]",PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer,837
0,NCT01758731,Phase I,"Active, not recruiting","[{'id': 1999, 'therapyName': 'Olaparib + Cetuximab'}]",Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History,1999
0,NCT02898207,Phase I,Recruiting,"[{'id': 4729, 'therapyName': 'Olaparib + Onalespib'}]","Olaparib and Hsp90 Inhibitor AT13387 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer",4729
0,NCT02861573,Phase I,Recruiting,"[{'id': 5343, 'therapyName': 'Dexamethasone + Docetaxel + Pembrolizumab + Prednisone'}, {'id': 5342, 'therapyName': 'Olaparib + Pembrolizumab'}, {'id': 2666, 'therapyName': 'Enzalutamide + Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365),5342
0,NCT03057145,Phase I,Recruiting,"[{'id': 5332, 'therapyName': 'Olaparib + Prexasertib'}]",Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors,5332
0,NCT03008278,Phase Ib/II,Not yet recruiting,"[{'id': 5165, 'therapyName': 'Olaparib + Ramucirumab'}]",Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery,5165
0,NCT03162627,Phase I,Recruiting,"[{'id': 5793, 'therapyName': 'Olaparib + Selumetinib'}]",Selumetinib and Olaparib in Solid Tumors,5793
0,NCT01858168,Phase I,Recruiting,"[{'id': 1438, 'therapyName': 'Olaparib + Temozolomide'}]",Phase I Study of Olaprib and Temozolomide for Ewings Sarcoma,1438
0,NCT02576444,Phase II,Recruiting,"[{'id': 3140, 'therapyName': 'MK-1775 + Olaparib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 3141, 'therapyName': 'Olaparib + Vistusertib'}, {'id': 3139, 'therapyName': 'AZD5363 + Olaparib'}]",OLAParib COmbinations,3141
0,NCT02659020,Phase Ib/II,Recruiting,"[{'id': 3269, 'therapyName': 'Olaratumab'}, {'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}]",A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma,3269
1,NCT02451943,Phase III,"Active, not recruiting","[{'id': 3269, 'therapyName': 'Olaratumab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma,3269
2,NCT02677116,Phase I,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 3618, 'therapyName': 'Irinotecan + Vincristine'}, {'id': 3269, 'therapyName': 'Olaratumab'}]",A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,3269
0,NCT03086369,Phase Ib/II,Recruiting,"[{'id': 5482, 'therapyName': 'Olaratumab + nab-paclitaxel + Gemcitabine'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer,5482
0,NCT03126591,Phase I,Recruiting,"[{'id': 5715, 'therapyName': 'Olaratumab + Pembrolizumab'}]",A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma,5715
0,NCT02029417,Phase II,Terminated,"[{'id': 1794, 'therapyName': 'Omacetaxine + Cytarabine + Decitabine'}]","Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia",1794
0,NCT02141477,Phase II,Terminated,"[{'id': 1762, 'therapyName': 'Omacetaxine + Decitabine'}]",Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS),1762
0,NCT02298387,Phase I,"Active, not recruiting","[{'id': 2732, 'therapyName': 'OMP-305B83 '}]",A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors,2732
0,NCT03030287,Phase I,Recruiting,"[{'id': 5264, 'therapyName': 'OMP-305B83 + Paclitaxel'}]","A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer",5264
0,NCT03119428,Phase I,Recruiting,"[{'id': 5696, 'therapyName': 'OMP-313M32'}]",A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors,5696
0,NCT03295942,Phase I,Recruiting,"[{'id': 6264, 'therapyName': 'OMP-336B11'}]",A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors,6264
0,NCT02627430,Phase I,Withdrawn,"[{'id': 3317, 'therapyName': 'Onalespib + Talazoparib'}]","Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer",3317
0,NCT01662869,Phase III,Completed,"[{'id': 838, 'therapyName': 'Onartuzumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric),838
1,NCT01456325,Phase III,Completed,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 838, 'therapyName': 'Onartuzumab'}]",A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung),838
0,NCT01974258,Phase I,Withdrawn,"[{'id': 1306, 'therapyName': 'Onartuzumab + Vemurafenib'}, {'id': 1307, 'therapyName': 'Onartuzumab + Cobimetinib'}, {'id': 1308, 'therapyName': 'Onartuzumab + Cobimetinib + Vemurafenib'}]","Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients",1307
0,NCT01974258,Phase I,Withdrawn,"[{'id': 1306, 'therapyName': 'Onartuzumab + Vemurafenib'}, {'id': 1307, 'therapyName': 'Onartuzumab + Cobimetinib'}, {'id': 1308, 'therapyName': 'Onartuzumab + Cobimetinib + Vemurafenib'}]","Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients",1308
0,NCT01887886,Phase III,Completed,"[{'id': 1280, 'therapyName': 'Onartuzumab + Erlotinib'}]",A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating EGFR Mutation,1280
0,NCT02044601,Phase Ib/II,Withdrawn,"[{'id': 1370, 'therapyName': 'Onartuzumab + Paclitaxel + Carboplatin'}, {'id': 1371, 'therapyName': 'Onartuzumab + Erlotinib + Paclitaxel + Carboplatin'}]",Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT),1371
0,NCT02044601,Phase Ib/II,Withdrawn,"[{'id': 1370, 'therapyName': 'Onartuzumab + Paclitaxel + Carboplatin'}, {'id': 1371, 'therapyName': 'Onartuzumab + Erlotinib + Paclitaxel + Carboplatin'}]",Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT),1370
0,NCT01974258,Phase I,Withdrawn,"[{'id': 1306, 'therapyName': 'Onartuzumab + Vemurafenib'}, {'id': 1307, 'therapyName': 'Onartuzumab + Cobimetinib'}, {'id': 1308, 'therapyName': 'Onartuzumab + Cobimetinib + Vemurafenib'}]","Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients",1306
0,NCT02525692,Phase II,Recruiting,"[{'id': 1687, 'therapyName': 'ONC201'}]",Oral ONC201 in Adult Recurrent Glioblastoma,1687
1,NCT03295396,Phase II,Not yet recruiting,"[{'id': 1687, 'therapyName': 'ONC201'}]",ONC201 in Adults With Recurrent High-grade Glioma,1687
2,NCT02250781,Phase I,Recruiting,"[{'id': 1687, 'therapyName': 'ONC201'}]",Akt/ERK Inhibitor ONC201 in Treating Patients With Advanced Solid Tumors,1687
3,NCT02324621,Phase I,Recruiting,"[{'id': 1687, 'therapyName': 'ONC201'}]",Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors,1687
4,NCT02863991,Phase II,Recruiting,"[{'id': 1687, 'therapyName': 'ONC201'}]",Oral ONC201 in Relapsed/Refractory Multiple Myeloma,1687
5,NCT02038699,Phase Ib/II,Withdrawn,"[{'id': 1687, 'therapyName': 'ONC201'}]",A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer,1687
6,NCT02392572,Phase Ib/II,Recruiting,"[{'id': 1687, 'therapyName': 'ONC201'}]",ONC201 in Relapsed/Refractory Acute Leukemias and High-risk Myelodysplastic Syndromes (HR-MDS),1687
7,NCT02420795,Phase Ib/II,Recruiting,"[{'id': 1687, 'therapyName': 'ONC201'}]",Study of Oral ONC201 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma,1687
8,NCT03034200,Phase II,Recruiting,"[{'id': 1687, 'therapyName': 'ONC201'}]",Phase 2 Study of ONC201 in Neuroendocrine Tumors,1687
9,NCT03099499,Phase II,Recruiting,"[{'id': 1687, 'therapyName': 'ONC201'}]",Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer,1687
10,NCT03134131,Expanded access,Available,"[{'id': 1687, 'therapyName': 'ONC201'}]",Expanded Access Program for ONC201 to Treat Recurrent Histone H3 Mutant Glioma,1687
0,NCT02963831,Phase Ib/II,Recruiting,"[{'id': 4978, 'therapyName': 'ONCOS-102 + MEDI4736'}]","A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies",4978
0,NCT02270372,Phase I,Completed,"[{'id': 2525, 'therapyName': 'Varlilumab'}, {'id': 3051, 'therapyName': 'ONT-10'}]",Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer,3051
0,NCT03092635,Phase I,Recruiting,"[{'id': 5908, 'therapyName': 'OPC + Metformin'}]",AGE Levels in ER+ Metastatic Breast Cancer Patients Receiving Endocrine Therapy,5908
0,NCT02449239,Phase III,Recruiting,"[{'id': 6290, 'therapyName': 'Oportuzumab monatox'}]",Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG,6290
0,NCT02227914,Phase Ib/II,Withdrawn,"[{'id': 2422, 'therapyName': 'Oprozomib'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,2422
0,NCT02970539,Phase I,Recruiting,"[{'id': 5032, 'therapyName': 'Oraxol + Ramucirumab'}]","Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers",5032
0,NCT01959672,Phase II,Recruiting,"[{'id': 827, 'therapyName': 'Nelfinavir'}, {'id': 1189, 'therapyName': 'Oregovomab'}, {'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Combination Chemotherapy With or Without Oregovomab Followed by Stereotactic Body Radiation Therapy and Nelfinavir Mesylate in Treating Patients With Locally Advanced Pancreatic Cancer,1189
0,NCT01616303,Phase II,"Active, not recruiting","[{'id': 1190, 'therapyName': 'Oregovomab + Carboplatin + Paclitaxel'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]", A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer,1190
0,NCT03162562,Phase I,Recruiting,"[{'id': 5792, 'therapyName': 'Oregovomab + poly ICLC '}]",The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer,5792
0,NCT01809691,Phase III,"Active, not recruiting","[{'id': 2671, 'therapyName': 'Orteronel '}, {'id': 1507, 'therapyName': 'Bicalutamide'}]","S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",2671
1,NCT01990209,Phase II,Recruiting,"[{'id': 2671, 'therapyName': 'Orteronel '}]",Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR),2671
0,NCT02654587,Phase III,"Active, not recruiting","[{'id': 4327, 'therapyName': 'OSE 2101 '}, {'id': 4328, 'therapyName': 'Docetaxel + Pemetrexed'}]",Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC (ATALANTE 1),4327
0,NCT02789345,Phase I,Recruiting,"[{'id': 4379, 'therapyName': 'Osimertinib + Ramucirumab'}, {'id': 4380, 'therapyName': 'Necitumumab + Osimertinib'}]",A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer,4379
0,NCT02143466,Phase I,Recruiting,"[{'id': 2224, 'therapyName': 'AZD9291 + Savolitinib'}, {'id': 2225, 'therapyName': 'Osimertinib + Selumetinib'}, {'id': 2223, 'therapyName': 'AZD9291 + MEDI4736'}]",AZD9291 in Combination With Ascending Doses of Novel Therapeutics,2225
0,NCT01644253,Phase I,Recruiting,"[{'id': 4745, 'therapyName': 'Idelalisib + Otlertuzumab + Rituximab'}, {'id': 4742, 'therapyName': 'Otlertuzumab + Rituximab'}, {'id': 4743, 'therapyName': 'Obinutuzumab + Otlertuzumab'}, {'id': 4744, 'therapyName': 'Ibrutinib + Otlertuzumab'}]","Phase 1b Safety and Efficacy Study of TRU-016 and Rituximab, Obinutuzumab, Idelalisib, or Ibrutinib in Chronic Lymphocytic Leukemia",4742
0,NCT01910545,Phase I,Completed,"[{'id': 3951, 'therapyName': 'OTS167'}]",Phase 1 Study of OTS167 in Patients With Solid Tumors,3951
0,NCT02698176,Phase I,Terminated,"[{'id': 2034, 'therapyName': 'OTX015'}]",A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006),2034
1,NCT02259114,Phase I,Completed,"[{'id': 2034, 'therapyName': 'OTX015'}]","A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors",2034
2,NCT02698189,Phase I,"Active, not recruiting","[{'id': 2034, 'therapyName': 'OTX015'}]",A Dose Exploration Study With MK-8628 in Participants With Selected Hematologic Malignancies (MK-8628-005),2034
0,NCT02625610,Phase III,Recruiting,"[{'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}]",Avelumab in First-Line Gastric Cancer (JAVELIN Gastric 100),1104
1,NCT01213238,Phase I,"Active, not recruiting","[{'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab",1104
2,NCT02244489,Phase I,Terminated,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 823, 'therapyName': 'Momelotinib'}]",Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma,1104
3,NCT01580410,Phase II,"Active, not recruiting","[{'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}]",Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix,1104
4,NCT02620865,Phase Ib/II,Suspended,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}]",Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer,1104
5,NCT01488552,Phase Ib/II,Completed,"[{'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1031, 'therapyName': 'Metformin'}]",Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer,1104
6,NCT01775501,Phase II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Sorafenib + mFOLFOX for Hepatocellular Carcinoma,1104
7,NCT03136406,Phase Ib/II,Recruiting,"[{'id': 1018, 'therapyName': 'GI-4000'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 6163, 'therapyName': 'ETBX-011'}, {'id': 3060, 'therapyName': 'ALT-803'}]",QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy,1104
8,NCT01061515,Phase I,Recruiting,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}]",Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer,1104
9,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1104
0,NCT02576301,Phase Ib/II,Recruiting,"[{'id': 3524, 'therapyName': 'OXi4503'}, {'id': 3887, 'therapyName': 'Cytarabine + OXi4503'}]",Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS,3524
0,NCT03288493,Phase I,Recruiting,"[{'id': 6280, 'therapyName': 'P-BCMA-101 CAR-T cells'}]",P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM),6280
0,NCT02355535,Phase I,Recruiting,"[{'id': 4602, 'therapyName': 'PAC-1'}]",Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies,4602
0,NCT01501487,FDA approved,"Active, not recruiting","[{'id': 1902, 'therapyName': 'Docetaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1485, 'therapyName': 'Trastuzumab + Docetaxel + Carboplatin'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]",MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I,1103
1,NCT02073487,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1583, 'therapyName': 'Trastuzumab emtansine + Lapatinib'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 619, 'therapyName': 'Abraxane'}]",Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab With Lapatinib and Paclitaxel,1103
2,NCT02312804,Phase I,Withdrawn,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 674, 'therapyName': 'BGJ398'}]",Ph Ib/BGJ398/Cervix and Other Solid Tumors,1103
3,NCT01215136,Phase II,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma,1103
4,NCT02389751,Phase I,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 745, 'therapyName': 'Ganetespib'}]",A Study of Ganetespib in Combination With Chemoradiation,1103
5,NCT02134067,Phase I,Recruiting,"[{'id': 1400, 'therapyName': 'TAS-119'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors",1103
6,NCT02470585,Phase III,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}]","Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1103
7,NCT01892046,Phase I,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 866, 'therapyName': 'SNX-5422'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors,1103
8,NCT02117024,Phase II,"Active, not recruiting","[{'id': 2472, 'therapyName': 'HS-110 + Cyclophosphamide'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer,1103
9,NCT02855944,Phase III,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 906, 'therapyName': 'Rucaparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients",1103
10,NCT01320592,Phase I,"Active, not recruiting","[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",PD0332991/Paclitaxel in Advanced Breast Cancer,1103
11,NCT02581943,Phase II,Suspended,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer,1103
12,NCT02725268,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1282, 'therapyName': 'Sapanisertib'}, {'id': 1283, 'therapyName': 'MLN1117 + Sapanisertib'}]","Phase 2 Study of MLN0128, Combination of MLN0128 With MLN1117, Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial Cancer",1103
13,NCT01187199,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 936, 'therapyName': 'Temsirolimus'}]","Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer",1103
14,NCT01281176,,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors,1103
15,NCT02301988,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 747, 'therapyName': 'Ipatasertib'}]",A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Patients With Early Stage Triple Negative Breast Cancer,1103
16,NCT02009449,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2621, 'therapyName': 'AM0010 '}, {'id': 619, 'therapyName': 'Abraxane'}]",A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors,1103
17,NCT02419495,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Selinexor in Combination With Standard Chemotherapy,1103
18,NCT01248949,Phase I,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1176, 'therapyName': 'MEDI3617'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors,1103
19,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,1103
20,NCT01641939,Phase III,Terminated,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer,1103
21,NCT01962948,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 745, 'therapyName': 'Ganetespib'}]","Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1103
22,NCT02502266,Phase II,Suspended,"[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1001, 'therapyName': 'Cediranib'}]","Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1103
23,NCT02551055,Phase I,Terminated,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 626, 'therapyName': 'Alisertib'}, {'id': 3146, 'therapyName': 'TAK-659'}, {'id': 1033, 'therapyName': 'MLN1117'}]","MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma",1103
24,NCT00989651,Phase I,"Active, not recruiting","[{'id': 3047, 'therapyName': 'Bevacizumab + Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]","Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",1103
25,NCT02651610,Phase II,Withdrawn,"[{'id': 3545, 'therapyName': 'Bavituximab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer,1103
26,NCT02264990,Phase III,"Active, not recruiting","[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers,1103
27,NCT00993655,Phase III,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}]"," Comparing Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",1103
28,NCT01042522,Phase II,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1137, 'therapyName': 'Bleomycin'}]","Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors",1103
29,NCT01572038,Phase III,"Active, not recruiting","[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE),1103
30,NCT01952249,Phase Ib/II,Completed,"[{'id': 2007, 'therapyName': 'Demcizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian,1103
31,NCT02412722,Phase I,"Active, not recruiting","[{'id': 1282, 'therapyName': 'Sapanisertib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","Safety, Tolerability, and Pharmacokinetics of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies",1103
32,NCT02419417,Phase Ib/II,Recruiting,"[{'id': 2811, 'therapyName': 'BMS986158'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Study of BMS-986158 in Subjects With Select Advanced Solid Tumors,1103
33,NCT01820754,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC),1103
34,NCT02194829,Phase Ib/II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 822, 'therapyName': 'MK-1775'}]",Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery,1103
35,NCT02229149,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1105, 'therapyName': 'Capecitabine'}]","Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer",1103
36,NCT02620865,Phase Ib/II,Suspended,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}]",Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer,1103
37,NCT02446600,Phase III,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1001, 'therapyName': 'Cediranib'}]","Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1103
38,NCT01236547,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer,1103
39,NCT01656538,Phase II,"Active, not recruiting","[{'id': 893, 'therapyName': 'Reolysin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer,1103
40,NCT02929576,Phase III,Withdrawn,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 3725, 'therapyName': 'Enzalutamide + Paclitaxel'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]","Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer (ENDEAR)",1103
41,NCT02625623,Phase III,"Active, not recruiting","[{'id': 3144, 'therapyName': 'Avelumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300),1103
42,NCT02162719,Phase II,"Active, not recruiting","[{'id': 1588, 'therapyName': 'Ipatasertib + Paclitaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Front-line Treatment for Patients With Metastatic Triple-Negative Breast Cancer,1103
43,NCT01366144,Phase I,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction",1103
44,NCT02038647,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 626, 'therapyName': 'Alisertib'}]",Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC),1103
45,NCT02483247,Phase Ib/II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1945, 'therapyName': 'BBI503'}]",A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer,1103
46,NCT02819518,Phase III,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355),1103
47,NCT02041533,Phase III,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)",1103
48,NCT01779050,Phase II,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1087, 'therapyName': 'Epirubicin + Cyclophosphamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}, {'id': 1834, 'therapyName': 'Docetaxel + Carboplatin'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}]",Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells,1103
49,NCT02142738,Phase III,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024),1103
50,NCT01796197,Phase II,"Active, not recruiting","[{'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa,1103
51,NCT01249443,Phase I,Terminated,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Vorinostat in Combination With Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection,1103
52,NCT02230319,Phase II,Unknown status,"[{'id': 1103, 'therapyName': 'Paclitaxel'}]",Prevention of Paclitaxel Neuropathy With Cryotherapy,1103
53,NCT02581982,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer,1103
54,NCT01493505,Phase III,Terminated,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1218, 'therapyName': 'Trebananib'}]", TRINOVA-3,1103
55,NCT02474173,Phase I,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 645, 'therapyName': 'AT13387'}]",HSP90 Inhibitor AT13387 and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer,1103
56,NCT01572727,Phase II,Completed,"[{'id': 1545, 'therapyName': 'BKM120 + Paclitaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation",1103
57,NCT01653470,Phase I,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 2545, 'therapyName': 'BMS-906024'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors",1103
58,NCT01792050,Phase II,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 2976, 'therapyName': 'indoximod'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer,1103
59,NCT02366949,Phase I,Recruiting,"[{'id': 3447, 'therapyName': 'BAY1217389 + Paclitaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel,1103
60,NCT02122770,Phase I,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1026, 'therapyName': 'Itraconazole'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1688, 'therapyName': 'MLN4924'}, {'id': 1689, 'therapyName': 'Fluconazole'}]","Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors",1103
61,NCT01362374,Phase I,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 747, 'therapyName': 'Ipatasertib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]","Safety and Pharmacology Of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors",1103
62,NCT02187991,Phase II,Recruiting,"[{'id': 626, 'therapyName': 'Alisertib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer,1103
63,NCT03181100,Phase II,Recruiting,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}, {'id': 3049, 'therapyName': 'Atezolizumab + nab-paclitaxel'}, {'id': 4825, 'therapyName': 'Atezolizumab + Vemurafenib + Cobimetinib'}, {'id': 5606, 'therapyName': 'Atezolizumab + Paclitaxel'}]",Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas,1103
64,NCT02514551,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer,1103
65,NCT02341456,Phase I,"Active, not recruiting","[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours,1103
66,NCT02367794,Phase III,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC),1103
67,NCT01982448,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Cisplatin vs Paclitaxel for Triple Neg,1103
68,NCT02440425,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer,1103
69,NCT02390427,Phase I,Recruiting,"[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 1016, 'therapyName': 'GDC-0032'}]",Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer,1103
70,NCT02297230,Phase Ib/II,Completed,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}]",Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics,1103
71,NCT03125902,Phase III,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 5606, 'therapyName': 'Atezolizumab + Paclitaxel'}]",A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IMpassion131),1103
72,NCT00828009,Phase II,Unknown status,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 2142, 'therapyName': 'Emepepimut-S  '}, {'id': 1092, 'therapyName': 'Carboplatin'}]",BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery,1103
73,NCT01407562,Phase I,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}]","Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors",1103
74,NCT02322814,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1004, 'therapyName': 'Cobimetinib'}]",A Study of Cobimetinib in Combination With Paclitaxel as First-line Treatment for Patients With Metastatic Triple-negative Breast Cancer,1103
75,NCT01015222,Phase I,"Active, not recruiting","[{'id': 1032, 'therapyName': 'methylnaltrexone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies",1103
76,NCT02826161,Phase III,Terminated,"[{'id': 2586, 'therapyName': 'BBI608 + Paclitaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer (CanStem43L)",1103
77,NCT01897441,Phase I,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]",Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer,1103
78,NCT02302807,Phase III,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Study of MPDL3280A Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer,1103
79,NCT02437812,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1031, 'therapyName': 'Metformin'}]","Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma",1103
80,NCT01281150,Phase I,Completed,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors,1103
81,NCT02576574,Phase III,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100),1103
82,NCT02599324,Phase Ib/II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors,1103
83,NCT02178956,Phase III,"Active, not recruiting","[{'id': 2057, 'therapyName': 'BBI608'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer,1103
84,NCT01803282,Phase I,Recruiting,"[{'id': 3320, 'therapyName': 'GS-5745'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Safety and Tolerability Study in Solid Tumors,1103
85,NCT02322281,Phase III,"Active, not recruiting","[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1003, 'therapyName': 'CO1686'}]","TIGER-3 Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy",1103
86,NCT02574078,Phase I,Recruiting,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2114, 'therapyName': 'Bevacizumab + Pemetrexed'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",A Master Protocol Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate 370),1103
87,NCT02312245,Phase II,Recruiting,"[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",1103
88,NCT01357161,Phase II,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 822, 'therapyName': 'MK-1775'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]", A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004),1103
89,NCT01454102,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)",1103
90,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1103
91,NCT02403895,Phase II,Completed,"[{'id': 991, 'therapyName': 'Vistusertib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",AZD2014 and Weekly Paclitaxel in Squamous NSCLC,1103
0,NCT02317874,Phase I,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 682, 'therapyName': 'Talazoparib'}]","PARP Inhibitor BMN-673, Carboplatin, and Paclitaxel in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",1124
1,NCT02513563,Phase II,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 822, 'therapyName': 'MK-1775'}]",AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer,1124
2,NCT00954174,Phase III,"Active, not recruiting","[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1125, 'therapyName': 'Paclitaxel + Ifosfamide'}]","Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritorium Cavity Cancer",1124
3,NCT02713386,Phase Ib/II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1124
4,NCT02718417,Phase III,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100),1124
5,NCT02051868,Phase II,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}]",International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel (InterAACT),1124
6,NCT02453282,Phase III,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC).,1124
7,NCT02106546,Phase III,"Active, not recruiting","[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer",1124
8,NCT02530437,Phase Ib/II,Recruiting,"[{'id': 1587, 'therapyName': 'Taladegib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","A Phase 1B/2 Study of LY2940680 in Combination With Weekly Paclitaxel, Carboplatin, and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction",1124
9,NCT01769391,Phase II,"Active, not recruiting","[{'id': 826, 'therapyName': 'Necitumumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer,1124
10,NCT02032277,Phase III,"Active, not recruiting","[{'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer,1124
11,NCT01711541,Phase Ib/II,Suspended,"[{'id': 1544, 'therapyName': 'Carboplatin + Etoposide + Veliparib'}, {'id': 1849, 'therapyName': 'Cisplatin + Fluorouracil + Hydroxyurea'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer,1124
12,NCT02520154,Phase II,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer,1124
13,NCT02358200,Phase I,"Active, not recruiting","[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 682, 'therapyName': 'Talazoparib'}]",Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer,1124
14,NCT02591615,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]",Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC,1124
15,NCT01578551,Phase II,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",A Randomized Phase II Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma.,1124
16,NCT01803282,Phase I,Recruiting,"[{'id': 3320, 'therapyName': 'GS-5745'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Safety and Tolerability Study in Solid Tumors,1124
17,NCT02876107,Phase II,Recruiting,"[{'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 3386, 'therapyName': 'Carboplatin + Paclitaxel + Panitumumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Phase II Study of Using Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen (AC) for New Triple-Negative Inflammatory Breast Cancer (TN-IBC),1124
18,NCT02998268,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma,1124
19,NCT02124421,Phase II,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1812, 'therapyName': 'Cisplatin + Paclitaxel'}]","Outcomes in CRS/HIPEC as Initial Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Cancer",1124
20,NCT01196390,Phase III,"Active, not recruiting","[{'id': 1887, 'therapyName': 'Paclitaxel + Carboplatin + Trastuzumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",1124
21,NCT01367002,Phase II,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer,1124
22,NCT01506609,Phase II,"Active, not recruiting","[{'id': 1193, 'therapyName': 'Veliparib + Temozolomide'}, {'id': 1544, 'therapyName': 'Carboplatin + Etoposide + Veliparib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer,1124
23,NCT01616303,Phase II,"Active, not recruiting","[{'id': 1190, 'therapyName': 'Oregovomab + Carboplatin + Paclitaxel'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]", A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer,1124
24,NCT02436993,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting,1124
25,NCT02163694,Phase III,Recruiting,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer",1124
26,NCT02525757,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",MPDL3280A With Chemoradiation for Lung Cancer,1124
27,NCT02730546,Phase Ib/II,Suspended,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery",1124
28,NCT00980954,Phase III,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy,1124
29,NCT02272413,Phase III,"Active, not recruiting","[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin Plus Chemotherapy in Patients With Lung Cancer,1124
30,NCT02542293,Phase III,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]",Study of 1st Line Therapy Study of MEDI4736 With Tremelimumab Versus SoC in Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE).,1124
31,NCT02658214,Phase I,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors,1124
32,NCT01386385,Phase Ib/II,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1544, 'therapyName': 'Carboplatin + Etoposide + Veliparib'}]","Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery",1124
33,NCT02220894,Phase III,Recruiting,"[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of MK-3475 (Pembrolizumab) Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer (MK-3475-042/KEYNOTE-042),1124
34,NCT02883062,Phase II,Not yet recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1203, 'therapyName': 'Atezolizumab + Carboplatin + Paclitaxel'}]","Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer",1124
35,NCT02186847,Phase II,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer,1124
36,NCT02775435,Phase III,Recruiting,"[{'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407),1124
37,NCT03036488,Phase III,Recruiting,"[{'id': 1087, 'therapyName': 'Epirubicin + Cyclophosphamide'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522),1124
38,NCT02065687,Phase III,Recruiting,"[{'id': 1381, 'therapyName': 'Paclitaxel + Carboplatin + Metformin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",1124
39,NCT02412371,Phase II,Recruiting,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer,1124
40,NCT01966003,Phase III,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2141, 'therapyName': 'Bevacizumab-awwb'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer,1124
41,NCT02476955,Phase I,Recruiting,"[{'id': 635, 'therapyName': 'ARQ092'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Open-label Phase 1b Study of ARQ 092 in Combination With Carboplatin Plus Paclitaxel,1124
42,NCT02429843,Phase I,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1242, 'therapyName': 'TRC105'}]",A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer,1124
43,NCT00979212,Phase II,"Active, not recruiting","[{'id': 845, 'therapyName': 'Panitumumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer (Cetuximab Closed as of 05/14/10),1124
44,NCT01868022,Phase I,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 2899, 'therapyName': 'GSK3052230'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling",1124
0,NCT02122185,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1827, 'therapyName': 'Paclitaxel + Carboplatin + Docetaxel'}]","Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1827
0,NCT01649947,Phase II,Completed,"[{'id': 1487, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel + Hydroxychloroquine'}, {'id': 1488, 'therapyName': 'Paclitaxel + Carboplatin + Hydroxychloroquine'}]",Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II,1488
0,NCT02050009,Phase I,Withdrawn,"[{'id': 1381, 'therapyName': 'Paclitaxel + Carboplatin + Metformin'}]","Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1381
1,NCT02065687,Phase III,Recruiting,"[{'id': 1381, 'therapyName': 'Paclitaxel + Carboplatin + Metformin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",1381
0,NCT01196390,Phase III,"Active, not recruiting","[{'id': 1887, 'therapyName': 'Paclitaxel + Carboplatin + Trastuzumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",1887
0,NCT00660218,Phase Ib/II,Unknown status,"[{'id': 1988, 'therapyName': 'Paclitaxel + Cetuximab'}]","A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer",1988
0,NCT02957968,Phase II,Recruiting,"[{'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 5729, 'therapyName': 'Doxorubicin + Cyclophosphamide + Paclitaxel + Carboplatin'}]",Neoadj Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca,1495
1,NCT02379585,Phase Ib/II,Terminated,"[{'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]",Study of Short-term Fasting on Neoadjuvant Chemotherapy in Patients With Newly Diagnosed Breast Cancer,1495
2,NCT01275677,Phase III,"Active, not recruiting","[{'id': 1503, 'therapyName': 'Paclitaxel + Trastuzumab + Doxorubicin + Cyclophosphamide'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}, {'id': 1882, 'therapyName': 'Docetaxel + Cyclophosphamide + Trastuzumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}]",Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,1495
3,NCT02132949,Phase II,"Active, not recruiting","[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1895, 'therapyName': 'Cyclophosphamide + Fluorouracil + Docetaxel + Epirubicin  '}]","A Study Evaluating Perjeta (Pertuzumab) Combined With Herceptin (Trastuzumab) and Standard Anthracycline-based Chemotherapy in Patients With HER2-positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer.",1495
4,NCT01042379,Phase II,Recruiting,"[{'id': 1218, 'therapyName': 'Trebananib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 746, 'therapyName': 'Ganitumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1494, 'therapyName': 'MK2206 + Trastuzumab'}, {'id': 1493, 'therapyName': 'Trebananib + Trastuzumab'}, {'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}]",I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer,1495
5,NCT02637375,Phase I,Withdrawn,"[{'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 745, 'therapyName': 'Ganetespib'}]",A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer,1495
0,NCT00954174,Phase III,"Active, not recruiting","[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1125, 'therapyName': 'Paclitaxel + Ifosfamide'}]","Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritorium Cavity Cancer",1125
0,NCT03154294,Phase I,Not yet recruiting,"[{'id': 5731, 'therapyName': 'Paclitaxel + MLN0128 + MLN1117'}]",Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors,5731
0,NCT01008150,Phase II,Unknown status,"[{'id': 1504, 'therapyName': 'Paclitaxel + Trastuzumab + Neratinib + Doxorubicin + Cyclophosphamide'}, {'id': 1503, 'therapyName': 'Paclitaxel + Trastuzumab + Doxorubicin + Cyclophosphamide'}, {'id': 1505, 'therapyName': 'Paclitaxel + Neratinib + Doxorubicin + Cyclophosphamide'}]",Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,1505
1,NCT03101748,Phase Ib/II,Not yet recruiting,"[{'id': 3187, 'therapyName': 'Neratinib + Paclitaxel + Pertuzumab + Trastuzumab'}, {'id': 1505, 'therapyName': 'Paclitaxel + Neratinib + Doxorubicin + Cyclophosphamide'}]",3HT With Taxol for Metastatic Breast Cancer,1505
0,NCT03136055,Phase II,Recruiting,"[{'id': 5643, 'therapyName': 'Irinotecan + Pembrolizumab'}, {'id': 4021, 'therapyName': 'Paclitaxel + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas,4021
1,NCT02734290,Phase Ib/II,Recruiting,"[{'id': 4022, 'therapyName': 'Capecitabine + Pembrolizumab'}, {'id': 4021, 'therapyName': 'Paclitaxel + Pembrolizumab'}]",Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer,4021
2,NCT03018080,Phase II,Recruiting,"[{'id': 4021, 'therapyName': 'Paclitaxel + Pembrolizumab'}]",Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer (PePPy),4021
0,NCT03199885,Phase III,Not yet recruiting,"[{'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}, {'id': 5956, 'therapyName': 'Paclitaxel + Pembrolizumab + Pertuzumab + Trastuzumab'}]","Paclitaxel, Trastuzumab, and Pertuzumab With or Without Pembrolizumab in Treating Patients With Metastatic Breast Cancer",5956
0,NCT02824575,Phase I,Recruiting,"[{'id': 4433, 'therapyName': 'Paclitaxel + Rebastinib'}, {'id': 4434, 'therapyName': 'Eribulin + Rebastinib'}]",Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer,4433
0,NCT02599363,Phase I,Recruiting,"[{'id': 3206, 'therapyName': 'Paclitaxel + Ribociclib'}]",A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer,3206
0,NCT02195973,Phase Ib/II,"Active, not recruiting","[{'id': 1620, 'therapyName': 'Paclitaxel + Sonidegib'}]",Phase IB/II Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer,1620
0,NCT01275677,Phase III,"Active, not recruiting","[{'id': 1503, 'therapyName': 'Paclitaxel + Trastuzumab + Doxorubicin + Cyclophosphamide'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}, {'id': 1882, 'therapyName': 'Docetaxel + Cyclophosphamide + Trastuzumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}]",Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,1503
1,NCT01008150,Phase II,Unknown status,"[{'id': 1504, 'therapyName': 'Paclitaxel + Trastuzumab + Neratinib + Doxorubicin + Cyclophosphamide'}, {'id': 1503, 'therapyName': 'Paclitaxel + Trastuzumab + Doxorubicin + Cyclophosphamide'}, {'id': 1505, 'therapyName': 'Paclitaxel + Neratinib + Doxorubicin + Cyclophosphamide'}]",Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,1503
0,NCT01774851,Phase II,Terminated,"[{'id': 1892, 'therapyName': 'Paclitaxel + Trastuzumab + MM-111'}, {'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}]","A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach",1892
0,NCT01008150,Phase II,Unknown status,"[{'id': 1504, 'therapyName': 'Paclitaxel + Trastuzumab + Neratinib + Doxorubicin + Cyclophosphamide'}, {'id': 1503, 'therapyName': 'Paclitaxel + Trastuzumab + Doxorubicin + Cyclophosphamide'}, {'id': 1505, 'therapyName': 'Paclitaxel + Neratinib + Doxorubicin + Cyclophosphamide'}]",Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,1504
0,NCT03179904,Phase II,Recruiting,"[{'id': 5874, 'therapyName': 'Paclitaxel + Trastuzumab + TVB-2640'}]","FASN Inhibitor TVB-2640, Paclitaxel, and Trastuzumab in Treating Patients With HER2 Positive Advanced Breast Cancer",5874
0,NCT00781612,Phase II,Recruiting,"[{'id': 5471, 'therapyName': 'Trastuzumab + trastuzumab emtansine'}, {'id': 5470, 'therapyName': 'Paclitaxel + trastuzumab emtansine'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 3930, 'therapyName': 'Docetaxel + T-DM1'}, {'id': 1976, 'therapyName': 'trastuzumab emtansine + Capecitabine'}, {'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}]",A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies,5470
0,NCT01697293,Phase Ib/II,Recruiting,"[{'id': 3054, 'therapyName': 'Paclitaxel + Triciribine'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]","Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer",3054
0,NCT02469415,Phase II,Terminated,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2006, 'therapyName': 'Pacritinib'}]",Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS),2006
1,NCT02277093,Phase II,Terminated,"[{'id': 2006, 'therapyName': 'Pacritinib'}]",Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer,2006
2,NCT02251821,Phase II,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 2006, 'therapyName': 'Pacritinib'}, {'id': 823, 'therapyName': 'Momelotinib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis,2006
0,NCT02532010,Phase II,"Active, not recruiting","[{'id': 3177, 'therapyName': 'Pacritinib + Decitabine'}, {'id': 3176, 'therapyName': 'Pacritinib + Cytarabine'}]",Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML,3176
0,NCT02532010,Phase II,"Active, not recruiting","[{'id': 3177, 'therapyName': 'Pacritinib + Decitabine'}, {'id': 3176, 'therapyName': 'Pacritinib + Cytarabine'}]",Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML,3177
1,NCT02323607,Phase I,Suspended,"[{'id': 3219, 'therapyName': 'Cytarabine + Daunorubicin + Pacritinib'}, {'id': 3177, 'therapyName': 'Pacritinib + Decitabine'}]",Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations,3177
2,NCT02564536,Phase I,Withdrawn,"[{'id': 3177, 'therapyName': 'Pacritinib + Decitabine'}]",Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS),3177
0,NCT01037790,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}]",PD 0332991 in Treating Patients With Refractory Solid Tumors,850
1,NCT01723774,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 759, 'therapyName': 'Goserelin'}]",PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer,850
2,NCT02030483,Phase I,Terminated,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}]",Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma,850
3,NCT02499120,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}]",Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer,850
4,NCT02154490,Phase II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 1016, 'therapyName': 'GDC-0032'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 629, 'therapyName': 'AMG102'}]",Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,850
5,NCT02296801,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 794, 'therapyName': 'Letrozole'}]",A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer,850
6,NCT03132454,Phase I,Recruiting,"[{'id': 5637, 'therapyName': 'Palbociclib + Decitabine'}, {'id': 5636, 'therapyName': 'Palbociclib + Dexamethasone'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 5638, 'therapyName': 'Palbociclib + Sorafenib'}]",Study of Palbociclib Alone and in Combination in Patients With Relapsed and Refractory (R/R) Leukemias,850
7,NCT01356628,Phase II,"Active, not recruiting","[{'id': 850, 'therapyName': 'Palbociclib'}]",A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer,850
8,NCT03147287,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 3205, 'therapyName': 'Fulvestrant + Palbociclib'}, {'id': 5684, 'therapyName': 'Fulvestrant + Palbociclib + Avelumab'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Palbociclib After CDK and Endocrine Therapy (PACE),850
9,NCT02334527,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}]",Phase II Trial of Palbociclib (PD-0332991) in Patients With Metastatic Urothelial Cancer (UC) After Failure of First-Line Chemotherapy,850
10,NCT02255461,Phase I,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}]","Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors",850
11,NCT02513394,Phase III,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}]",PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer (PALLAS),850
12,NCT02693535,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 690, 'therapyName': 'Bosutinib'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer,850
13,NCT01320592,Phase I,"Active, not recruiting","[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",PD0332991/Paclitaxel in Advanced Breast Cancer,850
14,NCT01864746,Phase III,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}]",A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery,850
15,NCT02905318,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}]",Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer,850
16,NCT02630693,Phase II,"Active, not recruiting","[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]","Study Comparing Two Different Schedules of Palbociclib Plus Second Line Endocrine Therapy in Women With Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer",850
17,NCT03170206,Phase Ib/II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 807, 'therapyName': 'Binimetinib'}, {'id': 5838, 'therapyName': 'Binimetinib + Palbociclib'}]",Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor Binimetinib (MEK162) for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer,850
18,NCT02764541,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]",Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS),850
19,NCT02896335,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}]",Palbociclib In Progressive Brain Metastases,850
20,NCT02384239,Phase II,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]",A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer,850
21,NCT01536743,Phase II,"Active, not recruiting","[{'id': 850, 'therapyName': 'Palbociclib'}]",A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression,850
22,NCT02040857,Phase II,"Active, not recruiting","[{'id': 738, 'therapyName': 'Exemestane'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}]",Palbociclib + Endocrine Therapy for HR + BrCa,850
23,NCT02626507,Phase I,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1040, 'therapyName': 'PF-05212384'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer,850
24,NCT02059213,Phase II,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 795, 'therapyName': 'Leuprolide'}]", A Phase II Study of Androgen Deprivation Therapy With or Without PD 0332991 in RB-Positive Metastatic Prostate Cancer,850
25,NCT03304080,,Not yet recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 850, 'therapyName': 'Palbociclib'}]","Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in Her-positive, Her2-positive Metastatic Breast",850
26,NCT03123744,Phase II,Not yet recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}]",Histology-Independent Study of Palbociclib in Patients With Advanced Cancer,850
27,NCT02785939,Phase II,"Active, not recruiting","[{'id': 850, 'therapyName': 'Palbociclib'}]",Lung-MAP: Palbociclib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches,850
0,NCT02101034,Phase Ib/II,Recruiting,"[{'id': 1705, 'therapyName': 'Palbociclib + Cetuximab'}]",PD 0332991 and Cetuximab in Patients With Incurable SCCHN,1705
0,NCT03132454,Phase I,Recruiting,"[{'id': 5637, 'therapyName': 'Palbociclib + Decitabine'}, {'id': 5636, 'therapyName': 'Palbociclib + Dexamethasone'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 5638, 'therapyName': 'Palbociclib + Sorafenib'}]",Study of Palbociclib Alone and in Combination in Patients With Relapsed and Refractory (R/R) Leukemias,5637
0,NCT03132454,Phase I,Recruiting,"[{'id': 5637, 'therapyName': 'Palbociclib + Decitabine'}, {'id': 5636, 'therapyName': 'Palbociclib + Dexamethasone'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 5638, 'therapyName': 'Palbociclib + Sorafenib'}]",Study of Palbociclib Alone and in Combination in Patients With Relapsed and Refractory (R/R) Leukemias,5636
0,NCT01522989,Phase I,"Active, not recruiting","[{'id': 1703, 'therapyName': 'Palbociclib + Fluorouracil + Oxaliplatin'}]","PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies",1703
0,NCT02142868,Phase III,No longer available,"[{'id': 2922, 'therapyName': 'Palbociclib + Letrozole'}]","Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate",2922
1,NCT02692755,Phase II,Recruiting,"[{'id': 2922, 'therapyName': 'Palbociclib + Letrozole'}]",Palbociclib / Letrozole in African American Women With HR+ HER2- Breast Cancer (PALINA),2922
2,NCT03007979,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 3205, 'therapyName': 'Fulvestrant + Palbociclib'}, {'id': 2922, 'therapyName': 'Palbociclib + Letrozole'}]",Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer,2922
0,NCT03284957,Phase Ib/II,Recruiting,"[{'id': 6293, 'therapyName': 'SAR439859'}, {'id': 6294, 'therapyName': 'Palbociclib + SAR439859'}]",Phase 1 / 2 Study of SAR439859 Single Agent and in Combination With Palbociclib in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer,6294
0,NCT03132454,Phase I,Recruiting,"[{'id': 5637, 'therapyName': 'Palbociclib + Decitabine'}, {'id': 5636, 'therapyName': 'Palbociclib + Dexamethasone'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 5638, 'therapyName': 'Palbociclib + Sorafenib'}]",Study of Palbociclib Alone and in Combination in Patients With Relapsed and Refractory (R/R) Leukemias,5638
0,NCT02668666,Phase II,Recruiting,"[{'id': 3542, 'therapyName': 'Palbociclib + Tamoxifen'}]",Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer,3542
0,NCT02065063,Phase I,Completed,"[{'id': 1368, 'therapyName': 'Palbociclib + Trametinib'}]","A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors",1368
0,NCT02774681,Phase II,Recruiting,"[{'id': 3041, 'therapyName': 'Palbociclib + Trastuzumab'}]",Palbociclib in Treating Patients With Metastatic HER-2 Positive or Triple-Negative Breast Cancer With Brain Metastasis,3041
0,NCT01111188,,"Active, not recruiting","[{'id': 1730, 'therapyName': 'Palbociclib + Velcade'}]", Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma,1730
0,NCT03259503,Phase Ib/II,Not yet recruiting,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas,2373
1,NCT02356159,Phase Ib/II,Recruiting,"[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 2292, 'therapyName': 'Doxorubicin + Etoposide + Fludarabine + Vincristine '}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation,2373
2,NCT02653196,Phase II,Terminated,"[{'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 3948, 'therapyName': 'Cyclosporine + Mycophenolate mofetil + Tacrolimus'}]",A Multi-Institutional Phase II Feasibility Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors,2373
3,NCT02506959,Phase II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma,2373
4,NCT01746849,Phase II,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 2373, 'therapyName': 'Palifermin'}]",Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation,2373
5,NCT02589145,Phase Ib/II,Recruiting,"[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 3278, 'therapyName': 'Enoxaparin'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}]",Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype,2373
0,NCT03120832,Phase I,Recruiting,"[{'id': 5704, 'therapyName': 'PAN-301-1'}]",Phase 1 Trial of PAN-301-1 in Cancer Patients,5704
0,NCT02906670,Phase Ib/II,Recruiting,"[{'id': 3885, 'therapyName': 'Pan-HER'}]",Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies,3885
0,NCT02415881,Phase I,Recruiting,"[{'id': 845, 'therapyName': 'Panitumumab'}]",Phase I Panitumumab IRDye800 Optical Imaging Study,845
1,NCT00842257,Phase II,Completed,"[{'id': 845, 'therapyName': 'Panitumumab'}]",Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer,845
2,NCT01814501,Phase II,Recruiting,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 845, 'therapyName': 'Panitumumab'}]",Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab,845
3,NCT00979212,Phase II,"Active, not recruiting","[{'id': 845, 'therapyName': 'Panitumumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer (Cetuximab Closed as of 05/14/10),845
4,NCT01202409,Phase II,"Active, not recruiting","[{'id': 845, 'therapyName': 'Panitumumab'}]",CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater,845
5,NCT03087071,Phase II,Not yet recruiting,"[{'id': 845, 'therapyName': 'Panitumumab'}, {'id': 2, 'therapyName': 'Trametinib'}]",Panitumumab in Combination With Trametinib in Cetuximab-Refractory Stage IV Colorectal Cancer,845
6,NCT01312857,Phase II,Recruiting,"[{'id': 845, 'therapyName': 'Panitumumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1941, 'therapyName': 'Floxuridine'}]","Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type KRAS Who Have Resected Hepatic Metastases From Colorectal Cancer",845
7,NCT01260415,Phase II,Completed,"[{'id': 845, 'therapyName': 'Panitumumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases,845
8,NCT01128387,Phase Ib/II,Completed,"[{'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 845, 'therapyName': 'Panitumumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Trial of Panitumumab/Cisplatin/Fluorouracil With XRT in Esophageal Cancer,845
9,NCT00610948,Phase I,Completed,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 845, 'therapyName': 'Panitumumab'}]","Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Solid Tumors That Did Not Respond to Treatment",845
10,NCT02448810,Phase II,Terminated,"[{'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}, {'id': 2996, 'therapyName': 'Imalumab'}, {'id': 845, 'therapyName': 'Panitumumab'}]",Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer,845
11,NCT00658658,Phase I,Completed,"[{'id': 845, 'therapyName': 'Panitumumab'}]",Panitumumab Pediatric Study,845
12,NCT01927341,Phase Ib/II,Completed,"[{'id': 807, 'therapyName': 'Binimetinib'}, {'id': 845, 'therapyName': 'Panitumumab'}]","Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors",845
13,NCT02508077,Phase II,Terminated,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 845, 'therapyName': 'Panitumumab'}]",FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer,845
0,NCT01036087,Phase II,"Active, not recruiting","[{'id': 1984, 'therapyName': 'Panitumumab + Abraxane + Carboplatin'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}]","Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer",1984
0,NCT02008383,Phase I,Recruiting,"[{'id': 1985, 'therapyName': 'Panitumumab + cabozantinib'}]",Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer,1985
0,NCT01750918,Phase II,"Active, not recruiting","[{'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1718, 'therapyName': 'Panitumumab + Dabrafenib'}, {'id': 1992, 'therapyName': 'Panitumumab + Trametinib + Dabrafenib'}, {'id': 1991, 'therapyName': 'Panitumumab + Trametinib'}]",BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC),1718
0,NCT00940316,Phase II,"Active, not recruiting","[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1940, 'therapyName': 'Panitumumab + Erlotinib'}]",Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer,1940
0,NCT01307956,Phase II,Unknown status,"[{'id': 1986, 'therapyName': 'Panitumumab + FOLFOX'}]","Panitumumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Advanced Esophageal or Gastroesophageal Junction Cancer",1986
0,NCT02399943,Phase II,Recruiting,"[{'id': 1991, 'therapyName': 'Panitumumab + Trametinib'}]",A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer,1991
1,NCT01750918,Phase II,"Active, not recruiting","[{'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1718, 'therapyName': 'Panitumumab + Dabrafenib'}, {'id': 1992, 'therapyName': 'Panitumumab + Trametinib + Dabrafenib'}, {'id': 1991, 'therapyName': 'Panitumumab + Trametinib'}]",BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC),1991
0,NCT01750918,Phase II,"Active, not recruiting","[{'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1718, 'therapyName': 'Panitumumab + Dabrafenib'}, {'id': 1992, 'therapyName': 'Panitumumab + Trametinib + Dabrafenib'}, {'id': 1991, 'therapyName': 'Panitumumab + Trametinib'}]",BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC),1992
0,NCT02032810,Phase I,"Active, not recruiting","[{'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma,1080
1,NCT01321346,Phase I,Completed,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1080, 'therapyName': 'Panobinostat'}]",A Study Of Panobinostat In Children With Refractory Hematologic Malignancies,1080
2,NCT01169636,Phase Ib/II,Completed,"[{'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}]","Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma",1080
3,NCT01336842,Phase I,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors,1080
4,NCT02506959,Phase II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma,1080
5,NCT02720510,Phase II,Recruiting,"[{'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}]","A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)",1080
6,NCT00946647,Phase II,"Active, not recruiting","[{'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 651, 'therapyName': 'Azacitidine'}]","A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).",1080
7,NCT01032148,Phase I,Terminated,"[{'id': 1080, 'therapyName': 'Panobinostat'}]","Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma",1080
8,NCT02717455,Phase I,Recruiting,"[{'id': 1080, 'therapyName': 'Panobinostat'}]",Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma,1080
9,NCT02722941,Phase II,Recruiting,"[{'id': 1080, 'therapyName': 'Panobinostat'}]",Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT),1080
0,NCT02518750,Phase II,Recruiting,"[{'id': 1604, 'therapyName': 'Panobinostat + Bortezomib + Dexamethasone'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3217, 'therapyName': 'Cyclophosphamide + Etoposide'}, {'id': 3216, 'therapyName': 'Cytarabine + Methotrexate + Prednisone'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma,1604
1,NCT02654990,Phase II,Recruiting,"[{'id': 1604, 'therapyName': 'Panobinostat + Bortezomib + Dexamethasone'}]",Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma,1604
2,NCT02568943,Phase I,Available,"[{'id': 1604, 'therapyName': 'Panobinostat + Bortezomib + Dexamethasone'}]","An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma",1604
3,NCT02204553,Phase I,No longer available,"[{'id': 1604, 'therapyName': 'Panobinostat + Bortezomib + Dexamethasone'}]",Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma,1604
0,NCT00918333,Phase Ib/II,"Active, not recruiting","[{'id': 1964, 'therapyName': 'Panobinostat + Everolimus'}]","Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma",1964
1,NCT01582009,Phase Ib/II,Terminated,"[{'id': 1964, 'therapyName': 'Panobinostat + Everolimus'}]",Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate,1964
2,NCT00978432,Phase II,Terminated,"[{'id': 1964, 'therapyName': 'Panobinostat + Everolimus'}]",Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL),1964
0,NCT01543763,Phase I,"Active, not recruiting","[{'id': 3046, 'therapyName': 'Panobinostat + Pazopanib'}]","Phase I Tolerability, Efficacy, and Safety Study of Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors",3046
0,NCT01005797,Phase I,Completed,"[{'id': 1131, 'therapyName': 'Panobinostat + Sorafenib'}]","Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers",1131
0,NCT01270321,Phase II,"Active, not recruiting","[{'id': 2260, 'therapyName': 'Pasireotide'}, {'id': 735, 'therapyName': 'Everolimus'}]",A Trial of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer,2260
1,NCT01313559,Phase II,Terminated,"[{'id': 2261, 'therapyName': 'Everolimus + Pasireotide'}, {'id': 2260, 'therapyName': 'Pasireotide'}]","Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer",2260
0,NCT02134015,Phase III,Terminated,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2530, 'therapyName': 'Patritumab + Erlotinib'}]",Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung),2530
0,NCT02014636,Phase I,"Active, not recruiting","[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC),848
1,NCT02406521,Phase I,"Active, not recruiting","[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Exploratory Study of Radium-223 and Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases,848
2,NCT01599832,Phase I,Terminated,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer,848
3,NCT02049905,Phase III,Completed,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1440, 'therapyName': 'Aldoxorubicin'}, {'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}]",Phase 3 Study to Treat Patients With Soft Tissue Sarcomas,848
4,NCT01217931,Phase II,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy,848
5,NCT01759303,Phase II,"Active, not recruiting","[{'id': 848, 'therapyName': 'Pazopanib'}]",Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung,848
6,NCT01552356,Phase I,"Active, not recruiting","[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors,848
7,NCT02729194,Phase I,Recruiting,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma,848
8,NCT02180867,Phase II,Recruiting,"[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1472, 'therapyName': 'Doxorubicin + Ifosfamide'}]",Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can be Removed by Surgery (PAZNTIS),848
9,NCT01767636,Phase II,Recruiting,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib in Treating Patients With Metastatic Non-Clear Cell Kidney Cancer,848
10,NCT01832259,Phase II,"Active, not recruiting","[{'id': 848, 'therapyName': 'Pazopanib'}]",A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection,848
11,NCT02300545,Phase II,Recruiting,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy,848
12,NCT02193152,Phase I,Recruiting,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib in Molecularly Selected Patients With Advanced NSCLC,848
13,NCT01575548,Phase III,"Active, not recruiting","[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,848
14,NCT02009449,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2621, 'therapyName': 'AM0010 '}, {'id': 619, 'therapyName': 'Abraxane'}]",A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors,848
15,NCT02307474,Phase I,Withdrawn,"[{'id': 848, 'therapyName': 'Pazopanib'}]",A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer,848
16,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,848
17,NCT02560012,Phase II,Terminated,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Personalized Targeted Inhibitors Treatment in Renal Cell Cancer,848
18,NCT02601209,Phase Ib/II,Suspended,"[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1282, 'therapyName': 'Sapanisertib'}]",Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma,848
19,NCT02979899,Phase III,Recruiting,"[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1431, 'therapyName': 'TRC105 + Pazopanib'}]",A RANDOMIZED PHASE 3 TRIAL OF TRC105 AND PAZOPANIB VERSUS PAZOPANIB ALONE IN PATIENTS WITH ADVANCED ANGIOSARCOMA (TAPPAS),848
20,NCT01361113,Phase II,Completed,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Neoadjuvant Pazopanib in Renal Cell Carcinoma,848
21,NCT02956798,Phase II,Not yet recruiting,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib Vs. Local Therapy for Renal Cancer With Metastases,848
22,NCT01841736,Phase II,"Active, not recruiting","[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors,848
23,NCT01407562,Phase I,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}]","Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors",848
24,NCT01466972,Phase II,"Active, not recruiting","[{'id': 848, 'therapyName': 'Pazopanib'}]",Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib,848
25,NCT01956669,Phase II,Recruiting,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors,848
26,NCT01506596,,Completed,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma,848
27,NCT01330966,Phase II,"Active, not recruiting","[{'id': 848, 'therapyName': 'Pazopanib'}]",Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma,848
28,NCT01221506,Phase I,Completed,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC),848
29,NCT01236547,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer,848
30,NCT01462630,Phase II,Recruiting,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma,848
31,NCT01582204,Phase I,Recruiting,"[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma,848
32,NCT01158521,Phase II,Completed,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer,848
33,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,848
34,NCT01339871,Phase I,Completed,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Phase I Study of Pazopanib and Vorinostat,848
35,NCT01392183,Phase II,"Active, not recruiting","[{'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC),848
36,NCT01468922,Phase I,Completed,"[{'id': 636, 'therapyName': 'Tivantinib'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib and ARQ 197 for Advanced Solid Tumors,848
0,NCT01684397,Phase Ib/II,Recruiting,"[{'id': 1230, 'therapyName': 'Pazopanib + Bevacizumab'}]",Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer,1230
0,NCT01716416,Phase I,"Active, not recruiting","[{'id': 1838, 'therapyName': 'Pazopanib + Cetuximab'}]",Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC),1838
0,NCT01446809,Phase I,"Active, not recruiting","[{'id': 1472, 'therapyName': 'Doxorubicin + Ifosfamide'}, {'id': 1471, 'therapyName': 'Pazopanib + Doxorubicin + Ifosfamide'}]",Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma,1471
0,NCT03139331,Phase I,Recruiting,"[{'id': 5635, 'therapyName': 'Pazopanib + Irinotecan + Temozolomide'}]",PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma,5635
0,NCT01107665,Phase II,"Active, not recruiting","[{'id': 1143, 'therapyName': 'Pazopanib + Paclitaxel'}]",Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma,1143
1,NCT01108055,Phase II,Completed,"[{'id': 1143, 'therapyName': 'Pazopanib + Paclitaxel'}]",Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer,1143
2,NCT01179269,Phase II,Withdrawn,"[{'id': 1143, 'therapyName': 'Pazopanib + Paclitaxel'}]",Stage IIIB/IV Non-Small Cell Lung Cancer,1143
0,NCT01548144,Phase I,"Active, not recruiting","[{'id': 1153, 'therapyName': 'Crizotinib + Pazopanib'}, {'id': 1151, 'therapyName': 'Crizotinib + Pemetrexed'}, {'id': 1156, 'therapyName': 'Pazopanib + Pemetrexed'}, {'id': 1155, 'therapyName': 'Crizotinib + Pazopanib + Pemetrexed'}]",Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer,1156
0,NCT01465659,Phase Ib/II,Recruiting,"[{'id': 2040, 'therapyName': 'Pazopanib + Temozolomide'}]",Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery,2040
0,NCT01438554,Phase I,"Active, not recruiting","[{'id': 1310, 'therapyName': 'Pazopanib + Trametinib'}]","Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma",1310
0,NCT02403193,Phase Ib/II,Recruiting,"[{'id': 4741, 'therapyName': 'PBF-509 + PDR001'}, {'id': 4740, 'therapyName': 'PBF-509'}]",Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (AdenONCO),4740
0,NCT02403193,Phase Ib/II,Recruiting,"[{'id': 4741, 'therapyName': 'PBF-509 + PDR001'}, {'id': 4740, 'therapyName': 'PBF-509'}]",Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (AdenONCO),4741
0,NCT01347866,Phase I,Terminated,"[{'id': 1040, 'therapyName': 'PF-05212384'}, {'id': 849, 'therapyName': 'PD-0325901'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer,849
1,NCT02096471,Phase II,"Active, not recruiting","[{'id': 849, 'therapyName': 'PD-0325901'}]",MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1,849
0,NCT02022982,Phase Ib/II,Recruiting,"[{'id': 1823, 'therapyName': 'PD-0325901 + Palbociclib'}]",PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors,1823
0,NCT01976169,Phase I,Recruiting,"[{'id': 1731, 'therapyName': 'PD-0332991 + T-DM1'}]",Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1),1731
0,NCT02404441,Phase Ib/II,Recruiting,"[{'id': 2659, 'therapyName': 'PDR001'}]",Phase I/II Study of PDR001 in Patients With Advanced Malignancies,2659
1,NCT02605967,Phase II,Recruiting,"[{'id': 2659, 'therapyName': 'PDR001'}]",Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma,2659
2,NCT02795429,Phase Ib/II,Recruiting,"[{'id': 2659, 'therapyName': 'PDR001'}, {'id': 4492, 'therapyName': 'INC280 + PDR001'}]",Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC,2659
3,NCT02608268,Phase Ib/II,Recruiting,"[{'id': 2659, 'therapyName': 'PDR001'}, {'id': 3560, 'therapyName': 'MBG453'}]",Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies,2659
4,NCT02460224,Phase Ib/II,Recruiting,"[{'id': 2887, 'therapyName': 'LAG525'}, {'id': 2659, 'therapyName': 'PDR001'}]",Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies,2659
5,NCT02955069,Phase II,Recruiting,"[{'id': 2659, 'therapyName': 'PDR001'}]","Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin",2659
6,NCT03111992,Phase I,Recruiting,"[{'id': 5311, 'therapyName': 'PDR001 + LCL161'}, {'id': 5397, 'therapyName': 'PDR001 + CJM112'}, {'id': 2659, 'therapyName': 'PDR001'}]","Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma",2659
0,NCT02900664,Phase I,Recruiting,"[{'id': 5399, 'therapyName': 'PDR001 + EGF816'}, {'id': 5397, 'therapyName': 'PDR001 + CJM112'}, {'id': 5398, 'therapyName': 'PDR001 + Trametinib'}, {'id': 5395, 'therapyName': 'PDR001 + Canakinumab'}]","A Study of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib)",5395
0,NCT02900664,Phase I,Recruiting,"[{'id': 5399, 'therapyName': 'PDR001 + EGF816'}, {'id': 5397, 'therapyName': 'PDR001 + CJM112'}, {'id': 5398, 'therapyName': 'PDR001 + Trametinib'}, {'id': 5395, 'therapyName': 'PDR001 + Canakinumab'}]","A Study of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib)",5397
1,NCT03111992,Phase I,Recruiting,"[{'id': 5311, 'therapyName': 'PDR001 + LCL161'}, {'id': 5397, 'therapyName': 'PDR001 + CJM112'}, {'id': 2659, 'therapyName': 'PDR001'}]","Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma",5397
0,NCT02900664,Phase I,Recruiting,"[{'id': 5399, 'therapyName': 'PDR001 + EGF816'}, {'id': 5397, 'therapyName': 'PDR001 + CJM112'}, {'id': 5398, 'therapyName': 'PDR001 + Trametinib'}, {'id': 5395, 'therapyName': 'PDR001 + Canakinumab'}]","A Study of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib)",5399
0,NCT02890069,Phase I,Recruiting,"[{'id': 5311, 'therapyName': 'PDR001 + LCL161'}, {'id': 5312, 'therapyName': 'PDR001 + Everolimus'}, {'id': 5313, 'therapyName': 'PDR001 + Panobinostat'}]","A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat",5312
0,NCT03111992,Phase I,Recruiting,"[{'id': 5311, 'therapyName': 'PDR001 + LCL161'}, {'id': 5397, 'therapyName': 'PDR001 + CJM112'}, {'id': 2659, 'therapyName': 'PDR001'}]","Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma",5311
1,NCT02890069,Phase I,Recruiting,"[{'id': 5311, 'therapyName': 'PDR001 + LCL161'}, {'id': 5312, 'therapyName': 'PDR001 + Everolimus'}, {'id': 5313, 'therapyName': 'PDR001 + Panobinostat'}]","A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat",5311
0,NCT02452268,Phase I,Recruiting,"[{'id': 6032, 'therapyName': 'PDR001 + NIZ985'}]",A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers,6032
0,NCT02890069,Phase I,Recruiting,"[{'id': 5311, 'therapyName': 'PDR001 + LCL161'}, {'id': 5312, 'therapyName': 'PDR001 + Everolimus'}, {'id': 5313, 'therapyName': 'PDR001 + Panobinostat'}]","A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat",5313
0,NCT03081494,Phase I,Recruiting,"[{'id': 5930, 'therapyName': 'PDR001 + Regorafenib'}]",Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer,5930
0,NCT03294694,Phase I,Not yet recruiting,"[{'id': 6285, 'therapyName': 'Fulvestrant + PDR001 + Ribociclib'}, {'id': 6284, 'therapyName': 'PDR001 + Ribociclib'}]",Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer,6284
0,NCT02988440,Phase I,Recruiting,"[{'id': 5590, 'therapyName': 'PDR001 + Sorafenib'}]",Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients,5590
0,NCT02900664,Phase I,Recruiting,"[{'id': 5399, 'therapyName': 'PDR001 + EGF816'}, {'id': 5397, 'therapyName': 'PDR001 + CJM112'}, {'id': 5398, 'therapyName': 'PDR001 + Trametinib'}, {'id': 5395, 'therapyName': 'PDR001 + Canakinumab'}]","A Study of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib)",5398
0,NCT02112916,Phase III,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,1638
1,NCT03007147,Phase III,Recruiting,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 5167, 'therapyName': 'Methylprednisolone'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 5168, 'therapyName': 'Prednisolone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,1638
2,NCT01483690,Phase Ib/II,Terminated,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}]",A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL,1638
3,NCT03020030,Phase III,Recruiting,"[{'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents,1638
4,NCT02518750,Phase II,Recruiting,"[{'id': 1604, 'therapyName': 'Panobinostat + Bortezomib + Dexamethasone'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3217, 'therapyName': 'Cyclophosphamide + Etoposide'}, {'id': 3216, 'therapyName': 'Cytarabine + Methotrexate + Prednisone'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma,1638
5,NCT02419755,Phase II,Terminated,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies,1638
6,NCT02043587,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia &amp; Lymphoblastic Lymphoma,1638
7,NCT02535806,Phase II,Terminated,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults,1638
8,NCT02553460,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I,1638
9,NCT02883049,Phase III,Suspended,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations,1638
10,NCT01523977,Phase I,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL,1638
11,NCT03117751,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,1638
0,NCT02834403,Phase Ib/II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 6123, 'therapyName': 'Docetaxel + L-NMMA'}, {'id': 6096, 'therapyName': 'L-NMMA'}]",L-NMMA Plus Docetaxel in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients,1476
1,NCT00983398,Phase Ib/II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2587, 'therapyName': 'Carboplatin + Melphalan'}]","Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors",1476
2,NCT01256398,Phase II,"Active, not recruiting","[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1824, 'therapyName': 'Vincristine + Methotrexate + Mercaptopurine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,1476
3,NCT03136146,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1090, 'therapyName': 'Ofatumumab'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]","Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)",1476
4,NCT00303849,Phase Ib/II,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2562, 'therapyName': 'Etoposide + Melphalan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]",Combination Chemotherapy With BBBD Followed By Sodium Thiosulfate in Treating Patients With Anaplastic Oligodendroglioma or Oligoastrocytoma,1476
5,NCT01424982,Phase II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 2048, 'therapyName': 'Cytarabine + Methotrexate + Ponatinib'}, {'id': 2049, 'therapyName': 'Ponatinib + Vincristine'}, {'id': 2046, 'therapyName': 'Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine '}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),1476
6,NCT02181218,Phase I,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1611, 'therapyName': 'Gemcitabine + Oxaliplatin + Dexamethasone'}]","Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas",1476
7,NCT01501487,FDA approved,"Active, not recruiting","[{'id': 1902, 'therapyName': 'Docetaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1485, 'therapyName': 'Trastuzumab + Docetaxel + Carboplatin'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]",MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I,1476
8,NCT03197935,Phase III,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer (IMpassion031),1476
9,NCT00293475,Phase Ib/II,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 2669, 'therapyName': 'Carboplatin + Methotrexate + Rituximab'}]",Rituximab and Methotrexate Chemotherapy w/Blood-Brain Barrier Disruption (BBBD) &amp; Sodium Thiosulfate Chemoprotection for Patients With Newly Diagnosed PCNSL,1476
10,NCT01319981,Phase II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia,1476
11,NCT01879085,Phase Ib/II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Phase 1b/2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma,1476
12,NCT02531308,Phase II,Terminated,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}]",Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL),1476
13,NCT02087176,Phase II,Terminated,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]",A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer,1476
14,NCT01169636,Phase Ib/II,Completed,"[{'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}]","Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma",1476
15,NCT02543255,Phase II,Recruiting,"[{'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 3079, 'therapyName': 'Abiraterone + Leuprolide + Prednisone'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]",Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial),1476
16,NCT03102606,Phase II,Recruiting,"[{'id': 3678, 'therapyName': 'Plinabulin'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]",Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective-1),1476
0,NCT01964300,Phase II,Recruiting,"[{'id': 2624, 'therapyName': 'peginterferon alfa-2b'}]",Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery,2624
1,NCT02737046,Phase II,Recruiting,"[{'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 2624, 'therapyName': 'peginterferon alfa-2b'}, {'id': 4361, 'therapyName': 'Belinostat + Zidovudine'}]",Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma,2624
2,NCT02089685,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2624, 'therapyName': 'peginterferon alfa-2b'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29),2624
0,NCT02982720,Phase II,Recruiting,"[{'id': 2625, 'therapyName': 'peginterferon alfa-2b + Pembrolizumab'}]",Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron,2625
1,NCT02112032,Phase I,"Active, not recruiting","[{'id': 2625, 'therapyName': 'peginterferon alfa-2b + Pembrolizumab'}]",Treatment of Advanced Melanoma With MK-3475 and Peginterferon,2625
0,NCT02563548,Phase I,Recruiting,"[{'id': 5779, 'therapyName': 'PEGPH20 + Pembrolizumab'}]",Phase 1b Open-Label Study of PEGPH20 With Pembrolizumab,5779
0,NCT01145430,Phase I,"Active, not recruiting","[{'id': 2167, 'therapyName': 'pegylated liposomal doxorubicin + Veliparib'}]","Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer",2167
0,NCT03091478,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Patients With Leptomeningeal Disease,1447
1,NCT02437071,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients,1447
2,NCT03295227,Phase I,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma,1447
3,NCT03224871,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC.,1447
4,NCT02621151,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder",1447
5,NCT02541565,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 897, 'therapyName': 'Rituximab'}]",Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma,1447
6,NCT02489357,Phase I,"Active, not recruiting","[{'id': 1814, 'therapyName': 'Degarelix'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer",1447
7,NCT02460198,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164),1447
8,NCT02919969,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Refractory Metastatic Anal Cancer,1447
9,NCT03166254,Phase I,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Combination of a Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab in Non-Small Cell Lung Cancer,1447
10,NCT02316002,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer,1447
11,NCT03142334,Phase III,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564),1447
12,NCT03237572,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer (Breast-48),1447
13,NCT02858869,Phase 0,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases,1447
14,NCT03304639,,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Merkel Cell Cancer,1447
15,NCT02411656,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",MK-3475 for Metastatic Inflammatory Breast Cancer (MIBC),1447
16,NCT02132754,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2829, 'therapyName': 'MK-4166'}]",Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001),1447
17,NCT02574533,Phase I,Completed,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1157, 'therapyName': 'FANG vaccine'}]",Pilot Study of Vigil + Pembrolizumab for Advanced Melanoma,1447
18,NCT02500121,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Testing the PD-1 Inhibitor Pembrolizumab After Initial Chemotherapy in Patients With Metastatic Bladder Cancer,1447
19,NCT02305186,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer,1447
20,NCT03056599,,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1733, 'therapyName': 'interferon gamma '}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 3420, 'therapyName': 'trabectedin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma,1447
21,NCT03089606,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab TX-naive Distant Mets Melanoma and Use of AMT (PET) at Baseline as Imaging Biomarker,1447
22,NCT02365766,Phase Ib/II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Study of Neoadjuvant Pembrolizumab in Combination With Gemcitabine Based Therapy in Cis-eligible or -Ineligible Subjects With Urothelial Cancer,1447
23,NCT02819518,Phase III,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355),1447
24,NCT02620423,Phase I,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 893, 'therapyName': 'Reolysin'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab With REOLYSIN and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma,1447
25,NCT02268825,Phase Ib/II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase I/IIA Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers,1447
26,NCT02494583,Phase III,"Active, not recruiting","[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062),1447
27,NCT02638090,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC),1447
28,NCT03087019,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma,1447
29,NCT02252042,Phase III,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040),1447
30,NCT02499952,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors,1447
31,NCT02311582,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas,1447
32,NCT02407171,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC,1447
33,NCT02255097,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055),1447
34,NCT02684461,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel,1447
35,NCT02642809,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab With Locally Delivered Radiation Therapy for the Initial Treatment of Metastatic Esophageal Cancers,1447
36,NCT02256436,Phase III,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)",1447
37,NCT02977468,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer (Pembro/IORT),1447
38,NCT02535247,Phase II,Suspended,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of MK-3475 in Relapsed or Refractory Peripheral T-cell Non-Hodgkin Lymphoma,1447
39,NCT03286114,Phase I,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab,1447
40,NCT02608385,Phase I,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors,1447
41,NCT03274661,Phase II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab Activity in Patients With HR Competent and Deficient Tumors,1447
42,NCT02637531,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3363, 'therapyName': 'IPI-549'}]","A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549",1447
43,NCT02332668,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051)",1447
44,NCT02625961,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057),1447
45,NCT03225664,Phase Ib/II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1450, 'therapyName': 'Pembrolizumab + Trametinib'}]",BATTLE-2 Program - A Biomarker-Integrated Targeted Therapy in Non-Small Cell Lung Cancer (NSCLC),1447
46,NCT02853305,Phase III,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 4686, 'therapyName': 'Carboplatin + Cisplatin + Gemcitabine'}]",Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361),1447
47,NCT02362048,Phase II,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer,1447
48,NCT02628067,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158),1447
49,NCT02899793,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer,1447
50,NCT02906332,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM),1447
51,NCT02611960,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 4203, 'therapyName': 'Capecitabine + Docetaxel + Gemcitabine'}]","Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122, KEYNOTE-122)",1447
52,NCT02730546,Phase Ib/II,Suspended,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery",1447
53,NCT03287050,Phase I,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma",1447
54,NCT02537444,Phase II,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer (KEYNOTE191),1447
55,NCT02635360,Phase II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer,1447
56,NCT03277638,Phase Ib/II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Laser Interstitial Thermotherapy Combined With Checkpoint Inhibitor for Recurrent Glioblastoma,1447
57,NCT02343952,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Consolidation Pembrolizumab (MK-3475), Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC",1447
58,NCT02702414,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) as Monotherapy in Adults With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224),1447
59,NCT03051672,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC,1447
60,NCT02673333,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma,1447
61,NCT02408042,Phase Ib/II,Withdrawn,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2486, 'therapyName': 'Brentuximab vedotin'}]",Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme),1447
62,NCT03255018,Phase II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extra-Nodal Diffuse Large B-cell Lymphomas",1447
63,NCT02528357,Phase I,Recruiting,"[{'id': 5177, 'therapyName': 'GSK3174998'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors,1447
64,NCT02530502,Phase Ib/II,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma,1447
65,NCT02940496,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab (MK-3475) in Hepatocellular Carcinoma,1447
66,NCT02301039,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas,1447
67,NCT02335411,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}]",A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059),1447
68,NCT02325557,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3050, 'therapyName': 'ADXS31-142 '}]",ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046,1447
69,NCT02506153,Phase III,"Active, not recruiting","[{'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery,1447
70,NCT03087760,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer,1447
71,NCT02769520,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck",1447
72,NCT02688608,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer,1447
73,NCT01876511,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors,1447
74,NCT02014636,Phase I,"Active, not recruiting","[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC),1447
75,NCT03244384,Phase III,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer,1447
76,NCT02579863,Phase III,Suspended,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}]",Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185),1447
77,NCT02707666,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}]",A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma,1447
78,NCT03241927,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT),1447
79,NCT02009449,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2621, 'therapyName': 'AM0010 '}, {'id': 619, 'therapyName': 'Abraxane'}]",A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors,1447
80,NCT02621021,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab,1447
81,NCT02964559,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer,1447
82,NCT02432963,Phase I,Recruiting,"[{'id': 1038, 'therapyName': 'MVAp53'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy,1447
83,NCT02440425,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer,1447
84,NCT03092323,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032),1447
85,NCT02564263,Phase III,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2282, 'therapyName': 'Docetaxel + Irinotecan + Paclitaxel'}]",Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181),1447
86,NCT02678572,Phase III,Recruiting,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma,1447
87,NCT02690948,Phase II,Recruiting,"[{'id': 3727, 'therapyName': 'Pembrolizumab + Vismodegib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer,1447
88,NCT03057613,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Study of the Addition of Pembrolizumab to Postoperative Radiotherapy in Resected High Risk Cutaneous Squamous Cell Cancer of the Head and Neck,1447
89,NCT02599779,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients,1447
90,NCT02332980,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Phase II Study of Anti-PD-1 Antibody (MK-3475) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Other Low Grade B Cell Non-Hodgkin Lymphoma,1447
91,NCT02289209,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Reirradiation With MK-3475 in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck,1447
92,NCT02841748,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study",1447
93,NCT02708641,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients 60 With AML,1447
94,NCT02771197,Phase II,Recruiting,"[{'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant,1447
95,NCT02963090,Phase II,Recruiting,"[{'id': 5532, 'therapyName': 'Pembrolizumab + Topotecan'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer,1447
96,NCT02358031,Phase III,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048),1447
97,NCT03126630,Phase Ib/II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 5596, 'therapyName': 'Pembrolizumab + Anetumab ravtansine'}]",Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma,1447
98,NCT02448303,Phase II,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab Alone and In Combination With ACP-196 in Subjects With Advanced Non-small Cell Lung Cancer,1447
99,NCT02359851,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Patients With Advanced Uveal Melanoma,1447
100,NCT02752074,Phase III,"Active, not recruiting","[{'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma,1447
101,NCT02650999,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas,1447
102,NCT02658097,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","A Randomized Two Arm Phase II Trial of Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC",1447
103,NCT02674061,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Efficacy and Safety Study of Pembrolizumab (MK-3475) in Women With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100),1447
104,NCT03072160,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer,1447
105,NCT03273153,Phase III,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma,1447
106,NCT02444741,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",MK-3475 and Hypofractionated Stereotactic Radiation Therapy in Patients With Non-Small Cell Lung Cancer (NSCLC),1447
107,NCT02267603,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer,1447
108,NCT02493361,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2990, 'therapyName': 'IL-12 gene'}]",Trial of pIL-12/MK-3475 in Metastatic Melanoma,1447
109,NCT02837042,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma,1447
110,NCT02306850,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma,1447
111,NCT03070392,Phase II,Recruiting,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3847, 'therapyName': 'IMCgp100'}]",Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma,1447
112,NCT03136055,Phase II,Recruiting,"[{'id': 5643, 'therapyName': 'Irinotecan + Pembrolizumab'}, {'id': 4021, 'therapyName': 'Paclitaxel + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas,1447
113,NCT03267888,Phase I,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma,1447
114,NCT02555657,Phase III,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119),1447
115,NCT03085719,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN,1447
116,NCT02331251,Phase Ib/II,"Active, not recruiting","[{'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 619, 'therapyName': 'Abraxane'}]",Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus),1447
117,NCT02359019,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Patients With Extensive Stage Small Cell Lung Cancer After Completion of Combination Chemotherapy,1447
118,NCT02740920,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Assessment of Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography (CT) Texture Analysis as a Predictive Biomarker,1447
119,NCT02954874,Phase III,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer,1447
120,NCT02632344,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Study of Anti-PD-1 Therapy for HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal and/or Pulmonary Involvement",1447
121,NCT02837263,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer,1447
122,NCT03233724,Phase Ib/II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","The Immune Checkpoint Inhibitor Pembrolizumab in Combination With Oral Decitabine and Tetrahydrouridine as First-Line Therapy for Inoperable, Locally Advanced or Metastatic Non-small Cell Lung Cancer",1447
123,NCT03197506,Phase II,Recruiting,"[{'id': 5221, 'therapyName': 'Pembrolizumab + Temozolomide'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma,1447
124,NCT02520154,Phase II,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer,1447
125,NCT02467361,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2057, 'therapyName': 'BBI608'}]",A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers,1447
126,NCT02546986,Phase II,"Active, not recruiting","[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer,1447
127,NCT02710396,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Genetic Predictors of Benefit to Pembrolizumab,1447
128,NCT02351739,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1605, 'therapyName': 'Acalabrutinib'}]",Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum-refractory Metastatic Bladder Cancer,1447
129,NCT02892201,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in HNSCC With Residual Disease After Radiation,1447
130,NCT02559687,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180),1447
131,NCT02998268,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma,1447
132,NCT02767934,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia,1447
133,NCT03036488,Phase III,Recruiting,"[{'id': 1087, 'therapyName': 'Epirubicin + Cyclophosphamide'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522),1447
134,NCT02959463,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Adjuvant Pembrolizumab After Radiation Therapy for Lung-Intact Malignant Pleural Mesothelioma,1447
135,NCT03099564,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab Plus Y90 Radioembolization in HCC Subjects,1447
136,NCT02981914,Phase 0,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation,1447
137,NCT03035331,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma",1447
138,NCT03189186,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas,1447
139,NCT02852655,Phase 0,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma",1447
140,NCT02521870,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3084, 'therapyName': 'SD-101'}]",A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma,1447
141,NCT02375672,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer,1447
142,NCT02359565,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas or Diffuse Intrinsic Pontine Gliomas",1447
143,NCT02337686,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pharmacodynamic Study of Pembrolizumab in Patients With Recurrent Glioblastoma,1447
144,NCT02451930,Phase I,"Active, not recruiting","[{'id': 826, 'therapyName': 'Necitumumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC,1447
145,NCT03065400,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",PD-1 Inhibition in Advanced Myeloproliferative Neoplasms,1447
146,NCT02603887,Phase I,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab for Smoldering Multiple Myeloma (SMM),1447
147,NCT01174121,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer,1447
148,NCT02557321,Phase Ib/II,Recruiting,"[{'id': 879, 'therapyName': 'PV-10'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma,1447
149,NCT02499835,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer",1447
150,NCT02422381,Phase Ib/II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC),1447
151,NCT02434354,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma,1447
152,NCT02563002,Phase III,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177),1447
153,NCT01953692,Phase I,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013),1447
154,NCT02318771,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Urothelial Cancer, Melanoma, and Non-Small Cell Lung Cancer",1447
155,NCT03179917,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma,1447
156,NCT02999477,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 619, 'therapyName': 'Abraxane'}]",A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer,1447
157,NCT02658019,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma,1447
158,NCT02775435,Phase III,Recruiting,"[{'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407),1447
159,NCT02702401,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240),1447
160,NCT02955758,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer,1447
161,NCT02142738,Phase III,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024),1447
162,NCT02775851,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery,1447
163,NCT01822652,Phase I,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]","3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN",1447
164,NCT02728830,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers,1447
165,NCT02768792,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML,1447
166,NCT02447003,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086),1447
167,NCT02362035,Phase Ib/II,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]","ACP-196 in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (KEYNOTE145)",1447
168,NCT02939651,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Study of Pembrolizumab in Patients With Neuroendocrine Tumors,1447
169,NCT02730130,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients,1447
170,NCT02212730,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031),1447
171,NCT03007732,Phase II,Recruiting,"[{'id': 5166, 'therapyName': 'Pembrolizumab + SD-101'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Combination With Intratumoral SD-101 Therapy,1447
172,NCT02581943,Phase II,Suspended,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer,1447
173,NCT02886585,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab In Central Nervous System Metastases,1447
174,NCT02882282,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) for High Risk Oral Intra-Epithelial Neoplasias,1447
175,NCT02576977,Phase III,Suspended,"[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183),1447
176,NCT02576990,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Advanced Primary Mediastinal Large B-cell Lymphoma (MK-3475-170/KEYNOTE-170),1447
177,NCT02362997,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab After ASCT for Hodgkin Lymphoma and DLBCL,1447
178,NCT02646748,Phase I,Recruiting,"[{'id': 3088, 'therapyName': 'INCB050465 '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2406, 'therapyName': 'INCB039110'}]",Pembrolizumab Combined With INCB039110 and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors,1447
179,NCT02658279,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype,1447
180,NCT03259867,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Combination of TATE and PD-1 Inhibitor in Liver Cancer,1447
181,NCT02362594,Phase III,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/KEYNOTE-054),1447
182,NCT03025035,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Advanced BRCA-mutated Breast Cancer,1447
183,NCT02591615,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]",Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC,1447
184,NCT02595866,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms",1447
185,NCT02879994,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer",1447
186,NCT02453594,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087),1447
187,NCT02511184,Phase I,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Crizotinib Plus Pembrolizumab In Alk-positive Advanced Non Small Cell Lung Cancer Patients,1447
188,NCT02437370,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer,1447
189,NCT03210662,Phase II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab and Fractionated External Beam Radiotherapy (EBRT) in Patients With Non-Hodgkin Lymphoma (NHL),1447
190,NCT02303990,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",RADVAX A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers,1447
191,NCT02263508,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2695, 'therapyName': 'talimogene laherparepvec '}]",MK-3475 With or Without Talimogene Laherparepvec in Unresected Melanoma,1447
192,NCT02830594,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer",1447
193,NCT02784171,Phase II,Recruiting,"[{'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma,1447
194,NCT01993719,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Immunotherapy Using Tumor Infiltrating Lymphocytes Comparing 2 Different Conditioning Regimens for Patients With Metastatic Melanoma,1447
195,NCT02578680,Phase III,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Non-squamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189),1447
196,NCT03004183,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 5172, 'therapyName': 'AdV-tk + Valacyclovir'}]",SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC,1447
197,NCT02324582,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",MK-3475/BCG in High Risk Superficial Bladder Cancer,1447
198,NCT02483247,Phase Ib/II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1945, 'therapyName': 'BBI503'}]",A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer,1447
199,NCT02089685,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2624, 'therapyName': 'peginterferon alfa-2b'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29),1447
200,NCT02331368,Phase II,"Active, not recruiting","[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma,1447
201,NCT02853344,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427),1447
202,NCT02581982,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer,1447
203,NCT03302234,Phase III,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2106, 'therapyName': 'Ipilimumab + Pembrolizumab '}]",Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer (MK-3475-598/KEYNOTE-598),1447
204,NCT02818920,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Neoadjuvant Pembrolizumab,1447
205,NCT02335424,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52),1447
206,NCT02296684,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma,1447
207,NCT02337491,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2119, 'therapyName': 'Bevacizumab + Pembrolizumab'}]",Pembrolizumab +/- Bevacizumab for Recurrent GBM,1447
208,NCT02971956,Phase II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Phase II Study of Pembrolizumab in Refractory Advanced Esophageal Cancer,1447
209,NCT02575404,Phase I,Recruiting,"[{'id': 2975, 'therapyName': 'GR-MD-02'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",GR-MD-02 Plus Pembrolizumab in Melanoma Patients,1447
210,NCT02971748,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Study of Anti-PD-1 (Pembrolizumab) + Hormonal Therapy in HR-positive Localized IBC Patients With Non-pCR to Neoadjuvant Chemotherapy,1447
211,NCT02644369,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors,1447
212,NCT02721732,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors,1447
213,NCT02641093,Phase II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma,1447
214,NCT02501096,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 792, 'therapyName': 'Lenvatinib'}]",Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors,1447
215,NCT02949219,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery,1447
216,NCT02085070,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",MK-3475 in Melanoma and NSCLC Patients With Brain Metastases,1447
217,NCT02339324,Phase I,"Active, not recruiting","[{'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b,1447
218,NCT03217071,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer,1447
219,NCT02382406,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}]",Carboplatin/Nab-Paclitaxel and MK-3475 in NSCLC,1447
220,NCT02693535,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 690, 'therapyName': 'Bosutinib'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer,1447
221,NCT02399371,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Patients With Malignant Mesothelioma,1447
222,NCT02787005,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Chemotherapy (MK-3475-199/KEYNOTE-199),1447
223,NCT03279692,Phase II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma,1447
224,NCT02454179,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1605, 'therapyName': 'Acalabrutinib'}]",Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Head and Neck Squamous Cell Carcinoma,1447
225,NCT02364076,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",MK-3475 in Patients With Thymic Carcinoma,1447
226,NCT03190213,Phase II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma (Pembro NEC),1447
227,NCT02591654,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",MRI/PET Imaging to Assess Response to Pembrolizumab in Metastatic Melanoma,1447
228,NCT02684292,Phase III,Recruiting,"[{'id': 2486, 'therapyName': 'Brentuximab vedotin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204),1447
229,NCT02054806,Phase I,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28),1447
230,NCT03290079,Phase II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Advanced Poorly Differentiated and/or High Grade Neuroendocrine Tumors/Carcinomas,1447
231,NCT02609503,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin,1447
232,NCT02755272,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer,1447
233,NCT02220894,Phase III,Recruiting,"[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of MK-3475 (Pembrolizumab) Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer (MK-3475-042/KEYNOTE-042),1447
234,NCT02178722,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2575, 'therapyName': 'Epacadostat'}]","A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors and Advanced NSCLC (INCB 24360-202 / MK-3475-037 / KEYNOTE-037)",1447
235,NCT02179918,Phase I,Completed,"[{'id': 5086, 'therapyName': 'Utomilumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036),1447
236,NCT02880345,Phase 0,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",RADVAX: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy,1447
237,NCT02987166,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",HDCRT Plus Pembrolizumab in Advanced Malignancies (UVA-AM-001),1447
0,NCT02879760,Phase Ib/II,Recruiting,"[{'id': 5085, 'therapyName': 'Pembrolizumab + Ad-MAGEA3 + MG1-MAGEA3'}]",Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients,5085
0,NCT03126630,Phase Ib/II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 5596, 'therapyName': 'Pembrolizumab + Anetumab ravtansine'}]",Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma,5596
0,NCT03149822,Phase Ib/II,Not yet recruiting,"[{'id': 5680, 'therapyName': 'Pembrolizumab + Cabozantinib'}]",Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma,5680
0,NCT02713373,Phase Ib/II,Recruiting,"[{'id': 1910, 'therapyName': 'Pembrolizumab + Cetuximab'}]",Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery,1910
1,NCT03082534,Phase II,Recruiting,"[{'id': 1910, 'therapyName': 'Pembrolizumab + Cetuximab'}]",Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma,1910
2,NCT02318901,Phase Ib/II,"Active, not recruiting","[{'id': 1909, 'therapyName': 'Pembrolizumab + trastuzumab emtansine'}, {'id': 1908, 'therapyName': 'Pembrolizumab + Trastuzumab'}, {'id': 1910, 'therapyName': 'Pembrolizumab + Cetuximab'}]",Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer,1910
0,NCT02130466,Phase Ib/II,Recruiting,"[{'id': 1450, 'therapyName': 'Pembrolizumab + Trametinib'}, {'id': 1448, 'therapyName': 'Pembrolizumab + Dabrafenib'}, {'id': 1449, 'therapyName': 'Pembrolizumab + Dabrafenib + Trametinib'}]",A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022),1448
0,NCT03149029,Phase II,Not yet recruiting,"[{'id': 1449, 'therapyName': 'Pembrolizumab + Dabrafenib + Trametinib'}, {'id': 1450, 'therapyName': 'Pembrolizumab + Trametinib'}]",Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma,1449
1,NCT02130466,Phase Ib/II,Recruiting,"[{'id': 1450, 'therapyName': 'Pembrolizumab + Trametinib'}, {'id': 1448, 'therapyName': 'Pembrolizumab + Dabrafenib'}, {'id': 1449, 'therapyName': 'Pembrolizumab + Dabrafenib + Trametinib'}]",A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022),1449
0,NCT02996474,Phase Ib/II,Recruiting,"[{'id': 5127, 'therapyName': 'Pembrolizumab + Decitabine'}]",Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia,5127
0,NCT03029403,Phase II,Not yet recruiting,"[{'id': 5266, 'therapyName': 'Pembrolizumab + DPX-Survivac + Cyclophosphamide'}]","Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer",5266
0,NCT03077828,Phase II,Recruiting,"[{'id': 5435, 'therapyName': 'Pembrolizumab + Etoposide + Carboplatin + Ifosfamide'}]",Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma,5435
0,NCT03083808,Phase II,Recruiting,"[{'id': 5497, 'therapyName': 'Pembrolizumab + Gemcitabine'}, {'id': 5496, 'therapyName': 'Docetaxel + Pembrolizumab'}, {'id': 5498, 'therapyName': 'Pemetrexed + Pembrolizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Phase II Trial of Continuation Therapy in Advanced NSCLC,5497
0,NCT02950220,Phase I,Recruiting,"[{'id': 4917, 'therapyName': 'Pembrolizumab + Ibrutinib'}]",Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma,4917
1,NCT03153202,Phase Ib/II,Recruiting,"[{'id': 4917, 'therapyName': 'Pembrolizumab + Ibrutinib'}]",Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL),4917
2,NCT03021460,Phase II,Suspended,"[{'id': 4917, 'therapyName': 'Pembrolizumab + Ibrutinib'}]",Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,4917
0,NCT03063632,Phase II,Not yet recruiting,"[{'id': 5367, 'therapyName': 'Pembrolizumab + interferon gamma'}]",Pembrolizumab and Interferon Gamma-1b in Treating Patients With Stage IB-IVB Relapsed or Refractory Mycosis Fungoides and Sezary Syndrome,5367
0,NCT03030378,Phase I,Not yet recruiting,"[{'id': 5263, 'therapyName': 'Pembrolizumab + Interleukin-12'}]",Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors,5263
0,NCT02930902,Phase I,Recruiting,"[{'id': 4903, 'therapyName': 'Pembrolizumab + Paricalcitol'}, {'id': 4904, 'therapyName': 'Pembrolizumab + Paricalcitol + Gemcitabine + nab-paclitaxel'}]",Preoperative Pilot Study to Assess Safety and Immunological Effect of Pembrolizumab (Keytruda) in Combination With Paricalcitol With or Without Chemotherapy in Patients With Resectable Pancreatic Cancer,4903
0,NCT02930902,Phase I,Recruiting,"[{'id': 4903, 'therapyName': 'Pembrolizumab + Paricalcitol'}, {'id': 4904, 'therapyName': 'Pembrolizumab + Paricalcitol + Gemcitabine + nab-paclitaxel'}]",Preoperative Pilot Study to Assess Safety and Immunological Effect of Pembrolizumab (Keytruda) in Combination With Paricalcitol With or Without Chemotherapy in Patients With Resectable Pancreatic Cancer,4904
0,NCT02452424,Phase Ib/II,"Active, not recruiting","[{'id': 2736, 'therapyName': 'Pembrolizumab + PLX3397'}]",A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors,2736
0,NCT02834052,Phase Ib/II,Not yet recruiting,"[{'id': 4458, 'therapyName': 'Pembrolizumab + poly ICLC '}]",Pembrolizumab + Poly-ICLC in MRP Colon Cancer,4458
0,NCT03099161,Phase I,Recruiting,"[{'id': 5518, 'therapyName': 'Preladenant'}, {'id': 5519, 'therapyName': 'Pembrolizumab + Preladenant'}]",Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062),5519
0,NCT02680184,Phase I,Recruiting,"[{'id': 4001, 'therapyName': 'Pembrolizumab + QbG10'}]",Clinical Study of CMP-001 in Combination With Pembrolizumab,4001
1,NCT03084640,Phase Ib/II,Recruiting,"[{'id': 4001, 'therapyName': 'Pembrolizumab + QbG10'}]",Phase 1b Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Subjects With Advanced Melanoma,4001
0,NCT03093428,Phase II,Recruiting,"[{'id': 5542, 'therapyName': 'Pembrolizumab + Ra 223'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}]",Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC,5542
0,NCT02719015,Phase Ib/II,Not yet recruiting,"[{'id': 3943, 'therapyName': 'Pembrolizumab + rAd.CD40L'}]",Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma,3943
0,NCT02443324,Phase I,"Active, not recruiting","[{'id': 2896, 'therapyName': 'Pembrolizumab + Ramucirumab'}]","A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC or Transitional Cell Carcinoma of the Urothelium",2896
0,NCT02446457,Phase II,Recruiting,"[{'id': 3279, 'therapyName': 'Pembrolizumab + Rituximab'}]",Study of Rituximab Plus Pembrolizumab (MK-3475) in Subjects With Relapsed Follicular Lymphoma,3279
0,NCT03012230,Phase I,Not yet recruiting,"[{'id': 5227, 'therapyName': 'Pembrolizumab + Ruxolitinib'}]",Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer,5227
0,NCT02703714,Phase II,Recruiting,"[{'id': 4217, 'therapyName': 'Pembrolizumab + Sargramostim'}]",Pembrolizumab and GM-CSF in Biliary Cancer,4217
0,NCT03007732,Phase II,Recruiting,"[{'id': 5166, 'therapyName': 'Pembrolizumab + SD-101'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Combination With Intratumoral SD-101 Therapy,5166
0,NCT02376699,Phase I,Recruiting,"[{'id': 5781, 'therapyName': 'Pembrolizumab + SEA-CD40'}, {'id': 5780, 'therapyName': 'SEA-CD40'}]",Safety Study of SEA-CD40 in Cancer Patients,5781
0,NCT02901899,Phase II,Recruiting,"[{'id': 4725, 'therapyName': 'Pembrolizumab + SGI-110'}]","Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",4725
0,NCT03211416,Phase Ib/II,Recruiting,"[{'id': 6041, 'therapyName': 'Pembrolizumab + Sorafenib'}]",Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer,6041
0,NCT03161431,Phase I,Not yet recruiting,"[{'id': 5786, 'therapyName': 'SX-682'}, {'id': 5787, 'therapyName': 'Pembrolizumab + SX-682'}]",SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab,5787
0,NCT02626000,Phase Ib/II,Recruiting,"[{'id': 4035, 'therapyName': 'Pembrolizumab + talimogene laherparepvec '}]",Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck,4035
1,NCT02965716,Phase II,Recruiting,"[{'id': 4035, 'therapyName': 'Pembrolizumab + talimogene laherparepvec '}]",Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma,4035
2,NCT03069378,Phase II,Recruiting,"[{'id': 4035, 'therapyName': 'Pembrolizumab + talimogene laherparepvec '}]",A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma,4035
0,NCT02395627,Phase II,Recruiting,"[{'id': 3114, 'therapyName': 'Pembrolizumab + Tamoxifen + vorinostat'}]",Reversing Hormone Therapy Resistance With Epigenetic-Immune Modification,3114
0,NCT03197506,Phase II,Recruiting,"[{'id': 5221, 'therapyName': 'Pembrolizumab + Temozolomide'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma,5221
1,NCT03018288,Phase II,Recruiting,"[{'id': 5221, 'therapyName': 'Pembrolizumab + Temozolomide'}, {'id': 5220, 'therapyName': 'Pembrolizumab + Temozolomide + Vitespen'}]",Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM),5221
0,NCT03018288,Phase II,Recruiting,"[{'id': 5221, 'therapyName': 'Pembrolizumab + Temozolomide'}, {'id': 5220, 'therapyName': 'Pembrolizumab + Temozolomide + Vitespen'}]",Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM),5220
0,NCT03283137,Phase I,Not yet recruiting,"[{'id': 6237, 'therapyName': 'Pembrolizumab + TGR-1202'}]",Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL,6237
0,NCT02535286,Phase Ib/II,Recruiting,"[{'id': 3475, 'therapyName': 'Pembrolizumab + TGR-1202 + Ublituximab'}]",Study of Pembrolizumab in Combination With Ublituximab and TGR-1202 in Patients With Relapsed-refractory CLL,3475
0,NCT02963090,Phase II,Recruiting,"[{'id': 5532, 'therapyName': 'Pembrolizumab + Topotecan'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer,5532
0,NCT03299088,Phase I,Not yet recruiting,"[{'id': 1450, 'therapyName': 'Pembrolizumab + Trametinib'}]",Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations,1450
1,NCT03149029,Phase II,Not yet recruiting,"[{'id': 1449, 'therapyName': 'Pembrolizumab + Dabrafenib + Trametinib'}, {'id': 1450, 'therapyName': 'Pembrolizumab + Trametinib'}]",Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma,1450
2,NCT02130466,Phase Ib/II,Recruiting,"[{'id': 1450, 'therapyName': 'Pembrolizumab + Trametinib'}, {'id': 1448, 'therapyName': 'Pembrolizumab + Dabrafenib'}, {'id': 1449, 'therapyName': 'Pembrolizumab + Dabrafenib + Trametinib'}]",A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022),1450
3,NCT03225664,Phase Ib/II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1450, 'therapyName': 'Pembrolizumab + Trametinib'}]",BATTLE-2 Program - A Biomarker-Integrated Targeted Therapy in Non-Small Cell Lung Cancer (NSCLC),1450
0,NCT02318901,Phase Ib/II,"Active, not recruiting","[{'id': 1909, 'therapyName': 'Pembrolizumab + trastuzumab emtansine'}, {'id': 1908, 'therapyName': 'Pembrolizumab + Trastuzumab'}, {'id': 1910, 'therapyName': 'Pembrolizumab + Cetuximab'}]",Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer,1908
0,NCT03032107,Phase I,Recruiting,"[{'id': 1909, 'therapyName': 'Pembrolizumab + trastuzumab emtansine'}]",A Study Of Pembrolizumab In Combination With Trastuzumab-DM1,1909
1,NCT02318901,Phase Ib/II,"Active, not recruiting","[{'id': 1909, 'therapyName': 'Pembrolizumab + trastuzumab emtansine'}, {'id': 1908, 'therapyName': 'Pembrolizumab + Trastuzumab'}, {'id': 1910, 'therapyName': 'Pembrolizumab + Cetuximab'}]",Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer,1909
0,NCT03239145,Phase I,Recruiting,"[{'id': 6102, 'therapyName': 'Pembrolizumab + Trebananib'}]",Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor,6102
0,NCT03200847,Phase Ib/II,Not yet recruiting,"[{'id': 5988, 'therapyName': 'Pembrolizumab + Tretinoin'}]",Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma,5988
0,NCT02818023,Phase I,Recruiting,"[{'id': 4406, 'therapyName': 'Pembrolizumab + Vemurafenib'}]",Dose-seeking and Efficacy Study of Pembrolizumab Plus Vemurafenib Advanced Melanoma,4406
0,NCT02690948,Phase II,Recruiting,"[{'id': 3727, 'therapyName': 'Pembrolizumab + Vismodegib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer,3727
0,NCT02538510,Phase Ib/II,"Active, not recruiting","[{'id': 3077, 'therapyName': 'Pembrolizumab + Vorinostat'}]",Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer and Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery,3077
1,NCT03150329,Phase I,Recruiting,"[{'id': 3077, 'therapyName': 'Pembrolizumab + Vorinostat'}]","Pembrolizumab and Vorinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma",3077
2,NCT02619253,Phase Ib/II,Recruiting,"[{'id': 3077, 'therapyName': 'Pembrolizumab + Vorinostat'}]",Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma,3077
0,NCT02823405,Phase I,Recruiting,"[{'id': 4436, 'therapyName': 'Pembrolizumab + X4P-001'}]",Neoadjuvant X4P-001 and Pembrolizumab in Patients With Resectable Melanoma (X4P-001-MELA),4436
0,NCT03095781,Phase I,Recruiting,"[{'id': 5533, 'therapyName': 'Pembrolizumab + XL888'}]",Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer,5533
0,NCT02117024,Phase II,"Active, not recruiting","[{'id': 2472, 'therapyName': 'HS-110 + Cyclophosphamide'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer,854
1,NCT02387216,Phase II,Recruiting,"[{'id': 820, 'therapyName': 'Seribantumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC,854
2,NCT03257267,Phase III,Recruiting,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 5656, 'therapyName': 'REGN2810'}, {'id': 942, 'therapyName': 'Topotecan'}]",Study of REGN2810 in Adults With Cervical Cancer,854
3,NCT01708993,Phase II,Completed,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1110, 'therapyName': 'Reolysin + Pemetrexed'}, {'id': 1111, 'therapyName': 'Reolysin + Docetaxel'}]"," Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy",854
4,NCT02041533,Phase III,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)",854
5,NCT01553942,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Afatinib With CT and RT for EGFR-Mutant NSCLC,854
6,NCT01646125,,Terminated,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 647, 'therapyName': 'AUY922'}, {'id': 854, 'therapyName': 'Pemetrexed'}]"," An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations",854
7,NCT02079636,Phase I,Recruiting,"[{'id': 1069, 'therapyName': 'LY3023414'}, {'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC),854
8,NCT01700400,Phase I,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]"," Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer",854
9,NCT02264990,Phase III,"Active, not recruiting","[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers,854
10,NCT02419495,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Selinexor in Combination With Standard Chemotherapy,854
11,NCT02578680,Phase III,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Non-squamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189),854
12,NCT01828112,Phase III,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 789, 'therapyName': 'Ceritinib'}]",LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib,854
13,NCT02134912,Phase II,Recruiting,"[{'id': 1151, 'therapyName': 'Crizotinib + Pemetrexed'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib,854
14,NCT02220894,Phase III,Recruiting,"[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of MK-3475 (Pembrolizumab) Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer (MK-3475-042/KEYNOTE-042),854
15,NCT03137771,Phase II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}]",Maintenance Chemotherapy With or Without Stereotactic Body Radiation Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,854
16,NCT03057106,Phase II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC,854
17,NCT00950365,Phase II,Unknown status,"[{'id': 1290, 'therapyName': 'Erlotinib + Pemetrexed'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Pharmacodynamic Separation of Pemetrexed and Erlotinib as Second-line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC),854
18,NCT01928160,Phase II,Withdrawn,"[{'id': 1290, 'therapyName': 'Erlotinib + Pemetrexed'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1291, 'therapyName': 'Erlotinib + Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1292, 'therapyName': 'Erlotinib + Cisplatin'}]",Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib,854
19,NCT03083808,Phase II,Recruiting,"[{'id': 5497, 'therapyName': 'Pembrolizumab + Gemcitabine'}, {'id': 5496, 'therapyName': 'Docetaxel + Pembrolizumab'}, {'id': 5498, 'therapyName': 'Pemetrexed + Pembrolizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Phase II Trial of Continuation Therapy in Advanced NSCLC,854
20,NCT01336842,Phase I,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors,854
21,NCT01107626,Phase III,"Active, not recruiting","[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,854
22,NCT02322281,Phase III,"Active, not recruiting","[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1003, 'therapyName': 'CO1686'}]","TIGER-3 Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy",854
23,NCT01664754,Phase I,"Active, not recruiting","[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 738, 'therapyName': 'Exemestane'}]","Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer",854
24,NCT01454102,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)",854
25,NCT02477826,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, Trial of Nivolumab and Nivolumab Plus Ipilimumab Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC)",854
26,NCT02409342,Phase III,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Comparative Study of MPDL3280A (Anti-PDL1 Antibody) With Cisplatin or Carboplatin + Pemetrexed in Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC),854
27,NCT02574078,Phase I,Recruiting,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2114, 'therapyName': 'Bevacizumab + Pemetrexed'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",A Master Protocol Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate 370),854
28,NCT02576574,Phase III,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100),854
29,NCT02657434,Phase III,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer,854
30,NCT02142738,Phase III,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024),854
31,NCT01344824,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}]","Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Who Are Light or Never Smokers",854
0,NCT01878617,Phase II,Recruiting,"[{'id': 956, 'therapyName': 'Vismodegib'}, {'id': 1800, 'therapyName': 'Cyclophosphamide + Cisplatin + Vincristine '}, {'id': 1801, 'therapyName': 'Pemetrexed + Gemcitabine'}]",A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma,1801
0,NCT01376310,Phase II,"Active, not recruiting","[{'id': 1264, 'therapyName': 'Docetaxel + Trametinib'}, {'id': 1265, 'therapyName': 'Erlotinib + Trametinib'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 1266, 'therapyName': 'Pemetrexed + GSK1120212'}, {'id': 1267, 'therapyName': 'Carboplatin + GSK1120212'}, {'id': 1268, 'therapyName': 'nab-paclitaxel + GSK1120212'}, {'id': 1269, 'therapyName': 'Gemcitabine + GSK1120212'}, {'id': 1271, 'therapyName': 'Everolimus + GSK1120212'}]",GSK1120212 Rollover Study,1266
0,NCT03064854,Phase I,Recruiting,"[{'id': 6027, 'therapyName': 'Carboplatin + Paclitaxel + PDR001'}, {'id': 6026, 'therapyName': 'Cisplatin + Pemetrexed + PDR001'}, {'id': 6025, 'therapyName': 'Cisplatin + Gemcitabine + PDR001'}, {'id': 6024, 'therapyName': 'Pemetrexed + PDR001 + Cisplatin + Carboplatin'}]","PDR001 in Combination With Platinum-doublet Chemotherapy in PD-L1 Unselected, Metastatic NSCLC Patients (ElevatION:NSCLC-101 Trial)",6024
0,NCT03083808,Phase II,Recruiting,"[{'id': 5497, 'therapyName': 'Pembrolizumab + Gemcitabine'}, {'id': 5496, 'therapyName': 'Docetaxel + Pembrolizumab'}, {'id': 5498, 'therapyName': 'Pemetrexed + Pembrolizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Phase II Trial of Continuation Therapy in Advanced NSCLC,5498
0,NCT02124148,Phase I,Recruiting,"[{'id': 1994, 'therapyName': 'Cisplatin + Prexasertib'}, {'id': 1993, 'therapyName': 'Cetuximab + Prexasertib'}, {'id': 6248, 'therapyName': 'Pemetrexed + Prexasertib'}, {'id': 6247, 'therapyName': 'LY3023414 + Prexasertib'}, {'id': 6246, 'therapyName': 'Fluoruracil + Leucovorin + Prexasertib'}]",A Study of LY2606368 With Cisplatin or Cetuximab in Participants With Advanced Cancer,6248
0,NCT01450384,Phase I,Completed,"[{'id': 1482, 'therapyName': 'Pemetrexed + Sorafenib'}]",Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors,1482
1,NCT02624700,Phase II,Recruiting,"[{'id': 1482, 'therapyName': 'Pemetrexed + Sorafenib'}]",Study of Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer,1482
0,NCT02936323,,Recruiting,"[{'id': 5819, 'therapyName': 'PEN-221'}]",PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers,5819
0,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,3161
1,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,3161
0,NCT02193347,Phase I,Recruiting,"[{'id': 1635, 'therapyName': 'PEPIDH1M vaccine'}]",RESIST: Patients With IDH1 Positive Recurrent Grade II Glioma Enrolled in a Safety and Immunogenicity Study of Tumor-Specific Peptide Vaccine,1635
0,NCT00776867,Phase I,Completed,"[{'id': 855, 'therapyName': 'Perifosine'}]",Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors,855
0,NCT02238496,Phase II,"Active, not recruiting","[{'id': 2194, 'therapyName': 'Perifosine + Temsirolimus'}]",Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas,2194
0,NCT01016886,Phase Ib/II,"Active, not recruiting","[{'id': 1897, 'therapyName': 'Bisoprolol'}, {'id': 1896, 'therapyName': 'Perindopril'}]",Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research,1896
0,NCT02651415,Phase II,"Active, not recruiting","[{'id': 3410, 'therapyName': 'Perindopril + Regorafenib'}]",Phase II Study of Perindopril and Regorafenib in mCRC,3410
0,NCT01774786,Phase III,"Active, not recruiting","[{'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 1894, 'therapyName': 'Capecitabine + Fluorouracil + Cisplatin + Trastuzumab'}]",A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction or Gastric Cancer,856
1,NCT01904903,Phase II,Recruiting,"[{'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Cardiac Safety Study in Patients With HER2+ Breast Cancer (SAFE-HEaRt),856
2,NCT02947685,Phase III,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 947, 'therapyName': 'Trastuzumab'}]","Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (PATINA)",856
3,NCT01358877,Phase III,"Active, not recruiting","[{'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer,856
4,NCT03304080,,Not yet recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 850, 'therapyName': 'Palbociclib'}]","Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in Her-positive, Her2-positive Metastatic Breast",856
5,NCT01912963,Phase II,"Active, not recruiting","[{'id': 728, 'therapyName': 'Eribulin'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 947, 'therapyName': 'Trastuzumab'}]","Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer",856
6,NCT02605915,Phase I,Recruiting,"[{'id': 3250, 'therapyName': 'Atezolizumab + Trastuzumab'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 856, 'therapyName': 'Pertuzumab'}]",Safety and Pharmacokinetics of Atezolizumab in Combination With Trastuzumab Emtansine or With Trastuzumab and Pertuzumab in Participants With HER2-Positive Breast Cancer,856
7,NCT01875666,Phase I,"Active, not recruiting","[{'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]","Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib",856
8,NCT02390427,Phase I,Recruiting,"[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 1016, 'therapyName': 'GDC-0032'}]",Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer,856
0,NCT03135171,Phase I,Recruiting,"[{'id': 5648, 'therapyName': 'Pertuzumab + Tocilizumab + Trastuzumab'}]",Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab,5648
0,NCT03238495,Phase II,Recruiting,"[{'id': 1879, 'therapyName': 'Pertuzumab + Trastuzumab + Carboplatin + Docetaxel'}, {'id': 6101, 'therapyName': 'Metformin + Pertuzumab + Trastuzumab + Carboplatin + Docetaxel'}]",Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer,1879
1,NCT02003209,Phase III,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1879, 'therapyName': 'Pertuzumab + Trastuzumab + Carboplatin + Docetaxel'}]","Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",1879
2,NCT02131064,Phase III,"Active, not recruiting","[{'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}, {'id': 1879, 'therapyName': 'Pertuzumab + Trastuzumab + Carboplatin + Docetaxel'}]",A Study Comparing Kadcyla Plus Perjeta Treatment to Chemotherapy Combined With Herceptin Plus Perjeta in Patients With HER2-Positive Breast Cancer,1879
0,NCT01966471,Phase III,"Active, not recruiting","[{'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}, {'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}]",A Study of Kadcyla (Trastuzumab Emtansine) Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer,1978
1,NCT02345772,Phase I,Terminated,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]","Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Taxotere, Trastuzumab and Pertuzumab) in Patients With HER2-positive and ER-Positive Breast Cancer",1978
2,NCT02379585,Phase Ib/II,Terminated,"[{'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]",Study of Short-term Fasting on Neoadjuvant Chemotherapy in Patients With Newly Diagnosed Breast Cancer,1978
3,NCT02402712,Phase III,"Active, not recruiting","[{'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]",Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer,1978
4,NCT01501487,FDA approved,"Active, not recruiting","[{'id': 1902, 'therapyName': 'Docetaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1485, 'therapyName': 'Trastuzumab + Docetaxel + Carboplatin'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]",MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I,1978
0,NCT01855828,Phase II,Recruiting,"[{'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}, {'id': 1550, 'therapyName': 'Pertuzumab + Trastuzumab + Fluorouracil + Epirubicin + Cyclophosphamide'}]",Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer,1550
0,NCT03199885,Phase III,Not yet recruiting,"[{'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}, {'id': 5956, 'therapyName': 'Paclitaxel + Pembrolizumab + Pertuzumab + Trastuzumab'}]","Paclitaxel, Trastuzumab, and Pertuzumab With or Without Pembrolizumab in Treating Patients With Metastatic Breast Cancer",1549
1,NCT01730833,Phase II,Recruiting,"[{'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}]","Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Metastatic Breast Cancer",1549
2,NCT01276041,Phase II,"Active, not recruiting","[{'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}]","Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer",1549
3,NCT01847001,Phase II,"Active, not recruiting","[{'id': 1912, 'therapyName': 'Propranolol'}, {'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}]",Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy,1549
4,NCT01966471,Phase III,"Active, not recruiting","[{'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}, {'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}]",A Study of Kadcyla (Trastuzumab Emtansine) Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer,1549
5,NCT01855828,Phase II,Recruiting,"[{'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}, {'id': 1550, 'therapyName': 'Pertuzumab + Trastuzumab + Fluorouracil + Epirubicin + Cyclophosphamide'}]",Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer,1549
0,NCT01565083,Phase II,Completed,"[{'id': 1666, 'therapyName': 'Pertuzumab + Trastuzumab + Vinorelbine'}]",A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer,1666
0,NCT02299635,Phase II,Terminated,"[{'id': 859, 'therapyName': 'PF-03084014'}]",A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations,859
1,NCT02109445,Phase II,Terminated,"[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 859, 'therapyName': 'PF-03084014'}]",Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies,859
2,NCT02137564,Phase II,Withdrawn,"[{'id': 859, 'therapyName': 'PF-03084014'}]",Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma,859
3,NCT02955446,Expanded access,No longer available,"[{'id': 859, 'therapyName': 'PF-03084014'}]",Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies,859
4,NCT01981551,Phase II,"Active, not recruiting","[{'id': 859, 'therapyName': 'PF-03084014'}]",Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis,859
0,NCT01876251,,Terminated,"[{'id': 1115, 'therapyName': 'PF-03084014 + Docetaxel'}]", A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer,1115
0,NCT02116894,Phase I,Completed,"[{'id': 2035, 'therapyName': 'PF-03446962 + Regorafenib'}]",Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer,2035
0,NCT01546038,Phase Ib/II,"Active, not recruiting","[{'id': 1748, 'therapyName': 'PF-04449913'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}]",A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,1748
1,NCT01841333,Phase II,Recruiting,"[{'id': 1748, 'therapyName': 'PF-04449913'}]",PF-04449913 For Patients With Acute Leukemia at High Risk of Relapse After Donor Stem Cell Transplant,1748
2,NCT01842646,Phase II,"Active, not recruiting","[{'id': 1748, 'therapyName': 'PF-04449913'}]",Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS),1748
0,NCT02315066,Phase I,Recruiting,"[{'id': 4333, 'therapyName': 'PF-04518600'}, {'id': 4448, 'therapyName': 'PF-04518600 + Utomilumab'}]",Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566,4333
0,NCT02315066,Phase I,Recruiting,"[{'id': 4333, 'therapyName': 'PF-04518600'}, {'id': 4448, 'therapyName': 'PF-04518600 + Utomilumab'}]",Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566,4448
0,NCT01347866,Phase I,Terminated,"[{'id': 1040, 'therapyName': 'PF-05212384'}, {'id': 849, 'therapyName': 'PD-0325901'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer,1040
1,NCT02626507,Phase I,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1040, 'therapyName': 'PF-05212384'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer,1040
2,NCT01937715,Phase II,Terminated,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1040, 'therapyName': 'PF-05212384'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer,1040
0,NCT01920061,Phase I,Recruiting,"[{'id': 1287, 'therapyName': 'PF-05212384 + Dacomitinib'}, {'id': 1286, 'therapyName': 'PF-05212384 + Cisplatin'}, {'id': 1285, 'therapyName': 'PF-05212384 + Docetaxel'}]",A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents,1286
0,NCT01920061,Phase I,Recruiting,"[{'id': 1287, 'therapyName': 'PF-05212384 + Dacomitinib'}, {'id': 1286, 'therapyName': 'PF-05212384 + Cisplatin'}, {'id': 1285, 'therapyName': 'PF-05212384 + Docetaxel'}]",A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents,1287
0,NCT01920061,Phase I,Recruiting,"[{'id': 1287, 'therapyName': 'PF-05212384 + Dacomitinib'}, {'id': 1286, 'therapyName': 'PF-05212384 + Cisplatin'}, {'id': 1285, 'therapyName': 'PF-05212384 + Docetaxel'}]",A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents,1285
0,NCT03052608,Phase III,Recruiting,"[{'id': 869, 'therapyName': 'PF-06463922'}, {'id': 706, 'therapyName': 'Crizotinib'}]",A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC,869
1,NCT03107988,Phase I,Recruiting,"[{'id': 5580, 'therapyName': 'PF-06463922 + Cyclophosphamide + Topotecan'}, {'id': 869, 'therapyName': 'PF-06463922'}]",Study of Lorlatinib (PF-06463922),869
2,NCT01970865,Phase Ib/II,Recruiting,"[{'id': 869, 'therapyName': 'PF-06463922'}, {'id': 706, 'therapyName': 'Crizotinib'}]",A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations,869
3,NCT02927340,Phase II,Recruiting,"[{'id': 869, 'therapyName': 'PF-06463922'}]",A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions,869
4,NCT02584634,Phase I,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 869, 'therapyName': 'PF-06463922'}]","Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)",869
0,NCT03107988,Phase I,Recruiting,"[{'id': 5580, 'therapyName': 'PF-06463922 + Cyclophosphamide + Topotecan'}, {'id': 869, 'therapyName': 'PF-06463922'}]",Study of Lorlatinib (PF-06463922),5580
0,NCT02222922,Phase I,Recruiting,"[{'id': 1689, 'therapyName': 'Fluconazole'}, {'id': 4421, 'therapyName': 'PF-06647020'}]",A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors,4421
0,NCT02078752,Phase I,Completed,"[{'id': 4324, 'therapyName': 'PF-06647263 '}]",A Study Of PF-06647263 In Patients With Advanced Solid Tumors,4324
0,NCT02954653,Phase I,Recruiting,"[{'id': 6087, 'therapyName': 'PF-06747143'}, {'id': 6092, 'therapyName': 'Cytarabine + Daunorubicin + PF-06747143'}, {'id': 6093, 'therapyName': 'Azacitidine + Decitabine + PF-06747143'}]","A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia",6087
0,NCT02349633,Phase I,Recruiting,"[{'id': 2527, 'therapyName': 'PF-06747775  '}]",Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M),2527
0,NCT02616185,Phase I,Recruiting,"[{'id': 3565, 'therapyName': 'PF-06755990 + PF-06755992 + Sunitinib + Tremelimumab'}]",A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR),3565
0,NCT01301391,Phase II,"Active, not recruiting","[{'id': 2654, 'therapyName': 'PHA-848125AC'}]",Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy,2654
1,NCT01011439,Phase II,"Active, not recruiting","[{'id': 2654, 'therapyName': 'PHA-848125AC'}]",Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma,2654
0,NCT01790204,Phase Ib/II,Completed,"[{'id': 1457, 'therapyName': 'phenethyl isothiocyanate'}]",A Study of the Effects of PEITC on Oral Cells With Mutant p53,1457
0,NCT02530125,Phase II,"Active, not recruiting","[{'id': 3338, 'therapyName': 'Pidilizumab'}]",Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission,3338
0,NCT01992874,Phase I,Completed,"[{'id': 871, 'therapyName': 'Pimasertib'}]",Relative Bioavailability of Pimasertib in Cancer Patients,871
1,NCT01693068,Phase II,Completed,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 871, 'therapyName': 'Pimasertib'}]",Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma,871
0,NCT02730195,Phase II,Recruiting,"[{'id': 3125, 'therapyName': 'Pioglitazone'}]",Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia,3125
1,NCT01655719,Phase II,Completed,"[{'id': 3125, 'therapyName': 'Pioglitazone'}]",Pioglitazone in Thyroid Cancers,3125
0,NCT02442414,Phase I,Unknown status,"[{'id': 2908, 'therapyName': 'Pirotinib'}]",A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors,2908
0,NCT01621477,Phase II,Terminated,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}]",T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant,1756
1,NCT02570542,Phase II,Recruiting,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 3359, 'therapyName': 'Carmustine + Cytarabine + Etoposide + Melphalan'}]",Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL),1756
2,NCT02200380,Phase II,Terminated,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 3007, 'therapyName': 'CDX-301'}]",A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs,1756
3,NCT01547806,Phase II,"Active, not recruiting","[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1756, 'therapyName': 'Plerixafor'}]",Collection of Transplant Stem Cells for Plasma Cell Myeloma,1756
4,NCT01526096,Phase I,Recruiting,"[{'id': 5985, 'therapyName': 'Basiliximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 1207, 'therapyName': 'Melphalan'}]",Stem Cell Transplantation for Patients With Multiple Myeloma,1756
5,NCT01977677,Phase Ib/II,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1756, 'therapyName': 'Plerixafor'}]",Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma,1756
6,NCT02098109,Phase II,Completed,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma,1756
7,NCT02343666,Phase I,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 2556, 'therapyName': 'O6-benzylguanine'}]",HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection,1756
8,NCT03277209,Phase I,Recruiting,"[{'id': 1756, 'therapyName': 'Plerixafor'}]","To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas",1756
0,NCT01352650,Phase I,"Active, not recruiting","[{'id': 1770, 'therapyName': 'Plerixafor + Decitabine'}]",Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML),1770
0,NCT03102606,Phase II,Recruiting,"[{'id': 3678, 'therapyName': 'Plinabulin'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]",Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective-1),3678
0,NCT01004861,Phase I,"Active, not recruiting","[{'id': 874, 'therapyName': 'PLX3397'}]",Safety Study of PLX108-01 in Patients With Solid Tumors,874
1,NCT01790503,Phase Ib/II,"Active, not recruiting","[{'id': 874, 'therapyName': 'PLX3397'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma,874
2,NCT02472275,Phase I,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 874, 'therapyName': 'PLX3397'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 1814, 'therapyName': 'Degarelix'}]","PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer",874
3,NCT02401815,Phase Ib/II,Recruiting,"[{'id': 874, 'therapyName': 'PLX3397'}, {'id': 2602, 'therapyName': 'PLX9486'}]",A Study of PLX9486 as a Single Agent and in Combination With PLX3397 in Patients With Advanced Solid Tumors Including GIST,874
4,NCT02390752,Phase Ib/II,Recruiting,"[{'id': 874, 'therapyName': 'PLX3397'}]",PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN),874
5,NCT01596751,Phase Ib/II,"Active, not recruiting","[{'id': 728, 'therapyName': 'Eribulin'}, {'id': 874, 'therapyName': 'PLX3397'}]",Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer,874
6,NCT02371369,Phase III,"Active, not recruiting","[{'id': 874, 'therapyName': 'PLX3397'}]",PLX3397 Phase 3 Study for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS),874
0,NCT01525602,Phase I,"Active, not recruiting","[{'id': 1395, 'therapyName': 'PLX3397 + Paclitaxel'}]",Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors,1395
0,NCT02584647,Phase Ib/II,Recruiting,"[{'id': 3155, 'therapyName': 'PLX3397 + Sirolimus'}]",Combination of PLX3397 and Sirolimus in Unresectable Sarcoma (Phase 1) and Malignant Peripheral Nerve Sheath Tumors (Phase 2),3155
0,NCT01826448,Phase I,Terminated,"[{'id': 1339, 'therapyName': 'PLX3397 + Vemurafenib'}]"," A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma",1339
0,NCT02673736,Phase I,"Active, not recruiting","[{'id': 4332, 'therapyName': 'PLX73086'}]",A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor,4332
0,NCT01804530,Phase I,"Active, not recruiting","[{'id': 2651, 'therapyName': 'PLX7486'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",Phase 1 Study of PLX7486 as Single Agent and With Gemcitabine Plus Nab-Paclitaxel in Patients With Advanced Solid Tumors,2651
0,NCT02428712,Phase Ib/II,Recruiting,"[{'id': 1041, 'therapyName': 'PLX8394'}]","A Study of PLX8394 as a Single Agent in Patients With Advanced, Unresectable Solid Tumors",1041
1,NCT02012231,Phase Ib/II,Terminated,"[{'id': 1041, 'therapyName': 'PLX8394'}]","Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.",1041
0,NCT02401815,Phase Ib/II,Recruiting,"[{'id': 874, 'therapyName': 'PLX3397'}, {'id': 2602, 'therapyName': 'PLX9486'}]",A Study of PLX9486 as a Single Agent and in Combination With PLX3397 in Patients With Advanced Solid Tumors Including GIST,2602
0,NCT01299636,Phase I,Completed,"[{'id': 1459, 'therapyName': 'PM060184'}]",Study of PM060184 in Patients With Advanced Solid Tumors,1459
0,NCT02226965,Phase II,"Active, not recruiting","[{'id': 2581, 'therapyName': 'PNT2258'}]",Wolverine: PNT2258 for Treatment of Patients With r/r DLBCL,2581
0,NCT02257567,Phase Ib/II,"Active, not recruiting","[{'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 4226, 'therapyName': 'Polatuzumab Vedotin'}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]",A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma,4226
1,NCT03274492,Phase III,Not yet recruiting,"[{'id': 4226, 'therapyName': 'Polatuzumab Vedotin'}, {'id': 6177, 'therapyName': 'R-CHP'}, {'id': 2195, 'therapyName': 'R-CHOP'}]","A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma",4226
2,NCT01992653,Phase I,"Active, not recruiting","[{'id': 4248, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 4226, 'therapyName': 'Polatuzumab Vedotin'}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]","A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma",4226
0,NCT01691898,Phase Ib/II,"Active, not recruiting","[{'id': 4415, 'therapyName': 'Obinutuzumab + Pinatuzumab Vedotin + Rituximab'}, {'id': 4416, 'therapyName': 'Polatuzumab Vedotin + Pinatuzumab Vedotin + Rituximab'}, {'id': 4417, 'therapyName': 'Obinutuzumab + Polatuzumab Vedotin'}]",A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (ROMULUS),4416
0,NCT02166905,Phase Ib/II,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 1324, 'therapyName': 'DEC-205-NY-ESO-1 fusion protein vaccine'}, {'id': 2575, 'therapyName': 'Epacadostat'}]","DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission",2595
1,NCT01188096,Phase II,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}]",A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas,2595
2,NCT02078648,Phase Ib/II,"Active, not recruiting","[{'id': 3010, 'therapyName': 'SL-701'}, {'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme",2595
3,NCT02332889,Phase Ib/II,Terminated,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 2595, 'therapyName': 'poly ICLC  '}]",Phase I/II Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs,2595
4,NCT02413827,Phase Ib/II,Terminated,"[{'id': 2526, 'therapyName': 'Nivolumab + Varlilumab'}, {'id': 1324, 'therapyName': 'DEC-205-NY-ESO-1 fusion protein vaccine'}, {'id': 2595, 'therapyName': 'poly ICLC  '}]",A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma,2595
5,NCT01130077,Phase I,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}]",A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas,2595
6,NCT02126579,Phase Ib/II,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 3009, 'therapyName': 'Long peptide vaccine 7'}]",Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists,2595
7,NCT02334735,Phase II,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 3012, 'therapyName': 'Melan-A/MART-1 peptide vaccine'}, {'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}]",A Comparison of Matured Dendritic Cells and Montanide&#174; in Study Subjects With High Risk of Melanoma Recurrence,2595
8,NCT02423863,Phase II,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}]","In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol",2595
9,NCT02754362,Phase II,Enrolling by invitation,"[{'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 667, 'therapyName': 'Bevacizumab'}]",A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma,2595
10,NCT02425306,Phase Ib/II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2620, 'therapyName': '6MHP vaccine'}, {'id': 2595, 'therapyName': 'poly ICLC  '}]",Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma,2595
11,NCT01532960,Phase I,Terminated,"[{'id': 2595, 'therapyName': 'poly ICLC  '}]",Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer (Breast 41),2595
12,NCT02510950,Phase I,Recruiting,"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma,2595
13,NCT02358187,Phase II,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}]",A Vaccine Trial for Low Grade Gliomas,2595
14,NCT02427581,Phase I,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}]",Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy,2595
0,NCT01734928,Phase III,"Active, not recruiting","[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}]","Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma",1622
1,NCT01998971,Phase I,Recruiting,"[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1475, 'therapyName': 'Thalidomide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 3323, 'therapyName': 'Montelukast'}]",A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma,1622
2,NCT02576977,Phase III,Suspended,"[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183),1622
3,NCT02616640,Phase I,"Active, not recruiting","[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma,1622
4,NCT02188368,Phase II,Recruiting,"[{'id': 1625, 'therapyName': 'Bortezomib + Carfilzomib + Clarithromycin'}, {'id': 1674, 'therapyName': 'Doxil + Pomalidomide'}, {'id': 1622, 'therapyName': 'Pomalidomide'}]",Pomalidomide for Lenalidomide for Failures,1622
5,NCT02400242,Phase I,"Active, not recruiting","[{'id': 3311, 'therapyName': 'Citarinostat'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1622, 'therapyName': 'Pomalidomide'}]",Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma,1622
6,NCT02343042,Phase Ib/II,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 2479, 'therapyName': 'Dexamethasone + Selinexor'}, {'id': 1622, 'therapyName': 'Pomalidomide'}]",Phase 1b/2 Study of Selinexor (KPT-330) in Combination w/ Backbone Treatments for Resistant/Refractory Multiple Myeloma,1622
0,NCT01889420,Phase I,Terminated,"[{'id': 2312, 'therapyName': 'Pomalidomide + Everolimus + Dexamethasone'}]","Phase I Trial of Everolimus, Pomalidomide and Dexamethasone Patients With Relapsed/Refractory Multiple Myeloma",2312
0,NCT03143985,Phase I,Recruiting,"[{'id': 5875, 'therapyName': 'Pomalidomide + TEW 7197'}]",TEW-7197 in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma,5875
0,NCT02467270,Phase II,Recruiting,"[{'id': 877, 'therapyName': 'Ponatinib'}]",Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia (CML) to Characterize the Efficacy and Safety of a Range of Doses,877
1,NCT02779283,Phase I,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,877
2,NCT01888562,Phase I,Withdrawn,"[{'id': 877, 'therapyName': 'Ponatinib'}]",Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma,877
3,NCT01620216,Phase II,Recruiting,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Validation of an in Vitro Assay to Predict Targeted Therapies for Acute Leukemia Patients,877
4,NCT01935336,Phase II,Recruiting,"[{'id': 877, 'therapyName': 'Ponatinib'}]",Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers,877
5,NCT01813734,Phase II,Recruiting,"[{'id': 877, 'therapyName': 'Ponatinib'}]",Ponatinib in Advanced NSCLC w/ RET Translocations,877
6,NCT01838642,Phase II,Terminated,"[{'id': 877, 'therapyName': 'Ponatinib'}]",Ponatinib for Advanced Medullary Thyroid Cancer,877
7,NCT02272998,Phase II,Recruiting,"[{'id': 877, 'therapyName': 'Ponatinib'}]",Ponatinib Hydrochloride in Treating Patients With Refractory Metastatic Cancers and Genetic Alterations,877
8,NCT01570868,Phase II,Terminated,"[{'id': 877, 'therapyName': 'Ponatinib'}]",Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP),877
9,NCT02265341,Phase II,"Active, not recruiting","[{'id': 877, 'therapyName': 'Ponatinib'}]",Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions,877
10,NCT03147612,Phase II,Not yet recruiting,"[{'id': 5682, 'therapyName': 'Mesna'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Study of the Combination of Low-Intensity Chemotherapy and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),877
11,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,877
12,NCT02478164,Phase II,"Active, not recruiting","[{'id': 877, 'therapyName': 'Ponatinib'}]",Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma,877
13,NCT01874665,Phase II,Completed,"[{'id': 877, 'therapyName': 'Ponatinib'}]",A Phase 2 Trial of Ponatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor,877
0,NCT01424982,Phase II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 2048, 'therapyName': 'Cytarabine + Methotrexate + Ponatinib'}, {'id': 2049, 'therapyName': 'Ponatinib + Vincristine'}, {'id': 2046, 'therapyName': 'Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine '}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),2049
0,NCT02659514,Phase II,Recruiting,"[{'id': 1042, 'therapyName': 'poziotinib'}]",Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer,1042
1,NCT03066206,Phase II,Recruiting,"[{'id': 1042, 'therapyName': 'poziotinib'}]",Poziotinib in EGFR Exon 20 Mutant Advanced Non-Small Cell Lung Cancer (NSCLC),1042
0,NCT02483858,Phase I,Recruiting,"[{'id': 2019, 'therapyName': 'PQR309'}]",Study of Oral PQR309 in Patients With Advanced Solid Tumors,2019
1,NCT02249429,Phase Ib/II,Recruiting,"[{'id': 2019, 'therapyName': 'PQR309'}]","Open-Label, Non Randomized Phase 2 Study With Safety Run-In",2019
2,NCT02669511,Phase II,Recruiting,"[{'id': 2019, 'therapyName': 'PQR309'}]",PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma,2019
0,NCT01993641,Phase II,Completed,"[{'id': 1758, 'therapyName': 'Pracinostat'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 650, 'therapyName': 'Decitabine'}]",Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA,1758
0,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,1327
0,NCT03007147,Phase III,Recruiting,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 5167, 'therapyName': 'Methylprednisolone'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 5168, 'therapyName': 'Prednisolone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,5168
0,NCT01614197,Phase I,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma,2188
1,NCT01523977,Phase I,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL,2188
2,NCT02626455,Phase III,Recruiting,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 3388, 'therapyName': 'Aldoxorubicin +Cyclophosphamide + Prednisone + Rituximab + Vincristine'}, {'id': 995, 'therapyName': 'Copanlisib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL),2188
3,NCT02538926,Phase II,Not yet recruiting,"[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 3212, 'therapyName': 'Doxorubicin + Etoposide + Vincristine '}, {'id': 2206, 'therapyName': 'Asparaginase'}]","Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",2188
4,NCT02522715,Phase Ib/II,Recruiting,"[{'id': 3056, 'therapyName': 'Cabazitaxel + Enzalutamide'}, {'id': 2188, 'therapyName': 'Prednisone'}]","Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Hormone-Resistant Prostate Cancer",2188
5,NCT00859781,Phase II,Recruiting,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 2858, 'therapyName': 'Ketoconazole'}]",177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer,2188
6,NCT01949337,Phase III,"Active, not recruiting","[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,2188
7,NCT02268175,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate,2188
8,NCT01576172,Phase II,"Active, not recruiting","[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 954, 'therapyName': 'Veliparib'}]",Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,2188
9,NCT01848067,Phase Ib/II,"Active, not recruiting","[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 626, 'therapyName': 'Alisertib'}]","Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer",2188
10,NCT01681433,Phase II,Terminated,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1807, 'therapyName': 'OGX-427'}]",OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone,2188
11,NCT01717053,Phase II,"Active, not recruiting","[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 759, 'therapyName': 'Goserelin'}]","Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer",2188
12,NCT01998971,Phase I,Recruiting,"[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1475, 'therapyName': 'Thalidomide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 3323, 'therapyName': 'Montelukast'}]",A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma,2188
13,NCT03020030,Phase III,Recruiting,"[{'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents,2188
14,NCT03023046,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}]","Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",2188
15,NCT02419755,Phase II,Terminated,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies,2188
16,NCT03150056,Phase I,Recruiting,"[{'id': 6034, 'therapyName': 'Abiraterone + GSK525762'}, {'id': 6035, 'therapyName': 'Enzalutamide + GSK525762'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer,2188
17,NCT03269669,Phase II,Recruiting,"[{'id': 6257, 'therapyName': 'Obinutuzumab + CHOP'}, {'id': 6302, 'therapyName': 'Lenalidomide + Obinutuzumab\t'}, {'id': 6301, 'therapyName': 'Obinutuzumab + TGR-1202'}, {'id': 2188, 'therapyName': 'Prednisone'}]","Obinutuzumab With or Without PI3K-delta Inhibitor TGR-1202, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma",2188
18,NCT00084695,Phase II,Unknown status,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases,2188
19,NCT02636322,Phase II,Recruiting,"[{'id': 2482, 'therapyName': 'Cyclophosphamide + Doxorubicin + Etoposide + Vincristine '}, {'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}, {'id': 2188, 'therapyName': 'Prednisone'}]","A Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Dose Adjusted Chemotherapy For Patients With High Risk Diffuse Large B-Cell Lymphoma",2188
20,NCT01972217,Phase II,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 837, 'therapyName': 'Olaparib'}]",Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer,2188
21,NCT02883049,Phase III,Suspended,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations,2188
22,NCT02403505,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1814, 'therapyName': 'Degarelix'}]",Discovery Stage Clinical Study About Oncology Drugs and Single Nucleotide Polymorphisms,2188
23,NCT02723994,Phase II,Recruiting,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 2346, 'therapyName': 'Mercaptopurine + Thioguanine'}, {'id': 2394, 'therapyName': 'Asparaginase + Cytarabine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}]",A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia,2188
24,NCT02496585,Phase II,Recruiting,"[{'id': 831, 'therapyName': 'Nintedanib'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis,2188
25,NCT02043678,Phase III,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}]","Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms",2188
26,NCT01786265,Phase II,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1814, 'therapyName': 'Degarelix'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone,2188
27,NCT02535806,Phase II,Terminated,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults,2188
28,NCT01503229,Phase II,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,2188
29,NCT02034552,Phase II,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC),2188
30,NCT02379390,Phase II,Terminated,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}]",Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enz (PRIMCAB),2188
31,NCT03117751,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,2188
32,NCT01553188,Phase II,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1218, 'therapyName': 'Trebananib'}]",AMG 386 and Abiraterone for Advanced Prostate Cancer,2188
33,NCT03093272,Phase II,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 5521, 'therapyName': 'ARN-509 + Docetaxel'}]",A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer,2188
34,NCT02490878,Phase II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases,2188
35,NCT02356159,Phase Ib/II,Recruiting,"[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 2292, 'therapyName': 'Doxorubicin + Etoposide + Fludarabine + Vincristine '}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation,2188
36,NCT01961843,Phase I,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",Abiraterone Acetate for Castrate Resistant Prostate Cancer,2188
37,NCT00536991,Phase Ib/II,Terminated,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 2889, 'therapyName': 'calcitriol'}, {'id': 2858, 'therapyName': 'Ketoconazole'}]","Calcitriol, Ketoconazole, and Hydrocortisone in Treating Patients With Advanced or Recurrent Prostate Cancer",2188
38,NCT02337985,Phase I,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 2482, 'therapyName': 'Cyclophosphamide + Doxorubicin + Etoposide + Vincristine '}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma,2188
0,NCT03099161,Phase I,Recruiting,"[{'id': 5518, 'therapyName': 'Preladenant'}, {'id': 5519, 'therapyName': 'Pembrolizumab + Preladenant'}]",Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062),5518
0,NCT02735980,Phase II,Recruiting,"[{'id': 1651, 'therapyName': 'Prexasertib'}]",A Study of LY2606368 in Participants With Extensive Stage Disease Small Cell Lung Cancer,1651
1,NCT02873975,Phase II,Recruiting,"[{'id': 1651, 'therapyName': 'Prexasertib'}]",A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency,1651
2,NCT02203513,Phase II,Recruiting,"[{'id': 1651, 'therapyName': 'Prexasertib'}]","Chk1/2 Inhibitor (LY2606368) in Women With BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Non-High Risk Triple Negative Breast Cancer, and Grade Serous Ovarian Cancer at Low Genetic Risk",1651
3,NCT02555644,Phase I,Recruiting,"[{'id': 1651, 'therapyName': 'Prexasertib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Study of LY2606368 With Chemotherapy and Radiation in Participants With Head and Neck Cancer,1651
4,NCT02808650,Phase I,Recruiting,"[{'id': 1651, 'therapyName': 'Prexasertib'}]",Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors,1651
0,NCT02860780,Phase I,Completed,"[{'id': 4587, 'therapyName': 'Prexasertib + Ralimetinib'}]",A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer,4587
0,NCT02413853,Phase II,Withdrawn,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1083, 'therapyName': 'Pri-724'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer,1083
1,NCT01606579,Phase Ib/II,Completed,"[{'id': 2466, 'therapyName': 'Cytarabine + Pri-724'}, {'id': 2465, 'therapyName': 'Dasatinib + Pri-724'}, {'id': 1083, 'therapyName': 'Pri-724'}]",Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies,1083
2,NCT01302405,Phase I,Terminated,"[{'id': 1083, 'therapyName': 'Pri-724'}]",Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors,1083
0,NCT02608125,Phase I,Recruiting,"[{'id': 3583, 'therapyName': 'PRN1371'}]",A Dose Escalation and Dose Expansion Study of PRN1371 in Adult Patients With Advanced Solid Tumors,3583
0,NCT01847001,Phase II,"Active, not recruiting","[{'id': 1912, 'therapyName': 'Propranolol'}, {'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}]",Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy,1912
1,NCT01504126,Phase I,"Active, not recruiting","[{'id': 1912, 'therapyName': 'Propranolol'}]",Beta-Blocker / Ovarian,1912
0,NCT01867333,Phase II,"Active, not recruiting","[{'id': 3069, 'therapyName': 'PROSTVAC-F/TRICOM '}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer,3069
0,NCT02506114,Phase II,Recruiting,"[{'id': 4892, 'therapyName': 'PROSTVAC-V/F'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 4895, 'therapyName': 'PROSTVAC-V/F + Ipilimumab'}]",Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer,4892
0,NCT02933255,Phase Ib/II,Recruiting,"[{'id': 4895, 'therapyName': 'PROSTVAC-V/F + Ipilimumab'}, {'id': 4893, 'therapyName': 'PROSTVAC-V/F + Nivolumab + Ipilimumab'}, {'id': 4894, 'therapyName': 'PROSTVAC-V/F + Nivolumab'}]",PROSTVAC in Combination With Nivolumab and/or Ipilimumab in Men With Prostate Cancer,4895
1,NCT02506114,Phase II,Recruiting,"[{'id': 4892, 'therapyName': 'PROSTVAC-V/F'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 4895, 'therapyName': 'PROSTVAC-V/F + Ipilimumab'}]",Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer,4895
0,NCT02933255,Phase Ib/II,Recruiting,"[{'id': 4895, 'therapyName': 'PROSTVAC-V/F + Ipilimumab'}, {'id': 4893, 'therapyName': 'PROSTVAC-V/F + Nivolumab + Ipilimumab'}, {'id': 4894, 'therapyName': 'PROSTVAC-V/F + Nivolumab'}]",PROSTVAC in Combination With Nivolumab and/or Ipilimumab in Men With Prostate Cancer,4894
0,NCT02933255,Phase Ib/II,Recruiting,"[{'id': 4895, 'therapyName': 'PROSTVAC-V/F + Ipilimumab'}, {'id': 4893, 'therapyName': 'PROSTVAC-V/F + Nivolumab + Ipilimumab'}, {'id': 4894, 'therapyName': 'PROSTVAC-V/F + Nivolumab'}]",PROSTVAC in Combination With Nivolumab and/or Ipilimumab in Men With Prostate Cancer,4893
0,NCT02974738,Phase I,Recruiting,"[{'id': 5820, 'therapyName': 'PT 2977'}]",A Trial of PT2977 Tablets In Patients With Advanced Solid Tumors,5820
0,NCT02266745,Phase I,Recruiting,"[{'id': 2920, 'therapyName': 'PT-112'}]",A Phase 1 Study of PT-112 Injection in Subjects With Advanced Solid Tumors,2920
0,NCT03108066,Phase II,"Active, not recruiting","[{'id': 4146, 'therapyName': 'PT2385'}]",PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma,4146
1,NCT02293980,Phase I,"Active, not recruiting","[{'id': 4146, 'therapyName': 'PT2385'}, {'id': 4347, 'therapyName': 'PT2385 + Nivolumab'}]","A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma",4146
2,NCT03216499,Phase II,Recruiting,"[{'id': 4146, 'therapyName': 'PT2385'}]",HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma,4146
0,NCT02293980,Phase I,"Active, not recruiting","[{'id': 4146, 'therapyName': 'PT2385'}, {'id': 4347, 'therapyName': 'PT2385 + Nivolumab'}]","A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma",4347
0,NCT02404480,Phase I,Unknown status,"[{'id': 5407, 'therapyName': 'PTC596'}]",PTC596 in Patients With Advanced Solid Tumors,5407
0,NCT02411786,Phase I,Recruiting,"[{'id': 4297, 'therapyName': 'pTVG-AR '}, {'id': 1873, 'therapyName': 'Sargramostim'}]",A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF,4297
0,NCT01706458,Phase II,"Active, not recruiting","[{'id': 2698, 'therapyName': 'pTVG-HP plasmid DNA vaccine'}, {'id': 2648, 'therapyName': 'Sipuleucel-T'}]",Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer,2698
0,NCT01393509,Phase I,"Active, not recruiting","[{'id': 1162, 'therapyName': 'PU-H71'}]",The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies,1162
1,NCT01581541,Phase I,Terminated,"[{'id': 1162, 'therapyName': 'PU-H71'}]", PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin s Lymphoma That Have Not Responded to Standard Treatment,1162
0,NCT03166085,Phase I,Recruiting,"[{'id': 5796, 'therapyName': 'PU-H71 + nab-paclitaxel'}]",PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer,5796
0,NCT02557321,Phase Ib/II,Recruiting,"[{'id': 879, 'therapyName': 'PV-10'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma,879
1,NCT00986661,Phase I,Recruiting,"[{'id': 879, 'therapyName': 'PV-10'}]",A Study to Assess PV-10 Chemoablation of Cancer of the Liver,879
0,NCT02886065,Phase I,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 5082, 'therapyName': 'PVX-410 + MEDI4736'}, {'id': 5081, 'therapyName': 'PVX-410 + MEDI4736 + lenalidomide'}]","A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Durvalumab (Anti-PDL1) With and Without Lenalidomide for Patients With Smoldering Multiple Myeloma",5082
0,NCT02886065,Phase I,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 5082, 'therapyName': 'PVX-410 + MEDI4736'}, {'id': 5081, 'therapyName': 'PVX-410 + MEDI4736 + lenalidomide'}]","A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Durvalumab (Anti-PDL1) With and Without Lenalidomide for Patients With Smoldering Multiple Myeloma",5081
0,NCT02961816,Phase II,Withdrawn,"[{'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 4976, 'therapyName': 'Busulfan + Gemcitabine + Melphalan + Panobinostat'}, {'id': 4977, 'therapyName': 'Dexamethasone + Filgrastim + Palifermin + Rituximab'}]",Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma,3277
1,NCT02506959,Phase II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma,3277
2,NCT02701673,Phase Ib/II,Withdrawn,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1078, 'therapyName': 'Belinostat'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}]",Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma,3277
3,NCT02589145,Phase Ib/II,Recruiting,"[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 3278, 'therapyName': 'Enoxaparin'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}]",Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype,3277
4,NCT03259503,Phase Ib/II,Not yet recruiting,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas,3277
0,NCT02500199,Phase I,Recruiting,"[{'id': 3082, 'therapyName': 'Pyrotinib'}]",Open Label Oral Use of Pyrotinib in Patients With HER2 Positive Solid Tumors Who Failed Prior HER2 Targeted Therapy,3082
0,NCT02039726,Phase III,"Active, not recruiting","[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 3193, 'therapyName': 'Cytarabine + Fludarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 882, 'therapyName': 'Quizartinib'}]",An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects,882
1,NCT01892371,Phase Ib/II,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 882, 'therapyName': 'Quizartinib'}]",AC220 With 5-Aza or Low Dose Cytarabine,882
2,NCT02668653,Phase III,Recruiting,"[{'id': 3543, 'therapyName': 'Cytarabine + Daunorubicin + Idarubicin'}, {'id': 882, 'therapyName': 'Quizartinib'}]",Quizartinib With Standard of Care Chemotherapy and as Maintenance Therapy in Patients With Newly Diagnosed FLT3-ITD (+) AML,882
0,NCT02605694,Phase II,Withdrawn,"[{'id': 3389, 'therapyName': 'Duvelisib + Rituximab'}, {'id': 2195, 'therapyName': 'R-CHOP'}]",Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO),2195
1,NCT01334502,Phase I,Completed,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 2195, 'therapyName': 'R-CHOP'}]","Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma",2195
2,NCT03263026,Phase III,Not yet recruiting,"[{'id': 2195, 'therapyName': 'R-CHOP'}, {'id': 1682, 'therapyName': 'Enzastaurin'}]",Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1,2195
3,NCT03274492,Phase III,Not yet recruiting,"[{'id': 4226, 'therapyName': 'Polatuzumab Vedotin'}, {'id': 6177, 'therapyName': 'R-CHP'}, {'id': 2195, 'therapyName': 'R-CHOP'}]","A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma",2195
0,NCT03274492,Phase III,Not yet recruiting,"[{'id': 4226, 'therapyName': 'Polatuzumab Vedotin'}, {'id': 6177, 'therapyName': 'R-CHP'}, {'id': 2195, 'therapyName': 'R-CHOP'}]","A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma",6177
0,NCT01193842,Phase Ib/II,"Active, not recruiting","[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 3395, 'therapyName': 'R-EPOCH'}]",Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,3395
1,NCT02700022,Phase I,"Active, not recruiting","[{'id': 626, 'therapyName': 'Alisertib'}, {'id': 3395, 'therapyName': 'R-EPOCH'}]",A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas,3395
2,NCT00114738,Phase II,"Active, not recruiting","[{'id': 3395, 'therapyName': 'R-EPOCH'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 688, 'therapyName': 'Bortezomib'}]",EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma,3395
0,NCT01574729,Phase II,Unknown status,"[{'id': 1680, 'therapyName': 'rAD-p53'}]",Surgery Combined With rAd-p53 Gene in Treatment Advanced Non-small-cell Carcinoma,1680
0,NCT02366130,Phase II,Recruiting,"[{'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}, {'id': 1198, 'therapyName': 'Denosumab'}]",Phase II Trial of Ra-223 Dichloride and Hormonal Treatment,2001
1,NCT02406521,Phase I,"Active, not recruiting","[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Exploratory Study of Radium-223 and Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases,2001
2,NCT02463799,Phase II,Recruiting,"[{'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}, {'id': 2648, 'therapyName': 'Sipuleucel-T'}]",Ph 2 Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC,2001
3,NCT03093428,Phase II,Recruiting,"[{'id': 5542, 'therapyName': 'Pembrolizumab + Ra 223'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}]",Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC,2001
4,NCT02396368,Phase I,Withdrawn,"[{'id': 2699, 'therapyName': 'Tasquinimod'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}]",A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer,2001
5,NCT02605356,Phase Ib/II,Withdrawn,"[{'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma,2001
6,NCT02034552,Phase II,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC),2001
7,NCT02258464,Phase II,Recruiting,"[{'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}]",Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer,2001
8,NCT02258451,Phase II,Recruiting,"[{'id': 1966, 'therapyName': 'Exemestane + Everolimus'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}]",Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane / Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer,2001
9,NCT02043678,Phase III,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}]","Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms",2001
10,NCT02507570,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}]",Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis,2001
0,NCT01663857,Phase Ib/II,"Active, not recruiting","[{'id': 3296, 'therapyName': 'Ralimetinib'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",A Study of LY2228820 for Recurrent Ovarian Cancer,3296
0,NCT03147196,Phase II,Recruiting,"[{'id': 5686, 'therapyName': 'Raloxifene + Bicalutamide'}, {'id': 5685, 'therapyName': 'Raloxifene'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery,5685
0,NCT03147196,Phase II,Recruiting,"[{'id': 5686, 'therapyName': 'Raloxifene + Bicalutamide'}, {'id': 5685, 'therapyName': 'Raloxifene'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery,5686
0,NCT02426125,Phase III,"Active, not recruiting","[{'id': 886, 'therapyName': 'Ramucirumab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer,886
1,NCT02514551,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer,886
2,NCT02597036,Phase I,"Active, not recruiting","[{'id': 3562, 'therapyName': 'LY3127804 '}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors,886
3,NCT02314117,Phase III,"Active, not recruiting","[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer,886
4,NCT02079636,Phase I,Recruiting,"[{'id': 1069, 'therapyName': 'LY3023414'}, {'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC),886
5,NCT02411448,Phase III,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Participants With EGFR Mutation-Positive Metastatic NSCLC,886
6,NCT02564198,Phase I,Recruiting,"[{'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors,886
7,NCT02711553,Phase II,"Active, not recruiting","[{'id': 886, 'therapyName': 'Ramucirumab'}, {'id': 1030, 'therapyName': 'LY2801653'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer,886
8,NCT02443883,Phase II,"Active, not recruiting","[{'id': 886, 'therapyName': 'Ramucirumab'}]",A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer,886
9,NCT02435433,Phase III,Recruiting,"[{'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (REACH-2),886
10,NCT02581215,Phase II,Recruiting,"[{'id': 886, 'therapyName': 'Ramucirumab'}, {'id': 1903, 'therapyName': 'FOLFIRINOX'}]",Phase II Randomized Trial of FOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer,886
11,NCT02065765,Phase II,No longer available,"[{'id': 886, 'therapyName': 'Ramucirumab'}]",International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer,886
12,NCT02520141,Phase II,Recruiting,"[{'id': 886, 'therapyName': 'Ramucirumab'}]",Ramucirumab for Advanced Pre-treated Biliary Cancers,886
0,NCT02831491,Phase II,Withdrawn,"[{'id': 1423, 'therapyName': 'Ramucirumab + Docetaxel'}]",A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer,1423
0,NCT03281369,Phase Ib/II,Not yet recruiting,"[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 6274, 'therapyName': 'mFOLFOX-6 + Atezolizumab + Cobimetinib'}, {'id': 6275, 'therapyName': 'mFOLFOX-6 + Atezolizumab'}, {'id': 6276, 'therapyName': 'Atezolizumab + Linagliptin'}, {'id': 5941, 'therapyName': 'Atezolizumab + PEGPH20'}, {'id': 5942, 'therapyName': 'Atezolizumab + BKT140'}, {'id': 1721, 'therapyName': 'Ramucirumab + Paclitaxel'}, {'id': 5850, 'therapyName': 'mFOLFOX-6'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (UMBRELLA),1721
0,NCT02726399,Phase II,Recruiting,"[{'id': 3999, 'therapyName': 'Capecitabine + Cisplatin'}, {'id': 3998, 'therapyName': 'Ramucirumab + Trastuzumab'}]",Ramucirumab With Trastuzumab and Capecitabine/Cisplatin in Patients With Metastatic HER2-Positive Gastroesophageal Junction and Gastric Cancer,3998
0,NCT00513474,Phase I,Completed,"[{'id': 2313, 'therapyName': 'Rasburicase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2314, 'therapyName': 'Busulfan + Cyclophosphamide + Etoposide'}]",Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant,2313
0,NCT02168777,Phase Ib/II,Terminated,"[{'id': 1424, 'therapyName': 'Regorafenib + Refametinib'}, {'id': 888, 'therapyName': 'Refametinib'}]","Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer",888
0,NCT01915602,Phase II,Completed,"[{'id': 2221, 'therapyName': 'Refametinib + Sorafenib'}]",Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC),2221
0,NCT01727869,Phase I,Completed,"[{'id': 1246, 'therapyName': 'REGN1400 + Erlotinib'}, {'id': 1247, 'therapyName': 'REGN1400 + Cetuximab'}, {'id': 1072, 'therapyName': 'REGN1400'}]", Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer,1072
0,NCT01727869,Phase I,Completed,"[{'id': 1246, 'therapyName': 'REGN1400 + Erlotinib'}, {'id': 1247, 'therapyName': 'REGN1400 + Cetuximab'}, {'id': 1072, 'therapyName': 'REGN1400'}]", Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer,1247
0,NCT01727869,Phase I,Completed,"[{'id': 1246, 'therapyName': 'REGN1400 + Erlotinib'}, {'id': 1247, 'therapyName': 'REGN1400 + Cetuximab'}, {'id': 1072, 'therapyName': 'REGN1400'}]", Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer,1246
0,NCT02651662,Phase I,Recruiting,"[{'id': 5656, 'therapyName': 'REGN2810'}, {'id': 6152, 'therapyName': 'REGN1979 + REGN2810'}]",Study of REGN2810 and REGN1979 in Patients With Lymphoma,6152
0,NCT03132636,Phase II,Recruiting,"[{'id': 5656, 'therapyName': 'REGN2810'}]","PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy",5656
1,NCT02651662,Phase I,Recruiting,"[{'id': 5656, 'therapyName': 'REGN2810'}, {'id': 6152, 'therapyName': 'REGN1979 + REGN2810'}]",Study of REGN2810 and REGN1979 in Patients With Lymphoma,5656
2,NCT03257267,Phase III,Recruiting,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 5656, 'therapyName': 'REGN2810'}, {'id': 942, 'therapyName': 'Topotecan'}]",Study of REGN2810 in Adults With Cervical Cancer,5656
3,NCT02383212,Phase I,"Active, not recruiting","[{'id': 5722, 'therapyName': 'REGN2810 + Carboplatin + Docetaxel'}, {'id': 5721, 'therapyName': 'REGN2810 + Carboplatin + Pemetrexed'}, {'id': 5723, 'therapyName': 'REGN2810 + GM-CSF + Cyclophosphamide'}, {'id': 5718, 'therapyName': 'REGN2810 + Cyclophosphamide'}, {'id': 5656, 'therapyName': 'REGN2810'}, {'id': 5720, 'therapyName': 'REGN2810 + Carboplatin + Paclitaxel'}, {'id': 5719, 'therapyName': 'REGN2810 + Docetaxel'}]",Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies,5656
4,NCT02760498,Phase II,Recruiting,"[{'id': 5656, 'therapyName': 'REGN2810'}]",Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma,5656
5,NCT03194867,,Recruiting,"[{'id': 5656, 'therapyName': 'REGN2810'}]",Isatuximab in Combination With REGN2810 in Relapsed/Refractory Multiple Myeloma (RRMM) Patients,5656
0,NCT02383212,Phase I,"Active, not recruiting","[{'id': 5722, 'therapyName': 'REGN2810 + Carboplatin + Docetaxel'}, {'id': 5721, 'therapyName': 'REGN2810 + Carboplatin + Pemetrexed'}, {'id': 5723, 'therapyName': 'REGN2810 + GM-CSF + Cyclophosphamide'}, {'id': 5718, 'therapyName': 'REGN2810 + Cyclophosphamide'}, {'id': 5656, 'therapyName': 'REGN2810'}, {'id': 5720, 'therapyName': 'REGN2810 + Carboplatin + Paclitaxel'}, {'id': 5719, 'therapyName': 'REGN2810 + Docetaxel'}]",Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies,5722
0,NCT02383212,Phase I,"Active, not recruiting","[{'id': 5722, 'therapyName': 'REGN2810 + Carboplatin + Docetaxel'}, {'id': 5721, 'therapyName': 'REGN2810 + Carboplatin + Pemetrexed'}, {'id': 5723, 'therapyName': 'REGN2810 + GM-CSF + Cyclophosphamide'}, {'id': 5718, 'therapyName': 'REGN2810 + Cyclophosphamide'}, {'id': 5656, 'therapyName': 'REGN2810'}, {'id': 5720, 'therapyName': 'REGN2810 + Carboplatin + Paclitaxel'}, {'id': 5719, 'therapyName': 'REGN2810 + Docetaxel'}]",Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies,5720
0,NCT02383212,Phase I,"Active, not recruiting","[{'id': 5722, 'therapyName': 'REGN2810 + Carboplatin + Docetaxel'}, {'id': 5721, 'therapyName': 'REGN2810 + Carboplatin + Pemetrexed'}, {'id': 5723, 'therapyName': 'REGN2810 + GM-CSF + Cyclophosphamide'}, {'id': 5718, 'therapyName': 'REGN2810 + Cyclophosphamide'}, {'id': 5656, 'therapyName': 'REGN2810'}, {'id': 5720, 'therapyName': 'REGN2810 + Carboplatin + Paclitaxel'}, {'id': 5719, 'therapyName': 'REGN2810 + Docetaxel'}]",Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies,5721
0,NCT02383212,Phase I,"Active, not recruiting","[{'id': 5722, 'therapyName': 'REGN2810 + Carboplatin + Docetaxel'}, {'id': 5721, 'therapyName': 'REGN2810 + Carboplatin + Pemetrexed'}, {'id': 5723, 'therapyName': 'REGN2810 + GM-CSF + Cyclophosphamide'}, {'id': 5718, 'therapyName': 'REGN2810 + Cyclophosphamide'}, {'id': 5656, 'therapyName': 'REGN2810'}, {'id': 5720, 'therapyName': 'REGN2810 + Carboplatin + Paclitaxel'}, {'id': 5719, 'therapyName': 'REGN2810 + Docetaxel'}]",Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies,5718
0,NCT02383212,Phase I,"Active, not recruiting","[{'id': 5722, 'therapyName': 'REGN2810 + Carboplatin + Docetaxel'}, {'id': 5721, 'therapyName': 'REGN2810 + Carboplatin + Pemetrexed'}, {'id': 5723, 'therapyName': 'REGN2810 + GM-CSF + Cyclophosphamide'}, {'id': 5718, 'therapyName': 'REGN2810 + Cyclophosphamide'}, {'id': 5656, 'therapyName': 'REGN2810'}, {'id': 5720, 'therapyName': 'REGN2810 + Carboplatin + Paclitaxel'}, {'id': 5719, 'therapyName': 'REGN2810 + Docetaxel'}]",Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies,5719
0,NCT02383212,Phase I,"Active, not recruiting","[{'id': 5722, 'therapyName': 'REGN2810 + Carboplatin + Docetaxel'}, {'id': 5721, 'therapyName': 'REGN2810 + Carboplatin + Pemetrexed'}, {'id': 5723, 'therapyName': 'REGN2810 + GM-CSF + Cyclophosphamide'}, {'id': 5718, 'therapyName': 'REGN2810 + Cyclophosphamide'}, {'id': 5656, 'therapyName': 'REGN2810'}, {'id': 5720, 'therapyName': 'REGN2810 + Carboplatin + Paclitaxel'}, {'id': 5719, 'therapyName': 'REGN2810 + Docetaxel'}]",Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies,5723
0,NCT03005782,Phase I,Recruiting,"[{'id': 5736, 'therapyName': 'REGN3767 + REGN2810'}, {'id': 5735, 'therapyName': 'REGN3767'}]",Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers,5735
0,NCT03005782,Phase I,Recruiting,"[{'id': 5736, 'therapyName': 'REGN3767 + REGN2810'}, {'id': 5735, 'therapyName': 'REGN3767'}]",Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers,5736
0,NCT02119676,Phase II,Terminated,"[{'id': 890, 'therapyName': 'Regorafenib'}, {'id': 907, 'therapyName': 'Ruxolitinib'}]",Study of Ruxolitinib in Colorectal Cancer Patients,890
1,NCT02278783,Phase II,Terminated,"[{'id': 890, 'therapyName': 'Regorafenib'}]","Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer",890
2,NCT02080260,Phase II,"Active, not recruiting","[{'id': 890, 'therapyName': 'Regorafenib'}]",A Study of Regorafenib in Advanced Pancreatic Cancer Patients,890
3,NCT02402036,Phase II,"Active, not recruiting","[{'id': 890, 'therapyName': 'Regorafenib'}]",A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer,890
4,NCT02023333,Phase II,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma,890
5,NCT01896856,Phase Ib/II,Recruiting,"[{'id': 2015, 'therapyName': 'SGI-110 + Irinotecan'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Phase I Study of SGI-110 With Irinotecan Followed by Randomized Phase II Study of SGI-110 With Irinotecan Versus Regorafenib in Previously Treated Metastatic Colorectal Cancer,890
6,NCT02241720,Phase II,Terminated,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers,890
7,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,890
8,NCT02664077,Phase III,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer (ARGO),890
9,NCT02048722,Phase II,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]","Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma",890
10,NCT02459119,Phase II,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477),890
11,NCT02657551,Phase II,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer,890
12,NCT02195011,Phase II,"Active, not recruiting","[{'id': 890, 'therapyName': 'Regorafenib'}]",Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases,890
13,NCT02425683,Phase II,"Active, not recruiting","[{'id': 890, 'therapyName': 'Regorafenib'}]",Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX,890
14,NCT02788279,Phase III,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}]",A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma,890
15,NCT02439723,Phase I,Not yet recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Effects of LBM and PPIs on Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer Patients,890
16,NCT02098538,Phase II,"Active, not recruiting","[{'id': 890, 'therapyName': 'Regorafenib'}]","Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma",890
17,NCT01538680,Phase III,No longer available,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy,890
18,NCT01774344,Phase III,"Active, not recruiting","[{'id': 890, 'therapyName': 'Regorafenib'}]",Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma (RESORCE),890
19,NCT02466802,Phase I,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}, {'id': 3066, 'therapyName': 'Sildenafil'}]",Study of Regorafenib and Sildenafil for Advanced Solid Tumors,890
20,NCT01939223,Phase III,Completed,"[{'id': 890, 'therapyName': 'Regorafenib'}]","COlorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo?Controlled Phase-III STudy (COAST)",890
21,NCT02048371,Phase II,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]","A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas",890
22,NCT02581059,Phase II,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Efficacy of Ginseng for Patients on Regorafenib,890
23,NCT02693535,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 690, 'therapyName': 'Bosutinib'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer,890
24,NCT02259725,Phase II,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors,890
25,NCT03042689,Phase I,Not yet recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Study of Regorafenib in Patients With Advanced Myeloid Malignancies,890
26,NCT02234180,Phase II,Completed,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Study of Adjuvant Regorafenib vs Placebo in Patients With Node Positive Esophageal Cancer That Completed Pre-operative Therapy,890
27,NCT02287025,FDA approved,Terminated,"[{'id': 890, 'therapyName': 'Regorafenib'}]",A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Out Comes?,890
28,NCT02287727,Phase II,Withdrawn,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment,890
29,NCT02096354,Phase II,"Active, not recruiting","[{'id': 890, 'therapyName': 'Regorafenib'}]","A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer",890
30,NCT01949194,Phase II,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers,890
31,NCT02053376,Phase II,"Active, not recruiting","[{'id': 890, 'therapyName': 'Regorafenib'}]",A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy,890
32,NCT01853046,Phase I,Completed,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment,890
33,NCT02115542,Phase II,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Single Agent Regorafenib in Refractory Advanced Biliary Cancers,890
34,NCT02164240,Phase I,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST,890
35,NCT02795156,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations,890
36,NCT02466009,Phase II,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Regorafenib in Metastatic Colorectal Cancer,890
37,NCT02316340,Phase II,Recruiting,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1316, 'therapyName': 'Hydroxychloroquine'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer,890
38,NCT01298570,Phase II,"Active, not recruiting","[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer,890
0,NCT02095054,Phase I,"Active, not recruiting","[{'id': 1305, 'therapyName': 'Regorafenib + Cetuximab'}]",Regorafenib and Cetuximab in Patients With Advanced Malignancy,1305
1,NCT01973868,Phase I,"Active, not recruiting","[{'id': 1305, 'therapyName': 'Regorafenib + Cetuximab'}]",Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination,1305
0,NCT01913639,Phase II,"Active, not recruiting","[{'id': 2014, 'therapyName': 'Regorafenib + FOLFOX'}]",FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer,2014
0,NCT02199223,Phase I,Terminated,"[{'id': 1617, 'therapyName': 'Regorafenib + Panitumumab'}]",Regorafenib + Panitumumab,1617
0,NCT02168777,Phase Ib/II,Terminated,"[{'id': 1424, 'therapyName': 'Regorafenib + Refametinib'}, {'id': 888, 'therapyName': 'Refametinib'}]","Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer",1424
0,NCT03085095,Phase III,Recruiting,"[{'id': 5492, 'therapyName': 'Relugolix'}, {'id': 795, 'therapyName': 'Leuprolide'}]",A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer (HERO),5492
0,NCT01656538,Phase II,"Active, not recruiting","[{'id': 893, 'therapyName': 'Reolysin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer,893
1,NCT02620423,Phase I,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 893, 'therapyName': 'Reolysin'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab With REOLYSIN and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma,893
2,NCT01619813,Phase II,Completed,"[{'id': 2462, 'therapyName': 'Docetaxel + Prednisone'}, {'id': 893, 'therapyName': 'Reolysin'}]",Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer,893
3,NCT01622543,Phase II,"Active, not recruiting","[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 893, 'therapyName': 'Reolysin'}]",Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer,893
0,NCT01708993,Phase II,Completed,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1110, 'therapyName': 'Reolysin + Pemetrexed'}, {'id': 1111, 'therapyName': 'Reolysin + Docetaxel'}]"," Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy",1111
0,NCT01708993,Phase II,Completed,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1110, 'therapyName': 'Reolysin + Pemetrexed'}, {'id': 1111, 'therapyName': 'Reolysin + Docetaxel'}]"," Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy",1110
0,NCT03028103,Phase I,Recruiting,"[{'id': 5267, 'therapyName': 'Tazemetostat + Fluconazole'}, {'id': 5285, 'therapyName': 'Repaglinide + Omeprazole + Tazemetostat'}]","Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, the Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma Subjects",5285
0,NCT02370238,Phase II,Recruiting,"[{'id': 2930, 'therapyName': 'Reparixin'}]",A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer,2930
0,NCT02420691,Phase II,"Active, not recruiting","[{'id': 790, 'therapyName': 'Ribociclib'}]",LEE011 in Neuroendocrine Tumors of Foregut Origin,790
1,NCT02300987,Phase II,"Active, not recruiting","[{'id': 790, 'therapyName': 'Ribociclib'}]","A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent Progression",790
2,NCT02657343,Phase Ib/II,Recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}]","An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.",790
3,NCT02607124,Phase Ib/II,Recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}]",Administration of Ribociclib Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG),790
4,NCT01958021,Phase III,"Active, not recruiting","[{'id': 790, 'therapyName': 'Ribociclib'}, {'id': 794, 'therapyName': 'Letrozole'}]",Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2),790
5,NCT02278120,Phase III,"Active, not recruiting","[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 790, 'therapyName': 'Ribociclib'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 633, 'therapyName': 'Anastrozole'}]","Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer",790
6,NCT03078751,Phase III,Recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}]",Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer (EarLEE-1),790
7,NCT01747876,Phase I,Completed,"[{'id': 790, 'therapyName': 'Ribociclib'}]",Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma,790
8,NCT02632045,Phase II,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 790, 'therapyName': 'Ribociclib'}]",Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ H2N- Advanced Breast Cancer,790
9,NCT02422615,Phase III,"Active, not recruiting","[{'id': 790, 'therapyName': 'Ribociclib'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.,790
10,NCT02555189,Phase Ib/II,Recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]","Enzalutamide With and Without Ribociclib for Metastatic, Castrate-Resistant, Chemotherapy-Naive Prostate Cancer That Retains RB Expression",790
11,NCT02933736,Phase 0,Recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}]",Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients,790
12,NCT02345824,Phase I,Recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}]",Early-Phase Study to Assess Inhibitor LEE011 in Patients With Recurrent Glioblastoma or Anaplastic Glioma,790
13,NCT02934568,Phase II,Recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}]",Ribociclib (LEE011) Rollover Study for Continued Access,790
14,NCT01237236,Phase I,Completed,"[{'id': 790, 'therapyName': 'Ribociclib'}]",A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma.,790
15,NCT02524119,Phase II,Recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}]",LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma (LEE001),790
16,NCT02187783,Phase II,"Active, not recruiting","[{'id': 790, 'therapyName': 'Ribociclib'}]",LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE),790
17,NCT03285412,,Not yet recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}]","CDK 4/6 Inhibitor, LEE011 (Ribociclib), in Combination With Adjuvant Endocrine Therapy at Varying Duration for ER-positive Breast Cancer",790
0,NCT03090165,Phase Ib/II,Recruiting,"[{'id': 5479, 'therapyName': 'Ribociclib + Bicalutamide'}]",Ribociclib and Bicalutamide in AR+ TNBC,5479
0,NCT03114527,Phase II,Recruiting,"[{'id': 5073, 'therapyName': 'Ribociclib + Everolimus'}]",Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS),5073
1,NCT03070301,Phase II,Recruiting,"[{'id': 5073, 'therapyName': 'Ribociclib + Everolimus'}]",A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors,5073
2,NCT02985125,Phase Ib/II,Recruiting,"[{'id': 5073, 'therapyName': 'Ribociclib + Everolimus'}]",LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy,5073
0,NCT03008408,Phase II,Recruiting,"[{'id': 5180, 'therapyName': 'Ribociclib + Everolimus + Letrozole'}]","Phase II Ribociclib, Everolimus and Letrozole in Endometrial Cancer",5180
0,NCT02941926,Phase III,Recruiting,"[{'id': 5310, 'therapyName': 'Ribociclib + Letrozole + Goserelin'}]",Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC,5310
0,NCT02703571,Phase Ib/II,Recruiting,"[{'id': 4472, 'therapyName': 'Ribociclib + Trametinib'}]",Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors,4472
0,NCT01765543,Phase I,Completed,"[{'id': 1256, 'therapyName': 'Rifampin + Vemurafenib'}]",A Pharmacokinetics Study to Investigate the Effect of Rifampin on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy,1256
0,NCT01584531,Phase II,Completed,"[{'id': 1046, 'therapyName': 'rigosertib'}]","Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome",1046
1,NCT01928537,Phase III,"Active, not recruiting","[{'id': 1046, 'therapyName': 'rigosertib'}]",Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine,1046
2,NCT02562443,Phase III,Recruiting,"[{'id': 1046, 'therapyName': 'rigosertib'}]",Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA (INSPIRE),1046
3,NCT02107235,Phase I,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1046, 'therapyName': 'rigosertib'}]",Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer,1046
0,NCT01303341,Phase I,"Active, not recruiting","[{'id': 1724, 'therapyName': 'Rilutek + Sorafenib'}]",Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma,1724
0,NCT02792114,Phase I,Recruiting,"[{'id': 5992, 'therapyName': 'Rimiducid'}, {'id': 6029, 'therapyName': 'Mesothelin CAR-T cells'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",T-Cell Therapy for Advanced Breast Cancer,5992
1,NCT02487459,Phase I,Not yet recruiting,"[{'id': 6053, 'therapyName': 'BPX-501'}, {'id': 5992, 'therapyName': 'Rimiducid'}]",Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies,5992
2,NCT02786485,Phase I,Not yet recruiting,"[{'id': 5992, 'therapyName': 'Rimiducid'}, {'id': 6053, 'therapyName': 'BPX-501'}]",Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT,5992
3,NCT02477878,Phase I,Recruiting,"[{'id': 5995, 'therapyName': 'BPX-601'}, {'id': 5992, 'therapyName': 'Rimiducid'}]",Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant,5992
4,NCT02743611,Phase I,Recruiting,"[{'id': 5992, 'therapyName': 'Rimiducid'}, {'id': 5991, 'therapyName': 'BPX-701'}]",Dose Finding Study Evaluating Safety and Feasibility in Patients With Relapsed or Refractory Myeloid Neoplasms,5992
5,NCT01744223,Phase Ib/II,Recruiting,"[{'id': 5992, 'therapyName': 'Rimiducid'}, {'id': 6053, 'therapyName': 'BPX-501'}]",Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant,5992
6,NCT02065869,Phase Ib/II,Recruiting,"[{'id': 6053, 'therapyName': 'BPX-501'}, {'id': 5992, 'therapyName': 'Rimiducid'}]",Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant,5992
0,NCT00267865,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma,897
1,NCT02043587,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia &amp; Lymphoblastic Lymphoma,897
2,NCT02367040,Phase III,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 995, 'therapyName': 'Copanlisib'}]",Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL),897
3,NCT01871675,Phase I,Completed,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1024, 'therapyName': 'Duvelisib'}, {'id': 1231, 'therapyName': 'Bendamustine'}]","Phase Ib Study of IPI-145 in Combination With Bendamustine, Rituximab or Bendamustine/Rituximab in Hematologic Malignancies",897
4,NCT01992653,Phase I,"Active, not recruiting","[{'id': 4248, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 4226, 'therapyName': 'Polatuzumab Vedotin'}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]","A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma",897
5,NCT02203526,Phase I,Suspended,"[{'id': 1607, 'therapyName': 'Temozolomide + Etoposide + Doxil + Dexamethasone + Ibrutinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 897, 'therapyName': 'Rituximab'}]","Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma",897
6,NCT02626455,Phase III,Recruiting,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 3388, 'therapyName': 'Aldoxorubicin +Cyclophosphamide + Prednisone + Rituximab + Vincristine'}, {'id': 995, 'therapyName': 'Copanlisib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL),897
7,NCT01319981,Phase II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia,897
8,NCT02733042,Phase Ib/II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 4278, 'therapyName': 'lenalidomide + MEDI4736 + Rituximab'}, {'id': 4279, 'therapyName': 'Bendamustine + MEDI4736 + Rituximab'}, {'id': 2573, 'therapyName': 'Ibrutinib + MEDI4736'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia (FUSION NHL 001)",897
9,NCT02205333,Phase Ib/II,Terminated,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1653, 'therapyName': 'MEDI6469'}, {'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies,897
10,NCT02423915,Phase Ib/II,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}, {'id': 917, 'therapyName': 'Sirolimus'}]",Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention,897
11,NCT01983969,Phase Ib/II,"Active, not recruiting","[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2557, 'therapyName': 'Azacitidine + Gemcitabine + vorinostat'}]",Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma,897
12,NCT02406742,Phase Ib/II,Recruiting,"[{'id': 1646, 'therapyName': 'Obinutuzumab'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 2358, 'therapyName': 'CC-122'}]","A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Rituximab, Ibrutinib and Obinutuzumab in Subjects With Relapsed/Refractory CLL/SLL (ENHANCE)",897
13,NCT01701986,Phase Ib/II,Recruiting,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 3992, 'therapyName': 'Busulfan + Clofarabine + Gemcitabine'}]",Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas,897
14,NCT03147612,Phase II,Not yet recruiting,"[{'id': 5682, 'therapyName': 'Mesna'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Study of the Combination of Low-Intensity Chemotherapy and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),897
15,NCT03136146,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1090, 'therapyName': 'Ofatumumab'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]","Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)",897
16,NCT02055820,Phase I,"Active, not recruiting","[{'id': 1562, 'therapyName': 'Venetoclax'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]",A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma,897
17,NCT02018861,Phase I,"Active, not recruiting","[{'id': 2406, 'therapyName': 'INCB039110'}, {'id': 3097, 'therapyName': 'INCB039110 + INCB050465'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 3088, 'therapyName': 'INCB050465 '}]","A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies",897
18,NCT02531308,Phase II,Terminated,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}]",Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL),897
19,NCT02589145,Phase Ib/II,Recruiting,"[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 3278, 'therapyName': 'Enoxaparin'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}]",Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype,897
20,NCT00074490,Phase II,Completed,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,897
21,NCT01686165,Phase II,"Active, not recruiting","[{'id': 1078, 'therapyName': 'Belinostat'}, {'id': 897, 'therapyName': 'Rituximab'}]",Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma,897
22,NCT00114738,Phase II,"Active, not recruiting","[{'id': 3395, 'therapyName': 'R-EPOCH'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 688, 'therapyName': 'Bortezomib'}]",EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma,897
23,NCT03023046,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}]","Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",897
24,NCT02532192,Phase I,Withdrawn,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1689, 'therapyName': 'Fluconazole'}, {'id': 1078, 'therapyName': 'Belinostat'}]","A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma",897
25,NCT03150693,Phase III,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 3628, 'therapyName': 'Allopurinol'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]",Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia,897
26,NCT01415752,Phase II,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1164, 'therapyName': 'lenalidomide'}]","Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",897
27,NCT01732913,Phase III,Terminated,"[{'id': 1023, 'therapyName': 'Idelalisib'}, {'id': 897, 'therapyName': 'Rituximab'}]",Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas,897
28,NCT01855750,Phase III,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}]","A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma",897
29,NCT02337985,Phase I,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 2482, 'therapyName': 'Cyclophosphamide + Doxorubicin + Etoposide + Vincristine '}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma,897
30,NCT00092222,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1187, 'therapyName': 'Alpha 2 Interferon'}, {'id': 2211, 'therapyName': 'EPOCH'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1008, 'therapyName': 'Doxil'}]",Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity,897
31,NCT02408042,Phase Ib/II,Withdrawn,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2486, 'therapyName': 'Brentuximab vedotin'}]",Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme),897
32,NCT02031419,Phase I,Recruiting,"[{'id': 2376, 'therapyName': 'CC-122 + CC-292'}, {'id': 2377, 'therapyName': 'CC-223 + CC-292'}, {'id': 2375, 'therapyName': 'CC-122 + CC-223'}, {'id': 897, 'therapyName': 'Rituximab'}]","Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma",897
33,NCT02005471,Phase III,"Active, not recruiting","[{'id': 1562, 'therapyName': 'Venetoclax'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 897, 'therapyName': 'Rituximab'}]",A Study of GDC-0199 (ABT-199) Plus MabThera/Rituxan (Rituximab) Compared With Bendamustine Plus MabThera/Rituxan (Rituximab) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,897
34,NCT02007044,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 897, 'therapyName': 'Rituximab'}]",Ibrutinib Versus Ibrutinib + Rituximab (i vs iR) in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL),897
35,NCT02541565,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 897, 'therapyName': 'Rituximab'}]",Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma,897
36,NCT01619761,Phase I,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1847, 'therapyName': 'lenalidomide + Fludarabine + Melphalan'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1843, 'therapyName': 'Tacrolimus'}]",Natural Killer (NK) Cells in Cord Blood Transplantation,897
37,NCT00577278,Phase II,"Active, not recruiting","[{'id': 767, 'therapyName': 'Ibritumomab'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}]","Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma",897
38,NCT01665768,Phase II,"Active, not recruiting","[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 735, 'therapyName': 'Everolimus'}]",Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma,897
39,NCT01453205,Phase II,Completed,"[{'id': 2354, 'therapyName': 'Cisplatin + Cytarabine + Dexamethasone'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2407, 'therapyName': 'MEDI-551'}]","A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",897
40,NCT01326702,Phase Ib/II,Completed,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1231, 'therapyName': 'Bendamustine'}]"," Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors",897
41,NCT03117751,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,897
42,NCT02538926,Phase II,Not yet recruiting,"[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 3212, 'therapyName': 'Doxorubicin + Etoposide + Vincristine '}, {'id': 2206, 'therapyName': 'Asparaginase'}]","Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",897
43,NCT02204982,Phase III,Terminated,"[{'id': 1024, 'therapyName': 'Duvelisib'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of IPI-145 in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma (DYNAMO + R),897
44,NCT02790515,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation,897
45,NCT03259503,Phase Ib/II,Not yet recruiting,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas,897
46,NCT02356159,Phase Ib/II,Recruiting,"[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 2292, 'therapyName': 'Doxorubicin + Etoposide + Fludarabine + Vincristine '}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation,897
0,NCT01267812,Phase II,"Active, not recruiting","[{'id': 1649, 'therapyName': 'Rituximab + Bortezomib'}]",Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation,1649
1,NCT01058239,Phase II,"Active, not recruiting","[{'id': 1649, 'therapyName': 'Rituximab + Bortezomib'}]",Bortezomib Plus Rituximab for EBV+ PTLD,1649
0,NCT00520130,Phase Ib/II,"Active, not recruiting","[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2305, 'therapyName': 'Alemtuzumab + Cyclosporine'}, {'id': 2306, 'therapyName': 'Rituximab + Fludarabine + EPOCH'}, {'id': 2307, 'therapyName': 'Fludarabine + EPOCH'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,2306
0,NCT02200848,Phase I,Terminated,"[{'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}]","Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory CLL",1610
1,NCT03232307,Phase II,Not yet recruiting,"[{'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}]",Ibrutinib Plus Rituximab and Lenalidomide in Elderly Patients With Newly Diagnosed Mantle Cell Lymphoma (MCL),1610
2,NCT02532257,Phase II,Recruiting,"[{'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}]",Study of Ibrutinib in Combination With Rituximab and Lenalidomide,1610
3,NCT02446236,Phase I,Recruiting,"[{'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}]","Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)",1610
4,NCT02077166,Phase Ib/II,Recruiting,"[{'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}]",Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma,1610
5,NCT02636322,Phase II,Recruiting,"[{'id': 2482, 'therapyName': 'Cyclophosphamide + Doxorubicin + Etoposide + Vincristine '}, {'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}, {'id': 2188, 'therapyName': 'Prednisone'}]","A Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Dose Adjusted Chemotherapy For Patients With High Risk Diffuse Large B-Cell Lymphoma",1610
6,NCT02160015,Phase I,"Active, not recruiting","[{'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}]","Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",1610
0,NCT01253460,Phase II,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 3215, 'therapyName': 'Rituximab + sapacitabine'}]","Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)",3215
0,NCT03255096,Phase I,Recruiting,"[{'id': 6179, 'therapyName': 'Rituximab + TEN-010 + Venetoclax'}]","A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",6179
0,NCT02555878,Phase III,Recruiting,"[{'id': 4119, 'therapyName': 'Rivaroxaban'}]",A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants,4119
0,NCT02422979,Phase I,Recruiting,"[{'id': 2918, 'therapyName': 'RM-1929'}]",Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer,2918
0,NCT02624258,Phase I,Recruiting,"[{'id': 6000, 'therapyName': 'RNA CART19 cells'}]","Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma",6000
0,NCT01154452,Phase Ib/II,Completed,"[{'id': 956, 'therapyName': 'Vismodegib'}, {'id': 1096, 'therapyName': 'Vismodegib + RO4929097'}, {'id': 902, 'therapyName': 'RO4929097'}]",Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma,902
0,NCT02670044,Phase Ib/II,Recruiting,"[{'id': 4171, 'therapyName': 'Cobimetinib + Venetoclax'}, {'id': 4172, 'therapyName': 'RO5503781 + Venetoclax'}]",A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy,4172
0,NCT02141295,Phase II,Completed,"[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 1598, 'therapyName': 'RO5520985'}, {'id': 1599, 'therapyName': 'Bevacizumab + Fluorouracil + Leucovorin'}, {'id': 1600, 'therapyName': 'RO5520985 + Leucovorin + Fluorouracil'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study Comparing the Efficacy and Safety of RO5520985 and FOLFOX With Bevacizumab and FOLFOX in Patients With Untreated Metastatic Colorectal Cancer (McCAVE),1598
0,NCT02141295,Phase II,Completed,"[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 1598, 'therapyName': 'RO5520985'}, {'id': 1599, 'therapyName': 'Bevacizumab + Fluorouracil + Leucovorin'}, {'id': 1600, 'therapyName': 'RO5520985 + Leucovorin + Fluorouracil'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study Comparing the Efficacy and Safety of RO5520985 and FOLFOX With Bevacizumab and FOLFOX in Patients With Untreated Metastatic Colorectal Cancer (McCAVE),1600
0,NCT02665416,Phase I,Recruiting,"[{'id': 3468, 'therapyName': 'RO5520985 + RO7009789'}]","Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors",3468
0,NCT02098967,Phase I,"Active, not recruiting","[{'id': 2155, 'therapyName': 'RO6839921'}]","A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.",2155
0,NCT02627274,Phase I,Recruiting,"[{'id': 5364, 'therapyName': 'RO6874281'}]","A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 in Participants With Advanced and/or Metastatic Solid Tumors",5364
0,NCT03063762,Phase I,Recruiting,"[{'id': 5365, 'therapyName': 'RO6874281 + Obinutuzumab + Atezolizumab'}, {'id': 5366, 'therapyName': 'RO6874281 + Obinutuzumab + Atezolizumab + Bevacizumab'}]","Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)",5365
0,NCT03063762,Phase I,Recruiting,"[{'id': 5365, 'therapyName': 'RO6874281 + Obinutuzumab + Atezolizumab'}, {'id': 5366, 'therapyName': 'RO6874281 + Obinutuzumab + Atezolizumab + Bevacizumab'}]","Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)",5366
0,NCT02558140,Phase I,Recruiting,"[{'id': 4330, 'therapyName': 'RO6874813'}]",A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors,4330
0,NCT02350673,Phase I,Recruiting,"[{'id': 2886, 'therapyName': 'RO6895882'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of Intravenous RO6895882 and MPDL3280A Combination in Patients With Locally Advanced and/or Metastatic Solid Tumors,2886
1,NCT02004106,Phase I,Completed,"[{'id': 2886, 'therapyName': 'RO6895882'}]",A Study of RO6895882 in Patients With Advanced and/or Metastatic Solid Tumors,2886
0,NCT02304393,Phase I,Recruiting,"[{'id': 2672, 'therapyName': 'RO7009789'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of RO7009789 in Combination With MPDL3280A in Patients With Locally Advanced and Metastatic Solid Tumors,2672
0,NCT03289962,Phase I,Not yet recruiting,"[{'id': 6234, 'therapyName': 'RO7198457'}, {'id': 6235, 'therapyName': 'Atezolizumab + RO7198457'}]",A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors,6234
0,NCT01976741,Phase I,Recruiting,"[{'id': 2030, 'therapyName': 'Rogaratinib'}]",Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor,2030
0,NCT02181218,Phase I,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1611, 'therapyName': 'Gemcitabine + Oxaliplatin + Dexamethasone'}]","Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas",1075
1,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,1075
2,NCT01897012,Phase I,Recruiting,"[{'id': 1075, 'therapyName': 'romidepsin'}, {'id': 626, 'therapyName': 'Alisertib'}]",Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas,1075
3,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1075
4,NCT03278782,Phase Ib/II,Not yet recruiting,"[{'id': 1075, 'therapyName': 'romidepsin'}, {'id': 5728, 'therapyName': 'Romidepsin + Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Combination With Romidepsin,1075
5,NCT01638533,Phase I,Recruiting,"[{'id': 1075, 'therapyName': 'romidepsin'}]","Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction",1075
0,NCT02512172,Phase I,Recruiting,"[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}, {'id': 5728, 'therapyName': 'Romidepsin + Pembrolizumab'}, {'id': 5782, 'therapyName': 'Azacitidine + Pembrolizumab + Romidepsin'}]",A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer,5728
1,NCT03278782,Phase Ib/II,Not yet recruiting,"[{'id': 1075, 'therapyName': 'romidepsin'}, {'id': 5728, 'therapyName': 'Romidepsin + Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Combination With Romidepsin,5728
0,NCT02482441,Phase I,Recruiting,"[{'id': 4401, 'therapyName': 'Rosmantuzumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]","A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10",4401
0,NCT02317016,Phase I,"Active, not recruiting","[{'id': 660, 'therapyName': 'AZD9291'}, {'id': 2928, 'therapyName': 'Rosuvastatin'}]","Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer",2928
0,NCT03061812,Phase III,Recruiting,"[{'id': 3544, 'therapyName': 'Rovalpituzumab Tesirine'}, {'id': 942, 'therapyName': 'Topotecan'}]",Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE) (TAHOE),3544
1,NCT02874664,Phase I,Recruiting,"[{'id': 3544, 'therapyName': 'Rovalpituzumab Tesirine'}]",A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer,3544
2,NCT02674568,Phase II,"Active, not recruiting","[{'id': 3544, 'therapyName': 'Rovalpituzumab Tesirine'}]",Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY),3544
3,NCT02709889,Phase Ib/II,Recruiting,"[{'id': 3544, 'therapyName': 'Rovalpituzumab Tesirine'}]",Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors,3544
4,NCT02819999,Phase I,Recruiting,"[{'id': 4827, 'therapyName': 'Rovalpituzumab Tesirine + Cisplatin + Etoposide'}, {'id': 3544, 'therapyName': 'Rovalpituzumab Tesirine'}]",A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Delta-Like Protein 3-Expressing Extensive Stage Small Cell Lung Cancer,3544
0,NCT02819999,Phase I,Recruiting,"[{'id': 4827, 'therapyName': 'Rovalpituzumab Tesirine + Cisplatin + Etoposide'}, {'id': 3544, 'therapyName': 'Rovalpituzumab Tesirine'}]",A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Delta-Like Protein 3-Expressing Extensive Stage Small Cell Lung Cancer,4827
0,NCT03033511,Phase III,Recruiting,"[{'id': 5307, 'therapyName': 'Rovalpituzumab Tesirine + Dexamethasone'}]",A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) (MERU),5307
0,NCT03026166,Phase I,Recruiting,"[{'id': 5640, 'therapyName': 'Rovalpituzumab Tesirine + Nivolumab + Ipilimumab'}, {'id': 5641, 'therapyName': 'Rovalpituzumab Tesirine + Nivolumab'}]",A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer,5641
0,NCT03026166,Phase I,Recruiting,"[{'id': 5640, 'therapyName': 'Rovalpituzumab Tesirine + Nivolumab + Ipilimumab'}, {'id': 5641, 'therapyName': 'Rovalpituzumab Tesirine + Nivolumab'}]",A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer,5640
0,NCT03119467,Phase I,Recruiting,"[{'id': 5761, 'therapyName': 'RP4010'}]","Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",5761
0,NCT02567656,Phase I,Recruiting,"[{'id': 2020, 'therapyName': 'RP6530'}]",Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma,2020
0,NCT02489903,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 3680, 'therapyName': 'RRx-001'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 619, 'therapyName': 'Abraxane'}]","RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens",3680
1,NCT02452970,Phase II,"Active, not recruiting","[{'id': 3680, 'therapyName': 'RRx-001'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy (EPIC),3680
2,NCT02215512,Phase I,"Active, not recruiting","[{'id': 3680, 'therapyName': 'RRx-001'}]",Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases,3680
0,NCT02871843,Phase I,Recruiting,"[{'id': 4596, 'therapyName': 'RRx-001 + Temozolomide'}]",Phase 1 Two Part Dose Escalation Trial of RRx-001 + Radiation + Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas (G-FORCE-1),4596
0,NCT02259231,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 3062, 'therapyName': 'RTA 408'}]",RTA 408 Capsules in Patients With Melanoma - REVEAL,3062
0,NCT01482715,,"Active, not recruiting","[{'id': 906, 'therapyName': 'Rucaparib'}]",A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II),906
1,NCT02042378,Phase II,Completed,"[{'id': 906, 'therapyName': 'Rucaparib'}]",A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation,906
2,NCT02855944,Phase III,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 906, 'therapyName': 'Rucaparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients",906
3,NCT02975934,Phase III,Recruiting,"[{'id': 906, 'therapyName': 'Rucaparib'}]",A Study of Rucaparib Verses Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency,906
4,NCT01968213,Phase III,"Active, not recruiting","[{'id': 906, 'therapyName': 'Rucaparib'}]","A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer",906
5,NCT02952534,Phase II,Recruiting,"[{'id': 906, 'therapyName': 'Rucaparib'}]",A Study of Rucaparib in Patients With MetA Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON2),906
6,NCT03140670,Phase II,Recruiting,"[{'id': 906, 'therapyName': 'Rucaparib'}]",Rucaparib in BRCA1/2 or PALB2 Mutated Pancreatic Cancer,906
7,NCT01891344,Phase II,"Active, not recruiting","[{'id': 906, 'therapyName': 'Rucaparib'}]","A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)",906
0,NCT02131584,Phase II,"Active, not recruiting","[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Administration of Jakafi (Ruxolitinib) for Symptom Control of Patients With Chronic Lymphocytic Leukemia (CLL),907
1,NCT01787487,Phase III,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}]",Evaluation of RUX and AZA Combination as a Therapy For Patients With Myelofibrosis And Myelodysplastic Syndrome/ Myeloproliferative Neoplasm,907
2,NCT01164163,Phase I,Completed,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]","INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease",907
3,NCT02928978,Phase II,Not yet recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib for Premalignant Breast Disease,907
4,NCT01822756,Phase I,Terminated,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors,907
5,NCT03153982,Phase II,Not yet recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib in Operable Head and Neck Cancer,907
6,NCT01895842,Phase I,"Active, not recruiting","[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS),907
7,NCT02092324,Phase II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia,907
8,NCT01712659,Phase II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib for Adult T-Cell Leukemia,907
9,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,907
10,NCT02251821,Phase II,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 2006, 'therapyName': 'Pacritinib'}, {'id': 823, 'therapyName': 'Momelotinib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis,907
11,NCT01431209,Phase II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma,907
12,NCT02420717,Phase II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 2046, 'therapyName': 'Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine '}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 3194, 'therapyName': 'Mercaptopurine + Methotrexate + Prednisone + Vincristine'}]",Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL),907
13,NCT02117479,Phase III,Terminated,"[{'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1),907
14,NCT03286530,Phase II,Not yet recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib + Allogeneic Stem Cell Transplantation in AML,907
15,NCT02723994,Phase II,Recruiting,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 2346, 'therapyName': 'Mercaptopurine + Thioguanine'}, {'id': 2394, 'therapyName': 'Asparaginase + Cytarabine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}]",A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia,907
16,NCT02713386,Phase Ib/II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",907
17,NCT03117751,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,907
18,NCT02119676,Phase II,Terminated,"[{'id': 890, 'therapyName': 'Regorafenib'}, {'id': 907, 'therapyName': 'Ruxolitinib'}]",Study of Ruxolitinib in Colorectal Cancer Patients,907
19,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,907
20,NCT01562873,,Terminated,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]", Ruxolitinib in Patients With Breast Cancer,907
21,NCT01776723,Phase II,"Active, not recruiting","[{'id': 907, 'therapyName': 'Ruxolitinib'}]",A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib,907
22,NCT01751425,Phase II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD),907
23,NCT03041636,Phase II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Administration of Jakafi (Ruxolitinib) to Patients With High-Risk Chronic Lymphocytic Leukemia (CLL),907
24,NCT02974647,Phase II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma,907
25,NCT02015208,Phase Ib/II,Completed,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia,907
0,NCT02120417,Phase II,Terminated,"[{'id': 1615, 'therapyName': 'Ruxolitinib + Capecitabine'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer,1615
1,NCT02119663,Phase III,Terminated,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1615, 'therapyName': 'Ruxolitinib + Capecitabine'}]",A Study of Ruxolitinib in Pancreatic Cancer Patients,1615
0,NCT02119650,Phase II,Terminated,"[{'id': 1856, 'therapyName': 'Ruxolitinib + Cisplatin + Pemetrexed'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}]",Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer,1856
0,NCT02076191,Phase Ib/II,Recruiting,"[{'id': 1735, 'therapyName': 'Ruxolitinib + Decitabine'}]",Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML,1735
1,NCT02257138,Phase Ib/II,Recruiting,"[{'id': 1735, 'therapyName': 'Ruxolitinib + Decitabine'}]",Study of Ruxolitinib Plus Decitabine in Patients With Acute Myeloid Leukemia (AML),1735
0,NCT02155465,Phase Ib/II,"Active, not recruiting","[{'id': 1858, 'therapyName': 'Ruxolitinib + Erlotinib'}]",Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib,1858
0,NCT01594216,Phase II,"Active, not recruiting","[{'id': 1108, 'therapyName': 'Ruxolitinib + Exemestane'}]", Ruxolitinib in Estrogen Receptor Positive Breast Cancer,1108
0,NCT01702064,Phase I,"Active, not recruiting","[{'id': 1116, 'therapyName': 'Ruxolitinib + Nilotinib'}]",Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients,1116
1,NCT02973711,Phase Ib/II,Recruiting,"[{'id': 1116, 'therapyName': 'Ruxolitinib + Nilotinib'}]",A Phase I/II Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML,1116
2,NCT01914484,Phase II,Recruiting,"[{'id': 1116, 'therapyName': 'Ruxolitinib + Nilotinib'}]",Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia,1116
0,NCT02041429,Phase Ib/II,"Active, not recruiting","[{'id': 1369, 'therapyName': 'Ruxolitinib + Paclitaxel'}]",Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca,1369
0,NCT02528877,Phase I,Withdrawn,"[{'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 3181, 'therapyName': 'Ruxolitinib + Sirolimus + Tacrolimus'}]","Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis",3181
0,NCT02066532,Phase Ib/II,Recruiting,"[{'id': 1578, 'therapyName': 'Ruxolitinib + Trastuzumab'}]",Phase I/II Trial of Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer,1578
0,NCT02003092,Phase I,Recruiting,"[{'id': 6224, 'therapyName': 'RX-5902'}]",RX-5902 Treatment of Subjects With Solid Tumors,6224
0,NCT02352025,Phase I,Recruiting,"[{'id': 2596, 'therapyName': 'S-equol  '}]",S-equol in Women With Triple Negative Breast Cancer,2596
0,NCT01553071,Phase I,Recruiting,"[{'id': 1049, 'therapyName': 'Safingol'}, {'id': 2731, 'therapyName': 'Fenretinide'}]",Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies,1049
0,NCT02987504,Phase I,Suspended,"[{'id': 5535, 'therapyName': 'Samalizumab'}]",Study of Samalizumab in Patients With Advanced Cancer,5535
0,NCT00999401,Phase I,Recruiting,"[{'id': 1130, 'therapyName': 'Sapacitabine + Seliciclib'}]",A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors,1130
0,NCT02724020,Phase II,Recruiting,"[{'id': 1283, 'therapyName': 'MLN1117 + Sapanisertib'}, {'id': 1282, 'therapyName': 'Sapanisertib'}, {'id': 735, 'therapyName': 'Everolimus'}]",MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma,1282
1,NCT02133183,Phase I,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",TORC1/2 Inhibitor INK128 Before and After Surgery in Treating Patients With Recurrent Glioblastoma,1282
2,NCT02197572,Phase I,"Active, not recruiting","[{'id': 1282, 'therapyName': 'Sapanisertib'}]",Effect of MLN0128 on the QTc Interval in Participants With Advanced Solid Tumors,1282
3,NCT03047213,Phase II,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations,1282
4,NCT02091531,Phase II,"Active, not recruiting","[{'id': 1282, 'therapyName': 'Sapanisertib'}]",Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients,1282
5,NCT02619669,Phase I,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}, {'id': 794, 'therapyName': 'Letrozole'}]",Neoadjuvant Run-In Study With TAK-228 (MLN0128) Followed by Letrozole/TAK-228 (MLN0128) in Women With High-Risk ER+/HER2- Breast Cancer,1282
6,NCT02412722,Phase I,"Active, not recruiting","[{'id': 1282, 'therapyName': 'Sapanisertib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","Safety, Tolerability, and Pharmacokinetics of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies",1282
7,NCT03097328,Phase II,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma,1282
8,NCT02514824,Phase Ib/II,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma,1282
9,NCT02244463,Phase II,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer,1282
10,NCT02601209,Phase Ib/II,Suspended,"[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1282, 'therapyName': 'Sapanisertib'}]",Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma,1282
11,NCT02893930,Phase II,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery,1282
12,NCT02987959,Phase II,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas,1282
13,NCT02417701,Phase II,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",TORC1/2 Inhibitor MLN0128 in Treating Patients With Stage IV or Recurrent Lung Cancer,1282
14,NCT02575339,Phase Ib/II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1282, 'therapyName': 'Sapanisertib'}]",MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma,1282
15,NCT01058707,Phase I,"Active, not recruiting","[{'id': 1282, 'therapyName': 'Sapanisertib'}]",Dose Escalation Study of MLN0128 in Subjects With Advanced Malignancies,1282
16,NCT02484430,Phase II,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",TORC1/2 Inhibitor INK128 in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia,1282
17,NCT02725268,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1282, 'therapyName': 'Sapanisertib'}, {'id': 1283, 'therapyName': 'MLN1117 + Sapanisertib'}]","Phase 2 Study of MLN0128, Combination of MLN0128 With MLN1117, Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial Cancer",1282
0,NCT01391533,Phase I,Completed,"[{'id': 2159, 'therapyName': 'SAR125844'}]",Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors,2159
1,NCT02435121,Phase II,Completed,"[{'id': 2159, 'therapyName': 'SAR125844'}]",A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification,2159
0,NCT01596270,Phase I,Completed,"[{'id': 1051, 'therapyName': 'SAR245409'}]",A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma,1051
1,NCT01587040,Phase Ib/II,"Active, not recruiting","[{'id': 1050, 'therapyName': 'XL147'}, {'id': 1051, 'therapyName': 'SAR245409'}]",Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen,1051
0,NCT01673737,Phase I,Completed,"[{'id': 1052, 'therapyName': 'SAR260301'}, {'id': 1225, 'therapyName': 'SAR260301 + Vemurafenib'}]", A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer,1052
0,NCT01673737,Phase I,Completed,"[{'id': 1052, 'therapyName': 'SAR260301'}, {'id': 1225, 'therapyName': 'SAR260301 + Vemurafenib'}]", A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer,1225
0,NCT01636479,Phase I,"Active, not recruiting","[{'id': 2078, 'therapyName': 'SAR405838'}]",Phase 1 Safety Testing of SAR405838,2078
0,NCT02575781,Phase I,Recruiting,"[{'id': 4026, 'therapyName': 'SAR428926'}]",A Study of SAR428926 in Patients With Advanced Solid Tumors,4026
0,NCT03192345,Phase I,Recruiting,"[{'id': 5934, 'therapyName': 'SAR439459 + REGN2810'}, {'id': 5933, 'therapyName': 'SAR439459'}]","A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and REGN2810 in Patients With Advanced Solid Tumors",5933
0,NCT03192345,Phase I,Recruiting,"[{'id': 5934, 'therapyName': 'SAR439459 + REGN2810'}, {'id': 5933, 'therapyName': 'SAR439459'}]","A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and REGN2810 in Patients With Advanced Solid Tumors",5934
0,NCT03284957,Phase Ib/II,Recruiting,"[{'id': 6293, 'therapyName': 'SAR439859'}, {'id': 6294, 'therapyName': 'Palbociclib + SAR439859'}]",Phase 1 / 2 Study of SAR439859 Single Agent and in Combination With Palbociclib in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer,6293
0,NCT02984683,Phase II,Recruiting,"[{'id': 5825, 'therapyName': 'SAR566658'}]",Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer,5825
0,NCT01216176,Phase Ib/II,"Active, not recruiting","[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 912, 'therapyName': 'Saracatinib'}]",A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZDO530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer,912
0,NCT02339571,Phase II,Suspended,"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,1873
1,NCT03126916,Phase III,Not yet recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 5595, 'therapyName': 'Isotretinoin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 2286, 'therapyName': 'Dinutuximab  '}]",Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma,1873
2,NCT01903330,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1873, 'therapyName': 'Sargramostim'}]",ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme,1873
3,NCT01479244,Phase III,Completed,"[{'id': 3766, 'therapyName': 'E75'}, {'id': 1873, 'therapyName': 'Sargramostim'}]",Efficacy and Safety Study of NeuVax (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence,1873
4,NCT02636582,Phase II,Recruiting,"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 5152, 'therapyName': 'Nelipepimut-S Plus GM-CSF'}]",Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer,1873
5,NCT01570036,Phase II,Recruiting,"[{'id': 3766, 'therapyName': 'E75'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax,1873
6,NCT01857934,Phase II,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 2627, 'therapyName': 'Levetiracetam'}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 2458, 'therapyName': 'Hu14.18K322A'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}]",Therapy for Children With Advanced Stage Neuroblastoma,1873
7,NCT01530984,Phase II,Withdrawn,"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Ipilimumab and GMCSF Immunotherapy for Prostate Cancer,1873
8,NCT02009397,Phase Ib/II,Recruiting,"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients,1873
9,NCT01265433,Phase II,Completed,"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 2893, 'therapyName': 'WT1 vaccine'}]",Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy,1873
10,NCT02510950,Phase I,Recruiting,"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma,1873
11,NCT02620865,Phase Ib/II,Suspended,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}]",Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer,1873
12,NCT01827137,Phase I,"Active, not recruiting","[{'id': 2893, 'therapyName': 'WT1 vaccine'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1873, 'therapyName': 'Sargramostim'}]",WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation,1873
13,NCT02297698,Phase II,Recruiting,"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 3766, 'therapyName': 'E75'}]",Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients,1873
14,NCT00621036,Phase II,Unknown status,"[{'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1873, 'therapyName': 'Sargramostim'}]",Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma,1873
15,NCT02411786,Phase I,Recruiting,"[{'id': 4297, 'therapyName': 'pTVG-AR '}, {'id': 1873, 'therapyName': 'Sargramostim'}]",A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF,1873
16,NCT01890980,Phase II,"Active, not recruiting","[{'id': 2893, 'therapyName': 'WT1 vaccine'}, {'id': 1873, 'therapyName': 'Sargramostim'}]",Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134,1873
0,NCT02761057,Phase II,Recruiting,"[{'id': 2161, 'therapyName': 'Savolitinib'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}]","Cabozantinib-S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer",2161
1,NCT02127710,Phase II,"Active, not recruiting","[{'id': 2161, 'therapyName': 'Savolitinib'}]",A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC),2161
2,NCT03091192,Phase III,Recruiting,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 2161, 'therapyName': 'Savolitinib'}]",Savolitinib vs. Sunitinib in MET-driven PRCC,2161
0,NCT03035279,Phase I,Recruiting,"[{'id': 5748, 'therapyName': 'SC-006'}]",A Study of SC-006 in Subjects With Advanced Cancer,5748
0,NCT02266147,Phase Ib/II,Completed,"[{'id': 3084, 'therapyName': 'SD-101'}]",Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma,3084
1,NCT01745354,Phase I,Terminated,"[{'id': 3084, 'therapyName': 'SD-101'}]",Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT),3084
2,NCT02521870,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3084, 'therapyName': 'SD-101'}]",A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma,3084
0,NCT02743637,Phase I,Recruiting,"[{'id': 4326, 'therapyName': 'SDX-7320'}]",A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors (SDX-0101),4326
0,NCT02376699,Phase I,Recruiting,"[{'id': 5781, 'therapyName': 'Pembrolizumab + SEA-CD40'}, {'id': 5780, 'therapyName': 'SEA-CD40'}]",Safety Study of SEA-CD40 in Cancer Patients,5780
0,NCT03008187,Phase Ib/II,Suspended,"[{'id': 3693, 'therapyName': 'SEL24-B489'}]",SEL24 in Patients With AML,3693
0,NCT02351505,Phase II,Terminated,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer,1749
1,NCT02416908,Phase Ib/II,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}, {'id': 3178, 'therapyName': 'Cladribine + Cytarabine + Plerixafor'}]",Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia,1749
2,NCT02138786,Phase II,Terminated,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Study of Selinexor (KPT-330) in Patients With Refractory and/or Relapsed Richter's Transformation (RT),1749
3,NCT03193437,Phase II,Not yet recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy,1749
4,NCT02606461,Phase II,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]",KCP-330-020 SEAL (Selinexor in Advanced Liposarcoma) (SEAL),1749
5,NCT02227251,Phase II,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (SADAL),1749
6,NCT02471911,Phase I,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3360, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide + Rituximab'}, {'id': 1749, 'therapyName': 'Selinexor'}]",KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma,1749
7,NCT02088541,Phase II,"Active, not recruiting","[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}]",Selinexor (KPT-330) in Older Patients With Relapsed AML,1749
8,NCT02228525,Phase II,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes,1749
9,NCT02250885,Phase II,Completed,"[{'id': 1749, 'therapyName': 'Selinexor'}]",KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors,1749
10,NCT02573363,Phase I,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia,1749
11,NCT02323880,Phase I,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Study of Selinexor in Pediatric Solid Tumors,1749
12,NCT01607905,Phase I,Completed,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer,1749
13,NCT02299518,Phase I,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}]",Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,1749
14,NCT02419495,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Selinexor in Combination With Standard Chemotherapy,1749
15,NCT02215161,Phase II,"Active, not recruiting","[{'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor (KPT-330) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Prior Therapy With Abiraterone and/or Enzalutamide,1749
16,NCT02146833,Phase II,Terminated,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Study of Selinexor (KPT-330) in Metastatic Castrate Resistant Prostate Adenocarcinoma,1749
17,NCT02403310,Phase I,"Active, not recruiting","[{'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}, {'id': 1749, 'therapyName': 'Selinexor'}]",A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML,1749
18,NCT01986348,Phase II,"Active, not recruiting","[{'id': 1749, 'therapyName': 'Selinexor'}]",Phase 2 Study of Selinexor (KPT-330) in Patients With Recurrent Glioblastoma After Failure of Radiation and Temozolomide,1749
19,NCT02069730,Phase I,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]",A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes,1749
20,NCT02091245,Phase I,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]","Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML",1749
21,NCT02212561,Phase Ib/II,Completed,"[{'id': 1749, 'therapyName': 'Selinexor'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 2345, 'therapyName': 'Cytarabine + Dexamethasone+ Methotrexate '}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome,1749
22,NCT02120222,Phase I,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery,1749
23,NCT02536495,Phase Ib/II,Withdrawn,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer,1749
24,NCT03147885,Phase Ib/II,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma,1749
25,NCT02485535,Phase I,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant,1749
26,NCT02402764,Phase II,"Active, not recruiting","[{'id': 1749, 'therapyName': 'Selinexor'}]",Phase 2 Trial of Selinexor (KPT-330) for Metastatic TNBC,1749
0,NCT03110562,Phase III,Recruiting,"[{'id': 5639, 'therapyName': 'Selinexor + Bortezomib + Dexamethasone'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}]","Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma (BOSTON)",5639
0,NCT03042819,Phase I,Recruiting,"[{'id': 5286, 'therapyName': 'Selinexor + Doxorubicin'}]",Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas,5286
0,NCT03071276,Phase II,Recruiting,"[{'id': 5448, 'therapyName': 'Selinexor + Fludarabine phosphate + Cytarabine + Methotrexate + Prednisone'}]",Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia,5448
0,NCT02530476,Phase Ib/II,Recruiting,"[{'id': 3189, 'therapyName': 'Selinexor + Sorafenib'}]","Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia",3189
0,NCT03259633,Expanded access,Available,"[{'id': 913, 'therapyName': 'Selumetinib'}]",An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1,913
1,NCT02503358,Phase I,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}, {'id': 619, 'therapyName': 'Abraxane'}]",Selumetinib and Nab-Paclitaxel (Albumin-stabilized Nanoparticle Formulation) as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer,913
2,NCT03040986,Phase II,Not yet recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}]",Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations,913
3,NCT01306045,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 816, 'therapyName': 'MK2206'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 913, 'therapyName': 'Selumetinib'}]","Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies",913
4,NCT02407405,Phase II,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}]",Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas That Cannot Be Removed by Surgery,913
5,NCT03095248,Phase II,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}]",Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors,913
6,NCT02337530,Phase II,"Active, not recruiting","[{'id': 913, 'therapyName': 'Selumetinib'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}]",Selumetinib in Patients Receiving Pemetrexed and Cisplatin in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer,913
7,NCT02839720,Phase I,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}]",Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Dermal Neurofibroma,913
8,NCT03155620,Phase II,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}, {'id': 2650, 'therapyName': 'LOXO-101'}, {'id': 1069, 'therapyName': 'LY3023414'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 913, 'therapyName': 'Selumetinib'}, {'id': 961, 'therapyName': 'X-396'}]",Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Advanced Refractory Solid Tumors or Lymphomas,913
9,NCT02768766,Phase I,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}]",Intermittent Selumetinib for Uveal Melanoma,913
10,NCT01089101,Phase Ib/II,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}]",Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma,913
11,NCT03109301,Phase II,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}]",A Phase II Trial of the Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST),913
12,NCT01783197,Phase I,"Active, not recruiting","[{'id': 913, 'therapyName': 'Selumetinib'}]", Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC,913
13,NCT01362803,Phase I,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}]",AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors,913
14,NCT02188264,Phase I,"Active, not recruiting","[{'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 913, 'therapyName': 'Selumetinib'}]",Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer,913
15,NCT01843062,Phase III,"Active, not recruiting","[{'id': 913, 'therapyName': 'Selumetinib'}]",Study Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer,913
16,NCT02393690,Phase II,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}]",Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer,913
17,NCT03213691,Phase II,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}]","Pediatric MATCH: Selumetinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations",913
0,NCT02151084,Phase II,Recruiting,"[{'id': 2222, 'therapyName': 'Selumetinib + Cisplatin + Gemcitabine'}]",A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer,2222
0,NCT01974752,Phase III,Completed,"[{'id': 1432, 'therapyName': 'Selumetinib + Dacarbazine'}]",Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT),1432
0,NCT02179671,Phase II,Completed,"[{'id': 1117, 'therapyName': 'Selumetinib + Docetaxel'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 660, 'therapyName': 'AZD9291'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer",1117
1,NCT01933932,Phase III,"Active, not recruiting","[{'id': 1117, 'therapyName': 'Selumetinib + Docetaxel'}]",Assess Efficacy and Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC,1117
2,NCT01750281,Phase II,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1117, 'therapyName': 'Selumetinib + Docetaxel'}]",Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.,1117
0,NCT01642342,Phase I,Recruiting,"[{'id': 3013, 'therapyName': 'sEphB4-HSA'}]",Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors,3013
0,NCT03049618,Phase II,Recruiting,"[{'id': 3944, 'therapyName': 'sEphB4-HSA + Pembrolizumab'}]","Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475",3944
1,NCT02717156,Phase II,Recruiting,"[{'id': 3944, 'therapyName': 'sEphB4-HSA + Pembrolizumab'}]",Recombinant EphB4-HSA Fusion Protein and Pembrolizumab in Treating Patients With Metastatic or Recurrent Urothelial Cancer That Is Refractory to Certain Chemotherapy Drugs,3944
0,NCT02387216,Phase II,Recruiting,"[{'id': 820, 'therapyName': 'Seribantumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC,820
1,NCT02538627,Phase I,Terminated,"[{'id': 820, 'therapyName': 'Seribantumab'}, {'id': 821, 'therapyName': 'MM-151'}]",Phase 1 Combination Study of MM-151 and MM-121,820
2,NCT03241810,,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 820, 'therapyName': 'Seribantumab'}]",Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer,820
0,NCT02337309,Phase I,Recruiting,"[{'id': 915, 'therapyName': 'SF1126'}]",SF1126 for Patients With Relapsed or Refractory Neuroblastoma,915
1,NCT02644122,Phase II,Recruiting,"[{'id': 915, 'therapyName': 'SF1126'}]",SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes,915
2,NCT03059147,Phase I,Recruiting,"[{'id': 915, 'therapyName': 'SF1126'}]",A Study of Single Agent SF1126 Inhibitor in Patients With Advanced Hepatocellular Carcinoma,915
0,NCT02684162,Phase II,Recruiting,"[{'id': 1949, 'therapyName': 'SGI-110'}]",SGI-110 With Donor Lymphocyte Infusion (DLI) for Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing Post Allogeneic Stem Cell Transplantation (AlloSCT),1949
1,NCT02348489,Phase III,"Active, not recruiting","[{'id': 1949, 'therapyName': 'SGI-110'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 650, 'therapyName': 'Decitabine'}]","SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction",1949
2,NCT03075826,Phase II,Recruiting,"[{'id': 1949, 'therapyName': 'SGI-110'}]",A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms,1949
3,NCT03165721,Phase II,Recruiting,"[{'id': 1949, 'therapyName': 'SGI-110'}]","A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer",1949
4,NCT01966289,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1949, 'therapyName': 'SGI-110'}, {'id': 2977, 'therapyName': 'GVAX colorectal cancer vaccine'}]",SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC),1949
5,NCT02096055,Phase II,Recruiting,"[{'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1949, 'therapyName': 'SGI-110'}, {'id': 1022, 'therapyName': 'Idarubicin'}]",4-Arm Phase II Study of SGI-110 in Elderly Acute Myeloid Leukemia (AML),1949
6,NCT02907359,Phase III,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1949, 'therapyName': 'SGI-110'}]",Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs,1949
7,NCT02920008,Phase III,Recruiting,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1949, 'therapyName': 'SGI-110'}]","Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia",1949
8,NCT02429466,Phase I,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1949, 'therapyName': 'SGI-110'}]",Study of the Hypomethylating Drug SGI-110 Plus Cisplatin in Relapsed Refractory Germ Cell Tumors,1949
9,NCT02131597,Phase II,Recruiting,"[{'id': 1949, 'therapyName': 'SGI-110'}]",SGI-110 in Higher Risk Myelodysplastic Syndrome (MDS),1949
0,NCT01896856,Phase Ib/II,Recruiting,"[{'id': 2015, 'therapyName': 'SGI-110 + Irinotecan'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Phase I Study of SGI-110 With Irinotecan Followed by Randomized Phase II Study of SGI-110 With Irinotecan Versus Regorafenib in Previously Treated Metastatic Colorectal Cancer,2015
0,NCT03085849,Phase I,Recruiting,"[{'id': 5488, 'therapyName': 'SGI-110 + MEDI4736 + Tremelimumab'}]",SGI-110 Plus Durvalumab/Tremelimumab in SCLC,5488
0,NCT02952989,Phase I,Recruiting,"[{'id': 5896, 'therapyName': 'SGN-2FF'}]",A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors,5896
0,NCT01969643,Phase I,Recruiting,"[{'id': 3615, 'therapyName': 'SGN-LIV1A '}]",A Safety Study of SGN-LIV1A in Breast Cancer Patients,3615
0,NCT02340117,Phase II,Recruiting,"[{'id': 2518, 'therapyName': 'SGT-53'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer,2518
1,NCT02340156,Phase II,Recruiting,"[{'id': 2518, 'therapyName': 'SGT-53'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma,2518
0,NCT02354547,Phase I,Recruiting,"[{'id': 3617, 'therapyName': 'SGT-53 + Cyclophosphamide + Topotecan'}]",A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors,3617
0,NCT02466802,Phase I,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}, {'id': 3066, 'therapyName': 'Sildenafil'}]",Study of Regorafenib and Sildenafil for Advanced Solid Tumors,3066
0,NCT02061397,Phase Ib/II,Recruiting,"[{'id': 2239, 'therapyName': 'Simvastatin'}]",Safety of Simvastatin in LAM and TSC,2239
0,NCT02036918,Phase I,Recruiting,"[{'id': 2648, 'therapyName': 'Sipuleucel-T'}]",Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer,2648
1,NCT02353715,Phase I,Recruiting,"[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2648, 'therapyName': 'Sipuleucel-T'}]","Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge), Abiraterone Acetate (Zytiga) or Enzalutamide (Xtandi) Undergoing Cardiopulmonary EXercise Testing",2648
2,NCT01706458,Phase II,"Active, not recruiting","[{'id': 2698, 'therapyName': 'pTVG-HP plasmid DNA vaccine'}, {'id': 2648, 'therapyName': 'Sipuleucel-T'}]",Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer,2648
3,NCT01807065,Phase II,"Active, not recruiting","[{'id': 2648, 'therapyName': 'Sipuleucel-T'}]",Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer,2648
4,NCT02159950,Phase II,Completed,"[{'id': 2648, 'therapyName': 'Sipuleucel-T'}, {'id': 2699, 'therapyName': 'Tasquinimod'}]",Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,2648
5,NCT01560923,Phase II,"Active, not recruiting","[{'id': 2648, 'therapyName': 'Sipuleucel-T'}]",Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer,2648
6,NCT02463799,Phase II,Recruiting,"[{'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}, {'id': 2648, 'therapyName': 'Sipuleucel-T'}]",Ph 2 Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC,2648
7,NCT01818986,Phase II,Recruiting,"[{'id': 2648, 'therapyName': 'Sipuleucel-T'}]",Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC),2648
0,NCT01791088,Phase I,"Active, not recruiting","[{'id': 917, 'therapyName': 'Sirolimus'}]",Sirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery,917
1,NCT02753309,Phase 0,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}]",A Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder Cancer,917
2,NCT03298958,Phase III,Not yet recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}]",Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer,917
3,NCT02009332,Phase Ib/II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}]",Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer,917
4,NCT02110069,Phase II,Recruiting,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 917, 'therapyName': 'Sirolimus'}]",A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors,917
5,NCT01231412,Phase III,"Active, not recruiting","[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2272, 'therapyName': 'Cyclosporine + Mycophenolate mofetil'}]",Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant,917
6,NCT00092222,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1187, 'therapyName': 'Alpha 2 Interferon'}, {'id': 2211, 'therapyName': 'EPOCH'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1008, 'therapyName': 'Doxil'}]",Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity,917
7,NCT02722668,Phase II,Recruiting,"[{'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}]",UCB Transplant for Hematological DIseases Using a Non Myeloablative Prep,917
8,NCT01843998,Phase II,Withdrawn,"[{'id': 917, 'therapyName': 'Sirolimus'}]",Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL),917
9,NCT02756572,Phase I,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5215, 'therapyName': 'mitoxantrone hydrochloride'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myelodysplastic Syndrome or Acute Myeloid Leukemia,917
10,NCT02790515,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation,917
11,NCT01658007,Phase I,Terminated,"[{'id': 917, 'therapyName': 'Sirolimus'}]",Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma,917
12,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,917
13,NCT00602693,Phase I,Completed,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2311, 'therapyName': 'Allopurinol + Cyclophosphamide + Fludarabine'}]",T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer,917
14,NCT01203722,Phase Ib/II,Recruiting,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}]","Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies",917
15,NCT02145559,Phase I,"Active, not recruiting","[{'id': 1593, 'therapyName': 'Sirolimus + Metformin'}, {'id': 917, 'therapyName': 'Sirolimus'}]",A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors,917
16,NCT01522820,Phase I,Completed,"[{'id': 1324, 'therapyName': 'DEC-205-NY-ESO-1 fusion protein vaccine'}, {'id': 917, 'therapyName': 'Sirolimus'}]",Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors,917
17,NCT01195922,Phase Ib/II,Completed,"[{'id': 917, 'therapyName': 'Sirolimus'}]",Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma,917
18,NCT02423915,Phase Ib/II,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}, {'id': 917, 'therapyName': 'Sirolimus'}]",Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention,917
19,NCT00305682,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant,917
20,NCT02583893,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}]",Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia,917
21,NCT00923845,Phase II,Completed,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2308, 'therapyName': 'Cyclophosphamide + Pentostatin'}]",Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer,917
22,NCT01265030,Phase Ib/II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}]",A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis,917
23,NCT00513474,Phase I,Completed,"[{'id': 2313, 'therapyName': 'Rasburicase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2314, 'therapyName': 'Busulfan + Cyclophosphamide + Etoposide'}]",Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant,917
24,NCT01331135,Phase I,"Active, not recruiting","[{'id': 917, 'therapyName': 'Sirolimus'}]",Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors,917
25,NCT01163357,Phase I,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2288, 'therapyName': 'Bortezomib + Fludarabine + Melphalan'}]","Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma",917
26,NCT02793544,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide,917
27,NCT01764607,,Terminated,"[{'id': 917, 'therapyName': 'Sirolimus'}]",Sirolimus in Kidney Transplant Patients With Squamous Cell Skin Carcinoma,917
28,NCT01087554,Phase I,"Active, not recruiting","[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer,917
29,NCT01853423,Phase I,Completed,"[{'id': 917, 'therapyName': 'Sirolimus'}]",Tuberou Sclerosis Complex: Facial Angiofibroma Skin Cream,917
0,NCT03099356,Phase II,Recruiting,"[{'id': 5513, 'therapyName': 'Sirolimus + Cyclophosphamide'}]","Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer",5513
0,NCT01689987,Phase I,Completed,"[{'id': 2385, 'therapyName': 'Sirolimus + Cyclophosphamide + Dexamethasone + Hydroxychloroquine'}]","Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma",2385
0,NCT01670175,Phase I,Completed,"[{'id': 1224, 'therapyName': 'Sirolimus + Cyclophosphamide + Topotecan'}]",Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors,1224
0,NCT01266057,Phase I,"Active, not recruiting","[{'id': 1135, 'therapyName': 'Vorinostat + Hydroxychloroquine'}, {'id': 1177, 'therapyName': 'Sirolimus + Hydroxychloroquine'}]",Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer,1177
0,NCT02048384,Phase Ib/II,Recruiting,"[{'id': 1593, 'therapyName': 'Sirolimus + Metformin'}, {'id': 1031, 'therapyName': 'Metformin'}]",A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer,1593
1,NCT02145559,Phase I,"Active, not recruiting","[{'id': 1593, 'therapyName': 'Sirolimus + Metformin'}, {'id': 917, 'therapyName': 'Sirolimus'}]",A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors,1593
0,NCT01162551,Phase II,Completed,"[{'id': 2304, 'therapyName': 'Sirolimus + Methotrexate'}]",Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma,2304
0,NCT00577278,Phase II,"Active, not recruiting","[{'id': 767, 'therapyName': 'Ibritumomab'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}]","Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma",2238
1,NCT02356159,Phase Ib/II,Recruiting,"[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 2292, 'therapyName': 'Doxorubicin + Etoposide + Fludarabine + Vincristine '}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation,2238
2,NCT00520130,Phase Ib/II,"Active, not recruiting","[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2305, 'therapyName': 'Alemtuzumab + Cyclosporine'}, {'id': 2306, 'therapyName': 'Rituximab + Fludarabine + EPOCH'}, {'id': 2307, 'therapyName': 'Fludarabine + EPOCH'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,2238
0,NCT00411788,Phase II,Completed,"[{'id': 1979, 'therapyName': 'Sirolimus + Trastuzumab'}]",A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer,1979
0,NCT01537107,Phase I,Suspended,"[{'id': 1329, 'therapyName': 'Sirolimus + Vismodegib'}]",Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery,1329
0,NCT02270463,Phase Ib/II,Recruiting,"[{'id': 2005, 'therapyName': 'SL-401'}]",SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission,2005
0,NCT02078648,Phase Ib/II,"Active, not recruiting","[{'id': 3010, 'therapyName': 'SL-701'}, {'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme",3010
0,NCT02667873,Phase I,Recruiting,"[{'id': 6223, 'therapyName': 'SL-801'}]",A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors,6223
0,NCT02796898,Phase Ib/II,Recruiting,"[{'id': 5866, 'therapyName': 'SM88'}]","Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer",5866
0,NCT03037645,Phase Ib/II,Recruiting,"[{'id': 5281, 'therapyName': 'SNS-062'}]","Safety, PK, PD, and Antitumor Activity of SNS-062 in B Lymphoid Cancers",5281
0,NCT01635712,Phase I,Completed,"[{'id': 866, 'therapyName': 'SNX-5422'}]",Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies,866
1,NCT02612285,Phase II,Terminated,"[{'id': 866, 'therapyName': 'SNX-5422'}]",Study of SNX-5422 in TP53 Null Cancers,866
2,NCT01848756,Phase Ib/II,Terminated,"[{'id': 866, 'therapyName': 'SNX-5422'}]",Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers,866
3,NCT02063958,Phase I,"Active, not recruiting","[{'id': 866, 'therapyName': 'SNX-5422'}]",Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors,866
4,NCT01892046,Phase I,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 866, 'therapyName': 'SNX-5422'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors,866
0,NCT02111187,Phase I,Completed,"[{'id': 1428, 'therapyName': 'Sonidegib'}]",A Pre-surgical Study of LDE225 in Men With High-risk Localized Prostate Cancer,1428
1,NCT01769768,Phase I,Completed,"[{'id': 1428, 'therapyName': 'Sonidegib'}, {'id': 2505, 'therapyName': 'Warfarin'}, {'id': 2506, 'therapyName': 'Bupropion'}]",Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients,1428
2,NCT02002689,Phase II,Terminated,"[{'id': 1428, 'therapyName': 'Sonidegib'}]",LDE225 for Patients With PTCH1 or SMO Mutated Tumors,1428
3,NCT02182622,Phase I,Unknown status,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1428, 'therapyName': 'Sonidegib'}]",LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel,1428
4,NCT02151864,Phase I,"Active, not recruiting","[{'id': 1428, 'therapyName': 'Sonidegib'}]",LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A Cirrhosis,1428
5,NCT01485744,Phase I,"Active, not recruiting","[{'id': 1903, 'therapyName': 'FOLFIRINOX'}, {'id': 1428, 'therapyName': 'Sonidegib'}]","LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer",1428
6,NCT01757327,Phase II,Withdrawn,"[{'id': 1428, 'therapyName': 'Sonidegib'}]",LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer,1428
7,NCT02129101,Phase I,"Active, not recruiting","[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 1428, 'therapyName': 'Sonidegib'}]",Azacitidine and Sonidegib in Treating Patients With Myeloid Malignancies,1428
0,NCT01624285,Phase II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer,920
1,NCT01141478,Phase I,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}]",Proton Beam Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With Hepatocellular Carcinoma Exceeding San Francisco Criteria,920
2,NCT02560012,Phase II,Terminated,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Personalized Targeted Inhibitors Treatment in Renal Cell Cancer,920
3,NCT01724606,Phase I,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}]",Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM),920
4,NCT03164057,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia,920
5,NCT01761266,Phase III,"Active, not recruiting","[{'id': 792, 'therapyName': 'Lenvatinib'}, {'id': 920, 'therapyName': 'Sorafenib'}]","A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma",920
6,NCT02406521,Phase I,"Active, not recruiting","[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Exploratory Study of Radium-223 and Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases,920
7,NCT02279719,Phase Ib/II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2361, 'therapyName': 'BBI503 + Sorafenib'}, {'id': 2362, 'therapyName': 'BBI608 + Sorafenib'}]","A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma",920
8,NCT01817751,Phase II,Recruiting,"[{'id': 1076, 'therapyName': 'Valproic acid'}, {'id': 920, 'therapyName': 'Sorafenib'}]","Sorafenib Tosylate, Valproic Acid, and Sildenafil Citrate in Treating Patients With Recurrent High-Grade Glioma",920
9,NCT01730937,Phase III,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer,920
10,NCT02412475,Phase I,"Active, not recruiting","[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 650, 'therapyName': 'Decitabine'}]",Epigenetic Reprogramming in Relapse AML,920
11,NCT01621906,,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}]",18F-FLT-PET Imaging of the Brain in Patients With Metastatic Breast Cancer to the Brain Treated With Whole Brain Radiation Therapy With or Without Sorafenib,920
12,NCT02728050,Phase Ib/II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 4363, 'therapyName': 'Cladribine + Cytarabine + Filgrastim + Mitoxantrone'}]","Filgrastim, Cladribine, Cytarabine and Mitoxantrone With or Without Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome",920
13,NCT01276210,Phase I,Completed,"[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases,920
14,NCT02406508,Phase II,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC,920
15,NCT01849588,FDA approved,Terminated,"[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib for Hepatocellular Cancer With Chronic Hepatitis C,920
16,NCT01900002,Phase II,"Active, not recruiting","[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma (HCC),920
17,NCT02072486,Phase I,"Active, not recruiting","[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery,920
18,NCT01197170,Phase I,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Hormone Blockade in Combination With Targeted Agents,920
19,NCT01754987,Phase Ib/II,Completed,"[{'id': 920, 'therapyName': 'Sorafenib'}]",A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective,920
20,NCT00625378,Phase III,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib Long Term Extension Program (STEP),920
21,NCT02562755,Phase III,Recruiting,"[{'id': 3341, 'therapyName': 'JX-594'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone,920
22,NCT02576509,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 920, 'therapyName': 'Sorafenib'}]",A Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma,920
23,NCT02460991,Phase I,Terminated,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma,920
24,NCT02066181,Phase III,"Active, not recruiting","[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,920
25,NCT02627963,Phase III,"Active, not recruiting","[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1055, 'therapyName': 'Tivozanib'}]",A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC,920
26,NCT02642913,Phase Ib/II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients,920
27,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,920
28,NCT01248247,Phase I,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1098, 'therapyName': 'MK2206 + Selumetinib'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1097, 'therapyName': 'Erlotinib + MK2206'}]",BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study,920
29,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,920
30,NCT02559778,Phase I,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2629, 'therapyName': 'Eflornithine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 717, 'therapyName': 'Dasatinib'}]",Pediatric Precision Laboratory Advanced Neuroblastoma Therapy,920
31,NCT01187199,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 936, 'therapyName': 'Temsirolimus'}]","Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer",920
32,NCT01775501,Phase II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Sorafenib + mFOLFOX for Hepatocellular Carcinoma,920
33,NCT02288507,Phase I,Unknown status,"[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer,920
34,NCT02143726,Phase II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 735, 'therapyName': 'Everolimus'}]","Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Thyroid Cancer",920
35,NCT02575339,Phase Ib/II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1282, 'therapyName': 'Sapanisertib'}]",MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma,920
36,NCT03298451,Phase III,Not yet recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma,920
37,NCT01371981,Phase III,"Active, not recruiting","[{'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2392, 'therapyName': 'Cytarabine + Etoposide'}, {'id': 2393, 'therapyName': 'Cytarabine + Mitoxantrone'}, {'id': 2394, 'therapyName': 'Asparaginase + Cytarabine'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,920
38,NCT02779283,Phase I,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,920
39,NCT01578109,Phase I,"Active, not recruiting","[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia,920
40,NCT01801163,Phase I,Withdrawn,"[{'id': 920, 'therapyName': 'Sorafenib'}]",A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC),920
41,NCT01887717,Phase III,"Active, not recruiting","[{'id': 920, 'therapyName': 'Sorafenib'}]",Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein,920
42,NCT01015833,Phase III,"Active, not recruiting","[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,920
43,NCT02015728,Phase I,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1804, 'therapyName': 'Temozolomide + Etoposide'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors,920
44,NCT01620216,Phase II,Recruiting,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Validation of an in Vitro Assay to Predict Targeted Therapies for Acute Leukemia Patients,920
45,NCT02227914,Phase Ib/II,Withdrawn,"[{'id': 2422, 'therapyName': 'Oprozomib'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,920
0,NCT01871766,Phase II,Recruiting,"[{'id': 1119, 'therapyName': 'Sorafenib + Avastin + Cyclophosphamide'}, {'id': 1436, 'therapyName': 'Vincristine + Dactinomycin'}, {'id': 1435, 'therapyName': 'Vincristine + Dactinomycin + Cyclophosphamide'}]","Treatment of Localized Rhabdomyosarcoma With Chemotherapy, Radiotherapy, and Surgery",1119
1,NCT00665990,Phase I,Completed,"[{'id': 1119, 'therapyName': 'Sorafenib + Avastin + Cyclophosphamide'}]",Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia,1119
0,NCT02196857,Phase II,Recruiting,"[{'id': 1633, 'therapyName': 'Sorafenib + Azacitidine'}]",Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation,1633
0,NCT00538005,Phase Ib/II,Unknown status,"[{'id': 2132, 'therapyName': 'Sorafenib + Bevacizumab + Oxaliplatin'}]","Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma",2132
0,NCT01640665,Phase I,Completed,"[{'id': 2428, 'therapyName': 'Sorafenib + Capecitabine'}]",Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors,2428
1,NCT01471353,Phase II,"Active, not recruiting","[{'id': 2428, 'therapyName': 'Sorafenib + Capecitabine'}]",Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer,2428
0,NCT02323906,Phase Ib/II,Terminated,"[{'id': 2430, 'therapyName': 'Sorafenib + CC-122'}]",Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer,2430
0,NCT02035527,Phase Ib/II,"Active, not recruiting","[{'id': 2431, 'therapyName': 'Sorafenib + Cisplatin + Docetaxel'}]","Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck",2431
0,NCT01194869,Phase II,Terminated,"[{'id': 1534, 'therapyName': 'Sorafenib + Cisplatin + Paclitaxel'}]","Preoperative Clinical Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Triple Negative (ER-, PR-, Her2-)Early Stage Breast Cancer",1534
0,NCT01634893,Phase I,Completed,"[{'id': 1208, 'therapyName': 'Sorafenib + Hydroxychloroquine'}]",Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors,1208
0,NCT02747537,Phase II,Recruiting,"[{'id': 1323, 'therapyName': 'Sorafenib + Irinotecan'}]",Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan,1323
1,NCT01518413,Phase I,Completed,"[{'id': 1323, 'therapyName': 'Sorafenib + Irinotecan'}]",Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors,1323
0,NCT01666756,Phase I,"Active, not recruiting","[{'id': 2387, 'therapyName': 'Sorafenib + KD018'}]",Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer,2387
0,NCT01687673,Phase II,"Active, not recruiting","[{'id': 2388, 'therapyName': 'Sorafenib + Temsirolimus'}]",Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma,2388
0,NCT02292173,Phase I,Recruiting,"[{'id': 2197, 'therapyName': 'Sorafenib + Trametinib'}]",Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer,2197
0,NCT01306058,Phase Ib/II,"Active, not recruiting","[{'id': 2389, 'therapyName': 'Sorafenib + TRC105'}]",Sorafenib and TRC105 in Hepatocellular Cancer,2389
1,NCT02560779,Phase Ib/II,Recruiting,"[{'id': 2389, 'therapyName': 'Sorafenib + TRC105'}]",Trial of TRC105 and Sorafenib in Patients With HCC,2389
0,NCT00764972,Phase Ib/II,Unknown status,"[{'id': 2357, 'therapyName': 'Sorafenib + Vinorelbine'}]",Phase IB/II Trial Combining Vinorelbine With Sorafenib as First-Line Treatment in Patients With Metastatic Breast Cancer,2357
0,NCT01075113,Phase I,"Active, not recruiting","[{'id': 2356, 'therapyName': 'Sorafenib + Vorinostat'}]",Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer,2356
0,NCT03078400,Phase I,Recruiting,"[{'id': 5763, 'therapyName': 'SPL-108'}]",Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer,5763
0,NCT03221400,Phase Ib/II,Recruiting,"[{'id': 4842, 'therapyName': 'STA-8666'}]",PEN-866 in Patients With Advanced Solid Malignancies,4842
0,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,4304
0,NCT02549937,Phase I,Recruiting,"[{'id': 3666, 'therapyName': 'Sulfatinib'}]","A Multi-Center, Open-Label Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors",3666
0,NCT01370109,Phase I,Recruiting,"[{'id': 930, 'therapyName': 'Sunitinib'}]",Cardiovascular Effects of Sunitinib Therapy (CREST),930
1,NCT00843037,Phase II,Completed,"[{'id': 930, 'therapyName': 'Sunitinib'}]",Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma,930
2,NCT02164240,Phase I,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST,930
3,NCT00981890,Phase I,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}]",Stereotactic Radiosurgery With Sunitinib for Brain Metastases,930
4,NCT03141177,Phase III,Recruiting,"[{'id': 2068, 'therapyName': 'Cabozantinib + Ipilimumab + Nivolumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 2067, 'therapyName': 'Cabozantinib + Nivolumab'}]",A Study of Nivolumab Combined With Cabozantinib or Nivolumab and Ipilimumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER),930
5,NCT01396148,Phase II,Completed,"[{'id': 930, 'therapyName': 'Sunitinib'}]",A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor,930
6,NCT01099423,Phase III,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}]",Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer,930
7,NCT02420821,Phase III,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of MPDL3280A (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma,930
8,NCT01164228,Phase II,Recruiting,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery,930
9,NCT00717587,Phase II,Unknown status,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 2129, 'therapyName': 'girentuximab'}, {'id': 2128, 'therapyName': 'motexafin gadolinium'}]",Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer,930
10,NCT02465060,Phase II,Recruiting,"[{'id': 660, 'therapyName': 'AZD9291'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 958, 'therapyName': 'VS-6063'}, {'id': 765, 'therapyName': 'GSK2636771'}]",NCI-MATCH Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,930
11,NCT01984242,Phase II,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) as Monotherapy or in Combination With Avastin (Bevacizumab) Compared to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma,930
12,NCT03091192,Phase III,Recruiting,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 2161, 'therapyName': 'Savolitinib'}]",Savolitinib vs. Sunitinib in MET-driven PRCC,930
13,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,930
14,NCT02315625,Phase II,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery,930
15,NCT02432846,Phase II,Recruiting,"[{'id': 930, 'therapyName': 'Sunitinib'}]",Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC) (MERECA),930
16,NCT01582672,Phase III,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}]",Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC),930
17,NCT01620216,Phase II,Recruiting,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Validation of an in Vitro Assay to Predict Targeted Therapies for Acute Leukemia Patients,930
18,NCT02483247,Phase Ib/II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1945, 'therapyName': 'BBI503'}]",A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer,930
19,NCT00463060,Phase Ib/II,Unknown status,"[{'id': 930, 'therapyName': 'Sunitinib'}]",Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer,930
20,NCT02853331,Phase III,Recruiting,"[{'id': 2494, 'therapyName': 'Axitinib + Pembrolizumab'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426),930
21,NCT03035630,Phase II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma,930
22,NCT01603004,Phase I,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Potential Imaging and Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors,930
23,NCT01829217,Phase II,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}]",Sunitinib in Never-Smokers With Lung Adenocarcinoma,930
24,NCT00747305,Phase I,Terminated,"[{'id': 930, 'therapyName': 'Sunitinib'}]",Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery,930
25,NCT02231749,Phase III,"Active, not recruiting","[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214),930
26,NCT01396408,Phase II,"Active, not recruiting","[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 930, 'therapyName': 'Sunitinib'}]",A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours,930
27,NCT01582204,Phase I,Recruiting,"[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma,930
28,NCT02560012,Phase II,Terminated,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Personalized Targeted Inhibitors Treatment in Renal Cell Cancer,930
29,NCT00702884,Phase II,Completed,"[{'id': 930, 'therapyName': 'Sunitinib'}]",Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer,930
30,NCT02811861,Phase III,Recruiting,"[{'id': 1713, 'therapyName': 'Everolimus + Lenvatinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 4782, 'therapyName': 'Lenvatinib + Pembrolizumab'}]",Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma,930
31,NCT00375674,,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}]", A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer,930
32,NCT01306045,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 816, 'therapyName': 'MK2206'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 913, 'therapyName': 'Selumetinib'}]","Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies",930
33,NCT01499121,Phase II,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}]",Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule,930
34,NCT02693535,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 690, 'therapyName': 'Bosutinib'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer,930
35,NCT03109015,Phase II,Recruiting,"[{'id': 930, 'therapyName': 'Sunitinib'}]",Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing (ASSET),930
36,NCT01026337,Phase I,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}]",Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer,930
37,NCT02068586,Phase II,Recruiting,"[{'id': 1076, 'therapyName': 'Valproic acid'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma,930
38,NCT02060370,Phase II,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}]",Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC),930
39,NCT02761057,Phase II,Recruiting,"[{'id': 2161, 'therapyName': 'Savolitinib'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}]","Cabozantinib-S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer",930
40,NCT01525550,FDA approved,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}]",A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors,930
41,NCT00794950,Phase II,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}]",Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma,930
42,NCT01014065,Phase II,Completed,"[{'id': 930, 'therapyName': 'Sunitinib'}]",A Prospective Study of Acute Cardiovascular Effects of First-line Sunitinib in Metastatic Renal Cell Carcinoma Patients (SUnitinib Prospective CardiovasculaR Effect),930
43,NCT01391962,Phase II,Recruiting,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1001, 'therapyName': 'Cediranib'}]",Sunitinib or Cediranib for Alveolar Soft Part Sarcoma,930
44,NCT02779283,Phase I,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,930
45,NCT02684006,Phase III,Recruiting,"[{'id': 3145, 'therapyName': 'Avelumab + Axitinib'}, {'id': 930, 'therapyName': 'Sunitinib'}]",A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101),930
46,NCT01517243,Phase II,Unknown status,"[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Phase II Study of Alternating Sunitinib and Temsirolimus,930
47,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,930
48,NCT00915993,Phase I,Unknown status,"[{'id': 930, 'therapyName': 'Sunitinib'}]",MRI in Predicting Response to Sunitinib Malate in Patients With Stage IV Kidney Cancer,930
49,NCT01621568,Phase II,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}]",Sunitinib for Advanced Thymus Cancer Following Earlier Treatment,930
0,NCT02074878,Phase I,Terminated,"[{'id': 1962, 'therapyName': 'Sunitinib + Crizotinib'}]",CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer,1962
0,NCT00489944,Phase II,Unknown status,"[{'id': 1963, 'therapyName': 'Sunitinib + Tamoxifen + Cisplatin'}]","Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma",1963
0,NCT02928575,Phase II,Recruiting,"[{'id': 4905, 'therapyName': 'Sunitinib + Temozolomide'}]","Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma",4905
0,NCT02386111,Phase Ib/II,Terminated,"[{'id': 3057, 'therapyName': 'Sunitinib + Varlilumab'}]",A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma,3057
0,NCT03161431,Phase I,Not yet recruiting,"[{'id': 5786, 'therapyName': 'SX-682'}, {'id': 5787, 'therapyName': 'Pembrolizumab + SX-682'}]",SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab,5786
0,NCT03134638,Phase I,Recruiting,"[{'id': 5700, 'therapyName': 'SY-1365'}]",A Phase 1 Study of SY-1365 in Adult Patients With Advanced Solid Tumors,5700
0,NCT02083653,Phase II,"Active, not recruiting","[{'id': 931, 'therapyName': 'SYM004'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer,931
1,NCT02965417,Phase II,Withdrawn,"[{'id': 931, 'therapyName': 'SYM004'}]",Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients,931
2,NCT02540161,Phase II,Recruiting,"[{'id': 931, 'therapyName': 'SYM004'}]",Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma,931
0,NCT02648724,Phase Ib/II,Recruiting,"[{'id': 4322, 'therapyName': 'SYM015'}]",Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies,4322
0,NCT02391727,Phase I,Recruiting,"[{'id': 5330, 'therapyName': 'SYN004'}]","Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid Tumors (SYN004_Ph_1)",5330
0,NCT02073916,Phase I,Recruiting,"[{'id': 1907, 'therapyName': 'T-DM1 + Lapatinib + Abraxane'}]",TDM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer,1907
0,NCT02131064,Phase III,"Active, not recruiting","[{'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}, {'id': 1879, 'therapyName': 'Pertuzumab + Trastuzumab + Carboplatin + Docetaxel'}]",A Study Comparing Kadcyla Plus Perjeta Treatment to Chemotherapy Combined With Herceptin Plus Perjeta in Patients With HER2-Positive Breast Cancer,1492
1,NCT01966471,Phase III,"Active, not recruiting","[{'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}, {'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}]",A Study of Kadcyla (Trastuzumab Emtansine) Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer,1492
2,NCT00781612,Phase II,Recruiting,"[{'id': 5471, 'therapyName': 'Trastuzumab + trastuzumab emtansine'}, {'id': 5470, 'therapyName': 'Paclitaxel + trastuzumab emtansine'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 3930, 'therapyName': 'Docetaxel + T-DM1'}, {'id': 1976, 'therapyName': 'trastuzumab emtansine + Capecitabine'}, {'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}]",A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies,1492
3,NCT02326974,Phase II,Recruiting,"[{'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}]",T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA,1492
4,NCT01042379,Phase II,Recruiting,"[{'id': 1218, 'therapyName': 'Trebananib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 746, 'therapyName': 'Ganitumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1494, 'therapyName': 'MK2206 + Trastuzumab'}, {'id': 1493, 'therapyName': 'Trebananib + Trastuzumab'}, {'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}]",I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer,1492
0,NCT02790515,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation,1843
1,NCT01338987,Phase II,"Active, not recruiting","[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Pilot Study of Lupron to Improve Immune Function After Allogeneic Bone Marrow Transplantation,1843
2,NCT01529827,Phase II,"Active, not recruiting","[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1166, 'therapyName': 'Fludarabine'}]","Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies",1843
3,NCT01701986,Phase Ib/II,Recruiting,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 3992, 'therapyName': 'Busulfan + Clofarabine + Gemcitabine'}]",Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas,1843
4,NCT01203722,Phase Ib/II,Recruiting,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}]","Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies",1843
5,NCT02333162,Phase I,Recruiting,"[{'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}]","Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant",1843
6,NCT01823198,Phase Ib/II,Recruiting,"[{'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1846, 'therapyName': 'Busulfan + Fludarabine + anti-thymocyte globulin'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies,1843
7,NCT02081755,,Recruiting,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 735, 'therapyName': 'Everolimus'}]",Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer,1843
8,NCT01760655,Phase II,Recruiting,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1842, 'therapyName': 'Fludarabine + Thiotepa + Cyclophosphamide'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}]",Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies,1843
9,NCT01256398,Phase II,"Active, not recruiting","[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1824, 'therapyName': 'Vincristine + Methotrexate + Mercaptopurine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,1843
10,NCT02251821,Phase II,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 2006, 'therapyName': 'Pacritinib'}, {'id': 823, 'therapyName': 'Momelotinib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis,1843
11,NCT00513474,Phase I,Completed,"[{'id': 2313, 'therapyName': 'Rasburicase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2314, 'therapyName': 'Busulfan + Cyclophosphamide + Etoposide'}]",Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant,1843
12,NCT01621477,Phase II,Terminated,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}]",T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant,1843
13,NCT00857389,Phase II,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies,1843
14,NCT03247088,Phase Ib/II,Recruiting,"[{'id': 6122, 'therapyName': 'Busulfan + Sorafenib + Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Study Of Sorafenib Added To Busulfan And Fludarabine Conditioning Regimen In Patients With Relapsed/Refractory AML Undergoing Stem Cell Transplantation,1843
15,NCT01790568,Phase II,"Active, not recruiting","[{'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant,1843
16,NCT02508038,Phase I,Recruiting,"[{'id': 2971, 'therapyName': 'Zoledronic acid'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}]", Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa,1843
17,NCT01619761,Phase I,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1847, 'therapyName': 'lenalidomide + Fludarabine + Melphalan'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1843, 'therapyName': 'Tacrolimus'}]",Natural Killer (NK) Cells in Cord Blood Transplantation,1843
0,NCT02440464,Phase II,Recruiting,"[{'id': 3321, 'therapyName': 'Tacrolimus + Methotrexate'}, {'id': 1359, 'therapyName': 'Ixazomib'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302),3321
0,NCT02000934,Phase I,Recruiting,"[{'id': 3146, 'therapyName': 'TAK-659'}]",A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies,3146
1,NCT02551055,Phase I,Terminated,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 626, 'therapyName': 'Alisertib'}, {'id': 3146, 'therapyName': 'TAK-659'}, {'id': 1033, 'therapyName': 'MLN1117'}]","MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma",3146
2,NCT02323113,Phase Ib/II,Recruiting,"[{'id': 3146, 'therapyName': 'TAK-659'}]","Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)",3146
0,NCT03011034,Phase II,Recruiting,"[{'id': 5809, 'therapyName': 'Talacotuzumab'}, {'id': 1630, 'therapyName': 'Daratumumab'}]",Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment,5809
0,NCT01722292,Phase Ib/II,Terminated,"[{'id': 1587, 'therapyName': 'Taladegib'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Study of LY2940680 in Small Cell Lung Cancer,1587
1,NCT02530437,Phase Ib/II,Recruiting,"[{'id': 1587, 'therapyName': 'Taladegib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","A Phase 1B/2 Study of LY2940680 in Combination With Weekly Paclitaxel, Carboplatin, and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction",1587
0,NCT02997176,Phase I,Recruiting,"[{'id': 682, 'therapyName': 'Talazoparib'}]",An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800),682
1,NCT02282345,Phase II,Recruiting,"[{'id': 682, 'therapyName': 'Talazoparib'}]",Neoadjuvant BMN673 for Patients With a BRCA Deleterious Mutation,682
2,NCT02034916,Phase II,"Active, not recruiting","[{'id': 682, 'therapyName': 'Talazoparib'}]","A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)",682
3,NCT02358200,Phase I,"Active, not recruiting","[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 682, 'therapyName': 'Talazoparib'}]",Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer,682
4,NCT01989546,Phase Ib/II,Completed,"[{'id': 682, 'therapyName': 'Talazoparib'}]","Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations",682
5,NCT02326844,Phase II,Terminated,"[{'id': 682, 'therapyName': 'Talazoparib'}]","BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment",682
6,NCT03042910,Phase I,Completed,"[{'id': 682, 'therapyName': 'Talazoparib'}]",A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors,682
7,NCT02401347,Phase II,Recruiting,"[{'id': 682, 'therapyName': 'Talazoparib'}]",Talazoparib Beyond BRCA (TBB) Trial,682
8,NCT02316834,Phase I,"Active, not recruiting","[{'id': 682, 'therapyName': 'Talazoparib'}]",POSITION: A PilOt Study of InducTion PARP InhibitiON in Ovarian Cancer,682
9,NCT03148795,Phase II,Recruiting,"[{'id': 682, 'therapyName': 'Talazoparib'}]",A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer,682
10,NCT02286687,Phase II,"Active, not recruiting","[{'id': 682, 'therapyName': 'Talazoparib'}]",Phase II Study of BMN 673,682
11,NCT02921919,Phase II,Recruiting,"[{'id': 682, 'therapyName': 'Talazoparib'}]",Open-Label Extension and Safety Study of Talazoparib,682
12,NCT02567396,Phase I,Withdrawn,"[{'id': 682, 'therapyName': 'Talazoparib'}]",Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction,682
13,NCT01945775,Phase III,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 682, 'therapyName': 'Talazoparib'}, {'id': 728, 'therapyName': 'Eribulin'}]","A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)",682
14,NCT01286987,Phase I,Completed,"[{'id': 682, 'therapyName': 'Talazoparib'}]","Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors",682
15,NCT02537561,Phase I,Withdrawn,"[{'id': 682, 'therapyName': 'Talazoparib'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors,682
16,NCT02317874,Phase I,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 682, 'therapyName': 'Talazoparib'}]","PARP Inhibitor BMN-673, Carboplatin, and Paclitaxel in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",682
17,NCT02997163,Phase I,Recruiting,"[{'id': 682, 'therapyName': 'Talazoparib'}]",An Open-Label Pharmacokinetics and Safety Study of Talazoparib,682
0,NCT02116777,Phase Ib/II,Recruiting,"[{'id': 1377, 'therapyName': 'Talazoparib + Temozolomide'}]",BMN-673 and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies,1377
1,NCT02049593,Phase I,"Active, not recruiting","[{'id': 1377, 'therapyName': 'Talazoparib + Temozolomide'}, {'id': 1378, 'therapyName': 'Irinotecan + Talazoparib'}]",PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors,1377
0,NCT01740297,Phase Ib/II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2695, 'therapyName': 'talimogene laherparepvec '}]",Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma,2695
1,NCT02263508,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2695, 'therapyName': 'talimogene laherparepvec '}]",MK-3475 With or Without Talimogene Laherparepvec in Unresected Melanoma,2695
0,NCT03088176,Phase I,Recruiting,"[{'id': 5481, 'therapyName': 'talimogene laherparepvec + Dabrafenib + Trametinib'}]",Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma,5481
0,NCT02978625,Phase II,Recruiting,"[{'id': 5080, 'therapyName': 'Talimogene laherparepvec + Nivolumab'}]",Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers,5080
0,NCT02228681,Phase II,"Active, not recruiting","[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 2401, 'therapyName': 'Medroxyprogesterone'}, {'id': 1621, 'therapyName': 'Everolimus + Letrozole'}]",Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer,1456
1,NCT02269670,Phase II,"Active, not recruiting","[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1869, 'therapyName': 'Megestrol'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 633, 'therapyName': 'Anastrozole'}]",Everolimus and Hormone Therapy in Treating Patients With Advanced Hormone Receptor Positive Breast Cancer That Has Progressed or Recurred on Everolimus and Exemestane Therapy,1456
2,NCT02936206,Phase I,Recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Examination of Breast Cancer Cells of Pre-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.,1456
3,NCT00900744,FDA approved,Completed,"[{'id': 1456, 'therapyName': 'Tamoxifen'}]",A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6,1456
4,NCT01272037,Phase III,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}]","Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",1456
5,NCT02204098,Phase I,Recruiting,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]",Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy,1456
6,NCT02384239,Phase II,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]",A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer,1456
7,NCT02476786,Phase II,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}]",Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score,1456
8,NCT03238703,FDA approved,Not yet recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}]","Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer",1456
9,NCT02040857,Phase II,"Active, not recruiting","[{'id': 738, 'therapyName': 'Exemestane'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}]",Palbociclib + Endocrine Therapy for HR + BrCa,1456
10,NCT00492687,Phase II,Unknown status,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]","Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas",1456
11,NCT01674140,Phase III,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}]",S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,1456
12,NCT01293032,Phase I,Completed,"[{'id': 1456, 'therapyName': 'Tamoxifen'}]",Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer,1456
13,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1456
14,NCT02197897,Phase II,Recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}]",Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors,1456
15,NCT02913430,Phase II,Recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Phase II Treatment of Metastatic Breast Cancer With Fulvestrant or Tamoxifen,1456
16,NCT02311933,Phase II,"Active, not recruiting","[{'id': 3076, 'therapyName': 'Z-endoxifen HCl'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]","Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",1456
17,NCT02764541,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]",Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS),1456
18,NCT02630693,Phase II,"Active, not recruiting","[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]","Study Comparing Two Different Schedules of Palbociclib Plus Second Line Endocrine Therapy in Women With Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer",1456
19,NCT02753686,Phase I,Recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 1966, 'therapyName': 'Exemestane + Everolimus'}]",Treatment of Canadian Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy (Treat ER+ight),1456
20,NCT02206984,Phase I,Recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Endocrine Response in Women With Invasive Lobular Breast Cancer,1456
21,NCT02278120,Phase III,"Active, not recruiting","[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 790, 'therapyName': 'Ribociclib'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 633, 'therapyName': 'Anastrozole'}]","Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer",1456
22,NCT01124695,Phase II,Unknown status,"[{'id': 1456, 'therapyName': 'Tamoxifen'}]",Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,1456
23,NCT02993159,Phase II,Recruiting,"[{'id': 5132, 'therapyName': 'Afimoxifene'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]",Tamoxifen Citrate or Afimoxifene in Treating Patients With Estrogen Receptor Positive Breast Cancer,1456
24,NCT01027416,Phase I,Completed,"[{'id': 1456, 'therapyName': 'Tamoxifen'}]",Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients,1456
0,NCT01647828,Phase Ib/II,Completed,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2547, 'therapyName': 'Tarextumab'}]",A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer,2547
1,NCT01859741,Phase Ib/II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2547, 'therapyName': 'Tarextumab'}]",A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Platinum Therapy in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE),2547
0,NCT02855125,Phase II,Recruiting,"[{'id': 1407, 'therapyName': 'TS-1'}, {'id': 4527, 'therapyName': 'TAS-114 + TS-1'}]",A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1,4527
0,NCT02965885,Phase I,Recruiting,"[{'id': 2768, 'therapyName': 'TAS-116'}]",A Study of TAS-116 in Patients With Solid Tumors,2768
0,NCT02134067,Phase I,Recruiting,"[{'id': 1400, 'therapyName': 'TAS-119'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors",1400
1,NCT02448589,Phase I,Recruiting,"[{'id': 1400, 'therapyName': 'TAS-119'}]",An Investigation of TAS-119 Monotherapy and in Combination With Docetaxel,1400
0,NCT02052778,Phase Ib/II,Recruiting,"[{'id': 1053, 'therapyName': 'TAS-120'}]",A Dose Finding Study Followed by a Safety and Efficacy Study in Patients With Advanced Solid Tumors or Multiple Myeloma With FGF/FGFR-Related Abnormalities,1053
0,NCT02566772,Phase I,Recruiting,"[{'id': 4329, 'therapyName': 'TAS3681'}]",Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer,4329
0,NCT02978235,Phase Ib/II,Recruiting,"[{'id': 5897, 'therapyName': 'TAS4464'}]",A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma,5897
0,NCT02396368,Phase I,Withdrawn,"[{'id': 2699, 'therapyName': 'Tasquinimod'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}]",A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer,2699
1,NCT01513733,Phase I,Completed,"[{'id': 2699, 'therapyName': 'Tasquinimod'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}]",The CATCH Prostate Cancer Trial Cabazitaxel And Tasquinimod in Men With Prostate Cancer,2699
2,NCT02159950,Phase II,Completed,"[{'id': 2648, 'therapyName': 'Sipuleucel-T'}, {'id': 2699, 'therapyName': 'Tasquinimod'}]",Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,2699
0,NCT03155620,Phase II,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}, {'id': 2650, 'therapyName': 'LOXO-101'}, {'id': 1069, 'therapyName': 'LY3023414'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 913, 'therapyName': 'Selumetinib'}, {'id': 961, 'therapyName': 'X-396'}]",Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Advanced Refractory Solid Tumors or Lymphomas,2683
1,NCT02601937,Phase I,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}]",A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma,2683
2,NCT02875548,Phase II,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}]",Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study,2683
3,NCT03213665,Phase II,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}]","Pediatric MATCH: Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations",2683
4,NCT02601950,Phase II,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}]","A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma",2683
5,NCT03217253,Phase I,Not yet recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}]",Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction,2683
6,NCT02860286,Phase II,"Active, not recruiting","[{'id': 2683, 'therapyName': 'Tazemetostat'}]",Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma,2683
0,NCT03028103,Phase I,Recruiting,"[{'id': 5267, 'therapyName': 'Tazemetostat + Fluconazole'}, {'id': 5285, 'therapyName': 'Repaglinide + Omeprazole + Tazemetostat'}]","Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, the Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma Subjects",5267
0,NCT02748135,Phase Ib/II,Recruiting,"[{'id': 4704, 'therapyName': 'TB-403'}]",A Two-Part Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma,4704
0,NCT02423057,Phase I,Recruiting,"[{'id': 2907, 'therapyName': 'TdCyd'}]",Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors,2907
0,NCT02314156,Phase II,Recruiting,"[{'id': 2820, 'therapyName': 'Telapristone'}]",Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy,2820
0,NCT02530502,Phase Ib/II,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma,1141
1,NCT01514201,Phase Ib/II,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 954, 'therapyName': 'Veliparib'}]","Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas",1141
2,NCT02311920,Phase I,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Temozolomide in Combination With Ipilimumab and/or Nivolumab in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma,1141
3,NCT02179086,Phase II,Recruiting,"[{'id': 1141, 'therapyName': 'Temozolomide'}]",Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma,1141
4,NCT01800695,Phase I,Completed,"[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 976, 'therapyName': 'ABT-414'}]",Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme,1141
5,NCT01835145,Phase II,"Active, not recruiting","[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye,1141
6,NCT01430351,Phase I,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1784, 'therapyName': 'Memantine'}, {'id': 1031, 'therapyName': 'Metformin'}, {'id': 1785, 'therapyName': 'Mefloquine'}]","Phase I Factorial Trial of Temozolomide, Memantine, Mefloquine, and Metformin for Post-Radiation Therapy (RT) Glioblastoma Multiforme (GBM)",1141
7,NCT02052648,Phase Ib/II,Recruiting,"[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 2976, 'therapyName': 'indoximod'}]",Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors,1141
8,NCT02137759,Phase II,Recruiting,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",MRSI to Predict Response to RT/TMZ and Vorinostat in GBM,1141
9,NCT01638546,Phase II,Completed,"[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 954, 'therapyName': 'Veliparib'}]",Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer,1141
10,NCT02366728,,Recruiting,"[{'id': 5985, 'therapyName': 'Basiliximab'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",DC Migration Study for Newly-Diagnosed GBM,1141
11,NCT02392793,Phase I,Recruiting,"[{'id': 1378, 'therapyName': 'Irinotecan + Talazoparib'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies,1141
12,NCT02510950,Phase I,Recruiting,"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma,1141
13,NCT02023905,Phase II,Recruiting,"[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 735, 'therapyName': 'Everolimus'}]",Everolimus With and Without Temozolomide in Adult Low Grade Glioma,1141
14,NCT02446704,Phase Ib/II,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy,1141
15,NCT02977780,Phase II,Recruiting,"[{'id': 1000, 'therapyName': 'CC-115'}, {'id': 5028, 'therapyName': 'Abemaciclib + Temozolomide'}, {'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 5029, 'therapyName': 'Neratinib + Temozolomide'}]",INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT),1141
16,NCT01409174,Phase Ib/II,Terminated,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1299, 'therapyName': 'Interferon alfa-2b '}]",IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma,1141
17,NCT02152982,Phase II,Suspended,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,1141
18,NCT02573324,Phase II,Recruiting,"[{'id': 976, 'therapyName': 'ABT-414'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification,1141
19,NCT01790503,Phase Ib/II,"Active, not recruiting","[{'id': 874, 'therapyName': 'PLX3397'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma,1141
20,NCT02617589,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1141, 'therapyName': 'Temozolomide'}]","Study of Nivolumab Versus Temozolomide, Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate 498)",1141
21,NCT02667587,Phase II,Recruiting,"[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 3724, 'therapyName': 'Nivolumab + Temozolomide'}]","Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer).",1141
22,NCT00492687,Phase II,Unknown status,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]","Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas",1141
23,NCT02414165,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 3211, 'therapyName': 'Toca 511 + Toca FC'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA (Toca5),1141
24,NCT02502708,Phase I,Recruiting,"[{'id': 2976, 'therapyName': 'indoximod'}, {'id': 1141, 'therapyName': 'Temozolomide'}]","Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Primary Malignant Brain Tumors",1141
25,NCT02315534,Phase Ib/II,Recruiting,"[{'id': 2057, 'therapyName': 'BBI608'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma,1141
26,NCT02340156,Phase II,Recruiting,"[{'id': 2518, 'therapyName': 'SGT-53'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma,1141
27,NCT02655601,Phase Ib/II,Recruiting,"[{'id': 5841, 'therapyName': 'BMX-001 + Temozolomide'}, {'id': 1141, 'therapyName': 'Temozolomide'}]","Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001",1141
28,NCT01977677,Phase Ib/II,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1756, 'therapyName': 'Plerixafor'}]",Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma,1141
29,NCT01390948,Phase II,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",A Study of Avastin (Bevacizumab) in Combination With Temolozomide (TMZ) and Radiotherapy in Paediatric and Adolescent Patients With High-Grade Glioma,1141
30,NCT02343406,Phase II,Recruiting,"[{'id': 2075, 'therapyName': 'Lomustine'}, {'id': 976, 'therapyName': 'ABT-414'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma,1141
31,NCT02010606,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma,1141
0,NCT02015728,Phase I,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1804, 'therapyName': 'Temozolomide + Etoposide'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors,1804
0,NCT02203526,Phase I,Suspended,"[{'id': 1607, 'therapyName': 'Temozolomide + Etoposide + Doxil + Dexamethasone + Ibrutinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 897, 'therapyName': 'Rituximab'}]","Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma",1607
0,NCT01217437,Phase II,"Active, not recruiting","[{'id': 1462, 'therapyName': 'Temozolomide + Irinotecan'}, {'id': 1463, 'therapyName': 'Temozolomide + Irinotecan + Bevacizumab'}]",Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors,1462
1,NCT01767194,Phase II,Suspended,"[{'id': 2286, 'therapyName': 'Dinutuximab  '}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1462, 'therapyName': 'Temozolomide + Irinotecan'}]",Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Monoclonal Antibody Ch14.18 in Treating Younger Patients With Refractory or Relapsed Neuroblastoma,1462
0,NCT01189643,Phase I,"Active, not recruiting","[{'id': 1463, 'therapyName': 'Temozolomide + Irinotecan + Bevacizumab'}]","Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor",1463
1,NCT00876993,Phase I,Completed,"[{'id': 1463, 'therapyName': 'Temozolomide + Irinotecan + Bevacizumab'}]",Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors,1463
2,NCT01217437,Phase II,"Active, not recruiting","[{'id': 1462, 'therapyName': 'Temozolomide + Irinotecan'}, {'id': 1463, 'therapyName': 'Temozolomide + Irinotecan + Bevacizumab'}]",Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors,1463
0,NCT02942264,Phase Ib/II,Recruiting,"[{'id': 5836, 'therapyName': 'TG02'}, {'id': 5851, 'therapyName': 'Temozolomide + TG02'}]",TG02 Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of TG02 Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma,5851
0,NCT03190967,Phase Ib/II,Recruiting,"[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 5932, 'therapyName': 'Temozolomide + Trastuzumab emtansine'}]",T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery,5932
0,NCT01087554,Phase I,"Active, not recruiting","[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer,936
1,NCT01396408,Phase II,"Active, not recruiting","[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 930, 'therapyName': 'Sunitinib'}]",A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours,936
2,NCT02423954,Phase Ib/II,"Active, not recruiting","[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus),936
3,NCT02420613,Phase I,Recruiting,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 936, 'therapyName': 'Temsirolimus'}]",Study of Suberoylanilide Hydroxamic Acid (SAHA) With Temsirolimus in Children With Diffuse Intrinsic Pontine Glioma (DIPG),936
4,NCT02446431,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1076, 'therapyName': 'Valproic acid'}]",Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence,936
5,NCT01517243,Phase II,Unknown status,"[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Phase II Study of Alternating Sunitinib and Temsirolimus,936
6,NCT02693535,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 690, 'therapyName': 'Bosutinib'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer,936
7,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,936
8,NCT01392183,Phase II,"Active, not recruiting","[{'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC),936
9,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,936
10,NCT02560012,Phase II,Terminated,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Personalized Targeted Inhibitors Treatment in Renal Cell Cancer,936
11,NCT01180049,FDA approved,"Active, not recruiting","[{'id': 936, 'therapyName': 'Temsirolimus'}]",Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma,936
12,NCT01614197,Phase I,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma,936
13,NCT02567435,Phase III,Suspended,"[{'id': 1435, 'therapyName': 'Vincristine + Dactinomycin + Cyclophosphamide'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Combination Chemotherapy and Irinotecan Hydrochloride or Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma,936
14,NCT01767194,Phase II,Suspended,"[{'id': 2286, 'therapyName': 'Dinutuximab  '}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1462, 'therapyName': 'Temozolomide + Irinotecan'}]",Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Monoclonal Antibody Ch14.18 in Treating Younger Patients With Refractory or Relapsed Neuroblastoma,936
15,NCT00838955,Phase II,Unknown status,"[{'id': 936, 'therapyName': 'Temsirolimus'}]",Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma,936
16,NCT01567930,Phase II,Unknown status,"[{'id': 936, 'therapyName': 'Temsirolimus'}]",Temsirolimus as Second-line Therapy in HCC,936
17,NCT01187199,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 936, 'therapyName': 'Temsirolimus'}]","Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer",936
18,NCT02456857,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 936, 'therapyName': 'Temsirolimus'}]","Liposomal Doxorubicin, Bevacizumab and Temsirolimus (DAT) in Triple-Negative Breast Cancer (TNBC) Insensitive to Standard Neoadjuvant Chemotherapy",936
0,NCT01552434,Phase I,Recruiting,"[{'id': 1376, 'therapyName': 'Temsirolimus + Bevacizumab + Valproic Acid + Cetuximab'}]","Bevacizumab, Temsirolimus, Valproic Acid, Cetuximab",1376
0,NCT01076543,Phase Ib/II,"Active, not recruiting","[{'id': 2280, 'therapyName': 'Temsirolimus + Lenalidomide'}]",Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma,2280
0,NCT01529593,Phase I,Recruiting,"[{'id': 1325, 'therapyName': 'Temsirolimus + Metformin'}]",Temsirolimus in Combination With Metformin in Patients With Advanced Cancers,1325
0,NCT01111825,Phase Ib/II,Completed,"[{'id': 1527, 'therapyName': 'Temsirolimus + Neratinib'}]",Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer,1527
0,NCT02343718,Phase I,"Active, not recruiting","[{'id': 2492, 'therapyName': 'Temsirolimus + Vinblastine'}]",Vinblastine and Temsirolimus in Pediatric Patients With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours,2492
0,NCT01174199,Phase I,Terminated,"[{'id': 2263, 'therapyName': 'Temsirolimus + vorinostat'}]",Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer,2263
0,NCT01987362,Phase I,"Active, not recruiting","[{'id': 937, 'therapyName': 'TEN-010'}]","A Two Part, Multicenter, Open-label Study of TEN-010 Given Subcutaneously",937
1,NCT03068351,Phase I,Recruiting,"[{'id': 937, 'therapyName': 'TEN-010'}, {'id': 5957, 'therapyName': 'Daratumumab + TEN-010'}]",Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma,937
2,NCT02308761,Phase I,Recruiting,"[{'id': 937, 'therapyName': 'TEN-010'}]",A Dose Escalation and Cohort Expansion Study of TEN-010 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome,937
0,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,4305
0,NCT01837329,Phase I,Recruiting,"[{'id': 3147, 'therapyName': 'Tetrathiomolybdate'}]",Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer,3147
0,NCT02160106,Phase I,Recruiting,"[{'id': 3011, 'therapyName': 'TEW 7197'}]",First in Human Dose Escalation Study of TEW-7197 in Subjects With Advanced Stage Solid Tumors,3011
1,NCT03074006,Phase Ib/II,Not yet recruiting,"[{'id': 3011, 'therapyName': 'TEW 7197'}]",Dose Escalation and Proof-of-Concept Studies of TEW-7197 Monotherapy in Patients With Myelodysplastic Syndrome (MDS),3011
0,NCT02104427,Phase II,Completed,"[{'id': 2853, 'therapyName': 'TG-0054'}, {'id': 1632, 'therapyName': 'Filgrastim'}]","PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients",2853
0,NCT02942264,Phase Ib/II,Recruiting,"[{'id': 5836, 'therapyName': 'TG02'}, {'id': 5851, 'therapyName': 'Temozolomide + TG02'}]",TG02 Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of TG02 Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma,5836
0,NCT02793583,Phase II,Recruiting,"[{'id': 2022, 'therapyName': 'TGR-1202'}, {'id': 2319, 'therapyName': 'TGR-1202 + Ublituximab'}]",Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients With Previously Treated Diffuse Large B-Cell Lymphoma (UNITY-DLBCL),2022
1,NCT01767766,Phase I,"Active, not recruiting","[{'id': 2022, 'therapyName': 'TGR-1202'}]",Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies,2022
2,NCT02742090,Phase II,Recruiting,"[{'id': 2022, 'therapyName': 'TGR-1202'}]",Evaluate the Efficacy and Safety of TGR-1202 in Patients With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy,2022
3,NCT02164006,Phase I,"Active, not recruiting","[{'id': 2022, 'therapyName': 'TGR-1202'}]","Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients",2022
4,NCT02612311,Phase III,Recruiting,"[{'id': 2287, 'therapyName': 'Ublituximab'}, {'id': 1648, 'therapyName': 'Obinutuzumab + Chlorambucil'}, {'id': 2022, 'therapyName': 'TGR-1202'}]",Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia,2022
5,NCT03178201,Phase II,Recruiting,"[{'id': 2022, 'therapyName': 'TGR-1202'}]",TGR1202 in Relapsed and Refractory Follicular Lymphoma,2022
6,NCT02574663,Phase I,"Active, not recruiting","[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2022, 'therapyName': 'TGR-1202'}]",TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors,2022
0,NCT02006485,Phase I,Recruiting,"[{'id': 2319, 'therapyName': 'TGR-1202 + Ublituximab'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",Ublituximab in Combination With TGR-1202 in Patients With B-cell Malignancies,2319
1,NCT02793583,Phase II,Recruiting,"[{'id': 2022, 'therapyName': 'TGR-1202'}, {'id': 2319, 'therapyName': 'TGR-1202 + Ublituximab'}]",Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients With Previously Treated Diffuse Large B-Cell Lymphoma (UNITY-DLBCL),2319
2,NCT02656303,Phase II,Recruiting,"[{'id': 2319, 'therapyName': 'TGR-1202 + Ublituximab'}]",An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304,2319
0,NCT02449681,Phase II,Terminated,"[{'id': 2910, 'therapyName': 'TH-4000'}]",Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS,2910
1,NCT02454842,Phase II,Terminated,"[{'id': 2910, 'therapyName': 'TH-4000'}]","Study for Treatment of Patients With EGFR Mutant, T790M-negative NSCLC",2910
0,NCT01356290,Phase II,Recruiting,"[{'id': 1475, 'therapyName': 'Thalidomide'}, {'id': 4418, 'therapyName': 'Fenofibrate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2124, 'therapyName': 'Celecoxib'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}]",Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma (MEMMAT),1475
1,NCT01998971,Phase I,Recruiting,"[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1475, 'therapyName': 'Thalidomide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 3323, 'therapyName': 'Montelukast'}]",A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma,1475
2,NCT01661400,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors,1475
3,NCT03004287,Phase II,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy,1475
0,NCT00826085,Phase Ib/II,Completed,"[{'id': 1054, 'therapyName': 'ThermoDox'}]",Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall,1054
0,NCT00550992,Phase I,Unknown status,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia,1641
1,NCT02112916,Phase III,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,1641
2,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1641
3,NCT02883049,Phase III,Suspended,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations,1641
4,NCT00549848,Phase III,"Active, not recruiting","[{'id': 1781, 'therapyName': 'Vincristine + Pegaspargase + Daunorubicin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1782, 'therapyName': 'Clofarabine + Etoposide + Cyclophosphamide'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia,1641
5,NCT03007147,Phase III,Recruiting,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 5167, 'therapyName': 'Methylprednisolone'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 5168, 'therapyName': 'Prednisolone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,1641
6,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,1641
7,NCT03150693,Phase III,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 3628, 'therapyName': 'Allopurinol'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]",Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia,1641
8,NCT02521493,Phase III,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 5912, 'therapyName': 'Asparaginase Erwinia chrysanthemi'}, {'id': 5215, 'therapyName': 'mitoxantrone hydrochloride'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2206, 'therapyName': 'Asparaginase'}]",Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome,1641
0,NCT02653196,Phase II,Terminated,"[{'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 3948, 'therapyName': 'Cyclosporine + Mycophenolate mofetil + Tacrolimus'}]",A Multi-Institutional Phase II Feasibility Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors,2563
1,NCT03126916,Phase III,Not yet recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 5595, 'therapyName': 'Isotretinoin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 2286, 'therapyName': 'Dinutuximab  '}]",Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma,2563
2,NCT02790515,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation,2563
3,NCT00857389,Phase II,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies,2563
4,NCT00621036,Phase II,Unknown status,"[{'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1873, 'therapyName': 'Sargramostim'}]",Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma,2563
5,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,2563
6,NCT01505569,Phase I,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2101, 'therapyName': 'Etoposide + Ifosfamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Auto Transplant for High Risk or Relapsed Solid or CNS Tumors,2563
7,NCT01746849,Phase II,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 2373, 'therapyName': 'Palifermin'}]",Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation,2563
0,NCT01664000,Phase I,Completed,"[{'id': 2999, 'therapyName': 'thioureidobutyronitrile'}]","A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors",2999
1,NCT03042702,Phase II,Recruiting,"[{'id': 2999, 'therapyName': 'thioureidobutyronitrile'}]",A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer,2999
0,NCT00006199,Phase I,Unknown status,"[{'id': 938, 'therapyName': 'Tipifarnib'}, {'id': 942, 'therapyName': 'Topotecan'}]","Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32)",938
1,NCT02807272,Phase II,Recruiting,"[{'id': 938, 'therapyName': 'Tipifarnib'}]",Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia (CMML),938
2,NCT02383927,Phase II,Recruiting,"[{'id': 938, 'therapyName': 'Tipifarnib'}]",Phase II Study of Tipifarnib in Advanced Cancers With HRAS Mutations,938
3,NCT02464228,Phase II,Recruiting,"[{'id': 938, 'therapyName': 'Tipifarnib'}]",Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma,938
4,NCT02779777,Phase II,Recruiting,"[{'id': 938, 'therapyName': 'Tipifarnib'}]","Tipifarnib in Subjects With Transfusion-dependent, Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes",938
0,NCT02174549,Phase I,Recruiting,"[{'id': 3028, 'therapyName': 'tirapazamine'}]",Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer,3028
1,NCT03145558,Phase II,Not yet recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 3028, 'therapyName': 'tirapazamine'}]",TATE Versus TACE in Intermediate Stage HCC (TATE),3028
0,NCT03123939,Phase II,Available,"[{'id': 5981, 'therapyName': 'Tisagenlecleucel'}]",Expanded Treatment Protocol in Acute Lymphoblastic Leukemia,5981
1,NCT02435849,Phase II,Recruiting,"[{'id': 5981, 'therapyName': 'Tisagenlecleucel'}]",Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL (ELIANA),5981
2,NCT02445248,Phase II,Recruiting,"[{'id': 5981, 'therapyName': 'Tisagenlecleucel'}]",Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients (JULIET),5981
3,NCT02228096,Phase II,Recruiting,"[{'id': 5981, 'therapyName': 'Tisagenlecleucel'}]",Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients,5981
0,NCT03245736,Phase II,Recruiting,"[{'id': 6113, 'therapyName': 'Tisotumab Vedotin'}]",Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.,6113
0,NCT02150733,Phase I,Completed,"[{'id': 636, 'therapyName': 'Tivantinib'}]",Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment,636
1,NCT01468922,Phase I,Completed,"[{'id': 636, 'therapyName': 'Tivantinib'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib and ARQ 197 for Advanced Solid Tumors,636
2,NCT01755767,Phase III,Completed,"[{'id': 636, 'therapyName': 'Tivantinib'}]",Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma Who Have Been Treated With One Prior Therapy,636
0,NCT01625156,Phase I,Completed,"[{'id': 1200, 'therapyName': 'Tivantinib + Temsirolimus'}]",Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed By Surgery,1200
0,NCT01654965,Phase I,"Active, not recruiting","[{'id': 1477, 'therapyName': 'Tivantinib + Topotecan + Pegfilgrastim'}]",Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors,1477
0,NCT01835223,Phase Ib/II,"Active, not recruiting","[{'id': 1055, 'therapyName': 'Tivozanib'}]",Tivozanib in Treating Patients With Liver Cancer That is Metastatic or Cannot Be Removed by Surgery,1055
1,NCT02627963,Phase III,"Active, not recruiting","[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1055, 'therapyName': 'Tivozanib'}]",A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC,1055
2,NCT01972516,Phase II,Terminated,"[{'id': 1055, 'therapyName': 'Tivozanib'}]",Tivozanib As Maintenance Therapy In GYN,1055
3,NCT01853644,Phase II,Recruiting,"[{'id': 1055, 'therapyName': 'Tivozanib'}]","Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer",1055
0,NCT02657005,Phase I,Recruiting,"[{'id': 4314, 'therapyName': 'TK216'}]",TK216 in Patients With Relapsed or Refractory Ewing Sarcoma,4314
0,NCT01985256,Phase I,"Active, not recruiting","[{'id': 3209, 'therapyName': 'Toca 511'}]",Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor,3209
0,NCT02414165,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 3211, 'therapyName': 'Toca 511 + Toca FC'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA (Toca5),3211
1,NCT02576665,Phase I,Recruiting,"[{'id': 3211, 'therapyName': 'Toca 511 + Toca FC'}]","A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6)",3211
2,NCT01156584,Phase I,"Active, not recruiting","[{'id': 3211, 'therapyName': 'Toca 511 + Toca FC'}]",A Study of a Retroviral Replicating Vector Administered to Subjects With Recurrent Malignant Glioma,3211
0,NCT02906371,Phase I,Recruiting,"[{'id': 5647, 'therapyName': 'Tocilizumab'}]",Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome,5647
1,NCT02057770,Phase I,Recruiting,"[{'id': 5724, 'therapyName': 'Busulfan + Fludarabine phosphate + Cyclophosphamide'}, {'id': 5647, 'therapyName': 'Tocilizumab'}]",Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,5647
0,NCT02487095,Phase Ib/II,Recruiting,"[{'id': 2879, 'therapyName': 'VX-970'}, {'id': 942, 'therapyName': 'Topotecan'}]","Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer",942
1,NCT02502266,Phase II,Suspended,"[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1001, 'therapyName': 'Cediranib'}]","Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",942
2,NCT03061812,Phase III,Recruiting,"[{'id': 3544, 'therapyName': 'Rovalpituzumab Tesirine'}, {'id': 942, 'therapyName': 'Topotecan'}]",Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE) (TAHOE),942
3,NCT02200757,Phase II,Recruiting,"[{'id': 1440, 'therapyName': 'Aldoxorubicin'}, {'id': 942, 'therapyName': 'Topotecan'}]",Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer,942
4,NCT02114229,Phase II,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2449, 'therapyName': 'Methotrexate + Cisplatin + Cyclophosphamide + Vincristine'}, {'id': 626, 'therapyName': 'Alisertib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 942, 'therapyName': 'Topotecan'}]",Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors,942
5,NCT02101788,Phase II,Recruiting,"[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 2173, 'therapyName': 'Doxil + Letrozole + Tamoxifen + Paclitaxel'}, {'id': 2, 'therapyName': 'Trametinib'}]",Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,942
6,NCT02312245,Phase II,Recruiting,"[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",942
7,NCT02631876,Phase II,Recruiting,"[{'id': 3574, 'therapyName': 'Doxil + Paclitaxel'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3232, 'therapyName': 'IMGN853'}]","PH2 Study of IMGN853 vs Investigator's Choice of Chemo in Adults With FRa+ Adv. EOC, Primary Peritoneal or Primary Fallopian Tube Cancer",942
8,NCT02514447,Phase Ib/II,Recruiting,"[{'id': 3074, 'therapyName': 'Trilaciclib'}, {'id': 942, 'therapyName': 'Topotecan'}]",Study of G1T28 in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy,942
9,NCT00006199,Phase I,Unknown status,"[{'id': 938, 'therapyName': 'Tipifarnib'}, {'id': 942, 'therapyName': 'Topotecan'}]","Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32)",942
10,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,942
11,NCT03257267,Phase III,Recruiting,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 5656, 'therapyName': 'REGN2810'}, {'id': 942, 'therapyName': 'Topotecan'}]",Study of REGN2810 in Adults With Cervical Cancer,942
12,NCT02419495,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Selinexor in Combination With Standard Chemotherapy,942
13,NCT03126916,Phase III,Not yet recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 5595, 'therapyName': 'Isotretinoin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 2286, 'therapyName': 'Dinutuximab  '}]",Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma,942
14,NCT02481830,Phase III,"Active, not recruiting","[{'id': 2951, 'therapyName': 'Amrubicin'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 942, 'therapyName': 'Topotecan'}]",Efficacy Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer,942
15,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,942
0,NCT00800345,Phase I,Completed,"[{'id': 1469, 'therapyName': 'Topotecan + Pazopanib'}]",Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors,1469
1,NCT02303028,Phase Ib/II,Recruiting,"[{'id': 1469, 'therapyName': 'Topotecan + Pazopanib'}]",Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid and CNS Tumours,1469
2,NCT02357810,Phase II,Recruiting,"[{'id': 1469, 'therapyName': 'Topotecan + Pazopanib'}]",Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas,1469
3,NCT02348398,Phase II,Withdrawn,"[{'id': 1469, 'therapyName': 'Topotecan + Pazopanib'}]",Phase II Study of Pazopanib and Topotecan in Cervical Cancer,1469
4,NCT01931098,Phase II,Not yet recruiting,"[{'id': 1469, 'therapyName': 'Topotecan + Pazopanib'}]",Phase II Pazopanib Plus Topotecan for Recurrent Glioblastoma Multiforme (GBM),1469
0,NCT01683149,Phase I,Completed,"[{'id': 1228, 'therapyName': 'Topotecan + Sorafenib'}]", Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies,1228
0,NCT03238703,FDA approved,Not yet recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}]","Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer",4419
1,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,4419
0,NCT02729298,Phase I,Recruiting,"[{'id': 3826, 'therapyName': 'TP-0903'}]",First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors,3826
0,NCT01933815,Phase Ib/II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2274, 'therapyName': 'TPI 287'}]",Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma,2274
0,NCT03093116,Phase Ib/II,Recruiting,"[{'id': 3950, 'therapyName': 'TPX-0005'}]","A Study of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements",3950
0,NCT03056599,,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1733, 'therapyName': 'interferon gamma '}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 3420, 'therapyName': 'trabectedin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma,3420
0,NCT03138161,Phase Ib/II,Recruiting,"[{'id': 5800, 'therapyName': 'trabectedin + Ipilimumab + Nivolumab'}]","Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma",5800
0,NCT02257424,Phase Ib/II,Recruiting,"[{'id': 2, 'therapyName': 'Trametinib'}]","The BAMM Trial: BRAF, Autophagy and MEK Inhibition in Metastatic Melanoma: A Phase I/2 Trial of Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma",2
1,NCT01902173,Phase Ib/II,Suspended,"[{'id': 2, 'therapyName': 'Trametinib'}, {'id': 2200, 'therapyName': 'Dabrafenib + GSK2141795'}]","GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer",2
2,NCT02465060,Phase II,Recruiting,"[{'id': 660, 'therapyName': 'AZD9291'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 958, 'therapyName': 'VS-6063'}, {'id': 765, 'therapyName': 'GSK2636771'}]",NCI-MATCH Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,2
3,NCT02580708,Phase Ib/II,Completed,"[{'id': 2, 'therapyName': 'Trametinib'}, {'id': 1003, 'therapyName': 'CO1686'}]",A Phase 1/2 Study of the Safety and Efficacy of Rociletinib When Administered in Combination With Trametinib in Patients With Activating EGFR Mutation-positive Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC),2
4,NCT02780128,Phase I,Recruiting,"[{'id': 2186, 'therapyName': 'HDM201'}, {'id': 2638, 'therapyName': 'Ceritinib + LEE011'}, {'id': 2, 'therapyName': 'Trametinib'}]",Next Generation Personalized Neuroblastoma Therapy,2
5,NCT03091257,Phase I,Recruiting,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 2, 'therapyName': 'Trametinib'}]",A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma,2
6,NCT02101788,Phase II,Recruiting,"[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 2173, 'therapyName': 'Doxil + Letrozole + Tamoxifen + Paclitaxel'}, {'id': 2, 'therapyName': 'Trametinib'}]",Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,2
7,NCT02881242,Phase II,Not yet recruiting,"[{'id': 2, 'therapyName': 'Trametinib'}]",Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer,2
8,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,2
9,NCT01979523,Phase II,"Active, not recruiting","[{'id': 2, 'therapyName': 'Trametinib'}, {'id': 1298, 'therapyName': 'Trametinib + GSK2141795'}]",Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma,2
10,NCT02296112,Phase II,Recruiting,"[{'id': 2, 'therapyName': 'Trametinib'}]",Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations,2
11,NCT01935973,Phase II,"Active, not recruiting","[{'id': 2, 'therapyName': 'Trametinib'}, {'id': 1298, 'therapyName': 'Trametinib + GSK2141795'}]",Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer,2
12,NCT02015117,Phase I,"Active, not recruiting","[{'id': 2, 'therapyName': 'Trametinib'}]",Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases,2
13,NCT02070549,Phase I,Recruiting,"[{'id': 2, 'therapyName': 'Trametinib'}]",Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction,2
14,NCT02152995,Phase II,Recruiting,"[{'id': 2, 'therapyName': 'Trametinib'}]",Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer,2
15,NCT01231594,Phase I,Recruiting,"[{'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 2, 'therapyName': 'Trametinib'}]",A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors,2
16,NCT03148275,Phase II,Recruiting,"[{'id': 2, 'therapyName': 'Trametinib'}]","Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That Is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery",2
17,NCT02042443,Phase II,Completed,"[{'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 2, 'therapyName': 'Trametinib'}]",Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery,2
18,NCT02124772,Phase I,Recruiting,"[{'id': 2, 'therapyName': 'Trametinib'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]","Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations",2
19,NCT02016729,Phase I,Completed,"[{'id': 2, 'therapyName': 'Trametinib'}, {'id': 1452, 'therapyName': 'AMG 232'}]",A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia,2
20,NCT03087071,Phase II,Not yet recruiting,"[{'id': 845, 'therapyName': 'Panitumumab'}, {'id': 2, 'therapyName': 'Trametinib'}]",Panitumumab in Combination With Trametinib in Cetuximab-Refractory Stage IV Colorectal Cancer,2
21,NCT01940809,Phase II,Recruiting,"[{'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 779, 'therapyName': 'Ipilimumab'}]","Ipilimumab With or Without Dabrafenib, and/or Trametinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery",2
22,NCT02140840,Phase II,Withdrawn,"[{'id': 2, 'therapyName': 'Trametinib'}]","A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib",2
23,NCT01553851,Phase II,Completed,"[{'id': 2, 'therapyName': 'Trametinib'}]",GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer,2
24,NCT01827384,Phase II,Recruiting,"[{'id': 1194, 'therapyName': 'MK-1775 + Carboplatin '}, {'id': 1193, 'therapyName': 'Veliparib + Temozolomide'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 2, 'therapyName': 'Trametinib'}]",Molecular Profiling-Based Targeted Therapy in Treating Patients With Advanced Solid Tumors,2
25,NCT03190915,Phase II,Recruiting,"[{'id': 2, 'therapyName': 'Trametinib'}]",Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia,2
26,NCT02705963,Phase I,Recruiting,"[{'id': 2, 'therapyName': 'Trametinib'}]",A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors,2
27,NCT01376310,Phase II,"Active, not recruiting","[{'id': 1264, 'therapyName': 'Docetaxel + Trametinib'}, {'id': 1265, 'therapyName': 'Erlotinib + Trametinib'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 1266, 'therapyName': 'Pemetrexed + GSK1120212'}, {'id': 1267, 'therapyName': 'Carboplatin + GSK1120212'}, {'id': 1268, 'therapyName': 'nab-paclitaxel + GSK1120212'}, {'id': 1269, 'therapyName': 'Gemcitabine + GSK1120212'}, {'id': 1271, 'therapyName': 'Everolimus + GSK1120212'}]",GSK1120212 Rollover Study,2
28,NCT01990196,Phase II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 1815, 'therapyName': 'Degarelix + Enzalutamide'}]",Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer,2
29,NCT01725100,Phase I,Completed,"[{'id': 2, 'therapyName': 'Trametinib'}]","A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies",2
30,NCT01467310,Phase I,Completed,"[{'id': 2, 'therapyName': 'Trametinib'}]",Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,2
31,NCT01658553,Phase I,Completed,"[{'id': 2, 'therapyName': 'Trametinib'}]"," A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212",2
0,NCT01726738,Phase II,"Active, not recruiting","[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations,1066
1,NCT01989585,Phase Ib/II,Recruiting,"[{'id': 1303, 'therapyName': 'Trametinib + Dabrafenib + Navitoclax'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]","Dabrafenib, Trametinib, and Navitoclax in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by Surgery",1066
2,NCT03091257,Phase I,Recruiting,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 2, 'therapyName': 'Trametinib'}]",A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma,1066
3,NCT02974803,Phase II,Not yet recruiting,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Concurrent Dabrafenib and Trametinib With Sterotactic Radiation in Patients With BRAF Mutation-Positive Malignant Melanoma and Brain Metastases,1066
4,NCT02224781,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma,1066
5,NCT01336634,Phase II,"Active, not recruiting","[{'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.,1066
6,NCT02196181,Phase II,Recruiting,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,1066
7,NCT01701037,Phase II,Terminated,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}, {'id': 3, 'therapyName': 'Dabrafenib'}]", Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery,1066
8,NCT02039947,Phase II,"Active, not recruiting","[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain,1066
9,NCT02231775,Phase II,Recruiting,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Combi-Neo Study for Stage IV Melanoma,1066
10,NCT01978236,Phase II,Completed,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}, {'id': 3, 'therapyName': 'Dabrafenib'}]","Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites",1066
11,NCT02124772,Phase I,Recruiting,"[{'id': 2, 'therapyName': 'Trametinib'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]","Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations",1066
12,NCT01723202,Phase II,"Active, not recruiting","[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}, {'id': 3, 'therapyName': 'Dabrafenib'}]",Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer,1066
13,NCT02110355,Phase Ib/II,Recruiting,"[{'id': 1454, 'therapyName': 'AMG 232 + Trametinib'}, {'id': 1453, 'therapyName': 'AMG 232 + Trametinib + Dabrafenib'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma,1066
14,NCT01682083,Phase III,"Active, not recruiting","[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]", A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection.,1066
15,NCT02967692,Phase III,Recruiting,"[{'id': 6023, 'therapyName': 'Dabrafenib + Trametinib + PDR001'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]","A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma",1066
16,NCT02034110,Phase II,Recruiting,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers,1066
0,NCT01989585,Phase Ib/II,Recruiting,"[{'id': 1303, 'therapyName': 'Trametinib + Dabrafenib + Navitoclax'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]","Dabrafenib, Trametinib, and Navitoclax in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by Surgery",1303
0,NCT02138292,Phase I,"Active, not recruiting","[{'id': 1446, 'therapyName': 'Trametinib + Digoxin'}]",A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma,1446
0,NCT01740648,Phase I,"Active, not recruiting","[{'id': 1113, 'therapyName': 'Trametinib + Fluorouracil'}]","Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer",1113
0,NCT01979523,Phase II,"Active, not recruiting","[{'id': 2, 'therapyName': 'Trametinib'}, {'id': 1298, 'therapyName': 'Trametinib + GSK2141795'}]",Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma,1298
1,NCT01935973,Phase II,"Active, not recruiting","[{'id': 2, 'therapyName': 'Trametinib'}, {'id': 1298, 'therapyName': 'Trametinib + GSK2141795'}]",Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer,1298
2,NCT01989598,Phase II,"Active, not recruiting","[{'id': 1298, 'therapyName': 'Trametinib + GSK2141795'}]",Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma,1298
3,NCT01907815,Phase II,"Active, not recruiting","[{'id': 1298, 'therapyName': 'Trametinib + GSK2141795'}]",Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia,1298
4,NCT01964924,Phase II,"Active, not recruiting","[{'id': 1298, 'therapyName': 'Trametinib + GSK2141795'}]",Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer,1298
5,NCT01941927,Phase II,Unknown status,"[{'id': 1298, 'therapyName': 'Trametinib + GSK2141795'}]",Trametinib With GSK2141795 in BRAF Wild-type Melanoma,1298
0,NCT02079740,Phase Ib/II,Recruiting,"[{'id': 1386, 'therapyName': 'Trametinib + Navitoclax'}]",Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors,1386
0,NCT03085056,Phase I,Recruiting,"[{'id': 5493, 'therapyName': 'Trametinib + Paclitaxel'}]",Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer,5493
0,NCT02273102,Phase I,Recruiting,"[{'id': 6126, 'therapyName': 'Tranylcypromine + Tretinoin '}]",Phase 1 Study of TCP-ATRA for Adult Patients With AML and MDS (TCP-ATRA),6126
0,NCT02336984,Phase Ib/II,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 5222, 'therapyName': 'HER2-pulsed DC1 vaccine'}]",A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS,947
1,NCT02390427,Phase I,Recruiting,"[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 1016, 'therapyName': 'GDC-0032'}]",Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer,947
2,NCT02571530,Phase I,Recruiting,"[{'id': 947, 'therapyName': 'Trastuzumab'}]",Super-selective Intra-arterial Cerebral Infusion of Trastuzumab for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer,947
3,NCT02657343,Phase Ib/II,Recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}]","An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.",947
4,NCT01875666,Phase I,"Active, not recruiting","[{'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]","Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib",947
5,NCT02492711,Phase III,Recruiting,"[{'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 808, 'therapyName': 'MGAH22'}]",Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer,947
6,NCT01358877,Phase III,"Active, not recruiting","[{'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer,947
7,NCT01367002,Phase II,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer,947
8,NCT02213042,Phase II,"Active, not recruiting","[{'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer,947
9,NCT02229149,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1105, 'therapyName': 'Capecitabine'}]","Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer",947
10,NCT02286843,Phase I,Recruiting,"[{'id': 947, 'therapyName': 'Trastuzumab'}]","Can HER2 Targeted 89Zr-trastuzumab PET/CT Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?",947
11,NCT02414646,Phase II,Recruiting,"[{'id': 947, 'therapyName': 'Trastuzumab'}]",Trastuzumab Emtansine in Treating Older Patients With Human Epidermal Growth Factor Receptor 2-Positive Stage I-III Breast Cancer,947
12,NCT01772472,Phase III,"Active, not recruiting","[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE),947
13,NCT01106898,Phase II,Unknown status,"[{'id': 1980, 'therapyName': 'Cyclophosphamide + Paclitaxel'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Treating Women With Stage I or Stage II Breast Cancer Who Have Undergone Surgery,947
14,NCT01480583,Phase II,Completed,"[{'id': 947, 'therapyName': 'Trastuzumab'}]",GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases,947
15,NCT01750073,Phase II,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1980, 'therapyName': 'Cyclophosphamide + Paclitaxel'}]",Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Stage I-III Breast Cancer,947
16,NCT01325207,Phase Ib/II,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}]",Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer,947
17,NCT02675231,Phase II,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 744, 'therapyName': 'Fulvestrant'}]","A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer",947
18,NCT00968968,Phase III,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}]",Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone,947
19,NCT00574587,Phase Ib/II,Unknown status,"[{'id': 1983, 'therapyName': 'vorinostat + Paclitaxel'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]","Trial for Locally Advanced Her2 Positive Breast Cancer Using Paclitaxel, Trastuzumab, Doxorubicin and Cyclophasmide on a Weekly Basis",947
20,NCT03304080,,Not yet recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 850, 'therapyName': 'Palbociclib'}]","Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in Her-positive, Her2-positive Metastatic Breast",947
21,NCT01904903,Phase II,Recruiting,"[{'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Cardiac Safety Study in Patients With HER2+ Breast Cancer (SAFE-HEaRt),947
22,NCT02297698,Phase II,Recruiting,"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 3766, 'therapyName': 'E75'}]",Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients,947
23,NCT01912963,Phase II,"Active, not recruiting","[{'id': 728, 'therapyName': 'Eribulin'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 947, 'therapyName': 'Trastuzumab'}]","Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer",947
24,NCT02924883,Phase II,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 3250, 'therapyName': 'Atezolizumab + Trastuzumab'}]",A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab and Taxane Based Therapy,947
25,NCT02947685,Phase III,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 947, 'therapyName': 'Trastuzumab'}]","Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (PATINA)",947
26,NCT00796978,Phase II,Unknown status,"[{'id': 947, 'therapyName': 'Trastuzumab'}]",Trastuzumab in Treating Older Women With Early-Stage Breast Cancer,947
27,NCT01779050,Phase II,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1087, 'therapyName': 'Epirubicin + Cyclophosphamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}, {'id': 1834, 'therapyName': 'Docetaxel + Carboplatin'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}]",Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells,947
28,NCT00912340,Phase II,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Randomized Phase II Trial of Trastuzumab or EVEROLIMUS in Hormone-refractory Metastatic Breast Cancer,947
29,NCT02260531,Phase II,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Cabozantinib + / - Trastuzumab In Breast Cancer Patients w/ Brain Metastases,947
30,NCT00971737,Phase II,Unknown status,"[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer,947
31,NCT01570036,Phase II,Recruiting,"[{'id': 3766, 'therapyName': 'E75'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax,947
32,NCT02213289,Phase Ib/II,Recruiting,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1913, 'therapyName': 'FOLTAX'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 629, 'therapyName': 'AMG102'}]",PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression,947
33,NCT01928290,Phase II,Recruiting,"[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1903, 'therapyName': 'FOLFIRINOX'}]","Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer",947
34,NCT02465060,Phase II,Recruiting,"[{'id': 660, 'therapyName': 'AZD9291'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 958, 'therapyName': 'VS-6063'}, {'id': 765, 'therapyName': 'GSK2636771'}]",NCI-MATCH Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,947
35,NCT01566721,Phase III,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}]",A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer),947
36,NCT01491737,Phase II,"Active, not recruiting","[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]","A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer",947
37,NCT01160211,Phase III,"Active, not recruiting","[{'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 738, 'therapyName': 'Exemestane'}]","A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer",947
0,NCT01191697,Phase II,"Active, not recruiting","[{'id': 1596, 'therapyName': 'Trastuzumab + Bevacizumab'}, {'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}]","CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer",1596
0,NCT01959490,Phase II,Completed,"[{'id': 1486, 'therapyName': 'Bevacizumab + Doxorubicin + Cyclophosphamide + Paclitaxel '}, {'id': 1485, 'therapyName': 'Trastuzumab + Docetaxel + Carboplatin'}]",Trastuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer,1485
1,NCT02187744,Phase III,Completed,"[{'id': 1485, 'therapyName': 'Trastuzumab + Docetaxel + Carboplatin'}]",A Study Of PF-05280014 Or Trastuzumab Plus Taxotere&#174; And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04),1485
2,NCT01501487,FDA approved,"Active, not recruiting","[{'id': 1902, 'therapyName': 'Docetaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1485, 'therapyName': 'Trastuzumab + Docetaxel + Carboplatin'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]",MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I,1485
0,NCT01305941,Phase II,"Active, not recruiting","[{'id': 1411, 'therapyName': 'Trastuzumab + Everolimus + Vinorelbine'}]","A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases",1411
0,NCT01160211,Phase III,"Active, not recruiting","[{'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 738, 'therapyName': 'Exemestane'}]","A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer",1414
1,NCT02073487,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1583, 'therapyName': 'Trastuzumab emtansine + Lapatinib'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 619, 'therapyName': 'Abraxane'}]",Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab With Lapatinib and Paclitaxel,1414
2,NCT00790816,Phase I,Completed,"[{'id': 1410, 'therapyName': 'Lapatinib + Paclitaxel'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 1399, 'therapyName': 'Lapatinib + Capecitabine'}, {'id': 1497, 'therapyName': 'Lapatinib + Letrozole'}, {'id': 1498, 'therapyName': 'Lapatinib + Oxaliplatin + Capecitabine'}, {'id': 1499, 'therapyName': 'Lapatinib + Gemcitabine'}, {'id': 1500, 'therapyName': 'Lapatinib + Docetaxel'}, {'id': 1501, 'therapyName': 'Lapatinib + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 1502, 'therapyName': 'Lapatinib + Irinotecan + Leucovorin + Fluorouracil'}]",Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents,1414
3,NCT01875666,Phase I,"Active, not recruiting","[{'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]","Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib",1414
4,NCT01273610,Phase II,"Active, not recruiting","[{'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}]",Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Metastatic Breast Cancer,1414
5,NCT02213042,Phase II,"Active, not recruiting","[{'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer,1414
6,NCT00968968,Phase III,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}]",Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone,1414
0,NCT01901146,Phase III,Completed,"[{'id': 1087, 'therapyName': 'Epirubicin + Cyclophosphamide'}, {'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}]",Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Subjects With HER2 Positive Early Breast Cancer (Lilac),1551
1,NCT01897441,Phase I,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]",Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer,1551
2,NCT01989676,Phase III,"Active, not recruiting","[{'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}]",A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02),1551
3,NCT01853748,Phase II,Recruiting,"[{'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial),1551
4,NCT02297230,Phase Ib/II,Completed,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}]",Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics,1551
5,NCT01774851,Phase II,Terminated,"[{'id': 1892, 'therapyName': 'Paclitaxel + Trastuzumab + MM-111'}, {'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}]","A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach",1551
0,NCT02536339,Phase II,"Active, not recruiting","[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]",Pertuzumab With High-Dose Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy,1389
1,NCT01796197,Phase II,"Active, not recruiting","[{'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa,1389
2,NCT02436993,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting,1389
3,NCT02689921,Phase II,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 738, 'therapyName': 'Exemestane'}]",NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (NEOADAPT),1389
4,NCT02091141,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 698, 'therapyName': 'Alectinib'}, {'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]","My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors",1389
5,NCT01875666,Phase I,"Active, not recruiting","[{'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]","Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib",1389
6,NCT01937117,Phase II,"Active, not recruiting","[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]",Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer,1389
7,NCT02598427,Phase I,Recruiting,"[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]",Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer,1389
8,NCT02132949,Phase II,"Active, not recruiting","[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1895, 'therapyName': 'Cyclophosphamide + Fluorouracil + Docetaxel + Epirubicin  '}]","A Study Evaluating Perjeta (Pertuzumab) Combined With Herceptin (Trastuzumab) and Standard Anthracycline-based Chemotherapy in Patients With HER2-positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer.",1389
9,NCT02229149,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1105, 'therapyName': 'Capecitabine'}]","Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer",1389
10,NCT02693535,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 690, 'therapyName': 'Bosutinib'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer,1389
11,NCT01572038,Phase III,"Active, not recruiting","[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE),1389
12,NCT02000596,Phase II,Terminated,"[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1911, 'therapyName': 'Anastrozole  + Fulvestrant'}]",Trastuzmab and Pertuzumab Alone or in Combination With Hormonal Therapy or Chemotherapy With Eribulin in Women Aged 60 and Over With HER2/Neu Overexpressed Locally Advanced or MBC,1389
13,NCT01042379,Phase II,Recruiting,"[{'id': 1218, 'therapyName': 'Trebananib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 746, 'therapyName': 'Ganitumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1494, 'therapyName': 'MK2206 + Trastuzumab'}, {'id': 1493, 'therapyName': 'Trebananib + Trastuzumab'}, {'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}]",I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer,1389
14,NCT02827877,Phase I,Recruiting,"[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]",Copper (Cu) 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Trastuzumab and Pertuzumab Before Surgery in Patients With HER2 Positive Breast Cancer,1389
15,NCT01491737,Phase II,"Active, not recruiting","[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]","A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer",1389
0,NCT02774421,Phase I,Recruiting,"[{'id': 1891, 'therapyName': 'Trastuzumab + Sargramostim'}]",Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent Ependymoma,1891
0,NCT00781612,Phase II,Recruiting,"[{'id': 5471, 'therapyName': 'Trastuzumab + trastuzumab emtansine'}, {'id': 5470, 'therapyName': 'Paclitaxel + trastuzumab emtansine'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 3930, 'therapyName': 'Docetaxel + T-DM1'}, {'id': 1976, 'therapyName': 'trastuzumab emtansine + Capecitabine'}, {'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}]",A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies,5471
0,NCT01816035,Phase I,Completed,"[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",Ado-Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery,1402
1,NCT02675829,Phase II,Recruiting,"[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers,1402
2,NCT01641939,Phase III,Terminated,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer,1402
3,NCT02657343,Phase Ib/II,Recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}]","An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.",1402
4,NCT02725541,Phase II,Withdrawn,"[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer,1402
5,NCT01904903,Phase II,Recruiting,"[{'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Cardiac Safety Study in Patients With HER2+ Breast Cancer (SAFE-HEaRt),1402
6,NCT01702571,Phase III,"Active, not recruiting","[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",A Study of Kadcyla (Trastuzumab Emtansine) in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment,1402
7,NCT01513083,Phase I,Completed,"[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function,1402
8,NCT00781612,Phase II,Recruiting,"[{'id': 5471, 'therapyName': 'Trastuzumab + trastuzumab emtansine'}, {'id': 5470, 'therapyName': 'Paclitaxel + trastuzumab emtansine'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 3930, 'therapyName': 'Docetaxel + T-DM1'}, {'id': 1976, 'therapyName': 'trastuzumab emtansine + Capecitabine'}, {'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}]",A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies,1402
9,NCT01772472,Phase III,"Active, not recruiting","[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE),1402
10,NCT03190967,Phase Ib/II,Recruiting,"[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 5932, 'therapyName': 'Temozolomide + Trastuzumab emtansine'}]",T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery,1402
11,NCT01853748,Phase II,Recruiting,"[{'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial),1402
12,NCT02289833,Phase II,"Active, not recruiting","[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}]","A Study of Trastuzumab Emtansine in Patients With HER2 IHC-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer",1402
13,NCT01702558,Phase II,Completed,"[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 1976, 'therapyName': 'trastuzumab emtansine + Capecitabine'}]",A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Patients With HER2-Positive Metastatic Breast Cancer and Patients With HER2-Positive Locally Advanced / Metastatic Gastric Cancer,1402
0,NCT00781612,Phase II,Recruiting,"[{'id': 5471, 'therapyName': 'Trastuzumab + trastuzumab emtansine'}, {'id': 5470, 'therapyName': 'Paclitaxel + trastuzumab emtansine'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 3930, 'therapyName': 'Docetaxel + T-DM1'}, {'id': 1976, 'therapyName': 'trastuzumab emtansine + Capecitabine'}, {'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}]",A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies,1976
1,NCT01702558,Phase II,Completed,"[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 1976, 'therapyName': 'trastuzumab emtansine + Capecitabine'}]",A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Patients With HER2-Positive Metastatic Breast Cancer and Patients With HER2-Positive Locally Advanced / Metastatic Gastric Cancer,1976
0,NCT02073487,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1583, 'therapyName': 'Trastuzumab emtansine + Lapatinib'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 619, 'therapyName': 'Abraxane'}]",Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab With Lapatinib and Paclitaxel,1583
0,NCT02658084,Phase Ib/II,Recruiting,"[{'id': 3429, 'therapyName': 'Trastuzumab emtansine + Vinorelbine'}]",Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer,3429
0,NCT02520063,Phase Ib/II,Recruiting,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 1242, 'therapyName': 'TRC105'}, {'id': 735, 'therapyName': 'Everolimus'}]","Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer",1242
1,NCT01648348,Phase Ib/II,"Active, not recruiting","[{'id': 1242, 'therapyName': 'TRC105'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme,1242
2,NCT02429843,Phase I,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1242, 'therapyName': 'TRC105'}]",A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer,1242
0,NCT01975519,Phase I,"Active, not recruiting","[{'id': 1431, 'therapyName': 'TRC105 + Pazopanib'}]",A Phase 1B Dose-escalation Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma,1431
1,NCT02979899,Phase III,Recruiting,"[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1431, 'therapyName': 'TRC105 + Pazopanib'}]",A RANDOMIZED PHASE 3 TRIAL OF TRC105 AND PAZOPANIB VERSUS PAZOPANIB ALONE IN PATIENTS WITH ADVANCED ANGIOSARCOMA (TAPPAS),1431
0,NCT02987829,Phase Ib/II,Recruiting,"[{'id': 5770, 'therapyName': 'TRC253'}]","A Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients",5770
0,NCT01042379,Phase II,Recruiting,"[{'id': 1218, 'therapyName': 'Trebananib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 746, 'therapyName': 'Ganitumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1494, 'therapyName': 'MK2206 + Trastuzumab'}, {'id': 1493, 'therapyName': 'Trebananib + Trastuzumab'}, {'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}]",I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer,1218
1,NCT01553188,Phase II,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1218, 'therapyName': 'Trebananib'}]",AMG 386 and Abiraterone for Advanced Prostate Cancer,1218
2,NCT01664182,Phase II,"Active, not recruiting","[{'id': 1223, 'therapyName': 'Trebananib + Sunitinib'}, {'id': 1220, 'therapyName': 'Trebananib + Pazopanib'}, {'id': 1221, 'therapyName': 'Trebananib + Sorafenib'}, {'id': 1218, 'therapyName': 'Trebananib'}, {'id': 1219, 'therapyName': 'Trebananib + Bevacizumab'}]","Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer",1218
3,NCT01290263,Phase Ib/II,Completed,"[{'id': 1219, 'therapyName': 'Trebananib + Bevacizumab'}, {'id': 1218, 'therapyName': 'Trebananib'}]",Amgen 386 for Recurrent Glioblastoma,1218
4,NCT01493505,Phase III,Terminated,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1218, 'therapyName': 'Trebananib'}]", TRINOVA-3,1218
0,NCT01290263,Phase Ib/II,Completed,"[{'id': 1219, 'therapyName': 'Trebananib + Bevacizumab'}, {'id': 1218, 'therapyName': 'Trebananib'}]",Amgen 386 for Recurrent Glioblastoma,1219
1,NCT01664182,Phase II,"Active, not recruiting","[{'id': 1223, 'therapyName': 'Trebananib + Sunitinib'}, {'id': 1220, 'therapyName': 'Trebananib + Pazopanib'}, {'id': 1221, 'therapyName': 'Trebananib + Sorafenib'}, {'id': 1218, 'therapyName': 'Trebananib'}, {'id': 1219, 'therapyName': 'Trebananib + Bevacizumab'}]","Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer",1219
0,NCT01664182,Phase II,"Active, not recruiting","[{'id': 1223, 'therapyName': 'Trebananib + Sunitinib'}, {'id': 1220, 'therapyName': 'Trebananib + Pazopanib'}, {'id': 1221, 'therapyName': 'Trebananib + Sorafenib'}, {'id': 1218, 'therapyName': 'Trebananib'}, {'id': 1219, 'therapyName': 'Trebananib + Bevacizumab'}]","Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer",1220
0,NCT01664182,Phase II,"Active, not recruiting","[{'id': 1223, 'therapyName': 'Trebananib + Sunitinib'}, {'id': 1220, 'therapyName': 'Trebananib + Pazopanib'}, {'id': 1221, 'therapyName': 'Trebananib + Sorafenib'}, {'id': 1218, 'therapyName': 'Trebananib'}, {'id': 1219, 'therapyName': 'Trebananib + Bevacizumab'}]","Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer",1221
0,NCT01664182,Phase II,"Active, not recruiting","[{'id': 1223, 'therapyName': 'Trebananib + Sunitinib'}, {'id': 1220, 'therapyName': 'Trebananib + Pazopanib'}, {'id': 1221, 'therapyName': 'Trebananib + Sorafenib'}, {'id': 1218, 'therapyName': 'Trebananib'}, {'id': 1219, 'therapyName': 'Trebananib + Bevacizumab'}]","Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer",1223
0,NCT01042379,Phase II,Recruiting,"[{'id': 1218, 'therapyName': 'Trebananib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 746, 'therapyName': 'Ganitumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1494, 'therapyName': 'MK2206 + Trastuzumab'}, {'id': 1493, 'therapyName': 'Trebananib + Trastuzumab'}, {'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}]",I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer,1493
0,NCT02868632,Phase I,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer",1652
1,NCT02519348,Phase II,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","A Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Unresectable Hepatocellular Carcinoma",1652
2,NCT02205333,Phase Ib/II,Terminated,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1653, 'therapyName': 'MEDI6469'}, {'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies,1652
3,NCT02551159,Phase III,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1914, 'therapyName': 'Cetuximab + Carboplatin + Fluorouracil'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN,1652
4,NCT02340975,Phase Ib/II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma",1652
5,NCT02301130,Phase I,"Active, not recruiting","[{'id': 2968, 'therapyName': 'Mogamulizumab '}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Study of Mogamulizumab + MEDI4736 and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors,1652
6,NCT02571725,Phase Ib/II,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 837, 'therapyName': 'Olaparib'}]",PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer,1652
7,NCT02352948,Phase III,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2438, 'therapyName': 'Erlotinib + Gemcitabine + Vinorelbine'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer",1652
8,NCT03007407,Phase II,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy,1652
9,NCT02262741,Phase I,"Active, not recruiting","[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 With Tremelimumab or Tremelimumab Alone in Head and Neck Cancer",1652
10,NCT02141542,Phase I,"Active, not recruiting","[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 1176, 'therapyName': 'MEDI3617'}]",Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma,1652
11,NCT02563925,Phase I,"Active, not recruiting","[{'id': 1652, 'therapyName': 'Tremelimumab'}]",Brain Irradiation and Tremelimumab in Metastatic Breast Cancer,1652
12,NCT02311361,Phase I,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer,1652
13,NCT02485990,Phase Ib/II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)",1652
14,NCT01853618,Phase I,"Active, not recruiting","[{'id': 1652, 'therapyName': 'Tremelimumab'}]",Tremelimumab With Chemoembolization or Ablation for Liver Cancer,1652
15,NCT02794883,Phase II,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma,1652
16,NCT02535078,Phase Ib/II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3847, 'therapyName': 'IMCgp100'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Cutaneous Melanoma,1652
17,NCT03026062,Phase II,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab and Tremelimumab in Combo Versus Sequential,1652
18,NCT02453282,Phase III,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC).,1652
19,NCT02319044,Phase II,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck",1652
20,NCT02537418,Phase I,"Active, not recruiting","[{'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens,1652
21,NCT02643303,Phase Ib/II,Recruiting,"[{'id': 3385, 'therapyName': 'MEDI4736 + poly ICLC '}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers",1652
22,NCT02179671,Phase II,Completed,"[{'id': 1117, 'therapyName': 'Selumetinib + Docetaxel'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 660, 'therapyName': 'AZD9291'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer",1652
23,NCT02558894,Phase II,Completed,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma,1652
24,NCT02626130,Phase I,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}]",Pilot Study of Presurgical Tremelimumab With or Without Cryoablation in Patients With Metastatic Renal Cell Carcinoma (RCC),1652
0,NCT01857934,Phase II,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 2627, 'therapyName': 'Levetiracetam'}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 2458, 'therapyName': 'Hu14.18K322A'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}]",Therapy for Children With Advanced Stage Neuroblastoma,1877
1,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,1877
2,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1877
3,NCT01526603,Phase I,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1092, 'therapyName': 'Carboplatin'}]",High Dose Chemotherapy and Autologous Transplant for Neuroblastoma,1877
0,NCT03223779,Phase Ib/II,Not yet recruiting,"[{'id': 4586, 'therapyName': 'Trifluridine'}]",Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer,4586
0,NCT01916447,Phase I,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2426, 'therapyName': 'trifluridine/tipiracil hydrochloride'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.,2426
1,NCT02500043,Phase III,Recruiting,"[{'id': 2426, 'therapyName': 'trifluridine/tipiracil hydrochloride'}]",Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer,2426
2,NCT02602327,Phase I,Recruiting,"[{'id': 2426, 'therapyName': 'trifluridine/tipiracil hydrochloride'}]",Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases,2426
3,NCT02301117,Phase I,Recruiting,"[{'id': 2426, 'therapyName': 'trifluridine/tipiracil hydrochloride'}]",A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment,2426
0,NCT02499770,Phase Ib/II,"Active, not recruiting","[{'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}, {'id': 3074, 'therapyName': 'Trilaciclib'}]",G1T28 (CDK 4/6 Inhibitor) in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC),3074
1,NCT02514447,Phase Ib/II,Recruiting,"[{'id': 3074, 'therapyName': 'Trilaciclib'}, {'id': 942, 'therapyName': 'Topotecan'}]",Study of G1T28 in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy,3074
0,NCT02685397,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Management of Castration-Resistant Prostate Cancer With Oligometastases,2050
1,NCT02346253,Phase Ib/II,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 1814, 'therapyName': 'Degarelix'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 759, 'therapyName': 'Goserelin'}]",High-Dose Brachytherapy in Treating Patients With Prostate Cancer,2050
2,NCT03279250,Phase II,Not yet recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1947, 'therapyName': 'ARN-509'}]",Effects of Apalutamide Plus LHRH Agonist or Apalutamide Plus Abiraterone Acetate Plus LHRH Agonist for Six Months for Prostate Cancer Patients at High Risk for Recurrence,2050
3,NCT02366494,Phase I,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Micro RNAs to Predict Response to Androgen Deprivation Therapy,2050
4,NCT02278185,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1814, 'therapyName': 'Degarelix'}, {'id': 2047, 'therapyName': 'Histrelin acetate'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer,2050
5,NCT00936390,Phase III,"Active, not recruiting","[{'id': 742, 'therapyName': 'Flutamide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,2050
0,NCT02990481,Phase I,Recruiting,"[{'id': 5835, 'therapyName': 'TRK-950'}]",A Study of TRK-950 in Patients With Advanced Solid Tumors,5835
0,NCT02628574,Phase I,Recruiting,"[{'id': 3613, 'therapyName': 'TRX518'}]",Dose Escalation Study of TRX518 in Adults With Advanced Solid Tumors,3613
1,NCT01239134,Phase I,Recruiting,"[{'id': 3613, 'therapyName': 'TRX518'}]",Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors,3613
0,NCT02855125,Phase II,Recruiting,"[{'id': 1407, 'therapyName': 'TS-1'}, {'id': 4527, 'therapyName': 'TAS-114 + TS-1'}]",A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1,1407
0,NCT02048488,Phase Ib/II,"Active, not recruiting","[{'id': 949, 'therapyName': 'TSR-011'}]","A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas",949
0,NCT03201913,Phase I,Not yet recruiting,"[{'id': 5960, 'therapyName': 'TTC-352'}]",Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy,5960
0,NCT02890368,Phase I,Recruiting,"[{'id': 5338, 'therapyName': 'TTI-621'}]",Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides,5338
1,NCT02663518,Phase I,Recruiting,"[{'id': 5338, 'therapyName': 'TTI-621'}]",A Trial of TTI-621 for Patients With Hematologic Malignancies,5338
0,NCT02980029,Phase I,Recruiting,"[{'id': 3611, 'therapyName': 'TVB-2640'}]",Pharmacodynamic Effects of Fatty Acid Synthase (FASN) Inhibition With TVB-2640 in Resectable Colon Cancer,3611
1,NCT02223247,Phase I,Completed,"[{'id': 3611, 'therapyName': 'TVB-2640'}]","A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors",3611
0,NCT02612311,Phase III,Recruiting,"[{'id': 2287, 'therapyName': 'Ublituximab'}, {'id': 1648, 'therapyName': 'Obinutuzumab + Chlorambucil'}, {'id': 2022, 'therapyName': 'TGR-1202'}]",Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia,2287
1,NCT02301156,Phase III,"Active, not recruiting","[{'id': 2287, 'therapyName': 'Ublituximab'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL),2287
0,NCT03190278,Phase I,Suspended,"[{'id': 5994, 'therapyName': 'UCART123'}]",Study Evaluating Safety and Efficacy of UCART123 in Patients With Acute Myeloid Leukemia,5994
1,NCT03203369,Phase I,Suspended,"[{'id': 5994, 'therapyName': 'UCART123'}]",Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN (ABC123),5994
0,NCT02746952,Phase I,Recruiting,"[{'id': 5997, 'therapyName': 'UCART19'}]",Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia (CALM),5997
0,NCT02472977,Phase Ib/II,Terminated,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 2847, 'therapyName': 'Ulocuplumab'}]",Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors,2847
0,NCT02252263,Phase I,"Active, not recruiting","[{'id': 2055, 'therapyName': 'Urelumab'}, {'id': 2583, 'therapyName': 'Lirilumab '}, {'id': 3343, 'therapyName': 'Elotuzumab'}]",A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma,2055
1,NCT02652455,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 3409, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine '}, {'id': 2055, 'therapyName': 'Urelumab'}]","Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma",2055
2,NCT02845323,Phase II,Recruiting,"[{'id': 2055, 'therapyName': 'Urelumab'}, {'id': 2567, 'therapyName': 'Nivolumab + Urelumab'}]",Neoadjuvant Nivolumab With and Without Urelumab in Patients With Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma of the Bladder,2055
0,NCT01307267,Phase I,Recruiting,"[{'id': 6111, 'therapyName': 'Utomilumab + Rituximab'}, {'id': 5086, 'therapyName': 'Utomilumab'}]",A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab,5086
1,NCT02179918,Phase I,Completed,"[{'id': 5086, 'therapyName': 'Utomilumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036),5086
0,NCT01307267,Phase I,Recruiting,"[{'id': 6111, 'therapyName': 'Utomilumab + Rituximab'}, {'id': 5086, 'therapyName': 'Utomilumab'}]",A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab,6111
0,NCT01478178,Phase Ib/II,Completed,"[{'id': 2921, 'therapyName': 'VAL-083'}]",Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma or Progressive Secondary Brain Tumor,2921
0,NCT02768363,Phase II,Recruiting,"[{'id': 5172, 'therapyName': 'AdV-tk + Valacyclovir'}, {'id': 5171, 'therapyName': 'Valacyclovir'}]",Randomized Controlled Trial of ProstAtak Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES),5171
1,NCT01436968,Phase III,Recruiting,"[{'id': 5171, 'therapyName': 'Valacyclovir'}, {'id': 5172, 'therapyName': 'AdV-tk + Valacyclovir'}]",Phase 3 Study of ProstAtak Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer,5171
0,NCT00670046,Phase II,Unknown status,"[{'id': 1076, 'therapyName': 'Valproic acid'}]","Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer",1076
1,NCT01817751,Phase II,Recruiting,"[{'id': 1076, 'therapyName': 'Valproic acid'}, {'id': 920, 'therapyName': 'Sorafenib'}]","Sorafenib Tosylate, Valproic Acid, and Sildenafil Citrate in Treating Patients With Recurrent High-Grade Glioma",1076
2,NCT02068586,Phase II,Recruiting,"[{'id': 1076, 'therapyName': 'Valproic acid'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma,1076
3,NCT01182285,Phase II,Completed,"[{'id': 2674, 'therapyName': 'liothyronine sodium  '}, {'id': 1076, 'therapyName': 'Valproic acid'}]",A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin,1076
4,NCT01738815,Phase I,Unknown status,"[{'id': 1076, 'therapyName': 'Valproic acid'}]",Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer,1076
5,NCT02446431,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1076, 'therapyName': 'Valproic acid'}]",Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence,1076
6,NCT00879437,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1076, 'therapyName': 'Valproic acid'}]",Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas,1076
7,NCT01007695,Phase I,Terminated,"[{'id': 1076, 'therapyName': 'Valproic acid'}]",Molecular Signature of Valproic Acid in Breast Cancer With Functional Imaging Assessment - a Pilot,1076
8,NCT01010958,Phase I,Terminated,"[{'id': 1076, 'therapyName': 'Valproic acid'}]",Adjuvant Valproate for High Grade Sarcomas,1076
9,NCT02520115,Phase I,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1076, 'therapyName': 'Valproic acid'}]",Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer,1076
0,NCT02015065,Phase II,"Active, not recruiting","[{'id': 953, 'therapyName': 'Vandetanib'}]",Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors,953
1,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,953
2,NCT01414426,Phase II,Recruiting,"[{'id': 953, 'therapyName': 'Vandetanib'}]",Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions,953
3,NCT01876784,Phase III,Completed,"[{'id': 953, 'therapyName': 'Vandetanib'}]","Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer",953
4,NCT01585415,Phase I,Terminated,"[{'id': 953, 'therapyName': 'Vandetanib'}]", Vemurafenib and White Blood Cell Therapy for Advanced Melanoma,953
5,NCT01934335,Phase I,Recruiting,"[{'id': 953, 'therapyName': 'Vandetanib'}]",Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer,953
0,NCT01582191,Phase I,Recruiting,"[{'id': 1163, 'therapyName': 'Vandetanib + Everolimus'}]",Vandetanib With Everolimus,1163
0,NCT01973309,Phase I,"Active, not recruiting","[{'id': 4398, 'therapyName': 'Vantictumab + Paclitaxel'}]",A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer,4398
0,NCT02284971,Phase I,Terminated,"[{'id': 2525, 'therapyName': 'Varlilumab'}]",Pilot Study of SBRT and CDX-1127 in Prostate Cancer (Prostate-04),2525
1,NCT02924038,Phase I,Recruiting,"[{'id': 4835, 'therapyName': 'IMA950 + poly ICLC '}, {'id': 2525, 'therapyName': 'Varlilumab'}]",A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG),2525
2,NCT02270372,Phase I,Completed,"[{'id': 2525, 'therapyName': 'Varlilumab'}, {'id': 3051, 'therapyName': 'ONT-10'}]",Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer,2525
0,NCT02511405,Phase III,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2276, 'therapyName': 'VB-111'}]","A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)",2276
0,NCT02921256,Phase II,Recruiting,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 4838, 'therapyName': 'Capecitabine + Veliparib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Veliparib and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer,954
1,NCT02890355,,Recruiting,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer,954
2,NCT02595905,Phase I,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 954, 'therapyName': 'Veliparib'}]",Cisplatin With or Without Veliparib in Treating Patients With Stage IV Triple-Negative and/or BRCA Mutation-Associated Breast Cancer,954
3,NCT01642251,Phase Ib/II,"Active, not recruiting","[{'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 954, 'therapyName': 'Veliparib'}]",Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer,954
4,NCT02412371,Phase II,Recruiting,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer,954
5,NCT02163694,Phase III,Recruiting,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer",954
6,NCT01514201,Phase Ib/II,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 954, 'therapyName': 'Veliparib'}]","Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas",954
7,NCT01638546,Phase II,Completed,"[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 954, 'therapyName': 'Veliparib'}]",Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer,954
8,NCT01351909,Phase Ib/II,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 954, 'therapyName': 'Veliparib'}]",Cyclophosphamide With or Without Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer,954
9,NCT02032277,Phase III,"Active, not recruiting","[{'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer,954
10,NCT02470585,Phase III,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}]","Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",954
11,NCT01585805,Phase II,Recruiting,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer,954
12,NCT01281150,Phase I,Completed,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors,954
13,NCT01326702,Phase Ib/II,Completed,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1231, 'therapyName': 'Bendamustine'}]"," Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors",954
14,NCT01576172,Phase II,"Active, not recruiting","[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 954, 'therapyName': 'Veliparib'}]",Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,954
15,NCT01017640,Phase I,Completed,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1134, 'therapyName': 'Veliparib + Mitomycin C'}]"," Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors",954
16,NCT02152982,Phase II,Suspended,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,954
17,NCT02009631,Phase I,Completed,"[{'id': 954, 'therapyName': 'Veliparib'}]",A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors,954
18,NCT01908478,Phase I,"Active, not recruiting","[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","A Phase I Study of Veliparib (ABT-888) in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Locally Advanced, Unresectable Pancreatic Cancer",954
19,NCT02849496,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 4511, 'therapyName': 'Atezolizumab + Veliparib'}, {'id': 954, 'therapyName': 'Veliparib'}]",Veliparib and Atezolizumab Either Alone or in Combination in Treating Patients With Stage III-IV Triple Negative Breast Cancer,954
20,NCT02106546,Phase III,"Active, not recruiting","[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer",954
21,NCT01853306,Phase I,Completed,"[{'id': 954, 'therapyName': 'Veliparib'}]","A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors",954
22,NCT01366144,Phase I,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction",954
23,NCT01489865,Phase Ib/II,Recruiting,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 954, 'therapyName': 'Veliparib'}]",ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer,954
24,NCT00576654,Phase I,Recruiting,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 954, 'therapyName': 'Veliparib'}]",Irinotecan Hydrochloride and Veliparib in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery,954
25,NCT01264432,Phase I,"Active, not recruiting","[{'id': 954, 'therapyName': 'Veliparib'}]","Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer",954
26,NCT02985658,Phase I,Available,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1685, 'therapyName': 'Vinorelbine'}]",Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer,954
27,NCT02264990,Phase III,"Active, not recruiting","[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers,954
28,NCT02305758,Phase II,Completed,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 954, 'therapyName': 'Veliparib'}]",Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer,954
29,NCT01459380,Phase I,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",954
30,NCT00892736,Phase I,"Active, not recruiting","[{'id': 954, 'therapyName': 'Veliparib'}]",Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy,954
0,NCT01434316,Phase I,Recruiting,"[{'id': 1277, 'therapyName': 'Veliparib + Dinaciclib'}, {'id': 1278, 'therapyName': 'Veliparib + Dinaciclib + carboplatin'}]",Veliparib and Dinaciclib With or Without Carboplatin in Treating Patients With Advanced Solid Tumors,1277
0,NCT01434316,Phase I,Recruiting,"[{'id': 1277, 'therapyName': 'Veliparib + Dinaciclib'}, {'id': 1278, 'therapyName': 'Veliparib + Dinaciclib + carboplatin'}]",Veliparib and Dinaciclib With or Without Carboplatin in Treating Patients With Advanced Solid Tumors,1278
0,NCT01017640,Phase I,Completed,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1134, 'therapyName': 'Veliparib + Mitomycin C'}]"," Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors",1134
0,NCT03061188,Phase I,Recruiting,"[{'id': 5368, 'therapyName': 'Veliparib + Nivolumab'}]",Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma With or Without Alterations in DNA Repair Genes,5368
0,NCT01827384,Phase II,Recruiting,"[{'id': 1194, 'therapyName': 'MK-1775 + Carboplatin '}, {'id': 1193, 'therapyName': 'Veliparib + Temozolomide'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 2, 'therapyName': 'Trametinib'}]",Molecular Profiling-Based Targeted Therapy in Treating Patients With Advanced Solid Tumors,1193
1,NCT01506609,Phase II,"Active, not recruiting","[{'id': 1193, 'therapyName': 'Veliparib + Temozolomide'}, {'id': 1544, 'therapyName': 'Carboplatin + Etoposide + Veliparib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer,1193
0,NCT01012817,Phase Ib/II,Recruiting,"[{'id': 1132, 'therapyName': 'Veliparib + Topotecan'}]","Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer",1132
0,NCT01709292,Phase II,"Active, not recruiting","[{'id': 342, 'therapyName': 'Vemurafenib'}]",Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer,342
1,NCT01739764,Phase III,Recruiting,"[{'id': 342, 'therapyName': 'Vemurafenib'}]", An Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol,342
2,NCT02382549,Phase Ib/II,Recruiting,"[{'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 2620, 'therapyName': '6MHP vaccine'}]",A Clinical Trial to Evaluate a Helper Peptide Vaccine Plus Vemurafenib in Melanoma,342
3,NCT01843738,Phase I,Withdrawn,"[{'id': 342, 'therapyName': 'Vemurafenib'}]",Radiation Use During Vemurafenib Treatment,342
4,NCT03155620,Phase II,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}, {'id': 2650, 'therapyName': 'LOXO-101'}, {'id': 1069, 'therapyName': 'LY3023414'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 913, 'therapyName': 'Selumetinib'}, {'id': 961, 'therapyName': 'X-396'}]",Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Advanced Refractory Solid Tumors or Lymphomas,342
5,NCT01586195,Phase II,Terminated,"[{'id': 342, 'therapyName': 'Vemurafenib'}]"," Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E",342
6,NCT02427893,Phase III,Withdrawn,"[{'id': 1004, 'therapyName': 'Cobimetinib'}, {'id': 342, 'therapyName': 'Vemurafenib'}]",Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma,342
7,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,342
8,NCT01781026,Phase II,Completed,"[{'id': 342, 'therapyName': 'Vemurafenib'}]",Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases,342
9,NCT01519323,Phase I,Terminated,"[{'id': 342, 'therapyName': 'Vemurafenib'}]", BRIM-P,342
10,NCT01748149,Phase I,Recruiting,"[{'id': 342, 'therapyName': 'Vemurafenib'}]",Vemurafenib in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas,342
11,NCT01495988,Phase II,Terminated,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 342, 'therapyName': 'Vemurafenib'}]",Trial of Vemurafenib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma,342
12,NCT02145910,Phase I,Withdrawn,"[{'id': 342, 'therapyName': 'Vemurafenib'}]",Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases,342
13,NCT01711632,Phase II,"Active, not recruiting","[{'id': 342, 'therapyName': 'Vemurafenib'}]","BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia",342
14,NCT02145143,Phase I,"Active, not recruiting","[{'id': 342, 'therapyName': 'Vemurafenib'}]","Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib",342
15,NCT01909453,Phase III,"Active, not recruiting","[{'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 796, 'therapyName': 'Encorafenib'}, {'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}]",Study Comparing Combination of LGX818 Plus MEK162 and LGX818 Monotherapy Versus Vemurafenib in BRAF Mutant Melanoma,342
16,NCT01667419,Phase III,"Active, not recruiting","[{'id': 342, 'therapyName': 'Vemurafenib'}]",BRIM8: A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma,342
17,NCT01767623,Phase I,"Active, not recruiting","[{'id': 342, 'therapyName': 'Vemurafenib'}]", A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Patients,342
18,NCT01813214,Phase II,Terminated,"[{'id': 342, 'therapyName': 'Vemurafenib'}]", The Effects of Vemurafenib on Immunity in Patients With Melanoma,342
19,NCT01942993,Phase II,Terminated,"[{'id': 342, 'therapyName': 'Vemurafenib'}]",The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma,342
20,NCT01524978,Phase II,"Active, not recruiting","[{'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Study of Zelboraf (Vemurafenib) in Patients With BRAF V600 Mutation-Positive Cancers,342
21,NCT03220035,Phase II,Recruiting,"[{'id': 342, 'therapyName': 'Vemurafenib'}]","Pediatric MATCH: Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations",342
22,NCT01659151,Phase II,"Active, not recruiting","[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 342, 'therapyName': 'Vemurafenib'}]", Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer &amp; High Dose IL-2 Metastatic Melanoma,342
0,NCT02050321,Phase II,Terminated,"[{'id': 1936, 'therapyName': 'Vemurafenib + Acitretin'}]",A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma,1936
0,NCT01636622,Phase I,"Active, not recruiting","[{'id': 1209, 'therapyName': 'Vemurafenib + Carboplatin + Paclitaxel '}]"," Study of Vemurafenib, Carboplatin, and Paclitaxel",1209
0,NCT01787500,Phase I,"Active, not recruiting","[{'id': 1331, 'therapyName': 'Vemurafenib + Cetuximab + Irinotecan '}]","Vemurafenib, Cetuximab, and Irinotecan in Advanced Solid Cancers",1331
1,NCT02164916,Phase II,"Active, not recruiting","[{'id': 1874, 'therapyName': 'Cetuximab + Irinotecan'}, {'id': 1331, 'therapyName': 'Vemurafenib + Cetuximab + Irinotecan '}]",S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,1331
0,NCT02036086,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}]",Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases,1657
1,NCT02693535,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 690, 'therapyName': 'Bosutinib'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer,1657
2,NCT02908672,Phase III,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 4825, 'therapyName': 'Atezolizumab + Vemurafenib + Cobimetinib'}]",A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Participants With Metastatic or Unresectable Locally Advanced Melanoma,1657
3,NCT03005639,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}]",ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma,1657
4,NCT03224767,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}]",Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma,1657
5,NCT02091141,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 698, 'therapyName': 'Alectinib'}, {'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]","My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors",1657
6,NCT02230306,Phase II,Terminated,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}]",Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases,1657
0,NCT01876641,Phase Ib/II,Recruiting,"[{'id': 1259, 'therapyName': 'Vemurafenib + Decitabine'}]",Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib,1259
0,NCT01596140,Phase I,"Active, not recruiting","[{'id': 1175, 'therapyName': 'Vemurafenib + Temsirolimus'}, {'id': 1174, 'therapyName': 'Vemurafenib + Everolimus'}]",Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer,1174
0,NCT01897116,Phase I,"Active, not recruiting","[{'id': 1281, 'therapyName': 'Vemurafenib + Hydroxychloroquine'}]", A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma,1281
0,NCT01943422,Phase Ib/II,"Active, not recruiting","[{'id': 1300, 'therapyName': 'Vemurafenib + Interferon alfa-2b'}]",Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma,1300
0,NCT01638676,Phase Ib/II,Recruiting,"[{'id': 1210, 'therapyName': 'Vemurafenib + Metformin '}]", A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients,1210
0,NCT01531361,Phase I,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 1326, 'therapyName': 'Vemurafenib + Sorafenib'}]",Sorafenib or Crizotinib and Vemurafenib in Advanced Cancer,1326
0,NCT01596140,Phase I,"Active, not recruiting","[{'id': 1175, 'therapyName': 'Vemurafenib + Temsirolimus'}, {'id': 1174, 'therapyName': 'Vemurafenib + Everolimus'}]",Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer,1175
0,NCT01844674,Phase I,Completed,"[{'id': 1241, 'therapyName': 'Vemurafenib + Tizanidine'}]",A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies,1241
0,NCT02068079,Phase I,Withdrawn,"[{'id': 1383, 'therapyName': 'Vemurafenib + Trientine'}]",A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma,1383
0,NCT01841463,Phase Ib/II,Suspended,"[{'id': 1238, 'therapyName': 'Vemurafenib + Voruciclib'}]",Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation,1238
0,NCT01794520,Phase I,"Active, not recruiting","[{'id': 1562, 'therapyName': 'Venetoclax'}]",Study Evaluating ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma,1562
1,NCT03214562,,Recruiting,"[{'id': 1562, 'therapyName': 'Venetoclax'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive Acute Myeloid Leukemia (AML) Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML),1562
2,NCT02055820,Phase I,"Active, not recruiting","[{'id': 1562, 'therapyName': 'Venetoclax'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]",A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma,1562
3,NCT01889186,Phase II,"Active, not recruiting","[{'id': 1562, 'therapyName': 'Venetoclax'}]",A Study of the Efficacy of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia With the 17p Deletion,1562
4,NCT02756611,Phase III,Recruiting,"[{'id': 1562, 'therapyName': 'Venetoclax'}]",A Study to Evaluate the Efficacy of Venetoclax in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL) Including Those With 17p Deletion or TP53 Mutation or Those Who Are Refractory or Intolerant to B-cell Receptor Inhibitors,1562
5,NCT02005471,Phase III,"Active, not recruiting","[{'id': 1562, 'therapyName': 'Venetoclax'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 897, 'therapyName': 'Rituximab'}]",A Study of GDC-0199 (ABT-199) Plus MabThera/Rituxan (Rituximab) Compared With Bendamustine Plus MabThera/Rituxan (Rituximab) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,1562
6,NCT02141282,Phase II,"Active, not recruiting","[{'id': 1562, 'therapyName': 'Venetoclax'}]",A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy,1562
7,NCT03236857,Phase I,Not yet recruiting,"[{'id': 1562, 'therapyName': 'Venetoclax'}]",A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies,1562
8,NCT02966782,Phase I,Recruiting,"[{'id': 1637, 'therapyName': 'GDC-0199 + Azacitidine'}, {'id': 1562, 'therapyName': 'Venetoclax'}]",A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure,1562
0,NCT03036904,Phase I,Recruiting,"[{'id': 5294, 'therapyName': 'Venetoclax + DA-EPOCH-R'}]",Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas (V+DA-EPOCH-R),5294
0,NCT03064867,Phase I,Recruiting,"[{'id': 5404, 'therapyName': 'Venetoclax + Rituximab + Ifosfamide + Carboplatin + Etoposide'}]",Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma,5404
0,NCT03033225,Phase II,Recruiting,"[{'id': 3319, 'therapyName': 'Verteporfin'}]",EUS-guided PDT in Pancreatic Tumors,3319
1,NCT03067051,Phase I,Recruiting,"[{'id': 3319, 'therapyName': 'Verteporfin'}]",Clinical Study to Assess the Safety and Adequacy of Effectiveness of the SpectraCure P18 System,3319
2,NCT02939274,Phase II,Recruiting,"[{'id': 3319, 'therapyName': 'Verteporfin'}]","An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne) for the Treatment of Cutaneous Metastases of Breast Cancer",3319
3,NCT02464761,Phase I,Recruiting,"[{'id': 3319, 'therapyName': 'Verteporfin'}]",Photodynamic Therapy for the Treatment of Vertebral Metastases,3319
0,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,2635
1,NCT00030264,Phase II,Completed,"[{'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas,2635
2,NCT03233347,,Not yet recruiting,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 2486, 'therapyName': 'Brentuximab vedotin'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","Doxorubicin Hydrochloride, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma",2635
3,NCT02840409,Phase II,Recruiting,"[{'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 5178, 'therapyName': 'Bevacizumab + Vinblastine'}]",Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG),2635
0,NCT01857934,Phase II,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 2627, 'therapyName': 'Levetiracetam'}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 2458, 'therapyName': 'Hu14.18K322A'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}]",Therapy for Children With Advanced Stage Neuroblastoma,1631
1,NCT02535806,Phase II,Terminated,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults,1631
2,NCT03117751,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,1631
3,NCT02110069,Phase II,Recruiting,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 917, 'therapyName': 'Sirolimus'}]",A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors,1631
4,NCT02112916,Phase III,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,1631
5,NCT03007147,Phase III,Recruiting,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 5167, 'therapyName': 'Methylprednisolone'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 5168, 'therapyName': 'Prednisolone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,1631
6,NCT01483690,Phase Ib/II,Terminated,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}]",A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL,1631
7,NCT02518750,Phase II,Recruiting,"[{'id': 1604, 'therapyName': 'Panobinostat + Bortezomib + Dexamethasone'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3217, 'therapyName': 'Cyclophosphamide + Etoposide'}, {'id': 3216, 'therapyName': 'Cytarabine + Methotrexate + Prednisone'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma,1631
8,NCT03020030,Phase III,Recruiting,"[{'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents,1631
9,NCT03126916,Phase III,Not yet recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 5595, 'therapyName': 'Isotretinoin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 2286, 'therapyName': 'Dinutuximab  '}]",Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma,1631
10,NCT01319981,Phase II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia,1631
11,NCT02043587,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia &amp; Lymphoblastic Lymphoma,1631
12,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1631
13,NCT03023046,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}]","Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",1631
14,NCT03150693,Phase III,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 3628, 'therapyName': 'Allopurinol'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]",Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia,1631
15,NCT02883049,Phase III,Suspended,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations,1631
16,NCT02626455,Phase III,Recruiting,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 3388, 'therapyName': 'Aldoxorubicin +Cyclophosphamide + Prednisone + Rituximab + Vincristine'}, {'id': 995, 'therapyName': 'Copanlisib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL),1631
17,NCT03147612,Phase II,Not yet recruiting,"[{'id': 5682, 'therapyName': 'Mesna'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Study of the Combination of Low-Intensity Chemotherapy and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),1631
18,NCT02553460,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I,1631
19,NCT01523977,Phase I,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL,1631
20,NCT02163356,Phase I,Recruiting,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 2731, 'therapyName': 'Fenretinide'}, {'id': 2858, 'therapyName': 'Ketoconazole'}]",Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma,1631
21,NCT00074490,Phase II,Completed,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,1631
0,NCT01871766,Phase II,Recruiting,"[{'id': 1119, 'therapyName': 'Sorafenib + Avastin + Cyclophosphamide'}, {'id': 1436, 'therapyName': 'Vincristine + Dactinomycin'}, {'id': 1435, 'therapyName': 'Vincristine + Dactinomycin + Cyclophosphamide'}]","Treatment of Localized Rhabdomyosarcoma With Chemotherapy, Radiotherapy, and Surgery",1436
0,NCT02567435,Phase III,Suspended,"[{'id': 1435, 'therapyName': 'Vincristine + Dactinomycin + Cyclophosphamide'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Combination Chemotherapy and Irinotecan Hydrochloride or Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma,1435
1,NCT01871766,Phase II,Recruiting,"[{'id': 1119, 'therapyName': 'Sorafenib + Avastin + Cyclophosphamide'}, {'id': 1436, 'therapyName': 'Vincristine + Dactinomycin'}, {'id': 1435, 'therapyName': 'Vincristine + Dactinomycin + Cyclophosphamide'}]","Treatment of Localized Rhabdomyosarcoma With Chemotherapy, Radiotherapy, and Surgery",1435
0,NCT01324180,Phase I,Completed,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1830, 'therapyName': 'Vincristine + Dexamethasone + Pegaspargase + Doxorubicin'}]","Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)",1830
1,NCT01769209,Phase II,"Active, not recruiting","[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 1830, 'therapyName': 'Vincristine + Dexamethasone + Pegaspargase + Doxorubicin'}]",Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,1830
0,NCT01946529,Phase II,"Active, not recruiting","[{'id': 1433, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide'}, {'id': 1434, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide + others'}]",Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors,1433
1,NCT02306161,Phase II,Recruiting,"[{'id': 1433, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide'}, {'id': 746, 'therapyName': 'Ganitumab'}]",Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma,1433
0,NCT01946529,Phase II,"Active, not recruiting","[{'id': 1433, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide'}, {'id': 1434, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide + others'}]",Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors,1434
0,NCT00020566,Phase III,Unknown status,"[{'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2670, 'therapyName': 'Vincristine + Doxorubicin + Dactinomycin + Ifosfamide + Etoposide'}]","Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma",2670
0,NCT01528046,Phase I,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1826, 'therapyName': 'Vincristine + Irinotecan + Temozolomide '}]",Metformin in Children With Relapsed or Refractory Solid Tumors,1826
0,NCT01256398,Phase II,"Active, not recruiting","[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1824, 'therapyName': 'Vincristine + Methotrexate + Mercaptopurine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,1824
1,NCT02143414,Phase II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1824, 'therapyName': 'Vincristine + Methotrexate + Mercaptopurine'}]","Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",1824
0,NCT00549848,Phase III,"Active, not recruiting","[{'id': 1781, 'therapyName': 'Vincristine + Pegaspargase + Daunorubicin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1782, 'therapyName': 'Clofarabine + Etoposide + Cyclophosphamide'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia,1781
0,NCT02861040,Phase I,Withdrawn,"[{'id': 4781, 'therapyName': 'Vincristine + Volasertib'}]",Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,4781
0,NCT02000622,Phase III,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.,1685
1,NCT02331251,Phase Ib/II,"Active, not recruiting","[{'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 619, 'therapyName': 'Abraxane'}]",Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus),1685
2,NCT02492711,Phase III,Recruiting,"[{'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 808, 'therapyName': 'MGAH22'}]",Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer,1685
3,NCT03257267,Phase III,Recruiting,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 5656, 'therapyName': 'REGN2810'}, {'id': 942, 'therapyName': 'Topotecan'}]",Study of REGN2810 in Adults With Cervical Cancer,1685
4,NCT03191786,Phase III,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}]",A Study of Atezolizumab Compared With Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Containing Therapy,1685
5,NCT02117024,Phase II,"Active, not recruiting","[{'id': 2472, 'therapyName': 'HS-110 + Cyclophosphamide'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer,1685
6,NCT02555657,Phase III,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119),1685
7,NCT01945775,Phase III,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 682, 'therapyName': 'Talazoparib'}, {'id': 728, 'therapyName': 'Eribulin'}]","A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)",1685
8,NCT02302807,Phase III,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Study of MPDL3280A Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer,1685
9,NCT02229149,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1105, 'therapyName': 'Capecitabine'}]","Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer",1685
10,NCT02985658,Phase I,Available,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1685, 'therapyName': 'Vinorelbine'}]",Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer,1685
0,NCT02213744,Phase II,Terminated,"[{'id': 1890, 'therapyName': 'Vinorelbine + Trastuzumab'}, {'id': 1409, 'therapyName': 'Capecitabine + Trastuzumab'}, {'id': 1889, 'therapyName': 'Gemcitabine + Trastuzumab'}, {'id': 1888, 'therapyName': 'MM-302 + Trastuzumab'}]",MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients,1890
0,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,956
1,NCT02639117,Phase I,Recruiting,"[{'id': 956, 'therapyName': 'Vismodegib'}]",Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas,956
2,NCT02067104,Phase II,Completed,"[{'id': 956, 'therapyName': 'Vismodegib'}]",Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention,956
3,NCT02115828,Phase I,"Active, not recruiting","[{'id': 956, 'therapyName': 'Vismodegib'}]",A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy,956
4,NCT01700049,Phase II,"Active, not recruiting","[{'id': 956, 'therapyName': 'Vismodegib'}]",Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes,956
5,NCT02693535,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 690, 'therapyName': 'Bosutinib'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer,956
6,NCT01367665,Phase II,Completed,"[{'id': 956, 'therapyName': 'Vismodegib'}]",STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma,956
7,NCT01898598,Phase II,Terminated,"[{'id': 956, 'therapyName': 'Vismodegib'}]",A Study of Vismodegib With Surgery in Patients With Previously Untreated Basal Cell Carcinoma,956
8,NCT01835626,Phase II,Recruiting,"[{'id': 956, 'therapyName': 'Vismodegib'}]",Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma,956
9,NCT01154452,Phase Ib/II,Completed,"[{'id': 956, 'therapyName': 'Vismodegib'}, {'id': 1096, 'therapyName': 'Vismodegib + RO4929097'}, {'id': 902, 'therapyName': 'RO4929097'}]",Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma,956
10,NCT01543581,,Completed,"[{'id': 956, 'therapyName': 'Vismodegib'}]",Vismodegib for Treatment of Basal Cell Carcinoma,956
11,NCT01774253,Phase II,Terminated,"[{'id': 956, 'therapyName': 'Vismodegib'}]",Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma,956
12,NCT01878617,Phase II,Recruiting,"[{'id': 956, 'therapyName': 'Vismodegib'}, {'id': 1800, 'therapyName': 'Cyclophosphamide + Cisplatin + Vincristine '}, {'id': 1801, 'therapyName': 'Pemetrexed + Gemcitabine'}]",A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma,956
13,NCT02523014,Phase II,Recruiting,"[{'id': 3078, 'therapyName': 'GSK2256098'}, {'id': 956, 'therapyName': 'Vismodegib'}]",A Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas,956
14,NCT02366312,Phase II,"Active, not recruiting","[{'id': 956, 'therapyName': 'Vismodegib'}]","A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors",956
15,NCT02091141,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 698, 'therapyName': 'Alectinib'}, {'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]","My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors",956
16,NCT01815840,Phase II,Completed,"[{'id': 956, 'therapyName': 'Vismodegib'}]",A Study of Two Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas,956
17,NCT02436408,FDA approved,Recruiting,"[{'id': 956, 'therapyName': 'Vismodegib'}]",VISmodegib for ORbital and Periocular Basal Cell Carcinoma,956
0,NCT01088815,Phase II,Unknown status,"[{'id': 1799, 'therapyName': 'Vismodegib + Gemcitabine + Abraxane'}]",Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas,1799
0,NCT02073838,Phase II,Recruiting,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 3179, 'therapyName': 'Vismodegib + Ribavirin'}]",Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML,3179
0,NCT01154452,Phase Ib/II,Completed,"[{'id': 956, 'therapyName': 'Vismodegib'}, {'id': 1096, 'therapyName': 'Vismodegib + RO4929097'}, {'id': 902, 'therapyName': 'RO4929097'}]",Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma,1096
0,NCT02619864,Phase Ib/II,Recruiting,"[{'id': 991, 'therapyName': 'Vistusertib'}]",mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme,991
1,NCT03071874,Phase II,Recruiting,"[{'id': 991, 'therapyName': 'Vistusertib'}]",Phase II Study Of Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas,991
2,NCT02831257,Phase II,"Active, not recruiting","[{'id': 991, 'therapyName': 'Vistusertib'}]",AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas,991
3,NCT02599714,Phase Ib/II,Recruiting,"[{'id': 3205, 'therapyName': 'Fulvestrant + Palbociclib'}, {'id': 991, 'therapyName': 'Vistusertib'}]",Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer (PASTOR),991
4,NCT02208375,Phase Ib/II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 655, 'therapyName': 'AZD5363'}, {'id': 991, 'therapyName': 'Vistusertib'}]",mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Cancer,991
5,NCT02403895,Phase II,Completed,"[{'id': 991, 'therapyName': 'Vistusertib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",AZD2014 and Weekly Paclitaxel in Squamous NSCLC,991
0,NCT01597388,Phase I,"Active, not recruiting","[{'id': 2199, 'therapyName': 'Vistusertib + Fulvestrant'}]",AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer,2199
0,NCT02452281,Phase Ib/II,Withdrawn,"[{'id': 2973, 'therapyName': 'Vitespen'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma,2973
0,NCT02372240,Phase Ib/II,Suspended,"[{'id': 5099, 'therapyName': 'VLX1570 + Dexamethasone'}]",A Study of VLX1570 and Dexamethasone in Myeloma Patients,5099
0,NCT02721875,Phase I,Terminated,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 957, 'therapyName': 'Volasertib'}]",Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes,957
0,NCT02003573,Phase I,Terminated,"[{'id': 1745, 'therapyName': 'Volasertib + Decitabine'}]",Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML),1745
0,NCT01193842,Phase Ib/II,"Active, not recruiting","[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 3395, 'therapyName': 'R-EPOCH'}]",Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,1077
1,NCT02083250,Phase I,Recruiting,"[{'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 3201, 'therapyName': 'Busulfan + Clofarabine + Fludarabine'}]",Fludarabine/Clofarabine/Busulfan Combined With SAHA in Acute Leukemia,1077
2,NCT03263936,Phase I,Recruiting,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Epigenetic Reprogramming in Relapse/Refractory AML,1077
3,NCT02137759,Phase II,Recruiting,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",MRSI to Predict Response to RT/TMZ and Vorinostat in GBM,1077
4,NCT03117751,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,1077
5,NCT02589145,Phase Ib/II,Recruiting,"[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 3278, 'therapyName': 'Enoxaparin'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}]",Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype,1077
6,NCT00719875,Phase Ib/II,Completed,"[{'id': 1077, 'therapyName': 'Vorinostat'}]",HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer,1077
7,NCT01339871,Phase I,Completed,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Phase I Study of Pazopanib and Vorinostat,1077
8,NCT01587352,Phase II,Suspended,"[{'id': 1077, 'therapyName': 'Vorinostat'}]",Vorinostat in Treating Patients With Metastatic Melanoma of the Eye,1077
9,NCT01064921,Phase I,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma,1077
10,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,1077
11,NCT01059552,Phase I,"Active, not recruiting","[{'id': 1077, 'therapyName': 'Vorinostat'}]",Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC),1077
12,NCT01087554,Phase I,"Active, not recruiting","[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer,1077
13,NCT01790568,Phase II,"Active, not recruiting","[{'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant,1077
14,NCT01249443,Phase I,Terminated,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Vorinostat in Combination With Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection,1077
15,NCT01879085,Phase Ib/II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Phase 1b/2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma,1077
16,NCT02553460,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I,1077
17,NCT02316340,Phase II,Recruiting,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1316, 'therapyName': 'Hydroxychloroquine'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer,1077
18,NCT02420613,Phase I,Recruiting,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 936, 'therapyName': 'Temsirolimus'}]",Study of Suberoylanilide Hydroxamic Acid (SAHA) With Temsirolimus in Children With Diffuse Intrinsic Pontine Glioma (DIPG),1077
19,NCT03259503,Phase Ib/II,Not yet recruiting,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas,1077
20,NCT02412475,Phase I,"Active, not recruiting","[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 650, 'therapyName': 'Decitabine'}]",Epigenetic Reprogramming in Relapse AML,1077
21,NCT02419755,Phase II,Terminated,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies,1077
22,NCT02559778,Phase I,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2629, 'therapyName': 'Eflornithine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 717, 'therapyName': 'Dasatinib'}]",Pediatric Precision Laboratory Advanced Neuroblastoma Therapy,1077
23,NCT03022565,Phase I,Not yet recruiting,"[{'id': 1077, 'therapyName': 'Vorinostat'}]",Vorinostat in Patients With Class 2 High Risk Uveal Melanoma,1077
24,NCT02638090,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC),1077
25,NCT01281176,,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors,1077
26,NCT01593670,Phase II,Terminated,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes,1077
0,NCT01294670,Phase Ib/II,"Active, not recruiting","[{'id': 1182, 'therapyName': 'Vorinostat + Etoposide'}]",Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients &lt; 21 Years at Diagnosis With Refractory Solid Tumors,1182
0,NCT01266057,Phase I,"Active, not recruiting","[{'id': 1135, 'therapyName': 'Vorinostat + Hydroxychloroquine'}, {'id': 1177, 'therapyName': 'Sirolimus + Hydroxychloroquine'}]",Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer,1135
1,NCT01023737,Phase I,Recruiting,"[{'id': 1135, 'therapyName': 'Vorinostat + Hydroxychloroquine'}]",Hydroxychloroquine + Vorinostat in Advanced Solid Tumors,1135
0,NCT00574587,Phase Ib/II,Unknown status,"[{'id': 1983, 'therapyName': 'vorinostat + Paclitaxel'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]","Trial for Locally Advanced Her2 Positive Breast Cancer Using Paclitaxel, Trastuzumab, Doxorubicin and Cyclophasmide on a Weekly Basis",1983
0,NCT01849744,Phase I,Terminated,"[{'id': 1933, 'therapyName': 'VS-4718'}]",Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies,1933
0,NCT01991938,Phase I,Terminated,"[{'id': 960, 'therapyName': 'VS-5584'}]",Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma,960
0,NCT02372227,Phase I,Terminated,"[{'id': 2464, 'therapyName': 'VS-5584 + VS-6063'}]","A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma",2464
0,NCT02943317,Phase I,Recruiting,"[{'id': 958, 'therapyName': 'VS-6063'}, {'id': 3144, 'therapyName': 'Avelumab'}]","Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer",958
1,NCT02004028,Phase II,Completed,"[{'id': 958, 'therapyName': 'VS-6063'}]",Window of Opportunity Study of VS-6063 (Defactinib) in Participants With Surgical Resectable Malignant Pleural Mesothelioma.,958
2,NCT01951690,Phase II,Completed,"[{'id': 958, 'therapyName': 'VS-6063'}]",Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer,958
3,NCT02465060,Phase II,Recruiting,"[{'id': 660, 'therapyName': 'AZD9291'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 958, 'therapyName': 'VS-6063'}, {'id': 765, 'therapyName': 'GSK2636771'}]",NCI-MATCH Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,958
4,NCT01870609,Phase II,Terminated,"[{'id': 958, 'therapyName': 'VS-6063'}]",Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma,958
0,NCT01628640,Phase I,Recruiting,"[{'id': 2423, 'therapyName': 'VSV-IFN-beta'}]",Viral Therapy in Treating Patient With Liver Cancer,2423
0,NCT02580448,Phase Ib/II,Recruiting,"[{'id': 2822, 'therapyName': 'VT-464'}]","A Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients With Advanced Breast Cancer",2822
0,NCT02487095,Phase Ib/II,Recruiting,"[{'id': 2879, 'therapyName': 'VX-970'}, {'id': 942, 'therapyName': 'Topotecan'}]","Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer",2879
1,NCT02157792,Phase I,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 2879, 'therapyName': 'VX-970'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy",2879
2,NCT02595892,Phase II,Recruiting,"[{'id': 2879, 'therapyName': 'VX-970'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","Gemcitabine Hydrochloride Alone or With VX-970 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",2879
3,NCT02589522,Phase I,Recruiting,"[{'id': 2879, 'therapyName': 'VX-970'}]",VX-970 and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer,2879
4,NCT02627443,Phase II,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2879, 'therapyName': 'VX-970'}]","Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",2879
0,NCT02595931,Phase I,Recruiting,"[{'id': 2883, 'therapyName': 'VX-970 + Irinotecan'}]",VX-970 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,2883
0,NCT02422589,Phase I,Recruiting,"[{'id': 2505, 'therapyName': 'Warfarin'}, {'id': 2685, 'therapyName': 'Midazolam'}, {'id': 789, 'therapyName': 'Ceritinib'}]","A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors",2505
1,NCT01769768,Phase I,Completed,"[{'id': 1428, 'therapyName': 'Sonidegib'}, {'id': 2505, 'therapyName': 'Warfarin'}, {'id': 2506, 'therapyName': 'Bupropion'}]",Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients,2505
0,NCT01904123,Phase I,Not yet recruiting,"[{'id': 2784, 'therapyName': 'WP1066'}]",A Phase I Trial of WP1066,2784
0,NCT01995708,Phase I,Recruiting,"[{'id': 2901, 'therapyName': 'WT1 senstized T cells'}]","CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation",2901
1,NCT00620633,Phase I,"Active, not recruiting","[{'id': 2901, 'therapyName': 'WT1 senstized T cells'}]",Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation,2901
2,NCT01640301,Phase Ib/II,Suspended,"[{'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 2901, 'therapyName': 'WT1 senstized T cells'}]","Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant",2901
0,NCT01827137,Phase I,"Active, not recruiting","[{'id': 2893, 'therapyName': 'WT1 vaccine'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1873, 'therapyName': 'Sargramostim'}]",WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation,2893
1,NCT01266083,Phase II,"Active, not recruiting","[{'id': 2893, 'therapyName': 'WT1 vaccine'}]",Trial of a WT-1 Analog Peptide Vaccine in Patients With Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL),2893
2,NCT01890980,Phase II,"Active, not recruiting","[{'id': 2893, 'therapyName': 'WT1 vaccine'}, {'id': 1873, 'therapyName': 'Sargramostim'}]",Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134,2893
3,NCT01621542,Phase I,Completed,"[{'id': 2893, 'therapyName': 'WT1 vaccine'}]",Clinical Study of WT2725 in Patients With Advanced Malignancies,2893
4,NCT01265433,Phase II,Completed,"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 2893, 'therapyName': 'WT1 vaccine'}]",Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy,2893
0,NCT02767804,Phase III,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 961, 'therapyName': 'X-396'}]",eXalt3: Study Comparing X-396 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients,961
1,NCT03213652,Phase II,Recruiting,"[{'id': 961, 'therapyName': 'X-396'}]","Pediatric MATCH: Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations",961
2,NCT02898116,Phase Ib/II,Recruiting,"[{'id': 4730, 'therapyName': 'MEDI4736 + X-396'}, {'id': 961, 'therapyName': 'X-396'}]","A Study of ALK Inhibitor, Ensartinib, and Anti-PD-L1, Durvalumab, in Subjects With ALK-rearranged Non-small Cell Lung Cancer",961
3,NCT01625234,Phase Ib/II,Recruiting,"[{'id': 961, 'therapyName': 'X-396'}]","Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer",961
4,NCT03155620,Phase II,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}, {'id': 2650, 'therapyName': 'LOXO-101'}, {'id': 1069, 'therapyName': 'LY3023414'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 913, 'therapyName': 'Selumetinib'}, {'id': 961, 'therapyName': 'X-396'}]",Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Advanced Refractory Solid Tumors or Lymphomas,961
0,NCT01296581,Phase I,"Active, not recruiting","[{'id': 962, 'therapyName': 'X-82'}]", Safety Study of X-82 in Patients With Advanced Solid Tumors,962
0,NCT02146222,Phase I,"Active, not recruiting","[{'id': 1442, 'therapyName': 'X-82 + Docetaxel'}]",VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors,1442
0,NCT01784861,Phase Ib/II,"Active, not recruiting","[{'id': 1272, 'therapyName': 'X-82 + Everolimus'}]",VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors,1272
0,NCT02667886,Phase Ib/II,Recruiting,"[{'id': 649, 'therapyName': 'Axitinib'}, {'id': 3570, 'therapyName': 'X4P-001'}]",Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma,3570
0,NCT02204072,Phase I,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2916, 'therapyName': 'Xentuzumab'}]",BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC),2916
0,NCT01587040,Phase Ib/II,"Active, not recruiting","[{'id': 1050, 'therapyName': 'XL147'}, {'id': 1051, 'therapyName': 'SAR245409'}]",Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen,1050
0,NCT02844439,Phase II,"Active, not recruiting","[{'id': 967, 'therapyName': 'XL647'}]",Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma,967
1,NCT02616393,Phase II,Recruiting,"[{'id': 967, 'therapyName': 'XL647'}]","Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases",967
0,NCT02154529,Phase Ib/II,Terminated,"[{'id': 1880, 'therapyName': 'XL647 + Trastuzumab'}]",Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer,1880
0,NCT01657591,Phase I,"Active, not recruiting","[{'id': 1217, 'therapyName': 'XL888 + Vemurafenib'}]", Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma,1217
0,NCT02952729,Phase I,Recruiting,"[{'id': 5834, 'therapyName': 'XMT-1522'}]",Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2,5834
0,NCT01956812,Phase III,Terminated,"[{'id': 3000, 'therapyName': 'Y90 clivatuzumab tetraxetan'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer (PANCRIT-1),3000
0,NCT02913417,Phase Ib/II,Recruiting,"[{'id': 4769, 'therapyName': 'Yttrium-90 + Nivolumab + Ipilimumab'}]","Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases",4769
0,NCT02311933,Phase II,"Active, not recruiting","[{'id': 3076, 'therapyName': 'Z-endoxifen HCl'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]","Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",3076
0,NCT02705469,Phase I,"Active, not recruiting","[{'id': 4032, 'therapyName': 'ZEN003694'}]",A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer,4032
0,NCT02047149,Phase I,Terminated,"[{'id': 1789, 'therapyName': 'Zileuton + Dasatinib'}]",Evaluating the Safety of Zileuton (Zyflo(R)) in Combination With Dasatinib (Sprycel (R) in Chronic Myelogenous Leukemia,1789
0,NCT01345019,Phase III,"Active, not recruiting","[{'id': 1198, 'therapyName': 'Denosumab'}, {'id': 2971, 'therapyName': 'Zoledronic acid'}]",Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma,2971
1,NCT02508038,Phase I,Recruiting,"[{'id': 2971, 'therapyName': 'Zoledronic acid'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}]", Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa,2971
0,NCT02892123,Phase I,Recruiting,"[{'id': 6240, 'therapyName': 'ZW25'}]",Trial of ZW25 in Patients With Advanced HER2-expressing Cancers,6240
